{"questions": [{"body": "Which is the main CHEK2 genetic variant, thought to be involved in familial breast cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17721994", "http://www.ncbi.nlm.nih.gov/pubmed/16998506", "http://www.ncbi.nlm.nih.gov/pubmed/12610780", "http://www.ncbi.nlm.nih.gov/pubmed/19763819", "http://www.ncbi.nlm.nih.gov/pubmed/14618615"], "triples": [], "ideal_answer": ["CHEK2 1100delC mutation is recurrently detected in the general population and is thought to confer a moderate risk for breast cancer."], "exact_answer": [["CHEK2 1100delC mutation"]], "concepts": [], "type": "factoid", "id": "5357b36cf1005d6b58000006", "snippets": [{"offsetInBeginSection": 560, "offsetInEndSection": 654, "text": "the two most studied breast cancer-predisposing variants of the CHEK2 gene, 1100delC and I157T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998506", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "The CHEK2-1100delC mutation is recurrent in the population and is a moderate risk factor for breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", "endSection": "abstract"}, {"offsetInBeginSection": 675, "offsetInEndSection": 904, "text": "The germline CHEK2-1100delC mutation was present among 8/1,646 (0.5%) sporadic, 2/400 (0.5%) early-onset and 3/302 (1%) familial breast cancer cases, but undetectable amongst 2,105 multiethnic controls, including 633 from the US.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", "endSection": "abstract"}, {"offsetInBeginSection": 986, "offsetInEndSection": 1145, "text": "1100delC appears to be the only recurrent CHEK2 mutation associated with a potentially significant contribution to breast cancer risk in the general population", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", "endSection": "abstract"}, {"offsetInBeginSection": 1559, "offsetInEndSection": 1830, "text": "Our findings highlight the notion that clinical testing for rare missense mutations within CHEK2 may have limited value in predicting breast cancer risk, but that testing for the 1100delC variant may be valuable in phenotypically- and geographically-selected populations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610780", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "We recently reported that a sequence variant in the cell-cycle-checkpoint kinase CHEK2 (CHEK2 1100delC) is a low-penetrance breast cancer-susceptibility allele in noncarriers of BRCA1 or BRCA2 mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610780", "endSection": "abstract"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1131, "text": "These results indicate that 1100delC may be the only CHEK2 allele that makes an appreciable contribution to breast cancer susceptibility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610780", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 781, "text": "CHEK2_1100delC was found in 5/903 (0.5%) breast cancer cases compared to 1/1016 (0.1%) controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19763819", "endSection": "abstract"}, {"offsetInBeginSection": 128, "offsetInEndSection": 446, "text": "Recently, the CHEK 2 gene, involved in DNA damage and replication checkpoints, has been pointed out as a good candidate; moreover, a specific variant in this gene,1100delC, has been found to increase breast cancer susceptibility among familial breast cancer cases not attributable to mutations in BRCA1 or BRCA2 genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14618615", "endSection": "abstract"}, {"offsetInBeginSection": 560, "offsetInEndSection": 654, "text": "the two most studied breast cancer-predisposing variants of the CHEK2 gene, 1100delC and I157T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16998506", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "The CHEK2-1100delC mutation is recurrent in the population and is a moderate risk factor for breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17721994", "endSection": "abstract"}]}, {"body": "What is the inheritance pattern of Hunter disease or mucopolysaccharidosis II?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20509947", "http://www.ncbi.nlm.nih.gov/pubmed/7492964", "http://www.ncbi.nlm.nih.gov/pubmed/7904121", "http://www.ncbi.nlm.nih.gov/pubmed/2112988", "http://www.ncbi.nlm.nih.gov/pubmed/3100113", "http://www.ncbi.nlm.nih.gov/pubmed/6418001", "http://www.ncbi.nlm.nih.gov/pubmed/409284"], "triples": [], "ideal_answer": "X- linked recessive", "exact_answer": ["X- linked recessive"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040582", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016532", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050172", "http://www.disease-ontology.org/api/metadata/DOID:12799"], "type": "factoid", "id": "5344155faeec6fbd07000005", "snippets": [{"offsetInBeginSection": 6, "offsetInEndSection": 182, "text": "ysosomal diseases (LD) are inherited as autosomal recessive traits, but two important conditions have X-linked inheritance: Fabry disease and Mucopolysaccharidosis II (MPS II).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20509947", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 98, "text": "unter disease, Mucopolysaccharidosis type II, is an X-linked recessive lysosomal storage disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7492964", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 49, "text": "unter syndrome is an X-linked recessive disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7904121", "endSection": "abstract"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1265, "text": "X chromosome heterozygosity and confirmed the paternal origin of one of the X chromosomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2112988", "endSection": "abstract"}, {"offsetInBeginSection": 18, "offsetInEndSection": 77, "text": " Hunter's disease in a female with an X-chromosome deletion", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3100113", "endSection": "title"}, {"offsetInBeginSection": 1009, "offsetInEndSection": 1107, "text": "Chromosome studies on the patient revealed a partial deletion of the long arm of one X-chromosome,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3100113", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 44, "text": "unter disease, an X-linked recessive lethal", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6418001", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 358, "text": "X-linked disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/409284", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 30, "text": "Hunter syndrome in females", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/409284", "endSection": "title"}]}, {"body": "What is the target protein of the drug Idelalisib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24323900", "http://www.ncbi.nlm.nih.gov/pubmed/24273091", "http://www.ncbi.nlm.nih.gov/pubmed/24261963", "http://www.ncbi.nlm.nih.gov/pubmed/24085367", "http://www.ncbi.nlm.nih.gov/pubmed/24060900", "http://www.ncbi.nlm.nih.gov/pubmed/24014301", "http://www.ncbi.nlm.nih.gov/pubmed/24009233", "http://www.ncbi.nlm.nih.gov/pubmed/23847354", "http://www.ncbi.nlm.nih.gov/pubmed/23617253"], "triples": [], "ideal_answer": "Idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform.", "exact_answer": ["PI3K-\u03b4", "phosphoinositol-3 kinase delta isoform"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011955", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004364"], "type": "factoid", "id": "5321bc309b2d7acc7e00000d", "snippets": [{"offsetInBeginSection": 1348, "offsetInEndSection": 1369, "text": " PI3K\u03b4 (idelalisib). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24323900", "endSection": "abstract"}, {"offsetInBeginSection": 1962, "offsetInEndSection": 1990, "text": "Idelalisib (PI3K inhibitor) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24273091", "endSection": "abstract"}, {"offsetInBeginSection": 425, "offsetInEndSection": 656, "text": "In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed, and at least fifteen compounds have progressed into clinical trials as new anticancer drugs. Among these, idelalisib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24261963", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1112, "text": " idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24085367", "endSection": "abstract"}, {"offsetInBeginSection": 551, "offsetInEndSection": 577, "text": "PI3K inhibitor idelalisib ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014301", "endSection": "abstract"}, {"offsetInBeginSection": 1181, "offsetInEndSection": 1211, "text": "the PI3K inhibitor idelalisib ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009233", "endSection": "abstract"}, {"offsetInBeginSection": 37, "offsetInEndSection": 64, "text": "PI3K-\u03b4 inhibitor idelalisib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23847354", "endSection": "abstract"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1077, "text": "idelalisib (GS-1101) -a specific isoform of the PI3K (PI3K) inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23617253", "endSection": "abstract"}]}, {"body": "What is the name for anorexia in gymnasts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24240086", "http://www.ncbi.nlm.nih.gov/pubmed/10551340"], "triples": [], "ideal_answer": ["Anorexia athletica"], "exact_answer": [["Anorexia Athletica"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006173", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000855", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000856"], "type": "factoid", "id": "53617eeb7d100faa0900000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Elite Rhythmic Gymnasts (RGs) constitute a unique metabolic model and they are prone to developing Anorexia Athletica.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240086", "endSection": "abstract"}, {"offsetInBeginSection": 201, "offsetInEndSection": 273, "text": "We studied 13 female juvenile elite gymnasts with anorexia athletica (AA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10551340", "endSection": "abstract"}]}, {"body": "What is known about the role of mHealth in the prevention of disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24294329", "http://www.ncbi.nlm.nih.gov/pubmed/24246427", "http://www.ncbi.nlm.nih.gov/pubmed/24133558", "http://www.ncbi.nlm.nih.gov/pubmed/24050486", "http://www.ncbi.nlm.nih.gov/pubmed/23992038", "http://www.ncbi.nlm.nih.gov/pubmed/23624056", "http://www.ncbi.nlm.nih.gov/pubmed/23549699", "http://www.ncbi.nlm.nih.gov/pubmed/23330022", "http://www.ncbi.nlm.nih.gov/pubmed/22920991", "http://www.ncbi.nlm.nih.gov/pubmed/22548607", "http://www.ncbi.nlm.nih.gov/pubmed/22548595"], "triples": [], "ideal_answer": ["Most reported uses of mHealth are for treatment, we identified report on approaches to child obesity prevention."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011322", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055502"], "type": "summary", "id": "535d7c247d100faa09000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "mHealth approaches to child obesity prevention", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24294329", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Daily text messaging for weight control among racial and ethnic minority women", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246427", "endSection": "title"}, {"offsetInBeginSection": 301, "offsetInEndSection": 378, "text": "text messaging intervention for weight loss among predominantly black women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246427", "endSection": "abstract"}, {"offsetInBeginSection": 1660, "offsetInEndSection": 1843, "text": "Given the increasing penetration of mobile devices, text messaging may be a useful self-monitoring tool for weight control, particularly among populations most in need of intervention", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246427", "endSection": "abstract"}, {"offsetInBeginSection": 798, "offsetInEndSection": 1151, "text": "The review revealed evidence that mHealth tools support HIV programmatic priorities, including: linkage to care, retention in care, and adherence to antiretroviral treatment. In terms of technical features, mHealth tools facilitate alerts and reminders, data collection, direct voice communication, educational messaging, information on demand, and more", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24133558", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 55, "text": "Mobile health messages help sustain recent weight loss.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24050486", "endSection": "title"}, {"offsetInBeginSection": 1076, "offsetInEndSection": 1272, "text": " A clinically significant decrease in mean weight, higher rate of sustained weight loss, and medium-to-large effects on sustained weight loss occurred in the promotion and prevention interventions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24050486", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "A mobile health intervention for weight management among young adults:", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23992038", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "HIV prevalence in Uganda has leveled off, however trends indicate that incidence is on the rise and disproportionately affects certain vulnerable groups, such as women. There is growing support for using mobile health (mHealth) programs to reach vulnerable populations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23549699", "endSection": "abstract"}, {"offsetInBeginSection": 1763, "offsetInEndSection": 1915, "text": "We successully designed and implemented a mobile phone SMS-based system to track pregnancy and maternal and child outcomes in limited resources setting.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23330022", "endSection": "abstract"}, {"offsetInBeginSection": 482, "offsetInEndSection": 841, "text": "The purpose of the study, Project ACTION (Adult smoking Cessation Treatment through Innovative Outreach to Neighborhoods), is to utilize a mobile clinic model, a network of community sites (i.e., community centers and churches) and an interactive mobile messaging system to reach and deliver smoking cessation treatment to underserved, low-income communities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22920991", "endSection": "abstract"}, {"offsetInBeginSection": 1465, "offsetInEndSection": 1749, "text": "Participants were randomized to usual prenatal care plus text messaging or usual care alone. The evaluation has a theoretical model of behavior change and measures mediators as well as behavioral outcomes. Results will inform how behavioral theory works within mobile health programs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22548595", "endSection": "abstract"}]}, {"body": "What is known about diseases associated with mutations in the CHCHD10 gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25428574", "http://www.ncbi.nlm.nih.gov/pubmed/25193783", "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "http://www.ncbi.nlm.nih.gov/pubmed/24934289"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0049608", "o": "D004194"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0015570", "o": "D004194"}], "ideal_answer": ["Mutation c.197G>T p.G66V in CHCHD10 is the cause of the lower motor neuron syndrome LOSMoN/SMAJ. \nMutations in the CHCHD10 gene have been identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment.\nOther findings links CHCHD10 mutations to mitochondrial myopathy.", "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000690", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057180", "http://www.disease-ontology.org/api/metadata/DOID:332", "http://www.disease-ontology.org/api/metadata/DOID:9255"], "type": "summary", "id": "5717e0717de986d80d000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Late onset spinal motor neuronopathy is caused by mutation in CHCHD10.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25428574", "endSection": "title"}, {"offsetInBeginSection": 911, "offsetInEndSection": 1249, "text": "Mutation c.197G>T p.G66V in CHCHD10 is the cause of the lower motor neuron syndrome LOSMoN/SMAJ. During the preparation of this article other mutations were reported to cause frontotemporal dementia-amyotrophic lateral sclerosis syndrome, indicating that the CHCHD10 gene is largely important for the motor and cognitive neuronal systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25428574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193783", "endSection": "title"}, {"offsetInBeginSection": 1448, "offsetInEndSection": 1599, "text": "Our findings identify a novel gene causing mitochondrial myopathy, thereby expanding the spectrum of mitochondrial myopathies caused by nuclear genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25193783", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 1458, "offsetInEndSection": 1783, "text": "The observation of a frontotemporal dementia-amyotrophic lateral sclerosis phenotype in a mitochondrial disease led us to analyse CHCHD10 in a cohort of 21 families with pathologically proven frontotemporal dementia-amyotrophic lateral sclerosis. We identified the same missense p.Ser59Leu mutation in one of these families. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24934289", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 841, "text": "This study demonstrates the implication of CHCHD10 in FTD and ALS spectrum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 419, "offsetInEndSection": 511, "text": "However, the exact contribution of CHCHD10 in FTD and ALS diseases spectrum remains unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 620, "offsetInEndSection": 731, "text": "In this study, we evaluated the frequency of CHCHD10 mutations in 115 patients with FTD and FTD-ALS phenotypes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 1696, "offsetInEndSection": 1942, "text": "The observation of a frontotemporal dementia-amyotrophic lateral sclerosis phenotype in a mitochondrial disease led us to analyse CHCHD10 in a cohort of 21 families with pathologically proven frontotemporal dementia-amyotrophic lateral sclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24934289", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24934289", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 810, "offsetInEndSection": 1008, "text": "The mutation was shown to segregate with the disease in 55 patients from 17 families.INTERPRETATION: Mutation c.197G>T p.G66V in CHCHD10 is the cause of the lower motor neuron syndrome LOSMoN/SMAJ. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25428574", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS), cerebellar ataxia, myopathy, and hearing impairment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 419, "offsetInEndSection": 512, "text": "However, the exact contribution of CHCHD10 in FTD and ALS diseases spectrum remains unknown. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 1458, "offsetInEndSection": 1705, "text": "The observation of a frontotemporal dementia-amyotrophic lateral sclerosis phenotype in a mitochondrial disease led us to analyse CHCHD10 in a cohort of 21 families with pathologically proven frontotemporal dementia-amyotrophic lateral sclerosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24934289", "endSection": "abstract"}, {"offsetInBeginSection": 766, "offsetInEndSection": 842, "text": "This study demonstrates the implication of CHCHD10 in FTD and ALS spectrum. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Mutations in the CHCHD10 gene have been recently identified in a large family with a complex phenotype variably associating frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25155093", "endSection": "abstract"}]}, {"body": "What was the aim of the HAMLET clinical trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23943217", "http://www.ncbi.nlm.nih.gov/pubmed/23868265", "http://www.ncbi.nlm.nih.gov/pubmed/17400593", "http://www.ncbi.nlm.nih.gov/pubmed/16965617", "http://www.ncbi.nlm.nih.gov/pubmed/14723030", "http://www.ncbi.nlm.nih.gov/pubmed/19269254", "http://www.ncbi.nlm.nih.gov/pubmed/17303527"], "triples": [], "ideal_answer": ["The aim of the HAMLET (Hemicraniectomy After Middle Cerebral Artery Infarction With Life-Threatening Edema Trial) clinical trial was to compare the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", "The  Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial  (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.  ", "The  Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial  (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.  ", "The  Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial  (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.  "], "concepts": [], "type": "summary", "id": "54d776453706e89528000018", "snippets": [{"offsetInBeginSection": 212, "offsetInEndSection": 531, "text": "METHODS: We assessed clinical outcomes, costs, and cost-effectiveness for the first 3 years in patients who were randomized to surgical decompression or best medical treatment within 48 hours after symptom onset in the Hemicraniectomy After Middle Cerebral Artery Infarction With Life-Threatening Edema Trial (HAMLET). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943217", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Surgical decompression for space-occupying cerebral infarction: outcomes at 3 years in the randomized HAMLET trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868265", "endSection": "title"}, {"offsetInBeginSection": 172, "offsetInEndSection": 413, "text": "METHODS: Patients with space-occupying hemispheric infarction, who were enrolled in the Hemicraniectomy After Middle cerebral artery infarction with Life-threatening Edema Trial within 4 days after stroke onset, were followed up at 3 years. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868265", "endSection": "abstract"}, {"offsetInBeginSection": 263, "offsetInEndSection": 622, "text": "We studied differences in recall of information and in appreciation of the informed consent procedure between representatives included in the Hemicraniectomy After Middle cerebral artery infarction with Life-threatening Edema Trial (HAMLET) and representatives of patients participating in the randomised trial of Paracetamol (Acetaminophen) In Stroke (PAIS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17400593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Hemicraniectomy after middle cerebral artery infarction with life-threatening Edema trial (HAMLET).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965617", "endSection": "title"}, {"offsetInBeginSection": 381, "offsetInEndSection": 577, "text": "This study is designed to compare the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965617", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 717, "text": "The 'Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial' (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14723030", "endSection": "abstract"}, {"offsetInBeginSection": 212, "offsetInEndSection": 531, "text": "METHODS: We assessed clinical outcomes, costs, and cost-effectiveness for the first 3 years in patients who were randomized to surgical decompression or best medical treatment within 48 hours after symptom onset in the Hemicraniectomy After Middle Cerebral Artery Infarction With Life-Threatening Edema Trial (HAMLET). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943217", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 717, "text": "The 'Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial' (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14723030", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 494, "text": "The aim of HAMLET was to assess the effect of decompressive surgery within 4 days of the onset of symptoms in patients with space-occupying hemispheric infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19269254", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 717, "text": "The 'Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial' (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14723030", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 494, "text": "The aim of HAMLET was to assess the effect of decompressive surgery within 4 days of the onset of symptoms in patients with space-occupying hemispheric infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19269254", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 717, "text": "The 'Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial' (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14723030", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 494, "text": "The aim of HAMLET was to assess the effect of decompressive surgery within 4 days of the onset of symptoms in patients with space-occupying hemispheric infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19269254", "endSection": "abstract"}, {"offsetInBeginSection": 375, "offsetInEndSection": 717, "text": "The 'Hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial' (HAMLET) is a newly-conceived randomised multi-centre clinical trial that compares the efficacy of decompressive surgery to improve functional outcome with that of conservative treatment in patients with space-occupying supratentorial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14723030", "endSection": "abstract"}, {"offsetInBeginSection": 331, "offsetInEndSection": 494, "text": "The aim of HAMLET was to assess the effect of decompressive surgery within 4 days of the onset of symptoms in patients with space-occupying hemispheric infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19269254", "endSection": "abstract"}]}, {"body": "What is the role played by mTOR in hypertrophic response and heart failure?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20644257"], "triples": [], "ideal_answer": "When subjected to pressure overload, mTOR-ablated mice demonstrated an impaired hypertrophic response and accelerated heart failure progression. Thus, mTOR complex 1 signaling plays an important role in myocardial response to stress, to regulate cardiomyocyte viability and heart failure.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006333", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054144", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058570", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002312", "http://www.uniprot.org/uniprot/MTOR_HUMAN", "http://www.disease-ontology.org/api/metadata/DOID:9775", "http://www.disease-ontology.org/api/metadata/DOID:11984", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206"], "type": "summary", "id": "5319a80fb166e2b80600002b", "snippets": [{"offsetInBeginSection": 212, "offsetInEndSection": 287, "text": "Myocardial MTOR activity changes during hypertrophy and heart failure (HF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644257", "endSection": "abstract"}, {"offsetInBeginSection": 794, "offsetInEndSection": 927, "text": "When subjected to pressure overload, Mtor-ablated mice demonstrated an impaired hypertrophic response and accelerated HF progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644257", "endSection": "abstract"}, {"offsetInBeginSection": 1068, "offsetInEndSection": 1486, "text": "Our results demonstrate a role for the MTORC1 signaling network in the myocardial response to stress. In particular, they highlight the role of 4E-BP1 in regulating cardiomyocyte viability and in HF. Because the effects of reduced MTOR activity were mediated through increased 4E-BP1 inhibitory activity, blunting this mechanism may represent a novel therapeutic strategy for improving cardiac function in clinical HF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644257", "endSection": "abstract"}]}, {"body": "What is apelin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25965959", "http://www.ncbi.nlm.nih.gov/pubmed/25931124", "http://www.ncbi.nlm.nih.gov/pubmed/26491547", "http://www.ncbi.nlm.nih.gov/pubmed/26149233", "http://www.ncbi.nlm.nih.gov/pubmed/25491175", "http://www.ncbi.nlm.nih.gov/pubmed/25668242", "http://www.ncbi.nlm.nih.gov/pubmed/25711427", "http://www.ncbi.nlm.nih.gov/pubmed/25362565", "http://www.ncbi.nlm.nih.gov/pubmed/25380625", "http://www.ncbi.nlm.nih.gov/pubmed/25486928"], "triples": [], "ideal_answer": ["Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor."], "exact_answer": [["Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor."]], "concepts": [], "type": "factoid", "id": "56e6dfc2edfc094c1f000003", "snippets": [{"offsetInBeginSection": 115, "offsetInEndSection": 215, "text": "Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25965959", "endSection": "abstract"}, {"offsetInBeginSection": 247, "offsetInEndSection": 334, "text": "Apelin is an adipocyte-derived hormone that plays important roles in energy metabolism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25931124", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 248, "text": "Apelin, as the endogenous ligand of G protein-coupled receptor APJ, participates in a number of physiological and pathological processes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26491547", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Apelin is a novel bioactive peptide as the endogenous ligand for APJ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149233", "endSection": "abstract"}, {"offsetInBeginSection": 36, "offsetInEndSection": 53, "text": "adipokine apelin ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25491175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Apelin is the endogenous ligand of the APJ receptor, a member of the G protein-coupled receptor family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25668242", "endSection": "abstract"}, {"offsetInBeginSection": 857, "offsetInEndSection": 1019, "text": "To date four adipokines (leptin, visfatin, apelin and ghrelin) have been investigated and all affect myometrial contractility, but some more potently than others.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25711427", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "The adipocytokine apelin is a peptide, Apelin and its receptor are abundantly expressed in the nervous and cardiovascular systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25362565", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The aim of this study was to determine the levels of regulatory peptides apelin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25380625", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 432, "text": "Apelin is a vaso-dilatory peptide that also has a modulatory role in pain processing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25486928", "endSection": "abstract"}]}, {"body": "Is the transcriptional regulator BACH1 an activator or a repressor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21555518", "http://www.ncbi.nlm.nih.gov/pubmed/20501657", "http://www.ncbi.nlm.nih.gov/pubmed/23562577", "http://www.ncbi.nlm.nih.gov/pubmed/22698995", "http://www.ncbi.nlm.nih.gov/pubmed/22107958", "http://www.ncbi.nlm.nih.gov/pubmed/21812759", "http://www.ncbi.nlm.nih.gov/pubmed/20388958", "http://www.ncbi.nlm.nih.gov/pubmed/20345481", "http://www.ncbi.nlm.nih.gov/pubmed/20127796", "http://www.ncbi.nlm.nih.gov/pubmed/19897490", "http://www.ncbi.nlm.nih.gov/pubmed/19439223", "http://www.ncbi.nlm.nih.gov/pubmed/19282658", "http://www.ncbi.nlm.nih.gov/pubmed/19119918", "http://www.ncbi.nlm.nih.gov/pubmed/19011633", "http://www.ncbi.nlm.nih.gov/pubmed/18555605", "http://www.ncbi.nlm.nih.gov/pubmed/18426999", "http://www.ncbi.nlm.nih.gov/pubmed/17942419", "http://www.ncbi.nlm.nih.gov/pubmed/17701549", "http://www.ncbi.nlm.nih.gov/pubmed/17257585", "http://www.ncbi.nlm.nih.gov/pubmed/16894358", "http://www.ncbi.nlm.nih.gov/pubmed/16724942", "http://www.ncbi.nlm.nih.gov/pubmed/16530877", "http://www.ncbi.nlm.nih.gov/pubmed/16487043", "http://www.ncbi.nlm.nih.gov/pubmed/15855052", "http://www.ncbi.nlm.nih.gov/pubmed/15743416", "http://www.ncbi.nlm.nih.gov/pubmed/15734732", "http://www.ncbi.nlm.nih.gov/pubmed/15613547", "http://www.ncbi.nlm.nih.gov/pubmed/15464985", "http://www.ncbi.nlm.nih.gov/pubmed/15175654", "http://www.ncbi.nlm.nih.gov/pubmed/15068251", "http://www.ncbi.nlm.nih.gov/pubmed/14660636", "http://www.ncbi.nlm.nih.gov/pubmed/14580148", "http://www.ncbi.nlm.nih.gov/pubmed/14504288", "http://www.ncbi.nlm.nih.gov/pubmed/12511571", "http://www.ncbi.nlm.nih.gov/pubmed/12356737", "http://www.ncbi.nlm.nih.gov/pubmed/11387216"], "triples": [], "ideal_answer": "BACH1 is, in most contexts, a transcriptional repressor", "exact_answer": ["Repressor"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050976", "http://www.uniprot.org/uniprot/BACH1_MOUSE", "http://www.uniprot.org/uniprot/BACH1_HUMAN", "http://www.uniprot.org/uniprot/FANCJ_HUMAN", "http://www.uniprot.org/uniprot/FANCJ_MOUSE"], "type": "factoid", "id": "52fa6ac72059c6d71c000055", "snippets": [{"offsetInBeginSection": 948, "offsetInEndSection": 995, "text": "the impact of BACH1 repression on transcription", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21555518", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 268, "text": "Bach1 is a repressor of the oxidative stress response", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501657", "endSection": "abstract"}, {"offsetInBeginSection": 2113, "offsetInEndSection": 2147, "text": "transcriptional repressor Bach-1, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23562577", "endSection": "abstract"}, {"offsetInBeginSection": 423, "offsetInEndSection": 475, "text": "Bach1, a transcriptional repressor of the HMOX1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22698995", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 315, "text": "The mechanism underlying Bach1-mediated HO-1 repression is less well understood", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107958", "endSection": "abstract"}, {"offsetInBeginSection": 715, "offsetInEndSection": 905, "text": "Transcription factor BACH1 [BTB (broad-complex, tramtrack and bric-a-brac) and CNC (cap'n'collar protein) homology 1] binds to ARE-like sequences, functioning as a transcriptional repressor ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759", "endSection": "abstract"}, {"offsetInBeginSection": 23, "offsetInEndSection": 87, "text": "Bach1) is a transcriptional repressor of heme oxygenase-1 (HO-1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20388958", "endSection": "abstract"}, {"offsetInBeginSection": 346, "offsetInEndSection": 437, "text": " its regulatory mechanism by the transcriptional repressor, BTB and CNC homology 1 (Bach1),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345481", "endSection": "abstract"}, {"offsetInBeginSection": 88, "offsetInEndSection": 201, "text": "Bach1, a basic leucine zipper mammalian transcriptional repressor, negatively regulates heme oxygenase 1 (HMOX1),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20127796", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 295, "text": "Bach1, the negative regulator of Nrf2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897490", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 72, "text": "ach1 is a transcriptional repressor of the heme oxygenase (HO)-1 gene. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19439223", "endSection": "abstract"}, {"offsetInBeginSection": 1570, "offsetInEndSection": 1668, "text": "The inhibitory role for Bach1 may stem from its activity to repress gene expression including HO-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19282658", "endSection": "abstract"}, {"offsetInBeginSection": 228, "offsetInEndSection": 290, "text": "Bach1 is a transcriptional repressor of the HO-1 gene (Hmox-1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19119918", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 413, "text": "Here we show that the transcription factor Bach1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1), which inhibits oxidative stress-inducible genes, is a crucial negative regulator of oxidative stress-induced cellular senescence", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19011633", "endSection": "abstract"}, {"offsetInBeginSection": 374, "offsetInEndSection": 427, "text": "Bach1 is a transcriptional repressor of the HO-1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555605", "endSection": "abstract"}, {"offsetInBeginSection": 1590, "offsetInEndSection": 1645, "text": "Bach1 repressively controls myocardial HO-1 expression ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18426999", "endSection": "abstract"}, {"offsetInBeginSection": 202, "offsetInEndSection": 263, "text": " the transcriptional repressor BACH1 binds ARE-like enhancers", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17942419", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 123, "text": " transcription factor Bach1 functions as a repressor of the enhancers of heme oxygenase-1 (HO-1) gene (Hmox-1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17701549", "endSection": "abstract"}, {"offsetInBeginSection": 238, "offsetInEndSection": 297, "text": "Bach1, a transcription factor that suppresses the HO-1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17257585", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 742, "text": "Bach1, a transcriptional repressor that is negatively regulated by heme in mammalian cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16894358", "endSection": "abstract"}, {"offsetInBeginSection": 1142, "offsetInEndSection": 1184, "text": "Bach1 normally represses HO-1 expression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16724942", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 300, "text": "Bach1, a heme binding protein that represses gene expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16530877", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1137, "text": "complexes with Bach1 repress MARE-dependent gene expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16487043", "endSection": "abstract"}, {"offsetInBeginSection": 24, "offsetInEndSection": 55, "text": "transcriptional repressor Bach1", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15855052", "endSection": "title"}, {"offsetInBeginSection": 469, "offsetInEndSection": 525, "text": "bach1-ablation resulted in increased expression of HO-1 ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15743416", "endSection": "abstract"}, {"offsetInBeginSection": 1478, "offsetInEndSection": 1541, "text": "Bach1 contributes to the down-regulation of ARE-regulated genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15734732", "endSection": "abstract"}, {"offsetInBeginSection": 1361, "offsetInEndSection": 1458, "text": "evidence that BACH1 acts as a transcriptional repressor in the regulation of MARE-dependent genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15613547", "endSection": "abstract"}, {"offsetInBeginSection": 27, "offsetInEndSection": 150, "text": "Bach1 forms a heterodimer with small Maf family, and functions as a repressor of the Maf recognition element (MARE) in vivo", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15464985", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 79, "text": "ach1 is a transcriptional repressor of heme oxygenase-1 and beta-globin genes,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15175654", "endSection": "abstract"}, {"offsetInBeginSection": 1460, "offsetInEndSection": 1494, "text": "BACH1 suppresses expression of HO1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15068251", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 138, "text": "transcription factor Bach1 heterodimerizes with small Maf proteins to repress Maf recognition element (MARE)-dependent gene expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14660636", "endSection": "abstract"}, {"offsetInBeginSection": 901, "offsetInEndSection": 994, "text": " Bach1 as a heme-regulated and hypoxia-inducible repressor for transcription of the HO-1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14580148", "endSection": "abstract"}, {"offsetInBeginSection": 34, "offsetInEndSection": 93, "text": "Bach1, a transcriptional repressor of heme oxygenase-1 gene", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14504288", "endSection": "title"}, {"offsetInBeginSection": 570, "offsetInEndSection": 619, "text": "Bach1, a heme-regulated transcriptional repressor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12511571", "endSection": "abstract"}, {"offsetInBeginSection": 238, "offsetInEndSection": 313, "text": "a heme-binding factor, Bach1, is a critical physiological repressor of ho-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12356737", "endSection": "abstract"}, {"offsetInBeginSection": 80, "offsetInEndSection": 109, "text": "transcription repressor Bach1", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11387216", "endSection": "title"}]}, {"body": "How is CBX1/M31 related to position-effect variegation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10779362", "http://www.ncbi.nlm.nih.gov/pubmed/10581035", "http://www.ncbi.nlm.nih.gov/pubmed/10516442", "http://www.ncbi.nlm.nih.gov/pubmed/10202156", "http://www.ncbi.nlm.nih.gov/pubmed/10671371", "http://www.ncbi.nlm.nih.gov/pubmed/1543904"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/umls/id/C2350241", "o": "http://linkedlifedata.com/resource/umls/id/C2350240"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2350240", "o": "http://linkedlifedata.com/resource/umls/label/A15579257"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C2350241", "o": "http://linkedlifedata.com/resource/umls/label/A15579258"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2350241", "o": "http://linkedlifedata.com/resource/umls/label/A15579258"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2350240", "o": "http://linkedlifedata.com/resource/umls/label/A15585170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15579258", "o": "Position Effect Variegation"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15583201", "o": "Position Effect, Chromosomal"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15579257", "o": "Chromosomal Position Effects"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C2350240", "o": "http://linkedlifedata.com/resource/umls/label/A15585171"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C2350240", "o": "http://linkedlifedata.com/resource/umls/label/A15579257"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15585171", "o": "Chromosomal Position Effect"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2350240", "o": "http://linkedlifedata.com/resource/umls/label/A15583201"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15585170", "o": "Position Effects, Chromosomal"}], "ideal_answer": "M31 is a heterochromatin component, that is concentrated in the XY body during spermatogenesis. M31 overexpression has two contrasting effects which are dependent on chromosomal context: (i) it enhanced PEV in those lines with centromeric or pericentromeric transgene locations; and (ii) it suppressed PEV when the transgene was non-centromeric.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055012", "http://www.biosemantics.org/jochem#4262550", "http://www.uniprot.org/uniprot/CBX1_HUMAN", "http://www.uniprot.org/uniprot/CBX1_MOUSE", "http://www.uniprot.org/uniprot/HXC8_MOUSE"], "type": "summary", "id": "530d7e8a38c1322806000001", "snippets": [{"offsetInBeginSection": 476, "offsetInEndSection": 650, "text": "First, forced expression of full-length SUV39H1 (412 amino acids) redistributes endogenous M31 (HP1beta) and induces abundant associations with inter- and metaphase chromatin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779362", "endSection": "abstract"}, {"offsetInBeginSection": 1456, "offsetInEndSection": 1669, "text": "Together, our data reveal a dominant role(s) for the SET domain of SUV39H1 in the distribution of prominent heterochromatic proteins and suggest a possible link between a chromosomal SU(VAR) protein and histone H3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779362", "endSection": "abstract"}, {"offsetInBeginSection": 381, "offsetInEndSection": 535, "text": "Using this motif, termed chromo box, we have cloned a mouse candidate modifier gene, M31, that also shows considerable sequence homology to Drosophila HP1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1543904", "endSection": "abstract"}, {"offsetInBeginSection": 537, "offsetInEndSection": 775, "text": "Here we report evidence of at least four independently segregating loci in the mouse homologous to the M31 cDNA. One of these loci--Cbx-rs1--maps to the X Chromosome (Chr), 1 cM proximal to Amg and outside the X-inactivation center region", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1543904", "endSection": "abstract"}, {"offsetInBeginSection": 625, "offsetInEndSection": 905, "text": "Although there is significant heterochromatic overlap between SUV39H1 and M31 (HP1(beta)) during interphase, mitotic SUV39H1 displays a more restricted spatial and temporal association pattern with metaphase chromosomes than M31 (HP1(beta)), or the related HP1(&agr;) gene product", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10671371", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 165, "text": "which complex with the heterochromatin component M31.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10202156", "endSection": "title"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1097, "text": "In addition, Suv39h1/SUV39H1 proteins associate with M31, currently the only other characterized mammalian SU(VAR) homologue", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10202156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "M31, a murine homolog of Drosophila HP1, is concentrated in the XY body during spermatogenesis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10516442", "endSection": "title"}, {"offsetInBeginSection": 328, "offsetInEndSection": 530, "text": "The HP1 class of chromobox genes are thought to encode proteins involved in the packaging of chromosomal DNA into repressive heterochromatin domains, as seen, for example, in position-effect variegation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10516442", "endSection": "abstract"}, {"offsetInBeginSection": 532, "offsetInEndSection": 780, "text": "Study of the distribution of a murine HP1-like chromodomain protein, M31, during spermatogenesis revealed spreading from the tip of the XY body in mid-stage pachytene spermatocytes to include the whole of the XY body in late-pachytene spermatocytes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10516442", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 958, "text": "We also demonstrate that the formation of the XY body during spermatogenic progression in neonatal mice coincides with the expression of a novel nuclear isoform of M31, M31(p21", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10516442", "endSection": "abstract"}, {"offsetInBeginSection": 623, "offsetInEndSection": 897, "text": "Furthermore, by overexpressing a mammalian homologue (M31) of Drosophila melanogaster heterochromatin protein 1 (HP1; refs 7,8) in transgenic mouse lines that exhibit PEV, it is possible to modify the proportion of cells that silence the transgene in a dose-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10581035", "endSection": "abstract"}, {"offsetInBeginSection": 899, "offsetInEndSection": 1165, "text": "Thus, we show M31 overexpression to have two contrasting effects which are dependent on chromosomal context: (i) it enhanced PEV in those lines with centromeric or pericentromeric transgene locations; and (ii) it suppressed PEV when the transgene was non-centromeric", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10581035", "endSection": "abstract"}]}, {"body": "Which kinase is inhibited by the small molecule KN-93?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22290426", "http://www.ncbi.nlm.nih.gov/pubmed/21187407", "http://www.ncbi.nlm.nih.gov/pubmed/17457979", "http://www.ncbi.nlm.nih.gov/pubmed/16896952", "http://www.ncbi.nlm.nih.gov/pubmed/15569687", "http://www.ncbi.nlm.nih.gov/pubmed/15175389", "http://www.ncbi.nlm.nih.gov/pubmed/14749212", "http://www.ncbi.nlm.nih.gov/pubmed/11827960", "http://www.ncbi.nlm.nih.gov/pubmed/11248432", "http://www.ncbi.nlm.nih.gov/pubmed/11164895", "http://www.ncbi.nlm.nih.gov/pubmed/9864285", "http://www.ncbi.nlm.nih.gov/pubmed/9596994", "http://www.ncbi.nlm.nih.gov/pubmed/8939965", "http://www.ncbi.nlm.nih.gov/pubmed/7690557", "http://www.ncbi.nlm.nih.gov/pubmed/1662507", "http://www.ncbi.nlm.nih.gov/pubmed/10712242"], "triples": [], "ideal_answer": ["The calcium/calmodulin-dependent protein kinase-II (CaMK-II) is inhibited by the small molecule KN-93. KN-93 is a membrane-permeant calcium/calmodulin- dependent kinase II (CaMK-II)-selective inhibitor"], "exact_answer": [["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"]], "concepts": ["http://www.biosemantics.org/jochem#4263678", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007266"], "type": "factoid", "id": "54f89e1a06d9727f76000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "KN-93, a membrane-permeant calcium/calmodulin- dependent kinase-selective inhibitor, induces apoptosis in some lines of human tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22290426", "endSection": "abstract"}, {"offsetInBeginSection": 494, "offsetInEndSection": 707, "text": "Knockdown of \u03b2CaMKII by lentiviral-mediated expression of shRNA prevented the synaptic inactivity-induced increase in GluA1, as did treatment with the CaM kinase inhibitor KN-93, but not the inactive analog KN-92.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187407", "endSection": "abstract"}, {"offsetInBeginSection": 5, "offsetInEndSection": 167, "text": "To investigate the effects of KN-93, a CaMKII selective inhibitor on cell proliferation and the expression of p53 or p21 protein in human hepatic stellate cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17457979", "endSection": "abstract"}, {"offsetInBeginSection": 939, "offsetInEndSection": 1113, "text": "Injection of the CaM kinase inhibitor KN-93 into pupae resulted in a reduced number of antennal lobe glial cells migrating into the neuropil to form borders around glomeruli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16896952", "endSection": "abstract"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1172, "text": "In contrast, addition of the intracellular Ca2+ chelator BAPTA-AM or the Ca2+/calmodulin-dependent (CaM) kinase inhibitor KN93 blocked reporter gene activation in response to IH.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15569687", "endSection": "abstract"}, {"offsetInBeginSection": 617, "offsetInEndSection": 761, "text": "These increases in CPEB phosphorylation were attenuated by a specific peptide inhibitor of CaMKII and by the general CaM-kinase inhibitor KN-93.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15175389", "endSection": "abstract"}, {"offsetInBeginSection": 897, "offsetInEndSection": 1141, "text": "Alternatively, treatment with KN-93, a selective inhibitor of CaMKII activation, or adenoviral overexpression of kinase-negative CaMKII-delta(2), inhibited ATP-dependent activation of ERK1/2 but had no effect on PDBu- or PDGF-stimulated ERK1/2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14749212", "endSection": "abstract"}, {"offsetInBeginSection": 425, "offsetInEndSection": 569, "text": "Ca(2+)/CaM-dependent protein kinase inhibitor KN-93 also blocked zygote elongation, while its ineffective analog KN-92 did not have such effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11827960", "endSection": "abstract"}, {"offsetInBeginSection": 263, "offsetInEndSection": 416, "text": "CaM kinase inhibitor KN93 on its own exhibits little toxicity up to 10 mM, as measured by release of lactate dehydrogenase (LDH) into the culture medium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11248432", "endSection": "abstract"}, {"offsetInBeginSection": 424, "offsetInEndSection": 586, "text": "To further elucidate the mechanism by which calcium-induced ERK activation occurs, we used the CaM-kinase inhibitor KN-93 and an inactive analog of KN-93 (KN-92).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11164895", "endSection": "abstract"}, {"offsetInBeginSection": 460, "offsetInEndSection": 598, "text": "Hearts were pretreated with the CaM kinase inhibitor KN-93 or the inactive analog KN-92 (0.5 microM) for 10 min before clofilium exposure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9864285", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "The calmodulin-dependent protein kinase-II (CaMK-II) inhibitor KN-93 has been shown to reversibly arrest mouse and human cells in the G1 phase of the cell cycle", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9596994", "endSection": "abstract"}, {"offsetInBeginSection": 842, "offsetInEndSection": 1009, "text": "NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8939965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7690557", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "KN-93, a membrane-permeant calcium/calmodulin- dependent kinase-selective inhibitor, induces apoptosis in some lines of human tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22290426", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 735, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10712242", "endSection": "abstract"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1164, "text": "In vitro, KN-93 potently inhibited rabbit myocardial CaM kinase activity (calculated Ki", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9864285", "endSection": "abstract"}, {"offsetInBeginSection": 758, "offsetInEndSection": 850, "text": "KN-93 also inhibited the autophosphorylation of both the alpha- and beta-subunits of CaMKII.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1662507", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 734, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10712242", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 734, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10712242", "endSection": "abstract"}, {"offsetInBeginSection": 642, "offsetInEndSection": 734, "text": "CaM kinase II activation was inhibited by KN-93 pretreatment (IC(50) approximately 1 microM)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10712242", "endSection": "abstract"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1238, "text": "In vitro, KN-93 potently inhibited rabbit myocardial CaM kinase activity (calculated Ki </= 2.58 microM), but the inactive analog KN-92 did not (Ki > 100 microM)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9864285", "endSection": "abstract"}]}, {"body": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23404999", "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "http://www.ncbi.nlm.nih.gov/pubmed/22809326", "http://www.ncbi.nlm.nih.gov/pubmed/22426402", "http://www.ncbi.nlm.nih.gov/pubmed/22363588", "http://www.ncbi.nlm.nih.gov/pubmed/22331875", "http://www.ncbi.nlm.nih.gov/pubmed/22227450", "http://www.ncbi.nlm.nih.gov/pubmed/21966475", "http://www.ncbi.nlm.nih.gov/pubmed/21514572", "http://www.ncbi.nlm.nih.gov/pubmed/19433452", "http://www.ncbi.nlm.nih.gov/pubmed/18927485", "http://www.ncbi.nlm.nih.gov/pubmed/18644871", "http://www.ncbi.nlm.nih.gov/pubmed/18635949", "http://www.ncbi.nlm.nih.gov/pubmed/18550537", "http://www.ncbi.nlm.nih.gov/pubmed/17284523", "http://www.ncbi.nlm.nih.gov/pubmed/16585521", "http://www.ncbi.nlm.nih.gov/pubmed/15331765", "http://www.ncbi.nlm.nih.gov/pubmed/12505983", "http://www.ncbi.nlm.nih.gov/pubmed/11208145", "http://www.ncbi.nlm.nih.gov/pubmed/11082038", "http://www.ncbi.nlm.nih.gov/pubmed/10806201", "http://www.ncbi.nlm.nih.gov/pubmed/21429245", "http://www.ncbi.nlm.nih.gov/pubmed/22653298", "http://www.ncbi.nlm.nih.gov/pubmed/19117012", "http://www.ncbi.nlm.nih.gov/pubmed/15325583"], "ideal_answer": ["Chaperone-mediated autophagy (CMA) is a lysosomal pathway for selective removal of damaged cytosolic proteins. The LAMP2A (Lysosome-associated membrane protein 2 isoform A) functions as a receptor for cytosolic proteins and also as essential component of the CMA translocation complex [28]. Cytosolic substrate proteins bind to monomers of LAMP-2A, which then multimerizes to form the complex required for substrate transmembrane import."], "exact_answer": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006914", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0072321", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0038024", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008565", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004872", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001343", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018832"], "type": "factoid", "id": "51bdd9c2047fa84d1d000002", "snippets": [{"offsetInBeginSection": 149, "offsetInEndSection": 346, "text": "These proteins are targeted by chaperones and delivered to lysosomes where they are translocated into the lysosomal lumen and degraded via the lysosome-associated membrane protein type 2A (LAMP-2A)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "sections.0"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1432, "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "endSection": "sections.0"}, {"offsetInBeginSection": 671, "offsetInEndSection": 756, "text": "CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426402", "endSection": "sections.0"}, {"offsetInBeginSection": 747, "offsetInEndSection": 900, "text": "Lysosomes from livers of lipid-challenged mice had a marked decrease in the levels of the CMA receptor, the lysosome-associated membrane protein type 2A,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22331875", "endSection": "sections.0"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1171, "text": "We report that Bcl-2-related early rod apoptosis was associated with the upregulation of autophagy markers including chaperone-mediated autophagy (CMA) substrate receptor LAMP-2", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227450", "endSection": "sections.0"}, {"offsetInBeginSection": 617, "offsetInEndSection": 710, "text": "we examined gene expression levels of lysosome-associated membrane 2 (LAMP-2), a CMA receptor", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514572", "endSection": "sections.0"}, {"offsetInBeginSection": 110, "offsetInEndSection": 236, "text": "The lysosomal-membrane protein type 2A (LAMP-2A) acts as the receptor for the substrates of chaperone-mediated autophagy (CMA)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18927485", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 373, "text": "Chaperone-mediated autophagy (CMA) is a selective type of autophagy by which specific cytosolic proteins are sent to lysosomes for degradation. Substrate proteins bind to the lysosomal membrane through the lysosome-associated membrane protein type 2A (LAMP-2A), one of the three splice variants of the lamp2 gene, and this binding is limiting for their degradation via CMA.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18644871", "endSection": "sections.0"}, {"offsetInBeginSection": 662, "offsetInEndSection": 837, "text": "Substrate proteins only bind to monomeric LAMP-2A, while the efficient translocation of substrates requires the formation of a particular high-molecular-weight LAMP-2A complex", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18644871", "endSection": "sections.0"}, {"offsetInBeginSection": 266, "offsetInEndSection": 394, "text": "We recently reported that UCH-L1 physically interacts with LAMP-2A, the lysosomal receptor for chaperone-mediated autophagy (CMA", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18635949", "endSection": "sections.0"}, {"offsetInBeginSection": 460, "offsetInEndSection": 562, "text": "In this study, we found that UCH-L1 physically interacts with LAMP-2A, the lysosomal receptor for CMA,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550537", "endSection": "sections.0"}, {"offsetInBeginSection": 113, "offsetInEndSection": 406, "text": "We have previously described an age-related decline in chaperone-mediated autophagy (CMA), a selective form of autophagy, by which particular cytosolic proteins are delivered to lysosomes after binding to the lysosome-associated membrane protein type 2A (LAMP-2A), a receptor for this pathway.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17284523", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "Chaperone-mediated autophagy (CMA) is a selective pathway for the degradation of cytosolic proteins in lysosomes. CMA declines with age because of a decrease in the levels of lysosome-associated membrane protein (LAMP) type 2A, a lysosomal receptor for this pathway.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16585521", "endSection": "sections.0"}, {"offsetInBeginSection": 543, "offsetInEndSection": 853, "text": "Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15331765", "endSection": "sections.0"}, {"offsetInBeginSection": 112, "offsetInEndSection": 296, "text": "We now demonstrate that this protease activity triggers the degradation of the lysosome-associated membrane protein type 2a (lamp2a), a receptor for chaperone-mediated autophagy (CMA).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12505983", "endSection": "sections.0"}, {"offsetInBeginSection": 185, "offsetInEndSection": 289, "text": "We have previously identified this receptor as the lysosome-associated membrane protein type 2a (lamp2a)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11208145", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11082038", "endSection": "sections.0"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1111, "text": "These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11082038", "endSection": "sections.0"}, {"offsetInBeginSection": 603, "offsetInEndSection": 760, "text": "A progressive age-related decrease in the levels of the lysosome-associated membrane protein type 2a that acts as a receptor for chaperone-mediated autophagy", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10806201", "endSection": "sections.0"}, {"offsetInBeginSection": 584, "offsetInEndSection": 736, "text": "Hsc70 and Hsp40 are members of a molecular chaperone complex required for protein transport into the lysosome during chaperone-mediated autophagy (CMA).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19117012", "endSection": "sections.0"}, {"offsetInBeginSection": 430, "offsetInEndSection": 696, "text": "Once there, substrate proteins bind to the lysosome-associated membrane protein type 2 isoform A (LAMP2A), inducing assembly of this receptor protein into a higher molecular weight protein complex that is used by the substrate proteins to reach the lysosomal lumen. ", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653298", "endSection": "sections.0"}, {"offsetInBeginSection": 428, "offsetInEndSection": 549, "text": "Protein substrates bind to a receptor in the lysosomal membrane, the lysosome-associated membrane protein (lamp) type 2a.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15325583", "endSection": "sections.0"}]}, {"body": "What is the role of NETs in systemic lupus erythematosus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23267025", "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "http://www.ncbi.nlm.nih.gov/pubmed/22345666", "http://www.ncbi.nlm.nih.gov/pubmed/21389264", "http://www.ncbi.nlm.nih.gov/pubmed/24838349", "http://www.ncbi.nlm.nih.gov/pubmed/24758196", "http://www.ncbi.nlm.nih.gov/pubmed/24205237", "http://www.ncbi.nlm.nih.gov/pubmed/24570026", "http://www.ncbi.nlm.nih.gov/pubmed/24497360", "http://www.ncbi.nlm.nih.gov/pubmed/25500436", "http://www.ncbi.nlm.nih.gov/pubmed/23945056", "http://www.ncbi.nlm.nih.gov/pubmed/24295292", "http://www.ncbi.nlm.nih.gov/pubmed/23224024", "http://www.ncbi.nlm.nih.gov/pubmed/23248629", "http://www.ncbi.nlm.nih.gov/pubmed/21613614", "http://www.ncbi.nlm.nih.gov/pubmed/20439745"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0081309", "o": "D008180"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A12999583", "o": "D008180"}], "ideal_answer": ["Neutrophil extracellular traps (NETs) are released via a novel form of cell death called NETosis. NETs, consisting of a chromatin meshwork decorated with antimicrobial peptides, play an important role in the innate response to microbial infections. Clearance of NETs is impaired in a subset of patients with systemic lupus erythematosus, and NETosis is increased in these patients low-density granulocytes, a phenotype that correlates with disease activity. NETs are composed of secreted chromatin that may act as a source of autoantigens typical for SLE. NETs can directly damage tissues - including the endothelium - with implications for lupus nephritis and accelerated atherosclerosis."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:9074", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008180"], "type": "summary", "id": "56ccccf55795f9a73e000037", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 498, "text": "Neutrophil extracellular traps (NETs) represent an important defense mechanism against microorganisms. Clearance of NETs is impaired in a subset of patients with systemic lupus erythematosus, and NETosis is increased in neutrophils and, particularly, in low-density granulocytes derived from lupus patients. NETs are toxic to the endothelium, expose immunostimulatory molecules, activate plasmacytoid dendritic cells, and may participate in organ damage through incompletely characterized pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23267025", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 755, "text": "Neutrophil extracellular traps (NETs) are released via a novel form of cell death called NETosis. NETs, consisting of a chromatin meshwork decorated with antimicrobial peptides, play an important role in the innate response to microbial infections. Some lupus patients do not clear NETs normally, a phenotype that correlates with disease activity. Further, lupus neutrophils - and, in particular, an aberrant subset called low-density granulocytes - have an increased propensity to undergo NETosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "endSection": "abstract"}, {"offsetInBeginSection": 1032, "offsetInEndSection": 1172, "text": " NETs can also directly damage tissues - including the endothelium - with implications for lupus nephritis and accelerated atherosclerosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "endSection": "abstract"}, {"offsetInBeginSection": 120, "offsetInEndSection": 264, "text": "Antimicrobial neutrophil extracellular traps (NETs) are composed of secreted chromatin that may act as a source of autoantigens typical for SLE.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22345666", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of systemic Lupus erythematosus (SLE), since netting neutrophils release potentially immunogenic autoantigens including histones, LL37, human neutrophil peptide (HNP), and self-DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205237", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Elevated Plasma cfDNA May be Associated with Active Lupus Nephritis and Partially Attributed to Abnormal Regulation of Neutrophil Extracellular Traps (NETs) in Patients with Systemic Lupus Erythematosus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25500436", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "The ability to degrade neutrophil extracellular traps (NETs) is reduced in a subset of patients with systemic lupus erythematosus (SLE)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945056", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "A decreased ability to degrade neutrophil extracellular traps (NETs) is seen in a subgroup of patients with systemic lupus erythematosus (SLE) and correlates with the presence of autoantibodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295292", "endSection": "abstract"}, {"offsetInBeginSection": 411, "offsetInEndSection": 571, "text": "Recent studies have demonstrated that dysregulation of NETs could be involved in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23224024", "endSection": "abstract"}, {"offsetInBeginSection": 415, "offsetInEndSection": 622, "text": "Both exuberant NETosis and impaired clearance of NETs have been implicated in the organ damage of autoimmune diseases, such as systemic lupus erythematosus (SLE), small vessel vasculitis (SVV), and psoriasis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248629", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21613614", "endSection": "title"}, {"offsetInBeginSection": 297, "offsetInEndSection": 781, "text": "Neutrophil extracellular trap (NET) formation is increased in SLE and has been proposed to contribute to endothelial damage, but the mechanism remains unclear.OBJECTIVE: To determine the mechanism by which enhanced NET formation by low-density granulocytes (LDGs) in SLE contributes to endothelial damage and disrupts the endothelium.RESULTS: The putative role of NET-externalised matrix metalloproteinases (MMPs) in altering the functional integrity of the endothelium was examined. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24570026", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 398, "text": "In this study, we investigated how complement interacts with NETs and how NET degradation is affected by complement in SLE patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22345666", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1131, "text": "NETs are a potent stimulus for IFN\u03b1 release by plasmacytoid dendritic cells, and, as such, may play an important role in propagation of the lupus phenotype. NETs can also directly damage tissues - including the endothelium - with implications for lupus nephritis and accelerated atherosclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1902, "text": "Active NOS, NOX, and MPO within NETs significantly modify HDL, rendering the lipoprotein proatherogenic. Since NET formation is enhanced in SLE, these findings support a novel role for NET-derived lipoprotein oxidation in SLE-associated CVD and identify additional proatherogenic roles of neutrophils and putative protective roles of antimalarials in autoimmunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838349", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1902, "text": "Active NOS, NOX, and MPO within NETs significantly modify HDL, rendering the lipoprotein proatherogenic. Since NET formation is enhanced in SLE, these findings support a novel role for NET-derived lipoprotein oxidation in SLE-associated CVD and identify additional proatherogenic roles of neutrophils and putative protective roles of antimalarials in autoimmunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838349", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1131, "text": "NETs are a potent stimulus for IFN\u03b1 release by plasmacytoid dendritic cells, and, as such, may play an important role in propagation of the lupus phenotype. NETs can also directly damage tissues - including the endothelium - with implications for lupus nephritis and accelerated atherosclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1902, "text": "Active NOS, NOX, and MPO within NETs significantly modify HDL, rendering the lipoprotein proatherogenic. Since NET formation is enhanced in SLE, these findings support a novel role for NET-derived lipoprotein oxidation in SLE-associated CVD and identify additional proatherogenic roles of neutrophils and putative protective roles of antimalarials in autoimmunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838349", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1902, "text": "Active NOS, NOX, and MPO within NETs significantly modify HDL, rendering the lipoprotein proatherogenic. Since NET formation is enhanced in SLE, these findings support a novel role for NET-derived lipoprotein oxidation in SLE-associated CVD and identify additional proatherogenic roles of neutrophils and putative protective roles of antimalarials in autoimmunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838349", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1131, "text": "NETs are a potent stimulus for IFN\u03b1 release by plasmacytoid dendritic cells, and, as such, may play an important role in propagation of the lupus phenotype. NETs can also directly damage tissues - including the endothelium - with implications for lupus nephritis and accelerated atherosclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1902, "text": "Active NOS, NOX, and MPO within NETs significantly modify HDL, rendering the lipoprotein proatherogenic. Since NET formation is enhanced in SLE, these findings support a novel role for NET-derived lipoprotein oxidation in SLE-associated CVD and identify additional proatherogenic roles of neutrophils and putative protective roles of antimalarials in autoimmunity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838349", "endSection": "abstract"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1131, "text": "NETs are a potent stimulus for IFN\u03b1 release by plasmacytoid dendritic cells, and, as such, may play an important role in propagation of the lupus phenotype. NETs can also directly damage tissues - including the endothelium - with implications for lupus nephritis and accelerated atherosclerosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22617827", "endSection": "abstract"}]}, {"body": "The drug JTV519 is derivative of which group of chemical compounds?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22509897", "http://www.ncbi.nlm.nih.gov/pubmed/23349825", "http://www.ncbi.nlm.nih.gov/pubmed/21989257", "http://www.ncbi.nlm.nih.gov/pubmed/17313373", "http://www.ncbi.nlm.nih.gov/pubmed/17112502", "http://www.ncbi.nlm.nih.gov/pubmed/15073377", "http://www.ncbi.nlm.nih.gov/pubmed/12551874", "http://www.ncbi.nlm.nih.gov/pubmed/12433661", "http://www.ncbi.nlm.nih.gov/pubmed/12359358", "http://www.ncbi.nlm.nih.gov/pubmed/11757794", "http://www.ncbi.nlm.nih.gov/pubmed/11429046", "http://www.ncbi.nlm.nih.gov/pubmed/11101196", "http://www.ncbi.nlm.nih.gov/pubmed/10864882", "http://www.ncbi.nlm.nih.gov/pubmed/10789707", "http://www.ncbi.nlm.nih.gov/pubmed/10683355"], "triples": [], "ideal_answer": ["JTV519 (K201), is a 1,4-benzothiazepine derivative and multi-channel blocker, which has been found to stabilize RyR2s and decrease SR Ca\u00b2\u207a leak.", "The 1,4-benzothiazepine derivative JTV-519 is a new type of calcium ion channel modulator.JTV-519, which has potential use as an antiarrhythmic [285800]. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998", "The 1,4-benzothiazepine derivative JTV-519 is a new type of calcium ion channel modulator.JTV-519, which has potential use as an antiarrhythmic [285800]. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998"], "exact_answer": [["1,4-benzothiazepine", "benzothiazepine"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=chemicals_and_drugs_category", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004339"], "type": "factoid", "id": "54f9b74306d9727f76000004", "snippets": [{"offsetInBeginSection": 202, "offsetInEndSection": 341, "text": "In these conditions, JTV519 (K201), a 1,4-benzothiazepine derivative and multi-channel blocker, stabilizes RyR2s and decrease SR Ca\u00b2\u207a leak.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22509897", "endSection": "abstract"}, {"offsetInBeginSection": 284, "offsetInEndSection": 514, "text": "The 1,4-benzothiazepine derivative JTV519, and the more specific derivative S107 (2,3,4,5,-tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine), are thought to improve skeletal muscle function by stabilizing the RyR1-FKBP12 complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349825", "endSection": "abstract"}, {"offsetInBeginSection": 198, "offsetInEndSection": 491, "text": "In this article, we synthesize derivatives of the channel activator 4-chloro-3-methyl phenol (4-CmC) and the 1,4-benzothiazepine channel inhibitor 4-[-3{1-(4-benzyl) piperidinyl}propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine (K201, JTV519) with enhanced electron donor properties.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21989257", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "K201 (JTV519), a benzothiazepine derivative, has been shown to possess anti-arrhythmic and cardioprotective properties, but the mechanism of its action is both complex and controversial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17313373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "K201 (JTV519) is a 1,4-benzothiazepine derivative that exhibits a strong cardioprotective action and acts as a multiple-channel blocker, including as a K+ channel blocker.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17112502", "endSection": "abstract"}, {"offsetInBeginSection": 456, "offsetInEndSection": 644, "text": "A derivative of 1,4-benzothiazepine (JTV519) increased the affinity of calstabin2 for RyR2, which stabilized the closed state of RyR2 and prevented the Ca2+ leak that triggers arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15073377", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 396, "text": "We report that a new drug, the 1,4-benzothiazepine derivative JTV519, reverses this pathogenic process. JTV519 is known to have a protective effect against Ca2+ overload-induced myocardial injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12551874", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1066, "text": "In conclusion, JTV519, a new 1,4-benzothiazepine derivative, corrected the defective channel gating in RyR (increase in both the rapid conformational change and the subsequent Ca(2+) release rate) in HF.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12433661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "A newly synthesized 1,4-benzothiazipine derivate, 4-[3-(4-benzylpiperidin-1-yl) propionyl]-7-methoxy-2,3,4,5-tetrahydro-1, 4-benzothiazepine monohydrochloride (JTV-519) was examined for its ability to reverse P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1) mediated multidrug resistance (MDR) in K562/MDR and KB/MRP cells, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12359358", "endSection": "abstract"}, {"offsetInBeginSection": 66, "offsetInEndSection": 269, "text": "JTV-519, which has potential use as an antiarrhythmic [285800]. The drug is a novel cardioprotectant derivative of 1,4-benzothiazepine for which phase I trials were completed in the third quarter of 1998", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11757794", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "The 1,4-benzothiazepine derivative JTV-519 is a new type of calcium ion channel modulator.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11429046", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "A new 1,4-benzothiazepine derivative, JTV519 (JTV), has strong protective effects against isoproterenol-induced myocardial injury. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101196", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "A newly synthesized benzothiazepine derivative, JTV-519 (JT) has been reported to be cardioprotective.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10864882", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Protective effect of JTV519, a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10789707", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 139, "text": "A new 1,4-benzothiazepine derivative, JTV519, has a strong protective effect against Ca(2+) overload-induced myocardial injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10683355", "endSection": "abstract"}, {"offsetInBeginSection": 185, "offsetInEndSection": 289, "text": " We report that a new drug, the 1,4-benzothiazepine derivative JTV519, reverses this pathogenic process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12551874", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Protective effect of JTV519, a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10789707", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "A new 1,4-benzothiazepine derivative, JTV519 (JTV), has strong protective effects against isoproterenol-induced myocardial injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101196", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "A new 1,4-benzothiazepine derivative, JTV519, has a strong protective effect against Ca(2+) overload-induced myocardial injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10683355", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 315, "text": " In these conditions, JTV519 (K201), a 1,4-benzothiazepine derivative and multi-channel blocker, stabilizes RyR2s and decrease SR Ca?\u207a leak.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22509897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat hearts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101196", "endSection": "title"}, {"offsetInBeginSection": 202, "offsetInEndSection": 341, "text": "In these conditions, JTV519 (K201), a 1,4-benzothiazepine derivative and multi-channel blocker, stabilizes RyR2s and decrease SR Ca\u00b2\u207a leak.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22509897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Protective effect of JTV519, a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10789707", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat hearts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101196", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "A new 1,4-benzothiazepine derivative, JTV519 (JTV), has strong protective effects against isoproterenol-induced myocardial injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11101196", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "K201 (JTV519) is a 1,4-benzothiazepine derivative that exhibits a strong cardioprotective action and acts as a multiple-channel blocker, including as a K+ channel blocker.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17112502", "endSection": "abstract"}, {"offsetInBeginSection": 456, "offsetInEndSection": 644, "text": "A derivative of 1,4-benzothiazepine (JTV519) increased the affinity of calstabin2 for RyR2, which stabilized the closed state of RyR2 and prevented the Ca2+ leak that triggers arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15073377", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "K201 (JTV519), a benzothiazepine derivative, has been shown to possess anti-arrhythmic and cardioprotective properties, but the mechanism of its action is both complex and controversial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17313373", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Protective effect of JTV519, a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10789707", "endSection": "title"}, {"offsetInBeginSection": 188, "offsetInEndSection": 290, "text": "We report that a new drug, the 1,4-benzothiazepine derivative JTV519, reverses this pathogenic process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12551874", "endSection": "abstract"}]}, {"body": "What is the Timothy syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23313911", "http://www.ncbi.nlm.nih.gov/pubmed/23299782", "http://www.ncbi.nlm.nih.gov/pubmed/22999068", "http://www.ncbi.nlm.nih.gov/pubmed/22990809", "http://www.ncbi.nlm.nih.gov/pubmed/24215710", "http://www.ncbi.nlm.nih.gov/pubmed/23690510", "http://www.ncbi.nlm.nih.gov/pubmed/23678275", "http://www.ncbi.nlm.nih.gov/pubmed/23580742", "http://www.ncbi.nlm.nih.gov/pubmed/22120178", "http://www.ncbi.nlm.nih.gov/pubmed/22106044", "http://www.ncbi.nlm.nih.gov/pubmed/21910241", "http://www.ncbi.nlm.nih.gov/pubmed/21878566", "http://www.ncbi.nlm.nih.gov/pubmed/21700933", "http://www.ncbi.nlm.nih.gov/pubmed/21307850", "http://www.ncbi.nlm.nih.gov/pubmed/20301577", "http://www.ncbi.nlm.nih.gov/pubmed/19916019", "http://www.ncbi.nlm.nih.gov/pubmed/19001023", "http://www.ncbi.nlm.nih.gov/pubmed/18536931", "http://www.ncbi.nlm.nih.gov/pubmed/18250309", "http://www.ncbi.nlm.nih.gov/pubmed/17467634", "http://www.ncbi.nlm.nih.gov/pubmed/21915623", "http://www.ncbi.nlm.nih.gov/pubmed/21685391"], "triples": [], "ideal_answer": "Timothy syndrome is a multisystem disorder characterized by cardiac, hand/foot, facial, and neurodevelopmental features. The two forms are type 1 (classic) and type 2, a rare form caused by mutations in a transcript variant of the same gene. Cardiac findings include a rate-corrected QT interval of between 480 ms and 700 ms and congenital heart defects (patent ductus arteriosus, patent foramen ovale, ventricular septal defect, tetralogy of Fallot, hypertrophic cardiomyopathy). Hand/foot findings are unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three. Facial findings include flat nasal bridge, low-set ears, thin upper lip, and round face. Neuropsychiatric involvement includes global developmental delays and autism spectrum disorders. Ventricular tachyarrhythmia is the leading cause of death, followed by infection and complications of intractable hypoglycemia. Average age of death is 2.5 years.", "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0060173"], "type": "summary", "id": "53173fc5b166e2b806000006", "snippets": [{"offsetInBeginSection": 133, "offsetInEndSection": 284, "text": "A point mutation in the gene encoding Ca(V)1.2 causes Timothy syndrome, a neurodevelopmental disorder associated with autism spectrum disorders (ASDs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313911", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 577, "text": "o circumvent this issue, we have developed a method using human-induced pluripotent stem cells to generate cardiomyocytes from individuals with Timothy syndrome (TS), a genetic disorder characterized by QT prolongation, ventricular tachycardia, and autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299782", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 472, "text": "Two de novo point mutations of Ca(v)1.2 glycine residues, G406R and G402S, cause a rare multisystem disorder called Timothy syndrome (TS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22999068", "endSection": "abstract"}, {"offsetInBeginSection": 473, "offsetInEndSection": 693, "text": "Here, we discuss recent work on the mechanisms by which Ca(v)1.2 channels bearing TS mutations display slowed inactivation that leads to increased Ca(2+) influx, prolonging the cardiac AP and promoting lethal arrhythmias", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22999068", "endSection": "abstract"}, {"offsetInBeginSection": 586, "offsetInEndSection": 669, "text": "Timothy syndrome is a human genetic disorder due to mutations in the Ca(V)1.2 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990809", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 390, "text": "Timothy syndrome (TS) is a disease caused by a gain-of-function mutation in the CaV1.2 channel (CaV1.2-TS) that decreases inactivation of the channel, which increases Ca(2+) influx, prolongs APs, and causes lethal arrhythmias. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24215710", "endSection": "abstract"}, {"offsetInBeginSection": 146, "offsetInEndSection": 414, "text": "Recent reports suggest that parental mosaicism is involved in the heritability of type 1 Timothy syndrome (TS1), an extremely rare and life-threatening multisystem disorder characterized by severe QT interval prolongation, syndactyly, and several other complications. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23690510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Timothy syndrome, long QT syndrome type 8, is highly malignant with ventricular tachyarrhythmia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23678275", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 144, "text": "Timothy syndrome (TS) is a rare long-QT syndrome caused by CACNA1C mutations G406R in exon 8A (TS1) and G402S/G406R in exon 8 (TS2).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580742", "endSection": "abstract"}, {"offsetInBeginSection": 179, "offsetInEndSection": 323, "text": "Timothy syndrome is caused by a missense mutation in the L-type calcium channel Ca(v)1.2 that is associated with developmental delay and autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22120178", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22106044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Timothy syndrome (TS) is an autosomal dominant condition with the constellation of features including prolonged QT interval, hand and foot abnormalities, and mental retardation or autism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22106044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Timothy syndrome type 1 (TS-1) is a rare disorder that affects multiple organ systems and has a high incidence of sudden death due to profound QT prolongation and resultant ventricular arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21910241", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 554, "text": "In some rare cases, such as Timothy syndrome (TS), a specific mutation in a single gene can be sufficient to generate autism or ASD in most patients, potentially offering insights into the etiology of autism in general. Both variants of TS (the milder TS1 and the more severe TS2) arise from missense mutations in alternatively spliced exons that cause the same G406R replacement in the Ca(V)1.2 L-type calcium channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21878566", "endSection": "abstract"}, {"offsetInBeginSection": 153, "offsetInEndSection": 306, "text": "A gain-of-function G406R mutation in a cytoplasmic loop of Ca(V)1.2 channels causes long QT syndrome 8 (LQT8), a disease also known as Timothy syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21700933", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 363, "text": "A missense mutation in the L-type calcium channel Ca(V)1.2 leads to LQTS in patients with Timothy syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21307850", "endSection": "abstract"}, {"offsetInBeginSection": 25, "offsetInEndSection": 1068, "text": "Timothy syndrome is a multisystem disorder characterized by cardiac, hand/foot, facial, and neurodevelopmental features. The two forms are type 1 (classic) and type 2, a rare form caused by mutations in a transcript variant of the same gene. Cardiac findings include a rate-corrected QT interval of between 480 ms and 700 ms and congenital heart defects (patent ductus arteriosus, patent foramen ovale, ventricular septal defect, tetralogy of Fallot, hypertrophic cardiomyopathy). Hand/foot findings are unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three. Facial findings include flat nasal bridge, low-set ears, thin upper lip, and round face. Neuropsychiatric involvement includes global developmental delays and autism spectrum disorders. Ventricular tachyarrhythmia is the leading cause of death, followed by infection and complications of intractable hypoglycemia. Average age of death is 2.5 years. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301577", "endSection": "abstract"}, {"offsetInBeginSection": 70, "offsetInEndSection": 260, "text": "The gain-of-function mutations were found at two mutually exclusive exons in patients with Timothy syndrome (TS). These patients exhibit prolonged QT interval and lethal cardiac arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19916019", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 611, "text": "TS patients also suffer from multi-organ dysfunction that includes neurological disorder such as autism and mental retardation reflecting the wide tissue distribution of CaV1.2 channel.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19916019", "endSection": "abstract"}, {"offsetInBeginSection": 705, "offsetInEndSection": 839, "text": "Unexpectedly, TS patients may develop recurrent infections and bronchitis that suggests a role of CaV1.2 channel in the immune system.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19916019", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 396, "text": "Timothy syndrome (TS) is a disease of excessive cellular Ca(2+) entry and life-threatening arrhythmias caused by a mutation in the primary cardiac L-type Ca(2+) channel (Ca(V)1.2). The TS mutation causes loss of normal voltage-dependent inactivation of Ca(V)1.2 current (I(Ca)). During cellular Ca(2+) overload, the calmodulin-dependent protein kinase II (CaMKII) causes arrhythmias. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19001023", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 336, "text": "Timothy syndrome is a multisystem disorder associated with the mutation of a Gly residue (G402 or G406) in the Ca(v)1.2 Ca(2+) channel. G406 is localized at the end of the IS6 segment and just before the intracellular I-II loop, which is important for the regulation of channel inactivation and the binding of the Ca(v)beta subunit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18536931", "endSection": "abstract"}, {"offsetInBeginSection": 357, "offsetInEndSection": 765, "text": "Inactivation of Ca2+ channel activity is perturbed in a rare yet devastating disorder known as Timothy syndrome (TS), whose features include autism or autism spectrum disorder along with severe cardiac arrhythmia and developmental abnormalities. Most cases of TS arise from a sporadic single nucleotide change that generates a mutation (G406R) in the pore-forming subunit of the L-type Ca2+ channel Ca(V)1.2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250309", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 257, "text": "Timothy syndrome is a multisystem disorder associated with QT interval prolongation and ventricular cardiac arrhythmias. The syndrome has been linked to mutations in Ca(V)1.2 resulting in gain of function of the L-type calcium current (I(Ca,L)).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17467634", "endSection": "abstract"}]}, {"body": "What is the function of the viral KP4 protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21303448", "http://www.ncbi.nlm.nih.gov/pubmed/21116630", "http://www.ncbi.nlm.nih.gov/pubmed/17849147", "http://www.ncbi.nlm.nih.gov/pubmed/17522822", "http://www.ncbi.nlm.nih.gov/pubmed/11901234", "http://www.ncbi.nlm.nih.gov/pubmed/11532143", "http://www.ncbi.nlm.nih.gov/pubmed/10748529", "http://www.ncbi.nlm.nih.gov/pubmed/8809749", "http://www.ncbi.nlm.nih.gov/pubmed/8616260", "http://www.ncbi.nlm.nih.gov/pubmed/7582897", "http://www.ncbi.nlm.nih.gov/pubmed/7966296", "http://www.ncbi.nlm.nih.gov/pubmed/8145639"], "ideal_answer": ["The virally encoded fungal toxin KP4  specifically blocks L-type voltage-gated calcium channels."], "concepts": ["http://www.uniprot.org/uniprot/KP4T_UMV4", "http://www.biosemantics.org/jochem#4265993", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014764"], "type": "summary", "id": "511a51331159fa8212000009", "snippets": [{"offsetInBeginSection": 359, "offsetInEndSection": 381, "text": "antifungal protein KP4", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303448", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116630", "endSection": "sections.0"}, {"offsetInBeginSection": 390, "offsetInEndSection": 645, "text": "Our previous work on a virally encoded fungal toxin, KP4, from Ustilago maydis and subsequently with the plant defensin, MsDef1, from Medicago sativa demonstrated that some of these proteins specifically blocked calcium channels in both fungi and animals.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849147", "endSection": "sections.0"}, {"offsetInBeginSection": 646, "offsetInEndSection": 838, "text": "The results presented here demonstrate that KP4 and three plant defensins, MsDef1, MtDef2, and RsAFP2, all inhibit root growth in germinating Arabidopsis seeds at low micromolar concentrations", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849147", "endSection": "sections.0"}, {"offsetInBeginSection": 148, "offsetInEndSection": 447, "text": ". There are three well-characterized killer toxins in U. maydis-KP1, KP4, and KP6-which are secreted by the P1, P4, and P6 subtypes, respectively. These killer toxins are small polypeptides encoded by segments of an endogenous, persistent double-stranded RNA (dsRNA) virus in each U. maydis subtype.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8809749", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "The viral gene for the killer protein 4 (KP4) has been explored for its antifungal effect", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17522822", "endSection": "sections.0"}, {"offsetInBeginSection": 22, "offsetInEndSection": 81, "text": "antifungal protein KP4 from Ustilago maydis-infecting virus", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10748529", "endSection": "sections.0"}, {"offsetInBeginSection": 399, "offsetInEndSection": 473, "text": "The antifungal activity correlated with the presence of the KP4 transgene.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10748529", "endSection": "sections.0"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1078, "text": "These results suggest that KP4 may inhibit cell growth and division by blocking calcium-regulated signal transduction pathways.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532143", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532143", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11901234", "endSection": "sections.0"}, {"offsetInBeginSection": 999, "offsetInEndSection": 1214, "text": "Our results defining the type of mammalian channel affected by this fungal toxin further support our contention that KP4 inhibits fungal growth by blocking transmembrane calcium flux through fungal calcium channels,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11901234", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "Killer toxins are polypeptides secreted by some fungal species that kill sensitive cells of the same or related species. In the best-characterized cases, they function by creating new pores in the cell membrane and disrupting ion fluxes", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8145639", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "KP4 is a virally encoded and highly specific toxin that kills fungi closely related to the fungus Ustilago maydis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7966296", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 167, "text": "The P4 strain of the corn smut fungus, Ustilago maydis, secretes a fungal toxin, KP4, encoded by a fungal virus (UMV4) that persistently infects its cells.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7582897", "endSection": "sections.0"}, {"offsetInBeginSection": 1307, "offsetInEndSection": 1438, "text": "These results led to experiments demonstrating that the toxin specifically inhibits voltage-gated Ca2+ channels in mammalian cells.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7582897", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Ustilago maydis killer toxins are small polypeptides (7-14 kDa) which kill susceptible cells of closely related fungal species. The KP4 toxin is a single polypeptide subunit with a molecular weight of 11.1 kDa", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8616260", "endSection": "sections.0"}]}, {"body": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23427148", "http://www.ncbi.nlm.nih.gov/pubmed/20621975", "http://www.ncbi.nlm.nih.gov/pubmed/18192286", "http://www.ncbi.nlm.nih.gov/pubmed/16760737", "http://www.ncbi.nlm.nih.gov/pubmed/10874640", "http://www.ncbi.nlm.nih.gov/pubmed/9571278", "http://www.ncbi.nlm.nih.gov/pubmed/7605558", "http://www.ncbi.nlm.nih.gov/pubmed/1785632", "http://www.ncbi.nlm.nih.gov/pubmed/23984569", "http://www.ncbi.nlm.nih.gov/pubmed/23023332", "http://www.ncbi.nlm.nih.gov/pubmed/22639450", "http://www.ncbi.nlm.nih.gov/pubmed/21307714", "http://www.ncbi.nlm.nih.gov/pubmed/20301454", "http://www.ncbi.nlm.nih.gov/pubmed/17979970", "http://www.ncbi.nlm.nih.gov/pubmed/17303258", "http://www.ncbi.nlm.nih.gov/pubmed/16970241", "http://www.ncbi.nlm.nih.gov/pubmed/15884042", "http://www.ncbi.nlm.nih.gov/pubmed/12846610", "http://www.ncbi.nlm.nih.gov/pubmed/9508238", "http://www.ncbi.nlm.nih.gov/pubmed/9130129", "http://www.ncbi.nlm.nih.gov/pubmed/8929375", "http://www.ncbi.nlm.nih.gov/pubmed/8563763", "http://www.ncbi.nlm.nih.gov/pubmed/7573131", "http://www.ncbi.nlm.nih.gov/pubmed/7573130", "http://www.ncbi.nlm.nih.gov/pubmed/15883926", "http://www.ncbi.nlm.nih.gov/pubmed/12878302"], "triples": [], "ideal_answer": ["Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.\nThe Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features.", "Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndromeMutations in Kif1-binding protein/KIAA1279 (KBP) cause the devastating neurological disorder Goldberg-Shprintzen syndrome (GSS) in humans.", "Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndromeMutations in Kif1-binding protein/KIAA1279 (KBP) cause the devastating neurological disorder Goldberg-Shprintzen syndrome (GSS) in humans.", "Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus.", "Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus.", "Hirschsprung disease is very often identified as an additional feature of the Goldberg-Shprintzen syndrome."], "exact_answer": [["Craniosynostosis"]], "concepts": [], "type": "factoid", "id": "5519110f622b19434500000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Goldberg-Shprintzen syndrome (GOSHS, MIM #609460) is an autosomal recessive disorder of intellectual disability, specific facial gestalt and Hirschsprung's disease (HSCR).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427148", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Goldberg-Shprintzen syndrome (GOSHS) is a rare clinical disorder characterized by central and enteric nervous system defects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621975", "endSection": "abstract"}, {"offsetInBeginSection": 1208, "offsetInEndSection": 1400, "text": "Thus, our data indicate that KBP is involved in neuronal differentiation and that the central and enteric nervous system defects seen in GOSHS are likely caused by microtubule-related defects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621975", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Mutations in Kif1-binding protein/KIAA1279 (KBP) cause the devastating neurological disorder Goldberg-Shprintzen syndrome (GSS) in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18192286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "We describe a brother and sister with Hirschsprung disease, hypotonia, and ptosis. Their condition resembles that in 2 sibs reported by Goldberg and Shprintzen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1785632", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "A 5-year-old girl with Hirschsprung disease, unusual facial appearance, psychomotor retardation, epilepsy, and congenital heart disease is reported", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605558", "endSection": "abstract"}, {"offsetInBeginSection": 352, "offsetInEndSection": 487, "text": "Cranial computed tomography demonstrated abnormal findings that may suggest defective neuronal migration and/or dysgenesis of the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7605558", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "In 1981, Goldberg and Shprintzen described siblings with short-segment Hirschsprung disease, cleft palate, microcephaly, mild mental retardation, short stature and distinctive facial appearance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9571278", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "A consanguineous family with Hirschsprung disease, microcephaly, and mental retardation (Goldberg-Shprintzen syndrome)", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10874640", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Hirschsprung disease, mental retardation, microcephaly, and specific craniofacial dysmorphism were observed in three children from a large, consanguineous, Moroccan family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10874640", "endSection": "abstract"}, {"offsetInBeginSection": 283, "offsetInEndSection": 402, "text": "The patient showed dysmorphic facies and weakness of connective tissue, and was scheduled to undergo abdominal surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23984569", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 558, "text": "Shprintzen-Goldberg syndrome (SGS) has considerable phenotypic overlap with MFS and LDS, including aortic aneurysm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23023332", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "We report on maternal half-sibs born to unaffected, non-consanguineous parents with classical Shprintzen-Goldberg syndrome (SGS) who had in addition intestinal malrotation and an aberrant subclavian artery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639450", "endSection": "abstract"}, {"offsetInBeginSection": 56, "offsetInEndSection": 441, "text": "keletal abnormalities common to 3 of them include bowing of long bones (with a variable degree of progression over time), flare of the metaphyses, a large anterior fontanel with persistent patency into the second to fourth years of life, 13 pairs of ribs, distinct vertebral abnormalities which were absent neonatally but evolved by the second year of life, and progressive osteopenia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573130", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Marfanoid phenotype with craniosynostosis (Shprintzen-Goldberg syndrome) is a rare disorder previously described in only 5 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8563763", "endSection": "title"}, {"offsetInBeginSection": 347, "offsetInEndSection": 503, "text": "Additional common findings include other craniofacial anomalies, hypotonia, obstructive apnea, foot deformity, and congenital weakness of the abdominal wall", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8563763", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 372, "text": " The radiological features were characterized by late-onset craniosynostosis, arachnodactyly, undermodeling of short tubular bones, mildly undermodeled and slightly bowed long bones, twisted ribs and tall vertebral bodies with elongated neural arches", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8929375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Aortic root replacement for annuloaortic ectasia in Shprintzen-Goldberg syndrome: a case report", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9130129", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Annuloaortic ectasia due to Shprintzen-Goldberg syndrome (SGS) is reported", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9130129", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Shprintzen-Goldberg syndrome is one of a group of disorders characterized by craniosynostosis and marfanoid habitus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9508238", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 195, "text": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12846610", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884042", "endSection": "abstract"}, {"offsetInBeginSection": 768, "offsetInEndSection": 913, "text": "Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15884042", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Shprintzen-Goldberg syndrome is a rare connective tissue disorder characterized by marfanoid habitus and additional dysmorphic stigmata.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16970241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Overall intelligibility, language, articulation, voice and resonance characteristics in a child with Shprintzen-Goldberg syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303258", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17979970", "endSection": "abstract"}, {"offsetInBeginSection": 25, "offsetInEndSection": 802, "text": "Shprintzen-Goldberg syndrome (SGS) is characterized by: craniosynostosis of the coronal, sagittal, or lambdoid sutures; dolichocephaly; distinctive craniofacial features; skeletal changes (dolichostenomelia, arachnodactyly, camptodactyly, pes planus, pectus excavatum or carinatum, scoliosis, joint hypermobility or contractures and C1/C2 spine malformation); neurologic abnormalities; intellectual disability; and brain anomalies (hydrocephalus, dilatation of the lateral ventricles, and Chiari 1 malformation). Cardiovascular anomalies may include mitral valve prolapse, mitral regurgitation/incompetence, aortic regurgitation and aortic root dilatation. Minimal subcutaneous fat, abdominal wall defects, myopia, and cryptorchidism in males, are also characteristic findings.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301454", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Surgical treatment for scoliosis in patients with Shprintzen-Goldberg syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21307714", "endSection": "title"}, {"offsetInBeginSection": 12, "offsetInEndSection": 106, "text": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21307714", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 358, "text": "We identified, by homozygosity mapping, a novel locus on 10q21.3-q22.1 for Goldberg-Shprintzen syndrome (GOSHS) in a consanguineous Moroccan family. Phenotypic features of GOSHS in this inbred family included microcephaly and mental retardation, which are both central nervous system defects, as well as Hirschsprung disease, an enteric nervous system defect", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15883926", "endSection": "abstract"}, {"offsetInBeginSection": 530, "offsetInEndSection": 839, "text": "We demonstrate that homozygous nonsense mutations in KIAA1279 at 10q22.1, encoding a protein with two tetratrico peptide repeats, underlie this syndromic form of Hirschsprung disease and generalized polymicrogyria, establishing the importance of KIAA1279 in both enteric and central nervous system development", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15883926", "endSection": "abstract"}, {"offsetInBeginSection": 337, "offsetInEndSection": 991, "text": "We report on four children in whom was diagnosed a neurocristopathy, associating Hirschsprung's disease with a wide spectrum of neurologic abnormalities. The patients included two children presenting the phenotypic features of the Goldberg-Shprintzen syndrome: distinct dysmorphic facial features, microcephaly, and mental retardation, along with agenesis of the corpus callosum and cortical malformations associated with intractable seizures in one child. The third newborn presented with the Haddad syndrome: short-segment Hirschsprung's disease associated with the congenital central hypoventilation syndrome requiring permanent artificial ventilation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12878302", "endSection": "abstract"}, {"offsetInBeginSection": 1155, "offsetInEndSection": 1394, "text": "Therefore, awareness of a possible neurocristopathy associated with neurologic abnormalities should be taken into account in any patient newly diagnosed with Hirschsprung's disease to detect the abnormalities early and promptly manage them", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12878302", "endSection": "abstract"}]}, {"body": "Elaborate on the TREAT-NMD initiative for DMD patients", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23913485", "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "http://www.ncbi.nlm.nih.gov/pubmed/22068481"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0098343", "o": "D010361"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0098257", "o": "D010361"}], "ideal_answer": ["TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients in Europe. TREAT-NMD has worked on the generation of brief standards of care for DMD. Guidelines are presented for diagnostics, neurological follow up, gastrointestinal and nutritional issues, respiratory and cardiac care as well as orthopaedics, rehabilitation, psychosocial interventions and oral care."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010361", "http://www.uniprot.org/uniprot/DMD_HUMAN", "http://www.uniprot.org/uniprot/DMD_RAT", "http://www.uniprot.org/uniprot/DMD_CANLF", "http://www.uniprot.org/uniprot/DMD_CHICK", "http://www.uniprot.org/uniprot/DMD_PIG"], "type": "summary", "id": "56acd7530a360a5e45000004", "snippets": [{"offsetInBeginSection": 524, "offsetInEndSection": 680, "text": "TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913485", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "title"}, {"offsetInBeginSection": 552, "offsetInEndSection": 762, "text": "TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 970, "text": "A worldwide effort is underway to generate care guidelines for DMD, which involves the Centre for Disease Control in the USA and the TREAT-NMD network of excellence for neuromuscular diseases in Europe. In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu). Guidelines are presented for diagnostics, neurological follow up, gastrointestinal and nutritional issues, respiratory and cardiac care as well as orthopaedics, rehabilitation, psychosocial interventions and oral care.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 747, "offsetInEndSection": 960, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 676, "offsetInEndSection": 832, "text": "TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913485", "endSection": "abstract"}, {"offsetInBeginSection": 747, "offsetInEndSection": 960, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 682, "text": "TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913485", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 715, "text": "In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068481", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 764, "text": "METHODS: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 752, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 764, "text": "METHODS: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 752, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 764, "text": "METHODS: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 764, "text": "METHODS: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 500, "offsetInEndSection": 764, "text": "METHODS: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 752, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 744, "text": "This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 812, "text": "In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients. We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068481", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 1073, "text": "The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913485", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 744, "text": "This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 748, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 738, "text": "A worldwide effort is underway to generate care guidelines for DMD, which involves the Centre for Disease Control in the USA and the TREAT-NMD network of excellence for neuromuscular diseases in Europe. In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 812, "text": "In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients. We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068481", "endSection": "abstract"}, {"offsetInBeginSection": 685, "offsetInEndSection": 1073, "text": "The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913485", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 813, "text": "TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients. The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23913485", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 744, "text": "This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 752, "text": "A worldwide effort is underway to generate care guidelines for DMD, which involves the Centre for Disease Control in the USA and the TREAT-NMD network of excellence for neuromuscular diseases in Europe. In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 971, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu). Guidelines are presented for diagnostics, neurological follow up, gastrointestinal and nutritional issues, respiratory and cardiac care as well as orthopaedics, rehabilitation, psychosocial interventions and oral care.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 812, "text": "In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients. We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068481", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 744, "text": "This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 752, "text": "A worldwide effort is underway to generate care guidelines for DMD, which involves the Centre for Disease Control in the USA and the TREAT-NMD network of excellence for neuromuscular diseases in Europe. In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 812, "text": "In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients. We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068481", "endSection": "abstract"}, {"offsetInBeginSection": 489, "offsetInEndSection": 744, "text": "This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility, recruitment, and other studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148153", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 752, "text": "A worldwide effort is underway to generate care guidelines for DMD, which involves the Centre for Disease Control in the USA and the TREAT-NMD network of excellence for neuromuscular diseases in Europe. In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 971, "text": "In advance of the full consensus document, TREAT-NMD has worked on the generation of brief standards of care for DMD, which are presented here and are available via the TREAT-NMD website (http://www.treat-nmd.eu). Guidelines are presented for diagnostics, neurological follow up, gastrointestinal and nutritional issues, respiratory and cardiac care as well as orthopaedics, rehabilitation, psychosocial interventions and oral care.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20225016", "endSection": "abstract"}, {"offsetInBeginSection": 581, "offsetInEndSection": 812, "text": "In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients. We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068481", "endSection": "abstract"}]}, {"body": "What is membrane scission?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25784211", "http://www.ncbi.nlm.nih.gov/pubmed/25783003", "http://www.ncbi.nlm.nih.gov/pubmed/25353823", "http://www.ncbi.nlm.nih.gov/pubmed/25429432", "http://www.ncbi.nlm.nih.gov/pubmed/24440309", "http://www.ncbi.nlm.nih.gov/pubmed/25202029", "http://www.ncbi.nlm.nih.gov/pubmed/24102355", "http://www.ncbi.nlm.nih.gov/pubmed/25664996", "http://www.ncbi.nlm.nih.gov/pubmed/24016602", "http://www.ncbi.nlm.nih.gov/pubmed/24753582", "http://www.ncbi.nlm.nih.gov/pubmed/24878737", "http://www.ncbi.nlm.nih.gov/pubmed/23252497", "http://www.ncbi.nlm.nih.gov/pubmed/23297414", "http://www.ncbi.nlm.nih.gov/pubmed/24099087"], "triples": [], "ideal_answer": ["Membrane scission is the final step in order to complete the budding process, pinching off of the vesicle. To promote membrane scission, dynamin proteins polymerize, wrap around, and constrict the membrane. The scission of biological membranes is facilitated by a variety of protein complexes that bind and manipulate lipid bilayers."], "concepts": [], "type": "summary", "id": "570a7594cf1c325851000026", "snippets": [{"offsetInBeginSection": 161, "offsetInEndSection": 341, "text": "To promote membrane scission, dynamin proteins polymerize, wrap around, and constrict the membrane; however, the mechanism underlying their role in membrane fusion remains unclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25784211", "endSection": "abstract"}, {"offsetInBeginSection": 276, "offsetInEndSection": 463, "text": " Its role in endocytosis may be mediated by its reported interaction with dynamin 2, a 100 kDa GTPase that polymerizes around the necks of budding vesicles and catalyzes membrane scission", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25783003", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 340, "text": "Because the neck's radius is, in general, finite, membrane scission and the consequent pinching off of the vesicle can only occur if it is narrowed to permit the necessary membrane topological reformation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Dynamin recruitment and membrane scission at the neck of a clathrin-coated pit.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25232009", "endSection": "title"}, {"offsetInBeginSection": 147, "offsetInEndSection": 277, "text": "ESCRT-III is the final complex in the pathway that assembles on endosomes and executes membrane scission of intraluminal vesicles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440309", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "The scission of biological membranes is facilitated by a variety of protein complexes that bind and manipulate lipid bilayers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25202029", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Dynamin-2 is a pleiotropic GTPase whose best-known function is related to membrane scission during vesicle budding from the plasma or Golgi membranes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24102355", "endSection": "abstract"}, {"offsetInBeginSection": 207, "offsetInEndSection": 310, "text": " Force produced by actin similarly contributes in membrane scission in endocytosis or Golgi remodeling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25664996", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 154, "text": "Dynamin 2 (Dyn2) is a ~100kDa GTPase that assembles around the necks of nascent endocytic and Golgi vesicles and catalyzes membrane scission. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24016602", "endSection": "abstract"}, {"offsetInBeginSection": 797, "offsetInEndSection": 833, "text": "membrane scission protein dynamin-2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24753582", "endSection": "abstract"}, {"offsetInBeginSection": 584, "offsetInEndSection": 657, "text": " Finally, a membrane scission event must occur to release the free virion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23252497", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 888, "text": " Furthermore, GTP-dependent membrane scission by dynamin was dramatically elevated by BAR domain proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23297414", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 275, "text": "few can mediate membrane scission to complete the budding process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24099087", "endSection": "abstract"}]}, {"body": "What is the method FASP used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24309553", "http://www.ncbi.nlm.nih.gov/pubmed/24289162", "http://www.ncbi.nlm.nih.gov/pubmed/24288579", "http://www.ncbi.nlm.nih.gov/pubmed/24051509", "http://www.ncbi.nlm.nih.gov/pubmed/24022122", "http://www.ncbi.nlm.nih.gov/pubmed/23784971", "http://www.ncbi.nlm.nih.gov/pubmed/23603217", "http://www.ncbi.nlm.nih.gov/pubmed/23436586", "http://www.ncbi.nlm.nih.gov/pubmed/23214492", "http://www.ncbi.nlm.nih.gov/pubmed/23126408", "http://www.ncbi.nlm.nih.gov/pubmed/22324799", "http://www.ncbi.nlm.nih.gov/pubmed/22092713", "http://www.ncbi.nlm.nih.gov/pubmed/22949036"], "triples": [], "ideal_answer": ["Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit."], "exact_answer": [["proteomic sample preparation"]], "concepts": [], "type": "factoid", "id": "5509f433c2af5d5b70000008", "snippets": [{"offsetInBeginSection": 197, "offsetInEndSection": 236, "text": "FASP (filter-aided sample preparation) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309553", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 684, "text": "mouse brain tissue lysate was prepared using filter-aided sample preparation (FASP) method ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289162", "endSection": "abstract"}, {"offsetInBeginSection": 897, "offsetInEndSection": 1047, "text": " an increased number of confident protein identifications are attained with a filter-aided digestion approach as compared to an in-solution digestion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24288579", "endSection": "abstract"}, {"offsetInBeginSection": 859, "offsetInEndSection": 897, "text": "filter-aided sample preparation (FASP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24051509", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 507, "text": "In the second step the isolated cells are lysed and processed using 'filter aided sample preparation' (FASP) technique. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24022122", "endSection": "abstract"}, {"offsetInBeginSection": 875, "offsetInEndSection": 914, "text": "filter-aided sample preparation (FASP),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23784971", "endSection": "abstract"}, {"offsetInBeginSection": 1087, "offsetInEndSection": 1135, "text": "filter assisted sample preparation (FASP) method", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23603217", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 278, "text": "d filter-aided sample preparation (FASP)-", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23436586", "endSection": "abstract"}, {"offsetInBeginSection": 86, "offsetInEndSection": 125, "text": " filter-aided sample preparation (FASP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214492", "endSection": "abstract"}, {"offsetInBeginSection": 400, "offsetInEndSection": 438, "text": "filter-aided sample preparation (FASP)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23126408", "endSection": "abstract"}, {"offsetInBeginSection": 318, "offsetInEndSection": 486, "text": "Filter Aided Sample Preparation (FASP), a type of proteomic reactor, in which samples dissolved in sodium dodecyl sulfate (SDS) are digested in an ultrafiltration unit.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22324799", "endSection": "abstract"}, {"offsetInBeginSection": 305, "offsetInEndSection": 354, "text": " filter-aided sample preparation (FASP) protocol ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22092713", "endSection": "abstract"}, {"offsetInBeginSection": 427, "offsetInEndSection": 482, "text": "by combining a filter-aided sample preparation method a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22949036", "endSection": "abstract"}]}, {"body": "Give an overview of visualizing genomes with oligopaint FISH probes.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24510436", "http://www.ncbi.nlm.nih.gov/pubmed/23236188"], "triples": [], "ideal_answer": ["Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. Coupled with fluorescence in situ hybridization (FISH) and a bioinformatic platform, this technology could be extended to any organism whose genome has been sequenced. The oligonucleotide probes are renewable, highly efficient, and able to robustly label chromosomes in cell culture, fixed tissues, and metaphase spreads. The method gives researchers precise control over the sequences they target and allows for single and multicolor imaging of chromosomal regions. It is anticipated that this technology will lead to an enhanced ability to visualize interphase and metaphase chromosomes."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015345"], "type": "summary", "id": "56c0ea0aef6e394741000029", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 1049, "text": "Here, we describe an oligonucleotide- and PCR-based strategy for fluorescence in situ hybridization (FISH) and a bioinformatic platform that enables this technology to be extended to any organism whose genome has been sequenced. The oligonucleotide probes are renewable, highly efficient, and able to robustly label chromosomes in cell culture, fixed tissues, and metaphase spreads. Our method gives researchers precise control over the sequences they target and allows for single and multicolor imaging of regions ranging from tens of kilobases to megabases with the same basic protocol. We anticipate this technology will lead to an enhanced ability to visualize interphase and metaphase chromosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23236188", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 355, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. This unit details how Oligopaint probes can be synthesized using basic molecular biological techniques, and provides protocols for FISH, 3D-FISH, and sample preparation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 356, "text": "Oligopaint probes are fluorescently labeled, single-stranded DNA oligonucleotides that can be used to visualize genomic regions ranging in size from tens of kilobases to many megabases. This unit details how Oligopaint probes can be synthesized using basic molecular biological techniques, and provides protocols for FISH, 3D-FISH, and sample preparation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24510436", "endSection": "abstract"}]}, {"body": "Which SWI/SNF protein complex subunit has been demonstrated to interact with the FANCA gene product?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11726552"], "triples": [], "ideal_answer": ["The Fanconi anemia protein FANCA has been shown to interact with the brm-related gene 1 (BRG1) product. BRG1 is a subunit of the SWI/SNF complex, which remodels chromatin structure through a DNA-dependent ATPase activity.", "FANCA was demonstrated to associate with the endogenous SWI/SNF complexFANCA may recruit the SWI/SNF complex to target genes, thereby enabling coupled nuclear functions such as transcription and DNA repair", "FANCA was demonstrated to associate with the endogenous SWI/SNF complexFANCA may recruit the SWI/SNF complex to target genes, thereby enabling coupled nuclear functions such as transcription and DNA repair"], "exact_answer": [["BRG1"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052217"], "type": "factoid", "id": "54edf81f94afd61504000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 111, "offsetInEndSection": 325, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product. BRG1 is a subunit of the SWI/SNF complex, which remodels chromatin structure through a DNA-dependent ATPase activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 327, "offsetInEndSection": 398, "text": "FANCA was demonstrated to associate with the endogenous SWI/SNF complex", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 997, "offsetInEndSection": 1131, "text": "FANCA may recruit the SWI/SNF complex to target genes, thereby enabling coupled nuclear functions such as transcription and DNA repair", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 111, "offsetInEndSection": 325, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product. BRG1 is a subunit of the SWI/SNF complex, which remodels chromatin structure through a DNA-dependent ATPase activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 208, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 887, "text": "Finally, we demonstrated co-localization in the nucleus between transfected FANCA and BRG1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 111, "offsetInEndSection": 207, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 886, "text": "Finally, we demonstrated co-localization in the nucleus between transfected FANCA and BRG1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 111, "offsetInEndSection": 207, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 796, "offsetInEndSection": 886, "text": "Finally, we demonstrated co-localization in the nucleus between transfected FANCA and BRG1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 207, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "title"}, {"offsetInBeginSection": 796, "offsetInEndSection": 886, "text": "Finally, we demonstrated co-localization in the nucleus between transfected FANCA and BRG1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 207, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 886, "text": "Finally, we demonstrated co-localization in the nucleus between transfected FANCA and BRG1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 207, "text": "We identified an interaction between the FA protein, FANCA and brm-related gene 1 (BRG1) product", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 886, "text": "Finally, we demonstrated co-localization in the nucleus between transfected FANCA and BRG1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726552", "endSection": "abstract"}]}, {"body": "Which protein phosphatase has been found to interact with the heat shock protein, HSP20?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24244723", "http://www.ncbi.nlm.nih.gov/pubmed/21493896"], "triples": [], "ideal_answer": ["Protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20. Cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, revealed an association between Hsp20 and PP1. Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "Moreover, protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20. Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling."], "exact_answer": [["Protein phosphatase 1", "PP1"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016791", "http://www.uniprot.org/uniprot/HSP20_NIPBR"], "type": "factoid", "id": "5506ce078e1671127b00000b", "snippets": [{"offsetInBeginSection": 1120, "offsetInEndSection": 1453, "text": " Moreover, protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20. Indeed, human genetic variants of inhibitor-1 (G147D) or Hsp20 (P20L) result in reduced binding and inhibition of protein phosphatase-1, suggesting aberrant enzymatic regulation in human carriers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 510, "offsetInEndSection": 1420, "text": " Hsp20 overexpression in intact animals resulted in significant enhancement of cardiac function, coupled with augmented Ca cycling and sarcoplasmic reticulum Ca load in isolated cardiomyocytes. This was associated with specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving its inhibition of the apparent Ca affinity of SERCA2a. Accordingly, the inotropic effects of Hsp20 were abrogated in cardiomyocytes expressing nonphosphorylatable PLN (S16A/T17A). Interestingly, the activity of type 1 protein phosphatase (PP1), a known regulator of PLN signaling, was significantly reduced by Hsp20 overexpression, suggesting that the Hsp20 stimulatory effects are partially mediated through the PP1-PLN axis. This hypothesis was supported by cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, which revealed an association between Hsp20, PP1, and PLN.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "abstract"}, {"offsetInBeginSection": 1564, "offsetInEndSection": 1799, "text": "Hsp20 is a novel regulator of sarcoplasmic reticulum Ca cycling by targeting the PP1-PLN axis. These findings, coupled with the well-recognized cardioprotective role of Hsp20, suggest a dual benefit of targeting Hsp20 in heart disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1255, "text": "Moreover, protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 1120, "offsetInEndSection": 1453, "text": " Moreover, protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20. Indeed, human genetic variants of inhibitor-1 (G147D) or Hsp20 (P20L) result in reduced binding and inhibition of protein phosphatase-1, suggesting aberrant enzymatic regulation in human carriers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1254, "text": "Moreover, protein phosphatase-1 activity is regulated by two binding partners, inhibitor-1 and the small heat shock protein 20, Hsp20", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244723", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493896", "endSection": "title"}]}, {"body": "Which is the cellular target of gefitinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23255952", "http://www.ncbi.nlm.nih.gov/pubmed/19276163", "http://www.ncbi.nlm.nih.gov/pubmed/18089711"], "triples": [], "ideal_answer": "The specific cellular target of Gefitinib (Iressa) is the epidermal growth factor receptor (EGFR).", "exact_answer": ["Epidermal growth factor receptor (EGFR)"], "concepts": ["http://www.biosemantics.org/jochem#4274201", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016503", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058990", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011958", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005006", "http://www.uniprot.org/uniprot/EGFR_CHICK"], "type": "factoid", "id": "53188480b166e2b806000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23255952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Gefitinib (Iressa) is a specific and effective epidermal growth factor receptor inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276163", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18089711", "endSection": "abstract"}]}, {"body": "What is  the clinical value of naltrexone in Parkinson's disease patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22426027", "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "http://www.ncbi.nlm.nih.gov/pubmed/152622", "http://www.ncbi.nlm.nih.gov/pubmed/25037206", "http://www.ncbi.nlm.nih.gov/pubmed/11254789", "http://www.ncbi.nlm.nih.gov/pubmed/23634190"], "triples": [], "ideal_answer": ["Naltrexone does not improve clinical features, including motor function, in Parkinson's disease patients. Naltrexone was shown to be effective for treatment of pathological gambling in Parkinson's disease patients."], "concepts": ["http://www.biosemantics.org/jochem#4249647", "http://www.disease-ontology.org/api/metadata/DOID:14330"], "type": "summary", "id": "55033064e9bde69634000036", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", "endSection": "title"}, {"offsetInBeginSection": 535, "offsetInEndSection": 685, "text": "These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", "endSection": "abstract"}, {"offsetInBeginSection": 843, "offsetInEndSection": 948, "text": "CONCLUSIONS: The opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 350, "text": "No improvement in the clinical features of either disorder was noted", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/152622", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "title"}, {"offsetInBeginSection": 415, "offsetInEndSection": 529, "text": "Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinsons disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "title"}, {"offsetInBeginSection": 535, "offsetInEndSection": 685, "text": "These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211", "endSection": "title"}]}, {"body": "Which treatment leads to an increase in neutrophil counts in severe congenital neutropenia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16822461", "http://www.ncbi.nlm.nih.gov/pubmed/7529539", "http://www.ncbi.nlm.nih.gov/pubmed/1705835", "http://www.ncbi.nlm.nih.gov/pubmed/1689595", "http://www.ncbi.nlm.nih.gov/pubmed/2683920", "http://www.ncbi.nlm.nih.gov/pubmed/21052952"], "triples": [], "ideal_answer": ["In patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections.", "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections  ", "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections  ", "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections  "], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050590"], "type": "summary", "id": "550313aae9bde6963400001f", "snippets": [{"offsetInBeginSection": 173, "offsetInEndSection": 441, "text": "This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropenia. Both disorders respond well to treatment with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", "endSection": "abstract"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1474, "text": "Data on more than 600 patients with CN collected by the Severe Chronic Neutropenia International Registry (SCNIR) demonstrate that, regardless of the particular CN subtype, more than 95% of these patients respond to recombinant human (rHu)G-CSF with ANCs that can be maintained above 1.0 x 10(9)/L.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822461", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 380, "text": "In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", "endSection": "abstract"}, {"offsetInBeginSection": 541, "offsetInEndSection": 660, "text": "A sustained ANC response was seen in 40/44 severe congenital neutropenia patients and 10/10 cyclic neutropenia patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529539", "endSection": "abstract"}, {"offsetInBeginSection": 200, "offsetInEndSection": 433, "text": "We examined peripheral blood mononuclear cells (PBMC) of SCN patients who demonstrated normalization of their blood neutrophil counts in a phase II clinical study with recombinant human granulocyte colony-stimulating factor (rhG-CSF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1705835", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Severe congenital neutropenia (SCN) is a disorder of myelopoiesis characterized by severe neutropenia secondary to a maturational arrest at the level of promyelocytes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689595", "endSection": "abstract"}, {"offsetInBeginSection": 942, "offsetInEndSection": 1170, "text": "In contrast to rhGM-CSF treatment, all five patients responded to rhG-CSF during the first 6 weeks of treatment with an increase in the ANC to above 1,000/microL. The level of ANC could be maintained during maintenance treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1689595", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 441, "text": "This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropenia. Both disorders respond well to treatment with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", "endSection": "abstract"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1474, "text": "Data on more than 600 patients with CN collected by the Severe Chronic Neutropenia International Registry (SCNIR) demonstrate that, regardless of the particular CN subtype, more than 95% of these patients respond to recombinant human (rHu)G-CSF with ANCs that can be maintained above 1.0 x 10(9)/L.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16822461", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 470, "text": "Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779444", "endSection": "abstract"}, {"offsetInBeginSection": 1256, "offsetInEndSection": 1333, "text": "In patients with chronic neutropenia, rhGM-CSF may increase neutrophil counts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2683920", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 470, "text": "Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779444", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 470, "text": "Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779444", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 470, "text": "Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779444", "endSection": "abstract"}, {"offsetInBeginSection": 256, "offsetInEndSection": 470, "text": "Treatment of these patients with granulocyte colony-stimulating factor (G-CSF) leads to a significant increase in circulating neutrophils and a reduction in infection-related events in more than 95% of the patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10779444", "endSection": "abstract"}]}, {"body": "What is the function of the enzymes known as dual specificity phoshpatases (DUSPs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24311790", "http://www.ncbi.nlm.nih.gov/pubmed/24308939", "http://www.ncbi.nlm.nih.gov/pubmed/24206177", "http://www.ncbi.nlm.nih.gov/pubmed/24155099", "http://www.ncbi.nlm.nih.gov/pubmed/23926106", "http://www.ncbi.nlm.nih.gov/pubmed/23190643", "http://www.ncbi.nlm.nih.gov/pubmed/22812510", "http://www.ncbi.nlm.nih.gov/pubmed/22266315", "http://www.ncbi.nlm.nih.gov/pubmed/21764456", "http://www.ncbi.nlm.nih.gov/pubmed/21300429", "http://www.ncbi.nlm.nih.gov/pubmed/21288197", "http://www.ncbi.nlm.nih.gov/pubmed/19228121", "http://www.ncbi.nlm.nih.gov/pubmed/24531476", "http://www.ncbi.nlm.nih.gov/pubmed/22769588"], "triples": [], "ideal_answer": ["Dual-specificity protein phosphatases participate in signal transduction pathways inactivating mitogen-activated protein kinases (MAP kinases). \nDual-specificity phosphatases (DUSPs) dephosphorylate phosphotyrosine and phosphoserine/phosphothreonine residues on target MAPKs. \nThese signaling pathways are of critical importance in the regulation of numerous biological processes, including cell proliferation, differentiation and development.", "DUSPs (dual-specificity phosphatases) are a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate. DUSPs have been implicated as major modulators of critical signalling pathways that are dysregulated in various diseases. DUSPs can be divided into six subgroups on the basis of sequence similarity that include slingshots, PRLs (phosphatases of regenerating liver), Cdc14 phosphatases (Cdc is cell division cycle), PTENs (phosphatase and tensin homologues deleted on chromosome 10), myotubularins, MKPs (mitogen-activated protein kinase phosphatases) and atypical DUSPs."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054637", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054638", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054641", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054640", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054642", "http://www.uniprot.org/uniprot/PTP3_CHLMO", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008138", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0003674", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0017017"], "type": "summary", "id": "5518e7a7622b194345000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "MAPK activity is negatively regulated by members of the dual specificity phosphatase (Dusp) family, which differ in expression, substrate specificity, and subcellular localization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311790", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 333, "text": "Dual-specificity phosphatases (DUSPs) dephosphorylate phosphotyrosine and phosphoserine/phosphothreonine residues on target MAPKs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24308939", "endSection": "abstract"}, {"offsetInBeginSection": 13, "offsetInEndSection": 340, "text": " The dual-specificity phosphatases (DUSPs) constitute a heterogeneous group of cysteine-based protein tyrosine phosphatases, whose members exert a pivotal role in cell physiology by dephosphorylation of phosphoserine, phosphothreonine, and phosphotyrosine residues from proteins, as well as other non-proteinaceous substrates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24206177", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Several dual-specificity phosphatases (DUSPs) that play key roles in the direct or indirect inactivation of different MAP kinases (MAPKs) have been implicated in human cancers over the past decade.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "Dual-specificity MAP kinase phosphatases (MKPs) provide a complex negative regulatory network that acts to shape the duration, magnitude and spatiotemporal profile of MAP kinase activities in response to both physiological and pathological stimuli", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22812510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 409, "text": "Dual-specificity phosphatases (DUSPs) is an emerging subclass of the protein tyrosine phosphatase gene superfamily, a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate. Recently, a series of investigations of DUSPs defined their essential roles in cell proliferation, cancer and the immune response. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190643", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "Mitogen-activated protein kinases (MAPKs) fulfill essential biological functions and are key pharmaceutical targets. Regulation of MAPKs is achieved via a plethora of regulatory proteins including activating MAPKKs and an abundance of deactivating phosphatases", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23926106", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "The protein tyrosine phosphatase family (PTP) contains a group of dual-specificity phosphatases (DUSPs) that regulate the activivity of MAP kinases (MAPKs), which are key effectors in the control of cell growth and survival in physiological and pathological processes, including cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288197", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 310, "text": "Dual-specificity protein phosphatases participate in signal transduction pathways inactivating mitogen-activated protein kinases (MAP kinases). These signaling pathways are of critical importance in the regulation of numerous biological processes, including cell proliferation, differentiation and development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Dual specificity phosphatase 1 (DUSP1) dephosphorylates and, hence, regulates the activity of MAP kinases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21764456", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 374, "text": "Dual-Specificity Phosphatases (DUSPs) are enzymes that remove phosphate groups from both phospho-tyrosine and phospho-serine/threonine residues. A subgroup of DUSPs specifically targets Mitogen-Activated Protein Kinases (MAPKs) and has been shown to participate in the regulation of differential cellular responses to the large variety of stimuli conveyed by MAPK-pathways. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266315", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 674, "text": "DUSPs (dual-specificity phosphatases) are a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate. DUSPs have been implicated as major modulators of critical signalling pathways that are dysregulated in various diseases. DUSPs can be divided into six subgroups on the basis of sequence similarity that include slingshots, PRLs (phosphatases of regenerating liver), Cdc14 phosphatases (Cdc is cell division cycle), PTENs (phosphatase and tensin homologues deleted on chromosome 10), myotubularins, MKPs (mitogen-activated protein kinase phosphatases) and atypical DUSPs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19228121", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 339, "text": "The dual-specificity phosphatases (DUSPs) constitute a heterogeneous group of cysteine-based protein tyrosine phosphatases, whose members exert a pivotal role in cell physiology by dephosphorylation of phosphoserine, phosphothreonine, and phosphotyrosine residues from proteins, as well as other non-proteinaceous substrates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24206177", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Dual-specificity protein phosphatases (DUSPs), which dephosphorylate both phosphoserine/threonine and phosphotyrosine, play vital roles in immune activation, brain function and cell-growth signalling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531476", "endSection": "abstract"}, {"offsetInBeginSection": 142, "offsetInEndSection": 332, "text": "Dual-specificity phosphatases (DUSPs), whose family currently contains 25 members, are phosphatases that can dephosphorylate both tyrosine and serine/threonine residues of their substrates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22769588", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "DUSPs (dual-specificity phosphatases) are a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19228121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Dual-Specificity Phosphatases (DUSPs) are enzymes that remove phosphate groups from both phospho-tyrosine and phospho-serine/threonine residues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266315", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "Dual-specificity protein phosphatases (DUSPs), which dephosphorylate both phosphoserine/threonine and phosphotyrosine, play vital roles in immune activation, brain function and cell-growth signalling", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24531476", "endSection": "abstract"}]}, {"body": "Describe Hot water reflex epilepsy.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24766826", "http://www.ncbi.nlm.nih.gov/pubmed/24929679", "http://www.ncbi.nlm.nih.gov/pubmed/24691294", "http://www.ncbi.nlm.nih.gov/pubmed/24691301", "http://www.ncbi.nlm.nih.gov/pubmed/25506178", "http://www.ncbi.nlm.nih.gov/pubmed/21932090", "http://www.ncbi.nlm.nih.gov/pubmed/20220445", "http://www.ncbi.nlm.nih.gov/pubmed/21808513", "http://www.ncbi.nlm.nih.gov/pubmed/10429817", "http://www.ncbi.nlm.nih.gov/pubmed/19597845", "http://www.ncbi.nlm.nih.gov/pubmed/10695897", "http://www.ncbi.nlm.nih.gov/pubmed/15297690", "http://www.ncbi.nlm.nih.gov/pubmed/19266219", "http://www.ncbi.nlm.nih.gov/pubmed/18367432", "http://www.ncbi.nlm.nih.gov/pubmed/3338422", "http://www.ncbi.nlm.nih.gov/pubmed/3284751", "http://www.ncbi.nlm.nih.gov/pubmed/18160259"], "triples": [], "ideal_answer": ["Hot water epilepsy (HWE) refers to a specific type of reflex epilepsy precipitated by the stimulus of bathing in hot water. Pathogenesis is still unknown and temporal lobe has been thought to take part in the epileptogenesis. HWE can be symptomatic of focal cortical malformation, and few cases were reported. Intermittent clobazam prophylaxis prior to head water bath might be a preferred mode of treatment of pure HWE."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004827"], "type": "summary", "id": "56c1f031ef6e39474100004e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 323, "text": "In this review we assess our currently available knowledge about reflex seizures with special emphasis on the difference between \"generalized\" reflex seizures induced by visual stimuli, thinking, praxis and language tasks, and \"focal\" seizures induced by startle, eating, music, hot water, somatosensory stimuli and orgasm.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24766826", "endSection": "abstract"}, {"offsetInBeginSection": 1034, "offsetInEndSection": 1158, "text": "CONCLUSIONS: Intermittent clobazam prophylaxis prior to head water bath might be a preferred mode of treatment of pure HWE. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24929679", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 430, "text": "Different types of reflex epilepsy such as eating, startle myoclonus, and hot water epilepsy were included in the study. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691294", "endSection": "abstract"}, {"offsetInBeginSection": 1249, "offsetInEndSection": 1393, "text": "Hot water epilepsy was triggered by contact with hot water either in the bath or by hand immersion, and VEEG showed fronto-parietal involvement.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691294", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 398, "text": "Hot water epilepsy is rarely described in European countries, where bathing epilepsy in younger children is more common and often confused with this type of epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "We studied the anatomical correlates of reflex hot water epilepsy (HWE) using multimodality investigations viz. magnetic resonance imaging (MRI), electroencephalography (EEG), and single photon emission computed tomography (SPECT). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506178", "endSection": "abstract"}, {"offsetInBeginSection": 815, "offsetInEndSection": 929, "text": "The clinical and SPECT studies suggested temporal lobe as the seizure onset zone in some of the patients with HWE.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506178", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 310, "text": "Hot water epilepsy (HWE) refers to a specific type of reflex epilepsy precipitated by the stimulus of bathing in hot water. Pathogenesis is still unknown and temporal lobe has been thought to take part in the epileptogenesis. HWE can be symptomatic of focal cortical malformation, and few cases were reported. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932090", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Hot water epilepsy is a reflex or sensory epilepsy in which seizures are triggered by the stimulus of bathing in hot water", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19597845", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Hot water epilepsy (HWE) refers to a specific type of reflex epilepsy precipitated by the stimulus of bathing in hot water", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932090", "endSection": "abstract"}, {"offsetInBeginSection": 1249, "offsetInEndSection": 1392, "text": "Hot water epilepsy was triggered by contact with hot water either in the bath or by hand immersion, and VEEG showed fronto-parietal involvement", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691294", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Hot water epilepsy: A rare form of reflex epilepsy", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808513", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Hot water epilepsy is a form of reflex epilepsy in childhood", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808513", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "We studied the anatomical correlates of reflex hot water epilepsy (HWE) using multimodality investigations viz. magnetic resonance imaging (MRI), electroencephalography (EEG), and single photon emission computed tomography (SPECT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506178", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Hot water epilepsy is a reflex or sensory epilepsy in which seizures are triggered by the stimulus of bathing in hot water. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19597845", "endSection": "abstract"}, {"offsetInBeginSection": 192, "offsetInEndSection": 592, "text": "The diagnosis of hot water epilepsy was supported by an ictal EEG. Hot water epilepsy, also known as bathing epilepsy or water-immersion epilepsy is, in the Caucasian population, a rare form of benign epilepsy, where seizures are provoked by immersion in a hot or even just a warm bath. This is the first comprehensive video publication of a seizure provoked by water-immersion in a Caucasian child. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18367432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Hot water epilepsy (HWE) is a form of reflex or sensory epilepsy wherein seizures are precipitated by an unusual stimulus, the contact of hot water over the head and body. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19266219", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy (HWE) is a rare form of reflex epilepsy caused by bathing with hot water. In this paper, we describe three cases with hot water epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "&quot;Hot water epilepsy&quot; (HWE), precipitated by a bath or shower in hot water, has been described infrequently in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3338422", "endSection": "abstract"}, {"offsetInBeginSection": 158, "offsetInEndSection": 399, "text": "A video-EEG recording was taken while hot water was poured onto his chest. Hot water epilepsy is rarely described in European countries, where bathing epilepsy in younger children is more common and often confused with this type of epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24691301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Hot water epilepsy (HWE) or bathing epilepsy is one of the reflex epilepsies induced by hot water pouring over the head,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220445", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 643, "text": "These two patients are the youngest reported cases of reflex hot water seizures, and the only reported cases in which reflex hot water seizures subsequently manifested episodes of alternating hemiplegia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18160259", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Hot water epilepsy is a reflex epilepsy. Seizures are provoked by hot water, and result from the association of both cutaneous and heat stimuli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10695897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy belongs to the group of reflex epilepsies. Seizures are provoked by hot water, due to the association of both cutaneous and heat stimuli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10429817", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy (HWE) is a rare form of reflex epilepsy caused by bathing with hot water. In this paper, we describe three cases with hot water epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "&quot;Hot water epilepsy&quot; (HWE), precipitated by a bath or shower in hot water, has been described infrequently in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3338422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "A patient with reflex epilepsy is described, in whom seizures were induced by bathing in hot water.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3284751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Hot water epilepsy (HWE) or bathing epilepsy is one of the reflex epilepsies induced by hot water pouring over the head,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220445", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy (HWE) is a rare form of reflex epilepsy caused by bathing with hot water. In this paper, we describe three cases with hot water epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "&quot;Hot water epilepsy&quot; (HWE), precipitated by a bath or shower in hot water, has been described infrequently in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3338422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Hot water epilepsy (HWE) or bathing epilepsy is one of the reflex epilepsies induced by hot water pouring over the head,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220445", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Hot water epilepsy is a reflex epilepsy. Seizures are provoked by hot water, and result from the association of both cutaneous and heat stimuli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10695897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy belongs to the group of reflex epilepsies. Seizures are provoked by hot water, due to the association of both cutaneous and heat stimuli.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10429817", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy (HWE) is a rare form of reflex epilepsy caused by bathing with hot water. In this paper, we describe three cases with hot water epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "&quot;Hot water epilepsy&quot; (HWE), precipitated by a bath or shower in hot water, has been described infrequently in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3338422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Hot water epilepsy (HWE) or bathing epilepsy is one of the reflex epilepsies induced by hot water pouring over the head,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220445", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Hot water epilepsy (HWE) is a rare form of reflex epilepsy caused by bathing with hot water. In this paper, we describe three cases with hot water epilepsy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15297690", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "&quot;Hot water epilepsy&quot; (HWE), precipitated by a bath or shower in hot water, has been described infrequently in the literature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3338422", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "A patient with reflex epilepsy is described, in whom seizures were induced by bathing in hot water.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3284751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Hot water epilepsy (HWE) or bathing epilepsy is one of the reflex epilepsies induced by hot water pouring over the head,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20220445", "endSection": "abstract"}]}, {"body": "What is the functionality of the Triplex R/bioconductor package?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23709494"], "triples": [], "ideal_answer": ["Triplex is an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences. The package provides functions that can be used to search Bioconductor genomes and other DNA sequence data for occurrence of nucleotide patterns capable of forming intramolecular triplexes (H-DNA). Functions producing 2D and 3D diagrams of the identified triplexes allow instant visualization of the search results. Leveraging the power of Biostrings and GRanges classes, the results get fully integrated into the existing Bioconductor framework, allowing their passage to other Genome visualization and annotation packages, such as GenomeGraphs, rtracklayer or Gviz."], "concepts": [], "type": "summary", "id": "56d1ddd267f0cb3d66000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 258, "offsetInEndSection": 829, "text": "The new package provides functions that can be used to search Bioconductor genomes and other DNA sequence data for occurrence of nucleotide patterns capable of forming intramolecular triplexes (H-DNA). Functions producing 2D and 3D diagrams of the identified triplexes allow instant visualization of the search results. Leveraging the power of Biostrings and GRanges classes, the results get fully integrated into the existing Bioconductor framework, allowing their passage to other Genome visualization and annotation packages, such as GenomeGraphs, rtracklayer or Gviz.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 91, "offsetInEndSection": 579, "text": "RESULTS: We combined a previously published implementation of a triplex DNA search algorithm with visualization to create a versatile R/Bioconductor package 'triplex'. The new package provides functions that can be used to search Bioconductor genomes and other DNA sequence data for occurrence of nucleotide patterns capable of forming intramolecular triplexes (H-DNA). Functions producing 2D and 3D diagrams of the identified triplexes allow instant visualization of the search results. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Triplex: an R/Bioconductor package for identification and visualization of potential intramolecular triplex patterns in DNA sequences.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23709494", "endSection": "title"}]}, {"body": "Which is the most well-accepted method for Down syndrome non-invasive prenatal diagnosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25218787", "http://www.ncbi.nlm.nih.gov/pubmed/23371439", "http://www.ncbi.nlm.nih.gov/pubmed/22773950", "http://www.ncbi.nlm.nih.gov/pubmed/22500647", "http://www.ncbi.nlm.nih.gov/pubmed/21303301", "http://www.ncbi.nlm.nih.gov/pubmed/22038362", "http://www.ncbi.nlm.nih.gov/pubmed/18207470", "http://www.ncbi.nlm.nih.gov/pubmed/17697502", "http://www.ncbi.nlm.nih.gov/pubmed/12498419", "http://www.ncbi.nlm.nih.gov/pubmed/22839575"], "triples": [], "ideal_answer": ["Currently, two applications for NIPD of Down syndrome have been developed with potential and have displayed positive results; the NIPD using next-generation sequencing technologies and the NIPD using the methylated DNA immunoprecipitation (MeDIP) real-time quantitative polymerase chain reaction (qPCR). This study examined the methylation difference in AIRE and RASSF1A between maternal and placental DNA, and the implication of this difference in the identification of free fetal DNA in maternal plasma and in prenatal diagnosis of trisomy 21. Diagnosis of trisomy 21 was established according to the ratio of fetal-specific AIRE to RASSF1A in maternal plasma. Both methods confirmed that AIRE and RASSF1A were hypomethylated in maternal blood cells but hypermethylated in placental or chorionic villus tissues. It was concluded that hypermethylated AIRE and RASSF1A may serve as fetal-specific markers for the identification of fetal DNA in maternal plasma and may be used for noninvasive prenatal diagnosis of trisomy 21.", "This study examined the methylation difference in AIRE and RASSF1A between maternal and placental DNA, and the implication of this difference in the identification of free fetal DNA in maternal plasma and in prenatal diagnosis of trisomy 21. Similarly, cell-free fetal DNA can be reliably recovered from maternal plasma and assessed by quantitative PCR to detect fetal trisomy 21 and paternally derived single gene mutations. The presence of foetal DNA in the plasma of pregnant women has opened up new possibilities for non-invasive prenatal diagnosis. Moreover, the differential methylation for each locus could be seen during the whole pregnant period."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011296", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004314", "http://www.disease-ontology.org/api/metadata/DOID:14250"], "type": "summary", "id": "56f403d009dd18d46b000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Potential of syncytiotrophoblasts isolated from the cervical mucus for early non-invasive prenatal diagnosis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218787", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Maternal serum protein profile and immune response protein subunits as markers for non-invasive prenatal diagnosis of trisomy 21, 18, and 13", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371439", "endSection": "title"}, {"offsetInBeginSection": 1335, "offsetInEndSection": 1565, "text": "Maternal serum protein profiling using proteomics may allow non-invasive diagnostic testing for the most common trisomies and may complement ultrasound-based methods to more accurately determine pregnancies with fetal aneuploidies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "The presence of foetal DNA in the plasma of pregnant women has opened up new possibilities for non-invasive prenatal diagnosis. The use of circulating foetal DNA for the non-invasive prenatal detection of foetal chromosomal aneuploidies is challenging as foetal DNA represents a minor fraction of maternal plasma DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22773950", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 704, "text": "Using massively parallel sequencing, foetal trisomies 21, 13 and 18 have been detected from maternal plasma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22773950", "endSection": "abstract"}, {"offsetInBeginSection": 1017, "offsetInEndSection": 1167, "text": "These developments suggest that the analysis of foetal DNA in maternal plasma would play an increasingly important role in future obstetrics practice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22773950", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 393, "text": "Currently, two applications for NIPD of Down syndrome have been developed with potential and have displayed positive results; the NIPD using next-generation sequencing technologies and the NIPD using the methylated DNA immunoprecipitation (MeDIP) real-time quantitative polymerase chain reaction (qPCR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22500647", "endSection": "abstract"}, {"offsetInBeginSection": 337, "offsetInEndSection": 644, "text": "Cell-free fetal RNA was extracted from the plasma of peripheral blood from 121 women 9-20 weeks of pregnancy. Five single nucleotide polymorphism (SNP) loci in PLAC4 gene were analyzed by reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA), followed by capillary electrophoresis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Non-invasive prenatal diagnosis of trisomy 21 by dosage ratio of fetal chromosome-specific epigenetic markers in maternal plasma", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038362", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "This study examined the methylation difference in AIRE and RASSF1A between maternal and placental DNA, and the implication of this difference in the identification of free fetal DNA in maternal plasma and in prenatal diagnosis of trisomy 21.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038362", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 867, "text": "Diagnosis of trisomy 21 was established according to the ratio of fetal-specific AIRE to RASSF1A in maternal plasma. Both methods confirmed that AIRE and RASSF1A were hypomethylated in maternal blood cells but hypermethylated in placental or chorionic villus tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038362", "endSection": "abstract"}, {"offsetInBeginSection": 1606, "offsetInEndSection": 1817, "text": "It was concluded that hypermethylated AIRE and RASSF1A may serve as fetal-specific markers for the identification of fetal DNA in maternal plasma and may be used for noninvasive prenatal diagnosis of trisomy 21.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038362", "endSection": "abstract"}, {"offsetInBeginSection": 764, "offsetInEndSection": 1131, "text": "Preliminary reports indicate that the detection of fetal aneuploidies might be possible using epigenetically modified genes, e.g. maspin on chromosome 18. Additionally, an exiting recent development is that it might be feasible to detect Down syndrome via the quantitative assessment of placentally derived cell-free mRNA of chromosome-21-specific genes such as PLAC4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18207470", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Candidate epigenetic biomarkers for non-invasive prenatal diagnosis of Down syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697502", "endSection": "title"}, {"offsetInBeginSection": 1124, "offsetInEndSection": 1286, "text": "Next, it was shown that the methylation status of chorionic villus sample DNA from first trimester pregnancies matched the hypermethylated state of term placenta.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Non-invasive prenatal diagnosis of trisomy 21 by reverse transcriptase multiplex ligation-dependent probe amplification.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303301", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "To study whether pregnant women would like to be informed if sex chromosomal abnormalities (SCA) were suspected with the non-invasive prenatal diagnosis of fetal Down syndrome (the NIFTY) test.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22839575", "endSection": "abstract"}]}, {"body": "Is Rheumatoid Arthritis more common in men or women?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23217568", "http://www.ncbi.nlm.nih.gov/pubmed/22853635", "http://www.ncbi.nlm.nih.gov/pubmed/21340496", "http://www.ncbi.nlm.nih.gov/pubmed/20889597", "http://www.ncbi.nlm.nih.gov/pubmed/20810033", "http://www.ncbi.nlm.nih.gov/pubmed/19158113", "http://www.ncbi.nlm.nih.gov/pubmed/18759162", "http://www.ncbi.nlm.nih.gov/pubmed/17965425", "http://www.ncbi.nlm.nih.gov/pubmed/16418123", "http://www.ncbi.nlm.nih.gov/pubmed/15083883", "http://www.ncbi.nlm.nih.gov/pubmed/12723987", "http://www.ncbi.nlm.nih.gov/pubmed/1563036"], "ideal_answer": ["Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome."], "exact_answer": ["Women"], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:7148", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001171", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012217", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013167", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015535"], "type": "factoid", "id": "5118dd1305c10fae75000001", "snippets": [{"offsetInBeginSection": 591, "offsetInEndSection": 678, "text": "Our results show a high prevalence of RA in LAC women with a ratio of 5.2 women per man", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217568", "endSection": "sections.0"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1394, "text": "RA in LAC women is not only more common but presents with some clinical characteristics that differ from RA presentation in men. Some of those characteristics could explain the high rates of disability and worse prognosis observed in women with RA in LAC", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23217568", "endSection": "sections.0"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1062, "text": "Intense anti-CCP2 reaction was 19.8-fold higher in females vs. males,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21340496", "endSection": "sections.0"}, {"offsetInBeginSection": 911, "offsetInEndSection": 944, "text": " men (n = 67) and women (n = 225)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889597", "endSection": "sections.0"}, {"offsetInBeginSection": 1808, "offsetInEndSection": 1943, "text": " Responses to treatment over time were better among men in this prebiologic era; women had worse progression despite similar treatment.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20889597", "endSection": "sections.0"}, {"offsetInBeginSection": 1550, "offsetInEndSection": 1629, "text": "BMI appears to be associated with RA disease activity in women, but not in men.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810033", "endSection": "sections.0"}, {"offsetInBeginSection": 729, "offsetInEndSection": 785, "text": "A total of 5,161 RA patients (4,082 women and 1,079 men)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810033", "endSection": "sections.0"}, {"offsetInBeginSection": 561, "offsetInEndSection": 744, "text": "In women the DAS28 was significantly higher than in men due to higher scores for general health and tender joints. Likewise, HAQ and VAS pain were rated significantly higher in women.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158113", "endSection": "sections.0"}, {"offsetInBeginSection": 263, "offsetInEndSection": 285, "text": "432 females, 125 males", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18759162", "endSection": "sections.0"}, {"offsetInBeginSection": 862, "offsetInEndSection": 1017, "text": "ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965425", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1563036", "endSection": "sections.0"}, {"offsetInBeginSection": 688, "offsetInEndSection": 830, "text": "The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15083883", "endSection": "sections.0"}, {"offsetInBeginSection": 453, "offsetInEndSection": 514, "text": "in 244 female and 91 male patients with rheumatoid arthritis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16418123", "endSection": "sections.0"}]}, {"body": "Which gene is responsible for the development of Sotos syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26043501", "http://www.ncbi.nlm.nih.gov/pubmed/25852445", "http://www.ncbi.nlm.nih.gov/pubmed/21834033", "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "http://www.ncbi.nlm.nih.gov/pubmed/16010675", "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "http://www.ncbi.nlm.nih.gov/pubmed/16232326", "http://www.ncbi.nlm.nih.gov/pubmed/21567906", "http://www.ncbi.nlm.nih.gov/pubmed/24192683", "http://www.ncbi.nlm.nih.gov/pubmed/22012791", "http://www.ncbi.nlm.nih.gov/pubmed/23190751", "http://www.ncbi.nlm.nih.gov/pubmed/25510705"], "triples": [], "ideal_answer": ["Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability. Haploinsufficiency of the NSD1 gene at 5q35.3, arising from 5q35 microdeletions, point mutations, and partial gene deletions, accounts for a majority of patients with SoS.", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene"], "exact_answer": [["NSD1 gene"]], "concepts": [], "type": "factoid", "id": "571f33bd0fd6f91b68000003", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Sotos syndrome is a well-known overgrowth syndrome characterized by excessive growth during childhood, macrocephaly, distinctive facial appearance and learning disability. This disorder is caused by mutations or deletions in NSD1 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043501", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 353, "text": "Sotos syndrome (SoS) is a multiple anomaly, congenital disorder characterized by overgrowth, macrocephaly, distinctive facial features and variable degree of intellectual disability. Haploinsufficiency of the NSD1 gene at 5q35.3, arising from 5q35 microdeletions, point mutations, and partial gene deletions, accounts for a majority of patients with SoS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852445", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 328, "offsetInEndSection": 469, "text": "The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16010675", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "Recently, deletions encompassing the nuclear receptor binding SET-Domain 1 (NSD1) gene have been described as the major cause of Japanese patients with the Sotos syndrome, whereas point mutations have been identified in the majority of European Sotos syndrome patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "Recently, deletions encompassing the nuclear receptor binding SET-Domain 1 (NSD1) gene have been described as the major cause of Japanese patients with the Sotos syndrome, whereas point mutations have been identified in the majority of European Sotos syndrome patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16232326", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Two cases of Sotos syndrome with novel mutations of the NSD1 gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567906", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16232326", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 282, "text": "Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16232326", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 304, "text": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567906", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Clinical and genetic spectrum of 18 unrelated Korean patients with Sotos syndrome: frequent 5q35 microdeletion and identification of four novel NSD1 mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23190751", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Craniofacial and oral features of Sotos syndrome: differences in patients with submicroscopic deletion and mutation of NSD1 gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22012791", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Prenatal diagnosis and molecular cytogenetic characterization of a 1.07-Mb microdeletion at 5q35.2-q35.3 associated with NSD1 haploinsufficiency and Sotos syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25510705", "endSection": "title"}, {"offsetInBeginSection": 186, "offsetInEndSection": 353, "text": "Autosomal dominant mutations and deletions of the nuclear receptor set domain gene (NSD1), which is located at chromosome 5q35, are responsible for most of the cases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24192683", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 312, "text": "There are two types of mutations that cause NSD1 haploinsufficiency: mutations within the NSD1 gene (mutation type) and a 5q35 submicroscopic deletion encompassing the entire NSD1 gene (deletion type). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22012791", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Sotos syndrome is a rare genetic disorder characterized by overgrowth associated with macrocephaly and delayed psychomotor development. Patients with Sotos syndrome show 5q35 deletions involving NSD1 or its point mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21834033", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Mutations in NSD1 are responsible for Sotos syndrome,", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 330, "text": "The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16010675", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 330, "text": "The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16010675", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 330, "text": "The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16010675", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20420030", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 330, "text": "The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16010675", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14571271", "endSection": "title"}]}, {"body": "Which intraflagellar transport (IFT) motor protein has been linked to human skeletal ciliopathies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25470043", "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "http://www.ncbi.nlm.nih.gov/pubmed/24183451"], "triples": [], "ideal_answer": ["Intraflagellar transport (IFT) depends on two evolutionarily conserved modules, subcomplexes A (IFT-A) and B (IFT-B), to drive ciliary assembly and maintenance. All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies"], "exact_answer": [["Intraflagellar transport (IFT) motor protein DYNC2H1"]], "concepts": [], "type": "factoid", "id": "57279ef20fd6f91b68000018", "snippets": [{"offsetInBeginSection": 295, "offsetInEndSection": 411, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 408, "text": "Intraflagellar transport (IFT) depends on two evolutionarily conserved modules, subcomplexes A (IFT-A) and B (IFT-B), to drive ciliary assembly and maintenance. All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 525, "text": "Bidirectional (anterograde and retrograde) motor-based intraflagellar transport (IFT) governs cargo transport and delivery processes that are essential for primary cilia growth and maintenance and for hedgehog signaling functions. The IFT dynein-2 motor complex that regulates ciliary retrograde protein transport contains a heavy chain dynein ATPase/motor subunit, DYNC2H1, along with other less well functionally defined subunits. Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 408, "offsetInEndSection": 656, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 617, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 408, "offsetInEndSection": 656, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 617, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 408, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 413, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 413, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 413, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 413, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 413, "text": "Cytoplasmic dynein-2 (dynein-2) performs intraflagellar transport and is associated with human skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470043", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 410, "text": " Intraflagellar transport (IFT) depends on two evolutionarily conserved modules, subcomplexes A (IFT-A) and B (IFT-B), to drive ciliary assembly and maintenance. All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 525, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS). Conversely, the 14 subunits in the IFT-B module, with the exception of IFT80, have unknown roles in human disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 243, "text": " Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies. Here, we define for the first time the composition of the human cytoplasmic dynein-2 complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 527, "text": "The IFT dynein-2 motor complex that regulates ciliary retrograde protein transport contains a heavy chain dynein ATPase/motor subunit, DYNC2H1, along with other less well functionally defined subunits. Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 527, "text": "Deficiency of IFT proteins, including DYNC2H1, underlies a spectrum of skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183451", "endSection": "abstract"}, {"offsetInBeginSection": 162, "offsetInEndSection": 410, "text": "All six IFT-A components and their motor protein, DYNC2H1, have been linked to human skeletal ciliopathies, including asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome), Sensenbrenner syndrome, and Mainzer-Saldino syndrome (MZSDS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport (IFT), and mutations in dynein-2 are known to cause skeletal ciliopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25205765", "endSection": "abstract"}]}, {"body": "To the ligand of which receptors does Denosumab (Prolia) bind?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23616122", "http://www.ncbi.nlm.nih.gov/pubmed/23241893", "http://www.ncbi.nlm.nih.gov/pubmed/22815651", "http://www.ncbi.nlm.nih.gov/pubmed/23139212", "http://www.ncbi.nlm.nih.gov/pubmed/22815185", "http://www.ncbi.nlm.nih.gov/pubmed/22401778", "http://www.ncbi.nlm.nih.gov/pubmed/22338309", "http://www.ncbi.nlm.nih.gov/pubmed/22322981", "http://www.ncbi.nlm.nih.gov/pubmed/21677475", "http://www.ncbi.nlm.nih.gov/pubmed/21623686", "http://www.ncbi.nlm.nih.gov/pubmed/21243489", "http://www.ncbi.nlm.nih.gov/pubmed/20671739", "http://www.ncbi.nlm.nih.gov/pubmed/20703154", "http://www.ncbi.nlm.nih.gov/pubmed/19098925", "http://www.ncbi.nlm.nih.gov/pubmed/18632461", "http://www.ncbi.nlm.nih.gov/pubmed/16527005", "http://www.ncbi.nlm.nih.gov/pubmed/16188502"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A9373021", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A9373021", "o": "C494392"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "PDQ"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "PDQ"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17995522", "o": "993449"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "CDR0000481348"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "CDR0000481348"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18087179", "o": "27218"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17995522", "o": "RXNORM"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "C61313"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17699205", "o": "C61313"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18084860", "o": "d07640"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18084860", "o": "Multum"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18087179", "o": "Multum"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://linkedlifedata.com/resource/pubmed/registryNumber", "s": "http://linkedlifedata.com/resource/pubmed/chemical/denosumab", "o": "615258-40-7"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/pubmed/chemical/denosumab", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "NCI Thesaurus"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17699205", "o": "NCI Thesaurus"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17995522"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11914653", "o": "Densosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18043383"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18087179"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12802315", "o": "Denosumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A18084860"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A12802315"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A9373021"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11920279"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A17699205"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1690432", "o": "http://linkedlifedata.com/resource/umls/label/A11914653"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18043383", "o": "DENOSUMAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11920279", "o": "denosumab"}], "ideal_answer": "Denosumab is a monoclonal antibody against the RANKL", "exact_answer": ["RANKL"], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0038023", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1900120", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1900121", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0030547", "http://www.biosemantics.org/jochem#4268082"], "type": "factoid", "id": "52bf1d9e03868f1b06000010", "snippets": [{"offsetInBeginSection": 414, "offsetInEndSection": 619, "text": "Whether the factor has the same role in humans is of clinical interest because an inhibitor for RANKL, denosumab, is already used for the treatment of bone disease and might benefit breast cancer patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23616122", "endSection": "abstract"}, {"offsetInBeginSection": 901, "offsetInEndSection": 1028, "text": "Treatment of AML cells with the clinically available RANKL Ab Denosumab resulted in enhanced NK cell anti-leukemia reactivity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23241893", "endSection": "abstract"}, {"offsetInBeginSection": 1263, "offsetInEndSection": 1653, "text": "The emerging clinical implication, supported by recent epidemiological studies, is that \u03b2AR-blockers and drugs interfering with RANKL signaling, such as Denosumab, could increase patient survival if used as adjuvant therapy to inhibit both the early colonization of bone by metastatic breast cancer cells and the initiation of the \"vicious cycle\" of bone destruction induced by these cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815651", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 822, "text": "Both the effects of RANKL on osteoclastogenesis and cytokine production by malignant cells could be blocked by disruption of RANK-RANKL interaction with denosumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23139212", "endSection": "abstract"}, {"offsetInBeginSection": 617, "offsetInEndSection": 1598, "text": "In the future, the armamentarium against osteoporotic fractures will likely be enriched by (1.) new bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1, PTH and PTHrp analogues, and possibly calcilytics; (2.) new inhibitors of bone resorption such as cathepsin K inhibitors which may suppress osteoclast function without impairing osteoclast viability and thus maintain bone formation by preserving the osteoclast-osteoblast crosstalk, and denosumab, an already widely available antibody against RANKL which inhibits osteoclast formation, function, and survival; and (3.) new therapeutic strategies based on an extended understanding of the pathophysiology of osteoporosis which may include sequential therapies with two or more bone active substances aimed at optimising the management of bone capital acquired during adolescence and maintained during adulthood in terms of both quantity and quality. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815185", "endSection": "abstract"}, {"offsetInBeginSection": 374, "offsetInEndSection": 606, "text": "Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22401778", "endSection": "abstract"}, {"offsetInBeginSection": 1922, "offsetInEndSection": 2054, "text": "Denosumab is a fully human monoclonal antibody to RANK Ligand that is administered as a 60-mg subcutaneous injection every 6 months.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22338309", "endSection": "abstract"}, {"offsetInBeginSection": 1478, "offsetInEndSection": 1617, "text": "More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322981", "endSection": "abstract"}, {"offsetInBeginSection": 1819, "offsetInEndSection": 1945, "text": "Denosumab is a neutralizing monoclonal antibody to RANKL and has recently been found to inhibit SRE more effectively than BP. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21677475", "endSection": "abstract"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1210, "text": "Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623686", "endSection": "abstract"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1381, "text": "Denosumab, an anti-RANKL monoclonal antibody with proven antiosteoclast activity, may suppress immune responses. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21243489", "endSection": "abstract"}, {"offsetInBeginSection": 1078, "offsetInEndSection": 1653, "text": "We also review unresolved controversies surrounding the management of these conditions by administration of nutritional vitamin D (ergocalciferol and cholecalciferol), vitamin D receptor activators (calcitriol, alphacalcidiol, doxercalciferol), D-mimetics (paricalcitol, maxacalcitol), calcimimetics (cinacalcet), recombinant PTH (teriparatide), and receptor activator of nuclear factor-kappaB ligand modulators (denosumab); compare mortality predictability of PTH and alkaline phosphatase; and examine potential risks of bone disorders and mineral disarrays in CKD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20671739", "endSection": "abstract"}, {"offsetInBeginSection": 495, "offsetInEndSection": 594, "text": "New therapies such as the antibody to RANKL (denosumab) are undergoing phase III clinical testing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20703154", "endSection": "abstract"}, {"offsetInBeginSection": 460, "offsetInEndSection": 672, "text": "Receptor activator of nuclear factor kappa B ligand is an important cytokine involved in osteoclast activation; denosumab, a fully human monoclonal antibody to this molecule, has finished a major fracture trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19098925", "endSection": "abstract"}, {"offsetInBeginSection": 731, "offsetInEndSection": 947, "text": "Initials studies have demonstrated that targeting RANK/ RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18632461", "endSection": "abstract"}, {"offsetInBeginSection": 799, "offsetInEndSection": 963, "text": "A highly specific, fully human antibody against RANKL has been produced (denosumab) that in early studies in humans reduces bone turnover and improves bone density.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16527005", "endSection": "abstract"}, {"offsetInBeginSection": 612, "offsetInEndSection": 802, "text": "Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16188502", "endSection": "abstract"}]}, {"body": "Which are the newly identified DNA nucleases that can be used to treat thalassemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24157834", "http://www.ncbi.nlm.nih.gov/pubmed/24155235"], "triples": [], "ideal_answer": "The newly identified DNA nucleases that can be used to treat thalassemia are the transcription activator-like effector nucleases (TALEN). These are engineered proteins able to stimulate targeted integration of therapeutic wild-type beta-globin cDNAs to the endogenous beta-globin locus.", "exact_answer": ["Transcription activator-like effector nucleases (TALEN)", "Zinc-finger nucleases"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003851", "http://www.disease-ontology.org/api/metadata/DOID:10241", "http://www.disease-ontology.org/api/metadata/DOID:1099", "http://www.disease-ontology.org/api/metadata/DOID:12241", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004518", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013789", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017085", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017086"], "type": "factoid", "id": "52fa74052059c6d71c00005a", "snippets": [{"offsetInBeginSection": 1, "offsetInEndSection": 597, "text": "al-effector nucleases (TALENs) are engineered proteins that can stimulate precise genome editing through specific DNA double-strand breaks. Sickle cell disease and \u03b2-thalassemia are common genetic disorders caused by mutations in \u03b2-globin, and we engineered a pair of highly active TALENs that induce modification of 54% of human \u03b2-globin alleles near the site of the sickle mutation. These TALENS stimulate targeted integration of therapeutic, full-length beta-globin cDNA to the endogenous \u03b2-globin locus in 19% of cells prior to selection as quantified by single molecule real-time sequencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157834", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 144, "text": "ranscription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free \u03b2-thalassemia induced pluripotent stem cells", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155235", "endSection": "title"}, {"offsetInBeginSection": 569, "offsetInEndSection": 806, "text": "Here, we describe a robust process combining efficient generation of integration-free \u03b2-Thal iPSCs from the cells of patients and transcription activator-like effector nuclease (TALEN)-based universal correction of HBB mutations in situ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155235", "endSection": "abstract"}]}, {"body": "Why can't humans synthesize Neu5Gc (N-Glycolylneuraminic acid)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24505439", "http://www.ncbi.nlm.nih.gov/pubmed/25003133", "http://www.ncbi.nlm.nih.gov/pubmed/25124893", "http://www.ncbi.nlm.nih.gov/pubmed/23520510", "http://www.ncbi.nlm.nih.gov/pubmed/22390546", "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "http://www.ncbi.nlm.nih.gov/pubmed/16806174", "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "http://www.ncbi.nlm.nih.gov/pubmed/19156207", "http://www.ncbi.nlm.nih.gov/pubmed/25517696", "http://www.ncbi.nlm.nih.gov/pubmed/15972653", "http://www.ncbi.nlm.nih.gov/pubmed/20452577"], "triples": [], "ideal_answer": ["N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds. Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. Losing this sugar changed how humans interact with some of our deadliest pathogens: malaria, influenza, and streptococcus among others."], "concepts": [], "type": "summary", "id": "57152ebbcb4ef8864c000002", "snippets": [{"offsetInBeginSection": 755, "offsetInEndSection": 1008, "text": "Human muscle from normal (no evident disease, n\u200a=\u200a3), Becker (BMD, n\u200a=\u200a3) and Duchenne (DMD, n\u200a=\u200a3) muscular dystrophy individuals had absent to very low Neu5Gc staining, but some punctate intracellular muscle staining was present in BMD and DMD muscles", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24505439", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 115, "text": "N-Glycolylneuraminic acid (Neu5Gc) is a sialic acid synthesized by animals, but not by humans or birds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25003133", "endSection": "abstract"}, {"offsetInBeginSection": 77, "offsetInEndSection": 387, "text": "Humans lack a functional cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) protein and cannot synthesize the sugar Neu5Gc, an innate mammalian signal of self. Losing this sugar changed how humans interact with some of our deadliest pathogens: malaria, influenza, and streptococcus among others.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124893", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 399, "text": "Anti-Neu5Gc antibodies are detected in all human sera, though with variable levels and epitope-recognition profiles. These antibodies likely play a role in several inflammation-mediated pathologies including cardiovascular diseases and cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23520510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Human polyclonal IgG antibodies directly against the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc) are potential biomarkers and mechanistic contributors to cancer and other diseases associated with chronic inflammation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22390546", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Human heterophile antibodies that agglutinate animal erythrocytes are known to detect the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18669916", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Nonhuman sialic acid Neu5Gc is very low in human embryonic stem cell-derived neural precursors differentiated with B27/N2 and noggin", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806174", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "A concern recently has been raised that human embryonic stem cell (HESC) lines cultured with currently available methods may have limited clinical usefulness due to the immunogenicity of the nonhuman sialic acid Neu5Gc incorporated into their membranes during culturing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16806174", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), but can metabolically incorporate it from dietary sources (particularly red meat and milk) into glycoproteins and glycolipids of human tumors, fetuses and some normal tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156207", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), but can metabolically incorporate it from dietary sources (particularly red meat and milk) into glycoproteins and glycolipids of human tumors, fetuses and some normal tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156207", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 292, "text": "Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), but can metabolically incorporate it from dietary sources (particularly red meat and milk) into glycoproteins and glycolipids of human tumors, fetuses and some normal tissues", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156207", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 335, "text": "Human cells cannot synthesize Neu5Gc due to dysfunction of the CMP-Neu5Ac hydroxylase (CMAH) gene, which converts CMP-Neu5Ac to CMP-Neu5Gc. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 335, "text": "Human cells cannot synthesize Neu5Gc due to dysfunction of the CMP-Neu5Ac hydroxylase (CMAH) gene, which converts CMP-Neu5Ac to CMP-Neu5Gc. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 335, "text": "Human cells cannot synthesize Neu5Gc due to dysfunction of the CMP-Neu5Ac hydroxylase (CMAH) gene, which converts CMP-Neu5Ac to CMP-Neu5Gc. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Humans are genetically incapable of producing the mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), due to an inactivating mutation in the enzyme synthesizing it. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15972653", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 335, "text": "Human cells cannot synthesize Neu5Gc due to dysfunction of the CMP-Neu5Ac hydroxylase (CMAH) gene, which converts CMP-Neu5Ac to CMP-Neu5Gc. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156207", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": " Mammals express the sialic acids N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) on cell surfaces, where they act as receptors for pathogens, including influenza A virus (IAV). Neu5Gc is synthesized from Neu5Ac by the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25517696", "endSection": "abstract"}, {"offsetInBeginSection": 2241, "offsetInEndSection": 2431, "text": "Human cells cannot synthesize Neu5Gc because of dysfunction of the CMP-N-acetylneuraminic acid hydroxylase gene but can exogenously and metabolically incorporate Neu5Gc from dietary sources.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 490, "offsetInEndSection": 648, "text": "Finally, we demonstrate that the synthesized Neu5Gc can be incorporated into the cell glycocalyx of human cells, which do not naturally synthesize this sugar.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20452577", "endSection": "abstract"}, {"offsetInBeginSection": 2241, "offsetInEndSection": 2431, "text": "Human cells cannot synthesize Neu5Gc because of dysfunction of the CMP-N-acetylneuraminic acid hydroxylase gene but can exogenously and metabolically incorporate Neu5Gc from dietary sources.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 2241, "offsetInEndSection": 2431, "text": "Human cells cannot synthesize Neu5Gc because of dysfunction of the CMP-N-acetylneuraminic acid hydroxylase gene but can exogenously and metabolically incorporate Neu5Gc from dietary sources.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24829344", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 655, "text": "Here we show that SubB has a strong preference for glycans terminating in the sialic acid N-glycolylneuraminic acid (Neu5Gc), a monosaccharide not synthesized in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971931", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Humans are genetically incapable of producing the mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), due to an inactivating mutation in the enzyme synthesizing it.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15972653", "endSection": "abstract"}]}, {"body": "How does trimetazidine affect intracellular kinase signaling in the heart?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20167841", "http://www.ncbi.nlm.nih.gov/pubmed/20383170", "http://www.ncbi.nlm.nih.gov/pubmed/19546072", "http://www.ncbi.nlm.nih.gov/pubmed/15616764"], "ideal_answer": ["Trimetazidine activates AMPK in diabetic myocardium. Trimetazidine  when administered before reperfusion results in activation of p38 mitogen-activated protein kinase and Akt signaling. Trimetazidine  when administered during reperfusion does not affect p38MAPK and JNK activation."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014292", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020930", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048848", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042656", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008349", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0033161", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048728", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048730", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048748", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048768", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004709", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000185", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004706", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048490", "http://www.uniprot.org/uniprot/ALPK2_MOUSE", "http://www.uniprot.org/uniprot/ALPK2_HUMAN", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0042655", "http://www.biosemantics.org/jochem#4250101", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0051390", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000165", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043408", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", "http://www.biosemantics.org/jochem#4059120", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020929", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0031435", "http://www.uniprot.org/uniprot/M4K2_MOUSE", "http://www.uniprot.org/uniprot/M4K1_HUMAN", "http://www.uniprot.org/uniprot/M4K1_MOUSE", "http://www.uniprot.org/uniprot/M4K4_MOUSE", "http://www.uniprot.org/uniprot/M4K5_HUMAN", "http://www.uniprot.org/uniprot/M4K5_MOUSE", "http://www.uniprot.org/uniprot/M4K3_RAT", "http://www.uniprot.org/uniprot/M4K3_MOUSE", "http://www.uniprot.org/uniprot/M4K3_HUMAN", "http://www.uniprot.org/uniprot/M4K2_HUMAN", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048670", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048369", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048370", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000197", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048669", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004708", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048688", "http://www.uniprot.org/uniprot/M3K1_ARATH", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000186", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008545", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0007243", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010627"], "type": "summary", "id": "5171393e8ed59a060a000005", "snippets": [{"offsetInBeginSection": 1121, "offsetInEndSection": 1377, "text": "The data suggest that trimetazidine significantly improves cardiac function in db/db mice by attenuating lipotoxicity and improving the oxidation status of the heart. Activation of AMPK and decreased expression of PGC-1 alpha were involved in this process.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383170", "endSection": "sections.0"}, {"offsetInBeginSection": 1405, "offsetInEndSection": 1751, "text": "the results demonstrated that TMZ is cardioprotective when administered before reperfusion and that this protection appears to be mediated by activation of p38 mitogen-activated protein kinase and Akt signaling. The study emphasizes the importance of administering TMZ before reflow to prevent reperfusion-mediated cardiac injury and dysfunction.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20167841", "endSection": "sections.0"}, {"offsetInBeginSection": 874, "offsetInEndSection": 937, "text": "TMZ induced cardioprotection did not involve p38 MAPK and JNKs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15616764", "endSection": "sections.0"}, {"offsetInBeginSection": 938, "offsetInEndSection": 1017, "text": "Phospho-p38 MAPK and JNKs levels after I/R were not changed with TMZ treatment.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15616764", "endSection": "sections.0"}, {"offsetInBeginSection": 1002, "offsetInEndSection": 1107, "text": "Trimetazidine also caused AMPK activation and reduced PGC-1 alpha expression in the hearts of db/db mice.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20383170", "endSection": "sections.0"}]}, {"body": "What is the mechanism of microRNA deregulation in carcinogenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23276969", "http://www.ncbi.nlm.nih.gov/pubmed/23175432", "http://www.ncbi.nlm.nih.gov/pubmed/23125218", "http://www.ncbi.nlm.nih.gov/pubmed/23087084", "http://www.ncbi.nlm.nih.gov/pubmed/23071542", "http://www.ncbi.nlm.nih.gov/pubmed/23064433", "http://www.ncbi.nlm.nih.gov/pubmed/23016435", "http://www.ncbi.nlm.nih.gov/pubmed/22616882", "http://www.ncbi.nlm.nih.gov/pubmed/22583478", "http://www.ncbi.nlm.nih.gov/pubmed/22548175", "http://www.ncbi.nlm.nih.gov/pubmed/22392644", "http://www.ncbi.nlm.nih.gov/pubmed/22056881", "http://www.ncbi.nlm.nih.gov/pubmed/21962230", "http://www.ncbi.nlm.nih.gov/pubmed/21931505", "http://www.ncbi.nlm.nih.gov/pubmed/22469780", "http://www.ncbi.nlm.nih.gov/pubmed/21903334", "http://www.ncbi.nlm.nih.gov/pubmed/19521961", "http://www.ncbi.nlm.nih.gov/pubmed/22898998", "http://www.ncbi.nlm.nih.gov/pubmed/21971665", "http://www.ncbi.nlm.nih.gov/pubmed/22126155", "http://www.ncbi.nlm.nih.gov/pubmed/21712563", "http://www.ncbi.nlm.nih.gov/pubmed/17700064", "http://www.ncbi.nlm.nih.gov/pubmed/22293089", "http://www.ncbi.nlm.nih.gov/pubmed/21102580", "http://www.ncbi.nlm.nih.gov/pubmed/20221895", "http://www.ncbi.nlm.nih.gov/pubmed/21860412", "http://www.ncbi.nlm.nih.gov/pubmed/20925959", "http://www.ncbi.nlm.nih.gov/pubmed/18036240", "http://www.ncbi.nlm.nih.gov/pubmed/23431261", "http://www.ncbi.nlm.nih.gov/pubmed/19721809", "http://www.ncbi.nlm.nih.gov/pubmed/19440243", "http://www.ncbi.nlm.nih.gov/pubmed/23209884", "http://www.ncbi.nlm.nih.gov/pubmed/22408395", "http://www.ncbi.nlm.nih.gov/pubmed/22666228", "http://www.ncbi.nlm.nih.gov/pubmed/18040713", "http://www.ncbi.nlm.nih.gov/pubmed/20842113", "http://www.ncbi.nlm.nih.gov/pubmed/23293655", "http://www.ncbi.nlm.nih.gov/pubmed/21559780", "http://www.ncbi.nlm.nih.gov/pubmed/19712461", "http://www.ncbi.nlm.nih.gov/pubmed/23509776", "http://www.ncbi.nlm.nih.gov/pubmed/23554741", "http://www.ncbi.nlm.nih.gov/pubmed/19638982", "http://www.ncbi.nlm.nih.gov/pubmed/21029445", "http://www.ncbi.nlm.nih.gov/pubmed/21284896", "http://www.ncbi.nlm.nih.gov/pubmed/22666523", "http://www.ncbi.nlm.nih.gov/pubmed/21811665", "http://www.ncbi.nlm.nih.gov/pubmed/23391324", "http://www.ncbi.nlm.nih.gov/pubmed/22384020", "http://www.ncbi.nlm.nih.gov/pubmed/23407615", "http://www.ncbi.nlm.nih.gov/pubmed/22312290", "http://www.ncbi.nlm.nih.gov/pubmed/22968430", "http://www.ncbi.nlm.nih.gov/pubmed/19912656", "http://www.ncbi.nlm.nih.gov/pubmed/18700954", "http://www.ncbi.nlm.nih.gov/pubmed/23024649", "http://www.ncbi.nlm.nih.gov/pubmed/23074383", "http://www.ncbi.nlm.nih.gov/pubmed/23158014", "http://www.ncbi.nlm.nih.gov/pubmed/16854228", "http://www.ncbi.nlm.nih.gov/pubmed/22938091", "http://www.ncbi.nlm.nih.gov/pubmed/21799879", "http://www.ncbi.nlm.nih.gov/pubmed/18927107", "http://www.ncbi.nlm.nih.gov/pubmed/23251295", "http://www.ncbi.nlm.nih.gov/pubmed/22303318", "http://www.ncbi.nlm.nih.gov/pubmed/18442408", "http://www.ncbi.nlm.nih.gov/pubmed/22417299", "http://www.ncbi.nlm.nih.gov/pubmed/21461395", "http://www.ncbi.nlm.nih.gov/pubmed/20716340", "http://www.ncbi.nlm.nih.gov/pubmed/23250910", "http://www.ncbi.nlm.nih.gov/pubmed/21418558", "http://www.ncbi.nlm.nih.gov/pubmed/22912875", "http://www.ncbi.nlm.nih.gov/pubmed/22194833", "http://www.ncbi.nlm.nih.gov/pubmed/19664288", "http://www.ncbi.nlm.nih.gov/pubmed/22303357"], "ideal_answer": ["MicroRNAs (miRNAs) are endogenous non-protein coding single-stranded RNAs (19\u201325 nucleotides in length) generated from  cleavage of larger non-coding RNAs by the ribonuclease III enzyme Dicer. They become part of the RNA-induced silencing complex and negatively regulate gene expression by binding to homologous 3'-UTR region of target protein-coding mRNAs as an imperfect match, causing translational repression or degradation. Approximately one-third of the protein-coding genes are susceptible to miRNA regulation. Accumulating evidence indicates that deregulated miRNA expression is associated with the onset and progression of a number of human cancers. Therefore, cancer-associated miRNAs (CA-miRNAs) could regulate target genes by acting either as \"oncogenes\" or \"tumor suppressor miRNA (TS-miRNAs)\". In line with this, numerous cancers (e.g. breast, lung, oesophageal, prostate, pancreatic, gastric and colon cancer) have been classified based on their unique miRNA expression profile."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"], "type": "summary", "id": "51718fbc8ed59a060a000010", "snippets": [{"offsetInBeginSection": 239, "offsetInEndSection": 537, "text": "MicroRNAs are a class of small non-coding RNAs that negatively regulate gene expression by interacting with the 3'UTR of protein-coding mRNA. MicroRNAs are implicated in nearly all major biological and cellular events, and recent findings further link microRNA deregulation to human carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276969", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-\u03baB pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175432", "endSection": "title"}, {"offsetInBeginSection": 195, "offsetInEndSection": 312, "text": "MicroRNAs (miRNAs), which are small non-coding RNAs, are involved in diverse biological functions and carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125218", "endSection": "sections.0"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1063, "text": "Moreover, we demonstrated that miR-106b downregulates APC expression by directly targeting the 3'-untranslated region of APC messenger RNA.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23087084", "endSection": "sections.0"}, {"offsetInBeginSection": 287, "offsetInEndSection": 657, "text": "Furthermore, miRNAs present a mechanism by which genes with diverse functions on multiple pathways can be simultaneously regulated at the post-transcriptional level. However, little is known about the cancer-related pathways through which cancer-associated miRNAs (CA-miRNAs) regulate these processes representing either positive or negative functions in carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064433", "endSection": "sections.0"}, {"offsetInBeginSection": 41, "offsetInEndSection": 602, "text": "MicroRNAs, known as small noncoding MiRNAs, 19 to 24 nt in length, are important gene regulators and recognized as key players in carcinogenesis. The mechanism lies in that the MiRNAs can conjugate with their targeted mRNA and then lead to the targeted mRNA degradation or repress their translation. Bioinformatic analysis indicates that each MiRNA can regulate hundreds of gene targets and could serve functionally as \"oncogenes\" or \"tumor suppressor genes\", and therefore regulate multiple cellular processes relevant to carcinogenesis and cancer progression.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016435", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "microRNAs (miRs) are endogenous small non-coding RNAs that are aberrantly expressed in various carcinomas.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21971665", "endSection": "sections.0"}, {"offsetInBeginSection": 89, "offsetInEndSection": 253, "text": "While deregulated miRNA expression levels have been detected in many tumors, whether miRNA functional impairment is also involved in carcinogenesis remains unknown.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898998", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "In the last years, microRNAs (miRNA) have emerged as new molecular players involved in carcinogenesis. Deregulation of miRNAs expression has been shown in different human cancer but the molecular mechanism underlying the alteration of miRNA expression is unknown.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19521961", "endSection": "sections.0"}, {"offsetInBeginSection": 269, "offsetInEndSection": 730, "text": "These are microRNAs (miRNAs), a class of noncoding RNAs, 20-23 nucleotides in length, that can up or downregulate gene expression of downstream gene targets (including transcription factors, oncogenes, and tumour suppressor genes) at the post-transcriptional level. Some members of this new class of genes seem to have the potential to act simultaneously either as oncogenes or as tumour suppressor genes depending on the molecular microenvironment of the cell.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903334", "endSection": "sections.0"}, {"offsetInBeginSection": 144, "offsetInEndSection": 240, "text": "MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22469780", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Regulation of hepatocarcinogenesis by microRNAs.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276969", "endSection": "title"}, {"offsetInBeginSection": 381, "offsetInEndSection": 537, "text": "MicroRNAs are implicated in nearly all major biological and cellular events, and recent findings further link microRNA deregulation to human carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23276969", "endSection": "sections.0"}, {"offsetInBeginSection": 195, "offsetInEndSection": 312, "text": "MicroRNAs (miRNAs), which are small non-coding RNAs, are involved in diverse biological functions and carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125218", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23087084", "endSection": "title"}, {"offsetInBeginSection": 453, "offsetInEndSection": 657, "text": "However, little is known about the cancer-related pathways through which cancer-associated miRNAs (CA-miRNAs) regulate these processes representing either positive or negative functions in carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064433", "endSection": "sections.0"}, {"offsetInBeginSection": 1406, "offsetInEndSection": 1681, "text": "Combined with previous cancer studies, the analysis of the relevance between functions of CA-miRNAs and cancer-related pathways exploring different internal carcinogenesis stimuli also revealed the potential of the top five pathways to regulate core carcinogenesis processes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064433", "endSection": "sections.0"}, {"offsetInBeginSection": 41, "offsetInEndSection": 186, "text": "MicroRNAs, known as small noncoding MiRNAs, 19 to 24 nt in length, are important gene regulators and recognized as key players in carcinogenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016435", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392644", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Deregulation of microRNAs (miRNAs) is common in advanced human hepatocellular carcinoma (HCC); however, the ones involved in early carcinogenesis have not yet been investigated.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392644", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056881", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22056881", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Growing evidence indicates that deregulation of microRNAs (miRNAs) contributes to tumorigenesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23175432", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "UNLABELLED: Deregulation of microRNAs (miRNAs) is common in advanced human hepatocellular carcinoma (HCC); however, the ones involved in early carcinogenesis have not yet been investigated.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392644", "endSection": "sections.0"}, {"offsetInBeginSection": 103, "offsetInEndSection": 263, "text": "Deregulation of miRNAs expression has been shown in different human cancer but the molecular mechanism underlying the alteration of miRNA expression is unknown.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19521961", "endSection": "sections.0"}]}, {"body": "Which protein is the E3-ubiquitin ligase that targets the tumor suppressor p53 for proteasomal degradation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23150437", "http://www.ncbi.nlm.nih.gov/pubmed/23671280", "http://www.ncbi.nlm.nih.gov/pubmed/22666487", "http://www.ncbi.nlm.nih.gov/pubmed/23581014", "http://www.ncbi.nlm.nih.gov/pubmed/19934289", "http://www.ncbi.nlm.nih.gov/pubmed/18235222", "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "http://www.ncbi.nlm.nih.gov/pubmed/16082221", "http://www.ncbi.nlm.nih.gov/pubmed/15632057", "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "http://www.ncbi.nlm.nih.gov/pubmed/12832479", "http://www.ncbi.nlm.nih.gov/pubmed/11948425", "http://www.ncbi.nlm.nih.gov/pubmed/24174547", "http://www.ncbi.nlm.nih.gov/pubmed/21075307", "http://www.ncbi.nlm.nih.gov/pubmed/19166840", "http://www.ncbi.nlm.nih.gov/pubmed/22819825"], "triples": [], "ideal_answer": ["The p53 tumour suppressor protein is tightly controlled by the E3 ubiquitin ligase, mouse double minute 2 (MDM2). The RING domain E3 ubiquitin ligase Mdm2 is the master regulator of the tumor suppressor p53. It targets p53 for proteasomal degradation, restraining the potent activity of p53 and enabling cell survival and proliferation. p53 is inactivated in many human malignancies through missense mutations or overexpression of the human homologue of Mdm2 (Hdm2), an E3 ubiquitin ligase that ubiquitinates p53, thereby promoting its proteasomal degradation.", "This is well illustrated by the E3 ubiquitin ligase MDM2 that targets p53 for proteasomal degradation under normal conditions and is essential for controlling p53 activity during development., p53 is inactivated in many human malignancies through missense mutations or overexpression of the human homologue of Mdm2 (Hdm2), an E3 ubiquitin ligase that ubiquitinates p53, thereby promoting its proteasomal degradation., Mdm2 has been thought to regulate the tumor suppressor p53 in two ways: by masking p53's access to transcriptional machinery, and by ubiquitinating p53, targeting it for proteasomal degradation"], "exact_answer": [["The mouse double minute 2 (mdm2)", "The human homologue of Mdm2 (Hdm2)"]], "concepts": [], "type": "factoid", "id": "55058af6f73303d458000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 322, "text": "p53 levels and activity are controlled in large part through regulated ubiquitination and subsequent destruction by the 26S proteasome. Monoubiquitination of p53 is mediated primarily by the RING-finger E3 ubiquitin ligase MDM2 and impacts p53 activity through modulation of p53 localization and transcription activities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23150437", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "The RING domain E3 ubiquitin ligase Mdm2 is the master regulator of the tumor suppressor p53. It targets p53 for proteasomal degradation, restraining the potent activity of p53 and enabling cell survival and proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671280", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 359, "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation. Aside from its ubiquitin ligase function, Mdm2 has been believed to be capable of suppressing p53's transcriptional activity by binding with and masking the transactivation domain of p53.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "The regulation of p53 expression levels is critical in controlling p53 activity in normal and damaged cells. This is well illustrated by the E3 ubiquitin ligase MDM2 that targets p53 for proteasomal degradation under normal conditions and is essential for controlling p53 activity during development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23581014", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 232, "text": "p53 is inactivated in many human malignancies through missense mutations or overexpression of the human homologue of Mdm2 (Hdm2), an E3 ubiquitin ligase that ubiquitinates p53, thereby promoting its proteasomal degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934289", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 530, "text": "Mdm2 has been thought to regulate the tumor suppressor p53 in two ways: by masking p53's access to transcriptional machinery, and by ubiquitinating p53, targeting it for proteasomal degradation. This dogma was recently challenged by data generated from knockin mice in which Mdm2's RING E3 ubiquitin ligase activity was abrogated by a single point mutation. The RING mutant Mdm2 is fully capable of binding with p53, yet cannot suppress p53 activity, suggesting that Mdm2 cannot block p53 by binding alone, without ubiquitination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18235222", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 322, "text": "The p53 tumor suppressor protein has a major role in protecting genome integrity. Under normal circumstances Mdmx and Mdm2 control the activity of p53. Both proteins inhibit the transcriptional regulation by p53, while Mdm2 also functions as an E3 ubiquitin ligase to target both p53 and Mdmx for proteasomal degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16082221", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 515, "text": "p53 is a critical coordinator of a wide range of stress responses. To facilitate a rapid response to stress, p53 is produced constitutively but is negatively regulated by MDM2. MDM2 can inhibit p53 in multiple independent ways: by binding to its transcription activation domain, inhibiting p53 acetylation, promoting nuclear export, and probably most importantly by promoting proteasomal degradation of p53. The latter is achieved via MDM2's E3 ubiquitin ligase activity harbored within the MDM2 RING finger domain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15632057", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein. Acetylation of p53 regulates p53's transcriptional activity and inhibits Mdm2-mediated p53 ubiquitination and degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 325, "text": "MDM2 is an E3 ubiquitin ligase that targets p53 for proteasomal degradation. Recent studies have shown, however, that the ring-finger domain (RFD) of MDM2, where the ubiquitin E3 ligase activity resides, is necessary but not sufficient for p53 ubiquitination, suggesting that an additional activity of MDM2 might be required.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12832479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 355, "text": "The Mdm2 proto-oncogene is amplified and over-expressed in a variety of tumors. One of the major functions of Mdm2 described to date is its ability to modulate the levels and activity of the tumor suppressor protein p53. Mdm2 binds to the N-terminus of p53 and, through its action as an E3 ubiquitin ligase, targets p53 for rapid proteasomal degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11948425", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 450, "text": "The HDM2-p53 loop is crucial for monitoring p53 level and human pathologies. Therefore, identification of novel molecules involved in this regulatory loop is necessary for understanding the dynamic regulation of p53 and treatment of human diseases. Here, we characterized that the ribosomal protein L6 binds to and suppresses the E3 ubiquitin ligase activity of HDM2, and subsequently attenuates HDM2-mediated p53 polyubiquitination and degradation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24174547", "endSection": "abstract"}, {"offsetInBeginSection": 1229, "offsetInEndSection": 1399, "text": "Together, our study identifies the crucial function of RPL6 in regulating HDM2-p53 pathway, which highlights the importance of RPL6 in human genetic diseases and cancers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24174547", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 356, "text": "Targeting the E3 ubiquitin ligase HDM2 can lead to a therapeutic surge in p53 levels. However, the efficacy of HDM2 inhibition can be compromised by overexpression of HDMX, an HDM2 homolog that binds and sequesters p53.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075307", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "The p53 tumour suppressor protein is tightly controlled by the E3 ubiquitin ligase, mouse double minute 2 (MDM2), but maintains MDM2 expression as part of a negative feedback loop. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19166840", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Murine double minute (MDM2) is an E3 ligase that promotes ubiquitination and degradation of tumor suppressor protein 53 (p53).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819825", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 300, "text": "This is well illustrated by the E3 ubiquitin ligase MDM2 that targets p53 for proteasomal degradation under normal conditions and is essential for controlling p53 activity during development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23581014", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "The RING domain E3 ubiquitin ligase Mdm2 is the master regulator of the tumor suppressor p53. It targets p53 for proteasomal degradation, restraining the potent activity of p53 and enabling cell survival and proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671280", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "The p53 transcription factor and tumor suppressor is regulated primarily by the E3 ubiquitin ligase Mdm2, which ubiquitinates p53 to target it for proteasomal degradation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666487", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Mdm2 is a RING finger E3 ubiquitin ligase, which promotes ubiquitination and proteasomal degradation of the p53 tumor suppressor protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15013777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16339144", "endSection": "abstract"}]}, {"body": "What is the color of the protein Ranasmurfin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20615601", "http://www.ncbi.nlm.nih.gov/pubmed/17077494"], "triples": [], "ideal_answer": ["Ranasmurfin is a blue protein."], "exact_answer": [["Blue"]], "concepts": [], "type": "factoid", "id": "56f961b3cf1c325851000003", "snippets": [{"offsetInBeginSection": 428, "offsetInEndSection": 554, "text": "Ranasmurfin, a blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20615601", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Crystallization of Ranasmurfin, a blue-coloured protein from Polypedates leucomystax.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17077494", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Ranasmurfin, a previously uncharacterized approximately 13 kDa blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue colour ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17077494", "endSection": "abstract"}]}, {"body": "What is the prevalence of short QT syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21855519", "http://www.ncbi.nlm.nih.gov/pubmed/18543308", "http://www.ncbi.nlm.nih.gov/pubmed/18070308", "http://www.ncbi.nlm.nih.gov/pubmed/17679619", "http://www.ncbi.nlm.nih.gov/pubmed/19303371"], "triples": [], "ideal_answer": "The prevalence of short QT syndrome is low and varies between 0.01% and 0.1%", "exact_answer": ["0.01% -0.1%"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015995"], "type": "factoid", "id": "52fb78572059c6d71c000067", "snippets": [{"offsetInBeginSection": 384, "offsetInEndSection": 714, "text": "We chose patients with a short Bazett QTc interval from a database consisting of 114,334 patients to determine the clinical characteristics and prognostic value of a short QT interval. RESULTS: A total of 427 patients (mean age 43.4 \u00b1 22.4 years) had a short QT interval with about a 1.2 times higher male predominance (234 men). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21855519", "endSection": "abstract"}, {"offsetInBeginSection": 965, "offsetInEndSection": 1347, "text": "Among 5,511 males, 69 subjects (1.25%) exhibited QTc < 354 msec(1/2) (2 standard deviations [SDs] below the mean in males), and among 5,473 females, 89 subjects (1.63%) exhibited QTc < 364 msec(1/2) (2 SDs below the mean in females). Only 3 subjects (0.03% in all subjects and 0.05% in males) exhibited QTc < 300 msec(1/2), however, none had clinical symptoms of short QT syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18543308", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 640, "text": "Of the 19,153 subjects, two met the criteria of short QT interval and allowed for prevalence and incidence estimates for short QT interval as 0.01% and 0.39/100,000 person-years, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18070308", "endSection": "abstract"}, {"offsetInBeginSection": 887, "offsetInEndSection": 1065, "text": "The prevalence of QT interval <320 ms based on QTc, QTfc, and QTnc was 0.10%, 0.08%, and 0.06%, and the prevalence of QT interval <340 ms was 0.4%, 0.3%, and 0.3%, respectively. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17679619", "endSection": "abstract"}]}, {"body": "Which is the molecular target of the immunosuppressant drug Rapamycin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23994756", "http://www.ncbi.nlm.nih.gov/pubmed/23301832", "http://www.ncbi.nlm.nih.gov/pubmed/23261661", "http://www.ncbi.nlm.nih.gov/pubmed/22442756", "http://www.ncbi.nlm.nih.gov/pubmed/18980246", "http://www.ncbi.nlm.nih.gov/pubmed/18451231", "http://www.ncbi.nlm.nih.gov/pubmed/17728765", "http://www.ncbi.nlm.nih.gov/pubmed/17041625", "http://www.ncbi.nlm.nih.gov/pubmed/15901852", "http://www.ncbi.nlm.nih.gov/pubmed/15627018", "http://www.ncbi.nlm.nih.gov/pubmed/15163844", "http://www.ncbi.nlm.nih.gov/pubmed/14508096"], "triples": [], "ideal_answer": "The molecular target of Rapamycin is mTOR", "exact_answer": ["mTOR"], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031929", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0032006", "http://www.biosemantics.org/jochem#4274961", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020123", "http://www.uniprot.org/uniprot/TOR_ORYSJ", "http://www.uniprot.org/uniprot/TOR_ARATH", "http://www.uniprot.org/uniprot/TOR_DROME", "http://www.uniprot.org/uniprot/TOR_DICDI"], "type": "factoid", "id": "53124bdae3eabad02100000b", "snippets": [{"offsetInBeginSection": 1170, "offsetInEndSection": 1205, "text": "molecular target of rapamycin (mTOR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23994756", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 679, "text": "molecular target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23301832", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 41, "text": "molecular target of rapamycin (mTOR) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23261661", "endSection": "abstract"}, {"offsetInBeginSection": 1839, "offsetInEndSection": 1875, "text": "molecular target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442756", "endSection": "abstract"}, {"offsetInBeginSection": 1363, "offsetInEndSection": 1399, "text": "molecular target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980246", "endSection": "abstract"}, {"offsetInBeginSection": 55, "offsetInEndSection": 92, "text": "molecular target of rapamycin (mTOR) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18451231", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 40, "text": "molecular target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17728765", "endSection": "abstract"}, {"offsetInBeginSection": 325, "offsetInEndSection": 363, "text": "the molecular Target Of Rapamycin, TOR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17041625", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1573, "text": "molecular target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15901852", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 49, "text": "molecular target of rapamycin (mTOR", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15627018", "endSection": "title"}, {"offsetInBeginSection": 1930, "offsetInEndSection": 1967, "text": "molecular target of rapamycin (mTOR) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15163844", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 41, "text": "molecular target of rapamycin (mTOR),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14508096", "endSection": "abstract"}]}, {"body": "Which is the most widely used model for the study of multiple sclerosis (MS)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23161666", "http://www.ncbi.nlm.nih.gov/pubmed/22530047", "http://www.ncbi.nlm.nih.gov/pubmed/22272832", "http://www.ncbi.nlm.nih.gov/pubmed/21255614", "http://www.ncbi.nlm.nih.gov/pubmed/21029240", "http://www.ncbi.nlm.nih.gov/pubmed/20829083", "http://www.ncbi.nlm.nih.gov/pubmed/20623621", "http://www.ncbi.nlm.nih.gov/pubmed/19894121", "http://www.ncbi.nlm.nih.gov/pubmed/19361871", "http://www.ncbi.nlm.nih.gov/pubmed/18950873", "http://www.ncbi.nlm.nih.gov/pubmed/18773082", "http://www.ncbi.nlm.nih.gov/pubmed/18673215", "http://www.ncbi.nlm.nih.gov/pubmed/17766043", "http://www.ncbi.nlm.nih.gov/pubmed/17463082", "http://www.ncbi.nlm.nih.gov/pubmed/17343922", "http://www.ncbi.nlm.nih.gov/pubmed/16440059", "http://www.ncbi.nlm.nih.gov/pubmed/16137612", "http://www.ncbi.nlm.nih.gov/pubmed/16126908", "http://www.ncbi.nlm.nih.gov/pubmed/16106061", "http://www.ncbi.nlm.nih.gov/pubmed/15949496", "http://www.ncbi.nlm.nih.gov/pubmed/15929040", "http://www.ncbi.nlm.nih.gov/pubmed/15898103", "http://www.ncbi.nlm.nih.gov/pubmed/15492125", "http://www.ncbi.nlm.nih.gov/pubmed/15288396", "http://www.ncbi.nlm.nih.gov/pubmed/15265674", "http://www.ncbi.nlm.nih.gov/pubmed/15039233", "http://www.ncbi.nlm.nih.gov/pubmed/11829341", "http://www.ncbi.nlm.nih.gov/pubmed/11391780", "http://www.ncbi.nlm.nih.gov/pubmed/7739505", "http://www.ncbi.nlm.nih.gov/pubmed/1793022"], "ideal_answer": ["Experimental autoimmune encephalomyelitis (EAE) is a classical, conventional and widely recognized animal model for studying multiple sclerosis (MS). EAE is the best available model for the inflammatory processes that occur in MS, and for the disease process. A less commonly used model is that of Theiler's murine encephalomyelitis virus (TMEV)."], "exact_answer": ["Experimental autoimmune encephalomyelitis (EAE)"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", "http://www.disease-ontology.org/api/metadata/DOID:2377", "http://www.disease-ontology.org/api/metadata/DOID:2376"], "type": "factoid", "id": "5139b31dbee46bd34c000004", "snippets": [{"offsetInBeginSection": 241, "offsetInEndSection": 323, "text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23161666", "endSection": "sections.0"}, {"offsetInBeginSection": 282, "offsetInEndSection": 427, "text": "Many aspects of MS can be mimicked in the animal model of myelin oligodendrocyte glycoprotein experimental autoimmune encephalomyelitis (MOG-EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21255614", "endSection": "sections.0"}, {"offsetInBeginSection": 531, "offsetInEndSection": 608, "text": "the chronic experimental autoimmune encephalomyelitis (EAE) mouse model of MS", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21029240", "endSection": "sections.0"}, {"offsetInBeginSection": 343, "offsetInEndSection": 548, "text": "The aim of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis (EAE) in the rat", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20829083", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (MS)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20623621", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Theiler's murine encephalomyelitis virus (TMEV) infection of mice is an experimental model for multiple sclerosis (MS)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19894121", "endSection": "sections.0"}, {"offsetInBeginSection": 508, "offsetInEndSection": 599, "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19361871", "endSection": "sections.0"}, {"offsetInBeginSection": 448, "offsetInEndSection": 593, "text": "In this study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis (EAE), similar changes occur", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18950873", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis (MS)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18673215", "endSection": "sections.0"}, {"offsetInBeginSection": 196, "offsetInEndSection": 271, "text": "we utilized the Theiler's murine encephalomyelitis virus (TMEV) model of MS", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17766043", "endSection": "sections.0"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1027, "text": "In a murine disease model, experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463082", "endSection": "sections.0"}, {"offsetInBeginSection": 45, "offsetInEndSection": 125, "text": "experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17463082", "endSection": "title"}, {"offsetInBeginSection": 613, "offsetInEndSection": 660, "text": "Theiler's murine encephalomyelitis virus (TMEV)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17343922", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Inflammatory diseases of the CNS, such as MS and its animal model EAE", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16440059", "endSection": "sections.0"}, {"offsetInBeginSection": 152, "offsetInEndSection": 243, "text": "the strong impact of the classical MS model experimental autoimmune encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16137612", "endSection": "sections.0"}, {"offsetInBeginSection": 43, "offsetInEndSection": 191, "text": "an animal model of multiple sclerosis (MS): disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1793022", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7739505", "endSection": "title"}, {"offsetInBeginSection": 178, "offsetInEndSection": 286, "text": "EAE is the best available model for the inflammatory processes that occur in MS, and for the disease process", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7739505", "endSection": "sections.0"}, {"offsetInBeginSection": 455, "offsetInEndSection": 561, "text": "The present study addressed this question using the model of experimental allergic encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11391780", "endSection": "sections.0"}, {"offsetInBeginSection": 261, "offsetInEndSection": 345, "text": "The conventional animal model of MS, experimental autoimmune encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15039233", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "To assess neurological impairments quantitatively in an animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15265674", "endSection": "sections.0"}, {"offsetInBeginSection": 155, "offsetInEndSection": 362, "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS, including central nervous system inflammation and demyelination", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15288396", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Both multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white matter", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15898103", "endSection": "sections.0"}, {"offsetInBeginSection": 370, "offsetInEndSection": 459, "text": "both MS patients and the MS animal model, experimental autoimmune encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15929040", "endSection": "sections.0"}, {"offsetInBeginSection": 289, "offsetInEndSection": 359, "text": "In the MS animal model experimental autoimmune encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15949496", "endSection": "sections.0"}, {"offsetInBeginSection": 20, "offsetInEndSection": 102, "text": "multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16106061", "endSection": "title"}, {"offsetInBeginSection": 143, "offsetInEndSection": 256, "text": "inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16126908", "endSection": "sections.0"}]}, {"body": "How are CRM (cis-regulatory modules) defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25268582", "http://www.ncbi.nlm.nih.gov/pubmed/22877946", "http://www.ncbi.nlm.nih.gov/pubmed/21152003", "http://www.ncbi.nlm.nih.gov/pubmed/19660565", "http://www.ncbi.nlm.nih.gov/pubmed/17711474", "http://www.ncbi.nlm.nih.gov/pubmed/15677727", "http://www.ncbi.nlm.nih.gov/pubmed/15883375", "http://www.ncbi.nlm.nih.gov/pubmed/15757364", "http://www.ncbi.nlm.nih.gov/pubmed/15215390", "http://www.ncbi.nlm.nih.gov/pubmed/25442502", "http://www.ncbi.nlm.nih.gov/pubmed/23409927", "http://www.ncbi.nlm.nih.gov/pubmed/19820186", "http://www.ncbi.nlm.nih.gov/pubmed/14534164", "http://www.ncbi.nlm.nih.gov/pubmed/22492356", "http://www.ncbi.nlm.nih.gov/pubmed/16980320"], "triples": [], "ideal_answer": ["In many species, especially higher eukaryotes, transcription factor binding sites tend to occur as homotypic or heterotypic clusters, also known as cis-regulatory modules. Several tools allow to detect significant co-occurrences of closely located binding sites (cis-regulatory modules, CRMs).", "Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules.", "Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules.", "Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules.", "Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules.", "Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules.", "CisMiner can be queried for the results presented in this work and can also perform a customized cis-regulatory module prediction on a query set of transcription factor binding sites provided by the user. In many species, especially higher eukaryotes, transcription factor binding sites tend to occur as homotypic or heterotypic clusters, also known as cis-regulatory modules. Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules. Our web server is available at http://creme.dcode.org.", "Several tools allow to detect significant co-occurrences of closely located binding sites (cis-regulatory modules, CRMs).  "], "concepts": [], "type": "summary", "id": "56f3eebd2ac5ed1459000016", "snippets": [{"offsetInBeginSection": 137, "offsetInEndSection": 281, "text": "Eukaryotic genes are often regulated by several transcription factors whose binding sites are tightly clustered and form cis-regulatory modules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15215390", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 303, "text": "In many species, especially higher eukaryotes, transcription factor binding sites tend to occur as homotypic or heterotypic clusters, also known as cis-regulatory modules", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15883375", "endSection": "abstract"}, {"offsetInBeginSection": 474, "offsetInEndSection": 604, "text": "This conserved sequence has therefore been proposed to act as a long-range, cis-acting regulator of limb-specific Shh expression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15677727", "endSection": "abstract"}, {"offsetInBeginSection": 975, "offsetInEndSection": 1187, "text": "The conserved upstream sequence can activate gene expression from basal promoters in the brain vesicle, although it requires additional cis-regulatory sequences to fully activate the CNS-specific gene expression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17711474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The genomic instructions used to regulate development are encoded within a set of functional DNA elements called cis-regulatory modules ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19660565", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 404, "text": "Several tools allow to detect significant co-occurrences of closely located binding sites (cis-regulatory modules, CRMs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25268582", "endSection": "abstract"}, {"offsetInBeginSection": 471, "offsetInEndSection": 714, "text": "However, studies on the cis-regulatory sequences mediating the synergistic effects of these transcription factors are complicated by the limited knowledge of notochord genes and cis-regulatory modules (CRMs) that are directly targeted by both.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19820186", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "The identification of transcription factor binding sites (TFBSs) and cis-regulatory modules (CRMs) is a crucial step in studying gene expression, but the computational method attempting to distinguish CRMs from NCNRs still remains a challenging problem due to the limited knowledge of specific interactions involved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23409927", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "In eukaryotes, transcriptional regulation is usually mediated by interactions of multiple transcription factors (TFs) with their respective specific cis-regulatory elements (CREs) in the so-called cis-regulatory modules (CRMs) in DNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25442502", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "The transcriptional regulation of a metazoan gene depends on the cooperative action of multiple transcription factors that bind to cis-regulatory modules (CRMs) located in the neighborhood of the gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14534164", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Dynamic in vivo binding of transcription factors to cis-regulatory modules of cer and gsc in the stepwise formation of the Spemann-Mangold organizer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492356", "endSection": "title"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "We also identified potential cis-regulatory modules (CRMs) defined as clusters of conserved TFBSs in the entire mouse genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980320", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "We also identified potential cis-regulatory modules (CRMs) defined as clusters of conserved TFBSs in the entire mouse genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980320", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "We also identified potential cis-regulatory modules (CRMs) defined as clusters of conserved TFBSs in the entire mouse genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980320", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "We also identified potential cis-regulatory modules (CRMs) defined as clusters of conserved TFBSs in the entire mouse genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980320", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 756, "text": "We also identified potential cis-regulatory modules (CRMs) defined as clusters of conserved TFBSs in the entire mouse genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980320", "endSection": "abstract"}]}, {"body": "Which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25328416", "http://www.ncbi.nlm.nih.gov/pubmed/25309450", "http://www.ncbi.nlm.nih.gov/pubmed/25228955", "http://www.ncbi.nlm.nih.gov/pubmed/25209314", "http://www.ncbi.nlm.nih.gov/pubmed/25191275", "http://www.ncbi.nlm.nih.gov/pubmed/25081404", "http://www.ncbi.nlm.nih.gov/pubmed/25044876", "http://www.ncbi.nlm.nih.gov/pubmed/23782526", "http://www.ncbi.nlm.nih.gov/pubmed/21507890", "http://www.ncbi.nlm.nih.gov/pubmed/22665960"], "triples": [], "ideal_answer": ["Hypertrophic cardiomyopathy (HCM) has been recently recognized as the most common inherited cardiovascular disorder, affecting 1 in 500 adults worldwide. HCM is characterized by myocyte hypertrophy resulting in thickening of the ventricular wall, myocyte disarray, interstitial and/or replacement fibrosis, decreased ventricular cavity volume and diastolic dysfunction. HCM is also the most common cause of sudden death in the young particularly among athletes. A large proportion of patients diagnosed with HCM have mutations in sarcomeric proteins. HCM is the most prevalent genetic disorder affecting the heart and is typically inherited in an autosomal dominant pattern. Adults with cardiomyopathy suffer SCD or adverse events such as stroke and heart failure from HCM."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:11984"], "type": "summary", "id": "54dcb29dc0bb8dce23000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 410, "text": "Hypertrophic cardiomyopathy (HCM) is a primary disease of the cardiac muscle that occurs mainly due to mutations (>1,400 variants) in genes encoding for the cardiac sarcomere. HCM, the most common familial form of cardiomyopathy, affecting one in every 500 people in the general population, is typically inherited in an autosomal dominant pattern, and presents variable expressivity and age-related penetrance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Familial hypertrophic cardiomyopathy (HCM), due to point mutations in genes for sarcomere proteins such as myosin, occurs in 1/500 people and is the most common cause of sudden death in young individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309450", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 689, "text": "n HCM, the modified protein function leads, over years to decades, to secondary remodeling with substantial morphological changes, such as hypertrophy, myofibrillar disarray, and extensive fibrosis associated with severe functional deterioration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309450", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in the young, particularly among athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25228955", "endSection": "abstract"}, {"offsetInBeginSection": 6, "offsetInEndSection": 134, "text": "Familial hypertrophic cardiomyopathy (HCM) is one the most common heart disorders, with gene mutations in the cardiac sarcomere.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25209314", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 522, "text": "Hypertrophic cardiomyopathy (HCM) has been recently recognized as the most common inherited cardiovascular disorder, affecting 1 in 500 adults worldwide. HCM is characterized by myocyte hypertrophy resulting in thickening of the ventricular wall, myocyte disarray, interstitial and/or replacement fibrosis, decreased ventricular cavity volume and diastolic dysfunction. HCM is also the most common cause of sudden death in the young. A large proportion of patients diagnosed with HCM have mutations in sarcomeric proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191275", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy. The prevalence of phenotypic expression, in the absence of another systemic or cardiac disease causing increased left ventricular (LV) wall thickness, is estimated to be 1:500. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25081404", "endSection": "abstract"}, {"offsetInBeginSection": 562, "offsetInEndSection": 819, "text": "HCM is the most prevalent genetic disorder affecting the heart, it often goes undiagnosed until midlife after patients show symptoms of myocardial remodeling. Adults with cardiomyopathy suffer SCD or adverse events such as stroke and heart failure from HCM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044876", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous autosomal dominant heart disease characterised by left ventricular hypertrophy in the absence of another cardiac or systemic disease that is capable of producing significant wall thickening.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21507890", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited genetic disease characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665960", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 410, "text": "Hypertrophic cardiomyopathy (HCM) is a primary disease of the cardiac muscle that occurs mainly due to mutations (>1,400 variants) in genes encoding for the cardiac sarcomere. HCM, the most common familial form of cardiomyopathy, affecting one in every 500 people in the general population, is typically inherited in an autosomal dominant pattern, and presents variable expressivity and age-related penetrance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25328416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Familial hypertrophic cardiomyopathy (HCM), due to point mutations in genes for sarcomere proteins such as myosin, occurs in 1/500 people and is the most common cause of sudden death in young individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25309450", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 217, "text": "Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous genetic heart disease characterized by left ventricular hypertrophy in the absence of another disease that could explain the wall thickening.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23782526", "endSection": "abstract"}]}, {"body": "What is HbVar?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11857738", "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "http://www.ncbi.nlm.nih.gov/pubmed/21932936"], "triples": [], "ideal_answer": ["HbVar (http://globin.cse.psu.edu) is a relational database of hemoglobin variants and thalassemia mutations. Extensive information is recorded for each variant and mutation, including a description of the variant and associated pathology, hematology, electrophoretic mobility, methods of isolation, stability information, ethnic occurrence, structure studies, functional studies, and references. The initial information was derived from books by Dr. Titus Huisman and colleagues [Huisman et al., 1996, 1997, 1998]. The current database is updated regularly with the addition of new data and corrections to previous data. Queries can be formulated based on fields in the database. Tables of common categories of variants, such as all those involving the alpha1-globin gene (HBA1) or all those that result in high oxygen affinity, are maintained by automated queries on the database. Users can formulate more precise queries, such as identifying \"all beta-globin variants associated with instability and found in Scottish populations.\" This new database should be useful for clinical diagnosis as well as in fundamental studies of hemoglobin biochemistry, globin gene regulation, and human sequence variation at these loci."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017085", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017086", "http://www.disease-ontology.org/api/metadata/DOID:1099", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006441", "http://www.disease-ontology.org/api/metadata/DOID:10241", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055538", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019991", "http://www.biosemantics.org/jochem#4249395", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005319", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013789"], "type": "summary", "id": "56c23652ef6e39474100005a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1281, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu. Extensive information is recorded for each variant and mutation, including a description of the variant and associated pathology, hematology, electrophoretic mobility, methods of isolation, stability information, ethnic occurrence, structure studies, functional studies, and references. The initial information was derived from books by Dr. Titus Huisman and colleagues [Huisman et al., 1996, 1997, 1998]. The current database is updated regularly with the addition of new data and corrections to previous data. Queries can be formulated based on fields in the database. Tables of common categories of variants, such as all those involving the alpha1-globin gene (HBA1) or all those that result in high oxygen affinity, are maintained by automated queries on the database. Users can formulate more precise queries, such as identifying \"all beta-globin variants associated with instability and found in Scottish populations.\" This new database should be useful for clinical diagnosis as well as in fundamental studies of hemoglobin biochemistry, globin gene regulation, and human sequence variation at these loci.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 611, "text": "A registry of these Hb variants and other information, a legacy from Professor Huisman, is now available online, at HbVar database (hhtp://globin.bx.psu.edu/hbvar).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 297, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 447, "offsetInEndSection": 611, "text": "A registry of these Hb variants and other information, a legacy from Professor Huisman, is now available online, at HbVar database (hhtp://globin.bx.psu.edu/hbvar).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 297, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 272, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 297, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "We have constructed a relational database of hemoglobin variants and thalassemia mutations, called HbVar, which can be accessed on the web at http://globin.cse.psu.edu.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 292, "offsetInEndSection": 456, "text": "A registry of these Hb variants and other information, a legacy from Professor Huisman, is now available online, at HbVar database (hhtp://globin.bx.psu.edu/hbvar).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 292, "offsetInEndSection": 456, "text": "A registry of these Hb variants and other information, a legacy from Professor Huisman, is now available online, at HbVar database (hhtp://globin.bx.psu.edu/hbvar).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 292, "offsetInEndSection": 456, "text": "A registry of these Hb variants and other information, a legacy from Professor Huisman, is now available online, at HbVar database (hhtp://globin.bx.psu.edu/hbvar).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}, {"offsetInBeginSection": 292, "offsetInEndSection": 456, "text": "A registry of these Hb variants and other information, a legacy from Professor Huisman, is now available online, at HbVar database (hhtp://globin.bx.psu.edu/hbvar).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21932936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is a locus-specific database (LSDB) developed in 2001 by a multi-center academic effort to provide timely information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 284, "text": "HbVar (http://globin.cse.psu.edu/globin/hbvar/) is a relational database developed by a multi-center academic effort to provide up-to-date and high quality information on the genomic sequence changes leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "HbVar (http://globin.bx.psu.edu/hbvar) is one of the oldest and most appreciated locus-specific databases launched in 2001 by a multi-center academic effort to provide timely information on the genomic alterations leading to hemoglobin variants and all types of thalassemia and hemoglobinopathies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17221864", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Updates of the HbVar database of human hemoglobin variants and thalassemia mutations.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24137000", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11857738", "endSection": "title"}]}, {"body": "Which JAK (Janus kinase) inhibitor is approved for treatment of rheumatoid arthritis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24285764", "http://www.ncbi.nlm.nih.gov/pubmed/24218541", "http://www.ncbi.nlm.nih.gov/pubmed/24193189", "http://www.ncbi.nlm.nih.gov/pubmed/24013646", "http://www.ncbi.nlm.nih.gov/pubmed/23961674", "http://www.ncbi.nlm.nih.gov/pubmed/23627915", "http://www.ncbi.nlm.nih.gov/pubmed/23599436", "http://www.ncbi.nlm.nih.gov/pubmed/23523202", "http://www.ncbi.nlm.nih.gov/pubmed/23384668", "http://www.ncbi.nlm.nih.gov/pubmed/23212593", "http://www.ncbi.nlm.nih.gov/pubmed/22971156", "http://www.ncbi.nlm.nih.gov/pubmed/22899318", "http://www.ncbi.nlm.nih.gov/pubmed/22777068", "http://www.ncbi.nlm.nih.gov/pubmed/22460142", "http://www.ncbi.nlm.nih.gov/pubmed/22374445", "http://www.ncbi.nlm.nih.gov/pubmed/22252297", "http://www.ncbi.nlm.nih.gov/pubmed/22209716", "http://www.ncbi.nlm.nih.gov/pubmed/22147632", "http://www.ncbi.nlm.nih.gov/pubmed/22121136", "http://www.ncbi.nlm.nih.gov/pubmed/22006202", "http://www.ncbi.nlm.nih.gov/pubmed/21952978", "http://www.ncbi.nlm.nih.gov/pubmed/21884580", "http://www.ncbi.nlm.nih.gov/pubmed/21548952", "http://www.ncbi.nlm.nih.gov/pubmed/21105711", "http://www.ncbi.nlm.nih.gov/pubmed/20732649", "http://www.ncbi.nlm.nih.gov/pubmed/20701804", "http://www.ncbi.nlm.nih.gov/pubmed/20233177", "http://www.ncbi.nlm.nih.gov/pubmed/19587388", "http://www.ncbi.nlm.nih.gov/pubmed/19565475", "http://www.ncbi.nlm.nih.gov/pubmed/19404006", "http://www.ncbi.nlm.nih.gov/pubmed/23642011"], "triples": [], "ideal_answer": "Tofacitinib (or CP690.550) is an oral JAK (Janus kinase) inhibitor that is approved for treatment of rheumatoid arthritis. Tofacitinib inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. Tofacitinib has also a proven efficacy as an immunosuppressive regimen after renal transplantation.  \nGLPG-0634 and INCB18424 are other JAK kinase inhibitors that are being studied for treatment of rheumatoid arthritis.", "exact_answer": ["tofacitinib"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053612", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001172", "http://www.uniprot.org/uniprot/JAK1_MOUSE", "http://www.uniprot.org/uniprot/JAK1_HUMAN", "http://www.uniprot.org/uniprot/JAK1_DANRE", "http://www.uniprot.org/uniprot/JAK1_CYPCA", "http://www.uniprot.org/uniprot/JAK2_PONAB", "http://www.uniprot.org/uniprot/JAK2_HUMAN", "http://www.uniprot.org/uniprot/JAK2_PIG", "http://www.uniprot.org/uniprot/JAK2_CHICK", "http://www.uniprot.org/uniprot/JAK2_MOUSE", "http://www.uniprot.org/uniprot/JAK2_RAT", "http://www.uniprot.org/uniprot/JAK3_RAT", "http://www.uniprot.org/uniprot/JAK3_MOUSE", "http://www.uniprot.org/uniprot/JAK3_HUMAN", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004713", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033673", "http://www.disease-ontology.org/api/metadata/DOID:7148", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053614", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053613", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053616"], "type": "factoid", "id": "53357193d6d3ac6a34000047", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285764", "endSection": "title"}, {"offsetInBeginSection": 774, "offsetInEndSection": 876, "text": "Tofacitinib is the first oral Janus kinase inhibitor indicated for treatment of moderate to severe RA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285764", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218541", "endSection": "title"}, {"offsetInBeginSection": 180, "offsetInEndSection": 434, "text": "The preclinical pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clinical PK/PD data from patients with rheumatoid arthritis (RA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24218541", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 430, "text": "With tofacitinib, the first Janus kinase (JAK) inhibitor has been approved in the USA, as well as in Switzerland and other countries. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193189", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 134, "text": "Tofacitinib, which is a Janus kinase (JAK) inhibitor, has shown clinical effects in the treatment of rheumatoid arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24013646", "endSection": "abstract"}, {"offsetInBeginSection": 257, "offsetInEndSection": 625, "text": "Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23627915", "endSection": "abstract"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1272, "text": " In patients treated with the JAK inhibitor tofacitinib, RR for hypercholesterolaemia was 1.70 (1.10 to 2.63) that was dose related. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23599436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "After two decades of research and development activity focussed on orally active kinase inhibitors, the first such drug (the JAK inhibitor Xeljanz, tofacitinib) was approved by the FDA in November 2012 for the treatment of rheumatoid arthritis (RA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523202", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593", "endSection": "title"}, {"offsetInBeginSection": 317, "offsetInEndSection": 474, "text": "An orally available JAK3 inhibitor, tofacitinib, has been applied for RA, with satisfactory effects and acceptable safety in multiple clinical examinations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593", "endSection": "abstract"}, {"offsetInBeginSection": 588, "offsetInEndSection": 935, "text": "Subsequently, multiple phase 3 studies were carried out, and tofacitinib with or without methotrexate (MTX) is efficacious and has a manageable safety profile in active RA patients who are MTX na\u00efve or show inadequate response to methotrexate (MTX-IR), disease-modifying antirheumatic drugs (DMARD)-IR, or tumor necrosis factor (TNF)-inhibitor-IR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593", "endSection": "abstract"}, {"offsetInBeginSection": 1369, "offsetInEndSection": 1519, "text": "Taken together, an orally available kinase inhibitor tofacitinib targeting JAK-mediated signals would be expected to be a new option for RA treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23212593", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 355, "text": "A non-selective JAK inhibitor, ruxolitinib, has recently been approved to treat myelofibrosis whereas tofacitinib is poised for approval to treat rheumatoid arthritis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22971156", "endSection": "abstract"}, {"offsetInBeginSection": 885, "offsetInEndSection": 1138, "text": "The recent disclosure of the clinical efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22971156", "endSection": "abstract"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1818, "text": "These results suggest that the JAK inhibitor tofacitinib suppresses osteoclast-mediated structural damage to arthritic joints, and this effect is secondary to decreased RANKL production.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22899318", "endSection": "abstract"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1285, "text": "More recently, the Janus kinase (JAK) inhibitor tofacitinib has been evaluated as a potential new treatment option in RA and is awaiting approval.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22777068", "endSection": "abstract"}, {"offsetInBeginSection": 1300, "offsetInEndSection": 1794, "text": "A total of 140 patients were randomised to tofacitinib 1, 3, 5, 10 mg or placebo twice daily and the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12, a primary end point, was significant for all tofacitinib treatment groups. Thus, an orally available tofacitinib in combination with MTX was efficacious and had a manageable safety profile. Tofacitinib at 5 and 10 mg twice a day appears suitable for further evaluation to optimise the treatment of RA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22460142", "endSection": "abstract"}, {"offsetInBeginSection": 1244, "offsetInEndSection": 1440, "text": "Moreover, induction of IL-10 production by DCs can be one mechanism of action of the JAK inhibitor (tofacitinib) which have shown high efficiency on active rheumatoid arthritis in clinical trials.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22374445", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 539, "text": "Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22252297", "endSection": "abstract"}, {"offsetInBeginSection": 10, "offsetInEndSection": 146, "text": " Tofacitinib (CP-690,550) is a novel JAK inhibitor that is currently in clinical trials for the treatment of rheumatoid arthritis (RA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147632", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 298, "text": "To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP-690,550) with placebo for the treatment of active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22006202", "endSection": "abstract"}, {"offsetInBeginSection": 1724, "offsetInEndSection": 1930, "text": "In patients with active RA in whom the response to MTX has been inadequate, the addition of tofacitinib at a dosage \u22653 mg twice daily showed sustained efficacy and a manageable safety profile over 24 weeks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22006202", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 279, "text": "OBJECTIVE: To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21952978", "endSection": "abstract"}, {"offsetInBeginSection": 1749, "offsetInEndSection": 1913, "text": "Tofacitinib monotherapy at \u22653 mg twice a day was efficacious in the treatment of patients with active RA over 24 weeks and demonstrated a manageable safety profile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21952978", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 107, "text": "The new JAK3 inhibitor, CP690,550, has shown efficacy in the treatment of rheumatoid arthritis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21884580", "endSection": "abstract"}, {"offsetInBeginSection": 175, "offsetInEndSection": 326, "text": "CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20701804", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20233177", "endSection": "title"}, {"offsetInBeginSection": 6, "offsetInEndSection": 369, "text": "To investigate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550, a novel Janus kinase (JAK) inhibitor in development as a therapy for rheumatoid arthritis (RA), to determine the effects of multiple doses of CP-690,550 on the PK of MTX, and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20233177", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587388", "endSection": "title"}, {"offsetInBeginSection": 981, "offsetInEndSection": 1101, "text": "CP-690,550 was efficacious in improving the pain, function and health status of patients with RA, from week 1 to week 6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19587388", "endSection": "abstract"}, {"offsetInBeginSection": 1537, "offsetInEndSection": 1730, "text": "Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clinically meaningful reductions in the signs and symptoms of RA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19565475", "endSection": "abstract"}, {"offsetInBeginSection": 458, "offsetInEndSection": 578, "text": "INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3 has been developed and is now on phase II clinical study for RA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19404006", "endSection": "abstract"}]}, {"body": "What is known about the effectiveness of electronic food diaries ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24205807", "http://www.ncbi.nlm.nih.gov/pubmed/23415822", "http://www.ncbi.nlm.nih.gov/pubmed/20307404"], "triples": [], "ideal_answer": ["Electronic dietary records were better than food diaries in terms of fat percentage reduction in our trials, indicating that teledietetics increases healthy-eating awareness."], "concepts": [], "type": "summary", "id": "5502fe13e9bde69634000009", "snippets": [{"offsetInBeginSection": 1617, "offsetInEndSection": 1791, "text": "Electronic dietary records were better than food diaries in terms of fat percentage reduction in our trials, indicating that teledietetics increases healthy-eating awareness.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24205807", "endSection": "abstract"}, {"offsetInBeginSection": 258, "offsetInEndSection": 512, "text": "Nutrition monitoring is a relevant method to gain an overview of factors influencing health. However, keeping a food diary often constitutes a challenge for a patient, and developing a user-friendly and useful electronic food diary is not straightforward", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415822", "endSection": "abstract"}, {"offsetInBeginSection": 2331, "offsetInEndSection": 3169, "text": "The analyzed apps reflected a variety of approaches to recording food intake and nutrition using different terminals--mostly mobile phones (35%), followed by PCs (29%) and PDAs (23%) for older studies, designed mainly for users with obesity (45%), diabetes mellitus (42%) and overweight (32%), or people who want to stay healthy (10%). The majority of the reviewed applications (67%) offered only input of food type and quantity. All approaches (n=31), except for two, relied on manual input of data, either by typing or by selecting a food type from a database. The exceptions (n=2) used a barcode scanning function. Users of mobile phone applications were not limited to data recording, but could view their data on the screen and send it via email. The tested web applications offered similar functionalities for recording food intake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23415822", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 425, "text": "electronic food diary on a mobile phone that includes an energy balance visualization and computes and displays the difference between energy intake from food entries and energy expenditure from a multiple-sensor device that provides objective estimates of energy expenditure in real time", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307404", "endSection": "abstract"}]}, {"body": "Which R/bioconductor package utilizes the Hilbert curve in order to visualize genomic data?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19297348"], "triples": [], "ideal_answer": ["The so-called Hilbert curve visualization can complement genome browsers and help to get further insights into the structure of one's data. An open-source application, called HilbertVis, has been developed for R/bioconductor that allows the user to produce and interactively explore such plots."], "exact_answer": [["HilbertVis"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023281"], "type": "factoid", "id": "56bdcc4cef6e394741000002", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 648, "text": "In many genomic studies, one works with genome-position-dependent data, e.g. ChIP-chip or ChIP-Seq scores. Using conventional tools, it can be difficult to get a good feel for the data, especially the distribution of features. This article argues that the so-called Hilbert curve visualization can complement genome browsers and help to get further insights into the structure of one's data. This is demonstrated with examples from different use cases. An open-source application, called HilbertVis, is presented that allows the user to produce and interactively explore such plots.AVAILABILITY: http://www.ebi.ac.uk/huber-srv/hilbert/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19297348", "endSection": "abstract"}]}, {"body": "What is the association of spermidine with \u03b1-synuclein neurotoxicity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25483063", "http://www.ncbi.nlm.nih.gov/pubmed/22662273"], "triples": [], "ideal_answer": ["Spermidine protects against \u03b1-synuclein neurotoxicity. In the fruit fly, simple feeding with spermidine inhibited loss of climbing activity and early organismal death upon heterologous expression of human \u03b1-synuclein, which is thought to be the principal toxic trigger of Parkinson's Disease (PD). In this line, administration of spermidine rescued \u03b1-synuclein-induced loss of dopaminergic neurons, a hallmark of PD, in nematodes. Alleviation of PD-related neurodegeneration by spermidine was accompanied by induction of autophagy, suggesting that this cytoprotective process may be responsible for the beneficial effects of spermidine administration."], "exact_answer": [["Spermidine protects against \u03b1-synuclein neurotoxicity"]], "concepts": ["http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275085", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013095", "http://www.biosemantics.org/jochem#4275085"], "type": "factoid", "id": "56c073fcef6e394741000020", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Spermidine protects against \u03b1-synuclein neurotoxicity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483063", "endSection": "title"}, {"offsetInBeginSection": 227, "offsetInEndSection": 1132, "text": "Here, we show that administration of the naturally occurring polyamine spermidine, which declines continuously during aging in various species, alleviates a series of PD-related degenerative processes in the fruit fly Drosophila melanogaster and the nematode Caenorhabditis elegans, two established model systems for PD pathology. In the fruit fly, simple feeding with spermidine inhibited loss of climbing activity and early organismal death upon heterologous expression of human \u03b1-synuclein, which is thought to be the principal toxic trigger of PD. In this line, administration of spermidine rescued \u03b1-synuclein-induced loss of dopaminergic neurons, a hallmark of PD, in nematodes. Alleviation of PD-related neurodegeneration by spermidine was accompanied by induction of autophagy, suggesting that this cytoprotective process may be responsible for the beneficial effects of spermidine administration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483063", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Spermidine protects against \u03b1-synuclein neurotoxicity", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483063", "endSection": "title"}, {"offsetInBeginSection": 558, "offsetInEndSection": 910, "text": "In the fruit fly, simple feeding with spermidine inhibited loss of climbing activity and early organismal death upon heterologous expression of human \u03b1-synuclein, which is thought to be the principal toxic trigger of PD. In this line, administration of spermidine rescued \u03b1-synuclein-induced loss of dopaminergic neurons, a hallmark of PD, in nematodes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25483063", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1483, "text": "Together with the fact that spermidine facilitates late stages of \u03b1-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including \u03b1-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of \u03b1-Syn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22662273", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1483, "text": "Together with the fact that spermidine facilitates late stages of \u03b1-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including \u03b1-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of \u03b1-Syn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22662273", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1483, "text": "Together with the fact that spermidine facilitates late stages of \u03b1-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including \u03b1-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of \u03b1-Syn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22662273", "endSection": "abstract"}, {"offsetInBeginSection": 1121, "offsetInEndSection": 1483, "text": "Together with the fact that spermidine facilitates late stages of \u03b1-Syn aggregation, our data demonstrate that spermidine promotes the very early stages of protein aggregation including \u03b1-Syn misfolding and dimerization. This finding suggests that increased levels of spermidine and potentially other polyamines can initiate the disease-related process of \u03b1-Syn.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22662273", "endSection": "abstract"}]}, {"body": "What is the cause of episodic ataxia type 6?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23107647"], "triples": [], "ideal_answer": ["Episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1. Reduced glutamate uptake by mutant excitatory amino acid transporter-1 (EAAT1) has been thought to be the main pathophysiological process in episodic ataxia type 6."], "exact_answer": [["EAAT1 mutations"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:963"], "type": "factoid", "id": "571e4293bb137a4b0c00000b", "snippets": [{"offsetInBeginSection": 98, "offsetInEndSection": 497, "text": "There are several genetically and clinically distinct forms of this disease, and one of them, episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1. So far, reduced glutamate uptake by mutant excitatory amino acid transporter-1 has been thought to be the main pathophysiological process in episodic ataxia type 6. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}, {"offsetInBeginSection": 1645, "offsetInEndSection": 1934, "text": "Episodic ataxia type 6 represents the first human disease found to be associated with altered function of excitatory amino acid transporter anion channels and illustrates possible physiological and pathophysiological impacts of this functional mode of this class of glutamate transporters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 497, "text": "There are several genetically and clinically distinct forms of this disease, and one of them, episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1. So far, reduced glutamate uptake by mutant excitatory amino acid transporter-1 has been thought to be the main pathophysiological process in episodic ataxia type 6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 332, "text": "There are several genetically and clinically distinct forms of this disease, and one of them, episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 332, "text": "There are several genetically and clinically distinct forms of this disease, and one of them, episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 332, "text": "There are several genetically and clinically distinct forms of this disease, and one of them, episodic ataxia type 6, is caused by mutations in the gene encoding a glial glutamate transporter, the excitatory amino acid transporter-1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107647", "endSection": "abstract"}]}, {"body": "How do Hsp70 and Hsp110 affect mRNA stability?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10358092"], "triples": [], "ideal_answer": ["Hsp70 and Hsp110 act as RNA-binding entities in vivo to guide the appropriate folding of RNA substrates for subsequent regulatory processes such as mRNA degradation and/or translation."], "concepts": [], "type": "summary", "id": "56cafb1b5795f9a73e00002f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 130, "offsetInEndSection": 201, "text": "Hsp/Hsc70 and Hsp110 proteins preferentially bound AU-rich RNA in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "abstract"}, {"offsetInBeginSection": 1070, "offsetInEndSection": 1268, "text": "certain heat shock proteins may act as RNA-binding entities in vivo to guide the appropriate folding of RNA substrates for subsequent regulatory processes such as mRNA degradation and/or translation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10358092", "endSection": "title"}]}, {"body": "Describe the involvement of conserved noncoding sequences in the regulation of Hox genes.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20616144", "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "http://www.ncbi.nlm.nih.gov/pubmed/16636282", "http://www.ncbi.nlm.nih.gov/pubmed/15509224", "http://www.ncbi.nlm.nih.gov/pubmed/14707166", "http://www.ncbi.nlm.nih.gov/pubmed/12799348", "http://www.ncbi.nlm.nih.gov/pubmed/10677514", "http://www.ncbi.nlm.nih.gov/pubmed/21688387", "http://www.ncbi.nlm.nih.gov/pubmed/24043829", "http://www.ncbi.nlm.nih.gov/pubmed/15867430"], "triples": [], "ideal_answer": ["Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.  The b-paralogs of the duplicated fugu Hox clusters are virtually devoid of unique ancient CNEs.  Elephant shark and human Hox clusters have lost fewer ancient CNEs. If these ancient CNEs are indeed enhancers directing tissue-specific expression of Hox genes, divergence of their sequences in vertebrate lineages might have led to altered expression patterns and presumably the functions of their associated Hox genes.  When compared, the amphioxus Hox cluster with the human HoxA, HoxB, HoxC, and HoxD clusters were found to have several conserved noncoding regions, both in intergenic and intronic regions. This suggests that the regulation of Hox genes is highly conserved across chordates, consistent with the similar Hox expression patterns in vertebrates and amphioxus."], "concepts": [], "type": "summary", "id": "553ccbaef32186855800000f", "snippets": [{"offsetInBeginSection": 948, "offsetInEndSection": 1130, "text": " The data presented herein identify many noncoding sequence motifs conserved over 800 million years that may function as genetic control motifs essential to the developmental process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10677514", "endSection": "abstract"}, {"offsetInBeginSection": 1031, "offsetInEndSection": 1295, "text": "by comparing conserved noncoding sequences upstream of these exons in different species, we were able to identify homology between some exons. Some alternative splicing variants are probably very ancient and were already coded for by the ancestral Hox gene cluster", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616144", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 886, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 1080, "offsetInEndSection": 1174, "text": "the b-paralogs of the duplicated fugu Hox clusters are virtually devoid of unique ancient CNEs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 1210, "offsetInEndSection": 1529, "text": "elephant shark and human Hox clusters have lost fewer ancient CNEs. If these ancient CNEs are indeed enhancers directing tissue-specific expression of Hox genes, divergence of their sequences in vertebrate lineages might have led to altered expression patterns and presumably the functions of their associated Hox genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}, {"offsetInBeginSection": 373, "offsetInEndSection": 575, "text": "We found that Hox intergenic regions are largely conserved between the two amphioxus species, especially in the case of genes located at the 3' of the cluster, a trend previously observed in vertebrates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "abstract"}, {"offsetInBeginSection": 577, "offsetInEndSection": 926, "text": "We further compared the amphioxus Hox cluster with the human HoxA, HoxB, HoxC, and HoxD clusters, finding several conserved noncoding regions, both in intergenic and intronic regions. This suggests that the regulation of Hox genes is highly conserved across chordates, consistent with the similar Hox expression patterns in vertebrates and amphioxus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Highly conserved syntenic blocks at the vertebrate Hox loci and conserved regulatory elements within and outside Hox gene clusters", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16636282", "endSection": "title"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1530, "text": "A large number of CNS was identified within the Hox clusters and outside the Hox clusters spread over large regions. The CNS include previously characterized enhancers and overlap with the 5' global control regions of HoxA and HoxD clusters. Most of the CNS are likely to be control regions involved in the regulation of Hox and other genes in these loci. We propose that the regulatory elements spread across large regions on either side of Hox clusters are a major evolutionary constraint that has maintained the exceptionally long syntenic blocks at the HoxA and HoxD loci", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16636282", "endSection": "abstract"}, {"offsetInBeginSection": 631, "offsetInEndSection": 1032, "text": "omparative sequence analysis between homologous human and mouse genomic sequence upstream of Hoxa13 revealed a remote 2.25-kb conserved noncoding sequence (mmA13CNS) within the fourth intron of the Hibadh gene. mmA13CNS shares a common 131-bp core identity within a conserved noncoding sequence upstream of Hoxd13, which is located within the previously identified distal limb enhancer critical region", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15509224", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 1050, "text": "HoxA cluster noncoding sequences conserved between bichir and euteleosts indicate that novel cis-sequences were acquired in the stem actinopterygians and maintained after cluster duplication", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14707166", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 882, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}, {"offsetInBeginSection": 573, "offsetInEndSection": 757, "text": "We further compared the amphioxus Hox cluster with the human HoxA, HoxB, HoxC, and HoxD clusters, finding several conserved noncoding regions, both in intergenic and intronic regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 882, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 810, "offsetInEndSection": 956, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 757, "text": "We have generated a comprehensive database of conserved Hox noncoding sequences that include cartilaginous, lobe-finned, and ray-finned fishes (bichir and teleosts).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21688387", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1330, "text": "Several conserved noncoding elements (CNEs) were predicted in the Hox clusters of lamprey, elephant shark, and human.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24043829", "endSection": "abstract"}, {"offsetInBeginSection": 573, "offsetInEndSection": 757, "text": "We further compared the amphioxus Hox cluster with the human HoxA, HoxB, HoxC, and HoxD clusters, finding several conserved noncoding regions, both in intergenic and intronic regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 882, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 810, "offsetInEndSection": 956, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}, {"offsetInBeginSection": 573, "offsetInEndSection": 757, "text": "We further compared the amphioxus Hox cluster with the human HoxA, HoxB, HoxC, and HoxD clusters, finding several conserved noncoding regions, both in intergenic and intronic regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 882, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 810, "offsetInEndSection": 956, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 757, "text": "We have generated a comprehensive database of conserved Hox noncoding sequences that include cartilaginous, lobe-finned, and ray-finned fishes (bichir and teleosts).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21688387", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}, {"offsetInBeginSection": 573, "offsetInEndSection": 757, "text": "We further compared the amphioxus Hox cluster with the human HoxA, HoxB, HoxC, and HoxD clusters, finding several conserved noncoding regions, both in intergenic and intronic regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 887, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 761, "text": "We have generated a comprehensive database of conserved Hox noncoding sequences that include cartilaginous, lobe-finned, and ray-finned fishes (bichir and teleosts).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21688387", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 887, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 964, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 840, "text": "Comparative sequence analysis between homologous human and mouse genomic sequence upstream of Hoxa13 revealed a remote 2.25-kb conserved noncoding sequence (mmA13CNS) within the fourth intron of the Hibadh gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15509224", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}, {"offsetInBeginSection": 888, "offsetInEndSection": 1183, "text": "We found that although bichir possesses four Hox gene clusters, its pattern of conservation of noncoding sequences is mosaic between outgroups, such as human, coelacanth, and shark, with four Hox gene clusters and teleosts, such as zebrafish and pufferfish, with seven or eight Hox gene clusters", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21688387", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 886, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 840, "text": "Comparative sequence analysis between homologous human and mouse genomic sequence upstream of Hoxa13 revealed a remote 2.25-kb conserved noncoding sequence (mmA13CNS) within the fourth intron of the Hibadh gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15509224", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 963, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 886, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 963, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 886, "text": "Comparisons of noncoding sequences of the elephant shark and human Hox clusters have identified a large number of conserved noncoding elements (CNEs), which represent putative cis-regulatory elements that may be involved in the regulation of Hox genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19805301", "endSection": "abstract"}, {"offsetInBeginSection": 630, "offsetInEndSection": 840, "text": "Comparative sequence analysis between homologous human and mouse genomic sequence upstream of Hoxa13 revealed a remote 2.25-kb conserved noncoding sequence (mmA13CNS) within the fourth intron of the Hibadh gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15509224", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 963, "text": "Then, a plethora of conserved noncoding sequences, which are putative enhancers, were identified around the three Hox genes closer to the splits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15867430", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Unexpectedly large number of conserved noncoding regions within the ancestral chordate Hox cluster.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18791732", "endSection": "title"}]}, {"body": "What are the structures formed when keratin molecules come together?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23396250", "http://www.ncbi.nlm.nih.gov/pubmed/23331681", "http://www.ncbi.nlm.nih.gov/pubmed/22963508", "http://www.ncbi.nlm.nih.gov/pubmed/22585043", "http://www.ncbi.nlm.nih.gov/pubmed/22507538", "http://www.ncbi.nlm.nih.gov/pubmed/22502568", "http://www.ncbi.nlm.nih.gov/pubmed/22250786", "http://www.ncbi.nlm.nih.gov/pubmed/22238362", "http://www.ncbi.nlm.nih.gov/pubmed/22168818", "http://www.ncbi.nlm.nih.gov/pubmed/21945137", "http://www.ncbi.nlm.nih.gov/pubmed/21844209", "http://www.ncbi.nlm.nih.gov/pubmed/21721843"], "triples": [], "ideal_answer": ["Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells."], "exact_answer": [["Intermediate filaments"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007633", "http://www.biosemantics.org/jochem#4249492", "http://www.uniprot.org/uniprot/KRT_CEREL", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000595", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017434", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017433"], "type": "factoid", "id": "5505db6a8e1671127b000003", "snippets": [{"offsetInBeginSection": 512, "offsetInEndSection": 619, "text": " Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23396250", "endSection": "abstract"}, {"offsetInBeginSection": 29, "offsetInEndSection": 59, "text": "keratin intermediate filaments", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23396250", "endSection": "title"}, {"offsetInBeginSection": 612, "offsetInEndSection": 642, "text": "keratin intermediate filaments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23331681", "endSection": "abstract"}, {"offsetInBeginSection": 56, "offsetInEndSection": 94, "text": "keratin intermediate filament protein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963508", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Keratin is a protein in the intermediate filament family ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963508", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 571, "text": "Keratins are the intermediate filament (IF) proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22585043", "endSection": "abstract"}, {"offsetInBeginSection": 577, "offsetInEndSection": 658, "text": "squamous keratinocytes contain polymerized keratin intermediate filament bundles ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22507538", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 470, "text": " keratin filaments ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22502568", "endSection": "abstract"}, {"offsetInBeginSection": 385, "offsetInEndSection": 506, "text": " In this study, we have examined the distribution of four groups of IFs [cytokeratins (CKs), vimentin, desmin and lamins]", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22250786", "endSection": "abstract"}, {"offsetInBeginSection": 547, "offsetInEndSection": 571, "text": "keratin filament network", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22238362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "An intact keratin 5/keratin 14 intermediate filament cytoskeleton is vital for the integrity of basal keratinocytes and for the development and maintenance of epidermal structures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22168818", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 903, "text": "keratin intermediate filament cytoskeleton.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21945137", "endSection": "abstract"}, {"offsetInBeginSection": 846, "offsetInEndSection": 864, "text": "keratin filaments,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21844209", "endSection": "abstract"}, {"offsetInBeginSection": 1119, "offsetInEndSection": 1148, "text": "keratin filamentous network. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21721843", "endSection": "abstract"}]}, {"body": "What does mTOR stands for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24312415", "http://www.ncbi.nlm.nih.gov/pubmed/24312355", "http://www.ncbi.nlm.nih.gov/pubmed/24311635", "http://www.ncbi.nlm.nih.gov/pubmed/24309100", "http://www.ncbi.nlm.nih.gov/pubmed/24307346", "http://www.ncbi.nlm.nih.gov/pubmed/24290217", "http://www.ncbi.nlm.nih.gov/pubmed/24295418", "http://www.ncbi.nlm.nih.gov/pubmed/24289602", "http://www.ncbi.nlm.nih.gov/pubmed/24287118", "http://www.ncbi.nlm.nih.gov/pubmed/24276258", "http://www.ncbi.nlm.nih.gov/pubmed/24270265"], "triples": [], "ideal_answer": ["mTOR stands for: mammalian target of rapamycin."], "exact_answer": [["mammalian target of rapamycin"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058570", "http://www.uniprot.org/uniprot/MTOR_RAT"], "type": "factoid", "id": "5505a587f73303d458000005", "snippets": [{"offsetInBeginSection": 141, "offsetInEndSection": 178, "text": " mammalian target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312415", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 318, "text": "mammalian target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312355", "endSection": "abstract"}, {"offsetInBeginSection": 16, "offsetInEndSection": 52, "text": "mammalian target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311635", "endSection": "abstract"}, {"offsetInBeginSection": 74, "offsetInEndSection": 110, "text": "mammalian target or rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24309100", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 131, "text": "mammalian target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24307346", "endSection": "abstract"}, {"offsetInBeginSection": 531, "offsetInEndSection": 568, "text": "mammalian target of rapamycin (mTOR) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24290217", "endSection": "abstract"}, {"offsetInBeginSection": 45, "offsetInEndSection": 82, "text": " mammalian target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24295418", "endSection": "abstract"}, {"offsetInBeginSection": 77, "offsetInEndSection": 111, "text": " mammal target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24289602", "endSection": "abstract"}, {"offsetInBeginSection": 602, "offsetInEndSection": 639, "text": " mammalian target of rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24287118", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 476, "text": "mammalian Target of Rapamycin (mTOR)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24276258", "endSection": "abstract"}, {"offsetInBeginSection": 304, "offsetInEndSection": 342, "text": " mammalian target of rapamycin (mTOR) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24270265", "endSection": "abstract"}]}, {"body": "Which type of genes are modulated by SATB1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21841785", "http://www.ncbi.nlm.nih.gov/pubmed/16034473", "http://www.ncbi.nlm.nih.gov/pubmed/15371550"], "triples": [], "ideal_answer": ["Release of SATB1 from the control of Foxp3 in T(reg) cells caused loss of suppressive function, establishment of transcriptional T(eff) cell programs and induction of T(eff) cell cytokines.", "Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation", "Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation", "Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation", "Lack of effector T cell (T(eff) cell) function and gain of suppressive activity by T(reg) cells are dependent on the transcriptional program induced by Foxp3. Here we report that repression of SATB1, a genome organizer that regulates chromatin structure and gene expression, was crucial for the phenotype and function of T(reg) cells. Release of SATB1 from the control of Foxp3 in T(reg) cells caused loss of suppressive function, establishment of transcriptional T(eff) cell programs and induction of T(eff) cell cytokines. At an Associative t-test threshold of P"], "exact_answer": [["it supresses cell cytokines and differentiation genes"]], "concepts": ["http://www.uniprot.org/uniprot/SATB1_MOUSE", "http://www.uniprot.org/uniprot/SATB1_HUMAN"], "type": "factoid", "id": "56fcf1b8cf1c325851000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21841785", "endSection": "title"}, {"offsetInBeginSection": 284, "offsetInEndSection": 424, "text": "SATB1, a genome organizer that regulates chromatin structure and gene expression, was crucial for the phenotype and function of T(reg) cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21841785", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 616, "text": "Foxp3, acting as a transcriptional repressor, directly suppressed the SATB1 locus and indirectly suppressed it through the induction of microRNAs that bound the SATB1 3' untranslated region.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21841785", "endSection": "abstract"}, {"offsetInBeginSection": 617, "offsetInEndSection": 806, "text": "Release of SATB1 from the control of Foxp3 in T(reg) cells caused loss of suppressive function, establishment of transcriptional T(eff) cell programs and induction of T(eff) cell cytokines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21841785", "endSection": "abstract"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1298, "text": "Consistent with previous reports in a non-superantigen in vivo anergy model, mRNA for CD18 and the transcription factor Satb1 (special AT-rich-binding protein 1) was increased in SEB-energized T cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16034473", "endSection": "abstract"}]}, {"body": "What are the skeletal muscle satellite cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26074812", "http://www.ncbi.nlm.nih.gov/pubmed/25732238", "http://www.ncbi.nlm.nih.gov/pubmed/26341996", "http://www.ncbi.nlm.nih.gov/pubmed/26248268", "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "http://www.ncbi.nlm.nih.gov/pubmed/21339173", "http://www.ncbi.nlm.nih.gov/pubmed/26055324", "http://www.ncbi.nlm.nih.gov/pubmed/24439806", "http://www.ncbi.nlm.nih.gov/pubmed/17996437", "http://www.ncbi.nlm.nih.gov/pubmed/17600112", "http://www.ncbi.nlm.nih.gov/pubmed/19265661", "http://www.ncbi.nlm.nih.gov/pubmed/21727135"], "triples": [], "ideal_answer": ["Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury.", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury"], "concepts": [], "type": "summary", "id": "571f356f0fd6f91b68000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 454, "text": "Skeletal muscle satellite cells (SCs) are Pax7(+) myogenic stem cells that reside between the basal lamina and the plasmalemma of the myofiber. In mature muscles, SCs are typically quiescent, but can be activated in response to muscle injury. Depending on the magnitude of tissue trauma, SCs may divide minimally to repair subtle damage within individual myofibers or produce a larger progeny pool that forms new myofibers in cases of overt muscle injury", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26074812", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Satellite cells (SC) are quiescent adult muscle stem cells critical for postnatal development", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25732238", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Satellite cells are multipotential stem cells that mediate postnatal muscle growth and respond differently to temperature based upon aerobic versus anaerobic fiber-type origin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26341996", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 493, "text": "Skeletal muscle mass, function, and repair capacity all progressively decline with aging, restricting mobility, voluntary function, and quality of life. Skeletal muscle repair is facilitated by a population of dedicated muscle stem cells (MuSCs), also known as satellite cells, that reside in anatomically defined niches within muscle tissues. In adult tissues, MuSCs are retained in a quiescent state until they are primed to regenerate damaged muscle through cycles of self-renewal divisions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26248268", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "The acquisition of a proliferating-cell status from a quiescent state as well as the shift between proliferation and differentiation are key developmental steps in skeletal-muscle stem cells (satellite cells) to provide proper muscle regeneration", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26055324", "endSection": "abstract"}, {"offsetInBeginSection": 127, "offsetInEndSection": 275, "text": "Satellite cells are essential for skeletal muscle regeneration as they ultimately provide the myogenic precursors that rebuild damaged muscle tissue", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24439806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Skeletal muscle satellite cells are committed to myogenesis and do not spontaneously adopt nonmyogenic fates.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339173", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Skeletal muscle satellite cells are committed to myogenesis and do not spontaneously adopt nonmyogenic fates.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339173", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Skeletal muscle satellite cells are committed to myogenesis and do not spontaneously adopt nonmyogenic fates.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339173", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Skeletal muscle satellite cells are committed to myogenesis and do not spontaneously adopt nonmyogenic fates.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21339173", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 367, "text": "These are normally quiescent in adult muscle, but act as a reserve population of cells, able to proliferate in response to injury and give rise to regenerated muscle and to more satellite cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 694, "offsetInEndSection": 853, "text": "Satellite cell-derived muscle precursor cells may be used to repair and regenerate damaged or myopathic skeletal muscle, or to act as vectors for gene therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 367, "text": "These are normally quiescent in adult muscle, but act as a reserve population of cells, able to proliferate in response to injury and give rise to regenerated muscle and to more satellite cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 694, "offsetInEndSection": 853, "text": "Satellite cell-derived muscle precursor cells may be used to repair and regenerate damaged or myopathic skeletal muscle, or to act as vectors for gene therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Research focusing on the canonical adult myogenic progenitor, the skeletal muscle satellite cell, is still an ever-growing field 46 years from their initial description.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17996437", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 390, "text": " Skeletal muscle satellite cells, located between the basal lamina and plasma membrane of myofibers, are required for skeletal muscle regeneration. The capacity of satellite cells as well as other cell lineages including mesoangioblasts, mesenchymal stem cells, and side population (SP) cells to contribute to muscle regeneration has complicated the identification of a satellite stem cell.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19265661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": " Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers. In adult muscle, satellite cells are normally mitotically quiescent.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": " Skeletal muscle is a highly specialized tissue composed of non-dividing, multi-nucleated muscle fibres that contract to generate force in a controlled and directed manner. Skeletal muscle is formed during embryogenesis from a subset of muscle precursor cells, which generate both differentiated muscle fibres and specialized muscle-forming stem cells known as satellite cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21727135", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 289, "text": " Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention. Sheep satellite cells have a greater similarity to human satellite cells with regard to metabolism, life span, proliferation and differentiation, than satellite cells of the rat and mouse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Skeletal muscle satellite cells play key roles in postnatal muscle growth and regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17600112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Skeletal muscle satellite cells play key roles in postnatal muscle growth and regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17600112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Skeletal muscle satellite cells play key roles in postnatal muscle growth and regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17600112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Skeletal muscle satellite cells are quiescent mononucleated myogenic cells, located between the sarcolemma and basement membrane of terminally-differentiated muscle fibres.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757751", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Skeletal muscle satellite cells, located between the basal lamina and plasma membrane of myofibers, are required for skeletal muscle regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19265661", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Skeletal muscle satellite cells are adult muscle-derived stem cells receiving increasing attention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22233500", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 377, "text": "Skeletal muscle is formed during embryogenesis from a subset of muscle precursor cells, which generate both differentiated muscle fibres and specialized muscle-forming stem cells known as satellite cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21727135", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Skeletal muscle satellite cells play key roles in postnatal muscle growth and regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17600112", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Muscle satellite cells are a stem cell population required for postnatal skeletal muscle development and regeneration, accounting for 2-5% of sublaminal nuclei in muscle fibers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24747722", "endSection": "abstract"}]}, {"body": "Is Hirschsprung disease a mendelian or a multifactorial disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15829955", "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "http://www.ncbi.nlm.nih.gov/pubmed/12239580", "http://www.ncbi.nlm.nih.gov/pubmed/8896569", "http://www.ncbi.nlm.nih.gov/pubmed/6650562", "http://www.ncbi.nlm.nih.gov/pubmed/20598273", "http://www.ncbi.nlm.nih.gov/pubmed/21995290", "http://www.ncbi.nlm.nih.gov/pubmed/23001136"], "triples": [], "ideal_answer": ["Coding sequence mutations in RET, GDNF, EDNRB, EDN3, and SOX10 are involved in the development of Hirschsprung disease. The majority of these genes was shown to be related to Mendelian syndromic forms of Hirschsprung's disease, whereas the non-Mendelian inheritance of sporadic non-syndromic Hirschsprung disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:10487", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006627", "http://www.disease-ontology.org/api/metadata/DOID:11372", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020412"], "type": "summary", "id": "55031181e9bde69634000014", "snippets": [{"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 554, "offsetInEndSection": 992, "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "endSection": "abstract"}, {"offsetInBeginSection": 397, "offsetInEndSection": 939, "text": "Coding sequence mutations in e.g. RET, GDNF, EDNRB, EDN3, and SOX10 lead to long-segment (L-HSCR) as well as syndromic HSCR but fail to explain the transmission of the much more common short-segment form (S-HSCR). Furthermore, mutations in the RET gene are responsible for approximately half of the familial and some sporadic cases, strongly suggesting, on the one hand, the importance of non-coding variations and, on the other hand, that additional genes involved in the development of the enteric nervous system still await their discovery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12239580", "endSection": "abstract"}, {"offsetInBeginSection": 941, "offsetInEndSection": 1279, "text": "For almost all of the identified HSCR genes incomplete penetrance of the HSCR phenotype has been reported, probably due to modifier loci. Therefore, HSCR has become a model for a complex oligo-/polygenic disorder in which the relationship between different genes creating a non-mendelian inheritance pattern still remains to be elucidated", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12239580", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 358, "text": " Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 1007, "text": " The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6650562", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 359, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20598273", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "BACKGROUND: RET is the major gene associated to Hirschsprung disease (HSCR) with differential contributions of its rare and common, coding and noncoding mutations to the multifactorial nature of this pathology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21995290", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 554, "offsetInEndSection": 992, "text": "In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 359, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 376, "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15858239", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "title"}, {"offsetInBeginSection": 715, "offsetInEndSection": 818, "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 375, "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15858239", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "title"}, {"offsetInBeginSection": 715, "offsetInEndSection": 818, "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 417, "offsetInEndSection": 615, "text": "On the basis of a skewed sex-ratio (M/F = 4/1) and a risk to relatives much higher than the incidence in the general population, HSCR has long been regarded as a sex-modified multifactorial disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8896569", "endSection": "abstract"}, {"offsetInBeginSection": 858, "offsetInEndSection": 1012, "text": "The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6650562", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 375, "text": "In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15858239", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "title"}, {"offsetInBeginSection": 715, "offsetInEndSection": 818, "text": "The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "endSection": "abstract"}, {"offsetInBeginSection": 820, "offsetInEndSection": 992, "text": "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 358, "text": "Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15829955", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "title"}]}, {"body": "Describe the usefulness of the SPIKE database in human signaling pathways", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21097778", "http://www.ncbi.nlm.nih.gov/pubmed/18289391"], "triples": [], "ideal_answer": ["The rapid accumulation of knowledge on biological signaling pathways and their regulatory mechanisms has highlighted the need for specific repositories that can store, organize and allow retrieval of pathway information in a way that will be useful for the research community. SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. To make database population and pathway comprehension straightforward, a simple yet informative data model is used, and pathways are laid out as maps that reflect the curator\u2019s understanding and make the utilization of the pathways easy. The database currently focuses primarily on pathways describing DNA damage response, cell cycle, programmed cell death and hearing related pathways. Pathways are regularly updated, and additional pathways are gradually added. The complete database and the individual maps are freely exportable in several formats. The database is accompanied by a stand-alone software tool for analysis and dynamic visualization of pathways.", "The rapid accumulation of knowledge on biological signaling pathways and their regulatory mechanisms has highlighted the need for specific repositories that can store, organize and allow retrieval of pathway information in a way that will be useful for the research community. SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. To make database population and pathway comprehension straightforward, a simple yet informative data model is used, and pathways are laid out as maps that reflect the curator\u2019s understanding and make the utilization of the pathways easy. The database currently focuses primarily on pathways describing DNA damage response, cell cycle, programmed cell death and hearing related pathways. Pathways are regularly updated, and additional pathways are gradually added. The complete database and the individual maps are freely exportable in several formats. The database is accompanied by a stand-alone software tool for analysis and dynamic visualization of pathways.", "The rapid accumulation of knowledge on biological signaling pathways and their regulatory mechanisms has highlighted the need for specific repositories that can store, organize and allow retrieval of pathway information in a way that will be useful for the research community. SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. To make database population and pathway comprehension straightforward, a simple yet informative data model is used, and pathways are laid out as maps that reflect the curator\u2019s understanding and make the utilization of the pathways easy. The database currently focuses primarily on pathways describing DNA damage response, cell cycle, programmed cell death and hearing related pathways. Pathways are regularly updated, and additional pathways are gradually added. The complete database and the individual maps are freely exportable in several formats. The database is accompanied by a stand-alone software tool for analysis and dynamic visualization of pathways.", "The rapid accumulation of knowledge on biological signaling pathways and their regulatory mechanisms has highlighted the need for specific repositories that can store, organize and allow retrieval of pathway information in a way that will be useful for the research community. SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. To make database population and pathway comprehension straightforward, a simple yet informative data model is used, and pathways are laid out as maps that reflect the curator\u2019s understanding and make the utilization of the pathways easy. The database currently focuses primarily on pathways describing DNA damage response, cell cycle, programmed cell death and hearing related pathways. Pathways are regularly updated, and additional pathways are gradually added. The complete database and the individual maps are freely exportable in several formats. The database is accompanied by a stand-alone software tool for analysis and dynamic visualization of pathways."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019991", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015398", "http://amigo.geneontology.org/amigo/term/GO:0007165"], "type": "summary", "id": "56bdc452a36a056b3d000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 1217, "text": "The rapid accumulation of knowledge on biological signaling pathways and their regulatory mechanisms has highlighted the need for specific repositories that can store, organize and allow retrieval of pathway information in a way that will be useful for the research community. SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. To make database population and pathway comprehension straightforward, a simple yet informative data model is used, and pathways are laid out as maps that reflect the curator\u2019s understanding and make the utilization of the pathways easy. The database currently focuses primarily on pathways describing DNA damage response, cell cycle, programmed cell death and hearing related pathways. Pathways are regularly updated, and additional pathways are gradually added. The complete database and the individual maps are freely exportable in several formats. The database is accompanied by a stand-alone software tool for analysis and dynamic visualization of pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 553, "offsetInEndSection": 830, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 553, "offsetInEndSection": 830, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 555, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 555, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 555, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 555, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 277, "offsetInEndSection": 555, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 559, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&amp;~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 559, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&amp;~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 559, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&amp;~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 559, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&amp;~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "SPIKE--a database, visualization and analysis tool of cellular signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18289391", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "SPIKE: a database of highly curated human signaling pathways.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "title"}, {"offsetInBeginSection": 278, "offsetInEndSection": 559, "text": "SPIKE (Signaling Pathways Integrated Knowledge Engine; http://www.cs.tau.ac.il/&amp;~spike/) is a database for achieving this goal, containing highly curated interactions for particular human pathways, along with literature-referenced information on the nature of each interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097778", "endSection": "abstract"}]}, {"body": "What is the mechanism of action of solanezumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24101429", "http://www.ncbi.nlm.nih.gov/pubmed/23663286", "http://www.ncbi.nlm.nih.gov/pubmed/23582316", "http://www.ncbi.nlm.nih.gov/pubmed/23574434", "http://www.ncbi.nlm.nih.gov/pubmed/23568994", "http://www.ncbi.nlm.nih.gov/pubmed/22672770", "http://www.ncbi.nlm.nih.gov/pubmed/22339463", "http://www.ncbi.nlm.nih.gov/pubmed/22288451", "http://www.ncbi.nlm.nih.gov/pubmed/22134132", "http://www.ncbi.nlm.nih.gov/pubmed/21868184", "http://www.ncbi.nlm.nih.gov/pubmed/21504387", "http://www.ncbi.nlm.nih.gov/pubmed/20375655"], "triples": [{"p": "http://data.linkedct.org/resource/linkedct/intervention_type", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Drug"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Solanezumab"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Intervention #13258 (Drug:Solanezumab)"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/umls/id/C2935150", "o": "http://linkedlifedata.com/resource/umls/id/C0003250"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18469068", "o": "solanezumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17949023", "o": "Antibodies, Monoclonal [Chemical/Ingredient]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0024758", "o": "Antibodies, Monoclonal"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7654540", "o": "Monoclonal Antibody"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A4346004", "o": "monoclonal antibodies"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7572230", "o": "Monoclonal Antibodies"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A10786467", "o": "MoAB"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2935150", "o": "http://linkedlifedata.com/resource/umls/label/A18469068"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1307845", "o": "MAb"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0319457", "o": "monoclonal antibody"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18469068", "o": "C550616"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18469068", "o": "solanezumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2935150", "o": "http://linkedlifedata.com/resource/umls/label/A18469068"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18469068", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18469068", "o": "solanezumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2935150", "o": "http://linkedlifedata.com/resource/umls/label/A18469068"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/umls/id/C2935151", "o": "http://linkedlifedata.com/resource/umls/id/C2935150"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18469068", "o": "solanezumab"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18472154", "o": "LY-2062430"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18456783", "o": "LY 2062430"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18465965", "o": "LY2062430"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2935150", "o": "http://linkedlifedata.com/resource/umls/label/A18469068"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention", "s": "http://data.linkedct.org/resource/trials/NCT00637130", "o": "http://data.linkedct.org/resource/intervention/13258"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00637130", "o": "Trial NCT00637130"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Solanezumab"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Intervention #13258 (Drug:Solanezumab)"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_id", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "13258"}, {"p": "http://data.linkedct.org/resource/linkedct/intervention_name", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Solanezumab"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/intervention/13258", "o": "Intervention #13258 (Drug:Solanezumab)"}], "ideal_answer": "Solanezumab, a humanized anti-A\u03b2 monoclonal antibody directed against the midregion of the A\u03b2 peptide, was shown to neutralize soluble A\u03b2 species.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"], "type": "summary", "id": "52fc94ae2059c6d71c000073", "snippets": [{"offsetInBeginSection": 1156, "offsetInEndSection": 1456, "text": "Anti-amyloid treatment in asymptomatic AD (A4) is a prevention trial aimed at treating older individuals with normal cognition but at risk of developing AD dementia on the basis of having biomarker evidence of amyloid (preclinical AD). They selected solanezumab for the anti-amyloid treatment for A4.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101429", "endSection": "abstract"}, {"offsetInBeginSection": 830, "offsetInEndSection": 1056, "text": "Passive immunotherapy with monoclonal antibodies (mAbs) against A\u03b2 is in late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting an N-terminal or central epitope, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663286", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 389, "text": "solanezumab, targeting monomeric A\u03b2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582316", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 387, "text": "Immunotherapeutic agents have been developed to remove the neurotoxic amyloid \u03b242 protein and prevent the hypothesized amyloid \u03b242-induced neurotoxicity and neurodegeneration. The most notable of these immunotherapies are bapineuzumab and solanezumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434", "endSection": "abstract"}, {"offsetInBeginSection": 742, "offsetInEndSection": 891, "text": "A\u03b2 removal and improved cognitive function in animal models of AD. Clinical trials on various drugs, including AN1792, bapineuzumab, and solanezumab,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23568994", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 156, "text": "solanezumab, an anti-\u03b2-amyloid (A\u03b2) antibody", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672770", "endSection": "abstract"}, {"offsetInBeginSection": 997, "offsetInEndSection": 1081, "text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", "endSection": "abstract"}, {"offsetInBeginSection": 1424, "offsetInEndSection": 1571, "text": "Solanezumab, a humanized anti-A\u03b2 monoclonal antibody directed against the midregion of the A\u03b2 peptide, was shown to neutralize soluble A\u03b2 species. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of \u03b2-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 176, "text": "Solanezumab is a humanized anti-amyloid \u03b2 monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134132", "endSection": "abstract"}, {"offsetInBeginSection": 358, "offsetInEndSection": 567, "text": "This situation was encountered in the development of LY2062430, a therapeutic mid-domain monoclonal anti-amyloid beta peptide (A\u03b2) antibody undergoing clinical trials for the treatment of Alzheimer's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21868184", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 250, "text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387", "endSection": "abstract"}, {"offsetInBeginSection": 865, "offsetInEndSection": 912, "text": "Solanezumab can neutralize soluble A\u03b2 peptides,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387", "endSection": "abstract"}, {"offsetInBeginSection": 139, "offsetInEndSection": 260, "text": "LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20375655", "endSection": "abstract"}]}, {"body": "What is the role of photodynamic therapy for meningioma treatment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24486853", "http://www.ncbi.nlm.nih.gov/pubmed/23465372", "http://www.ncbi.nlm.nih.gov/pubmed/16788926", "http://www.ncbi.nlm.nih.gov/pubmed/10327048", "http://www.ncbi.nlm.nih.gov/pubmed/8672259", "http://www.ncbi.nlm.nih.gov/pubmed/8384325", "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "http://www.ncbi.nlm.nih.gov/pubmed/1984490", "http://www.ncbi.nlm.nih.gov/pubmed/2176016", "http://www.ncbi.nlm.nih.gov/pubmed/2855780", "http://www.ncbi.nlm.nih.gov/pubmed/21073472"], "triples": [], "ideal_answer": ["Photodynamic therapy was shown to have activity againt meningioma treatment. Gefitinib and ciprofloxacin enhance efficacy of photodynamic therapy."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008579", "http://www.disease-ontology.org/api/metadata/DOID:3565", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812"], "type": "summary", "id": "56c097deef6e394741000027", "snippets": [{"offsetInBeginSection": 1221, "offsetInEndSection": 1382, "text": "CONCLUSIONS: Efficacy of 5-ALA PDT could be increased by adjunction of ciprofloxacin in conventional clinical dosing and by prolongation of ALA incubation time. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24486853", "endSection": "abstract"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1187, "text": "CONCLUSION: Gefitinib can inhibit ABCG2-mediated PpIX efflux from malignant brain tumor cells to increase the intracellular PpIX and thereby enhance the PDT effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23465372", "endSection": "abstract"}, {"offsetInBeginSection": 1528, "offsetInEndSection": 1630, "text": "CONCLUSION: ALA-PDT was more effective in killing U-105MG glioma cells than CH-157MN meningioma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10327048", "endSection": "abstract"}, {"offsetInBeginSection": 1726, "offsetInEndSection": 1889, "text": "These data indicate unique features of AlPc which suggests its application as a potent, non-toxic photosensitizer in the photodynamic therapy of human meningiomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8672259", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Photodynamic therapy is being investigated as an adjuvant treatment for intracranial neoplasms. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8384325", "endSection": "abstract"}, {"offsetInBeginSection": 563, "offsetInEndSection": 735, "text": "It was found that PDT using haematoporphyrin derivative as a photosensitizing drug showed dose-dependent activity against a variety of histological subtypes of meningioma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Photodynamic therapy is a promising treatment for human brain tumors because of the selective retention of certain compounds by tumor cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1984490", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073472", "endSection": "title"}, {"offsetInBeginSection": 1175, "offsetInEndSection": 1425, "text": "We conclude that differences in intracellular PpIX concentrations between HBL-52 and BEN-MEN-1 benign meningioma cells were mainly due to differences in FECH activity and that these differences correspond to their susceptibility to 5-ALA-induced PDT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073472", "endSection": "abstract"}, {"offsetInBeginSection": 462, "offsetInEndSection": 626, "text": "Photodynamic therapy (PDT) has been employed in the management of recurrent cerebral gliomas but its activity against meningiomas has not been specifically studied.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073472", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Enhancing the effect of 5-aminolevulinic acid based photodynamic therapy in human meningioma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24486853", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073472", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "An in vitro study of the effect of photodynamic therapy on human meningiomas.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "title"}, {"offsetInBeginSection": 300, "offsetInEndSection": 465, "text": "Photodynamic therapy (PDT) has been employed in the management of recurrent cerebral gliomas but its activity against meningiomas has not been specifically studied. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Susceptibility to 5-aminolevulinic acid based photodynamic therapy in WHO I meningioma cells corresponds to ferrochelatase activity.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073472", "endSection": "title"}, {"offsetInBeginSection": 300, "offsetInEndSection": 465, "text": "Photodynamic therapy (PDT) has been employed in the management of recurrent cerebral gliomas but its activity against meningiomas has not been specifically studied. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 465, "text": "Photodynamic therapy (PDT) has been employed in the management of recurrent cerebral gliomas but its activity against meningiomas has not been specifically studied. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 465, "text": "Photodynamic therapy (PDT) has been employed in the management of recurrent cerebral gliomas but its activity against meningiomas has not been specifically studied. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1388826", "endSection": "abstract"}]}, {"body": "What is the molecular function of the Chd1 protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21623345", "http://www.ncbi.nlm.nih.gov/pubmed/16468993", "http://www.ncbi.nlm.nih.gov/pubmed/16606615", "http://www.ncbi.nlm.nih.gov/pubmed/16263726", "http://www.ncbi.nlm.nih.gov/pubmed/15647753", "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "http://www.ncbi.nlm.nih.gov/pubmed/17098252", "http://www.ncbi.nlm.nih.gov/pubmed/23319591", "http://www.ncbi.nlm.nih.gov/pubmed/19948887"], "triples": [], "ideal_answer": ["The ATP-dependent chromatin-remodelling enzyme Chd1 is a 168-kDa protein consisting of a double chromodomain, Snf2-related ATPase domain, and a C-terminal DNA-binding domain. One of the two chromodomains of Chd1 specifically interacts with the methylated lysine 4 mark on histone H3 that is associated with transcriptional activity. Human CHD1 is an ATP-dependent chromatin remodeling protein, as a factor that directly and selectively recognizes histone H3 methylated on lysine 4."], "exact_answer": [["Chd1 is an ATP-dependent DNA helicase"]], "concepts": ["http://www.uniprot.org/uniprot/CHD1_DROME", "http://www.uniprot.org/uniprot/CHD1_MOUSE"], "type": "factoid", "id": "57092332cf1c325851000018", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The DNA-binding domain of the Chd1 chromatin-remodelling enzyme contains SANT and SLIDE domains", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623345", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "The ATP-dependent chromatin-remodelling enzyme Chd1 is a 168-kDa protein consisting of a double chromodomain, Snf2-related ATPase domain, and a C-terminal DNA-binding domain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623345", "endSection": "abstract"}, {"offsetInBeginSection": 449, "offsetInEndSection": 728, "text": "The presence of these domains in ISWI and Chd1 chromatin-remodelling enzymes may provide a means of efficiently harnessing the action of the Snf2-related ATPase domain for the purpose of nucleosome spacing and provide an explanation for partial redundancy between these proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623345", "endSection": "abstract"}, {"offsetInBeginSection": 694, "offsetInEndSection": 827, "text": "Here we identify the chromatin remodelling protein Chd1 (chromo-ATPase/helicase-DNA binding domain 1) as a component of SAGA and SLIK", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15647753", "endSection": "abstract"}, {"offsetInBeginSection": 856, "offsetInEndSection": 1012, "text": "one of the two chromodomains of Chd1 specifically interacts with the methylated lysine 4 mark on histone H3 that is associated with transcriptional activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15647753", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263726", "endSection": "title"}, {"offsetInBeginSection": 196, "offsetInEndSection": 375, "text": "In the current study, we identify human CHD1, an ATP-dependent chromatin remodeling protein, as a factor that directly and selectively recognizes histone H3 methylated on lysine 4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263726", "endSection": "abstract"}, {"offsetInBeginSection": 597, "offsetInEndSection": 692, "text": "human CHD1 binds to methylated H3K4 in a manner that requires both of its tandem chromodomains.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263726", "endSection": "abstract"}, {"offsetInBeginSection": 789, "offsetInEndSection": 1034, "text": "Our findings indicate that yeast and human CHD1 have diverged in their ability to discriminate covalently modified histones and link histone modification-recognition and non-covalent chromatin remodeling activities within a single human protein.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263726", "endSection": "abstract"}, {"offsetInBeginSection": 235, "offsetInEndSection": 397, "text": "We find that the yeast Isw1a, Isw2, and Chd1 enzymes preferentially move nucleosomes toward more central locations on short DNA fragments whereas Isw1b does not. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Analysis of nucleosome repositioning by yeast ISWI and Chd1 chromatin remodeling complexes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606615", "endSection": "title"}, {"offsetInBeginSection": 555, "offsetInEndSection": 719, "text": "However, a key difference is that the Isw1a, Isw2, and Chd1 enzymes are unable to move nucleosomes to positions closer than 15 bp from a DNA end, whereas Isw1b can.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606615", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The ISWI and CHD1 chromatin remodelling activities influence ADH2 expression and chromatin organization", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468993", "endSection": "title"}, {"offsetInBeginSection": 794, "offsetInEndSection": 1002, "text": "Here we show that the absence of the Isw1 and Chd1 ATP-dependent chromatin remodelling activities delays the maximal expression of ADH2 without impairing the chromatin remodelling that occurs upon activation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468993", "endSection": "abstract"}, {"offsetInBeginSection": 1494, "offsetInEndSection": 1701, "text": "Thus, the ISWI and Chd1 remodelling factors are not only involved in transcription-related chromatin remodelling, but also are required to maintain a specific chromatin configuration across the yeast genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468993", "endSection": "abstract"}, {"offsetInBeginSection": 1352, "offsetInEndSection": 1492, "text": "the lack of Chd1 combined with the absence of Isw1 and Isw2 impairs nucleosome spacing along the ADH2 gene, and genome-wide in S. cerevisiae", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16468993", "endSection": "abstract"}, {"offsetInBeginSection": 884, "offsetInEndSection": 991, "text": "Through inclusion of Chd1 sequences in homology searches SLIDE domains were identified in CHD6-9 proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623345", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1333, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 574, "text": "CHD1 is known to bind H3K4me3 in mammalian cells, and Neurospora CHD1 is required for proper regulation of the frequency (frq) gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23319591", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1358, "text": "Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Histone H3K4 and K36 methylation, Chd1 and Rpd3S oppose the functions of Saccharomyces cerevisiae Spt4-Spt5 in transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948887", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1358, "text": "Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Histone H3K4 and K36 methylation, Chd1 and Rpd3S oppose the functions of Saccharomyces cerevisiae Spt4-Spt5 in transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948887", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1358, "text": "Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Histone H3K4 and K36 methylation, Chd1 and Rpd3S oppose the functions of Saccharomyces cerevisiae Spt4-Spt5 in transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948887", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1358, "text": "Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Histone H3K4 and K36 methylation, Chd1 and Rpd3S oppose the functions of Saccharomyces cerevisiae Spt4-Spt5 in transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948887", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1358, "text": "Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Histone H3K4 and K36 methylation, Chd1 and Rpd3S oppose the functions of Saccharomyces cerevisiae Spt4-Spt5 in transcription.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948887", "endSection": "title"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1358, "text": "Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1184, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1359, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II. Thus, while CHD1 is localized to transcriptionally active regions of the genome, it can function to alter the levels of HP1a, perhaps through changes in methylation of H3K9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": " Chromodomain from heterochromatin protein 1 and polycomb protein is known to be a lysine-methylated histone H3 tail-binding module. Chromo-helicase/ATPase DNA-binding protein 1 (CHD1) is an ATP-dependent chromatin remodeling factor, containing two tandem chromodomains.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17098252", "endSection": "abstract"}, {"offsetInBeginSection": 857, "offsetInEndSection": 1185, "text": "Over-expression of an ATPase inactive form of CHD1 did not result in severe chromosomal defects, suggesting that the ATPase activity is required for this in vivo phenotype. Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1185, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1185, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1185, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "The molecular motor protein CHD1 has been implicated in the regulation of transcription and in the transcription-independent genome-wide incorporation of H3.3 into paternal chromatin in Drosophila melanogaster.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177652", "endSection": "abstract"}, {"offsetInBeginSection": 1030, "offsetInEndSection": 1185, "text": "Interestingly, changes in CHD1 protein levels did not correlate with changes in the levels of the euchromatin mark H3K4me3 or elongating RNA Polymerase II.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533627", "endSection": "abstract"}]}, {"body": "What is the effect of Allopurinol on asphyxia in neonates?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22564301", "http://www.ncbi.nlm.nih.gov/pubmed/22102633", "http://www.ncbi.nlm.nih.gov/pubmed/20167117", "http://www.ncbi.nlm.nih.gov/pubmed/17162192", "http://www.ncbi.nlm.nih.gov/pubmed/16778717", "http://www.ncbi.nlm.nih.gov/pubmed/16428356", "http://www.ncbi.nlm.nih.gov/pubmed/12436031", "http://www.ncbi.nlm.nih.gov/pubmed/9445490"], "ideal_answer": ["Allopurinol was shown in a number of clinical trial to be safe and effective for treatment of neonatal asphyxia. Allopurinol  improves short-term and long-term clinical outcomes of neonatal asphyxia. Allopurinol should be administered as soon as possible. Postulated mechanism of allopurinol action in this setting is prevention of hypoxia-perfusion injury by reduction of free radical formation."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000493", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001237", "http://www.biosemantics.org/jochem#4273300", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007231", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001238", "http://www.disease-ontology.org/api/metadata/DOID:11088"], "type": "summary", "id": "515df1d4298dcd4e5100002b", "snippets": [{"offsetInBeginSection": 1203, "offsetInEndSection": 1473, "text": "Potential neuroprotective strategies targeting different pathways leading to neuronal cell death in response to hypoxic-ischemic insult have been investigated: hypothermia, erythropoietin, iminobiotin, deferioxamine, magnesium, allopurinol, xenon, melatonin and statins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564301", "endSection": "sections.0"}, {"offsetInBeginSection": 138, "offsetInEndSection": 260, "text": "Allopurinol reduces the formation of free radicals, thereby potentially limiting the amount of hypoxia-reperfusion damage.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633", "endSection": "sections.0"}, {"offsetInBeginSection": 1458, "offsetInEndSection": 1771, "text": "There were no differences in long-term outcome between the allopurinol-treated infants and controls. However, subgroup analysis of the moderately asphyxiated group showed significantly less severe adverse outcome in the allopurinol-treated infants compared with controls (25% vs 65%; RR 0.40, 95%CI 0.17 to 0.94).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633", "endSection": "sections.0"}, {"offsetInBeginSection": 1785, "offsetInEndSection": 1910, "text": "The reported data may suggest a (neuro)protective effect of neonatal allopurinol treatment in moderately asphyxiated infants.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633", "endSection": "sections.0"}, {"offsetInBeginSection": 1225, "offsetInEndSection": 1356, "text": "The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17162192", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "In newborn infants, allopurinol is being tested as a free radical scavenger to prevent brain damage caused by reperfusion and oxygenation after perinatal hypoxia and ischemia (birth asphyxia).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778717", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356", "endSection": "title"}, {"offsetInBeginSection": 364, "offsetInEndSection": 468, "text": "The analysis showed an unaltered (high) mortality and morbidity in the infants treated with allopurinol.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356", "endSection": "sections.0"}, {"offsetInBeginSection": 482, "offsetInEndSection": 596, "text": "Allopurinol treatment started postnatally was too late to reduce the early reperfusion induced free radical surge.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356", "endSection": "sections.0"}, {"offsetInBeginSection": 323, "offsetInEndSection": 432, "text": "One randomized trial of allopurinol showed short-term benefits but was too small to test death or disability.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12436031", "endSection": "sections.0"}, {"offsetInBeginSection": 1235, "offsetInEndSection": 1279, "text": "No toxic side effects of ALLO were detected.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9445490", "endSection": "sections.0"}, {"offsetInBeginSection": 2087, "offsetInEndSection": 2235, "text": "This study suggests a beneficial effect of ALLO treatment on free radical formation, CBV, and electrical brain activity, without toxic side effects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9445490", "endSection": "sections.0"}]}, {"body": "What was the purpose of the FANTOM4 project?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21075797", "http://www.ncbi.nlm.nih.gov/pubmed/19374775", "http://www.ncbi.nlm.nih.gov/pubmed/19377474"], "triples": [], "ideal_answer": ["The international Functional Annotation Of the Mammalian Genomes 4 (FANTOM4) research collaboration set out to better understand the transcriptional network that regulates macrophage differentiation and to uncover novel components of the transcriptome employing a series of high-throughput experiments.", "The international Functional Annotation Of the Mammalian Genomes 4 (FANTOM4) research collaboration set out to better understand the transcriptional network that regulates macrophage differentiation and to uncover novel components of the transcriptome employing a series of high-throughput experiments."], "exact_answer": [["Better understand the transcriptional network that regulates macrophage differentiation"]], "concepts": [], "type": "factoid", "id": "569e7721ceceede94d000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "The international Functional Annotation Of the Mammalian Genomes 4 (FANTOM4) research collaboration set out to better understand the transcriptional network that regulates macrophage differentiation and to uncover novel components of the transcriptome employing a series of high-throughput experiments.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075797", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "The international Functional Annotation Of the Mammalian Genomes 4 (FANTOM4) research collaboration set out to better understand the transcriptional network that regulates macrophage differentiation and to uncover novel components of the transcriptome employing a series of high-throughput experiments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075797", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "Using deep sequencing (deepCAGE), the FANTOM4 study measured the genome-wide dynamics of transcription-start-site usage in the human monocytic cell line THP-1 throughout a time course of growth arrest and differentiation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19377474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 303, "text": "The international Functional Annotation Of the Mammalian Genomes 4 (FANTOM4) research collaboration set out to better understand the transcriptional network that regulates macrophage differentiation and to uncover novel components of the transcriptome employing a series of high-throughput experiments. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21075797", "endSection": "abstract"}]}, {"body": "Which biomarker is widely used in the diagnosis of Ewing sarcoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12783138"], "triples": [], "ideal_answer": ["CD99 is a hallmark marker for Ewing sarcoma and primitive neuroectodermal tumors."], "exact_answer": [["CD99"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012512", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415", "http://www.disease-ontology.org/api/metadata/DOID:3368", "http://www.disease-ontology.org/api/metadata/DOID:4980"], "type": "factoid", "id": "55376663bc4f83e82800000a", "snippets": [{"offsetInBeginSection": 218, "offsetInEndSection": 463, "text": "half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", "endSection": "abstract"}, {"offsetInBeginSection": 218, "offsetInEndSection": 463, "text": "half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 463, "text": "Moreover, half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 463, "text": "Moreover, half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 463, "text": "Moreover, half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 463, "text": "Moreover, half of B-LBL patients are negative for CD45 (leucocyte common antigen, LCA), a widely used marker for the diagnosis of lymphoma, and a significant portion express CD99, a marker for Ewing's sarcoma (ES) or primitive neuroectodermal tumor (PNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783138", "endSection": "abstract"}]}, {"body": "What is the implication of histone lysine methylation in medulloblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23184418", "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "http://www.ncbi.nlm.nih.gov/pubmed/23179372"], "triples": [], "ideal_answer": ["Aberrant patterns of H3K4, H3K9, and H3K27 histone lysine methylation were shown to result in histone code alterations, which induce changes in gene expression, and affect the proliferation rate of cells in medulloblastoma."], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0034968", "http://www.disease-ontology.org/api/metadata/DOID:3858", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016571", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031060", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051567", "http://www.disease-ontology.org/api/metadata/DOID:3873"], "type": "summary", "id": "5539062dbc4f83e828000013", "snippets": [{"offsetInBeginSection": 280, "offsetInEndSection": 1148, "text": "Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 923, "text": "we identified previously unknown amplifications and homozygous deletions, including recurrent, mutually exclusive, highly focal genetic events in genes targeting histone lysine methylation, particularly that of histone 3, lysine 9 (H3K9). Post-translational modification of histone proteins is critical for regulation of gene expression, can participate in determination of stem cell fates and has been implicated in carcinogenesis. Consistent with our genetic data, restoration of expression of genes controlling H3K9 methylation greatly diminishes proliferation of medulloblastoma in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1181, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1181, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1181, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 919, "offsetInEndSection": 1181, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Recent studies showed frequent mutations in histone H3 lysine 27 (H3K27) demethylases in medulloblastomas of Group 3 and Group 4, suggesting a role for H3K27 methylation in these tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23179372", "endSection": "abstract"}, {"offsetInBeginSection": 280, "offsetInEndSection": 1148, "text": "Through targeted re-sequencing, we identified mutations of MLL2 in 8 % (14/175) of MBs, the majority of which were loss of function. Notably, we also report mutations affecting the MLL2-binding partner KDM6A, in 4 % (7/175) of tumors. While MLL2 mutations were independent of age, gender, histological subtype, M-stage or molecular subgroup, KDM6A mutations were most commonly identified in Group 4 MBs, and were mutually exclusive with MLL2 mutations. Immunohistochemical staining for H3K4me3 and H3K27me3, the chromatin effectors of MLL2 and KDM6A activity, respectively, demonstrated alterations of the histone code in 24 % (53/220) of MBs across all subgroups. Correlating these MLL2- and KDM6A-driven histone marks with prognosis, we identified populations of MB with improved (K4+/K27-) and dismal (K4-/K27-) outcomes, observed primarily within Group 3 and 4 MBs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "abstract"}, {"offsetInBeginSection": 332, "offsetInEndSection": 923, "text": "we identified previously unknown amplifications and homozygous deletions, including recurrent, mutually exclusive, highly focal genetic events in genes targeting histone lysine methylation, particularly that of histone 3, lysine 9 (H3K9). Post-translational modification of histone proteins is critical for regulation of gene expression, can participate in determination of stem cell fates and has been implicated in carcinogenesis. Consistent with our genetic data, restoration of expression of genes controlling H3K9 methylation greatly diminishes proliferation of medulloblastoma in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184418", "endSection": "title"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1186, "text": "Copy number aberrations of genes with critical roles in writing, reading, removing and blocking the state of histone lysine methylation, particularly at H3K9, suggest that defective control of the histone code contributes to the pathogenesis of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19270706", "endSection": "abstract"}]}, {"body": "Which properties of the mRNA does N6-methyladenosine (m6A) affect?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26121403", "http://www.ncbi.nlm.nih.gov/pubmed/25569111", "http://www.ncbi.nlm.nih.gov/pubmed/25475057", "http://www.ncbi.nlm.nih.gov/pubmed/25452335", "http://www.ncbi.nlm.nih.gov/pubmed/25430002", "http://www.ncbi.nlm.nih.gov/pubmed/24981863", "http://www.ncbi.nlm.nih.gov/pubmed/22575960", "http://www.ncbi.nlm.nih.gov/pubmed/19180239", "http://www.ncbi.nlm.nih.gov/pubmed/6318439", "http://www.ncbi.nlm.nih.gov/pubmed/6592581", "http://www.ncbi.nlm.nih.gov/pubmed/3029112", "http://www.ncbi.nlm.nih.gov/pubmed/25412662", "http://www.ncbi.nlm.nih.gov/pubmed/9409616"], "triples": [], "ideal_answer": ["N(6)-methyladenosine (m6A) is the most abundant modified base in eukaryotic mRNA and has been linked to diverse effects on mRNA fate. m6A predominantly and directly reduces mRNA stability."], "exact_answer": [["mRNA stability"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012333", "http://www.biosemantics.org/jochem#4252558"], "type": "factoid", "id": "56df03c751531f7e3300000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "N(6)-methyladenosine (m6A) is the most abundant modified base in eukaryotic mRNA and has been linked to diverse effects on mRNA fate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26121403", "endSection": "abstract"}, {"offsetInBeginSection": 601, "offsetInEndSection": 722, "text": "m(6)A predominantly and directly reduces mRNA stability, including that of key na\u00efve pluripotency-promoting transcripts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25569111", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "Recent discoveries of reversible N(6)-methyladenosine (m(6)A) methylation on messenger RNA (mRNA) and mapping of m(6)A methylomes in mammals and yeast have revealed potential regulatory functions of this RNA modification", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25430002", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 764, "text": "Monitoring m6A levels upon WTAP depletion allowed the definition of accurate and near single-nucleotide resolution methylation maps and their classification into WTAP-dependent and -independent sites. WTAP-dependent sites are located at internal positions in transcripts, topologically static across a variety of systems we surveyed, and inversely correlated with mRNA stability, consistent with a role in establishing \"basal\" degradation rates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981863", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Methylations of adenosine residues (m6A) in pre-mRNA are important for formation of late simian virus 40 mRNAs", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6318439", "endSection": "title"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1493, "text": "The data argues for a role of internal m6A moieties in modulating the processing-linked transport of mRNA from the nucleus to the cytoplasm of nontransformed cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6318439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "N6-Methyladenosine (m6A) residues, which are found internally in viral and cellular mRNA populations at the sequences Apm6ApC and Gpm6ApC, have been proposed to play a role in mRNA processing and transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6592581", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The role of Fat Mass and Obesity-associated protein (FTO) and its substrate N6-methyladenosine (m6A) in mRNA processing and adipogenesis remains largely unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25412662", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "N6-Methyladenosine (m6A) residues, which are found internally in viral and cellular mRNA populations at the sequences Apm6ApC and Gpm6ApC, have been proposed to play a role in mRNA processing and transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6592581", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "N6-methyladenosine (m6A) is a common modification of mRNA with potential roles in fine-tuning the RNA life cycle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981863", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The role of Fat Mass and Obesity-associated protein (FTO) and its substrate N6-methyladenosine (m6A) in mRNA processing and adipogenesis remains largely unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25412662", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "N6-Methyladenosine (m6A) residues, which are found internally in viral and cellular mRNA populations at the sequences Apm6ApC and Gpm6ApC, have been proposed to play a role in mRNA processing and transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6592581", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The role of Fat Mass and Obesity-associated protein (FTO) and its substrate N6-methyladenosine (m6A) in mRNA processing and adipogenesis remains largely unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25412662", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 248, "text": "The results of that study and of experiments using inhibitors of methylation suggest that m6A might be involved in mRNA processing events. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3029112", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 300, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 248, "text": "The results of that study and of experiments using inhibitors of methylation suggest that m6A might be involved in mRNA processing events. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3029112", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 300, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 248, "text": "The results of that study and of experiments using inhibitors of methylation suggest that m6A might be involved in mRNA processing events. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3029112", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 300, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": " The methylation of internal adenosine residues in eukaryotic mRNA, forming N6-methyladenosine (m6A), is catalyzed by a complex multicomponent enzyme. Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 615, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. As a step toward better understanding the mechanism and function of this ubiquitous posttranscriptional modification, we have shown that HeLa mRNA (N6-adenosine)-methyltransferase requires at least two separate protein factors, MT-A and MT-B, and MT-A contains the AdoMet binding site on a 70-kDa subunit (MT-A70).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "The methylation of internal adenosine residues in eukaryotic mRNA, forming N6-methyladenosine (m6A), is catalyzed by a complex multicomponent enzyme. Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 615, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. As a step toward better understanding the mechanism and function of this ubiquitous posttranscriptional modification, we have shown that HeLa mRNA (N6-adenosine)-methyltransferase requires at least two separate protein factors, MT-A and MT-B, and MT-A contains the AdoMet binding site on a 70-kDa subunit (MT-A70).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "The methylation of internal adenosine residues in eukaryotic mRNA, forming N6-methyladenosine (m6A), is catalyzed by a complex multicomponent enzyme. Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 615, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. As a step toward better understanding the mechanism and function of this ubiquitous posttranscriptional modification, we have shown that HeLa mRNA (N6-adenosine)-methyltransferase requires at least two separate protein factors, MT-A and MT-B, and MT-A contains the AdoMet binding site on a 70-kDa subunit (MT-A70).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": " The methylation of internal adenosine residues in eukaryotic mRNA, forming N6-methyladenosine (m6A), is catalyzed by a complex multicomponent enzyme. Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 615, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. As a step toward better understanding the mechanism and function of this ubiquitous posttranscriptional modification, we have shown that HeLa mRNA (N6-adenosine)-methyltransferase requires at least two separate protein factors, MT-A and MT-B, and MT-A contains the AdoMet binding site on a 70-kDa subunit (MT-A70).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": " The methylation of internal adenosine residues in eukaryotic mRNA, forming N6-methyladenosine (m6A), is catalyzed by a complex multicomponent enzyme. Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 615, "text": "Previous studies suggested that m6A affects the efficiency of mRNA processing or transport, although the mechanism by which this occurs is not known. As a step toward better understanding the mechanism and function of this ubiquitous posttranscriptional modification, we have shown that HeLa mRNA (N6-adenosine)-methyltransferase requires at least two separate protein factors, MT-A and MT-B, and MT-A contains the AdoMet binding site on a 70-kDa subunit (MT-A70).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9409616", "endSection": "abstract"}]}, {"body": "What is the association between proBNP serum concentrations and stroke outcomes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25102374", "http://www.ncbi.nlm.nih.gov/pubmed/23701638", "http://www.ncbi.nlm.nih.gov/pubmed/16565563", "http://www.ncbi.nlm.nih.gov/pubmed/17904063"], "triples": [], "ideal_answer": ["ProBNP serum concentrations are elevated in stroke patients relative to healthy controls. Greater proBNP serum concentrations are associated with greater stroke severity and with increased risk for unfvorable functional outcomes."], "concepts": [], "type": "summary", "id": "54e1c5d5ae9738404b00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "N-terminal probrain natriuretic peptide levels as a predictor of functional outcomes in patients with ischemic stroke.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102374", "endSection": "title"}, {"offsetInBeginSection": 968, "offsetInEndSection": 1865, "text": "There was a strong positive correlation between the plasma level of NT-proBNP and the National Institutes of Health Stroke Scale score (r=0.415, P=0.000). Plasma levels of NT-proBNP in patients with an unfavorable outcome were significantly higher than those in patients with a favorable outcome [3432 (interquartile range, 1100-54991) vs. 978 (interquartile range, 123-1705) pg/ml; P=0.000]. In multivariate analyses, after adjusting for all other significant outcome predictors, the NT-proBNP level that remained can be seen as an independent unfavorable outcome predictor, with an adjusted odds ratios of 4.14 (95% confidence interval, 2.72-7.99; P=0.000). Our results show that plasma NT-proBNP levels were significantly elevated in patients with an unfavorable outcome and might be of clinical importance as a supplementary tool for the assessment of functional outcomes in patients with AIS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102374", "endSection": "abstract"}, {"offsetInBeginSection": 820, "offsetInEndSection": 1389, "text": "Plasma levels of BNP, NT-proBNP, cortisol and copeptin were associated with stroke severity, as well as short-term functional outcomes. After adjusting for all other significant outcome predictors, NT-proBNP, cortisol and copeptin remained as independent outcome predictors. In the receiver operating characteristic curve analysis, the biomarker panel (including BNP, NT-proBNP, cortisol and copeptin) predicted functional outcome and death within 90 days significantly more efficiently than the National Institute of Health Stroke Scale (NIHSS) or the biomarker alone.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23701638", "endSection": "abstract"}, {"offsetInBeginSection": 654, "offsetInEndSection": 798, "text": "The NT-proBNP levels were significantly higher at 4 intervals after ischemic stroke than in healthy and at-risk control subjects (all p<0.001). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565563", "endSection": "abstract"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1742, "text": "Multivariate analysis demonstrated that age and NIH Stroke Scale were the 2 strongest independent predictors of increased NT-proBNP levels (all p<0.01). Furthermore, increased NT-proBNP (> or = 150 pg/ml) was the strongest independent predictor of long-term (mean follow-up: 24 months) UFCO (26 patients) (all p<0.05). CONCLUSIONS: The NT-proBNP level was markedly elevated after acute ischemic stroke and declined substantially thereafter. An increased NT-proBNP level was strongly and independently correlated with UFCO in patients after ischemic stroke.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565563", "endSection": "abstract"}, {"offsetInBeginSection": 968, "offsetInEndSection": 1865, "text": "There was a strong positive correlation between the plasma level of NT-proBNP and the National Institutes of Health Stroke Scale score (r=0.415, P=0.000). Plasma levels of NT-proBNP in patients with an unfavorable outcome were significantly higher than those in patients with a favorable outcome [3432 (interquartile range, 1100-54991) vs. 978 (interquartile range, 123-1705) pg/ml; P=0.000]. In multivariate analyses, after adjusting for all other significant outcome predictors, the NT-proBNP level that remained can be seen as an independent unfavorable outcome predictor, with an adjusted odds ratios of 4.14 (95% confidence interval, 2.72-7.99; P=0.000). Our results show that plasma NT-proBNP levels were significantly elevated in patients with an unfavorable outcome and might be of clinical importance as a supplementary tool for the assessment of functional outcomes in patients with AIS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102374", "endSection": "abstract"}]}, {"body": "What is the mode of inheritance of short QT syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19482666", "http://www.ncbi.nlm.nih.gov/pubmed/16812977", "http://www.ncbi.nlm.nih.gov/pubmed/19829181"], "triples": [], "ideal_answer": "The short QT syndrome has an autosomal dominant mode of inheritance.", "exact_answer": ["autosomal dominant mode of inheritance"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014918"], "type": "factoid", "id": "52f509512059c6d71c000020", "snippets": [{"offsetInBeginSection": 259, "offsetInEndSection": 552, "text": "Congenital short QT syndrome is a new familial primary electrical disease of the heart, which is characterized by abnormally short QT interval and paroxysmal atrial and ventricular tachyarrhythmias, including sudden cardiac death. An autosomal dominant mode of inheritance has been suggested. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482666", "endSection": "abstract"}, {"offsetInBeginSection": 362, "offsetInEndSection": 924, "text": "From 1993, the Short QT Syndrome (SQTS) came to our attention, as a new inherited \"electrical disease\" associated with increased risk of sudden cardiac death and atrial fibrillation. Mutations of Ikr, Iks, Ikl channels cause dysfunctional Iks, Ikr, Ikl channels with an increase in the net outward K current leading to shortening of repolarization. This in turn leads to a shorter QT interval on the ECG and shorter atrial and ventricular refractory periods with increased susceptibility to VF and AF. There seems to be an autosomal dominant mode of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16812977", "endSection": "abstract"}]}, {"body": "How can the expression of SerH3 immobilization antigen be regulated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3336362", "http://www.ncbi.nlm.nih.gov/pubmed/3537733", "http://www.ncbi.nlm.nih.gov/pubmed/4054606", "http://www.ncbi.nlm.nih.gov/pubmed/3915784", "http://www.ncbi.nlm.nih.gov/pubmed/11973302", "http://www.ncbi.nlm.nih.gov/pubmed/7731807", "http://www.ncbi.nlm.nih.gov/pubmed/7828814", "http://www.ncbi.nlm.nih.gov/pubmed/8414992", "http://www.ncbi.nlm.nih.gov/pubmed/1522546", "http://www.ncbi.nlm.nih.gov/pubmed/2233735", "http://www.ncbi.nlm.nih.gov/pubmed/2854007", "http://www.ncbi.nlm.nih.gov/pubmed/3211135"], "triples": [{"p": "http://purl.uniprot.org/core/submittedName", "s": "http://purl.uniprot.org/uniprot/Q9U697", "o": "http://linkedlifedata.com/resource/#_513955363937005"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513955363937005", "o": "SerH3 immobilization antigen"}, {"p": "http://purl.uniprot.org/core/submittedName", "s": "http://purl.uniprot.org/uniprot/Q22YJ5", "o": "http://linkedlifedata.com/resource/#_513232594A35007"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513232594A35007", "o": "SerH3 immobilization antigen, putative"}, {"p": "http://purl.uniprot.org/core/submittedName", "s": "http://purl.uniprot.org/uniprot/Q23VE7", "o": "http://linkedlifedata.com/resource/#_513233564537007"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513233564537007", "o": "SerH3 immobilization antigen, putative"}, {"p": "http://purl.uniprot.org/core/submittedName", "s": "http://purl.uniprot.org/uniprot/Q22TF4", "o": "http://linkedlifedata.com/resource/#_513232544634007"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513232544634007", "o": "SerH3 immobilization antigen, putative"}, {"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/Q9U697", "o": "http://linkedlifedata.com/resource/#_513955363937008"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_513955363937008", "o": "SerH3"}], "ideal_answer": "The expression of Tetrahymena surface proteins serotype H3 (SerH3) is under temperature regulation. SerH3 is expressed when cells are incubated between the temperatures of 20 and 35 degrees C.", "exact_answer": ["Temperature regulation"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005786", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010468", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010467", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010628", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010629", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012703", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000941", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007103"], "type": "factoid", "id": "5335f053d6d3ac6a34000055", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "mRNA stability plays a major role in regulating the temperature-specific expression of a Tetrahymena thermophila surface protein.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3336362", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The presence of specific proteins (known as immobilization antigens) on the surface of the ciliated protozoan Tetrahymena thermophila is under environmental regulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3537733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "A temperature shift from 40 to 28 degrees C rapidly induced expression of a specific immobilization antigen at the cell surface in Tetrahymena thermophila. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3915784", "endSection": "abstract"}, {"offsetInBeginSection": 1016, "offsetInEndSection": 1163, "text": "Expression of each allele is regulated by temperature-sensitive mRNA stability. H mRNAs are stable at <36 degrees but are unstable at >36 degrees. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11973302", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "In Tetrahymena thermophila, the expression of the temperature-specific surface protein SerH3 is controlled primarily by a temperature-dependent change in the stability of its mRNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7731807", "endSection": "abstract"}, {"offsetInBeginSection": 318, "offsetInEndSection": 450, "text": "we studied SerH3-ts1, a temperature-sensitive allele of the temperature-regulated SerH3 gene normally expressed from 20-36 degrees. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7828814", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "In Tetrahymena thermophila, the expression of a temperature-specific surface protein known as SerH3 is primarily controlled by a temperature-dependent change in the stability of the mRNA that encodes this protein. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8414992", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "The expression of Tetrahymena surface proteins serotype H3 (SerH3) and serotype T (SerT) is under environmental regulation. SerH3 is expressed when cells are incubated between the temperatures of 20 and 35 degrees C, while SerT is expressed when cells are grown at temperatures above 35 degrees C. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3211135", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "The surfaces of Tetrahymena thermophila cells grown between 20 and 35 degrees C are covered by one or more variants of H antigens. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2854007", "endSection": "abstract"}, {"offsetInBeginSection": 30, "offsetInEndSection": 117, "text": "SerH3, a Tetrahymena thermophila gene encoding a temperature-regulated surface antigen.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2233735", "endSection": "title"}, {"offsetInBeginSection": 274, "offsetInEndSection": 473, "text": "In the holotrich Tetrahymena thermophila five alternative cell surface immobilization proteins (i-antigens) are expressed under different conditions of temperature (L, H, T) and culture media (I, S).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1522546", "endSection": "abstract"}]}, {"body": "Which is the defective protein causing the lysosomal storage disease Fabry?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19202000", "http://www.ncbi.nlm.nih.gov/pubmed/19146893", "http://www.ncbi.nlm.nih.gov/pubmed/15702403", "http://www.ncbi.nlm.nih.gov/pubmed/15533650", "http://www.ncbi.nlm.nih.gov/pubmed/9395081", "http://www.ncbi.nlm.nih.gov/pubmed/9323559"], "ideal_answer": ["Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme."], "exact_answer": ["alpha-galactosidase A"], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:14499", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000795", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008247", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0005764", "http://www.disease-ontology.org/api/metadata/DOID:3211", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016464"], "type": "factoid", "id": "51405cd123fec90375000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 339, "text": "The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. Defective lysosomal alpha-galactosidase A (Gla) is responsible for excessive Gb3 accumulation, and one cell sensitive to the effects of Gb3 accumulation is vascular endothelium.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19202000", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 282, "text": "Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702403", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9323559", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9395081", "endSection": "sections.0"}]}, {"body": "What is the common feature in congenital central hypoventilation and Mowat-Wilson syndromes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23001136", "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "http://www.ncbi.nlm.nih.gov/pubmed/16443855"], "triples": [], "ideal_answer": ["About 30% of Hirschsprung disease (HSCR) cases are syndromic. Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "In CCHS patients, the weak predisposing haplotype of the RET gene can be regarded as a quantitative trait, being a risk factor for the HSCR phenotype, while in MWS, for which the HSCR penetrance is high, the role of the RET predisposing haplotype is not significant.", "In CCHS patients, the weak predisposing haplotype of the RET gene can be regarded as a quantitative trait, being a risk factor for the HSCR phenotype, while in MWS, for which the HSCR penetrance is high, the role of the RET predisposing haplotype is not significant."], "concepts": [], "type": "summary", "id": "55167dec46478f2f2c00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 982, "text": "Hirschsprung's disease (HSCR) is a fairly frequent cause of intestinal obstruction in children. It is characterized as a sex-linked heterogonous disorder with variable severity and incomplete penetrance giving rise to a variable pattern of inheritance. Although Hirschsprung's disease occurs as an isolated phenotype in at least 70% of cases, it is not infrequently associated with a number of congenital abnormalities and associated syndromes, demonstrating a spectrum of congenital anomalies. Certain of these syndromic phenotypes have been linked to distinct genetic sites, indicating underlying genetic associations of the disease and probable gene-gene interaction, in its pathogenesis. These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 879, "text": "On the other hand, about 30% of HSCR are syndromic. Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 470, "offsetInEndSection": 642, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 764, "text": "The RET locus was genotyped in 143 CCHS patients, among whom 44 had HSCR, and in 30 MWS patients, among whom 20 had HSCR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1077, "text": "RET was shown to act as a modifier gene for the HSCR phenotype in patients with CCHS but not with MWS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 880, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 470, "offsetInEndSection": 643, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1078, "text": "RET was shown to act as a modifier gene for the HSCR phenotype in patients with CCHS but not with MWS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 1292, "offsetInEndSection": 1558, "text": "In CCHS patients, the weak predisposing haplotype of the RET gene can be regarded as a quantitative trait, being a risk factor for the HSCR phenotype, while in MWS, for which the HSCR penetrance is high, the role of the RET predisposing haplotype is not significant.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 979, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 506, "offsetInEndSection": 874, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 433, "offsetInEndSection": 606, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 690, "offsetInEndSection": 980, "text": "These associations with HSCR include Downs syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 880, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 460, "offsetInEndSection": 642, "text": "METHODS: The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 690, "offsetInEndSection": 980, "text": "These associations with HSCR include Downs syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 880, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 460, "offsetInEndSection": 642, "text": "METHODS: The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 982, "text": "Hirschsprung's disease (HSCR) is a fairly frequent cause of intestinal obstruction in children. It is characterized as a sex-linked heterogonous disorder with variable severity and incomplete penetrance giving rise to a variable pattern of inheritance. Although Hirschsprung's disease occurs as an isolated phenotype in at least 70% of cases, it is not infrequently associated with a number of congenital abnormalities and associated syndromes, demonstrating a spectrum of congenital anomalies. Certain of these syndromic phenotypes have been linked to distinct genetic sites, indicating underlying genetic associations of the disease and probable gene-gene interaction, in its pathogenesis. These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 879, "text": "On the other hand, about 30% of HSCR are syndromic. Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 880, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 983, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 880, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 983, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 880, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 878, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 691, "offsetInEndSection": 981, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 1589, "offsetInEndSection": 1791, "text": "The frequent, low penetrant, predisposing allele of the RET gene can be regarded as a risk factor for the HSCR phenotype in CCHS, BBS, and Down syndrome, while its role is not significant in MWS and WS4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 1453, "offsetInEndSection": 1587, "text": "RET acts as a modifier gene for the HSCR phenotype in patients with CCHS, BBS, and Down syndrome, but not in patients with MWS and WS4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 512, "offsetInEndSection": 878, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 691, "offsetInEndSection": 981, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 1589, "offsetInEndSection": 1791, "text": "The frequent, low penetrant, predisposing allele of the RET gene can be regarded as a risk factor for the HSCR phenotype in CCHS, BBS, and Down syndrome, while its role is not significant in MWS and WS4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 1453, "offsetInEndSection": 1587, "text": "RET acts as a modifier gene for the HSCR phenotype in patients with CCHS, BBS, and Down syndrome, but not in patients with MWS and WS4", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 440, "offsetInEndSection": 612, "text": "The syndromic HSCR entities studied were congenital central hypoventilation (CCHS) and Mowat-Wilson syndrome (MWS), caused by PHOX2B and ZFHX1B gene mutations, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16443855", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 982, "text": "These associations with HSCR include Down's syndrome and other chromosomal anomalies, Waardenburg syndrome and other Dominant sensorineural deafness, the Congenital Central Hypoventilation and Mowat-Wilson and other brain-related syndromes, as well as the MEN2 and other tumour associations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136", "endSection": "abstract"}, {"offsetInBeginSection": 513, "offsetInEndSection": 879, "text": "Hitherto, the disease causing gene has been identified for eight Mendelian syndromes with HSCR: congenital central hypoventilation (CCHS), Mowat-Wilson (MWS), Bardet-Biedl (BBS), Shah-Waardenburg (WS4), cartilage-hair-hypoplasia (CHH), Smith-Lemli-Opitz (SLO), Goldberg-Sprintzsen (GSS), and hydrocephalus due to congenital stenosis of the aqueduct of sylvius (HSAS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}, {"offsetInBeginSection": 1794, "offsetInEndSection": 1884, "text": "These data highlight the pivotal role of the RET gene in both isolated and syndromic HSCR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17397038", "endSection": "abstract"}]}, {"body": "What is evaluated using the EORTC QLQ \u2013 INFO25 questionnaire?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22638756", "http://www.ncbi.nlm.nih.gov/pubmed/22052786", "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "http://www.ncbi.nlm.nih.gov/pubmed/24834120", "http://www.ncbi.nlm.nih.gov/pubmed/25475735"], "triples": [], "ideal_answer": ["The European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO 25) evaluates the level of information patients have received in different areas of their disease, treatment and care, and evaluates qualitative aspects together with satisfaction with information."], "concepts": [], "type": "summary", "id": "54f49995d0d681a040000002", "snippets": [{"offsetInBeginSection": 688, "offsetInEndSection": 788, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 342, "text": "METHODS: The EORTC information questionnaire, EORTC QLQ-INFO25, was administered during the treatment process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052786", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "The EORTC information questionnaire, EORTC QLQ-INFO25. Validation study for Spanish patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "INTRODUCTION: The EORTC QLQ-INFO25 evaluates the information received by cancer patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 568, "offsetInEndSection": 986, "text": "We highlight the need to assess patients' characteristics and desires through questionnaires and interviews and present the European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO 25). This instrument evaluates the level of information patients have received in different areas of their disease, treatment and care, and evaluates qualitative aspects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "AIM: The EORTC Quality of Life (QOL) Group has developed an instrument to evaluate the information received by cancer patients. This study assessed the psychometric characteristics of the EORTC INFO module in a large international/multi-cultural sample of cancer patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 688, "offsetInEndSection": 788, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 688, "offsetInEndSection": 787, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "abstract"}, {"offsetInBeginSection": 688, "offsetInEndSection": 786, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 688, "offsetInEndSection": 786, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 688, "offsetInEndSection": 786, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "abstract"}, {"offsetInBeginSection": 688, "offsetInEndSection": 786, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21671697", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20674333", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301", "endSection": "abstract"}, {"offsetInBeginSection": 688, "offsetInEndSection": 786, "text": "The EORTC QLQ-INFO25 was used to evaluate the perceived level of and satisfaction with information", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22638756", "endSection": "abstract"}]}, {"body": "Which cell type has the protein Chromogranin A as marker?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25294889", "http://www.ncbi.nlm.nih.gov/pubmed/25294372", "http://www.ncbi.nlm.nih.gov/pubmed/25220535", "http://www.ncbi.nlm.nih.gov/pubmed/25177680", "http://www.ncbi.nlm.nih.gov/pubmed/25532001", "http://www.ncbi.nlm.nih.gov/pubmed/25501094", "http://www.ncbi.nlm.nih.gov/pubmed/25394660", "http://www.ncbi.nlm.nih.gov/pubmed/25099181", "http://www.ncbi.nlm.nih.gov/pubmed/24888775", "http://www.ncbi.nlm.nih.gov/pubmed/24897131"], "triples": [{"p": "http://purl.uniprot.org/core/reviewed", "s": "http://purl.uniprot.org/uniprot/P33716", "o": "true"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_503333373136007", "o": "Chromogranin-A"}, {"p": "http://purl.uniprot.org/core/recommendedName", "s": "http://purl.uniprot.org/uniprot/P33716", "o": "http://linkedlifedata.com/resource/#_503333373136007"}, {"p": "http://purl.uniprot.org/core/classifiedWith", "s": "http://purl.uniprot.org/uniprot/P33716", "o": "http://purl.uniprot.org/keywords/964"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_503333373136007", "o": "Chromogranin-A"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/keywords/964", "o": "Secreted"}, {"p": "http://purl.uniprot.org/core/recommendedName", "s": "http://purl.uniprot.org/uniprot/P33716", "o": "http://linkedlifedata.com/resource/#_503333373136007"}], "ideal_answer": ["Chromogranin A is a marker for neuroendocrine cells"], "exact_answer": [["neuroendocrine cells"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002864", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053379", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000943", "http://www.biosemantics.org/jochem#4266983", "http://www.biosemantics.org/jochem#4262122", "http://www.biosemantics.org/jochem#4218257", "http://www.uniprot.org/uniprot/CMGA_HUMAN", "http://www.uniprot.org/uniprot/CMGA_BOVIN"], "type": "factoid", "id": "54e262daae9738404b000018", "snippets": [{"offsetInBeginSection": 562, "offsetInEndSection": 642, "text": "Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294889", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1093, "text": "All paragangliomas were universally positive for chromogranin A ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294372", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 92, "text": "chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine tumors (pNET)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220535", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Together with Chromogranin B and Secretogranins, Chromogranin A (CGA) is stored in secretory (chromaffin) granules of the diffuse neuroendocrine system", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25177680", "endSection": "abstract"}, {"offsetInBeginSection": 21, "offsetInEndSection": 168, "text": "Chromogranin A (CgA) is the most important general tumour marker used in the diagnosis and follow-up of patients with neuroendocrine tumours (NET).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25532001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Chromogranin A (CgA) not only plays an important role in pathologic diagnosis, but is also used as a circulating biomarker in patients with gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25501094", "endSection": "abstract"}, {"offsetInBeginSection": 1206, "offsetInEndSection": 1274, "text": "numbers of chromogranin A (CHGA)-positive enteroendocrine cells (EEC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25394660", "endSection": "abstract"}, {"offsetInBeginSection": 1761, "offsetInEndSection": 1816, "text": " CgA is a reliable serum diagnostic biomarker for PNETs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099181", "endSection": "abstract"}, {"offsetInBeginSection": 81, "offsetInEndSection": 186, "text": "Chromogranin A (CgA) was considered as the most practical and useful serum tumor marker in PNET patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099181", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 461, "text": "the neuroendocrine markers chromogranin A and synaptophysin;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24888775", "endSection": "abstract"}]}, {"body": "What is known about the association between the use of selective serotonin reuptake inhibitors during pregnancy and risk for autism in offspring?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24065914", "http://www.ncbi.nlm.nih.gov/pubmed/23681158", "http://www.ncbi.nlm.nih.gov/pubmed/23604083", "http://www.ncbi.nlm.nih.gov/pubmed/23495208", "http://www.ncbi.nlm.nih.gov/pubmed/20018455", "http://www.ncbi.nlm.nih.gov/pubmed/21727247", "http://www.ncbi.nlm.nih.gov/pubmed/22090498", "http://www.ncbi.nlm.nih.gov/pubmed/23042258"], "triples": [], "ideal_answer": "Greater risk for autism spectrum disorders has been reported among mothers that have used selective serotonin reuptake inhibitors during pregnancy. However, others did not find an association between the use of selective serotonin reuptake inhibitors during pregnancy and risk for autism in offspring. Also, selective serotonin reuptake inhibitor use during pregnancy were associated with a greater number of gastrointestinal complaints in children with autism spectrum disorders.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017367", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001321", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011247", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0007565", "http://www.disease-ontology.org/api/metadata/DOID:12849", "http://www.disease-ontology.org/api/metadata/DOID:0060041"], "type": "summary", "id": "530cefaaad0bf1360c000009", "snippets": [{"offsetInBeginSection": 709, "offsetInEndSection": 1188, "text": "In doing so, we examined whether two proposed risk factors - low birth weight (LBW), and in utero exposure to selective serotonin reuptake inhibitors (SSRIs) - are associated with greater behavioral homogeneity. Using data from the Western Australian Autism Biological Registry, this study found that LBW and maternal SSRI use during pregnancy were associated with greater sleep disturbances and a greater number of gastrointestinal complaints in children with ASD, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24065914", "endSection": "abstract"}, {"offsetInBeginSection": 1034, "offsetInEndSection": 1173, "text": "The outcome of one study suggested that children with autism were more likely to have a mother who was prescribed an SSRI during pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23681158", "endSection": "abstract"}, {"offsetInBeginSection": 944, "offsetInEndSection": 1436, "text": "A history of maternal (adjusted odds ratio 1.49, 95% confidence interval 1.08 to 2.08) but not paternal depression was associated with an increased risk of autism spectrum disorders in offspring. In the subsample with available data on drugs, this association was confined to women reporting antidepressant use during pregnancy (3.34, 1.50 to 7.47, P=0.003), irrespective of whether selective serotonin reuptake inhibitors (SSRIs) or non-selective monoamine reuptake inhibitors were reported.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23604083", "endSection": "abstract"}, {"offsetInBeginSection": 1755, "offsetInEndSection": 1976, "text": "In utero exposure to both SSRIs and non-selective monoamine reuptake inhibitors (tricyclic antidepressants) was associated with an increased risk of autism spectrum disorders, particularly without intellectual disability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23604083", "endSection": "abstract"}, {"offsetInBeginSection": 104, "offsetInEndSection": 529, "text": "Repeated findings of elevated platelet serotonin levels in approximately one third of children with autism has led some to believe that dysfunctional serotonin signaling may be a causal mechanism for the disorder. Because serotonin is critical to fetal brain development, concerns have arisen regarding prenatal exposure to substances that manipulate serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23495208", "endSection": "abstract"}, {"offsetInBeginSection": 858, "offsetInEndSection": 1209, "text": "Though the majority of studies conducted in infants and children suggest prenatal exposure to SSRIs does not affect neurodevelopment, interpretation must be tempered given small sample sizes. The only published study that focused on prenatal SSRI exposure and ASD found an increased risk with exposure to SSRIs, especially during the first trimester. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23495208", "endSection": "abstract"}, {"offsetInBeginSection": 157, "offsetInEndSection": 818, "text": "Among the potential environmental factors, hyperserotonemia during pregnancy and its effect on brain development could be playing a role in this prevalence raise. In the rodent model developed by Whitaker-Azmitia and colleagues, hyperserotonemia during fetal development results in a dysfunction of the hypothalamo-pituitary axis, affecting the amygdala as well as pro-social hormone oxytocin regulation. Dysfunction of the amygdala and abnormal oxytocin levels may underlie many clinical features of ASD. Selective serotonin reuptake inhibitors (SSRI) are the most widely used class of antidepressants drugs, and they are not contraindicated during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20018455", "endSection": "abstract"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1554, "text": "In adjusted logistic regression models, we found a 2-fold increased risk of ASD associated with treatment with selective serotonin reuptake inhibitors by the mother during the year before delivery (adjusted odds ratio, 2.2 [95% confidence interval, 1.2-4.3]), with the strongest effect associated with treatment during the first trimester (adjusted odds ratio, 3.8 [95% confidence interval, 1.8-7.8]).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21727247", "endSection": "abstract"}, {"offsetInBeginSection": 1732, "offsetInEndSection": 1963, "text": "Although the number of children exposed prenatally to selective serotonin reuptake inhibitors in this population was low, results suggest that exposure, especially during the first trimester, may modestly increase the risk of ASD. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21727247", "endSection": "abstract"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1697, "text": "Together, these results indicate that administration of SSRIs during a sensitive period of brain development results in long-lasting alterations in NE-LC circuit function in adults and may be useful in understanding the etiology of pervasive developmental disorders such as autism spectrum disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090498", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1295, "text": " Although several studies have not confirmed an increased risk for adverse neurodevelopment, a recent study observed an increased risk for autism spectrum disorders in prenatally exposed offspring. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258", "endSection": "abstract"}, {"offsetInBeginSection": 1600, "offsetInEndSection": 1776, "text": "Considering the important role of serotonin in central nervous system development, more studies are needed to assess the possible adverse effects on long-term neurodevelopment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23042258", "endSection": "abstract"}]}, {"body": "What distinguishes lantibiotics from antibiotics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25787977", "http://www.ncbi.nlm.nih.gov/pubmed/23168402", "http://www.ncbi.nlm.nih.gov/pubmed/24069959", "http://www.ncbi.nlm.nih.gov/pubmed/24621781", "http://www.ncbi.nlm.nih.gov/pubmed/24210177", "http://www.ncbi.nlm.nih.gov/pubmed/19393544", "http://www.ncbi.nlm.nih.gov/pubmed/12361237", "http://www.ncbi.nlm.nih.gov/pubmed/8264800", "http://www.ncbi.nlm.nih.gov/pubmed/21905643", "http://www.ncbi.nlm.nih.gov/pubmed/11945173", "http://www.ncbi.nlm.nih.gov/pubmed/23475977", "http://www.ncbi.nlm.nih.gov/pubmed/21470152", "http://www.ncbi.nlm.nih.gov/pubmed/19009315", "http://www.ncbi.nlm.nih.gov/pubmed/15044440", "http://www.ncbi.nlm.nih.gov/pubmed/1482192"], "triples": [], "ideal_answer": ["One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides. Low levels of resistance have been reported for lantibiotics compared with commercial antibiotics. Nisin is the oldest and the most widely used lantibiotic, in food preservation, without having developed any significant resistance against it.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "Lantibiotic compounds are ribosomally synthesized antimicrobial peptides against which bacteria are not able to produce resistance, hence making them a good alternative to antibiotics. It is interesting that low levels of resistance have been reported for lantibiotics compared with commercial antibiotics. Given that there are very few examples of naturally occurring lantibiotic resistance, attempts have been made to deliberately induce resistance phenotypes in order to investigate this phenomenon. Other general forms of resistance include the formation of spores or biofilms, which are a common mechanistic response to many classes of antimicrobials."], "exact_answer": [["Lantibiotics are post-translationally modified natural peptides containing lanthionine"]], "concepts": ["http://www.biosemantics.org/jochem#4260744", "http://www.biosemantics.org/jochem#4275453"], "type": "factoid", "id": "5719f5c67de986d80d00000d", "snippets": [{"offsetInBeginSection": 124, "offsetInEndSection": 339, "text": "One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787977", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 460, "text": "low levels of resistance have been reported for lantibiotics compared with commercial antibiotics", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787977", "endSection": "abstract"}, {"offsetInBeginSection": 658, "offsetInEndSection": 877, "text": "Mechanisms that hinder the action of lantibiotics are often innate systems that react to the presence of any cationic peptides/proteins or ones which result from cell well damage, rather than being lantibiotic specific.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25787977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Lantibiotics are biologically active peptides produced by Gram-positive bacteria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23168402", "endSection": "abstract"}, {"offsetInBeginSection": 129, "offsetInEndSection": 269, "text": "Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a broad spectrum antimicrobial activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24069959", "endSection": "abstract"}, {"offsetInBeginSection": 103, "offsetInEndSection": 287, "text": "Lantibiotic compounds are ribosomally synthesized antimicrobial peptides against which bacteria are not able to produce resistance, hence making them a good alternative to antibiotics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621781", "endSection": "abstract"}, {"offsetInBeginSection": 282, "offsetInEndSection": 422, "text": "Lantibiotics are ribosomally synthesized peptide antibiotics that are posttranslationally modified to introduce (methyl)lanthionine bridges.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475977", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Lantibiotics are defined as peptide antibiotics containing the unusual amino acids mesolanthionine, 3-methyllanthionine, dehydroalanine, and dehydrobutyrine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Lantibiotics are antibiotic peptides distinguished by the presence of the rare thioether amino acids lanthionine and/or methyllanthionine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11945173", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Lantibiotics are ribosomally synthesized, post-translationally modified, peptide antibiotics containing unusual amino acids such as dehydrated amino acids and lanthionine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21470152", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Lantibiotics are peptide antibiotics, realizing their unique secondary structure by posttranslational modifications, the most important one being the formation of the characteristic amino acid lanthionine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21905643", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Lantibiotics are lanthionine-containing peptide antibiotics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15044440", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Lantibiotics are lanthionine-containing peptide antibiotics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15044440", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Lantibiotics, a group of lanthionine-containing peptides, display their antibiotic activity by combining different killing mechanisms within one molecule. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009315", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Lantibiotics are lanthionine-containing peptide antibiotics. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15044440", "endSection": "abstract"}, {"offsetInBeginSection": 601, "offsetInEndSection": 697, "text": "Lantibiotics are ribosomally synthesized as prepeptides, which are posttranslationally modified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Lantibiotics are defined as peptide antibiotics containing the unusual amino acids mesolanthionine, 3-methyllanthionine, dehydroalanine, and dehydrobutyrine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8264800", "endSection": "abstract"}]}, {"body": "What is the CRAPome database?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23921808"], "triples": [], "ideal_answer": "The CRAPome is a contaminant repository for affinity purification-mass spectrometry data.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019991", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030562"], "type": "summary", "id": "531e01ff267d7dd05300000e", "snippets": [{"offsetInBeginSection": 938, "offsetInEndSection": 1004, "text": "the contaminant repository for affinity purification (the CRAPome)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23921808", "endSection": "abstract"}]}, {"body": "In which cells are A-type lamins expressed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21842415", "http://www.ncbi.nlm.nih.gov/pubmed/20568006", "http://www.ncbi.nlm.nih.gov/pubmed/9367621", "http://www.ncbi.nlm.nih.gov/pubmed/7781761", "http://www.ncbi.nlm.nih.gov/pubmed/2404771", "http://www.ncbi.nlm.nih.gov/pubmed/2209722", "http://www.ncbi.nlm.nih.gov/pubmed/2415378", "http://www.ncbi.nlm.nih.gov/pubmed/9274531", "http://www.ncbi.nlm.nih.gov/pubmed/9363444", "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "http://www.ncbi.nlm.nih.gov/pubmed/9410886", "http://www.ncbi.nlm.nih.gov/pubmed/17203376", "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "http://www.ncbi.nlm.nih.gov/pubmed/8381765", "http://www.ncbi.nlm.nih.gov/pubmed/24213377"], "triples": [], "ideal_answer": ["Early embryonic cells and stem cells of mammals generally possess only lamin B while lamins A and C appear later during differentiation. Northern analysis and immunoblotting demonstrated that lamin A/C mRNA and protein were not detectable in some human cell lines whereas lamin B1 was always present. Hemopoietic cells from blood and bone marrow of mammals usually do not express lamins A/C but only lamin B, and this feature distinguishes these cells from the vast majority of somatic cells of the adult animal, which reveal lamins A/C as well as lamin B.", "In the rat brain, lamin A and C are expressed in relatively equal amounts, while the expressions of lamin B1 and B2 vary depending on the cell type. Human cells with reduced expression of the major B-type lamin protein, lamin B1, were generated using RNA interference. In addition, horizontal cells and a subpopulation of retinal ganglion cells expressed lamin A and C, while photoreceptor cells expressed neither lamin A nor C, and all other retinal neurons expressed lamin C only. Parallel in vivo experiments showed that treatment with thioglycollate caused the percentage of lamin A/C-positive peritoneal macrophages to increase from 5 to 80% between Days 0 and 6."], "exact_answer": [["late differentiating primary cells"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034904", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034882", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002477"], "type": "factoid", "id": "56ed27202ac5ed145900000c", "snippets": [{"offsetInBeginSection": 676, "offsetInEndSection": 845, "text": "Antibodies specific for mouse A/C lamins, human A/C lamins, or B lamins have been used to define the lamin complement as a function of time in culture and of cell type. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722", "endSection": "abstract"}, {"offsetInBeginSection": 847, "offsetInEndSection": 1234, "text": "dramatic increase in lamin A/C-positive cells was observed in the first 3 days of culture with both accessory cells and macrophages expressing lamins A/C as soon as such cell types could be identified. Parallel in vivo experiments showed that treatment with thioglycollate caused the percentage of lamin A/C-positive peritoneal macrophages to increase from 5 to 80% between Days 0 and 6.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722", "endSection": "abstract"}, {"offsetInBeginSection": 195, "offsetInEndSection": 332, "text": "Early embryonic cells and stem cells of mammals generally possess only lamin B while lamins A and C appear later during differentiation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2404771", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 334, "text": "Northern analysis and immunoblotting demonstrated that lamin A/C mRNA and protein were not detectable in some human cell lines whereas lamin B1 was always present", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9367621", "endSection": "abstract"}, {"offsetInBeginSection": 197, "offsetInEndSection": 345, "text": "In the rat brain, lamin A and C are expressed in relatively equal amounts, while the expressions of lamin B1 and B2 vary depending on the cell type.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21842415", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Hemopoietic cells from blood and bone marrow of mammals usually do not express lamins A/C but only lamin B, and this feature distinguishes these cells from the vast majority of somatic cells of the adult animal, which reveal lamins A/C as well as lamin B", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209722", "endSection": "abstract"}, {"offsetInBeginSection": 749, "offsetInEndSection": 941, "text": "These results demonstrated that EC cells devoid of lamins A and C nevertheless possessed the appropriate mechanisms for the localization and mitotic redistribution of exogenous lamins A and C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2404771", "endSection": "abstract"}, {"offsetInBeginSection": 1687, "offsetInEndSection": 1861, "text": "Spermatogonia and seminoma cells, which follow a differentiation pathway along the spermatogenic lineage and show characteristics of germ cells, do not express A-type lamins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9274531", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 667, "text": "While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 292, "offsetInEndSection": 476, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "The expression of A-type lamins coincides with cell differentiation and as A-type lamins specifically interact with chromatin, a role in the regulation of differential gene expression has been suggested for A-type lamins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9410886", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 660, "text": "In the literature it is conveyed that only B-type lamins are required in these early stages of development and that A-type lamins are not present or required until differentiation of specific cell types associated with specialized tissue is initiated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17203376", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 292, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 577, "text": "The nuclear lamina is a meshwork of intermediate filaments adjacent to the inner nuclear membrane that in mammalian cells is predominantly composed of three proteins: lamin A, lamin B, and lamin C. Because lamin A and C (A-type lamins) expression has been shown to be lacking in several types of undifferentiated or rapidly proliferating cells, we investigated lamin expression in the human liver in conditions with hepatocellular regeneration (cirrhosis of various etiologies and macroregenerative nodules) and in hepatocellular carcinomas of various grades of differentiation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8381765", "endSection": "abstract"}, {"offsetInBeginSection": 1320, "offsetInEndSection": 1513, "text": "Our results identify the absence of A-type lamin expression as a novel marker for undifferentiated ES cells and further support a role for nuclear lamins in cell maintenance and differentiation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 330, "offsetInEndSection": 523, "text": "In an attempt to provide an additional meaning to lamin-genome contacts, a recent study characterized the association of gene promoters with A-type lamins in progenitor and differentiated cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213377", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 450, "text": "Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Ectopic expression of an A-type lamin does not interfere with differentiation of lamin A-negative embryonal carcinoma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "title"}, {"offsetInBeginSection": 503, "offsetInEndSection": 617, "text": "Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 450, "text": "Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Ectopic expression of an A-type lamin does not interfere with differentiation of lamin A-negative embryonal carcinoma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "title"}, {"offsetInBeginSection": 503, "offsetInEndSection": 617, "text": "Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 450, "text": "Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Ectopic expression of an A-type lamin does not interfere with differentiation of lamin A-negative embryonal carcinoma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "title"}, {"offsetInBeginSection": 503, "offsetInEndSection": 617, "text": "Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Ectopic expression of an A-type lamin does not interfere with differentiation of lamin A-negative embryonal carcinoma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "title"}, {"offsetInBeginSection": 294, "offsetInEndSection": 450, "text": "Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 503, "offsetInEndSection": 617, "text": "Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 450, "text": "Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Ectopic expression of an A-type lamin does not interfere with differentiation of lamin A-negative embryonal carcinoma cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "title"}, {"offsetInBeginSection": 503, "offsetInEndSection": 617, "text": "Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 617, "text": "While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines. Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 450, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state. Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 503, "text": "On the basis of biochemical properties and sequence criteria, vertebrate lamin proteins are classified as either A- or B-type. While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 617, "text": "While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines. Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 450, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state. Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 617, "text": "While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines. Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 450, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state. Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 617, "text": "While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines. Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 450, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state. Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 335, "offsetInEndSection": 617, "text": "While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines. Intriguingly, expression of A-type lamins occurs concomitant with cell differentiation and embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 450, "text": "B-type lamins are present in almost all cell types, but A-type lamins are expressed predominantly in differentiated cells, suggesting a role in maintenance of the differentiated state. Previous studies have shown that lamin A/C is not expressed during mouse development before day 9, nor in undifferentiated mouse embryonic carcinoma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16179429", "endSection": "abstract"}, {"offsetInBeginSection": 208, "offsetInEndSection": 503, "text": "On the basis of biochemical properties and sequence criteria, vertebrate lamin proteins are classified as either A- or B-type. While B-type lamins are expressed in almost all cell types, no A-type lamins are present in early vertebrate embryos or undifferentiated embryonal carcinoma cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1808207", "endSection": "abstract"}]}, {"body": "What is BioASQ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25925131"], "triples": [], "ideal_answer": ["The BioASQ challenge is a competition on large-scale biomedical semantic indexing and question answering (QA). BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies. BIOASQ helped obtain a unified view of how techniques from text classification, semantic indexing, document and passage retrieval, question answering, and text summarization can be combined to allow biomedical experts to obtain concise, user-understandable answers to questions reflecting their real information needs.", "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies. "], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012660"], "type": "summary", "id": "56ae3cdc0a360a5e45000008", "snippets": [{"offsetInBeginSection": 2104, "offsetInEndSection": 2422, "text": "BIOASQ helped obtain a unified view of how techniques from text classification, semantic indexing, document and passage retrieval, question answering, and text summarization can be combined to allow biomedical experts to obtain concise, user-understandable answers to questions reflecting their real information needs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 485, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 214, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 472, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 564, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.RESULTS: The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1858, "text": "The BIOASQ infrastructure, including benchmark datasets, evaluation mechanisms, and the results of the participants and baseline methods, is publicly available.CONCLUSIONS: A publicly available evaluation infrastructure for biomedical semantic indexing and QA has been developed, which includes benchmark datasets, and can be used to evaluate systems that: assign MESH headings to published articles or to English questions; retrieve relevant RDF triples from ontologies, relevant articles and snippets from PUBMED Central; produce \"exact\" and paragraph-sized \"ideal\" answers (summaries). The results of the systems that participated in the 2013 BIOASQ competition are promising. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 1946, "offsetInEndSection": 2422, "text": "In Task 1b the systems received high scores in the manual evaluation of the \"ideal\" answers; hence, they produced high quality summaries as answers. Overall, BIOASQ helped obtain a unified view of how techniques from text classification, semantic indexing, document and passage retrieval, question answering, and text summarization can be combined to allow biomedical experts to obtain concise, user-understandable answers to questions reflecting their real information needs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 564, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.RESULTS: The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 2095, "offsetInEndSection": 2422, "text": "Overall, BIOASQ helped obtain a unified view of how techniques from text classification, semantic indexing, document and passage retrieval, question answering, and text summarization can be combined to allow biomedical experts to obtain concise, user-understandable answers to questions reflecting their real information needs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 564, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.RESULTS: The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1858, "text": "The BIOASQ infrastructure, including benchmark datasets, evaluation mechanisms, and the results of the participants and baseline methods, is publicly available.CONCLUSIONS: A publicly available evaluation infrastructure for biomedical semantic indexing and QA has been developed, which includes benchmark datasets, and can be used to evaluate systems that: assign MESH headings to published articles or to English questions; retrieve relevant RDF triples from ontologies, relevant articles and snippets from PUBMED Central; produce \"exact\" and paragraph-sized \"ideal\" answers (summaries). The results of the systems that participated in the 2013 BIOASQ competition are promising. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 1946, "offsetInEndSection": 2422, "text": "In Task 1b the systems received high scores in the manual evaluation of the \"ideal\" answers; hence, they produced high quality summaries as answers. Overall, BIOASQ helped obtain a unified view of how techniques from text classification, semantic indexing, document and passage retrieval, question answering, and text summarization can be combined to allow biomedical experts to obtain concise, user-understandable answers to questions reflecting their real information needs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "BACKGROUND: This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 215, "offsetInEndSection": 564, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.RESULTS: The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 2095, "offsetInEndSection": 2422, "text": "Overall, BIOASQ helped obtain a unified view of how techniques from text classification, semantic indexing, document and passage retrieval, question answering, and text summarization can be combined to allow biomedical experts to obtain concise, user-understandable answers to questions reflecting their real information needs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 544, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies. The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 474, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013. BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 544, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 474, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013. BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 544, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies. The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 474, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013. BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 544, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies. The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 474, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013. BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 544, "text": "BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies. The 2013 BIOASQ competition comprised two tasks, Task 1a and Task 1b.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 474, "text": "This article provides an overview of the first BIOASQ challenge, a competition on large-scale biomedical semantic indexing and question answering (QA), which took place between March and September 2013. BIOASQ assesses the ability of systems to semantically index very large numbers of biomedical scientific articles, and to return concise and user-understandable answers to given natural language questions by combining information from biomedical articles and ontologies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25925131", "endSection": "abstract"}]}, {"body": "Describe the known functions for the prothymosin alpha c-terminal peptide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23201434", "http://www.ncbi.nlm.nih.gov/pubmed/20467443", "http://www.ncbi.nlm.nih.gov/pubmed/18976813", "http://www.ncbi.nlm.nih.gov/pubmed/18856068", "http://www.ncbi.nlm.nih.gov/pubmed/17929838", "http://www.ncbi.nlm.nih.gov/pubmed/16453152", "http://www.ncbi.nlm.nih.gov/pubmed/2209614", "http://www.ncbi.nlm.nih.gov/pubmed/11744386", "http://www.ncbi.nlm.nih.gov/pubmed/18645619"], "triples": [{"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_423651354534004", "o": "Prothymosin alpha"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7615967", "o": "Prothymosin Alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_423945504C3900F", "o": "Prothymosin alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_433356565638006", "o": "Prothymosin alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_443057525431006", "o": "Prothymosin alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_503036343534001F", "o": "Prothymosin alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513135323032007", "o": "Prothymosin alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513633343532007", "o": "Prothymosin-alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_503031323532007", "o": "Prothymosin alpha"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_513239323836007", "o": "Prothymosin alpha"}], "ideal_answer": ["Prothymosin alpha (ProT\u03b1) (encoded in human by the PTMA gene) is a ubiquitous, highly acidic nuclear polypeptide. During early apoptosis, proT\u03b1 is cleaved by activated caspase-3, with a primary attach site being D99, close to its carboxyl-terminus. The role of the cleaved decapeptide -- proT\u03b1(100-109) -- is not fully understood. proT\u03b1(100-109), which contains the nuclear localization signal (NLS) for ProT\u03b1, has been demonstrated to have immunostimulatory properties, such as to stimulate lymphocytes and neutrophils and induce dendritic cell maturation."], "concepts": ["http://www.uniprot.org/uniprot/PTMA_BOVIN", "http://www.uniprot.org/uniprot/PTMA_RAT", "http://www.uniprot.org/uniprot/PTMAA_XENLA", "http://www.uniprot.org/uniprot/PTMA_RANES", "http://www.uniprot.org/uniprot/PTMAA_DANRE", "http://www.uniprot.org/uniprot/PTMA_PONAB", "http://www.uniprot.org/uniprot/PTMA_MOUSE", "http://www.uniprot.org/uniprot/PTMA_HUMAN", "http://www.uniprot.org/uniprot/PTMAB_DANRE", "http://www.uniprot.org/uniprot/PTMAB_XENLA"], "type": "summary", "id": "51be03c4047fa84d1d000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The C-terminal decapeptide of prothymosin \u03b1 is responsible for its stimulatory effect on the functions of human neutrophils in vitro", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201434", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 676, "text": "In this study, we investigated the ability of the immunoreactive fragment of the polypeptide prothymosin alpha (proT\u03b1), i.e., the decapeptide proT\u03b1(100-109), to enhance the functions of neutrophils isolated from the peripheral blood of breast cancer patients in comparison with those from healthy donors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201434", "endSection": "sections.0"}, {"offsetInBeginSection": 1473, "offsetInEndSection": 1590, "text": "Our results suggest that proT\u03b1(100-109) activates neutrophils, particularly those derived from breast cancer patients", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201434", "endSection": "sections.0"}, {"offsetInBeginSection": 577, "offsetInEndSection": 707, "text": "The Ca\u00b2(+)-dependent interaction between ProT\u03b1 and S100A13 was found to require the C-terminal peptide sequences of both proteins.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20467443", "endSection": "sections.0"}, {"offsetInBeginSection": 841, "offsetInEndSection": 1027, "text": "When cells were administered apoptogenic compounds, ProT\u03b1 was cleaved by caspase-3 to generate a C-terminal peptide-deficient fragment, which lacks the nuclear localization signal (NLS).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20467443", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18976813", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 178, "text": "Prothymosin alpha (ProTalpha) is a small acidic polypeptide with important immunostimulatory properties, which we have previously shown to be exerted by its carboxyl (C)-terminus", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18976813", "endSection": "sections.0"}, {"offsetInBeginSection": 288, "offsetInEndSection": 838, "text": "Here, we assayed the activity of synthetic peptides homologous to ProTalpha's C-terminus to stimulate lymphocyte functions, in particular natural killer cell cytotoxicity of peripheral blood mononuclear cells isolated from healthy donors. A synthetic decapeptide TKKQKTDEDD was identified as the most potent lymphocyte stimulator. The activity of this peptide was sequence-specific and comparable to that of the intact molecule, suggesting that ProTalpha's immunoactive segment encompasses the nuclear localization signal sequence of the polypeptide.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18976813", "endSection": "sections.0"}, {"offsetInBeginSection": 1543, "offsetInEndSection": 1918, "text": "These data, in conjunction with reports showing that the peptide TKKQKTDEDD is generated in vivo upon caspase-cleavage of ProTalpha during apoptosis, strengthen our hypothesis that immune response stimulation by ProTalpha is in principle exerted via its bioactive C-terminal decapaptide, which can acquire a sequence-specific beta-sheet conformation and induce DC maturation.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18976813", "endSection": "sections.0"}, {"offsetInBeginSection": 421, "offsetInEndSection": 763, "text": "Ability to stimulate p53-dependent transcription was lost by C-terminal mutants of prothymosin alpha with impaired nuclear accumulation, but not by N-terminal deletion mutants and by the double mutant of prothymosin alpha with impaired ability to bind Keap1, suggesting that prothymosinalpha-Keap1 interaction is dispensable for p53 response.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18856068", "endSection": "sections.0"}, {"offsetInBeginSection": 980, "offsetInEndSection": 1097, "text": "We found that zinc binding causes partial folding of the C-terminal half of ProTalpha, especially the Glu-rich region", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929838", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16453152", "endSection": "title"}, {"offsetInBeginSection": 866, "offsetInEndSection": 1303, "text": ". ProTalpha(89-102) and proTalpha(103-109) significantly fortified healthy donor-lymphocytes' immune responses to levels comparable to those induced by intact proTalpha. These effects were more pronounced in cancer patients, where peptides proTalpha(89-102) and proTalpha(103-109) partly, however significantly, restored the depressed AMLR and cytolytic ability of PBMC, by simulating the biological activity exerted by intact proTalpha.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16453152", "endSection": "sections.0"}, {"offsetInBeginSection": 1405, "offsetInEndSection": 1528, "text": "This is the first report showing that proTalpha's immunomodulating activity can be substituted by its C-terminal peptide(s)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16453152", "endSection": "sections.0"}, {"offsetInBeginSection": 677, "offsetInEndSection": 886, "text": "The peptide (1-88) of calf prothymosin alpha is shown not to accumulate in the Xenopus nucleus, demonstrating that the C-terminal 21 residues, which include a KKQK sequence, are required for nuclear migration.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2209614", "endSection": "sections.0"}, {"offsetInBeginSection": 261, "offsetInEndSection": 417, "text": "fProt-alpha contains 28 aspartic and 25 glutamic acid residues and presents the typical basic KKQK amino acid sequence in the close carboxyl terminal region", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11744386", "endSection": "sections.0"}, {"offsetInBeginSection": 1405, "offsetInEndSection": 1529, "text": "This is the first report showing that proTalpha's immunomodulating activity can be substituted by its C-terminal peptide(s).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16453152", "endSection": "sections.0"}]}, {"body": "Mention the only available genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23185044"], "triples": [], "ideal_answer": ["OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/) is a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. OikoBase facilitates retrieval and mining of a variety of useful genomics information and will provide a valuable resource for research in chordate development, genome evolution and plasticity and the molecular ecology of this important marine planktonic organism."], "exact_answer": [["OikoBase"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023281", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015509", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014561"], "type": "factoid", "id": "56ae6e650a360a5e4500000e", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1405, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. OikoBase facilitates retrieval and mining of a variety of useful genomics information. First, it includes a genome browser which interrogates 1260 genomic sequence scaffolds and features gene, transcript and CDS annotation tracks. Second, we annotated gene models with gene ontology (GO) terms and InterPro domains which are directly accessible in the browser with links to their entries in the GO (http://www.geneontology.org/) and InterPro (http://www.ebi.ac.uk/interpro/) databases, and we provide transcript and peptide links for sequence downloads. Third, we introduce the transcriptomics of a comprehensive set of developmental stages of O. dioica at high resolution and provide downloadable gene expression data for all developmental stages. Fourth, we incorporate a BLAST tool to identify homologs of genes and proteins. Finally, we include a tutorial that describes how to use OikoBase as well as a link to detailed methods, explaining the data generation and analysis pipeline. OikoBase will provide a valuable resource for research in chordate development, genome evolution and plasticity and the molecular ecology of this important marine planktonic organism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "OikoBase: a genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185044", "endSection": "title"}]}, {"body": "Which is the third subunit of the TSC1-TSC2 complex upstream of mTORC1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22795129"], "triples": [], "ideal_answer": "TBC1D7 was identified as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. It was demonstrated that TSC1-TSC2-TBC1D7 (TSC-TBC) is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity to negatively regulate mTORC1 activity. In agreement with this, TBC1D7 knockdown was shown to result in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions.", "exact_answer": ["TBC1D7"], "concepts": ["http://www.uniprot.org/uniprot/TSC2_HUMAN", "http://www.uniprot.org/uniprot/TSC1_HUMAN", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033596", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031931", "http://www.biosemantics.org/jochem#4266396"], "type": "factoid", "id": "5319ac99b166e2b806000034", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 328, "text": "The tuberous sclerosis complex (TSC) tumor suppressors form the TSC1-TSC2 complex, which limits cell growth in response to poor growth conditions. Through its GTPase-activating protein (GAP) activity toward Rheb, this complex inhibits the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1), a key promoter of cell growth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795129", "endSection": "abstract"}, {"offsetInBeginSection": 329, "offsetInEndSection": 633, "text": "Here, we identify and biochemically characterize TBC1D7 as a stably associated and ubiquitous third core subunit of the TSC1-TSC2 complex. We demonstrate that the TSC1-TSC2-TBC1D7 (TSC-TBC) complex is the functional complex that senses specific cellular growth conditions and possesses Rheb-GAP activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795129", "endSection": "abstract"}, {"offsetInBeginSection": 734, "offsetInEndSection": 894, "text": "TBC1D7 knockdown decreases the association of TSC1 and TSC2 leading to decreased Rheb-GAP activity, without effects on the localization of TSC2 to the lysosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795129", "endSection": "abstract"}, {"offsetInBeginSection": 895, "offsetInEndSection": 1072, "text": "Like the other TSC-TBC components, TBC1D7 knockdown results in increased mTORC1 signaling, delayed induction of autophagy, and enhanced cell growth under poor growth conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22795129", "endSection": "abstract"}]}, {"body": "Define marine metaproteomics", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24041543", "http://www.ncbi.nlm.nih.gov/pubmed/24060127", "http://www.ncbi.nlm.nih.gov/pubmed/24112684", "http://www.ncbi.nlm.nih.gov/pubmed/24212578", "http://www.ncbi.nlm.nih.gov/pubmed/23968355", "http://www.ncbi.nlm.nih.gov/pubmed/23831146", "http://www.ncbi.nlm.nih.gov/pubmed/23616470", "http://www.ncbi.nlm.nih.gov/pubmed/24060126", "http://www.ncbi.nlm.nih.gov/pubmed/22399469", "http://www.ncbi.nlm.nih.gov/pubmed/22517752", "http://www.ncbi.nlm.nih.gov/pubmed/23126454", "http://www.ncbi.nlm.nih.gov/pubmed/22225547", "http://www.ncbi.nlm.nih.gov/pubmed/21169428", "http://www.ncbi.nlm.nih.gov/pubmed/21068774", "http://www.ncbi.nlm.nih.gov/pubmed/20164862", "http://www.ncbi.nlm.nih.gov/pubmed/16176596"], "triples": [], "ideal_answer": "Marine metaproteomics is the study of the activities of whole marine microbial communities. The proteomic analyses are applied directly without the need for prior microbial culturing. The samples can be sediments,seawater, etc.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059001"], "type": "summary", "id": "530a3f8a970c65fa6b000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "Metaproteomics is a new field within the 'omics' science which investigates protein expression from a complex biological system and provides direct evidence of physiological and metabolic activities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24041543", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Metaproteomic studies of whole microbial communities from environmental samples (e.g., soil, sediments, freshwater, seawater, etc.) have rapidly increased in recent years due to many technological advances in mass spectrometry (MS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060127", "endSection": "abstract"}, {"offsetInBeginSection": 557, "offsetInEndSection": 775, "text": "Metatranscriptomics and metaproteomics are approaches based on different techniques and have recently emerged as promising techniques to describe microbial activities within a given environment at the molecular level. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23968355", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 194, "text": "Culture-independent techniques such as LC-MS/MS-based metaproteomic analyses are being increasingly utilized for the study of microbial composition and function in complex environmental samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23831146", "endSection": "abstract"}, {"offsetInBeginSection": 430, "offsetInEndSection": 612, "text": "Metaproteomic analysis and protein-stable isotope probing revealed Burkholderiales, Actinomycetales, and Rhizobiales as the most active microorganisms in the groundwater communities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23616470", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Advances in tandem mass spectrometry (tandem MS) and sequencing have enabled the field of community proteomics, which seeks to identify expressed proteins, their sequence variability, and the physiological responses of organisms to variable environmental conditions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060126", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 792, "text": "Marine community proteomic studies have verified the importance of nutrient transport, energy generation, and carbon fixation functions in bacteria and archaea and revealed spatial and temporal shifts in the expressed functions of communities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24060126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 371, "text": "Metagenomics is the study of microbial organisms using sequencing applied directly to environmental samples. Similarly, in metatranscriptomics and metaproteomics, the RNA and protein sequences of such samples are studied. The analysis of these kinds of data often starts by asking the questions of \"who is out there?\", \"what are they doing?\", and \"how do they compare?\". ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22399469", "endSection": "abstract"}, {"offsetInBeginSection": 412, "offsetInEndSection": 611, "text": "the study of the proteins collectively expressed by all the microorganisms present within an ecosystem (metaproteomics) is not only crucial but can also provide insights into microbial functionality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22225547", "endSection": "abstract"}, {"offsetInBeginSection": 896, "offsetInEndSection": 1133, "text": "Metaproteomics has been employed in very diverse environments, and this review discusses the recent advances achieved in the context of human biology, soil, marine and freshwater environments as well as natural and bioengineered systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22225547", "endSection": "abstract"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1317, "text": "To assess the functional dynamics of microbial communities, metatranscriptomics and metaproteomics have been developed. The combination of DNA-based, mRNA-based, and protein-based analyses of microbial communities present in different environments is a way to elucidate the compositions, functions, and interactions of microbial communities and to link these to environmental processes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169428", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Metaproteomics is one of a suite of new approaches providing insights into the activities of microorganisms in natural environments. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21068774", "endSection": "abstract"}, {"offsetInBeginSection": 316, "offsetInEndSection": 465, "text": "We used comparative membrane metaproteomics to identify functional responses of communities to different nutrient concentrations on an oceanic scale.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20164862", "endSection": "abstract"}, {"offsetInBeginSection": 230, "offsetInEndSection": 396, "text": "This study describes the application of proteomic approaches (metaproteomics) to observe expressed protein profiles of natural microbial communities (metaproteomes). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16176596", "endSection": "abstract"}, {"offsetInBeginSection": 526, "offsetInEndSection": 630, "text": "metaproteomics analysis of fecal samples to determine microbial gut composition and protein expression. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24212578", "endSection": "abstract"}, {"offsetInBeginSection": 587, "offsetInEndSection": 820, "text": "In this study, we used metaproteomics and metabolomics to investigate the intricate network of metabolic interactions in the chemosynthetic association between Olavius algarvensis, a gutless marine worm, and its bacterial symbionts. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22517752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "The role of planktonic Flavobacteria in processing algal organic matter in coastal East Antarctica revealed using metagenomics and metaproteomics.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23126454", "endSection": "title"}]}, {"body": "What is known about prostate cancer screening in the UK ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23728749", "http://www.ncbi.nlm.nih.gov/pubmed/21047592", "http://www.ncbi.nlm.nih.gov/pubmed/20507844", "http://www.ncbi.nlm.nih.gov/pubmed/17309171", "http://www.ncbi.nlm.nih.gov/pubmed/16978272", "http://www.ncbi.nlm.nih.gov/pubmed/16720000", "http://www.ncbi.nlm.nih.gov/pubmed/15049981", "http://www.ncbi.nlm.nih.gov/pubmed/12614245", "http://www.ncbi.nlm.nih.gov/pubmed/12587941", "http://www.ncbi.nlm.nih.gov/pubmed/11002455", "http://www.ncbi.nlm.nih.gov/pubmed/10682690", "http://www.ncbi.nlm.nih.gov/pubmed/10185137", "http://www.ncbi.nlm.nih.gov/pubmed/19138385", "http://www.ncbi.nlm.nih.gov/pubmed/22952783", "http://www.ncbi.nlm.nih.gov/pubmed/15946386", "http://www.ncbi.nlm.nih.gov/pubmed/19021912"], "triples": [], "ideal_answer": "There is still no national screening programme established in the UK. Prostate cancer screening of asymptomatic men is not recommended by the National Screening Council at present and is not encouraged in the NHS. However, PSA tests are being performed for prostate cancer screening. The CAP and ProtecT trials are aimed to evaluate prostate cancer screening in the UK.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011471", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055088", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008403", "http://www.disease-ontology.org/api/metadata/DOID:10286", "http://www.disease-ontology.org/api/metadata/DOID:10283"], "type": "summary", "id": "530cefaaad0bf1360c00000e", "snippets": [{"offsetInBeginSection": 95, "offsetInEndSection": 243, "text": "Screening for early disease has been available for many years, but there is still no national screening programme established in the United Kingdom.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728749", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047592", "endSection": "title"}, {"offsetInBeginSection": 1522, "offsetInEndSection": 1738, "text": "The CAP and ProtecT trials (ISRCTN92187251 and ISRCTN20141217) will help resolve the prostate cancer screening debate, define the optimum treatment for localised disease and generate evidence to improve men's health.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047592", "endSection": "abstract"}, {"offsetInBeginSection": 1686, "offsetInEndSection": 1818, "text": "Increased usage of Prosdex leads to more informed decision making, the key aim of the UK Prostate Cancer Risk Management Programme. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20507844", "endSection": "abstract"}, {"offsetInBeginSection": 1343, "offsetInEndSection": 1663, "text": "To date, the AIDIT team has established a website to facilitate communication between project collaborators (www.impact-study.co.uk), has been represented at several international meetings and has facilitated a conference for the IMPACT study to bring together international research teams, clinicians and policy makers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17309171", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 474, "text": " This prospective questionnaire study was nested within the case-finding component of the ProtecT (prostate testing for cancer and treatment) feasibility study (ISRCTN20141297). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16978272", "endSection": "abstract"}, {"offsetInBeginSection": 116, "offsetInEndSection": 247, "text": "The UK NHS Executive has issued extensive guidance stressing the importance of adequate counselling prior to performing this test. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16720000", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 187, "text": "To examine the pattern of use of prostate-specific antigen (PSA) testing in a UK region, where National Health Service policy does not recommend screening for prostate cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15049981", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 1322, "text": "In all, 165 862 PSA tests were performed on 84 669 men, and over a third of men aged > or = 50 years had at least one PSA test. Men aged < 50 years accounted for 12.9% of first tests. The proportion of tests from primary care increased from 47.2% in 1993 to 67.0% in 1999. The mean age of men tested once decreased from 65.6 to 61.9 years (P trend < 0.001) and the proportion with an elevated PSA level also declined during the period. Repeat testing increased with PSA level (P < 0.001) but 29.4% of men with a PSA level of < or = 4 ng/mL also had repeat testing. Raised PSA values were more common from hospital than primary care (32.4% vs 20.6%, P < 0.001) and in older men. Test rates varied 100-fold across general practices, a finding not explained by sociodemographic factors, but one which reflects differential adherence to national guidelines, suggesting that general practitioners are key targets for attempting to rationalise the use of the PSA test. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15049981", "endSection": "abstract"}, {"offsetInBeginSection": 1335, "offsetInEndSection": 1545, "text": "These findings suggest that PSA screening is taking place against evidence-based advice and has resulted in over 20 000 men being designated as having a raised PSA level, creating a need for further assessment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15049981", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 249, "text": "There is no current prostate cancer screening programme in the UK. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12614245", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Prostate cancer screening of asymptomatic men is not recommended by the National Screening Council at present and is not encouraged in the NHS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12587941", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 338, "text": "We used a nested case-control design on data from men in four prospective studies (from the UK, Maryland in the USA, and two from Finland) with available stored serum samples to determine whether there was an advantage in measuring both free prostate-specific antigen (PSA) and total PSA as a potential screening test for prostate cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10682690", "endSection": "abstract"}, {"offsetInBeginSection": 811, "offsetInEndSection": 1063, "text": "Some respondents were reluctant to give the leaflet to people enquiring about screening for prostate cancer, for example, because they thought that the leaflet would cause anxiety, or because prostate cancer screening was not freely available locally. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10185137", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "National guidance (executive letter) EL(97)12 stated that population screening should not be provided by the NHS, or be offered to the public until there is effective screening technology for prostate cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11002455", "endSection": "abstract"}, {"offsetInBeginSection": 383, "offsetInEndSection": 653, "text": "This postal questionnaire survey reveals that 81% (95% CI 75% to 87%) of responding general practitioners in North Staffordshire agreed with EL(97)12 and one in ten said that the executive letter changed their views, suggesting that such national guidance has an effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11002455", "endSection": "abstract"}]}, {"body": "What is the physiological role of LKB1 involved in Peutz-Jeghers syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20020146"], "triples": [], "ideal_answer": "LKB1 plays a physiological role in controlling the Wnt-signaling.", "exact_answer": ["LKB1 plays a physiological role in controlling the Wnt-signaling."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010580", "http://www.uniprot.org/uniprot/STK11_HUMAN", "http://www.disease-ontology.org/api/metadata/DOID:3852"], "type": "factoid", "id": "53175e9fb166e2b80600000a", "snippets": [{"offsetInBeginSection": 155, "offsetInEndSection": 423, "text": "Recent functional genetic studies have pointed out that LKB1 plays a physiological role in controlling the Wnt-signaling pathway and activation of the pathway as a consequence of LKB1 haploinsufficiency might be responsible for the development of harmatomatous polyps.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20020146", "endSection": "abstract"}, {"offsetInBeginSection": 945, "offsetInEndSection": 1078, "text": "PJS polyps from all patients showed generalized membrane and cytoplasmic localizations of beta-catenin along the mucosal endothelium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20020146", "endSection": "abstract"}]}, {"body": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25484038", "http://www.ncbi.nlm.nih.gov/pubmed/25354738", "http://www.ncbi.nlm.nih.gov/pubmed/25243910", "http://www.ncbi.nlm.nih.gov/pubmed/25132411", "http://www.ncbi.nlm.nih.gov/pubmed/25007392", "http://www.ncbi.nlm.nih.gov/pubmed/24827753", "http://www.ncbi.nlm.nih.gov/pubmed/24677511", "http://www.ncbi.nlm.nih.gov/pubmed/24452484", "http://www.ncbi.nlm.nih.gov/pubmed/24354461", "http://www.ncbi.nlm.nih.gov/pubmed/24157091", "http://www.ncbi.nlm.nih.gov/pubmed/24035250", "http://www.ncbi.nlm.nih.gov/pubmed/23998727", "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "http://www.ncbi.nlm.nih.gov/pubmed/23834907", "http://www.ncbi.nlm.nih.gov/pubmed/23730881", "http://www.ncbi.nlm.nih.gov/pubmed/23361084", "http://www.ncbi.nlm.nih.gov/pubmed/23290985", "http://www.ncbi.nlm.nih.gov/pubmed/23253932", "http://www.ncbi.nlm.nih.gov/pubmed/23106107", "http://www.ncbi.nlm.nih.gov/pubmed/22875601", "http://www.ncbi.nlm.nih.gov/pubmed/22595313", "http://www.ncbi.nlm.nih.gov/pubmed/22280236", "http://www.ncbi.nlm.nih.gov/pubmed/23448220", "http://www.ncbi.nlm.nih.gov/pubmed/25398488", "http://www.ncbi.nlm.nih.gov/pubmed/25268669", "http://www.ncbi.nlm.nih.gov/pubmed/24979544"], "triples": [], "ideal_answer": ["Secukinumab (AIN457) is a fully human anti-interleukin-17A monoclonal antibody that neutralizes interleukin-17A."], "exact_answer": [["interleukin-17A"]], "concepts": [], "type": "factoid", "id": "54e0d7471388e8454a000015", "snippets": [{"offsetInBeginSection": 670, "offsetInEndSection": 993, "text": "We identified 3 distinct clonotypes that efficiently neutralized IL17A in a cell-based in vitro assay. Their potencies were comparable to those of known neutralizing antibodies, including 2, AIN457 (secukinumab) and ixekizumab that are currently in clinical development for the treatment of various inflammatory disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25484038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Secukinumab, a fully human anti-IL-17A monoclonal antibody, neutralizes IL-17A, a key cytokine in the pathogenesis of psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25354738", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "BACKGROUND: Secukinumab is a fully human anti-interleukin-17A monoclonal antibody.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25243910", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, demonstrated efficacy and safety in moderate-to-severe plaque psoriasis when administered via subcutaneous injection. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25132411", "endSection": "abstract"}, {"offsetInBeginSection": 90, "offsetInEndSection": 226, "text": "We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007392", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 1177, "text": "Ustekinumab (a monoclonal antibody directed against the common p40 subunit of IL-23 and IL-12), secukinumab, ixekizumab (both monoclonal antibodies directed against IL-17A), and brodalumab a monoclonal antibody against the IL-17RA receptor) have been recently used in proof-of-concept and randomized trials in the ankylosing spondylitis and/or psoriatic arthritis subforms of SpA, with overall very promising clinical efficacy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24827753", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24677511", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 277, "text": "The family of interleukin 17 receptors (IL17Rs), subtypes IL17RA-IL17RE, is targeted by the group of pro-inflammatory IL17 cytokines (IL17A-F) and moreover the newly developed anti-IL17A antibody secukinumab (AIN457) has shown promise in Phase II trials in multiple sclerosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24677511", "endSection": "abstract"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1628, "text": " Three agents neutralizing IL-17 (i.e., secukinumab and ixekizumab) or antagonizing its receptor (i.e., brodalumab) are currently being tested for efficacy and safety in the treatment of plaque psoriasis and PsA. Secukinumab is a fully human IgG1 monoclonal antibody that selectively binds and neutralizes IL-17A whose efficacy in the therapy of chronic plaque psoriasis has been demonstrated in different phase II clinical trial. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24452484", "endSection": "abstract"}, {"offsetInBeginSection": 689, "offsetInEndSection": 913, "text": "Associations between IGA 0/1 responder rates and PASI scores were evaluated using data from two phase 2 studies with the anti-interleukin (IL)-17A monoclonal antibody secukinumab (AIN457) that utilized a similar 6-point IGA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24354461", "endSection": "abstract"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1249, "text": " Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157091", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035250", "endSection": "title"}, {"offsetInBeginSection": 336, "offsetInEndSection": 480, "text": "We assessed the efficacy and safety of the anti-IL-17A monoclonal antibody secukinumab in treating patients with active ankylosing spondylitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24035250", "endSection": "abstract"}, {"offsetInBeginSection": 236, "offsetInEndSection": 445, "text": "In a proof-of-concept study for the treatment of patients with Crohn's disease, secukinumab, a monoclonal antibody directed against IL-17A, was ineffective and associated with more adverse events than placebo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23998727", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 898, "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "endSection": "abstract"}, {"offsetInBeginSection": 1238, "offsetInEndSection": 1426, "text": "Further studies are needed to clarify whether the therapeutic blockade of IL-17A through the anti-IL-17A monoclonal antibody secukinumab is able to counteract the fibrogenic process in CD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23834907", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 339, "text": "Th-17A antagonism has been investigated by a randomized controlled trial in PsA patients with secukinumab, a fully human, high-affinity, monoclonal antibody in a cohort of patients with active PsA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730881", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23361084", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "OBJECTIVE: To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23361084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "PURPOSE: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290985", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Effect of IL-17A blockade with secukinumab in autoimmune diseases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23253932", "endSection": "title"}, {"offsetInBeginSection": 797, "offsetInEndSection": 1062, "text": "Early clinical data are now available on secukinumab (AIN457), a recombinant, highly selective, fully human monoclonal anti-IL-17A antibody of the IgG1/\u03ba isotype, enabling a preliminary assessment of the effects of IL-17A inhibition in multiple autoimmune diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23253932", "endSection": "abstract"}, {"offsetInBeginSection": 1267, "offsetInEndSection": 1607, "text": "In conjunction with studies using the humanised anti-IL-17A monoclonal antibody (mAb) ixekizumab (LY2439821) and the fully human anti-IL-17RA mAb brodalumab (AMG 827), the findings on secukinumab provide evidence for the role of IL-17A in the pathophysiology of autoimmune disease and suggest the potential value of targeting this cytokine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23253932", "endSection": "abstract"}, {"offsetInBeginSection": 485, "offsetInEndSection": 673, "text": "OBJECTIVES: To assess the efficacy and safety of different doses of secukinumab, a fully human anti-IL-17A IgG1\u03ba monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106107", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22875601", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22875601", "endSection": "abstract"}, {"offsetInBeginSection": 1595, "offsetInEndSection": 1778, "text": "Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22875601", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22595313", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22595313", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1365, "text": "Secukinumab is an IL-17A monoclonal antibody that is under development and preliminary results have suggested its efficacy in inflammatory mediated diseases such as psoriasis and ankylosing spondylitis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22280236", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "PURPOSE: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23290985", "endSection": "abstract"}, {"offsetInBeginSection": 670, "offsetInEndSection": 993, "text": "We identified 3 distinct clonotypes that efficiently neutralized IL17A in a cell-based in vitro assay. Their potencies were comparable to those of known neutralizing antibodies, including 2, AIN457 (secukinumab) and ixekizumab that are currently in clinical development for the treatment of various inflammatory disorders. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25484038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Secukinumab, a fully human anti-IL-17A monoclonal antibody, neutralizes IL-17A, a key cytokine in the pathogenesis of psoriasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25354738", "endSection": "abstract"}, {"offsetInBeginSection": 1052, "offsetInEndSection": 1200, "text": "Promising recent Phase II results on the anti-IL-17A antibody secukinumab (AIN457) are outlined and a short update on tabalumab (LY2127399) is given", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23448220", "endSection": "abstract"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1209, "text": "Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157091", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 896, "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "endSection": "abstract"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1209, "text": "Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157091", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 896, "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "endSection": "abstract"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1209, "text": "Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157091", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 896, "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 896, "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "endSection": "abstract"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1209, "text": "Several IL-17A inhibitors have advanced into clinical trials, including the anti-IL-17A monoclonal antibodies, secukinumab and ixekizumab, and the anti-17RA monoclonal antibody brodalumab", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24157091", "endSection": "abstract"}, {"offsetInBeginSection": 679, "offsetInEndSection": 896, "text": "Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23858337", "endSection": "abstract"}]}, {"body": "Which value of nuchal translucency thickness is set as the threshold for high-risk for Down Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19416569", "http://www.ncbi.nlm.nih.gov/pubmed/18726925", "http://www.ncbi.nlm.nih.gov/pubmed/18461550", "http://www.ncbi.nlm.nih.gov/pubmed/16912493", "http://www.ncbi.nlm.nih.gov/pubmed/9471429"], "triples": [], "ideal_answer": "NT is physiological for a measurement < 3 mm but the incidence of chromosomal abnormalities (essentially trisomies 21, 18 and 13) increases when NT > or = 3 mm. As women aged, this upper NT threshold value changed according to gestational age. In women aged 35 to 37 years, combined prenatal screening was always positive when NT exceeded 2.8 mm, 3.0 mm, and 3.4 mm at 11, 12, and 13 weeks of gestation, respectively.", "exact_answer": ["3mm"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048208", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004314", "http://www.disease-ontology.org/api/metadata/DOID:14250", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018566"], "type": "factoid", "id": "53592c1e9a4572de6f000002", "snippets": [{"offsetInBeginSection": 511, "offsetInEndSection": 610, "text": "Combined prenatal screening was always positive for Down syndrome when NT thickness exceeded 4.0 mm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416569", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 867, "text": "In women aged 35 to 37 years, combined prenatal screening was always positive when NT exceeded 2.8 mm, 3.0 mm, and 3.4 mm at 11, 12, and 13 weeks of gestation, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19416569", "endSection": "abstract"}, {"offsetInBeginSection": 459, "offsetInEndSection": 618, "text": "NT is physiological for a measurement < 3 mm but the incidence of chromosomal abnormalities (essentially trisomies 21, 18 and 13) increases when NT > or = 3 mm", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9471429", "endSection": "abstract"}]}, {"body": "Which glands are subject to attack by lymphocytes in Sjogren's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21777618", "http://www.ncbi.nlm.nih.gov/pubmed/20408860", "http://www.ncbi.nlm.nih.gov/pubmed/17823290", "http://www.ncbi.nlm.nih.gov/pubmed/17472721", "http://www.ncbi.nlm.nih.gov/pubmed/17127420", "http://www.ncbi.nlm.nih.gov/pubmed/16761498", "http://www.ncbi.nlm.nih.gov/pubmed/16221495", "http://www.ncbi.nlm.nih.gov/pubmed/11464341", "http://www.ncbi.nlm.nih.gov/pubmed/11439159"], "triples": [], "ideal_answer": "Sj\u00f6gren's syndrome (SjS) is a human autoimmune disease characterized by exocrine dysfunction resulting from chronic autoimmune attack primarily against the lacrimal and/or salivary glands.", "exact_answer": ["The lacrimal and/or salivary glands"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012859", "http://www.disease-ontology.org/api/metadata/DOID:12894", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0046649", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012469", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007765", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005088"], "type": "factoid", "id": "53189b05b166e2b80600001e", "snippets": [{"offsetInBeginSection": 280, "offsetInEndSection": 490, "text": "In Sj\u00f6gren's syndrome the autoimmune response is directed against the exocrine glands, which, as histopathological hallmark of the disease, display persistent and progressive focal mononuclear cell infiltrates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21777618", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Sj\u00f6gren's syndrome (SS) is an autoimmune disease characterized by clonal B cell attack of the exocrine glands and dysregulated expression of B cell-activating factor (BAFF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20408860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Sj\u00f6gren's syndrome (SjS) is a human autoimmune disease characterized by exocrine dysfunction resulting from chronic autoimmune attack primarily against the lacrimal and/or salivary glands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17823290", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Sj\u00f6gren's syndrome is an autoimmune disease in which immune cells chronically attack the lachrymal and salivary glands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17472721", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Sj\u00f6gren's syndrome (SjS) is a systemic autoimmune disease in which an immunological attack against the salivary and lacrimal glands results, respectively, in severe dry mouth and dry eye diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17127420", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "Sj\u00f6gren's syndrome (SS) is a chronic autoimmune disease affecting epithelial tissues. Exocrine glands are the primary target and their functional impairment comes as a result of immune attack of epithelial cells of the affected organs (autoimmune epithelitis).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16761498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Sj\u00f6gren's syndrome (SjS) is a human autoimmune disease characterized by the loss of exocrine function as a result of a chronic immune attack directed primarily against the salivary and lacrimal glands leading to xerostomia (dry mouth) and xerophthalmia (dry eyes).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16221495", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 391, "text": "The purpose of this qualitative research was to explore the lived experiences of women with Sjogren's Syndrome (SS), a chronic autoimmune syndrome in which invading lymphocytes attack moisture-producing glands of the body. This syndrome, affecting 4 million Americans, involves extreme dryness of the eyes and mouth and other systemic complications such as fatigue and muscle and joint pain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11464341", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "NOD mice manifest many features of autoimmune exocrinopathy (Sj\u00f6gren's syndrome), a disease generally characterized by a chronic, progressive immunological attack against the exocrine tissues of the salivary and lacrimal glands.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11439159", "endSection": "abstract"}]}, {"body": "The secreted frizzled-related protein 3 (sFPR3) is altered in human cancers.\nAre its level found to increase or to decrease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23408665", "http://www.ncbi.nlm.nih.gov/pubmed/21494614", "http://www.ncbi.nlm.nih.gov/pubmed/20160027", "http://www.ncbi.nlm.nih.gov/pubmed/17702698", "http://www.ncbi.nlm.nih.gov/pubmed/17420170", "http://www.ncbi.nlm.nih.gov/pubmed/17079093", "http://www.ncbi.nlm.nih.gov/pubmed/16266997", "http://www.ncbi.nlm.nih.gov/pubmed/11798016"], "ideal_answer": ["Secreted frizzled-related protein 3 is potentially acting as a tumor suppressor gene, thus it is down-regulated (decreased) in some cancers.", "SFRPs are down-regulated in several cancers and this is often correlated with poor prognosis, as has been shown for breast, colorectal, and a number of other cancers. (PMID: 21494614) We performed tissue microarray and found that the level of sFRP3 protein was high in normal kidney, low in primary renal cancer tissues, and high in metastatic renal cancer tissues. (PMID: 20160027)"], "type": "summary", "id": "5159502dd24251bc0500009b", "snippets": [{"offsetInBeginSection": 238, "offsetInEndSection": 419, "text": "We performed tissue microarray and found that the level of sFRP3 protein was high in normal kidney, low in primary renal cancer tissues, and high in metastatic renal cancer tissues.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20160027", "endSection": "sections.0"}, {"offsetInBeginSection": 1332, "offsetInEndSection": 1484, "text": "In conclusion, this is the first report to show that sFRP3 expression promotes cell growth, invasion, and inhibition of apoptosis in renal cancer cells.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20160027", "endSection": "sections.0"}, {"offsetInBeginSection": 486, "offsetInEndSection": 562, "text": "secreted frizzled-related protein-3 were produced by multiple myeloma cells.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702698", "endSection": "sections.0"}, {"offsetInBeginSection": 1837, "offsetInEndSection": 1908, "text": "these data suggest a tumor-suppressive potential for FRZB/sFRP3 in OGS.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17079093", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "The ability of Frzb/secreted Frizzled-related protein 3 (sFRP3) to inhibit Wnt signaling and the localization of Frzb/sFRP3 on chromosome 2q to a region frequently deleted in cancers have led some investigators to hypothesize that Frzb/sFRP3 is a tumor suppressor gene.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266997", "endSection": "sections.0"}, {"offsetInBeginSection": 1575, "offsetInEndSection": 1784, "text": "Together, these data suggest that Frzb/sFRP3 and DN-LRP5 exhibit antitumor activity through the reversal of epithelial-to-mesenchymal transition and inhibition of MMP activities in a subset of prostate cancer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266997", "endSection": "sections.0"}, {"offsetInBeginSection": 443, "offsetInEndSection": 531, "text": "secreted frizzled related protein (hsFRP) was found to be down-regulated in some cancer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11798016", "endSection": "sections.0"}, {"offsetInBeginSection": 597, "offsetInEndSection": 640, "text": "hsFRP is a potential tumor suppressor gene.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11798016", "endSection": "sections.0"}, {"offsetInBeginSection": 1181, "offsetInEndSection": 1274, "text": "All these cases were associated with either up-regulation of FzE3 or down-regulation of hsFRP", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11798016", "endSection": "sections.0"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1406, "text": "Since modified Wnt signaling and down-regulation of frizzled-related proteins have been observed in many human cancers, this variant may also affect the susceptibility to other cancers.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17420170", "endSection": "sections.0"}]}, {"body": "Which is the phosphorylated residue in the promoter paused form of RNA polymerase II?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23087403", "http://www.ncbi.nlm.nih.gov/pubmed/21385935", "http://www.ncbi.nlm.nih.gov/pubmed/21095588", "http://www.ncbi.nlm.nih.gov/pubmed/17942706", "http://www.ncbi.nlm.nih.gov/pubmed/14560008", "http://www.ncbi.nlm.nih.gov/pubmed/12612070", "http://www.ncbi.nlm.nih.gov/pubmed/8015613"], "triples": [], "ideal_answer": "The promoter paused form of RNA polymerase II is phosphorylated on serine 5 residues of the C-terminal heptapeptide repeat domain (CTD) of the largest subunit.", "exact_answer": ["Serine 5"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012319", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001055", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071620", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0071619"], "type": "factoid", "id": "5343bdd6aeec6fbd07000001", "snippets": [{"offsetInBeginSection": 1239, "offsetInEndSection": 1394, "text": "increase levels of serine-5 phosphorylated RNA polymerase II in the mutation target region, consistent with an effect on transcriptional elongation/pausing", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23087403", "endSection": "abstract"}, {"offsetInBeginSection": 741, "offsetInEndSection": 912, "text": "pol-II accumulated in the 5'-region of the gene, which indicated postinitiation pausing. pol-II binding, 5'-accumulation, C-terminal domain Ser-5 and Ser-2 phosphorylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385935", "endSection": "abstract"}, {"offsetInBeginSection": 695, "offsetInEndSection": 852, "text": "The carboxy-terminal domain of the paused polymerase large subunit is hyperphosphorylated on serine 5, and phosphorylation of serine 2 is first detected here", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21095588", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 697, "text": "the promoter-paused form of Pol II (Pol IIo(ser5)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17942706", "endSection": "abstract"}, {"offsetInBeginSection": 456, "offsetInEndSection": 648, "text": "Pause release depends on Cdk9-cyclin T1 (P-TEFb); Cdk7 is also required for Cdk9-activating phosphorylation and Cdk9-dependent downstream events--Pol II C-terminal domain Ser2 phosphorylation ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064645", "endSection": "abstract"}, {"offsetInBeginSection": 580, "offsetInEndSection": 749, "text": "For genes containing a 5' paused polymerase, passage of the paused RNA polymerase into an elongationally competent mode in vivo coincides with phosphorylation of the CTD", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8015613", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 815, "text": "Ser-5 phosphorylation of Pol II is concentrated near the promoter", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12612070", "endSection": "abstract"}, {"offsetInBeginSection": 564, "offsetInEndSection": 630, "text": "the promoter-paused Pol II shows Ser5 but not Ser2 phosphorylation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14560008", "endSection": "abstract"}]}, {"body": "Describe Heyde syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25935884", "http://www.ncbi.nlm.nih.gov/pubmed/25367238", "http://www.ncbi.nlm.nih.gov/pubmed/25251907", "http://www.ncbi.nlm.nih.gov/pubmed/24008540", "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "http://www.ncbi.nlm.nih.gov/pubmed/21864855", "http://www.ncbi.nlm.nih.gov/pubmed/20802419", "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "http://www.ncbi.nlm.nih.gov/pubmed/19276092", "http://www.ncbi.nlm.nih.gov/pubmed/12912718", "http://www.ncbi.nlm.nih.gov/pubmed/25208564", "http://www.ncbi.nlm.nih.gov/pubmed/8470439", "http://www.ncbi.nlm.nih.gov/pubmed/23605838", "http://www.ncbi.nlm.nih.gov/pubmed/17299265", "http://www.ncbi.nlm.nih.gov/pubmed/15764876", "http://www.ncbi.nlm.nih.gov/pubmed/10441816", "http://www.ncbi.nlm.nih.gov/pubmed/15568613", "http://www.ncbi.nlm.nih.gov/pubmed/11957793", "http://www.ncbi.nlm.nih.gov/pubmed/17357954"], "triples": [], "ideal_answer": ["Classical Heyde syndrome is described as the association of aortic stenosis, bleeding gastrointestinal angiodysplasia and secondary anemia. A deficiency of high molecular weight multimers of von Willebrand factor (type 2A von Willebrand disease) provides the link between this association."], "concepts": [], "type": "summary", "id": "56be14c7ef6e39474100000a", "snippets": [{"offsetInBeginSection": 129, "offsetInEndSection": 232, "text": "The association of AVS and gastrointestinal bleeding from angiodysplasia is defined as Heyde syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25935884", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Heyde syndrome is a triad of aortic stenosis, acquired coagulopathy, and anemia due to bleeding from intestinal angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25367238", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1353, "text": "Nine patients reported clinically significant bleeding, and seven had intestinal angiodysplasia and transfusion-dependent gastrointestinal bleeding (Heyde syndrome), with the median number of transfusions required being 20 (IQR 10-33; range 4-50). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25251907", "endSection": "abstract"}, {"offsetInBeginSection": 406, "offsetInEndSection": 545, "text": "Classical Heyde syndrome is described as the association of aortic stenosis, bleeding gastrointestinal angiodysplasia and secondary anemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24008540", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Gastrointestinal bleeding and aortic stenosis (Heyde syndrome): the role of aortic valve replacement.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Heyde syndrome (the combination of iron deficiency anemia and aortic stenosis) has been a controversial entity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "OBJECTIVE: We sought to evaluate the effectiveness of aortic valve replacement for reducing gastrointestinal bleeding in patients with Heyde syndrome, in whom gastrointestinal bleeding is associated with intestinal angiodysplasia and aortic valve stenosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21864855", "endSection": "abstract"}, {"offsetInBeginSection": 787, "offsetInEndSection": 958, "text": "CONCLUSIONS: The relationship between aortic valve stenosis, acquired von Willebrand disease and gastrointestinal bleeding in elderly patients is known as Heyde syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20802419", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "Aortic valve stenosis can be complicated by gastrointestinal bleeding from angiodysplasia. A deficiency of high molecular weight multimers of von Willebrand factor (vWF) (type 2A von Willebrand disease) provides the link between this association, which is known as Heyde syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Heyde syndrome--the link between aortic stenosis and gastrointestinal bleeding.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Heyde syndrome is a triad of aortic stenosis, an acquired coagulopathy and anaemia due to bleeding from intestinal angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276092", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Gastrointestinal bleeding and aortic stenosis (Heyde syndrome): the role of aortic valve replacement.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "[Calcifying aortic valve stenosis and occult gastrointestinal hemorrhage (Heyde syndrome): description of 2 cases].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10441816", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Risk of recurrent gastrointestinal bleeding after aortic valve replacement in patients with Heyde syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21864855", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "The Heyde syndrome consists of the association of gastrointestinal bleeding from angiodysplasia with aortic valve stenosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17299265", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Heyde syndrome (the combination of iron deficiency anemia and aortic stenosis) has been a controversial entity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 246, "text": "The association between aortic valve stenosis and gastrointestinal bleeding, traditionally known as Heyde's syndrome, is the result of a quantitative loss of the highest molecular weight von Willebrand multimers (type 2A von Willebrand syndrome).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25208564", "endSection": "abstract"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1341, "text": "The pathophysiology of Heyde's syndrome: an acquired von Willebrand deficiency syndrome has a much wider impact than was commonly thought, both in terms of how common it is and in how the association may be extrapolated to a wide range of bleeding disorders, rather than simply angiodysplasia associated gastrointestinal haemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23605838", "endSection": "abstract"}, {"offsetInBeginSection": 406, "offsetInEndSection": 544, "text": "Classical Heyde syndrome is described as the association of aortic stenosis, bleeding gastrointestinal angiodysplasia and secondary anemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24008540", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Heyde syndrome (the combination of iron deficiency anemia and aortic stenosis) has been a controversial entity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Gastrointestinal bleeding and aortic stenosis (Heyde syndrome): the role of aortic valve replacement", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692692", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Heyde syndrome--the link between aortic stenosis and gastrointestinal bleeding.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Heyde syndrome--the link between aortic stenosis and gastrointestinal bleeding.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Heyde syndrome--the link between aortic stenosis and gastrointestinal bleeding.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Heyde syndrome--the link between aortic stenosis and gastrointestinal bleeding.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20545255", "endSection": "title"}, {"offsetInBeginSection": 59, "offsetInEndSection": 355, "text": "Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia. We describe one characteristic case of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia which subsided after replacement with an aortic valve bioprosthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The Heyde syndrome describes the coincidence of aortic valve stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11957793", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The Heyde syndrome describes the association between calcific aortic stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15568613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The association between aortic stenosis and digestive angiodysplasia has been described for the first time by Heyde in 1958. This entity is thus known as Heyde&apos;s syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Heyde syndrome is described as the association of arteriovenous malformations (AVMs) of the gastrointestinal tract and aortic stenosis (AS); its existence,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12912718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": " Angiodysplasia are common in patients over the age of 60. Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 374, "text": "There is a relationship between aortic valve stenosis and gastrointestinal bleeding in elderly patients, called Heyde syndrome. The described patient had chronic anemia that worsened after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15764876", "endSection": "abstract"}, {"offsetInBeginSection": 59, "offsetInEndSection": 355, "text": "Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia. We describe one characteristic case of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia which subsided after replacement with an aortic valve bioprosthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The Heyde syndrome describes the coincidence of aortic valve stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11957793", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The Heyde syndrome describes the association between calcific aortic stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15568613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The association between aortic stenosis and digestive angiodysplasia has been described for the first time by Heyde in 1958. This entity is thus known as Heyde&apos;s syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Heyde syndrome is described as the association of arteriovenous malformations (AVMs) of the gastrointestinal tract and aortic stenosis (AS); its existence,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12912718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Angiodysplasia are common in patients over the age of 60. Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 374, "text": "There is a relationship between aortic valve stenosis and gastrointestinal bleeding in elderly patients, called Heyde syndrome. The described patient had chronic anemia that worsened after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15764876", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Heyde syndrome is a triad of aortic stenosis, acquired coagulopathy, and anemia due to bleeding from intestinal angiodysplasia. Here we describe a case of this syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25367238", "endSection": "abstract"}, {"offsetInBeginSection": 59, "offsetInEndSection": 355, "text": "Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia. We describe one characteristic case of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia which subsided after replacement with an aortic valve bioprosthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The Heyde syndrome describes the coincidence of aortic valve stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11957793", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The Heyde syndrome describes the association between calcific aortic stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15568613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The association between aortic stenosis and digestive angiodysplasia has been described for the first time by Heyde in 1958. This entity is thus known as Heyde&apos;s syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Heyde syndrome is described as the association of arteriovenous malformations (AVMs) of the gastrointestinal tract and aortic stenosis (AS); its existence,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12912718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": " Angiodysplasia are common in patients over the age of 60. Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 374, "text": "There is a relationship between aortic valve stenosis and gastrointestinal bleeding in elderly patients, called Heyde syndrome. The described patient had chronic anemia that worsened after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15764876", "endSection": "abstract"}, {"offsetInBeginSection": 59, "offsetInEndSection": 355, "text": "Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia. We describe one characteristic case of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia which subsided after replacement with an aortic valve bioprosthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The Heyde syndrome describes the coincidence of aortic valve stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11957793", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The Heyde syndrome describes the association between calcific aortic stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15568613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The association between aortic stenosis and digestive angiodysplasia has been described for the first time by Heyde in 1958. This entity is thus known as Heyde&apos;s syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Heyde syndrome is described as the association of arteriovenous malformations (AVMs) of the gastrointestinal tract and aortic stenosis (AS); its existence,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12912718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": " Angiodysplasia are common in patients over the age of 60. Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 374, "text": "There is a relationship between aortic valve stenosis and gastrointestinal bleeding in elderly patients, called Heyde syndrome. The described patient had chronic anemia that worsened after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15764876", "endSection": "abstract"}, {"offsetInBeginSection": 59, "offsetInEndSection": 355, "text": "Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia. We describe one characteristic case of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia which subsided after replacement with an aortic valve bioprosthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The association between aortic stenosis and digestive angiodysplasia has been described for the first time by Heyde in 1958. This entity is thus known as Heyde&apos;s syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470439", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "The Heyde syndrome describes the coincidence of aortic valve stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11957793", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "The Heyde syndrome describes the association between calcific aortic stenosis and intestinal bleeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15568613", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Heyde syndrome is described as the association of arteriovenous malformations (AVMs) of the gastrointestinal tract and aortic stenosis (AS); its existence,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12912718", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": " Angiodysplasia are common in patients over the age of 60. Heyde syndrome describes the coincidence of aortic valve stenosis and gastrointestinal bleeding from angiodysplasia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17357954", "endSection": "abstract"}, {"offsetInBeginSection": 177, "offsetInEndSection": 374, "text": "There is a relationship between aortic valve stenosis and gastrointestinal bleeding in elderly patients, called Heyde syndrome. The described patient had chronic anemia that worsened after surgery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15764876", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Heyde syndrome is a triad of aortic stenosis, acquired coagulopathy, and anemia due to bleeding from intestinal angiodysplasia. Here we describe a case of this syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25367238", "endSection": "abstract"}]}, {"body": "How does phospholamban affect the biological activity of the calcium ATPase SERCA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23308118", "http://www.ncbi.nlm.nih.gov/pubmed/22679139", "http://www.ncbi.nlm.nih.gov/pubmed/19708671", "http://www.ncbi.nlm.nih.gov/pubmed/15781867", "http://www.ncbi.nlm.nih.gov/pubmed/24101520", "http://www.ncbi.nlm.nih.gov/pubmed/21576492"], "triples": [], "ideal_answer": ["SR calcium uptake is mediated by a Ca(2+)-ATPase (SERCA2), whose activity is reversibly regulated by phospholamban (PLN). Dephosphorylated PLN is an inhibitor of SERCA and phosphorylation of PLN relieves this inhibition. Phospholamban (PLN) is a small integral membrane protein, which binds and inhibits in a yet unknown fashion the Ca(2+)-ATPase (SERCA) in the sarcoplasmic reticulum. Based on structural and dynamics data, a model in which PLN undergoes allosteric activation upon encountering SERCA has been proposed. The allosteric regulation of SERCA depends on the conformational equilibrium of PLN, whose cytoplasmic regulatory domain interconverts between three different states: a ground T state (helical and membrane associated), an excited R state (unfolded and membrane detached), and a B state (extended and enzyme-bound), which is noninhibitory. Phosphorylation of PLN shifts the populations toward the B state, increasing SERCA activity. Phospholamban (PLN) regulates cardiac contractility via its modulation of sarco(endo)plasmic reticulum calcium ATPase (SERCA) activity. Impairment of this regulatory process causes heart failure."], "concepts": ["http://www.uniprot.org/uniprot/AT2A_CHIOP", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053498"], "type": "summary", "id": "54fd5dd86ad7dcbc12000008", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Phospholamban (PLN) is a small integral membrane protein, which binds and inhibits in a yet unknown fashion the Ca(2+)-ATPase (SERCA) in the sarcoplasmic reticulum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23308118", "endSection": "abstract"}, {"offsetInBeginSection": 439, "offsetInEndSection": 660, "text": "SR calcium uptake is mediated by a Ca(2+)-ATPase (SERCA2), whose activity is reversibly regulated by phospholamban (PLN). Dephosphorylated PLN is an inhibitor of SERCA and phosphorylation of PLN relieves this inhibition. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22679139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 302, "text": "Regulation of the SERCA calcium pump by phospholamban (PLB) is largely due to interactions between their respective transmembrane domains. In spite of numerous mutagenesis and kinetic studies, we still do not have a clear mechanistic picture of how PLB influences the calcium transport cycle of SERCA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19708671", "endSection": "abstract"}, {"offsetInBeginSection": 151, "offsetInEndSection": 346, "text": "Phospholamban (PLN) regulates cardiac contractility via its modulation of sarco(endo)plasmic reticulum calcium ATPase (SERCA) activity. Impairment of this regulatory process causes heart failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15781867", "endSection": "abstract"}, {"offsetInBeginSection": 1411, "offsetInEndSection": 1538, "text": "Based on structural and dynamics data, we propose a model in which PLN undergoes allosteric activation upon encountering SERCA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15781867", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 303, "text": "The membrane protein complex between the sarcoplasmic reticulum Ca(2+)-ATPase (SERCA) and phospholamban (PLN) controls Ca(2+) transport in cardiomyocytes, thereby modulating cardiac contractility. \u03b2-Adrenergic-stimulated phosphorylation of PLN at Ser-16 enhances SERCA activity via an unknown mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101520", "endSection": "abstract"}, {"offsetInBeginSection": 484, "offsetInEndSection": 939, "text": "We found that the allosteric regulation of SERCA depends on the conformational equilibrium of PLN, whose cytoplasmic regulatory domain interconverts between three different states: a ground T state (helical and membrane associated), an excited R state (unfolded and membrane detached), and a B state (extended and enzyme-bound), which is noninhibitory. Phosphorylation at Ser-16 of PLN shifts the populations toward the B state, increasing SERCA activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24101520", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Phospholamban (PLN) is a type II membrane protein that inhibits the sarcoplasmic reticulum Ca(2+)-ATPase (SERCA), thereby regulating calcium homeostasis in cardiac muscle.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576492", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Phospholamban (PLN) is a small integral membrane protein, which binds and inhibits in a yet unknown fashion the Ca(2+)-ATPase (SERCA) in the sarcoplasmic reticulum.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23308118", "endSection": "abstract"}, {"offsetInBeginSection": 439, "offsetInEndSection": 660, "text": "SR calcium uptake is mediated by a Ca(2+)-ATPase (SERCA2), whose activity is reversibly regulated by phospholamban (PLN). Dephosphorylated PLN is an inhibitor of SERCA and phosphorylation of PLN relieves this inhibition. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22679139", "endSection": "abstract"}]}, {"body": "What is the role of edaravone in traumatic brain injury?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23564113", "http://www.ncbi.nlm.nih.gov/pubmed/23710445", "http://www.ncbi.nlm.nih.gov/pubmed/22982593", "http://www.ncbi.nlm.nih.gov/pubmed/22977573", "http://www.ncbi.nlm.nih.gov/pubmed/22251821", "http://www.ncbi.nlm.nih.gov/pubmed/21732763", "http://www.ncbi.nlm.nih.gov/pubmed/20398468", "http://www.ncbi.nlm.nih.gov/pubmed/19768539", "http://www.ncbi.nlm.nih.gov/pubmed/19590930", "http://www.ncbi.nlm.nih.gov/pubmed/17115943", "http://www.ncbi.nlm.nih.gov/pubmed/17115906", "http://www.ncbi.nlm.nih.gov/pubmed/24066191", "http://www.ncbi.nlm.nih.gov/pubmed/24163818", "http://www.ncbi.nlm.nih.gov/pubmed/21677777"], "triples": [], "ideal_answer": "Edaravone, a free radical scavenger, has been shown to have neuroprotective effects after traumatic brain injury. In animal models, edaravone has been shown to reduce neuronal damage by scavenging reactive oxygen species (ROS), maintain intact the autoregulation of the cerebral vasculature, decrease neuronal loss, reduce programmed cell death, the presence of inflammatory cytokines, cerebral edema, and blood-brain barrier (BBB) permeability. Edaravone also protects against neurological deficits and memory deficits following traumatic brain injury.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001930", "http://www.biosemantics.org/jochem#4278506", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006259"], "type": "summary", "id": "530e42bf5937551c09000005", "snippets": [{"offsetInBeginSection": 1132, "offsetInEndSection": 1447, "text": " The edaravone-treated animals also exhibited higher rCBF in the contralateral hemisphere compared with that seen in -vehicle-treated animals. It is suggested that edaravone reduces neuronal damage by scavenging reactive oxygen species (ROS) and by maintaining intact the autoregulation of the cerebral vasculature.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564113", "endSection": "abstract"}, {"offsetInBeginSection": 925, "offsetInEndSection": 1309, "text": "Edaravone administration after CCI resulted in a significant reduction in the injury volume and oxidative stress, particularly at the 3-hour time point. Moreover, the greatest decrease in O2 (\u2219-) levels was observed when edaravone was administered 3 hours following CCI. These findings suggest that edaravone could prove clinically useful to ameliorate the devastating effects of TBI.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710445", "endSection": "abstract"}, {"offsetInBeginSection": 956, "offsetInEndSection": 1092, "text": "Edaravone significantly suppressed axonal injury and oxidative stress in the cortex, corpus callosum, and hippocampus 24h after injury. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982593", "endSection": "abstract"}, {"offsetInBeginSection": 1577, "offsetInEndSection": 1741, "text": "These results suggest that edaravone protects against memory deficits following TBI and that this protection is mediated by suppression of TAI and oxidative stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982593", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 975, "text": "Concordantly, edaravone has been found to have neuroprotective effects in a number of animal models of disease, including stroke, spinal cord injury, traumatic brain injury, neurodegenerative diseases and brain tumors. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977573", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21732763", "endSection": "title"}, {"offsetInBeginSection": 657, "offsetInEndSection": 832, "text": "Edaravone treatment significantly decreased hippocampal CA3 neuron loss, reduced oxidative stress, and decreased neuronal programmed cell death compared to vehicle treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21732763", "endSection": "abstract"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1487, "text": "Lastly, edaravone treatment significantly reduced the presence of inflammatory cytokines, cerebral edema, blood-brain barrier (BBB) permeability, and, importantly, neurological deficits following TBI. Our results suggest that edaravone exerts a neuroprotective effect in the rat model of TBI. The likely mechanism is via inhibiting oxidative stress, leading to a decreased inflammatory response and glial activation, and thereby reducing neuronal death and improving neurological function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21732763", "endSection": "abstract"}, {"offsetInBeginSection": 1784, "offsetInEndSection": 2864, "text": "After treatment with edaravone, the degree of morphological injury, p-ERK1/2 level and number of apoptotic neurons decreased, latent period to find the safety platform was significantly shortened (in low-dose edaravone treatment group, p-ERK1/2 expression level at 6, 24, 48 hours was 2.46 + or - 0.22, 4.00 + or - 0.84, 2.38 + or - 0.32, and in high-dose edaravone treatment group was 1.67 + or - 0.15, 1.86 + or - 0.38, 1.27 + or - 0.28; in low-dose edaravone treatment group, the apoptotic cells at 6, 24, 48, 72 hours was 5.20 + or - 1.23, 7.10 + or - 1.72, 9.54 + or - 1.36, 14.12 + or - 3.19, and in high-dose edaravone treatment group was 3.40 + or - 0.49 , 4.39 + or - 0.73, 5.02 + or - 1.12, 8.78 + or - 2.16; in low-dose edaravone treatment group, latent period to find the safety platform at 7-10 days was 94.8 + or - 22.8, 65.2 + or - 19.0, 62.0 + or - 16.7, 59.5 + or - 15.6, and in high-dose edaravone treatment group it was 81.5 + or - 20.7, 55.4 + or - 18.5, 40.0 + or - 12.3, 32.2 + or - 11.0, all P<0.05). High-dose edaravone showed a better effect (all P<0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20398468", "endSection": "abstract"}, {"offsetInBeginSection": 2876, "offsetInEndSection": 3057, "text": " Edaravone gives good therapeutic effect on severe TBI, and the molecular mechanism is related to attenuation of ERK1/2 pathway and neuronal apoptosis following severe brain trauma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20398468", "endSection": "abstract"}, {"offsetInBeginSection": 414, "offsetInEndSection": 1046, "text": "Numbers of 8-OHdG-, 4-HNE-, and ssDNA-positive cells around the damaged area after TBI were significantly decreased in the edaravone group compared with the saline group (P < 0.01). There was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the edaravone group compared with the saline group (P < 0.01). Edaravone administration following TBI inhibited free radical-induced neuronal degeneration and apoptotic cell death around the damaged area. In summary, edaravone treatment improved cerebral dysfunction following TBI, suggesting its potential as an effective clinical therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19768539", "endSection": "abstract"}, {"offsetInBeginSection": 2284, "offsetInEndSection": 2562, "text": "Edaravone administration inhibited production of free radicals known to induce neuronal degeneration and cell death after brain injury, and protected nestin-positive cells, including NSCs, with the potential to differentiate into neurons and glia around the area damaged by TBI.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19590930", "endSection": "abstract"}, {"offsetInBeginSection": 293, "offsetInEndSection": 419, "text": "Under specific experimental conditions, edaravone minimized traumatic brain injury by functioning as a synthetic antioxidant. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17115943", "endSection": "abstract"}, {"offsetInBeginSection": 1465, "offsetInEndSection": 1564, "text": "Thus, edaravone can scavenge OR- and significantly reduce levels of these radicals in TBI patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17115906", "endSection": "abstract"}]}, {"body": "Which is the genetic cause for the development of Fanconi anemia complementation group D1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16920162", "http://www.ncbi.nlm.nih.gov/pubmed/15645491", "http://www.ncbi.nlm.nih.gov/pubmed/14695169", "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "http://www.ncbi.nlm.nih.gov/pubmed/12383764", "http://www.ncbi.nlm.nih.gov/pubmed/15695377", "http://www.ncbi.nlm.nih.gov/pubmed/18212739"], "triples": [], "ideal_answer": ["Fanconi anemia complementation group D1 (FANCD1) was shown to be induced by biallelic mutations in the BRCA2 breast-cancer-susceptibility gene."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024682", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856", "http://www.uniprot.org/uniprot/BRCA2_MOUSE"], "type": "summary", "id": "54ede34694afd61504000004", "snippets": [{"offsetInBeginSection": 155, "offsetInEndSection": 327, "text": "The discovery of biallelic BRCA2 mutations in the FA-D1 complementation group allows for the first time to study the characteristics of primary BRCA2-deficient human cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16920162", "endSection": "abstract"}, {"offsetInBeginSection": 383, "offsetInEndSection": 679, "text": "Although he lacked a strong family history of cancer, he was subsequently shown to carry biallelic mutations in the FANCD1/BRCA2 gene. These included an IVS7 splice-site mutation, which is strongly associated with early AML in homozygous or compound heterozygous carrier status in FA-D1 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15645491", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 317, "text": "Biallelic BRCA2 mutations were shown recently to cause FA-D1. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14695169", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 265, "text": "The breast cancer susceptibility gene BRCA2 was recently found to be associated with Fanconi anemia complementation group D1 (FA-D1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 369, "offsetInEndSection": 576, "text": "One kindred, of Ashkenazi Jewish ancestry, had five members who were diagnosed with breast cancer and two cousins who were BRCA2*6174delT/C3069X compound heterozygotes and had Fanconi anemia and brain tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 752, "text": "In another kindred of Ashkenazi Jewish and Lithuanian Catholic ancestry, a child with Fanconi anemia and a medulloblastoma was a BRCA2*6174delT/886delGT compound heterozygote", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 754, "offsetInEndSection": 1034, "text": "Two other kindreds each contained a Fanconi anemia-afflicted child who developed medulloblastoma; one child was of Latin American ancestry and a compound heterozygote for BRCA2*I2490T/ 5301insA and the other was African American and a compound heterozygote for BRCA2*Q3066X/E1308X", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "Surprisingly, biallelic mutations in the BRCA2 breast-cancer-susceptibility gene were found in Fanconi anemia (FA), a rare hereditary disorder characterized by chromosomal instability, hypersensitivity to DNA cross-linking agents, and cancer susceptibility", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12383764", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 265, "text": " The breast cancer susceptibility gene BRCA2 was recently found to be associated with Fanconi anemia complementation group D1 (FA-D1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Biallelic mutations in Fanconi anemia complementation group genes disrupt DNA repair and result in the complex Fanconi anemia phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15695377", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 327, "text": "The discovery of biallelic BRCA2 mutations in the FA-D1 complementation group allows for the first time to study the characteristics of primary BRCA2-deficient human cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16920162", "endSection": "abstract"}, {"offsetInBeginSection": 383, "offsetInEndSection": 679, "text": "Although he lacked a strong family history of cancer, he was subsequently shown to carry biallelic mutations in the FANCD1/BRCA2 gene. These included an IVS7 splice-site mutation, which is strongly associated with early AML in homozygous or compound heterozygous carrier status in FA-D1 patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15645491", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 254, "text": "Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18212739", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 316, "text": "Biallelic BRCA2 mutations were shown recently to cause FA-D1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14695169", "endSection": "abstract"}, {"offsetInBeginSection": 155, "offsetInEndSection": 327, "text": "The discovery of biallelic BRCA2 mutations in the FA-D1 complementation group allows for the first time to study the characteristics of primary BRCA2-deficient human cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16920162", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 265, "text": "The breast cancer susceptibility gene BRCA2 was recently found to be associated with Fanconi anemia complementation group D1 (FA-D1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 315, "text": "Biallelic BRCA2 mutations were shown recently to cause FA-D1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14695169", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 253, "text": "Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18212739", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 315, "text": "Biallelic BRCA2 mutations were shown recently to cause FA-D1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14695169", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 253, "text": "Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18212739", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 315, "text": "Biallelic BRCA2 mutations were shown recently to cause FA-D1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14695169", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 253, "text": "Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18212739", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 265, "text": "The breast cancer susceptibility gene BRCA2 was recently found to be associated with Fanconi anemia complementation group D1 (FA-D1)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}]}, {"body": "How can DUF families be deciphered?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19787035", "http://www.ncbi.nlm.nih.gov/pubmed/22629278", "http://www.ncbi.nlm.nih.gov/pubmed/23516388", "http://www.ncbi.nlm.nih.gov/pubmed/25044324", "http://www.ncbi.nlm.nih.gov/pubmed/25010333", "http://www.ncbi.nlm.nih.gov/pubmed/24237627", "http://www.ncbi.nlm.nih.gov/pubmed/24901469", "http://www.ncbi.nlm.nih.gov/pubmed/23572527", "http://www.ncbi.nlm.nih.gov/pubmed/23104832"], "triples": [], "ideal_answer": ["The genome projects have unearthed an enormous diversity of genes of unknown function that are still awaiting biological and biochemical characterization. These genes, as most others, can be grouped into families based on sequence similarity. The PFAM database currently contains over 2,200 such families, referred to as domains of unknown function (DUF). \nCritically examining domain covariation across metagenomic datasets can grant new perspectives on the roles and associations of DUFs in an ecological setting. Targeted attempts at DUF characterization in the laboratory or in silico may draw from these insights and opportunities to discover new associations and corroborate existing ones will arise as more large-scale metagenomic datasets emerge. \nIn a coordinated effort, the four large-scale centers of the NIH Protein Structure Initiative have determined the first three-dimensional structures for more than 250 of these DUF families."], "concepts": [], "type": "summary", "id": "5709f646cf1c325851000021", "snippets": [{"offsetInBeginSection": 549, "offsetInEndSection": 753, "text": " These families include proteins with domain of unknown function (DUF) DUF23, DUF246, and DUF266. The evidence for these proteins being GTs and their possible roles in cell wall biosynthesis is discussed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22629278", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 354, "text": "The genome projects have unearthed an enormous diversity of genes of unknown function that are still awaiting biological and biochemical characterization. These genes, as most others, can be grouped into families based on sequence similarity. The PFAM database currently contains over 2,200 such families, referred to as domains of unknown function (DUF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19787035", "endSection": "abstract"}, {"offsetInBeginSection": 356, "offsetInEndSection": 545, "text": "In a coordinated effort, the four large-scale centers of the NIH Protein Structure Initiative have determined the first three-dimensional structures for more than 250 of these DUF families.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19787035", "endSection": "abstract"}, {"offsetInBeginSection": 1768, "offsetInEndSection": 2165, "text": "Critically examining domain covariation across metagenomic datasets can grant new perspectives on the roles and associations of DUFs in an ecological setting. Targeted attempts at DUF characterization in the laboratory or in silico may draw from these insights and opportunities to discover new associations and corroborate existing ones will arise as more large-scale metagenomic datasets emerge.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23516388", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "Crystal structures of three members (BACOVA_00364 from Bacteroides ovatus, BACUNI_03039 from Bacteroides uniformis and BACEGG_00036 from Bacteroides eggerthii) of the Pfam domain of unknown function (DUF4488) were determined to 1.95, 1.66, and 1.81 \u00c5 resolutions, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044324", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 847, "text": "Bacterial species in the Enterobacteriaceae typically contain multiple paralogues of a small domain of unknown function (DUF1471) from a family of conserved proteins also known as YhcN or BhsA/McbA. Proteins containing DUF1471 may have a single or three copies of this domain. Representatives of this family have been demonstrated to play roles in several cellular processes including stress response, biofilm formation, and pathogenesis. We have conducted NMR and X-ray crystallographic studies of four DUF1471 domains from Salmonella representing three different paralogous DUF1471 subfamilies: SrfN, YahO, and SssB/YdgH (two of its three DUF1471 domains: the N-terminal domain I (residues 21-91), and the C-terminal domain III (residues 244-314)). Notably, SrfN has been shown to have a role in intracellular infection by Salmonella Typhimurium", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010333", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 502, "text": "Domain of unknown function (DUF) proteins represent a number of gene families that encode functionally uncharacterized proteins in eukaryotes. For example, DUF1618 family members in plants possess a 56-199-amino acid conserved domain and this family has not been described previously. Here, we report the characterization of 121 DUF1618 genes identified in the rice genome. Based on phylogenetic analysis, the rice DUF1618 family was divided into two major groups, each group consisting of two clades. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24237627", "endSection": "abstract"}, {"offsetInBeginSection": 237, "offsetInEndSection": 352, "text": "In this study we identified that a plant specific domain of unknown function, DUF581 is a zf-FCS type zinc finger. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24901469", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "DUF2233, a domain of unknown function (DUF), is present in many bacterial and several viral proteins and was also identified in the mammalian transmembrane glycoprotein N-acetylglucosamine-1-phosphodiester \u03b1-N-acetylglucosaminidase (\"uncovering enzyme\" (UCE)). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23572527", "endSection": "abstract"}]}, {"body": "What is known about the value of mindfulness interventions in prostate cancer patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23442556", "http://www.ncbi.nlm.nih.gov/pubmed/22853988", "http://www.ncbi.nlm.nih.gov/pubmed/22442202", "http://www.ncbi.nlm.nih.gov/pubmed/21625914", "http://www.ncbi.nlm.nih.gov/pubmed/18400281", "http://www.ncbi.nlm.nih.gov/pubmed/17521871", "http://www.ncbi.nlm.nih.gov/pubmed/16685074", "http://www.ncbi.nlm.nih.gov/pubmed/14749092", "http://www.ncbi.nlm.nih.gov/pubmed/12883107", "http://www.ncbi.nlm.nih.gov/pubmed/11696736", "http://www.ncbi.nlm.nih.gov/pubmed/7776900"], "triples": [], "ideal_answer": ["In prostate cancer patients, mindfulness interventions were well accepted and were effective in reducing stress, anxiety, avoidance, fear of cancer recurrence, cortisol levels and blood pressure, and improving quality of life, sleep quality and immune system functioning. In addition, mindfulness interventions promoted initiation of healthy dietary changes and decreases the rate of PSA increase and may slow the rate of tumor progression in cases of biochemically recurrent prostate cancer."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:10283", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064866"], "type": "summary", "id": "54f09a5894afd6150400001c", "snippets": [{"offsetInBeginSection": 1136, "offsetInEndSection": 1718, "text": "Participants reported regular mindfulness training practice, and there was a significant correlation between mindfulness training practice and changes in both initiation and maintenance of the change in A:V. These pilot results provide encouraging evidence for the feasibility of a dietary program that includes mindfulness training in supporting dietary change for men with recurrent prostate cancer and invite further study to explore the possible role of mindfulness training as a means of supporting both initiation of dietary changes and maintenance of those changes over time.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22853988", "endSection": "abstract"}, {"offsetInBeginSection": 782, "offsetInEndSection": 1428, "text": "FINDINGS: Following the 6-week MBSR program, patients showed improvements in stress and anxiety (p < .05); caregivers' psychological and QOL also improved but were not statistically significant. Both patients and caregivers had decreases in cortisol at Weeks 1 and 3 (p < .05) but not at Week 6. Similar to cortisol levels at Week 6, salivary interleukin-6 levels were lower overall (before/after an MBSR-C session), compared with Week 1 for patients and caregivers. CONCLUSIONS: MBSR-C may be a beneficial intervention for reducing stress, anxiety, cortisol levels, and symptoms in advanced-stage cancer patients and may also benefit caregivers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22442202", "endSection": "abstract"}, {"offsetInBeginSection": 730, "offsetInEndSection": 931, "text": "ESULTS: Significant improvements were observed for anxiety (p = 0.027), avoidance (p = 0.032), and mindfulness skills (p = 0.019), with a trend for a reduction in fear of cancer recurrence (p = 0.062).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625914", "endSection": "abstract"}, {"offsetInBeginSection": 1140, "offsetInEndSection": 1317, "text": "CONCLUSIONS: Mindfulness-based group interventions appear to have utility in this patient group and show promise for reducing anxiety, avoidance, and fear of cancer recurrence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625914", "endSection": "abstract"}, {"offsetInBeginSection": 941, "offsetInEndSection": 1625, "text": " Linear mixed modeling showed significant improvements in overall symptoms of stress which were maintained over the follow-up period. Cortisol levels decreased systematically over the course of the follow-up. Immune patterns over the year supported a continued reduction in Th1 (pro-inflammatory) cytokines. Systolic blood pressure (SBP) decreased from pre- to post-intervention and HR was positively associated with self-reported symptoms of stress. CONCLUSIONS: MBSR program participation was associated with enhanced quality of life and decreased stress symptoms, altered cortisol and immune patterns consistent with less stress and mood disturbance, and decreased blood pressure. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17521871", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 1077, "text": "Significant improvements were seen in overall quality of life, symptoms of stress, and sleep quality, but these improvements were not significantly correlated with the degree of program attendance or minutes of home practice. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14749092", "endSection": "abstract"}, {"offsetInBeginSection": 1747, "offsetInEndSection": 2001, "text": "CONCLUSIONS: MBSR program enrollment was associated with enhanced quality of life and decreased stress symptoms in breast and prostate cancer patients, and resulted in possibly beneficial changes in hypothalamic-pituitary-adrenal (HPA) axis functioning. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14749092", "endSection": "abstract"}, {"offsetInBeginSection": 836, "offsetInEndSection": 1142, "text": "Significant improvements were seen in overall quality of life, symptoms of stress, and sleep quality. Although there were no significant changes in the overall number of lymphocytes or cell subsets, T cell production of IL-4 increased and IFN-gamma decreased, whereas NK cell production of IL-10 decreased.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12883107", "endSection": "abstract"}, {"offsetInBeginSection": 1274, "offsetInEndSection": 1542, "text": "CONCLUSIONS: MBSR participation was associated with enhanced quality of life and decreased stress symptoms in breast and prostate cancer patients. This study is also the first to show changes in cancer-related cytokine production associated with program participation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12883107", "endSection": "abstract"}, {"offsetInBeginSection": 1404, "offsetInEndSection": 1638, "text": "CONCLUSIONS: Our small study provides evidence that a plant-based diet delivered in the context of MBSR decreases the rate of PSA increase and may slow the rate of tumor progression in cases of biochemically recurrent prostate cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11696736", "endSection": "abstract"}, {"offsetInBeginSection": 1136, "offsetInEndSection": 1718, "text": "Participants reported regular mindfulness training practice, and there was a significant correlation between mindfulness training practice and changes in both initiation and maintenance of the change in A:V. These pilot results provide encouraging evidence for the feasibility of a dietary program that includes mindfulness training in supporting dietary change for men with recurrent prostate cancer and invite further study to explore the possible role of mindfulness training as a means of supporting both initiation of dietary changes and maintenance of those changes over time.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22853988", "endSection": "abstract"}]}, {"body": "what is the role of GATA-4 in regeneration of the heart after myocardial infarction?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22898045", "http://www.ncbi.nlm.nih.gov/pubmed/22748493", "http://www.ncbi.nlm.nih.gov/pubmed/21344679", "http://www.ncbi.nlm.nih.gov/pubmed/20971132", "http://www.ncbi.nlm.nih.gov/pubmed/20870802", "http://www.ncbi.nlm.nih.gov/pubmed/19591228", "http://www.ncbi.nlm.nih.gov/pubmed/18290252", "http://www.ncbi.nlm.nih.gov/pubmed/16304579", "http://www.ncbi.nlm.nih.gov/pubmed/15883211", "http://www.ncbi.nlm.nih.gov/pubmed/20200331"], "triples": [], "ideal_answer": "GATA-4 is implicated in cardiogenic differentiation of cardiac c-kit+AT2+ cells that represent approximately 0.19% of total cardiac cells in infarcted heart. GATA-4 overexpression in mesenchymal stem cells increases both survival and angiogenic potential in ischemic myocardium and may therefore represent a novel and efficient therapeutic approach for postinfarct regenaration. In addition, interventions, such as hypergravity and 5-Aza treatment, induce expression of early muscle and cardiac markers like GATA-4 in BMSCs. A subpopulation of primitive cells from rat heart, expressing c-kit and myogenic transcriptional factors, GATA-4 and MEF 2C, exhibit a high in vitro proliferative potential. Progeny of these implanted cells have been shown to migrate along the infarcted scar, reconstitute regenerated cardiomyocytes with incorporation into host myocardium, and inhibit cardiac remodeling with decreased scar formation. In another study, TGF-beta has been shown to conduct the myogenic differentiation of stem cells by upregulating GATA-4 and NKx-2.5 expression and the intramyocardial implantation of TGF-beta-preprogrammed stem cells effectively assisted the myocardial regeneration. Furthermore, G-CSF treatment in postinfarcted murine hearts appears to be an effective approach for treating heart failure and also leads to induction of GATA-4 resulting in expression of various sarcomeric proteins.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012038", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009203", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050980"], "type": "summary", "id": "532f03e6d6d3ac6a34000022", "snippets": [{"offsetInBeginSection": 1704, "offsetInEndSection": 2038, "text": "TGF-beta conducted the myogenic differentiation of CD117+ stem cells by upregulating GATA-4 and NKx-2.5 expression. Therefore, the intramyocardial implantation of TGF-beta-preprogrammed CD117+ cells effectively assisted the myocardial regeneration and induced therapeutic angiogenesis, contributing to functional cardiac regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15883211", "endSection": "abstract"}, {"offsetInBeginSection": 765, "offsetInEndSection": 965, "text": "G-CSF treatment also led to activation of signal transducer and activator of transcription-3 and induction of GATA-4 and various sarcomeric proteins such as myosin heavy chain, troponin I and desmin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304579", "endSection": "abstract"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1516, "text": "We describe here the identification of a subpopulation of primitive cells from rat heart, processing stem cell marker, c-kit and myogenic transcriptional factors, GATA-4 and MEF 2C, and cardiac specific proteins, troponin-I, alpha-sarcomeric actinin and connexin-43. They exhibited a high in vitro proliferative potential. These findings strongly suggest that these cells are putative cardiomyocyte precursors. After transplantation, they were able to be retained and proliferate (13.63 +/- 5.97% after 2 weeks) within the ischemic heart. Progeny of implanted cells migrated along the infarcted scar, reconstituted regenerated cardiomyocytes with incorporation into host myocardium, and inhibited cardiac remodeling with decreased scar formation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18290252", "endSection": "abstract"}, {"offsetInBeginSection": 1369, "offsetInEndSection": 1822, "text": "Histological studies at week 12 post-transplantation demonstrated engraftment of the pre DiI-stained hCLCs into the scarred myocardium and their expression of human specific alpha-cardiac actin. Human alpha cardiac actin-positive cells also expressed cardiac nuclear factors; nkx2.5 and GATA-4. Our results suggest that intracoronary artery transplantation of hCLCs is a potentially effective therapeutic strategy for future cardiac tissue regeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22898045", "endSection": "abstract"}, {"offsetInBeginSection": 810, "offsetInEndSection": 988, "text": "This pattern of colocalization was also found in developing embryonic myocardium. Cardiac transcription factors Nkx-2.5 and GATA-4 were strongly expressed in the muscle bundles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22748493", "endSection": "abstract"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1318, "text": "After hypergravity and 5-Aza treatment, BMSCs showed positive for the early muscle and cardiac markers GATA-4, MEF-2, and Nkx2-5 with RT-PCR", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21344679", "endSection": "abstract"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1309, "text": "Experiments in murine models of myocardial infarction (MI) demonstrated population of VSELs expressed also early markers of cardiac and endothelial lineages (GATA-4, Nkx2.5/Csx, VE-cadherin, von Willebrand factor) which migrated to stromal-derived factor-1 (SDF-1) and other chemoattractant gradient and underwent rapid mobilization into peripheral blood in experimental MI mice models.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20971132", "endSection": "abstract"}, {"offsetInBeginSection": 1607, "offsetInEndSection": 1828, "text": "We conclude that GATA-4 overexpression in MSCs increased both MSC survival and angiogenic potential in ischemic myocardium and may therefore represent a novel and efficient therapeutic approach for postinfarct remodeling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20870802", "endSection": "abstract"}, {"offsetInBeginSection": 798, "offsetInEndSection": 1087, "text": "These cardiac c-kit+AT2+ cells, represented approximately 0.19% of total cardiac cells in infarcted heart, were characterized by upregulated transcription factors implicated in cardiogenic differentiation (Gata-4, Notch-2, Nkx-2.5) and genes required for self-renewal (Tbx-3, c-Myc, Akt). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19591228", "endSection": "abstract"}, {"offsetInBeginSection": 1608, "offsetInEndSection": 1738, "text": "these findings suggest G-CSF administration could be an effective approach to treating chronic heart failure following a large MI.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16304579", "endSection": "abstract"}]}, {"body": "Describe what is the advantage of using a stain free protein gel in a Western Blot experiment?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24429481", "http://www.ncbi.nlm.nih.gov/pubmed/23712695", "http://www.ncbi.nlm.nih.gov/pubmed/23085117"], "triples": [], "ideal_answer": ["Stain-Free technology can be used as a normalization tool in Western blot analysis."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015153", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005782", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013194"], "type": "summary", "id": "54da21bf4b1fd0d33c00000d", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "V3 stain-free workflow for a practical, convenient, and reliable total protein loading control in western blotting.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24429481", "endSection": "title"}, {"offsetInBeginSection": 1089, "offsetInEndSection": 1199, "text": "The V3 stain-free workflow makes the western blot process faster, transparent, more quantitative\u00a0and reliable.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24429481", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 430, "text": "Direct Blue 71 (DB71) staining-a novel, sensitive, dye-binding staining method compatible with immunodetection-may offer advantages over these traditional loading control methods.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23712695", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Direct Blue 71 staining as a destaining-free alternative loading control method for Western blotting.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23712695", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stain-Free technology as a normalization tool in Western blot analysis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085117", "endSection": "title"}, {"offsetInBeginSection": 1080, "offsetInEndSection": 1162, "text": "Stain-Free technology appears to be more reliable, more robust, and more sensitive", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085117", "endSection": "abstract"}, {"offsetInBeginSection": 1252, "offsetInEndSection": 1442, "text": "tain-Free technology offers the additional advantages of providing checkpoints throughout the Western blotting process by allowing rapid visualization of gel separation and protein transfer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085117", "endSection": "abstract"}]}, {"body": "Which hormone abnormalities are characteristic to Pendred syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23235354", "http://www.ncbi.nlm.nih.gov/pubmed/22116361", "http://www.ncbi.nlm.nih.gov/pubmed/22109890", "http://www.ncbi.nlm.nih.gov/pubmed/21511235", "http://www.ncbi.nlm.nih.gov/pubmed/20834201", "http://www.ncbi.nlm.nih.gov/pubmed/20822748", "http://www.ncbi.nlm.nih.gov/pubmed/20583162", "http://www.ncbi.nlm.nih.gov/pubmed/20501687", "http://www.ncbi.nlm.nih.gov/pubmed/20298745", "http://www.ncbi.nlm.nih.gov/pubmed/19692489", "http://www.ncbi.nlm.nih.gov/pubmed/19318451", "http://www.ncbi.nlm.nih.gov/pubmed/19205523", "http://www.ncbi.nlm.nih.gov/pubmed/19196800", "http://www.ncbi.nlm.nih.gov/pubmed/19189692", "http://www.ncbi.nlm.nih.gov/pubmed/18692402", "http://www.ncbi.nlm.nih.gov/pubmed/17697873", "http://www.ncbi.nlm.nih.gov/pubmed/17365057", "http://www.ncbi.nlm.nih.gov/pubmed/17120770", "http://www.ncbi.nlm.nih.gov/pubmed/16263499", "http://www.ncbi.nlm.nih.gov/pubmed/15863666", "http://www.ncbi.nlm.nih.gov/pubmed/15807875", "http://www.ncbi.nlm.nih.gov/pubmed/15279074", "http://www.ncbi.nlm.nih.gov/pubmed/11375792", "http://www.ncbi.nlm.nih.gov/pubmed/10650967", "http://www.ncbi.nlm.nih.gov/pubmed/9618167", "http://www.ncbi.nlm.nih.gov/pubmed/8706311", "http://www.ncbi.nlm.nih.gov/pubmed/7852510", "http://www.ncbi.nlm.nih.gov/pubmed/21745434", "http://www.ncbi.nlm.nih.gov/pubmed/8630497", "http://www.ncbi.nlm.nih.gov/pubmed/10700480", "http://www.ncbi.nlm.nih.gov/pubmed/7492068", "http://www.ncbi.nlm.nih.gov/pubmed/17322586", "http://www.ncbi.nlm.nih.gov/pubmed/18538122", "http://www.ncbi.nlm.nih.gov/pubmed/1159063", "http://www.ncbi.nlm.nih.gov/pubmed/10571950", "http://www.ncbi.nlm.nih.gov/pubmed/15355436", "http://www.ncbi.nlm.nih.gov/pubmed/10637573"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17838014", "o": "E07.1"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "274600"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "C536648"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "C536648"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "C536648"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17838014", "o": "ICD-10-CM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Metathesaurus Names"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/relationontology/hasInclusionCriteria", "s": "http://data.linkedct.org/resource/trials/NCT00216255", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00216255", "o": "Trial NCT00216255"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/relationontology/hasInclusionCriteria", "s": "http://data.linkedct.org/resource/trials/NCT00630370", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00630370", "o": "Trial NCT00630370"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#narrower", "s": "http://linkedlifedata.com/resource/umls/id/C0018023", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0064393", "o": "Goiters, Nodular"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0415707", "o": "GOITER NODULAR"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0064385", "o": "Goiter, Nodular"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17969523", "o": "Goiter, Nodular [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8395403", "o": "Nodular Goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0092674", "o": "Nodular Goiters"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8375698", "o": "Nodular goiter NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12019521", "o": "Nodular goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/id/C0018023"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0064393", "o": "Goiters, Nodular"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0415707", "o": "GOITER NODULAR"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0064385", "o": "Goiter, Nodular"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8395403", "o": "Nodular Goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17969523", "o": "Goiter, Nodular [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0092674", "o": "Nodular Goiters"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8375698", "o": "Nodular goiter NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12019521", "o": "Nodular goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/relationontology/hasInclusionCriteria", "s": "http://data.linkedct.org/resource/trials/NCT00239915", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://data.linkedct.org/resource/trials/NCT00239915", "o": "Trial NCT00239915"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/id/C0018784"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7577188", "o": "Sensorineural Hearing Loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8363138", "o": "Sensorineural hearing loss, unspecified"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18016059", "o": "Hearing Loss, Sensorineural [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0488964", "o": "sensorineural hearing loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12009292", "o": "Sensorineural hearing loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0066355", "o": "Hearing Loss, Sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17826267", "o": "Unspecified sensorineural hearing loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0913473", "o": "Deafness Sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0418108", "o": "HEARING DISORDER, NEURAL"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11966484", "o": "Deafness, sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0418105", "o": "HEARING DISORDER RETROCOCHLEAR"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7573621", "o": "Sensorineural Deafness"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17800546", "o": "Perceptive hearing loss NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11994439", "o": "Sensorineural deafness"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8373970", "o": "Perceptive hearing loss or deafness"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17467506", "o": "Hearing loss, perceptive"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11922573", "o": "Hearing loss, sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17851703", "o": "Sensorineural deafness NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0245849", "o": "HEARING DISORDER, SENSORINEURAL"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12023235", "o": "Deafness, neurosensory"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A16784526", "o": "Sensorineural Hearing Loss (disorder)"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0404241", "o": "DEAFNESS, PERCEPTIVE"}, {"p": "http://www.w3.org/2004/02/skos/core#narrower", "s": "http://linkedlifedata.com/resource/umls/id/C0018784", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7577188", "o": "Sensorineural Hearing Loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8363138", "o": "Sensorineural hearing loss, unspecified"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18016059", "o": "Hearing Loss, Sensorineural [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0488964", "o": "sensorineural hearing loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12009292", "o": "Sensorineural hearing loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0066355", "o": "Hearing Loss, Sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17826267", "o": "Unspecified sensorineural hearing loss"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0913473", "o": "Deafness Sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0418108", "o": "HEARING DISORDER, NEURAL"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11966484", "o": "Deafness, sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0418105", "o": "HEARING DISORDER RETROCOCHLEAR"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7573621", "o": "Sensorineural Deafness"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17800546", "o": "Perceptive hearing loss NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11994439", "o": "Sensorineural deafness"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8373970", "o": "Perceptive hearing loss or deafness"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17467506", "o": "Hearing loss, perceptive"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11922573", "o": "Hearing loss, sensorineural"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17851703", "o": "Sensorineural deafness NOS"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0245849", "o": "HEARING DISORDER, SENSORINEURAL"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12023235", "o": "Deafness, neurosensory"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A16784526", "o": "Sensorineural Hearing Loss (disorder)"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0404241", "o": "DEAFNESS, PERCEPTIVE"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113857879", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844388"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R119946067", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R03275989", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844387"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R60705962"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R60618697", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113836345", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113841830", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R71684698"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113842412", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113850402"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R60488385", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113850401", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113838723", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113850403"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844384"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R115219063", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R03348218"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R115213380"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113839841", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113842118", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113840203", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113840188", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R119806980"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113858879", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R57732439", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844386"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R119806981"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113857554", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113857879"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844385"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113856198", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113856198"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R60618697"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R57732440"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113840915", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113842413", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113857554"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R60575809", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R71684699", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R60705962", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844392"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R60488385"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://www.w3.org/2004/02/skos/core#inScheme", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R60560481", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844393"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113850403", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R03685854", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113860871"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R108937811", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844394"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R03690859"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R60575809"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R60575808", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113858879"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R60575808"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113860871", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R108937810"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113842729", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113850402", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R60560481"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relation", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/relation/R113844390"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R113840607", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}, {"p": "http://linkedlifedata.com/resource/umls/relatedConcept", "s": "http://linkedlifedata.com/resource/umls/relation/R119944384", "o": "http://linkedlifedata.com/resource/umls/id/C0271829"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17463293", "o": "TDH2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18464677", "o": "Pendred syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17462098"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016629"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17466910"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016630", "o": "DEAFNESS WITH GOITER"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016631"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17468130"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17463293"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18452359"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016629", "o": "PDS"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016630"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18455456"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466910", "o": "THYROID DYSHORMONOGENESIS 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A18464677"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17468130", "o": "THYROID HORMONOGENESIS, GENETIC DEFECT IN, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18452359", "o": "Goiter-deafness syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A17838014"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016628", "o": "PENDRED SYNDROME"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12060170"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12016631", "o": "GOITER-DEAFNESS SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18455456", "o": "Deafness with goiter"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462098", "o": "HYPOTHYROIDISM, CONGENITAL, DUE TO DYSHORMONOGENESIS, 2B"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12060170", "o": "Pendred's syndrome"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0271829", "o": "http://linkedlifedata.com/resource/umls/label/A12016628"}], "ideal_answer": ["Thyroid hormone abnormalities are characteristic to Pendred syndrome. Hypothyroidism is the most common thyroid hormone abnormality in Pendred syndrome. Pendred syndrome  is an autosomal recessive disorder characterized by sensorineural deafness, goiter and a partial defect in iodide organification."], "exact_answer": [["thyroid"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006728", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", "http://www.disease-ontology.org/api/metadata/DOID:225"], "type": "factoid", "id": "53148a07dae131f847000002", "snippets": [{"offsetInBeginSection": 154, "offsetInEndSection": 363, "text": "Loss or reduction of function mutations of SLC26A4 underlie Pendred syndrome, a disorder invariably leading to hearing loss with enlarged vestibular aqueducts and in some patients to hypothyroidism and goiter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235354", "endSection": "abstract"}, {"offsetInBeginSection": 618, "offsetInEndSection": 752, "text": "Goiter development and hypothyroidism vary among affected individuals and seem to be partially dependent on nutritional iodide intake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511235", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 1063, "text": "Elucidation of the molecular basis of Pendred syndrome and the function of pendrin has provided unexpected novel insights into the pathophysiology of the inner ear, thyroid hormone synthesis, and chloride/bicarbonate exchange in the kidney.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511235", "endSection": "abstract"}, {"offsetInBeginSection": 790, "offsetInEndSection": 833, "text": "Thyroid goiter was found in 46.5% of cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822748", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Biallelic mutations of SLC26A4 (encoding pendrin) cause Pendred syndrome (PS), an autosomal recessive genetic disorder with deafness and goiter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", "endSection": "abstract"}, {"offsetInBeginSection": 468, "offsetInEndSection": 620, "text": "From age 15 years, her thyroid gland showed progressive enlargement accompanied by elevation of serum thyroglobulin reaching 10-fold the normal amount. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", "endSection": "abstract"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1457, "text": "In summary, a molecularly confirmed PS patient showed goiter progression accompanied by elevated serum thyroglobulin and increased thyroidal iodine uptake, but normal serum TSH levels and normal iodine organification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "A coherent organization of differentiation proteins is required to maintain an appropriate thyroid function in the Pendred thyroid.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501687", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Pendred syndrome is an autosomal recessive disorder defined by sensorineural deafness, goiter and a partial organification defect of iodide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22116361", "endSection": "abstract"}, {"offsetInBeginSection": 333, "offsetInEndSection": 611, "text": "The clinical phenotype of patients with Pendred syndrome and the fact that pendrin can mediate iodide efflux in transfected cells suggest that this anion exchanger may be involved in mediating iodide efflux into the follicular lumen, a key step in thyroid hormone biosynthesis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22116361", "endSection": "abstract"}, {"offsetInBeginSection": 602, "offsetInEndSection": 813, "text": "Results of immunoblot and immunofluorescence experiments reveal that TSH and forskolin rapidly increase pendrin abundance at the plasma membrane through the protein kinase A pathway in PCCL-3 rat thyroid cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109890", "endSection": "abstract"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1360, "text": "These results demonstrate that pendrin translocates to the membrane in response to TSH and suggest that it may have a physiological role in apical iodide transport and thyroid hormone synthesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109890", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 202, "text": "Mutations in the SLC26A4 gene, coding for the anion transporter pendrin, are responsible for Pendred syndrome, characterized by congenital sensorineural deafness and dyshormonogenic goiter. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20834201", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "Pendred syndrome is an autosomal recessive disorder characterized by sensorineural deafness, goiter and a partial defect in iodide organification. Goiter development and hypothyroidism vary and appear to depend on nutritional iodide intake. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20298745", "endSection": "abstract"}, {"offsetInBeginSection": 370, "offsetInEndSection": 570, "text": "Pendrin is mainly expressed in the thyroid, the inner ear, and the kidney. In the thyroid, pendrin localizes to the apical membrane of thyrocytes, where it may be involved in mediating iodide efflux. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20298745", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Mutations of SLC26A4 cause an enlarged vestibular aqueduct, nonsyndromic deafness, and deafness as part of Pendred syndrome. SLC26A4 encodes pendrin, an anion exchanger located in the cochlea, thyroid, and kidney. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19692489", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Genetic causes of goiter and deafness: Pendred syndrome in a girl and cooccurrence of Pendred syndrome and resistance to thyroid hormone in her sister.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", "endSection": "title"}, {"offsetInBeginSection": 9, "offsetInEndSection": 290, "text": "Goiter and deafness can be associated in some genetic syndromes, e.g. Pendred syndrome (PS) and resistance to thyroid hormone (RTH). PS is an autosomal recessive disorder characterized by goiter and sensorineural hearing impairment with an enlarged vestibular aqueduct bilaterally.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", "endSection": "abstract"}, {"offsetInBeginSection": 754, "offsetInEndSection": 1011, "text": "The elder sister had an elevated TSH level at newborn screening followed by subclinical hypothyroidism, childhood-onset goiter, and bilateral progressive sensorineural hearing impairment with enlarged vestibular aqueducts, consistent with a diagnosis of PS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", "endSection": "abstract"}, {"offsetInBeginSection": 1611, "offsetInEndSection": 1769, "text": "This is the first report of the cooccurrence, in the same individual, of PS and RTH, two genetic syndromes both associated with goiter and hearing impairment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19318451", "endSection": "abstract"}, {"offsetInBeginSection": 89, "offsetInEndSection": 314, "text": "Its diagnosis requires identification of the classical triad of symptoms, including hypoacusis, thyroid goitre and iodine organification defect in the thyroid, which may lead to thyroid functional disorders of hypothyroidism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19205523", "endSection": "abstract"}, {"offsetInBeginSection": 1598, "offsetInEndSection": 1741, "text": "Endocrine examination showed hypothyroidism in 5, its subclinical form in 1, diffuse thyroid goitre in 4 and nodular thyroid goiter in 2 cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19205523", "endSection": "abstract"}, {"offsetInBeginSection": 1115, "offsetInEndSection": 1298, "text": "Biallelic mutations in the SLC26A4 gene lead to Pendred syndrome, an autosomal recessive disorder characterized by sensorineural deafness, goiter, and impaired iodide organification. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19196800", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Thyroidectomy in a patient with multinodular dyshormonogenetic goitre--a case of Pendred syndrome confirmed by mutations in the PDS/SLC26A4 gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189692", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "We report a young woman with genetically confirmed Pendred syndrome and discuss the current therapeutic strategies of dyshormonogenetic goitre.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189692", "endSection": "abstract"}, {"offsetInBeginSection": 600, "offsetInEndSection": 709, "text": "Management of a patient with Pendred syndrome requires careful follow-up and regular imaging of the thyroid. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19189692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 345, "text": "Pendred syndrome is an autosomal recessive disorder characterized by sensorineural hearing impairment, presence of goiter, and a partial defect in iodide organification, which may be associated with insufficient thyroid hormone synthesis. Goiter development and development of hypothyroidism are variable and depend on nutritional iodide intake.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18692402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Pendred syndrome (PS) is an autosomal recessive disease that is characterized by congenital sensorineural hearing loss, goiter, and a partial iodine organification defect. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697873", "endSection": "abstract"}, {"offsetInBeginSection": 568, "offsetInEndSection": 803, "text": "Levels of thyroid hormones were essentially normal in all patients: 2 patients had goiters and/or elevated serum thyroglobulin levels, whereas 2 other patients had positive thyroid antibodies and a positive perchlorate discharge test. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697873", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Pendred syndrome, defined as the constellation of goiter, sensori-neural hearing loss, and positive perchlorate discharge test, is the most frequent cause of congenital deafness. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17365057", "endSection": "abstract"}, {"offsetInBeginSection": 402, "offsetInEndSection": 589, "text": "Presuming the classic triad as the gold standard, we compared MRI findings in six such defined patients with six cases having goiter, hearing loss, and normal perchlorate discharge test. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17365057", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "For over 100 years after the first description of the disorder, the molecular pathology underlying the deafness and thyroid pathology in Pendred syndrome (PS) remained unknown. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17120770", "endSection": "abstract"}, {"offsetInBeginSection": 809, "offsetInEndSection": 1143, "text": "We review the literature to identify genetic defects involved in the iodination process of the thyroid hormone synthesis, particularly defects in iodide transport from circulation into the thyroid cell, defects in iodide transport from the thyroid cell to the follicular lumen (Pendred syndrome), and defects of iodide organification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16263499", "endSection": "abstract"}, {"offsetInBeginSection": 795, "offsetInEndSection": 1024, "text": "Among those causing dyshormonogenesis, the thyroid peroxidase and thyroglobulin genes were initially described, and more recently PDS (Pendred syndrome), NIS (sodium iodide symporter), and THOX2 (thyroid oxidase 2) gene defects. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863666", "endSection": "abstract"}, {"offsetInBeginSection": 1692, "offsetInEndSection": 1967, "text": "Among permanent CH cases, those with a goitre (n = 27) had an iodine organification defect (n = 10), Pendred syndrome (n = 1), a defect of thyroglobulin synthesis (n = 8), or a defect of sodium iodine symporter (n = 1), and in seven patients no aetiology could be determined.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15807875", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 315, "text": "Pendred syndrome consists in sensorineural deafness, goiter and impaired thyroid hormone synthesis while in EVA thyroid function seems to be preserved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", "endSection": "abstract"}, {"offsetInBeginSection": 1312, "offsetInEndSection": 1465, "text": "All patients harbouring mutations in the SLC26A4 gene had goiter and a positive perchlorate discharge test: 3 were slightly hypothyroid and 2 euthyroid. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", "endSection": "abstract"}, {"offsetInBeginSection": 1763, "offsetInEndSection": 1987, "text": "Patients with mutations in the SLC26A4 gene had larger thyroid volume (p<0.002), higher serum thyroglobulin (Tg) levels (p<0.002) and greater radioiodine discharge after perchlorate (p=0.09) than patients without mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 148, "text": "The autosomal recessive Pendred's syndrome is defined by congenital sensorineural deafness, goiter, and impaired iodide organification. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11375792", "endSection": "abstract"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1041, "text": "Two patients were hypothyroid, two individuals were euthyroid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11375792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Pendred syndrome is an autosomal recessive disorder characterized by congenital deafness and thyroid goiter. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10650967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Pendred syndrome is an autosomal recessive disorder characterized by the association between sensorineural hearing loss and thyroid swelling or goitre and is likely to be the most common form of syndromic deafness. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9618167", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 315, "text": "Pendred syndrome consists in sensorineural deafness, goiter and impaired thyroid hormone synthesis while in EVA thyroid function seems to be preserved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Pendred syndrome is a recessive inherited disorder that consists of developmental abnormalities of the cochlea, sensorineural hearing loss, and diffuse thyroid enlargement (goiter).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10571950", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 363, "text": "Loss or reduction of function mutations of SLC26A4 underlie Pendred syndrome, a disorder invariably leading to hearing loss with enlarged vestibular aqueducts and in some patients to hypothyroidism and goiter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23235354", "endSection": "abstract"}, {"offsetInBeginSection": 163, "offsetInEndSection": 313, "text": "Pendred syndrome consists in sensorineural deafness, goiter and impaired thyroid hormone synthesis while in EVA thyroid function seems to be preserved", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15279074", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Biallelic mutations of SLC26A4 (encoding pendrin) cause Pendred syndrome (PS), an autosomal recessive genetic disorder with deafness and goiter", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583162", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Pendred syndrome (PS) is an autosomal recessive disease that is characterized by congenital sensorineural hearing loss, goiter, and a partial iodine organification defect", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17697873", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1140, "text": "Individuals were assigned affected status based on the characteristic clinical features of Pendred's syndrome, namely the presence of congenital sensorineural hearing loss and the appearance in early life of a goitre", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8706311", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1140, "text": "Individuals were assigned affected status based on the characteristic clinical features of Pendred's syndrome, namely the presence of congenital sensorineural hearing loss and the appearance in early life of a goitre", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8706311", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1140, "text": "Individuals were assigned affected status based on the characteristic clinical features of Pendred's syndrome, namely the presence of congenital sensorineural hearing loss and the appearance in early life of a goitre", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8706311", "endSection": "abstract"}, {"offsetInBeginSection": 924, "offsetInEndSection": 1140, "text": "Individuals were assigned affected status based on the characteristic clinical features of Pendred's syndrome, namely the presence of congenital sensorineural hearing loss and the appearance in early life of a goitre", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8706311", "endSection": "abstract"}]}, {"body": "Describe armoured brain syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24403965", "http://www.ncbi.nlm.nih.gov/pubmed/23421586", "http://www.ncbi.nlm.nih.gov/pubmed/21319032", "http://www.ncbi.nlm.nih.gov/pubmed/19902386", "http://www.ncbi.nlm.nih.gov/pubmed/1580196"], "triples": [], "ideal_answer": ["Armoured brain syndrome is defined by calcified chronic subdural haematoma."], "concepts": [], "type": "summary", "id": "54cf42bdf693c3b16b000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Armoured brain is a rare condition where dense calcification occurs over the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", "endSection": "abstract"}, {"offsetInBeginSection": -1, "offsetInEndSection": 83, "text": "Armoured brain due to chronic subdural collections masking underlying hydrocephalus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421586", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Calcified chronic subdural collection (armoured brain) is a known long-standing complication of shunt overdrainage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The optimal surgical procedure for patients with calcified and organized chronic subdural haematoma (CSDH), or \"armoured brain\", has not been established because it is difficult to obtain good re-expansion of the brain after surgery. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319032", "endSection": "abstract"}, {"offsetInBeginSection": 436, "offsetInEndSection": 647, "text": "RESULTS: A patient with a bilateral symptomatic calcified chronic subdural hematoma, or so-called \"armoured brain\", was admitted to our intensive care unit with clinical signs of increased intracranial pressure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19902386", "endSection": "abstract"}, {"offsetInBeginSection": -1, "offsetInEndSection": 110, "text": "High-field magnetic resonance image of a huge calcified chronic subdural haematoma, so-called \"armoured brain\".", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1580196", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Calcification of chronic subdural haematoma is called \"armoured brain\" when it covers most of the cortical surface. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1580196", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Armoured brain is a rare condition where dense calcification occurs over the brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", "endSection": "abstract"}, {"offsetInBeginSection": -1, "offsetInEndSection": 83, "text": "Armoured brain due to chronic subdural collections masking underlying hydrocephalus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421586", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Calcified chronic subdural collection (armoured brain) is a known long-standing complication of shunt overdrainage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23421586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Armoured brain is a rare condition where dense calcification occurs over the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The optimal surgical procedure for patients with calcified and organized chronic subdural haematoma (CSDH), or \"armoured brain\", has not been established because it is difficult to obtain good re-expansion of the brain after surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Armoured brain is a rare condition where dense calcification occurs over the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The optimal surgical procedure for patients with calcified and organized chronic subdural haematoma (CSDH), or \"armoured brain\", has not been established because it is difficult to obtain good re-expansion of the brain after surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Armoured brain is a rare condition where dense calcification occurs over the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The optimal surgical procedure for patients with calcified and organized chronic subdural haematoma (CSDH), or \"armoured brain\", has not been established because it is difficult to obtain good re-expansion of the brain after surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319032", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Armoured brain is a rare condition where dense calcification occurs over the brain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24403965", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "The optimal surgical procedure for patients with calcified and organized chronic subdural haematoma (CSDH), or \"armoured brain\", has not been established because it is difficult to obtain good re-expansion of the brain after surgery", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21319032", "endSection": "abstract"}]}, {"body": "Which is the vector of Louping ill virus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22939093", "http://www.ncbi.nlm.nih.gov/pubmed/19685082", "http://www.ncbi.nlm.nih.gov/pubmed/19631009", "http://www.ncbi.nlm.nih.gov/pubmed/18471057", "http://www.ncbi.nlm.nih.gov/pubmed/17346361", "http://www.ncbi.nlm.nih.gov/pubmed/15252984", "http://www.ncbi.nlm.nih.gov/pubmed/11427261", "http://www.ncbi.nlm.nih.gov/pubmed/9802086", "http://www.ncbi.nlm.nih.gov/pubmed/7815482", "http://www.ncbi.nlm.nih.gov/pubmed/1337231", "http://www.ncbi.nlm.nih.gov/pubmed/14422369", "http://www.ncbi.nlm.nih.gov/pubmed/13383364", "http://www.ncbi.nlm.nih.gov/pubmed/22913287", "http://www.ncbi.nlm.nih.gov/pubmed/22452970", "http://www.ncbi.nlm.nih.gov/pubmed/21771532", "http://www.ncbi.nlm.nih.gov/pubmed/21593276", "http://www.ncbi.nlm.nih.gov/pubmed/21254926", "http://www.ncbi.nlm.nih.gov/pubmed/19925041", "http://www.ncbi.nlm.nih.gov/pubmed/18841330", "http://www.ncbi.nlm.nih.gov/pubmed/18823640", "http://www.ncbi.nlm.nih.gov/pubmed/18602711", "http://www.ncbi.nlm.nih.gov/pubmed/18562534", "http://www.ncbi.nlm.nih.gov/pubmed/12560576", "http://www.ncbi.nlm.nih.gov/pubmed/12557579", "http://www.ncbi.nlm.nih.gov/pubmed/12519399", "http://www.ncbi.nlm.nih.gov/pubmed/12233771"], "triples": [{"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/pubmed/keyword/VIRUSES%2Flouping-ill", "o": "http://linkedlifedata.com/resource/pubmed/Keyword"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A2035145", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A2035145", "o": "D004669"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A2035145", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A2035145", "o": "Louping ill viruses"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/pubmed/keyword/VIRUSES%2Flouping-ill", "o": "VIRUSES/louping-ill"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A7781838", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A7781838", "o": "D004669"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A7781838", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7781838", "o": "Louping ill virus"}, {"p": "http://purl.uniprot.org/core/commonName", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "Li"}, {"p": "http://purl.uniprot.org/core/complete", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "true"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/34613"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/34878"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/9606"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/9615"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/9796"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/9823"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/9913"}, {"p": "http://purl.uniprot.org/core/host", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/9940"}, {"p": "http://purl.uniprot.org/core/mnemonic", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "LIV"}, {"p": "http://purl.uniprot.org/core/partOfLineage", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "false"}, {"p": "http://purl.uniprot.org/core/rank", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/core/Species"}, {"p": "http://purl.uniprot.org/core/reviewed", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "true"}, {"p": "http://purl.uniprot.org/core/scientificName", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "Louping ill virus"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/core/Taxon"}, {"p": "http://www.w3.org/2000/01/rdf-schema#subClassOf", "s": "http://purl.uniprot.org/taxonomy/11086", "o": "http://purl.uniprot.org/taxonomy/29263"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0431097", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0431097", "o": "11086"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0431097", "o": "NCBI Taxonomy"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0431097", "o": "Louping ill virus"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0081054", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0081054", "o": "Metathesaurus Names"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0081054", "o": "Louping Ill"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0423465", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0423465", "o": "D008146"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0423465", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0423465", "o": "Ill, Louping"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A8352613", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8352613", "o": "063.1"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8352613", "o": "ICD-9-CM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8352613", "o": "Louping ill"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:10250", "o": "http://www.w3.org/2004/02/skos/core#Concept"}, {"p": "http://www.w3.org/2004/02/skos/core#altLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:10250", "o": "Louping ill"}, {"p": "http://www.w3.org/2004/02/skos/core#altLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:10250", "o": "Louping ill (disorder)"}], "ideal_answer": ["Louping ill virus (LIV) belongs to the mammalian tick-borne virus group of the genus Flavivirus  which cause central nervous system disease. LIV infects the red grouse Lagopus lagopus scoticus, causing high mortality. LIV is transmitted by the tick Ixodes ricinus.", "Deer are the key hosts of the vector (Ixodes ricinus) that transmits LIV to red grouse Lagopus lagopus scoticus, causing high mortality. (PMID: 22939093)"], "exact_answer": ["Ixodes ricinus"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008146", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004669", "http://www.disease-ontology.org/api/metadata/DOID:10250", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004675", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004199", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014780", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001179"], "type": "factoid", "id": "51716e808ed59a060a00000b", "snippets": [{"offsetInBeginSection": 528, "offsetInEndSection": 664, "text": "Deer are the key hosts of the vector (Ixodes ricinus) that transmits LIV to red grouse Lagopus lagopus scoticus, causing high mortality.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22939093", "endSection": "sections.0"}, {"offsetInBeginSection": 94, "offsetInEndSection": 426, "text": "n Europe the primary arthropod vectors of zoonotic diseases are ticks, which transmit Borrelia burgdorferi sensu lato (the agent of Lyme disease), tick-borne encephalitis virus and louping ill virus between humans, livestock and wildlife. Ixodes ricinus ticks and reported tick-borne disease cases are currently increasing in the UK", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19685082", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Many vector-borne pathogens whose primary vectors are generalists, such as Ixodid ticks, can infect a wide range of host species and are often zoonotic.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631009", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Tick-borne encephalitis virus (TBEV) and Louping ill virus (LIV) are viruses in the Mammalian tick-borne virus group/genus Flavivirus, causing central nervous system disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18471057", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "The complex pathogen-host-vector system of the tick-borne louping-ill virus causes economic losses to sheep and red grouse in upland United Kingdom.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17346361", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 396, "text": "For pathogens transmitted by biting vectors, one of the fundamental assumptions is often that vector bites are the sole or main route of host infection. Here, we demonstrate experimentally a transmission route whereby hosts (red grouse, Lagopus lagopus scoticus) became infected with a member of the tick-borne encephalitis virus complex, louping ill virus, after eating the infected tick vector.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15252984", "endSection": "sections.0"}, {"offsetInBeginSection": 411, "offsetInEndSection": 527, "text": "We used Susceptible Infected Recovered (SIR) models parameterized for the tick-borne louping ill virus (LIV) system.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22939093", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "This study has examined the efficacy following intramuscular administration of a recombinant Semliki Forest virus (rSFV) vaccine, encoding the prME and NS1 proteins of louping ill virus (LIV), in sheep.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11427261", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "Since the recognition that louping-ill, known for well over 100 years as an epizootic disease of sheep in Scotland, was caused by a virus transmitted by arthropods, many other arthropod-borne viruses capable of causing encephalitis in domestic animals or man have been discovered.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14422369", "endSection": "sections.0"}]}, {"body": "What is the effect of ROS on cyclin B1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24296129", "http://www.ncbi.nlm.nih.gov/pubmed/24147344", "http://www.ncbi.nlm.nih.gov/pubmed/24064966", "http://www.ncbi.nlm.nih.gov/pubmed/23567243", "http://www.ncbi.nlm.nih.gov/pubmed/22834967", "http://www.ncbi.nlm.nih.gov/pubmed/22147197", "http://www.ncbi.nlm.nih.gov/pubmed/20446899", "http://www.ncbi.nlm.nih.gov/pubmed/20444961", "http://www.ncbi.nlm.nih.gov/pubmed/19331169", "http://www.ncbi.nlm.nih.gov/pubmed/18023967", "http://www.ncbi.nlm.nih.gov/pubmed/17671211"], "triples": [], "ideal_answer": "Reactive oxygen species (ROS) production is able to cause growth arrest at the G2-M checkpoint of the cell cycle, partly by deregulation of Cyclin B1 expression.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056744", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016213", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0097125", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000302", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1901033", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:1901032"], "type": "summary", "id": "53175e68b166e2b806000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 484, "text": "The present study was undertaken to determine whether sulforaphane-derived reactive oxygen species (ROS) might cause growth arrest and apoptosis in human bladder cancer 5637 cells. Our results show that the reduced viability of 5637 cells by sulforaphane is due to mitotic arrest, but not the G2 phase. The sulforaphane-induced mitotic arrest correlated with an induction of cyclin B1 and phosphorylation of Cdk1, as well as a concomitant increased complex between cyclin B1 and Cdk1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24296129", "endSection": "abstract"}, {"offsetInBeginSection": 329, "offsetInEndSection": 759, "text": "Further mechanistic studies revealed that induction of apoptosis is associated with cell cycle arrest at G2/M phase, increased generation of reactive oxygen species (ROS), reduced mitochondrial membrane potential (MMP), release of cytochrome c (Cyto c) and apoptosis inducing factor (AIF) from mitochondria to cytosol, upregulation of Bax, p21 and p53, and down-regulation of Bcl-2, cyclin B1 and cyclin-dependent kinase 1 (CDK1).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147344", "endSection": "abstract"}, {"offsetInBeginSection": 941, "offsetInEndSection": 1240, "text": "LDH inhibition by oxamate induced G2/M cell cycle arrest via downregulation of the CDK1/cyclin B1 pathway and promoted apoptosis through enhancement of mitochondrial ROS generation. N-acetylcysteine, a specific scavenger of ROS, significantly blocked the growth inhibition effect induced by oxamate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064966", "endSection": "abstract"}, {"offsetInBeginSection": 290, "offsetInEndSection": 392, "text": "As well as DICO induced G2/M cell cycle arrest and apoptosis via a ROS-mediated mitochondrial pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567243", "endSection": "abstract"}, {"offsetInBeginSection": 572, "offsetInEndSection": 695, "text": "Meanwhile, the alterations of cyclin A and B1, p-CDK1 and p-cdc25c levels were also observed in response to DICO treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567243", "endSection": "abstract"}, {"offsetInBeginSection": 1173, "offsetInEndSection": 1455, "text": "Butyrate (> 2 mm) inhibited the expression of cdc2, cdc25C and cyclinB1 mRNAs and reduced the levels of Cdc2, Cdc25C and cyclinB1 proteins in GFs, as determined using RT-PCR and western blotting, respectively. This toxic effect of butyrate was associated with the production of ROS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22834967", "endSection": "abstract"}, {"offsetInBeginSection": 834, "offsetInEndSection": 970, "text": "Furthermore, costunolide induced cell cycle arrest in the G2/M phase via decrease in Cdc2, cyclin B1 and increase in p21WAF1 expression,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147197", "endSection": "abstract"}, {"offsetInBeginSection": 1065, "offsetInEndSection": 1136, "text": "In addition, costunolide had a slight induced effect on ROS generation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147197", "endSection": "abstract"}, {"offsetInBeginSection": 183, "offsetInEndSection": 472, "text": "This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446899", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 646, "text": "Other G(2)/M regulatory molecules such as Cdc25C, Cdk1, cyclin B1 were down-regulated by DIM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444961", "endSection": "abstract"}, {"offsetInBeginSection": 1422, "offsetInEndSection": 1532, "text": "Blocking ROS generation by N-acetyl cysteine protects the cells from DIM-mediated G(2)/M arrest and apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20444961", "endSection": "abstract"}, {"offsetInBeginSection": 934, "offsetInEndSection": 1404, "text": "Taken together, these findings suggest that emodin mediated oxidative injury (DNA damage) based on ROS production and ER stress based on the levels of GADD153 and GRP78 that acts as an early and upstream change in the cell death cascade to caspase- and mitochondria-dependent signaling pathways, triggers mitochondrial dysfunction from Bcl-2 and Bax modulation, mitochondrial cytochrome c release and caspase activation, consequently leading to apoptosis in SCC-4 cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19331169", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 422, "text": "In this study, treatment of human tongue cancer SCC-4 cells with various concentrations of emodin led to G2/M arrest through promoted p21 and Chk2 expression but inhibited cyclin B1 and cdc2;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19331169", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 473, "text": "Further investigation revealed that plumbagin's inhibition of cell growth was also evident in a nude mice model. Blockade of cell cycle was associated with increased levels of p21, and reduced amounts of cyclin B1, cyclin A, Cdc2, and Cdc25C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18023967", "endSection": "abstract"}, {"offsetInBeginSection": 690, "offsetInEndSection": 793, "text": "We also found the generation of ROS is a critical mediator in plumbagin-induced cell growth inhibition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18023967", "endSection": "abstract"}, {"offsetInBeginSection": 150, "offsetInEndSection": 500, "text": "IOA exhibited effective cell growth inhibition by inducing cancer cells to undergo G(2)-M phase arrest and apoptosis. Further investigation revealed that IOA's inhibition of cell growth was also evident in a nude mice model. Cell cycle blockade was associated with increased levels of p21 and reduced amounts of cyclin B1, cyclin A, cdc2, and cdc25C.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671211", "endSection": "abstract"}, {"offsetInBeginSection": 774, "offsetInEndSection": 902, "text": "We also found that the generation of reactive oxygen species (ROS) is a critical mediator in IOA-induced cell growth inhibition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671211", "endSection": "abstract"}]}, {"body": "What is the genetic basis of propionic acidemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15949719", "http://www.ncbi.nlm.nih.gov/pubmed/10101253", "http://www.ncbi.nlm.nih.gov/pubmed/8023851", "http://www.ncbi.nlm.nih.gov/pubmed/23053474", "http://www.ncbi.nlm.nih.gov/pubmed/22033733", "http://www.ncbi.nlm.nih.gov/pubmed/21986446", "http://www.ncbi.nlm.nih.gov/pubmed/21094621", "http://www.ncbi.nlm.nih.gov/pubmed/20950151", "http://www.ncbi.nlm.nih.gov/pubmed/20549364", "http://www.ncbi.nlm.nih.gov/pubmed/19157943", "http://www.ncbi.nlm.nih.gov/pubmed/19099776", "http://www.ncbi.nlm.nih.gov/pubmed/19025475", "http://www.ncbi.nlm.nih.gov/pubmed/18790721", "http://www.ncbi.nlm.nih.gov/pubmed/17051315", "http://www.ncbi.nlm.nih.gov/pubmed/15464417", "http://www.ncbi.nlm.nih.gov/pubmed/15235904", "http://www.ncbi.nlm.nih.gov/pubmed/15164333", "http://www.ncbi.nlm.nih.gov/pubmed/15059621", "http://www.ncbi.nlm.nih.gov/pubmed/12757933", "http://www.ncbi.nlm.nih.gov/pubmed/12559849", "http://www.ncbi.nlm.nih.gov/pubmed/12409268", "http://www.ncbi.nlm.nih.gov/pubmed/12385775", "http://www.ncbi.nlm.nih.gov/pubmed/12007220", "http://www.ncbi.nlm.nih.gov/pubmed/11914040", "http://www.ncbi.nlm.nih.gov/pubmed/11749052", "http://www.ncbi.nlm.nih.gov/pubmed/11592820", "http://www.ncbi.nlm.nih.gov/pubmed/11245989", "http://www.ncbi.nlm.nih.gov/pubmed/11136555", "http://www.ncbi.nlm.nih.gov/pubmed/10820128", "http://www.ncbi.nlm.nih.gov/pubmed/10502773", "http://www.ncbi.nlm.nih.gov/pubmed/10447268", "http://www.ncbi.nlm.nih.gov/pubmed/10329019", "http://www.ncbi.nlm.nih.gov/pubmed/9887338", "http://www.ncbi.nlm.nih.gov/pubmed/9683601", "http://www.ncbi.nlm.nih.gov/pubmed/9385377", "http://www.ncbi.nlm.nih.gov/pubmed/8188292", "http://www.ncbi.nlm.nih.gov/pubmed/2095843", "http://www.ncbi.nlm.nih.gov/pubmed/2249848", "http://www.ncbi.nlm.nih.gov/pubmed/2154743"], "triples": [], "ideal_answer": "Mutations in the PCCA or PCCB genes, encoding both subunits of propionyl-CoA carboxylase.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056693"], "type": "summary", "id": "5318813ab166e2b806000016", "snippets": [{"offsetInBeginSection": 1, "offsetInEndSection": 128, "text": "utations in the PCCA or PCCB genes coding for alpha and beta subunits of propionyl CoA carboxylase can cause propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15949719", "endSection": "abstract"}, {"offsetInBeginSection": 32, "offsetInEndSection": 228, "text": "propionic acidemia (PA) can result from mutations in either of the genes PCCA or PCCB, which encode the alpha and beta subunits, respectively, of the mitochondrial enzyme propionyl CoA-carboxylase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10101253", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 129, "text": "eficiency of propionyl-CoA carboxylase (PCC; alpha 4 beta 4) results in the rare, autosomal recessive disease propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8023851", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 290, "text": "PA is caused by mutations in either the PCCA or PCCB genes encoding the \u03b1- and \u03b2-subunits of the PCC enzyme ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23053474", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 122, "text": "eficiency of propionyl CoA carboxylase (PCC), a dodecamer of alpha and beta subunits, causes inherited propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22033733", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 466, "text": "Recent studies have identified the genomic mutations in the genes PCCA and PCCB", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21986446", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 77, "text": "ropionic acidemia is an organic acidemia that can lead to metabolic acidosis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21986446", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 184, "text": "plicing defects account for 16% of the mutant alleles in the PCCA and PCCB genes, encoding both subunits of the propionyl-CoA carboxylase (PCC) enzyme, defective in propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21094621", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 137, "text": "ropionic acidemia (PA) is an autosomal recessive disorder of metabolism caused by a deficiency of propionyl-coenzyme A carboxylase (PCC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20950151", "endSection": "abstract"}, {"offsetInBeginSection": 149, "offsetInEndSection": 296, "text": "In the PA patients, we have identified four different changes in the PCCA gene, including one novel one (c.414+5G>A) affecting the splicing process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20549364", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 86, "text": "utations in either the PCCA or PCCB genes are responsible for propionic acidemia (PA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19157943", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 360, "text": "Propionic acidemia is a common organic acidemia, caused by deficiency of propionyl-CoA carboxylase (PCC), which catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a dodecameric enzyme of alpha-PCC and beta-PCC subunits, nuclearly encoded by genes PCCA and PCCB, respectively. Mutation in either gene cause propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19099776", "endSection": "abstract"}, {"offsetInBeginSection": 115, "offsetInEndSection": 272, "text": "PA is inherited in an autosomal recessive fashion involving mutations in PCCA or PCCB encoding the alpha and beta subunits of propionyl-CoA carboxylase (PCC)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19025475", "endSection": "abstract"}, {"offsetInBeginSection": 478, "offsetInEndSection": 656, "text": "Two siblings affected with propionic acidemia were screened for putative mutations in PCCA and PCCB genes coding alpha and beta subunits of propionyl-coenzyme A (CoA) carboxylase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18790721", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 158, "text": "ropionic acidemia results from mutations in either of the two genes, PCCA or PCCB, that encode the two subunits of the propionyl-CoA carboxylase (PCC) enzyme", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17051315", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 118, "text": "utations in the PCCA or PCCB genes, encoding both subunits of propionyl-CoA carboxylase, result in propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15464417", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 273, "text": " we analyze splicing mutations identified in propionic acidemia patients to clarify their functional effects and their involvement in the disease phenotype. Two mutations in the PCCA gene detected in homozygous patients and involving consensus splice sequences ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15235904", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 324, "text": "An enzyme deficiency can result from mutations in either PCCA or PCCB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059621", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 122, "text": "(PA) is an inborn error of organic acid metabolism caused by a deficiency of propionyl-CoA carboxylase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15059621", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 391, "text": "Mutations in either gene cause PA and to date, up to 47 different allelic variations in the PCCB gene have been identified in different population", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757933", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 184, "text": "ropionic acidemia (PA) is a recessive disorder caused by a deficiency of propionyl-CoA carboxylase (PCC), a dodecameric enzyme composed of two different proteins alpha-PCC and beta-PC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12757933", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 412, "text": "PCC is a multimeric protein composed of two different alpha- and beta-PCC subunits, nuclearly encoded by the PCCA and PCCB genes, respectively. Mutations in either gene cause the clinically heterogeneous disease propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12559849", "endSection": "abstract"}, {"offsetInBeginSection": 564, "offsetInEndSection": 641, "text": "More than 24 mutations have been found in the PCCA gene in patients with PA, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12385775", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 272, "text": "ropionic acidemia (PA, MIM 232000 and 232050) is caused by a deficiency of mitochondrial biotin-dependent propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a heteropolymeric enzyme composed of alpha and beta subunits, which are encoded by the PCCA and PCCB genes, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12385775", "endSection": "abstract"}, {"offsetInBeginSection": 447, "offsetInEndSection": 560, "text": "Approximately 60 mutations have been reported in the nuclear genes PCCA and PCCB that encode the two PCC subunits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12007220", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 75, "text": "eficiency of propionyl-CoA carboxylase (PCC) results in propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12007220", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 107, "text": "ropionic acidemia can result from mutations in the PCCA or PCCB genes encoding the alpha and beta subunits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11914040", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 170, "text": "ropionic acidemia is an inherited metabolic disorder caused by deficiency of propionyl-CoA carboxylase, a dodecameric enzyme composed of alpha-PCC and beta-PCC subunits ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11749052", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 677, "text": "A genetic deficiency of PCC activity causes propionic acidemia, a potentially fatal disease with onset in severe cases in the newborn period. Affected patients may have mutations of either the PCCA or PCCB gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592820", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 358, "text": "PCC is composed of two equal subunits, alpha and beta, which are encoded by two separate genes at two distinct human loci. Mutations of either gene in humans results in propionic acidemia (PA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11245989", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 349, "text": "Deficiency of PCC results in propionic acidemia (PA), a metabolic disorder", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11136555", "endSection": "abstract"}, {"offsetInBeginSection": 164, "offsetInEndSection": 353, "text": " PCC consists of two subunits, alpha and beta, encoded by the PCCA and PCCB genes, respectively. Inherited PCC deficiency due to mutations in either gene results in propionic acidemia (PA),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10820128", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 75, "text": "mutations in the PCCA and PCCB genes causing propionic acidemia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10502773", "endSection": "title"}, {"offsetInBeginSection": 98, "offsetInEndSection": 226, "text": "Mutations in the PCCA and PCCB genes, which encode the a and b subunits of this heteropolymer, result in propionic acidemia (PA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10447268", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 254, "text": "ropionic acidemia is a rare autosomal recessive disorder of intermediary metabolism. It is caused by a deficiency of the mitochondrial enzyme propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a heteropolymeric protein composed of two subunits, alpha and beta", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10329019", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 222, "text": "ropionic acidemia is an autosomal recessive disorder caused by a deficiency in the mitochondrial enzyme propionyl-CoA carboxylase (PCC). PCC is composed of two subunits, alpha and beta, encoded by the PCCA and PCCB genes,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9887338", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 1534, "text": "Propionyl-CoA carboxylase (PCC) is a mitochondrial biotin-dependent enzyme composed of an equal number of alpha and beta subunits. Mutations in the PCCA (alpha subunit) or PCCB (beta subunit) gene can cause the inherited metabolic disease propionic acidemia (PA), which can be life threatening in the neonatal period. Lack of data on the genomic structure of PCCB has been a significant impediment to full characterization of PCCB mutant chromosomes. In this study, we describe the genomic organization of the coding sequence of the human PCCB gene and the characterization of mutations causing PA in a total of 29 unrelated patients-21 from Spain and 8 from Latin America. The implementation of long-distance PCR has allowed us to amplify the regions encompassing the exon/intron boundaries and all the exons. The gene consists of 15 exons of 57-183 bp in size. All splice sites are consistent with the gt/ag rule. The availability of the intron sequences flanking each exon has provided the basis for implementation of screening for mutations in the PCCB gene. A total of 56/58 mutant chromosomes studied have been defined, with a total of 16 different mutations detected. The mutation spectrum includes one insertion/deletion, two insertions, 10 missense mutations, one nonsense mutation, and two splicing defects. Thirteen of these mutations correspond to those not described yet in other populations. The mutation profile found in the chromosomes from the Latin American patients basically resembles that of the Spanish patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9683601", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 401, "text": "Inherited deficiency of PCC due to mutations in either the PCCA or the PCCB gene results in propionic acidemia (PA)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9385377", "endSection": "abstract"}, {"offsetInBeginSection": 219, "offsetInEndSection": 342, "text": "Mutations of the PCCA (alpha subunit) or PCCB (beta subunit) gene cause the inherited metabolic disease, propionic acidemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8188292", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 244, "text": "We have detected three types of mutation in the same exon of the coding sequence of beta-subunit of PCC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2095843", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 114, "text": "ropionic acidemia is an inborn error of organic acid metabolism caused by deficiency of propionyl-CoA carboxylase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2095843", "endSection": "abstract"}, {"offsetInBeginSection": 314, "offsetInEndSection": 395, "text": "we have identified two mutations of the PCCB gene in a propionic acidemia patient", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2249848", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 321, "text": "ropionic acidemia is an inherited disorder of organic acid metabolism that is caused by deficiency of propionyl-CoA carboxylase (PCC; EC 6.4.1.3). Affected patients fall into two complementation groups, pccA and pccBC (subgroups B, C, and BC), resulting from deficiency of the nonidentical alpha and beta subunits of PCC", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2154743", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 62, "text": "ropionic acidemia (PA) is an autosomal recessive inborn error", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12409268", "endSection": "abstract"}, {"offsetInBeginSection": 288, "offsetInEndSection": 345, "text": "It is caused by a deficiency of propionyl-CoA carboxylase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12409268", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 534, "text": "PCC is a heteropolymeric enzyme composed of alpha- and beta-subunits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12409268", "endSection": "abstract"}, {"offsetInBeginSection": 735, "offsetInEndSection": 890, "text": "Mutation analysis confirmed the diagnosis of propionic acidemia (PA) with compound heterozygosity for 2 new missense mutations L417W/Q293E in the PCCA gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15164333", "endSection": "abstract"}]}, {"body": "Which deficiency is the cause of restless leg syndrome", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23940258", "http://www.ncbi.nlm.nih.gov/pubmed/22486183", "http://www.ncbi.nlm.nih.gov/pubmed/22377249", "http://www.ncbi.nlm.nih.gov/pubmed/21358851", "http://www.ncbi.nlm.nih.gov/pubmed/21211209", "http://www.ncbi.nlm.nih.gov/pubmed/20814842", "http://www.ncbi.nlm.nih.gov/pubmed/20598107", "http://www.ncbi.nlm.nih.gov/pubmed/19935988", "http://www.ncbi.nlm.nih.gov/pubmed/19467991", "http://www.ncbi.nlm.nih.gov/pubmed/19081645", "http://www.ncbi.nlm.nih.gov/pubmed/19039990", "http://www.ncbi.nlm.nih.gov/pubmed/18360657", "http://www.ncbi.nlm.nih.gov/pubmed/16982219", "http://www.ncbi.nlm.nih.gov/pubmed/12530992", "http://www.ncbi.nlm.nih.gov/pubmed/11310286", "http://www.ncbi.nlm.nih.gov/pubmed/8363978"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:0050425", "o": "MSH:D012148"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:0050425", "o": "restless legs syndrome"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:0050425", "o": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:331"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:331", "o": "central nervous system disease"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:0050425", "o": "restless legs syndrome"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A11938025", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11938025", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11966695", "o": "RLS2"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11966695"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A11966695", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11938025", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11966695", "o": "RLS2"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11966695"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A11938025", "o": "608831"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11938025", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11966695", "o": "RLS2"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11966695"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A11966695", "o": "608831"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11938025", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 2"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A11966695", "o": "RLS2"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11966695"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1837285", "o": "http://linkedlifedata.com/resource/umls/label/A11938025"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17462703", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466336", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462703", "o": "RLS7"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17462703"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17466336"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A17466336", "o": "OMIM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466336", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462703", "o": "RLS7"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17462703"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17466336"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17462703", "o": "612853"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466336", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462703", "o": "RLS7"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17462703"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17466336"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17466336", "o": "612853"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17466336", "o": "RESTLESS LEGS SYNDROME, SUSCEPTIBILITY TO, 7"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17462703", "o": "RLS7"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17462703"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2748506", "o": "http://linkedlifedata.com/resource/umls/label/A17466336"}], "ideal_answer": "Iron deficiency (low serum ferritin) is a recognized cause for RLS. Further, in the striatum of subjects with restless legs syndrome, the dopamine transporter is decreased, which leads to impaired dopaminergic neurotransmission. There is also a report of magnesium deficiency underlying RLS.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012148"], "type": "summary", "id": "52f89a002059c6d71c00004c", "snippets": [{"offsetInBeginSection": 914, "offsetInEndSection": 1003, "text": "Homozygosity for the T-allele of BTBD9 rs9296249 was associated with lower serum ferritin", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22486183", "endSection": "abstract"}, {"offsetInBeginSection": 1272, "offsetInEndSection": 1371, "text": "This polymorphism has previously been associated with RLS, but not low iron stores in blood donors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22486183", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 476, "text": "Iron deficiency is a common cause of anemia in patients with end stage renal disease (ESRD). Intravenous iron administration, especially in those requiring treatment with erythropoiesis stimulating agents (ESA) is an essential component of the management of anemia in ESRD patients. Iron improves hemoglobin, reduces ESA dose requirement and also has nonerythropoietic effects including improvement in physical performance, cognition and amelioration of restless leg syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22377249", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358851", "endSection": "title"}, {"offsetInBeginSection": 868, "offsetInEndSection": 990, "text": "RLS subjects had significantly lower DAT binding in the striatum compared to controls on both the Day and the Night scans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358851", "endSection": "abstract"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1030, "text": "Secondary RLS is a complication of PD. Deficiency of iron and decreased inhibition function of spinal cord may lead to the occurrence of RLS in PD patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21211209", "endSection": "abstract"}, {"offsetInBeginSection": 538, "offsetInEndSection": 690, "text": "Association of iron deficiency with febrile seizures, pica, breath holding spells, restless leg syndrome and thrombosis is increasingly being recognized", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20814842", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 310, "text": "Iron depletion is common in regular blood donors. The objective of the study was to investigate the frequency and severity of iron depletion in regular blood donors and whether IV iron is more effective than oral to avoid iron depletion and symptoms thereof, especially restless legs syndrome (RLS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20598107", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1295, "text": "Iron status is poor in regular blood donors, restless legs syndrome is common,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20598107", "endSection": "abstract"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1365, "text": "Furthermore, there appears to be an association between iron deficiency and those suffering from Restless Leg Syndrome (RLS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19935988", "endSection": "abstract"}, {"offsetInBeginSection": 56, "offsetInEndSection": 209, "text": "Clinical studies have implicated the dopaminergic system in RLS, while others have suggested that it is associated with insufficient levels of brain iron", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19467991", "endSection": "abstract"}, {"offsetInBeginSection": 10, "offsetInEndSection": 119, "text": " Iron deficiency is associated with paediatric sleep disturbances; in particular, restless leg syndrome (RLS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081645", "endSection": "abstract"}, {"offsetInBeginSection": 160, "offsetInEndSection": 957, "text": "Here we described seven pediatric RLS patients. All of the parents of our patients had difficult times to make their children sleep due to irritability, restlessness, and demanding bedtime routines. All patients had asked their parents to rub their feet in bed, and it took more than half an hour to soothe them until they fell asleep. Their mothers had been exhausted from this night-time routine. However, they did not consider the routine abnormal, as it had been their habitual behavior since infancy. Some parents were too distressed or embarrassed to describe the symptoms of their child properly. Five patients had clear family history and none had obvious periodic leg movements during sleep. All patients showed low levels of ferritin and iron supplementation was effective in five cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19039990", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 608, "text": "RLS may also be secondary to a number of conditions including iron deficiency, pregnancy and end-stage renal failure and, perhaps, neuropathy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18360657", "endSection": "abstract"}, {"offsetInBeginSection": 692, "offsetInEndSection": 860, "text": "The pathogenesis of RLS probably involves the interplay of systemic or brain iron deficiency and impaired dopaminergic neurotransmission in the subcortex of the brain. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18360657", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Restless leg syndrome manifested by iron deficiency from chronic hemoptysis in cystic fibrosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16982219", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are considered to be a continuum of a neurological sleep disorder associated with abnormal iron metabolism or deficiency. I describe a case of RLS and PLMD in a cystic fibrosis patient with iron deficiency from chronic hemoptysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16982219", "endSection": "abstract"}, {"offsetInBeginSection": 755, "offsetInEndSection": 974, "text": "Iron deficiency in the central nervous system is known to cause motor impairment and cognitive deficits; more recently, it has been suggested that it may play a role in the pathophysiology of the restless leg syndrome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12530992", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 662, "text": "The syndrome is increasingly often diagnosed, particularly in association with iron deficiency, during pregnancy, in chronic renal failure and in patients with peripheral neuropathy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11310286", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Clinical, EEG, electromyographic and polysomnographic studies in restless legs syndrome caused by magnesium deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8363978", "endSection": "title"}]}, {"body": "What is Piebaldism?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23786947", "http://www.ncbi.nlm.nih.gov/pubmed/23016555", "http://www.ncbi.nlm.nih.gov/pubmed/23130293", "http://www.ncbi.nlm.nih.gov/pubmed/22670867", "http://www.ncbi.nlm.nih.gov/pubmed/22438235", "http://www.ncbi.nlm.nih.gov/pubmed/21382296", "http://www.ncbi.nlm.nih.gov/pubmed/20676476", "http://www.ncbi.nlm.nih.gov/pubmed/20137753", "http://www.ncbi.nlm.nih.gov/pubmed/12204004", "http://www.ncbi.nlm.nih.gov/pubmed/11174389", "http://www.ncbi.nlm.nih.gov/pubmed/7525736", "http://www.ncbi.nlm.nih.gov/pubmed/7529964"], "triples": [], "ideal_answer": ["Piebaldism is a rare autosomal dominant disorder of melanocyte development characterized by a congenital white forelock and multiple symmetrical stable hypopigmented or depigmented macules."], "exact_answer": [["Piebaldism is a rare autosomal dominant disorder of melanocyte development characterized by a congenital white forelock and multiple symmetrical stable hypopigmented or depigmented macules."]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016116"], "type": "factoid", "id": "54fc4e2e6ea36a810c000003", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 139, "text": "Human piebaldism is a rare autosomal dominant condition characterized by congenital white forelock and depigmented patches of s", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23786947", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Piebaldism is a rare genodermatosis caused by KIT mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23016555", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Piebaldism is a rare autosomal dominant disorder of melanocyte development characterized by a congenital white forelock and multiple symmetrical stable hypopigmented or depigmented macules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23130293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 188, "text": "Piebaldism is an autosomal dominant disorder characterized by congenital hypopigmented patches of skin and hair and has been found to be associated with mutations in the KIT or SLUG genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438235", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "Piebaldism is a rare autosomal dominant skin disorder characterized by a white forelock and depigmented patches of skin, generally located on the forehead, central chest and abdomen, upper arms, and lower extremities. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382296", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Piebaldism is a rare genodermatosis in which depigmented skin areas are unresponsive to topical or light treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20676476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "Piebaldism is a rare disorder present at birth and inherited as an autosomal dominant trait. It results from a mutation in the c-kit proto-oncogene and is associated with a defect in the migration and differentiation of melanoblasts from the neural crest. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20137753", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 278, "text": "Piebaldism is an autosomal dominant genetic disorder of pigmentation characterized by white patches of skin and hair. Melanocytes are lacking in these hypopigmented regions, the result of mutations of the KIT gene, which encodes the cell surface receptor for steel factor (SLF).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7529964", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 436, "text": "Piebaldism is an autosomal dominant genetic disorder of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes. Piebaldism results from mutations of the KIT proto-oncogene, which encodes the cell-surface receptor transmembrane tyrosine kinase for an embryonic growth factor, Steel factor. Several pathologic mutations of the KIT gene have now been identified in different patients with piebaldism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7525736", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Piebaldism is an autosomal dominant disorder of melanocyte development characterized by white skin (leukoderma) and white hair (poliosis).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11174389", "endSection": "abstract"}]}, {"body": "What is Tarlov Cyst?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25216402", "http://www.ncbi.nlm.nih.gov/pubmed/25191117", "http://www.ncbi.nlm.nih.gov/pubmed/23400656", "http://www.ncbi.nlm.nih.gov/pubmed/21830055", "http://www.ncbi.nlm.nih.gov/pubmed/11453427", "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "http://www.ncbi.nlm.nih.gov/pubmed/21139800", "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "http://www.ncbi.nlm.nih.gov/pubmed/10758434", "http://www.ncbi.nlm.nih.gov/pubmed/19110185", "http://www.ncbi.nlm.nih.gov/pubmed/20712856"], "triples": [], "ideal_answer": ["Tarlov or perineural cysts are nerve root cysts found most commonly at the sacral spine level arising between covering layers of the perineurium and the endoneurium near the dorsal root ganglion and are usually asymptomatic."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052958"], "type": "summary", "id": "56c1d848ef6e39474100002f", "snippets": [{"offsetInBeginSection": 753, "offsetInEndSection": 975, "text": "She underwent ultrasound, CT, and eventually MRI evaluations that led to the diagnosis of a giant (6.7 \u00d7 6.4 \u00d7 6.6 cm) Tarlov cyst originating from the right S-2 nerve root sleeve/sacral foramen with intrapelvic extension.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25216402", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 261, "text": "We report here a case of multiloculated disseminated perineural or Tarlov cysts (TCs). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191117", "endSection": "abstract"}, {"offsetInBeginSection": 865, "offsetInEndSection": 941, "text": "TCs are typically benign, asymptomatic lesions that can simply be monitored.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25191117", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Tarlov cyst syndrome is a rare, often asymptomatic disorder, characterised by isolated or multiple nerve-root cysts, usually occurring in the sacral spine, near the dorsal root ganglion, between the perineurium and endoneurium. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Perineural (Tarlov) cysts are most often found in the sacral region and are rare in the cervical spine. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21830055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "A case of symptomatic cervical perineural (Tarlov) cyst: clinical manifestation and management.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21830055", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Tarlov cysts or spinal perineurial cysts are uncommon lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Tarlov cyst syndrome is a rare, often asymptomatic disorder, characterised by isolated or multiple nerve-root cysts, usually occurring in the sacral spine, near the dorsal root ganglion, between the perineurium and endoneurium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400656", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Symptomatic sacral perineurial (Tarlov) cysts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "title"}, {"offsetInBeginSection": 668, "offsetInEndSection": 824, "text": "Subsequent MRI and CT myelography demonstrated the nature of the photopenic area as secondary to vertebral erosion by sacral perineurial cyst (Tarlov cyst).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10758434", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 202, "text": "Tarlov cysts are sacral perineural cysts. This case report describes the clinical course after biopsy of a very large Tarlov cyst via laparoscopy, which was thought preoperatively to be an adnexal mass.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110185", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 673, "text": "Subsequent MRI and CT myelography demonstrated the nature of the photopenic area as secondary to vertebral erosion by sacral perineurial cyst (Tarlov cyst).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10758434", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 563, "text": "A spinal MRI scan was then performed and revealed a sacral fracture which drained into an unknown perineurial cyst (Tarlov cyst).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20712856", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "Tarlov or perineurial cysts are lesions of the nerve root most often found in the sacral region. Although there is agreement that asymptomatic Tarlov cysts should be followed, it is still debated whether patients with symptomatic Tarlov cysts should be treated surgically.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11453427", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 287, "text": "Tarlov cysts (sacral perineural cysts) are nerve root cysts found most commonly in the sacral roots,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21139800", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Tarlov cysts or spinal perineurial cysts are uncommon lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Tarlov cysts or spinal perineurial cysts are uncommon lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Symptomatic sacral perineurial (Tarlov) cysts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Sacral perineurial (Tarlov) cysts are rare lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Tarlov cysts or spinal perineurial cysts are uncommon lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Symptomatic sacral perineurial (Tarlov) cysts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Sacral perineurial (Tarlov) cysts are rare lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Tarlov cysts or spinal perineurial cysts are uncommon lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Symptomatic sacral perineurial (Tarlov) cysts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Sacral perineurial (Tarlov) cysts are rare lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Tarlov cysts or spinal perineurial cysts are uncommon lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19569467", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "Symptomatic sacral perineurial (Tarlov) cysts.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102100", "endSection": "title"}]}, {"body": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23441899", "http://www.ncbi.nlm.nih.gov/pubmed/22119380", "http://www.ncbi.nlm.nih.gov/pubmed/22075452", "http://www.ncbi.nlm.nih.gov/pubmed/21903118", "http://www.ncbi.nlm.nih.gov/pubmed/21672583", "http://www.ncbi.nlm.nih.gov/pubmed/20447431", "http://www.ncbi.nlm.nih.gov/pubmed/19593760", "http://www.ncbi.nlm.nih.gov/pubmed/19423954", "http://www.ncbi.nlm.nih.gov/pubmed/18855935", "http://www.ncbi.nlm.nih.gov/pubmed/17727839", "http://www.ncbi.nlm.nih.gov/pubmed/17310075", "http://www.ncbi.nlm.nih.gov/pubmed/16960421", "http://www.ncbi.nlm.nih.gov/pubmed/16497099", "http://www.ncbi.nlm.nih.gov/pubmed/15878358", "http://www.ncbi.nlm.nih.gov/pubmed/16495765", "http://www.ncbi.nlm.nih.gov/pubmed/16842776", "http://www.ncbi.nlm.nih.gov/pubmed/15703202", "http://www.ncbi.nlm.nih.gov/pubmed/15678087", "http://www.ncbi.nlm.nih.gov/pubmed/15556149", "http://www.ncbi.nlm.nih.gov/pubmed/15231867", "http://www.ncbi.nlm.nih.gov/pubmed/11877314", "http://www.ncbi.nlm.nih.gov/pubmed/11408549"], "triples": [], "ideal_answer": ["SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), is a selective NCX inhibitor in vivo.", "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.  ", "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.  ", "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.  ", "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.  ", "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.  "], "exact_answer": [["Na(+)/Ca(2+) exchanger", "NCX"]], "concepts": [], "type": "factoid", "id": "5506c3e38e1671127b00000a", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 341, "text": "The plasma membrane Na(+)/Ca(2+) exchanger (NCX) is a bidirectional ion transporter that couples the translocation of Na(+) in one direction with that of Ca(2+) in the opposite direction. This system contributes to the regulation of intracellular Ca(2+) concentration via the forward mode (Ca(2+) efflux) or the reverse mode (Ca(2+) influx).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23441899", "endSection": "abstract"}, {"offsetInBeginSection": 891, "offsetInEndSection": 1161, "text": "Concerning the role of NCX in NO cytotoxicity, we have found, using the specific inhibitor of NCX 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400), that NCX is involved in NO-induced cytotoxicity in cultured microglia, astrocytes, and neuronal cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23441899", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 496, "text": "The Na(+)/Ca(2+)exchanger (NCX) principal function is taking 1 Ca(2+) out of the cytoplasm and introducing 3 Na(+). The increase of cytoplasmic Na(+) concentration induces the NCX reverse mode (NCX(REV)), favoring Ca(2+) influx. NCX(REV) can be inhibited by: KB-R7943 a non-specific compound that blocks voltage-dependent and store-operated Ca(2+) channels; SEA0400 that appears to be selective for NCX(REV), but difficult to obtain and SN-6, which efficacy has been shown only in cardiomyocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119380", "endSection": "abstract"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1187, "text": "SEA0400 (1 \u03bcM), a pharmacological inhibitor of NCX, significantly shortened the MAP duration (P < .01) and reduced dispersion (P < .05). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22075452", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 575, "text": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903118", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 626, "text": "The Na(+)/Ca(2+) exchanger (NCX) plays a role in the regulation of intracellular Ca(2+) levels, and nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, causes apoptotic-like cell death in cultured glial cells via NCX-mediated pathways and the mechanism for NO-induced cytotoxicity is cell type-dependent. The present study examined using the specific NCX inhibitor 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) whether NCX is involved in NO-induced injury in cultured neuronal cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672583", "endSection": "abstract"}, {"offsetInBeginSection": 396, "offsetInEndSection": 690, "text": "In view of the previous observation that NO stimulates the activity of the Na(+)/Ca(2+) exchanger (NCX), this study examines the involvement of NCX in cytotoxicity. The specific NCX inhibitor SEA0400 blocked SNP-induced phosphorylation of ERK, JNK and p38 MAPK, and decrease in cell viability. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20447431", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 533, "text": "The sodium-calcium exchanger (NCX) is one of the transporters contributing to the control of intracellular calcium (Ca(2+)) concentration by normally mediating net Ca(2+) efflux. However, the reverse mode of the NCX can cause intracellular Ca(2+) concentration overload, which exacerbates the myocardial tissue injury resulting from ischemia. Although the NCX inhibitor SEA0400 has been shown to therapeutically reduce myocardial injury, no in vivo technique exists to monitor intracellular Ca(2+) fluctuations produced by this drug.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19593760", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "We examined the involvement of the Na(+)/Ca(2+) exchanger in the automaticity of the pulmonary vein myocardium with a specific inhibitor, SEA0400.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19423954", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18855935", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727839", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "Involvement of the Na+/Ca2+ exchanger in ouabain-induced inotropy and arrhythmogenesis was examined with a specific inhibitor, SEA0400.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17310075", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 431, "text": "In right ventricular papillary muscle isolated from guinea-pig ventricle, 1 microM SEA0400, which specifically inhibits the Na+/Ca2+ exchanger by 80%, reduced the ouabain (1 microM)-induced positive inotropy by 40%, but had no effect on the inotropy induced by 100 microM isobutyl methylxantine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17310075", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 389, "text": "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 482, "text": "Given the potential clinical benefit of inhibiting Na+/Ca2+ exchanger (NCX) activity during myocardial ischemia reperfusion (I/R), pharmacological approaches have been pursued to both inhibit and clarify the importance of this exchanger. SEA0400 was reported to have a potent NCX selectivity. Thus, we examined the effect of SEA0400 on NCX currents and I/R induced intracellular Ca2+ overload in mouse ventricular myocytes using patch clamp techniques and fluorescence measurements.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497099", "endSection": "abstract"}, {"offsetInBeginSection": 1207, "offsetInEndSection": 1349, "text": "The results suggested that SEA0400 is a potent NCX inhibitor, which can protect mouse cardiac myocytes from Ca2+ overload during I/R injuries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "The effect of SEA0400, a novel Na+-Ca2+ exchanger inhibitor, on mechanical and electrophysiological parameters of coronary-perfused guinea-pig right ventricular tissue preparation was examined during no-flow ischemia and reperfusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15878358", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 286, "text": "The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16495765", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "The cardioprotective effects of SEA0400, a novel Na(+)-Ca(2+) exchanger inhibitor, were examined in isolated guinea pig myocardial tissue and ventricular myocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16842776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 403, "text": "The effects of a new, potent, and selective inhibitor of the Na(+)/Ca(2+) exchange, SEA-0400 (SEA), on steady-state outward (forward exchange), inward (reverse exchange), and Ca(2+)/Ca(2+) transport exchange modes were studied in internally dialyzed squid giant axons from both the extra- and intracellular sides. Inhibition by SEA takes place preferentially from the intracellular side of the membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15703202", "endSection": "abstract"}, {"offsetInBeginSection": 3, "offsetInEndSection": 256, "text": "Using SEA0400, a potent and selective inhibitor of the Na+-Ca2+ exchanger (NCX), we examined whether NCX is involved in nitric oxide (NO)-induced disturbance of endoplasmic reticulum (ER) Ca2+ homeostasis followed by apoptosis in cultured rat microglia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15678087", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "Activation of the Na+/Ca2+ exchanger may contribute to Ca2+ overload during reperfusion after transient ischemia. We examined the effects of 2-[4-[(2,5-difluorophenyl) methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a selective inhibitor of Na+/Ca2+ exchange, on a canine model of ischemia/reperfusion injury (myocardial stunning).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15556149", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 392, "text": "SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline) has recently been described as a potent and selective inhibitor of Na(+)-Ca(2+) exchange in cardiac, neuronal, and renal preparations. The inhibitory effects of SEA0400 were investigated on the cloned cardiac Na(+)-Ca(2+) exchanger, NCX1.1, expressed in Xenopus laevis oocytes to gain insight into its inhibitory mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231867", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 780, "text": "The effects of 2-[4-[(2,5-difluorophenyl) methoxy]phenoxy]-5-ethoxyaniline (SEA0400), a newly synthesized Na(+)-Ca(2+) exchanger (NCX) inhibitor, on the NCX current and other membrane currents were examined in isolated guinea-pig ventricular myocytes and compared with those of 2-[2-[4-(4-nitrobenzyloxy) phenyl]ethyl]isothiourea (KB-R7943). SEA0400 concentration-dependently inhibited the NCX current with a 10 fold higher potency than that of KB-R7943; 1 microM SEA0400 and 10 microM KB-R7943 inhibited the NCX current by more than 80%. KB-R7943, at 10 microM, inhibited the sodium current, L-type calcium current, delayed rectifier potassium current and inwardly rectifying potassium current by more than 50%, but SEA0400 (1 microM) had no significant effect on these currents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877314", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 997, "text": "These results indicate that SEA0400 is a potent and highly selective inhibitor of NCX, and would be a powerful tool for further studies on the role of NCX in the heart and the therapeutic potential of its inhibition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877314", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "The effect of the newly synthesized compound 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) on the Na+-Ca2+ exchanger (NCX) was investigated and compared against that of 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (KB-R7943).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408549", "endSection": "abstract"}, {"offsetInBeginSection": 255, "offsetInEndSection": 850, "text": "In addition, the effects of SEA0400 on reperfusion injury in vitro and in vivo were examined. SEA0400 was extremely more potent than KB-R7943 in inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia: IC50s of SEA0400 and KB-R7943 were 5 to 33 nM and 2 to 4 microM, respectively. SEA0400 at the concentration range that inhibited NCX exhibited negligible affinities for the Ca2+ channels, Na+ channels, K+ channels, norepinephrine transporter, and 14 receptors, and did not affect the activities of the Na+/H+ exchanger, Na+,K+-ATPase, Ca2+-ATPase, and five enzymes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408549", "endSection": "abstract"}, {"offsetInBeginSection": 1340, "offsetInEndSection": 1515, "text": "These results indicate that SEA0400 is the most potent and selective inhibitor of NCX, and suggest that the compound may exert protective effects on postischemic brain damage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11408549", "endSection": "abstract"}]}, {"body": "How are human accelerated regions (HAR) defined?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22412940", "http://www.ncbi.nlm.nih.gov/pubmed/22075116", "http://www.ncbi.nlm.nih.gov/pubmed/20502635", "http://www.ncbi.nlm.nih.gov/pubmed/16915236", "http://www.ncbi.nlm.nih.gov/pubmed/20179156"], "ideal_answer": ["Human accelerated regions (HAR) are defined as previously slowly evolving regions of the genome that have evolved most quickly along the human lineage. These represent genomic regions that are conserved among vertebrates but have accumulated substitutions on the human lineage at an accelerated rate."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012045"], "type": "summary", "id": "51603912298dcd4e5100003b", "snippets": [{"offsetInBeginSection": 344, "offsetInEndSection": 419, "text": "regions in the human genome that show significant evolutionary acceleration", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16915236", "endSection": "sections.0"}, {"offsetInBeginSection": 432, "offsetInEndSection": 576, "text": "This identified Human Accelerated Region 1 (HAR1), a rapidly-evolving cis-antisense locus that is specifically transcribed in the nervous system", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20179156", "endSection": "sections.0"}, {"offsetInBeginSection": 320, "offsetInEndSection": 419, "text": "We devised a ranking of regions in the human genome that show significant evolutionary acceleration", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16915236", "endSection": "sections.0"}]}, {"body": "What is the idea behind the fractal globule that has been proposed as a model of chromatin conformation in the nucleus of a cell?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23781815", "http://www.ncbi.nlm.nih.gov/pubmed/22988072", "http://www.ncbi.nlm.nih.gov/pubmed/21274616", "http://www.ncbi.nlm.nih.gov/pubmed/20461051", "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "http://www.ncbi.nlm.nih.gov/pubmed/22370293"], "triples": [], "ideal_answer": ["The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10 Mb (Lieberman-Aiden et al. 2009). The fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus is distinct from the more commonly used globular equilibrium model and emphasizes topological constraints as a primary factor driving formation of chromosomal territories.", "The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10\u00a0Mb (Lieberman-Aiden et al. 2009).  The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse. This state has gained renewed interest as one of the prime candidates for the non-entangled states of DNA molecules inside cell nuclei  ", "The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10\u00a0Mb (Lieberman-Aiden et al. 2009).  The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse. This state has gained renewed interest as one of the prime candidates for the non-entangled states of DNA molecules inside cell nuclei  ", "The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10\u00a0Mb (Lieberman-Aiden et al. 2009).  The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse. This state has gained renewed interest as one of the prime candidates for the non-entangled states of DNA molecules inside cell nuclei  ", "The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10\u00a0Mb (Lieberman-Aiden et al. 2009).  The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse. This state has gained renewed interest as one of the prime candidates for the non-entangled states of DNA molecules inside cell nuclei  ", "The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10\u00a0Mb (Lieberman-Aiden et al. 2009).  The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse. This state has gained renewed interest as one of the prime candidates for the non-entangled states of DNA molecules inside cell nuclei  "], "concepts": [], "type": "summary", "id": "5544e4635beec11c10000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 321, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse. This state has gained renewed interest as one of the prime candidates for the non-entangled states of DNA molecules inside cell nuclei", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 904, "text": "Additionally, the strings and binders switch model reproduces the recently proposed \"fractal-globule\" model, but only as one of many possible transient conformations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22988072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 629, "text": "The fractal globule is a compact polymer state that emerges during polymer condensation as a result of topological constraints which prevent one region of the chain from passing across another one. This long-lived intermediate state was introduced in 1988 (Grosberg et al. 1988) and has not been observed in experiments or simulations until recently (Lieberman-Aiden et al. 2009). Recent characterization of human chromatin using a novel chromosome conformational capture technique brought the fractal globule into the spotlight as a structural model of human chromosome on the scale of up to 10\u00a0Mb (Lieberman-Aiden et al. 2009).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21274616", "endSection": "abstract"}, {"offsetInBeginSection": 923, "offsetInEndSection": 1341, "text": "Next, we connect the fractal globule to recent studies that emphasize topological constraints as a primary factor driving formation of chromosomal territories. We discuss how theoretical predictions, made on the basis of the fractal globule model, can be tested experimentally. Finally, we discuss whether fractal globule architecture can be relevant for chromatin packing in other organisms such as yeast and bacteria", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21274616", "endSection": "abstract"}, {"offsetInBeginSection": 2260, "offsetInEndSection": 2482, "text": "Finally, ensemble analysis of the contact matrix, coupled with theoretical derivations and computational simulations, revealed that at the megabase scale Hi-C reveals features consistent with a fractal globule conformation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20461051", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 965, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus. The fractal globule is distinct from the more commonly used globular equilibrium model. Our results demonstrate the power of Hi-C to map the dynamic conformations of whole genomes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 781, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 1616, "offsetInEndSection": 1765, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 781, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 1616, "offsetInEndSection": 1765, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 781, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 1616, "offsetInEndSection": 1765, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 548, "offsetInEndSection": 781, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 1616, "offsetInEndSection": 1765, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 785, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 1628, "offsetInEndSection": 1776, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 785, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 784, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 1628, "offsetInEndSection": 1776, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 784, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 1628, "offsetInEndSection": 1776, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 784, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}, {"offsetInBeginSection": 1628, "offsetInEndSection": 1776, "text": "The existence of these power-laws could facilitate the formation of the recently proposed \"fractal globule\" for the confined chromatin organization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22370293", "endSection": "abstract"}, {"offsetInBeginSection": 553, "offsetInEndSection": 784, "text": "At the megabase scale, the chromatin conformation is consistent with a fractal globule, a knot-free, polymer conformation that enables maximally dense packing while preserving the ability to easily fold and unfold any genomic locus", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "The fractal globule, a self-similar compact polymer conformation where the chain is spatially segregated on all length scales, has been proposed to result from a sudden polymer collapse", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23781815", "endSection": "abstract"}]}, {"body": "What is the role of invadopodia in EMT?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24086398", "http://www.ncbi.nlm.nih.gov/pubmed/23991004", "http://www.ncbi.nlm.nih.gov/pubmed/23873099", "http://www.ncbi.nlm.nih.gov/pubmed/22529104", "http://www.ncbi.nlm.nih.gov/pubmed/21725138", "http://www.ncbi.nlm.nih.gov/pubmed/21397860", "http://www.ncbi.nlm.nih.gov/pubmed/19656240", "http://www.ncbi.nlm.nih.gov/pubmed/19169796"], "triples": [], "ideal_answer": "In a process of epithelial-mesenchymal transition (EMT), besides changing their adhesive repertoire, cancer cells employ developmental processes to gain migratory and invasive properties that involve a dramatic reorganization of the actin cytoskeleton and the concomitant formation of membrane protrusions required for invasive growth. An important type of such membrane protrusions are the invadopodia, which have been increasingly recognized as important drivers of local invasion in metastasis. They are basally-localized, actin-rich structures that concentrate protease activity to areas of the cell in contact with the extracellular matrix.", "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0001837", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058750"], "type": "summary", "id": "5319ac7fb166e2b806000033", "snippets": [{"offsetInBeginSection": 574, "offsetInEndSection": 651, "text": "FHOD1, a poorly studied formin, appeared to be markedly upregulated upon EMT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086398", "endSection": "abstract"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1475, "text": "Furthermore, functional assays demonstrated that FHOD1 contributes to cell migration and invasion. Finally, FHOD1 depletion reduced the ability of EMT cancer cells to form invadopodia and to degrade extracellular matrix. Our results indicate that FHOD1 participates in cytoskeletal changes in EMT.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24086398", "endSection": "abstract"}, {"offsetInBeginSection": 61, "offsetInEndSection": 230, "text": "Invadopodia are considered to be crucial structures that allow cancer cells to penetrate across the extracellular matrix (ECM) by using matrix metalloproteinases (MMPs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23991004", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 674, "text": "Previously, we isolated a highly invasive A431-III subline from parental A431 cells by Boyden chamber assay. The A431-III cells possess higher invasive and migratory abilities, elevated levels of MMP-9 and an enhanced epithelial-mesenchymal transition (EMT) phenotype. In this study, we discovered that A431-III cells had an increased potential to form invadopodia and an improved capacity to degrade ECM compared with the original A431 cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23991004", "endSection": "abstract"}, {"offsetInBeginSection": 472, "offsetInEndSection": 744, "text": "Activated Twist upregulates N-cadherin and downregulates E-cadherin, which are the hallmarks of EMT. Moreover, Twist plays an important role in some physiological processes involved in metastasis, like angiogenesis, invadopodia, extravasation, and chromosomal instability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23873099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 224, "text": "Transforming growth factor \u03b2 (TGF-\u03b2)-stimulated epithelial-mesenchymal transition (EMT) is an important developmental process that has also been implicated in increased cell invasion and metastatic potential of cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529104", "endSection": "abstract"}, {"offsetInBeginSection": 348, "offsetInEndSection": 566, "text": "Herein, we demonstrate that TGF-\u03b2-induced Hic-5 up-regulation or ectopic expression of Hic-5 in normal MCF10A cells promoted increased extracellular matrix degradation and invasion through the formation of invadopodia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529104", "endSection": "abstract"}, {"offsetInBeginSection": 1006, "offsetInEndSection": 1127, "text": "These data identify Hic-5 as a critical mediator of TGF-\u03b2-stimulated invadopodia formation, cell migration, and invasion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529104", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 638, "text": "Recently, invadopodia have been increasingly recognized as important drivers of local invasion in metastasis. Invadopodia are basally-localized, actin-rich structures that concentrate protease activity to areas of the cell in contact with the extracellular matrix. We recently found that the transcription factor Twist1, a central regulator of the epithelial-mesenchymal transition (EMT), promotes invadopodia formation via upregulation of platelet-derived growth factor receptor (PDGFR) expression and activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21725138", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Twist1-induced invadopodia formation promotes tumor metastasis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397860", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "The Twist1 transcription factor is known to promote tumor metastasis and induce Epithelial-Mesenchymal Transition (EMT). Here, we report that Twist1 is capable of promoting the formation of invadopodia, specialized membrane protrusions for extracellular matrix degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397860", "endSection": "abstract"}, {"offsetInBeginSection": 274, "offsetInEndSection": 493, "text": "Twist1 induces PDGFR\u03b1 expression, which in turn activates Src, to promote invadopodia formation. We show that Twist1 and PDGFR\u03b1 are central mediators of invadopodia formation in response to various EMT-inducing signals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21397860", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actin comet-embedded invadopodia", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656240", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Podosomes and invadopodia are actin-based structures at the ventral cell membrane, which have a role in cell adhesion, migration and invasion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656240", "endSection": "abstract"}, {"offsetInBeginSection": 1758, "offsetInEndSection": 2136, "text": "In conclusion, EMT affects the invasion machinery of oral squamous carcinoma cells. Non-invasive squamous carcinoma cells constitutively organize podosomes, whereas invasive cells form invadopodia. The club-ended cell extensions, or externalized invadopodia, are involved in ECM degradation and maintenance of contact to adhesion substrate and surrounding cells during invasion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656240", "endSection": "abstract"}, {"offsetInBeginSection": 227, "offsetInEndSection": 819, "text": "In a process of epithelial-mesenchymal transition (EMT), besides changing their adhesive repertoire, cancer cells employ developmental processes to gain migratory and invasive properties that involve a dramatic reorganization of the actin cytoskeleton and the concomitant formation of membrane protrusions required for invasive growth. The molecular processes underlying such cellular changes are still only poorly understood, and the various migratory organelles, including lamellipodia, filopodia, invadopodia and podosomes, still require a better functional and molecular characterization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169796", "endSection": "abstract"}]}, {"body": "Which drug should be used as an antidote in benzodiazepine overdose?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21785147", "http://www.ncbi.nlm.nih.gov/pubmed/19500521", "http://www.ncbi.nlm.nih.gov/pubmed/18175099", "http://www.ncbi.nlm.nih.gov/pubmed/14620397", "http://www.ncbi.nlm.nih.gov/pubmed/11349753", "http://www.ncbi.nlm.nih.gov/pubmed/11383664", "http://www.ncbi.nlm.nih.gov/pubmed/9306053", "http://www.ncbi.nlm.nih.gov/pubmed/8905360", "http://www.ncbi.nlm.nih.gov/pubmed/8644960", "http://www.ncbi.nlm.nih.gov/pubmed/8605789", "http://www.ncbi.nlm.nih.gov/pubmed/7629986", "http://www.ncbi.nlm.nih.gov/pubmed/8306565", "http://www.ncbi.nlm.nih.gov/pubmed/1286503", "http://www.ncbi.nlm.nih.gov/pubmed/8438687", "http://www.ncbi.nlm.nih.gov/pubmed/8239101", "http://www.ncbi.nlm.nih.gov/pubmed/1354979", "http://www.ncbi.nlm.nih.gov/pubmed/1996802", "http://www.ncbi.nlm.nih.gov/pubmed/1672103", "http://www.ncbi.nlm.nih.gov/pubmed/2231833", "http://www.ncbi.nlm.nih.gov/pubmed/2113543", "http://www.ncbi.nlm.nih.gov/pubmed/2575692", "http://www.ncbi.nlm.nih.gov/pubmed/3132054", "http://www.ncbi.nlm.nih.gov/pubmed/2899985", "http://www.ncbi.nlm.nih.gov/pubmed/2893240"], "ideal_answer": ["Flumazenil should be used in all patients presenting with suspected benzodiazepine overdose. Flumazenil is a  potent benzodiazepine receptor antagonist that competitively blocks the central effects of benzodiazepines and reverses behavioral, neurologic, and electrophysiologic effects of benzodiazepine overdose. Clinical efficacy and safety of flumazenil in treatment of benzodiazepine overdose has been confirmed in a number of rigorous clinical trials. In addition, flumazenil is also useful to to reverse benzodiazepine induced sedation and to and to diagnose benzodiazepine overdose."], "exact_answer": ["flumazenil"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001569", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062787"], "type": "factoid", "id": "514a0a57d24251bc05000051", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 250, "text": "Benzodiazepine (BZD) overdose (OD) continues to cause significant morbidity and mortality in the UK. Flumazenil is an effective antidote but there is a risk of seizures, particularly in those who have co-ingested tricyclic antidepressants.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785147", "endSection": "sections.0"}, {"offsetInBeginSection": 530, "offsetInEndSection": 698, "text": "Flumazenil was administered to 80 patients in 4504 BZD-related enquiries, 68 of whom did not have ventilatory failure or had recognised contraindications to flumazenil.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785147", "endSection": "sections.0"}, {"offsetInBeginSection": 1366, "offsetInEndSection": 1436, "text": "Flumazenil is used infrequently in the management of BZD OD in the UK.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21785147", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19500521", "endSection": "sections.0"}, {"offsetInBeginSection": 2100, "offsetInEndSection": 2227, "text": "Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18175099", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Flumazenil is indicated for reversal of sedation from benzodiazepines administered during therapeutic or diagnostic procedures and during induction or maintenance of general anesthesia, as well as for benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14620397", "endSection": "sections.0"}, {"offsetInBeginSection": 766, "offsetInEndSection": 990, "text": "When measures are required to ensure adequate recovery of a patient's respiratory function and mental awareness, such as in patients with benzodiazepine toxicity, consideration of continuous-infusion flumazenil is warranted.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14620397", "endSection": "sections.0"}, {"offsetInBeginSection": 439, "offsetInEndSection": 695, "text": "Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11349753", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "A 54-y-old man ingested 2 g of bulk laboratory diazepam and was treated with activated charcoal, enhanced diuresis and flumazenil infusion.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11383664", "endSection": "sections.0"}, {"offsetInBeginSection": 200, "offsetInEndSection": 390, "text": "Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9306053", "endSection": "sections.0"}, {"offsetInBeginSection": 391, "offsetInEndSection": 676, "text": "Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9306053", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 277, "text": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8905360", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 119, "text": "To develop clinical rules for the safe and effective use of flumazenil in suspected benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8644960", "endSection": "sections.0"}, {"offsetInBeginSection": 438, "offsetInEndSection": 637, "text": "Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", "endSection": "sections.0"}, {"offsetInBeginSection": 1685, "offsetInEndSection": 2084, "text": "Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", "endSection": "sections.0"}, {"offsetInBeginSection": 3379, "offsetInEndSection": 3459, "text": "Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", "endSection": "sections.0"}, {"offsetInBeginSection": 1430, "offsetInEndSection": 1550, "text": "Flumazenil is best left for reversal of therapeutic conscious sedation and rare select cases of benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7629986", "endSection": "sections.0"}, {"offsetInBeginSection": 161, "offsetInEndSection": 353, "text": "Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8306565", "endSection": "sections.0"}, {"offsetInBeginSection": 613, "offsetInEndSection": 862, "text": "It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8306565", "endSection": "sections.0"}, {"offsetInBeginSection": 1841, "offsetInEndSection": 2069, "text": "Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8306565", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", "endSection": "sections.0"}, {"offsetInBeginSection": 831, "offsetInEndSection": 971, "text": "The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", "endSection": "sections.0"}, {"offsetInBeginSection": 1346, "offsetInEndSection": 1539, "text": "Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", "endSection": "sections.0"}, {"offsetInBeginSection": 2286, "offsetInEndSection": 2454, "text": "The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1286503", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 269, "text": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8438687", "endSection": "sections.0"}, {"offsetInBeginSection": 2414, "offsetInEndSection": 2508, "text": "Flumazenil rapidly and effectively reverses the clinical signs and symptoms of a BDZ overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8239101", "endSection": "sections.0"}, {"offsetInBeginSection": 146, "offsetInEndSection": 288, "text": "Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1354979", "endSection": "sections.0"}, {"offsetInBeginSection": 645, "offsetInEndSection": 827, "text": "In the setting of isolated benzodiazepine overdose, flumazenil is capable of completely reversing coma within one to two minutes, with this effect lasting between one and five hours.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1996802", "endSection": "sections.0"}, {"offsetInBeginSection": 319, "offsetInEndSection": 682, "text": "Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672103", "endSection": "sections.0"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1048, "text": "We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672103", "endSection": "sections.0"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1307, "text": "Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2231833", "endSection": "sections.0"}, {"offsetInBeginSection": 1383, "offsetInEndSection": 1485, "text": "We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2113543", "endSection": "sections.0"}, {"offsetInBeginSection": 235, "offsetInEndSection": 380, "text": "Flumazenil is the first benzodiazepine antagonist which can be used in humans and is a well established for treatment of benzodiazepine overdose.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2575692", "endSection": "sections.0"}, {"offsetInBeginSection": 420, "offsetInEndSection": 631, "text": "Flumazenil, a 1,4-imidazobenzodiazepine, is a highly effective, specific benzodiazepine antagonist which is indicated for use when the effect of a benzodiazepine must be attenuated or terminated at short notice.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2893240", "endSection": "sections.0"}, {"offsetInBeginSection": 2200, "offsetInEndSection": 2509, "text": "Thus, flumazenil provides a safe and effective means of attenuating or reversing the CNS-depressant effects of benzodiazepines whenever indicated, e.g. following benzodiazepine-induced general anaesthesia, conscious sedation, or after benzodiazepine overdose, either alone or in combination with other agents.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2893240", "endSection": "sections.0"}, {"offsetInBeginSection": 3524, "offsetInEndSection": 3676, "text": "Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8605789", "endSection": "sections.0"}, {"offsetInBeginSection": 1222, "offsetInEndSection": 1648, "text": "The mean +/- SD CGIS score at ten minutes for BDZ-positive patients was 1.41 +/- 0.72 for patients who received flumazenil and 3.41 +/- 0.91 for the placebo group (P < .01). There was no difference in the mean CGIS score between the flumazenil (3.25 +/- 1.15) and placebo (3.75 +/- 0.69) groups in BDZ-negative patients. The GCS and NAS were also significantly better in patients who were BDZ-positive and received flumazenil.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8239101", "endSection": "sections.0"}, {"offsetInBeginSection": 145, "offsetInEndSection": 665, "text": "In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2 mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p less than 0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p less than 0.01).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2113543", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 416, "text": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3132054", "endSection": "sections.0"}, {"offsetInBeginSection": 417, "offsetInEndSection": 615, "text": "Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3132054", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "Flumazenil (Ro 15-1788) proved to be a very efficacious competitive antagonist of benzodiazepines that reliably counteracts their pharmacological actions within 1-2 min as could be demonstrated in clinical and EEG studies.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2899985", "endSection": "sections.0"}, {"offsetInBeginSection": 1243, "offsetInEndSection": 1411, "text": "In intensive care medicine, the antagonist may be used in the treatment of benzodiazepine overdose as well as in the differential diagnosis of a coma of unknown origin.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2899985", "endSection": "sections.0"}]}, {"body": "Which is the localization of the RIFIN family of proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23259643", "http://www.ncbi.nlm.nih.gov/pubmed/23166704", "http://www.ncbi.nlm.nih.gov/pubmed/22174947", "http://www.ncbi.nlm.nih.gov/pubmed/21332983", "http://www.ncbi.nlm.nih.gov/pubmed/19826486", "http://www.ncbi.nlm.nih.gov/pubmed/17719658", "http://www.ncbi.nlm.nih.gov/pubmed/17255224", "http://www.ncbi.nlm.nih.gov/pubmed/17148488", "http://www.ncbi.nlm.nih.gov/pubmed/17014697", "http://www.ncbi.nlm.nih.gov/pubmed/16679041", "http://www.ncbi.nlm.nih.gov/pubmed/15939796", "http://www.ncbi.nlm.nih.gov/pubmed/15306707", "http://www.ncbi.nlm.nih.gov/pubmed/15287581", "http://www.ncbi.nlm.nih.gov/pubmed/14668007", "http://www.ncbi.nlm.nih.gov/pubmed/19769795", "http://www.ncbi.nlm.nih.gov/pubmed/14573641", "http://www.ncbi.nlm.nih.gov/pubmed/12438381"], "triples": [], "ideal_answer": ["Plasmodium falciparum rifin proteins are mainly surface-expressed. Data has shown that while A-type RIFINs were found to be associated with the parasite and transported to the surface of infected erythrocytes via Maurer's clefts, B-type RIFINs appeared to be mostly retained inside the parasite."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011506", "http://www.disease-ontology.org/api/metadata/DOID:620"], "type": "summary", "id": "551ae73b6b348bb82c000001", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 245, "text": " The ability of Plasmodium falciparum to undergo antigenic variation, by switching expression among protein variants encoded by multigene families, such as var, rif and stevor, is key to the survival of this parasite in the human host", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259643", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 377, "text": " The human malaria parasite Plasmodium falciparum possesses a number of multi-copy gene families, including var, rif, stevor and pfmc-2tm, which encode variant antigens believed to be expressed on the surfaces of infected erythrocytes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166704", "endSection": "abstract"}, {"offsetInBeginSection": 1510, "offsetInEndSection": 1642, "text": " Immunofluorescence analyses performed in parallel revealed two stage-dependent localization patterns of RIFIN, STEVOR and PfMC-2TM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166704", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 283, "text": "d variant surface antigens PfEMP1 and RIFIN ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174947", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 277, "text": "RIFIN and STEVOR proteins are variable surface antigens uniquely found in the malaria parasites Plasmodium falciparum and P. reichenowi.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332983", "endSection": "abstract"}, {"offsetInBeginSection": 1604, "offsetInEndSection": 1659, "text": "parasite surface proteins such as PfEMP1, A-type RIFIN ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19826486", "endSection": "abstract"}, {"offsetInBeginSection": 577, "offsetInEndSection": 786, "text": "While A-type RIFINs were found to be associated with the parasite and transported to the surface of infected erythrocytes via Maurer's clefts, B-type RIFINs appeared to be mostly retained inside the parasite. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17719658", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Variant proteins of the Plasmodium falciparum RIFIN family show distinct subcellular localization and developmental expression patterns.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17719658", "endSection": "title"}, {"offsetInBeginSection": 1232, "offsetInEndSection": 1442, "text": "Interestingly, some RIFIN variants were detected only in intracellular stages and not in merozoites, pointing to differential developmental expression patterns for distinct members of this large protein family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17719658", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 749, "text": "At least three groups of antigens, P. falciparum erythrocyte membrane protein 1 (PfEMP1)/ RIFIN/SURFIN, P. falciparum histidine-rich protein 2 (PfHRP2), ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17255224", "endSection": "abstract"}, {"offsetInBeginSection": 260, "offsetInEndSection": 579, "text": "This catalog includes large families of predicted 2 transmembrane (2TM) proteins, including the Rifin, Stevor and Pfmc-2TM superfamilies, of which each possesses a region of extensive sequence diversity across paralogs and between isolates that is confined to a proposed surface-exposed loop on the infected erythrocyte", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17148488", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "RIFINs are clonally variant antigens expressed in Plasmodium falciparum. T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17014697", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "RIFIN proteins belong to the largest Plasmodium falciparum multicopy family of variant surface antigens (VSA) expressed by infected erythrocytes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16679041", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1046, "text": "SURFIN4.2 not only was found cotransported with PfEMP1 and RIFIN to the IE surface, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15939796", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Antibodies to rifin: a component of naturally acquired responses to Plasmodium falciparum variant surface antigens on infected erythrocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15306707", "endSection": "title"}, {"offsetInBeginSection": 845, "offsetInEndSection": 906, "text": "In contrast to other known PIESPs, such as PfEMP1 and Rifin, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15287581", "endSection": "abstract"}, {"offsetInBeginSection": 117, "offsetInEndSection": 292, "text": "We here present data revealing the existence of a unique common pathway for the surface bound traffic of the clonally variant antigens, repeated-interspersed-antigen (RIFINS) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14668007", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 527, "text": " rifin proteins (RIF proteins), belonging to the largest known family of variable infected erythrocyte surface-expressed proteins, are also naturally immunogenic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12438381", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 314, "text": "Plasmodium falciparum rifin proteins, belonging to the largest known family of variable infected-erythrocyte surface-expressed proteins encoded by rif genes, were recently shown to be capable of inducing a strong immune response in P. falciparum-infected adults living in an area in Gabon where malaria is endemic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14573641", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 518, "text": "RIFIN products are targets for the human immune response and contribute to the antigenic variability of the parasite. They are transmembrane proteins grouped into two sub-families (RIF_A and RIF_B). Although recent data show that RIF_A and RIF_B have different sub-cellular localisations and possibly different functions, the same structural organisation has been proposed for members of the two sub-families.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19769795", "endSection": "abstract"}]}, {"body": "Which is the genetic lesion associated with Huntington\u2019s disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7620118"], "triples": [], "ideal_answer": "The genetic lesion associated with Huntington's disease is a CAG trinucleotide repeat expansion in the HD (or HTT) gene.", "exact_answer": ["A CAG trinucleotide repeat expansion in the HD gene"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006816", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020022", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030342", "http://www.uniprot.org/uniprot/HD_HUMAN", "http://www.disease-ontology.org/api/metadata/DOID:12858", "http://www.disease-ontology.org/api/metadata/DOID:630", "http://www.disease-ontology.org/api/metadata/DOID:0050325", "http://www.disease-ontology.org/api/metadata/DOID:0050739"], "type": "factoid", "id": "5319a6e9b166e2b806000023", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 360, "text": "Early in 1993, an unstable, expanded trinucleotide repeat in a novel gene of unknown function was identified on HD chromosomes. This discovery unleased a flurry of experimentation that has established the expanded CAG repeat the almost universal cause of the characteristic neurologic symptoms and pathology of this neurodegenerative disorder of midlife onset.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7620118", "endSection": "abstract"}]}, {"body": "Which package is available for analysing genomic interactions in R/Bioconductor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23671339"], "triples": [], "ideal_answer": ["r3Cseq is an R/Bioconductor package designed to perform 3C-seq data analysis in a number of different experimental designs. The package reads a common aligned read input format, provides data normalization, allows the visualization of candidate interaction regions and detects statistically significant chromatin interactions, thus greatly facilitating hypothesis generation and the interpretation of experimental results."], "exact_answer": [["r3Cseq"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023281", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009693", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678"], "type": "factoid", "id": "56a39d60496b62f23f000006", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 596, "offsetInEndSection": 1097, "text": "We present r3Cseq, an R/Bioconductor package designed to perform 3C-seq data analysis in a number of different experimental designs. The package reads a common aligned read input format, provides data normalization, allows the visualization of candidate interaction regions and detects statistically significant chromatin interactions, thus greatly facilitating hypothesis generation and the interpretation of experimental results. We further demonstrate its use on a series of real-world applications", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "r3Cseq: an R/Bioconductor package for the discovery of long-range genomic interactions from chromosome conformation capture and next-generation sequencing data.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23671339", "endSection": "title"}]}, {"body": "What are the functions of sorting nexin 27?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23536889", "http://www.ncbi.nlm.nih.gov/pubmed/23524343", "http://www.ncbi.nlm.nih.gov/pubmed/22411990", "http://www.ncbi.nlm.nih.gov/pubmed/21926430", "http://www.ncbi.nlm.nih.gov/pubmed/21602791", "http://www.ncbi.nlm.nih.gov/pubmed/18690037", "http://www.ncbi.nlm.nih.gov/pubmed/21303929", "http://www.ncbi.nlm.nih.gov/pubmed/21300787", "http://www.ncbi.nlm.nih.gov/pubmed/20733053", "http://www.ncbi.nlm.nih.gov/pubmed/17828261", "http://www.ncbi.nlm.nih.gov/pubmed/17644068", "http://www.ncbi.nlm.nih.gov/pubmed/17577583", "http://www.ncbi.nlm.nih.gov/pubmed/17351151", "http://www.ncbi.nlm.nih.gov/pubmed/15466885"], "ideal_answer": ["Sorting nexin 27 (SNX27) regulates endocytic sorting/recycling and intracellular trafficking of ion channels and receptors."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058305", "http://www.uniprot.org/uniprot/SNX27_HUMAN"], "type": "summary", "id": "5162da97298dcd4e51000048", "snippets": [{"offsetInBeginSection": 808, "offsetInEndSection": 1027, "text": "Knockdown of SNX27 by siRNA in HEK293 cells raised MRP4 expression on the plasma membrane, increased the extrusion of 6-[(14)C]mercaptopurine, an MRP4 substrate, and conferred resistance against 6-[(14)C]mercaptopurine.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22411990", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Sorting nexin 27 (SNX27) is a 62-kDa protein localized to early endosomes and known to regulate the intracellular trafficking of ion channels and receptors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926430", "endSection": "sections.0"}, {"offsetInBeginSection": 1028, "offsetInEndSection": 1315, "text": "Finally, migration assays revealed that depletion of SNX27 from HeLa and mouse principal kidney cortical collecting duct cells significantly decreases cell motility. We propose a model by which SNX27 regulates trafficking of \u03b2-Pix to focal adhesions and thereby influences cell motility.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926430", "endSection": "sections.0"}, {"offsetInBeginSection": 1237, "offsetInEndSection": 1306, "text": "We found that SNX27a redirected part of 5-HT4(a)R to early endosomes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15466885", "endSection": "sections.0"}, {"offsetInBeginSection": 688, "offsetInEndSection": 800, "text": "sorting nexin 27 (SNX27), a recently described member of a protein family involved in intracellular trafficking,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17351151", "endSection": "sections.0"}, {"offsetInBeginSection": 1199, "offsetInEndSection": 1323, "text": "SNX27 co-localized with transferrin receptor-positive vesicles, pointing to its participation in T cell endocytic recycling.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17351151", "endSection": "sections.0"}, {"offsetInBeginSection": 631, "offsetInEndSection": 783, "text": "This protein is a unique member of the sorting nexin family of proteins, a group generally involved in the endocytic and intracellular sorting machinery", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17577583", "endSection": "sections.0"}, {"offsetInBeginSection": 815, "offsetInEndSection": 954, "text": "These previously unreported results indicate that SNX27 is a participant in NK cell polarization, as a mediator or target of the mechanism.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644068", "endSection": "sections.0"}, {"offsetInBeginSection": 271, "offsetInEndSection": 480, "text": "Like most sorting nexins, SNX27 possesses a functional PX domain that selectively binds the membrane phospholipid phosphatidylinositol-3-phosphate (PI3P) and is important for trafficking to the early endosome.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17828261", "endSection": "sections.0"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1130, "text": "This is consistent with a role of SNX27 as a general regulator for sorting of membrane proteins containing a PDZ-binding motif, and its absence may alter the trafficking of these proteins, leading to growth and survival defects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300787", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "Sorting nexin 27 (SNX27) belongs to the sorting nexin family of proteins, which participate in vesicular and protein trafficking. Similarly to all sorting nexin proteins, SNX27 has a functional PX domain that is important for endosome binding, but it is the only sorting nexin with a PDZ domain.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303929", "endSection": "sections.0"}, {"offsetInBeginSection": 1186, "offsetInEndSection": 1424, "text": "These results identify SNX27 as a PDZ-containing component of the T cell immunological synapse, and demonstrate a role for this protein in the regulation of the Ras-ERK pathway, suggesting a functional relationship between SNX27 and DGK\u03b6.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21303929", "endSection": "sections.0"}, {"offsetInBeginSection": 406, "offsetInEndSection": 500, "text": "Sorting nexins have been implicated in trafficking of proteins through endosomal compartments.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18690037", "endSection": "sections.0"}]}, {"body": "Which is the causative agent of malaria?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23405174", "http://www.ncbi.nlm.nih.gov/pubmed/23382752", "http://www.ncbi.nlm.nih.gov/pubmed/23349974", "http://www.ncbi.nlm.nih.gov/pubmed/23342028", "http://www.ncbi.nlm.nih.gov/pubmed/23326533", "http://www.ncbi.nlm.nih.gov/pubmed/23293353", "http://www.ncbi.nlm.nih.gov/pubmed/23088152", "http://www.ncbi.nlm.nih.gov/pubmed/23046708", "http://www.ncbi.nlm.nih.gov/pubmed/22929299", "http://www.ncbi.nlm.nih.gov/pubmed/22819049", "http://www.ncbi.nlm.nih.gov/pubmed/22628552", "http://www.ncbi.nlm.nih.gov/pubmed/22563351", "http://www.ncbi.nlm.nih.gov/pubmed/22543099", "http://www.ncbi.nlm.nih.gov/pubmed/22359643", "http://www.ncbi.nlm.nih.gov/pubmed/22341220", "http://www.ncbi.nlm.nih.gov/pubmed/22222968", "http://www.ncbi.nlm.nih.gov/pubmed/22216006", "http://www.ncbi.nlm.nih.gov/pubmed/22095915", "http://www.ncbi.nlm.nih.gov/pubmed/22028927", "http://www.ncbi.nlm.nih.gov/pubmed/21698217", "http://www.ncbi.nlm.nih.gov/pubmed/21329764", "http://www.ncbi.nlm.nih.gov/pubmed/21297002", "http://www.ncbi.nlm.nih.gov/pubmed/21209090", "http://www.ncbi.nlm.nih.gov/pubmed/20702404", "http://www.ncbi.nlm.nih.gov/pubmed/20635416", "http://www.ncbi.nlm.nih.gov/pubmed/20610151", "http://www.ncbi.nlm.nih.gov/pubmed/20500669", "http://www.ncbi.nlm.nih.gov/pubmed/20353400", "http://www.ncbi.nlm.nih.gov/pubmed/20078859", "http://www.ncbi.nlm.nih.gov/pubmed/19931645", "http://www.ncbi.nlm.nih.gov/pubmed/19801158", "http://www.ncbi.nlm.nih.gov/pubmed/19706885", "http://www.ncbi.nlm.nih.gov/pubmed/19706490", "http://www.ncbi.nlm.nih.gov/pubmed/19666593", "http://www.ncbi.nlm.nih.gov/pubmed/19666023", "http://www.ncbi.nlm.nih.gov/pubmed/19267910", "http://www.ncbi.nlm.nih.gov/pubmed/19184366", "http://www.ncbi.nlm.nih.gov/pubmed/18989463", "http://www.ncbi.nlm.nih.gov/pubmed/18563912", "http://www.ncbi.nlm.nih.gov/pubmed/18925948", "http://www.ncbi.nlm.nih.gov/pubmed/18628947", "http://www.ncbi.nlm.nih.gov/pubmed/18295508", "http://www.ncbi.nlm.nih.gov/pubmed/18248630", "http://www.ncbi.nlm.nih.gov/pubmed/18221799", "http://www.ncbi.nlm.nih.gov/pubmed/18082626", "http://www.ncbi.nlm.nih.gov/pubmed/17868038", "http://www.ncbi.nlm.nih.gov/pubmed/17822713", "http://www.ncbi.nlm.nih.gov/pubmed/17024857", "http://www.ncbi.nlm.nih.gov/pubmed/16458301", "http://www.ncbi.nlm.nih.gov/pubmed/16222020", "http://www.ncbi.nlm.nih.gov/pubmed/16203971", "http://www.ncbi.nlm.nih.gov/pubmed/16042788", "http://www.ncbi.nlm.nih.gov/pubmed/15950069", "http://www.ncbi.nlm.nih.gov/pubmed/15878595", "http://www.ncbi.nlm.nih.gov/pubmed/15703443", "http://www.ncbi.nlm.nih.gov/pubmed/15701514", "http://www.ncbi.nlm.nih.gov/pubmed/15339111", "http://www.ncbi.nlm.nih.gov/pubmed/15293910", "http://www.ncbi.nlm.nih.gov/pubmed/15265796", "http://www.ncbi.nlm.nih.gov/pubmed/15246528", "http://www.ncbi.nlm.nih.gov/pubmed/15147974", "http://www.ncbi.nlm.nih.gov/pubmed/15117937", "http://www.ncbi.nlm.nih.gov/pubmed/15073329", "http://www.ncbi.nlm.nih.gov/pubmed/15033330", "http://www.ncbi.nlm.nih.gov/pubmed/15003844", "http://www.ncbi.nlm.nih.gov/pubmed/14638789", "http://www.ncbi.nlm.nih.gov/pubmed/14627712", "http://www.ncbi.nlm.nih.gov/pubmed/14609342", "http://www.ncbi.nlm.nih.gov/pubmed/14556002", "http://www.ncbi.nlm.nih.gov/pubmed/14514358", "http://www.ncbi.nlm.nih.gov/pubmed/12930149", "http://www.ncbi.nlm.nih.gov/pubmed/12929205", "http://www.ncbi.nlm.nih.gov/pubmed/12626578", "http://www.ncbi.nlm.nih.gov/pubmed/12139027", "http://www.ncbi.nlm.nih.gov/pubmed/12125103", "http://www.ncbi.nlm.nih.gov/pubmed/11796125", "http://www.ncbi.nlm.nih.gov/pubmed/11839179", "http://www.ncbi.nlm.nih.gov/pubmed/11687659", "http://www.ncbi.nlm.nih.gov/pubmed/11559352", "http://www.ncbi.nlm.nih.gov/pubmed/11504465", "http://www.ncbi.nlm.nih.gov/pubmed/11087748", "http://www.ncbi.nlm.nih.gov/pubmed/11115107", "http://www.ncbi.nlm.nih.gov/pubmed/11085920", "http://www.ncbi.nlm.nih.gov/pubmed/10744765", "http://www.ncbi.nlm.nih.gov/pubmed/10703207", "http://www.ncbi.nlm.nih.gov/pubmed/10585859", "http://www.ncbi.nlm.nih.gov/pubmed/9927744", "http://www.ncbi.nlm.nih.gov/pubmed/9874251", "http://www.ncbi.nlm.nih.gov/pubmed/9514077", "http://www.ncbi.nlm.nih.gov/pubmed/8816746", "http://www.ncbi.nlm.nih.gov/pubmed/8631352", "http://www.ncbi.nlm.nih.gov/pubmed/7715553", "http://www.ncbi.nlm.nih.gov/pubmed/8300589", "http://www.ncbi.nlm.nih.gov/pubmed/1474844", "http://www.ncbi.nlm.nih.gov/pubmed/1813841", "http://www.ncbi.nlm.nih.gov/pubmed/1648659", "http://www.ncbi.nlm.nih.gov/pubmed/15463447", "http://www.ncbi.nlm.nih.gov/pubmed/2067482", "http://www.ncbi.nlm.nih.gov/pubmed/2067470", "http://www.ncbi.nlm.nih.gov/pubmed/2191201", "http://www.ncbi.nlm.nih.gov/pubmed/3011062", "http://www.ncbi.nlm.nih.gov/pubmed/3911876", "http://www.ncbi.nlm.nih.gov/pubmed/4047719", "http://www.ncbi.nlm.nih.gov/pubmed/6728514", "http://www.ncbi.nlm.nih.gov/pubmed/6760901", "http://www.ncbi.nlm.nih.gov/pubmed/23246819", "http://www.ncbi.nlm.nih.gov/pubmed/22990975", "http://www.ncbi.nlm.nih.gov/pubmed/22592550", "http://www.ncbi.nlm.nih.gov/pubmed/22524128", "http://www.ncbi.nlm.nih.gov/pubmed/22507744", "http://www.ncbi.nlm.nih.gov/pubmed/22057268", "http://www.ncbi.nlm.nih.gov/pubmed/22019287", "http://www.ncbi.nlm.nih.gov/pubmed/21989409", "http://www.ncbi.nlm.nih.gov/pubmed/21904052", "http://www.ncbi.nlm.nih.gov/pubmed/21866942", "http://www.ncbi.nlm.nih.gov/pubmed/21771420", "http://www.ncbi.nlm.nih.gov/pubmed/21670272", "http://www.ncbi.nlm.nih.gov/pubmed/21601941", "http://www.ncbi.nlm.nih.gov/pubmed/21570407", "http://www.ncbi.nlm.nih.gov/pubmed/21206476", "http://www.ncbi.nlm.nih.gov/pubmed/20034997", "http://www.ncbi.nlm.nih.gov/pubmed/19779742", "http://www.ncbi.nlm.nih.gov/pubmed/19768685", "http://www.ncbi.nlm.nih.gov/pubmed/19380379", "http://www.ncbi.nlm.nih.gov/pubmed/19038338", "http://www.ncbi.nlm.nih.gov/pubmed/19020475", "http://www.ncbi.nlm.nih.gov/pubmed/19013823", "http://www.ncbi.nlm.nih.gov/pubmed/18672695", "http://www.ncbi.nlm.nih.gov/pubmed/18611947", "http://www.ncbi.nlm.nih.gov/pubmed/18522993", "http://www.ncbi.nlm.nih.gov/pubmed/18164079", "http://www.ncbi.nlm.nih.gov/pubmed/23484017", "http://www.ncbi.nlm.nih.gov/pubmed/23483940"], "triples": [{"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/710", "o": "Malaria"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A17994656"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A17994656", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A17994656", "o": "N0000001924"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17994656", "o": "Malaria"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A7571934"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A7571934", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A7571934", "o": "C34797"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A7571934", "o": "NCI Thesaurus"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A7571934"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A7571934", "o": "Malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12365", "o": "http://www.w3.org/2004/02/skos/core#Concept"}, {"p": "http://www.w3.org/2004/02/skos/core#altLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12365", "o": "induced malaria"}, {"p": "http://www.w3.org/2004/02/skos/core#altLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12365", "o": "Induced malaria (disorder)"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12365", "o": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:0050245"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:14326", "o": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12365"}, {"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12919", "o": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:12365"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0082523", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0082523", "o": "U002785"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0082523", "o": "Library of Congress Subject Headings"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A0082523"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0082523", "o": "Malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0431821", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0431821", "o": "1656"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0431821", "o": "WHOART"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A0431821"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0431821", "o": "MALARIA"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A8312247", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8312247", "o": "67"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8312247", "o": "HL7 Version 2.5"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0206255", "o": "http://linkedlifedata.com/resource/umls/label/A8312247"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8312247", "o": "malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0431817", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A0431817"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0431817", "o": "MALARIA"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0483250", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0483250", "o": "2214-5569"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0483250", "o": "CRISP Thesaurus"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A0483250"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0483250", "o": "malaria"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A8339229"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A8339229", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8339229", "o": "Metathesaurus Names"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8339229", "o": "Malaria"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A8339229"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A0082525"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0082525", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0082525", "o": "D008288"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0082525", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A0082525"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0082525", "o": "Malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A8317042", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8317042", "o": "67"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8317042", "o": "HL7 Version 3.0"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0206255", "o": "http://linkedlifedata.com/resource/umls/label/A8317042"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8317042", "o": "malaria"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0024530", "o": "http://linkedlifedata.com/resource/umls/label/A15661537"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A15661537", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A15661537", "o": "T315"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A15661537", "o": "Malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0082521", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0082521", "o": "A73"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0082521", "o": "Malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0431820", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0431820", "o": "R0121672"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A0431820", "o": "Quick Medical Reference"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0431820", "o": "MALARIA"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0483249", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0483249", "o": "0000004887"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0483249", "o": "malaria"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A0431816", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0431816", "o": "U000432"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0431816", "o": "MALARIA"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A8340437", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8340437", "o": "084"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8340437", "o": "ICD-9-CM"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8340437", "o": "Malaria"}, {"p": "http://purl.uniprot.org/core/category", "s": "http://purl.uniprot.org/keywords/461", "o": "http://purl.uniprot.org/keywords/9995"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://purl.uniprot.org/keywords/461", "o": "http://purl.uniprot.org/core/Concept"}, {"p": "http://www.w3.org/2000/01/rdf-schema#comment", "s": "http://purl.uniprot.org/keywords/461", "o": "Protein involved in malaria, a human disease caused by Plasmodium, a parasitic protozoan that grows by sexual reproduction in the Anopheles mosquito."}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://purl.uniprot.org/keywords/461", "o": "Malaria"}, {"p": "http://www.w3.org/2000/01/rdf-schema#subClassOf", "s": "http://purl.uniprot.org/keywords/461", "o": "http://purl.uniprot.org/keywords/9995"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/pubmed/keyword/MALARIA", "o": "http://linkedlifedata.com/resource/pubmed/Keyword"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/pubmed/keyword/MALARIA", "o": "MALARIA"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/pubmed/mesh/Malaria", "o": "http://linkedlifedata.com/resource/pubmed/Mesh"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://linkedlifedata.com/resource/pubmed/mesh/Malaria", "o": "Malaria"}], "ideal_answer": ["Four Plasmodium species commonly infect humans (Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale). Plasmodium falciparum infects about 5-10% of the world human population per year and it is the causative agent of the most severe and lethal form of malaria. P. falciparum  causes fatal cerebral malaria and is responsible for most deaths, particularly in pregnant women and children under the age of five. P. falciparum is transmitted to the human host by Anopheles mosquitoes and is the most tremendous malaria vector in sub-Saharan Africa. Plasmodium vivax is the causative agent of benign malaria in more temperate climates of the world. Plasmodium gallinaceum is the main bird malaria causative agent and  Plasmodium yoelli is the principle rodent malaria agent."], "exact_answer": ["Plasmodium species", "Plasmodium spp."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:14324", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008288", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016778", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016780", "http://www.disease-ontology.org/api/metadata/DOID:14067", "http://www.disease-ontology.org/api/metadata/DOID:12365", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010965", "http://www.disease-ontology.org/api/metadata/DOID:12978"], "type": "factoid", "id": "517194ef8ed59a060a000011", "snippets": [{"offsetInBeginSection": 13, "offsetInEndSection": 107, "text": "lasmodium falciparum the main causative agent of malaria is an important public health vector.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382752", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 109, "text": "Plasmodium falciparum the main causative agent of malaria is an important public health vector. <", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382752", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Overcoming antigenic variation is one of the major challenges in the development of an effective vaccine against Plasmodium falciparum, a causative agent of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23293353", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "[The vivax malaria causative agent Plasmodium ovale: the present global area, intraspecies polymorphism, importation to the Russian Federation (1992-2011)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23088152", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "The global area for Plasmodium ovale is small as compared with that for other species of human malaria pathogens.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23088152", "endSection": "sections.0"}, {"offsetInBeginSection": 109, "offsetInEndSection": 1148, "text": "Parasites that have been described to affect the central nervous system (CNS), either as the dominant or as a collateral feature, include cestodes (Taenia solium (neurocysticerciasis), Echinococcus granulosus (cerebral cystic echinococcosis), E. multilocularis (cerebral alveolar echinococcosis), Spirometra mansoni (neurosparganosis)), nematodes (Toxocara canis and T. cati (neurotoxocariasis), Trichinella spiralis (neurotrichinelliasis), Angiostrongylus cantonensis and A. costaricensis (neuroangiostrongyliasis), Gnathostoma spinigerum (gnathostomiasis)), trematodes (Schistosoma mansoni (cerebral bilharziosis), Paragonimus westermani (neuroparagonimiasis)), or protozoa (Toxoplasma gondii (neurotoxoplasmosis), Acanthamoeba spp. or Balamuthia mandrillaris (granulomatous amoebic encephalitis), Naegleria (primary amoebic meningo-encephalitis), Entamoeba histolytica (brain abscess), Plasmodium falciparum (cerebral malaria), Trypanosoma brucei gambiense/rhodesiense (sleeping sickness) or Trypanosoma cruzi (cerebral Chagas disease))", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046708", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Plasmodium falciparum is the causative agent of malaria, a deadly infectious disease for which treatments are scarce and drug-resistant parasites are now increasingly found.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819049", "endSection": "sections.0"}, {"offsetInBeginSection": 107, "offsetInEndSection": 320, "text": "In contrast, it has been thought that Plasmodium spp., the causative agent of malaria, rely mainly on cytosolic glycolysis but not mitochondrial oxidative phosphorylation for energy production during blood stages.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628552", "endSection": "sections.0"}, {"offsetInBeginSection": 165, "offsetInEndSection": 447, "text": "Whereas no biological activity was previously identified for 1, the material derived from the efficient synthesis enabled additional bioactivity tests leading to the identification of a notable activity against insect cells and Plasmodium falciparum, the causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563351", "endSection": "sections.0"}, {"offsetInBeginSection": 102, "offsetInEndSection": 283, "text": "Plasmodium falciparum, the causative agent of malaria, encodes an SSB protein that localizes to the apicoplast and likely functions in the replication and maintenance of its genome.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22543099", "endSection": "sections.0"}, {"offsetInBeginSection": 174, "offsetInEndSection": 411, "text": "While observing cells by time-lapse imaging is a standard procedure in many systems, this technique was until recently not available for blood stages of Plasmodium falciparum, the causative agent of the most severe form of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22341220", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "The causative agent of malaria, Plasmodium, possesses three translationally active compartments: the cytosol, the mitochondrion and a relic plastid called the apicoplast.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22222968", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 166, "text": "The merozoite surface protein (MSP)-1 of Plasmodium falciparum, the causative agent of malaria tropica, is considered to be a promising vaccine candidate.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22095915", "endSection": "sections.0"}, {"offsetInBeginSection": 115, "offsetInEndSection": 255, "text": "The genus Plasmodium, the causative agent of malaria, has the smallest mt genome in the form of a tandemly repeated, linear element of 6 kb.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21329764", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "The culminating step of the intraerythrocytic development of Plasmodium falciparum, the causative agent of malaria, is the spectacular release of multiple invasive merozoites on rupture of the infected erythrocyte membrane.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21297002", "endSection": "sections.0"}, {"offsetInBeginSection": 158, "offsetInEndSection": 322, "text": "Plasmodium falciparum, the causative agent of human malaria, lacks a conventional tricarboxylic acid cycle and depends exclusively on glycolysis for ATP production.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21209090", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Plasmodium falciparum, the causative agent of the most deadly form of human malaria, is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702404", "endSection": "sections.0"}, {"offsetInBeginSection": 126, "offsetInEndSection": 325, "text": "The Hsp90 protein from the parasite Plasmodium falciparum, the causative agent of malaria, is critical for this organism's survival; the anti-Hsp90 drug geldanamycin is toxic to P. falciparum growth.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20635416", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "A novel family of 1H-imidazol-2-yl-pyrimidine-4,6-diamines has been identified with potent activity against the erythrocyte-stage of Plasmodium falciparum (Pf), the most common causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20610151", "endSection": "sections.0"}, {"offsetInBeginSection": 186, "offsetInEndSection": 326, "text": "The Plasmodium parasite, causative agent of malaria, infects RBC that are phagocytosed by DC and macrophages during the course of infection.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20500669", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "Plasmodium falciparum is the causative agent of malaria, a disease where new drug targets are required due to increasing resistance to current anti-malarials.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20353400", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "Plasmodium falciparum, the causative agent of human malaria, invades host erythrocytes using several proteins on the surface of the invasive merozoite, which have been proposed as potential vaccine candidates.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19931645", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Few studies have investigated the pathophysiologic mechanisms responsible for what seems to be a possible interaction between Plasmodium falciparum, the causative agent of malaria, and HIV-1 in dually infected patients.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19801158", "endSection": "sections.0"}, {"offsetInBeginSection": 309, "offsetInEndSection": 456, "text": "We show that orthochromatic cells are the earliest stages that may be invaded by Plasmodium falciparum, the causative agent of fatal human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706885", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Infection by Plasmodium, the causative agent of malaria, is associated with hemolysis and therefore with release of hemoglobin from RBC.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706490", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Plasmodium falciparum, the causative agent of malignant malaria, is among the most severe human infectious diseases", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666593", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Plasmodium falciparum, the most important causative agent of human malaria, undergoes antigenic variation as a means of prolonging infection and ensuring transmission between hosts.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666023", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "L-Malate dehydrogenase (PfMDH) from Plasmodium falciparum, the causative agent for the most severe form of malaria, has shown remarkable similarities to L: -lactate dehydrogenase (PfLDH).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19184366", "endSection": "sections.0"}, {"offsetInBeginSection": 138, "offsetInEndSection": 303, "text": "FQ is able to overcome the chloroquine (CQ) resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18563912", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "The causative agent of malaria, Plasmodium falciparum posses a single aquaglyceroporin (PfAQP) which represents a potential drug target for treatment of the disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18295508", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "An essential requisite for transmission of Plasmodium, the causative agent of malaria, is the successful completion of a complex developmental cycle in its mosquito vector.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18248630", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "In Plasmodium falciparum, the causative agent of cerebral malaria, silent information regulator 2 (Sir2) has been implicated in pathogenesis through its role in var gene silencing.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18221799", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Plasmodium falciparum, the causative agent of human malaria, is totally dependent on de novo pyrimidine biosynthetic pathway.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18082626", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Plasmodium falciparum, the causative agent of the fatal form of malaria, synthesizes GMP primarily from IMP and, hence, needs active GMPS (GMP synthetase) for its survival.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17868038", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Plasmodium falciparum is the causative agent of the most severe type of malaria, a life-threatening disease affecting the lives of over three billion people.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17822713", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 150, "text": "Plasmodium falciparum, the causative agent of the most serious form of malaria, infects about 5-10% of the world human population per year.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17024857", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 294, "text": "Plasmodium vivax is an important human pathogen causing malaria in more temperate climates of the world. Similar to Plasmodium falciparum, the causative agent for malaria tropica, drug resistance is beginning to emerge for this parasite species and this hampers adequate treatment of infection.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16458301", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "Malaria kills more than one million people a year, and understanding the historical association between its most notorious causative agent, Plasmodium falciparum, and its mosquito vectors is important in fighting the disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16222020", "endSection": "sections.0"}, {"offsetInBeginSection": 166, "offsetInEndSection": 347, "text": "We show here that macrophages are mandatory for NK cell IFN-gamma secretion in response to erythrocytes infected with Plasmodium falciparum (Pf), a causative agent of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16203971", "endSection": "sections.0"}, {"offsetInBeginSection": 76, "offsetInEndSection": 167, "text": "Plasmodium falciparum is the causative agent of the most severe and mortal type of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15950069", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "Plasmodium falciparum is the main causative agent of tropical malaria, the most severe parasitic disease in the world. Growing resistance of Plasmodia towards available drugs is an increasing problem in countries where malaria is endemic.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15878595", "endSection": "sections.0"}, {"offsetInBeginSection": 117, "offsetInEndSection": 234, "text": "The presence of antisense RNA in Plasmodium falciparum, the causative agent of severe malaria, remains controversial.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15703443", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Plasmodium falciparum, the causative agent of malaria, is sensitive to oxidative stress and therefore the family of antioxidant enzymes, peroxiredoxins (Prxs) represent a target for antimalarial drug design.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701514", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "In the Republic of Yemen, Plasmodium falciparum is the predominant causative agent of malaria and is associated with adverse consequences for pregnant women and their babies.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15339111", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, uses multiple ligand-receptor interactions to invade host red blood cells (RBCs).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15265796", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "Comparative genomic analysis of the malaria causative agent, Plasmodium falciparum, with other eukaryotes for which the complete genome is available, revealed that the genome from P. falciparum was more similar to the genome of a plant, Arabidopsis thaliana, than to other non-apicomplexan taxa.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15246528", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, totally depends on de novo pyrimidine biosynthetic pathway.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15147974", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Plasmodium falciparum, the causative agent of malaria, relies extensively on glycolysis coupled with homolactic fermentation during its blood-borne stages for energy production.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15117937", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Plasmodium falciparum is the causative agent of the most severe form of human malaria. The rapid multiplication of the parasite within human erythrocytes requires an active production of new membranes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15073329", "endSection": "sections.0"}, {"offsetInBeginSection": 157, "offsetInEndSection": 401, "text": "Seven sPLA(2)s from groups IA, IB, IIA and III, were tested here in different culture conditions for inhibition of the in vitro intraerythrocytic development of Plasmodium falciparum, the causative agent of the most severe form of human malaria", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15033330", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, relies on de novo pyrimidine biosynthesis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15003844", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "In spite of research efforts to develop vaccines against the causative agent of human malaria, Plasmodium falciparum, effective control remains elusive.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14638789", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Plasmodium, the causative agent of malaria, has to undergo sexual differentiation and development in anopheline mosquitoes for transmission to occur.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14627712", "endSection": "sections.0"}, {"offsetInBeginSection": 117, "offsetInEndSection": 254, "text": "For Plasmodium falciparum, a causative agent of tropical malaria, TrxR is an essential protein which has been validated as a drug target.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14609342", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Plasmodium, the causative agent of malaria, must first infect hepatocytes to initiate a mammalian infection.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14556002", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "Cyclin dependent protein kinases (CDKs) have become attractive drug targets in an effort to identify effective inhibitors of the parasite Plasmodium falciparum, the causative agent of the most severe form of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12930149", "endSection": "sections.0"}, {"offsetInBeginSection": 190, "offsetInEndSection": 377, "text": "It is well established that protection against one such disease, malaria, requires strong CD8(+) T cell responses targeted against the liver stages of the causative agent, Plasmodium spp.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12626578", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "A novel method for the in vitro detection of the protozoan Plasmodium, the causative agent of malaria, has been developed.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12139027", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Trypanosomes do not inhabit or grow in anopheles mosquitoes, the vector for the transmission of Plasmodium parasites the causative agent for malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125103", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "The genome sequence of Plasmodium falciparum, the causative agent of the most severe form of malaria in humans, rapidly approaches completion, but our ability to genetically manipulate this organism remains limited.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11796125", "endSection": "sections.0"}, {"offsetInBeginSection": 95, "offsetInEndSection": 229, "text": "It is caused by a number of species of the genus Plasmodium, and Plasmodium falciparum is the causative agent of the most lethal form.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11839179", "endSection": "sections.0"}, {"offsetInBeginSection": 181, "offsetInEndSection": 333, "text": "To complete its life cycle in the mosquito, Plasmodium, the causative agent of malaria, has to traverse the epithelia of the midgut and salivary glands.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11687659", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "In Plasmodium falciparum, the causative agent of human malaria, the catalytic subunit gene of cAMP-dependent protein kinase (Pfpka-c) exists as a single copy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11559352", "endSection": "sections.0"}, {"offsetInBeginSection": 189, "offsetInEndSection": 494, "text": "Sulfadoxine is the most extensively used drug of this group of drugs and is usually combined with pyrimethamine (Fansidar), particularly for the control of Plasmodium falciparum, the causative agent of the most lethal form of malaria. Resistance to the sulfadoxine/pyrimethamine combination is widespread.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11504465", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": "A putative glutathione peroxidase gene (Swiss-Prot accession number Z 68200) of Plasmodium falciparum, the causative agent of tropical malaria, was expressed in Escherichia coli and purified to electrophoretic homogeneity.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11087748", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Apical membrane antigen 1 (AMA1) is an asexual blood-stage protein expressed in the invasive merozoite form of Plasmodia species, which are the causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11115107", "endSection": "sections.0"}, {"offsetInBeginSection": 350, "offsetInEndSection": 571, "text": "In the case of Plasmodium falciparum, the causative agent of malaria tropica, this approach is especially interesting, because here both key enzymes, ODC and AdoMetDC, are combined in a bifunctional protein, ODC/AdoMetDC.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11085920", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Plasmodium falciparum, the causative agent of the most lethal form of human malaria, is incapable of de novo purine synthesis, and thus, purine acquisition from the host is an indispensable nutritional requirement.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10744765", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 267, "text": "A laboratory model of circulation of the malaria causative agent P. gallinaceum has been used to show that the effect of precocene (antijuvenoid) leads to a statistically significant reduction in the proportion of infected females developing eggs after blood suction.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10703207", "endSection": "sections.0"}, {"offsetInBeginSection": 447, "offsetInEndSection": 690, "text": "A cell-free incubation system prepared from asexual erythrocytic stages of Plasmodium falciparum, the causative agent of malaria in humans, is capable of synthesizing the same spectrum of GPIs as that found in metabolically labelled parasites.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585859", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "The Plasmodium falciparum malaria parasite is the causative agent of malaria tropica.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9927744", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The gene of an NADP+-specific glutamate dehydrogenase was cloned from Plasmodium falciparum, the causative agent of tropical malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9874251", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 229, "text": "This study describes the synergistic interaction of two calcium channel blockers, verapamil (VR) and SR33557 or fantofarone (SR), in reversing chloroquine resistance in Plasmodium falciparum, the causative agent of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9514077", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Plasmodium falciparum is the major causative agent of malaria, a disease of worldwide importance.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8816746", "endSection": "sections.0"}, {"offsetInBeginSection": 97, "offsetInEndSection": 422, "text": "Two enzymes were purified to homogeneity from the intraerythrocytic malarial parasite Plasmodium falciparum: glutathione disulfide reductase, an antioxidative enzyme, which appears to play an essential role for parasite growth and differentiation, and glutamate dehydrogenase, an enzyme not occurring in the host erythrocyte.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8631352", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "The paper provides evidence that the An. sacharovi females which do not develop mature eggs after blood-sucking on the malaria-infected donor could not be infected by the bird malaria agent P. gallinaceum.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7715553", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Plasmodium falciparum is the causative agent of malaria tropica in man.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8300589", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Plastid origin of an extrachromosomal DNA molecule from Plasmodium, the causative agent of malaria.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1474844", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "[New models of the circulation of the causative agent of malaria Plasmodium gallinaceum using malarial mosquitoes in the fauna of the USSR].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1813841", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "[Experimental research on the effect of biologically active substances on the susceptibility of mosquitoes to the causative agent of malaria. 3. Algae, fertilizers].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1648659", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 467, "text": "On a model pair Aedes aegypti--Plasmodium gallinaceum in has been shown that changes in the conditions of larvae development caused by the addition into the water medium of the live culture of Synochocystis sp. cyanobacteria or green seaweeds Chlorella vulgaris, acetone extracts from the live culture precipitate or Chlorella powder, as well as nitrogen-containing fertilizer--ammonium chloride did not lower the sensitivity of the imago flying to malaria parasites.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1648659", "endSection": "sections.0"}, {"offsetInBeginSection": 155, "offsetInEndSection": 479, "text": "The mechanism of chloroquine resistance has not been known but recent evidence from Plasmodium falciparum, the causative agent of the most severe form of human malaria, suggested similarities to the multidrug resistance phenotype (MDR) of mammalian tumour cells which is mediated by a protein molecule termed P-glycoprotein.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15463447", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "The feasibility was determined of influencing Ae. aegypti sensitivity to bird malaria agent P. gallinaceum by sublethal concentrations of herbicides (ordram and propanide) and fungicides (fundozol and blue vitriol) introduced into the larvae habitation medium or into the imago feed.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2067482", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "[An experimental study of the effect of different biologically active substances on the susceptibility of mosquitoes to the causative agent of malaria. 1. Insect development regulators].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2067470", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "It has been shown on the model pair Ae. aegypti-P. gallinaceum that dimilin, an inhibitor of insect chitin synthesis has practically no effect on female sensitivity to malaria agent.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2067470", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "[The absence of an action of the pyrethroids deltamethrin and cypermethrin on mosquito susceptibility to the causative agent of malaria].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2191201", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 293, "text": "Mosquitos Ae. aegypti and An. stephensi contact with sublethal doses of deltametrin and cypermetrin pyretroids at larval stage and in grown state, when diet includes sugar with pyretroids, had no influence on the sensitivity of survived females to malaria agents P. gallinaceum and P. berghei.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2191201", "endSection": "sections.0"}, {"offsetInBeginSection": 114, "offsetInEndSection": 368, "text": "This prompted us to purify and characterize the topoisomerases I and II present in the erythrocytes of protozoan parasites of the genus Plasmodium, the causative agent of malaria, in order to later use these enzymatic systems in antimalarial drug assays.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3011062", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "The problem of drug resistance of Plasmodium falciparum, the causative agent of tropical malaria and its role in the general system of malaria control are discussed.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3911876", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "[Effect of mosquito contact with DDT and their susceptibility to the causative agent of malaria].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4047719", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "[Lack of an effect from repeated blood sucking by mosquitoes on their infectivity with the causative agent of malaria].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6728514", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "The lack of repeated bloodsucking does not affect essentially the infection of Ae. aegypti mosquitoes with malaria agent, P. gallinaceum.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6728514", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "High resolution 31P-NMR has been used for the non-invasive observation of metabolites and metabolic rates in blood of normal mice and of mice infected with Plasmodium berghei, the causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6760901", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "BACKGROUND: Plasmodium falciparum the main causative agent of malaria is an important public health vector.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382752", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990975", "endSection": "sections.0"}, {"offsetInBeginSection": 351, "offsetInEndSection": 548, "text": "Infection by Plasmodium species, the causative agent of malaria, is currently treated with drug-based therapies, but an increase in drug resistance has led to the need for new methods of treatment.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22592550", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "BACKGROUND: The merozoite surface protein (MSP)-1 of Plasmodium falciparum, the causative agent of malaria tropica, is considered to be a promising vaccine candidate.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22095915", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "The 23-megabase genome of Plasmodium falciparum, the causative agent of severe human malaria, contains \u223c5300 genes, most of unknown function or lacking homologs in other organisms.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057268", "endSection": "sections.0"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1320, "text": "Results of the present study indicate that malaria is endemic in Nouakchott and that P. vivax is the principal causative agent.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22019287", "endSection": "sections.0"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1413, "text": "Plasmodium vivax was the main causative agent followed by Plasmodium falciparum.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21771420", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Toxoplasma gondii is a member of the phylum Apicomplexa that includes several important human pathogens, such as Cryptosporidium and Plasmodium falciparum, the causative agent of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670272", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Plasmodium falciparum, the major causative agent of human malaria, contains three separate genomes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21570407", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "Plasmodium parasites, the causative agent of malaria, are transmitted through the bites of infected Anopheles mosquitoes resulting in over 250 million new infections each year.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21206476", "endSection": "sections.0"}, {"offsetInBeginSection": 116, "offsetInEndSection": 351, "text": "The genus Plasmodium, causative agent of malaria, of the phylum Apicomplexa, has the smallest mt genome in the form of a circular and/or tandemly repeated linear element of 6 kb, encoding only three protein genes (cox1, cox3, and cob).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20034997", "endSection": "sections.0"}, {"offsetInBeginSection": 141, "offsetInEndSection": 227, "text": "Plasmodium falciparum is the causative agent of the most lethal form of human malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19779742", "endSection": "sections.0"}, {"offsetInBeginSection": 146, "offsetInEndSection": 337, "text": "In Plasmodium falciparum, the causative agent of the most lethal form of malaria, fatty acid biosynthesis occurs in the apicoplast organelle during the liver stage of the parasite life cycle.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19768685", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Plasmodium falciparum, the causative agent of malignant malaria, is among the most severe human infectious diseases.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19666593", "endSection": "sections.0"}, {"offsetInBeginSection": 34, "offsetInEndSection": 172, "text": "For transmission to occur, Plasmodium, the causative agent of malaria, must complete a complex developmental cycle in its mosquito vector.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19038338", "endSection": "sections.0"}, {"offsetInBeginSection": 267, "offsetInEndSection": 418, "text": "FQ is able to overcome the CQ resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19020475", "endSection": "sections.0"}, {"offsetInBeginSection": 272, "offsetInEndSection": 511, "text": "Some lycorine ester derivatives including LT1 were examined for their inhibitory activity against Trypanosoma brucei brucei, the parasite associated with sleeping sickness, and against Plasmodium falciparum, the causative agent of malaria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19013823", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 255, "text": "A three-dimensional structure of histo-aspartic protease (HAP), a pepsin-like enzyme from the causative agent of malaria Plasmodium falciparum, is suggested on the basis of homologous modeling followed by equilibration by the method of molecular dynamics.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18672695", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 220, "text": "BACKGROUND: Understanding gene regulation in Plasmodium, the causative agent of malaria, is an important step in deciphering its complex life cycle as well as leading to possible new targets for therapeutic applications.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18611947", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Plasmodium falciparum, the causative agent of malaria, relies on a complex protein-secretion system for protein targeting into numerous subcellular destinations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18522993", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "We have evaluated a technology called transcriptionally active PCR (TAP) for high throughput identification and prioritization of novel target antigens from genomic sequence data using the Plasmodium parasite, the causative agent of malaria, as a model.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18164079", "endSection": "sections.0"}]}, {"body": "What is the molecular pathogenesis of Spinal Muscular Atrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24112438", "http://www.ncbi.nlm.nih.gov/pubmed/23740936", "http://www.ncbi.nlm.nih.gov/pubmed/18572081"], "triples": [], "ideal_answer": "Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation, resulting in downregulated biogenesis of uridine-rich small nuclear RNAs (U snRNAs), which are major components of the splicing machinery.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009134", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014897", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055533", "http://www.disease-ontology.org/api/metadata/DOID:12377", "http://www.disease-ontology.org/api/metadata/DOID:0050529", "http://www.disease-ontology.org/api/metadata/DOID:12376", "http://www.disease-ontology.org/api/metadata/DOID:0060160", "http://www.disease-ontology.org/api/metadata/DOID:318", "http://www.disease-ontology.org/api/metadata/DOID:0050530"], "type": "summary", "id": "52f124a12059c6d71c000006", "snippets": [{"offsetInBeginSection": 1031, "offsetInEndSection": 1144, "text": "A mouse model of spinal muscular atrophy, in which the number of Gems is decreased, shows fewer subsets U snRNAs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24112438", "endSection": "abstract"}, {"offsetInBeginSection": 210, "offsetInEndSection": 514, "text": "TDP-43 associates with nuclear bodies including Gemini of coiled bodies (GEMs). GEMs contribute to the biogenesis of uridine-rich small nuclear RNA (U snRNA), a component of splicing machinery. The number of GEMs and a subset of U snRNAs decrease in spinal muscular atrophy, a lower motor neuron disease,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23740936", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18572081", "endSection": "abstract"}]}, {"body": "What is the mode of action of bedaquiline?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25203970", "http://www.ncbi.nlm.nih.gov/pubmed/25114537", "http://www.ncbi.nlm.nih.gov/pubmed/24563587", "http://www.ncbi.nlm.nih.gov/pubmed/24259600", "http://www.ncbi.nlm.nih.gov/pubmed/24173008", "http://www.ncbi.nlm.nih.gov/pubmed/23459487"], "triples": [], "ideal_answer": ["Bedaquiline works by inhibiting bacterial adenosine triphosphate (ATP) synthase and represents the first novel class of antituberculosis agents that is used for treatment of multi drug resistant tuberculosis."], "concepts": [], "type": "summary", "id": "54d9071a4b1fd0d33c000007", "snippets": [{"offsetInBeginSection": 122, "offsetInEndSection": 289, "text": "Bedaquiline works by inhibiting bacterial adenosine triphosphate (ATP) synthase and represents the first novel class of antituberculosis agents in more than 40 years. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25203970", "endSection": "abstract"}, {"offsetInBeginSection": 734, "offsetInEndSection": 974, "text": "Bedaquiline has an entirely novel mechanism of action and so should be active against otherwise highly resistant organisms. It acts on the transmembrane component of adenosine triphosphate synthase and acts by preventing electron transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25114537", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24563587", "endSection": "title"}, {"offsetInBeginSection": 159, "offsetInEndSection": 472, "text": " Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like active, dormant, replicating, non-replicating, intracellular and extracellular.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24563587", "endSection": "abstract"}, {"offsetInBeginSection": 779, "offsetInEndSection": 927, "text": "DATA SYNTHESIS: Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259600", "endSection": "abstract"}, {"offsetInBeginSection": 626, "offsetInEndSection": 764, "text": "By directly inhibiting adenosine triphosphate (ATP) synthase, bedaquiline is effective against both replicating and dormant mycobacteria. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24173008", "endSection": "abstract"}, {"offsetInBeginSection": 1258, "offsetInEndSection": 1396, "text": "Enhanced sterilizing capacity via synergistic depletion of ATP further exhibits the promising potential of bedaquiline with pyrazinamide. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24173008", "endSection": "abstract"}, {"offsetInBeginSection": 122, "offsetInEndSection": 289, "text": "Bedaquiline works by inhibiting bacterial adenosine triphosphate (ATP) synthase and represents the first novel class of antituberculosis agents in more than 40 years. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25203970", "endSection": "abstract"}, {"offsetInBeginSection": 734, "offsetInEndSection": 974, "text": "Bedaquiline has an entirely novel mechanism of action and so should be active against otherwise highly resistant organisms. It acts on the transmembrane component of adenosine triphosphate synthase and acts by preventing electron transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25114537", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 850, "text": "Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259600", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 850, "text": "Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259600", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 850, "text": "Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259600", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 850, "text": "Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259600", "endSection": "abstract"}]}, {"body": "Which E3 ubiquitin ligase mediates the ubiquitination and degradation of the interferon receptor type 1 (IFNAR1)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21173164", "http://www.ncbi.nlm.nih.gov/pubmed/19948722", "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "http://www.ncbi.nlm.nih.gov/pubmed/17873516", "http://www.ncbi.nlm.nih.gov/pubmed/16551269", "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "http://www.ncbi.nlm.nih.gov/pubmed/14532120"], "triples": [], "ideal_answer": ["Ubiquitination and degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.  ", "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.  ", "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.  ", "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.  ", "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.  "], "exact_answer": [["\u03b2Trcp", "beta-Trcp", "SCFbeta-Trcp", "SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein)", "Skp1-Cullin1-HOS-Roc1 (SCF(HOS))"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044767"], "type": "factoid", "id": "55192892622b194345000012", "snippets": [{"offsetInBeginSection": 409, "offsetInEndSection": 571, "text": "IFNAR1 ubiquitination is facilitated by the \u03b2Trcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173164", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 730, "text": "Both ligand-dependent and -independent pathways converge on phosphorylation of Ser(535) within the IFNAR1 degron leading to recruitment of beta-Trcp E3 ubiquitin ligase and concomitant ubiquitination and degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948722", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 696, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 242, "offsetInEndSection": 480, "text": " Levels of IFNAR1 (regulated via degradation mediated by the betaTrcp E3 ubiquitin ligase) and IFNalpha signaling were reduced in 1205Lu melanoma cell line that harbors activated BRAF and exhibits high levels of betaTrcp ubiquitin ligase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17873516", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 641, "text": "IFNalpha promotes the phosphorylation of IFNAR1 on Ser535, followed by recruitment of the E3 ubiquitin ligase, beta-TrCP2 (beta-transducin repeats-containing protein 2), ubiquitination of IFNAR1 and proteolysis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16551269", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 570, "text": "Here we show that IFNAR1 interacts with the Homolog of Slimb (HOS) F-box protein in a phosphorylation-dependent manner, and that this interaction is promoted by interferon alpha (IFNalpha). IFNAR1 is ubiquitinated by the Skp1-Cullin1-HOS-Roc1 (SCF(HOS)) ubiquitin ligase in vitro. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14532120", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 693, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 568, "text": "IFNAR1 ubiquitination is facilitated by the \u03b2Trcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173164", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 638, "text": "IFNalpha promotes the phosphorylation of IFNAR1 on Ser535, followed by recruitment of the E3 ubiquitin ligase, beta-TrCP2 (beta-transducin repeats-containing protein 2), ubiquitination of IFNAR1 and proteolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16551269", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 693, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 568, "text": "IFNAR1 ubiquitination is facilitated by the \u03b2Trcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173164", "endSection": "abstract"}, {"offsetInBeginSection": 426, "offsetInEndSection": 638, "text": "IFNalpha promotes the phosphorylation of IFNAR1 on Ser535, followed by recruitment of the E3 ubiquitin ligase, beta-TrCP2 (beta-transducin repeats-containing protein 2), ubiquitination of IFNAR1 and proteolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16551269", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 520, "offsetInEndSection": 693, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 511, "offsetInEndSection": 728, "text": "Both ligand-dependent and -independent pathways converge on phosphorylation of Ser(535) within the IFNAR1 degron leading to recruitment of beta-Trcp E3 ubiquitin ligase and concomitant ubiquitination and degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948722", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 568, "text": "IFNAR1 ubiquitination is facilitated by the \u03b2Trcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173164", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 696, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 409, "offsetInEndSection": 571, "text": "IFNAR1 ubiquitination is facilitated by the \u03b2Trcp E3 ubiquitin ligase that is recruited to IFNAR1 upon its degron phosphorylation, which is induced by the ligand.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21173164", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 730, "text": "Both ligand-dependent and -independent pathways converge on phosphorylation of Ser(535) within the IFNAR1 degron leading to recruitment of beta-Trcp E3 ubiquitin ligase and concomitant ubiquitination and degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948722", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 696, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 514, "offsetInEndSection": 730, "text": "Both ligand-dependent and -independent pathways converge on phosphorylation of Ser(535) within the IFNAR1 degron leading to recruitment of beta-Trcp E3 ubiquitin ligase and concomitant ubiquitination and degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948722", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 695, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 695, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 695, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 695, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 307, "text": "Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337770", "endSection": "abstract"}, {"offsetInBeginSection": 524, "offsetInEndSection": 695, "text": "The SCF(betaTrcp) (Skp1-Cullin1-F-box complex) E3 ubiquitin ligase that mediates IFNAR1 ubiquitination and degradation in cells can conjugate both types of chains in vitro", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056411", "endSection": "abstract"}]}, {"body": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16757361", "http://www.ncbi.nlm.nih.gov/pubmed/8613066", "http://www.ncbi.nlm.nih.gov/pubmed/21886451", "http://www.ncbi.nlm.nih.gov/pubmed/21779504", "http://www.ncbi.nlm.nih.gov/pubmed/12697967", "http://www.ncbi.nlm.nih.gov/pubmed/19783717", "http://www.ncbi.nlm.nih.gov/pubmed/19826477", "http://www.ncbi.nlm.nih.gov/pubmed/19509115", "http://www.ncbi.nlm.nih.gov/pubmed/16166322", "http://www.ncbi.nlm.nih.gov/pubmed/8178941", "http://www.ncbi.nlm.nih.gov/pubmed/21626008"], "ideal_answer": ["Activating point mutations most frequently in codon 12"], "exact_answer": ["Point mutations"], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0032856", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011905", "http://www.disease-ontology.org/api/metadata/DOID:305"], "type": "factoid", "id": "5177def18ed59a060a000034", "snippets": [{"offsetInBeginSection": 9, "offsetInEndSection": 79, "text": "activating mutations in KRAS are identified in most pancreatic cancers", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757361", "endSection": "sections.0"}, {"offsetInBeginSection": 11, "offsetInEndSection": 182, "text": "Mutations at codon 12 of the K-ras gene are present in 65%-100% of carcinomas of human exocrine pancreas and could be used as a potential tumor marker at the tissue level.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8613066", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Activating point mutations in the K-Ras oncogene are among the most common genetic alterations in pancreatic cancer, occurring early in the progression of the disease.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509115", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Activating K-ras mutations are found in approximately 90% of pancreatic carcinomas and may contribute to the poor prognosis of these tumors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16166322", "endSection": "sections.0"}, {"offsetInBeginSection": 1056, "offsetInEndSection": 1216, "text": "Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8178941", "endSection": "sections.0"}, {"offsetInBeginSection": 1050, "offsetInEndSection": 1095, "text": "Ki-RAS mutations in 38% of the overall series", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12697967", "endSection": "sections.0"}, {"offsetInBeginSection": 533, "offsetInEndSection": 665, "text": "KRAS exon 2 mutations were detected in a total of 62 patients with the two methods combined, comprising 11 different mutant alleles.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19783717", "endSection": "sections.0"}, {"offsetInBeginSection": 9, "offsetInEndSection": 119, "text": "gain-of-function mutations in ras genes were the first specific genetic alterations identified in human cancer", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21779504", "endSection": "sections.0"}]}, {"body": "What causes Katayama Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24916752", "http://www.ncbi.nlm.nih.gov/pubmed/24985919", "http://www.ncbi.nlm.nih.gov/pubmed/24469437", "http://www.ncbi.nlm.nih.gov/pubmed/22470757", "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "http://www.ncbi.nlm.nih.gov/pubmed/2515622", "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "http://www.ncbi.nlm.nih.gov/pubmed/1901428", "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "http://www.ncbi.nlm.nih.gov/pubmed/1411323", "http://www.ncbi.nlm.nih.gov/pubmed/15582175", "http://www.ncbi.nlm.nih.gov/pubmed/24176480"], "triples": [], "ideal_answer": ["Katayama fever is an acute clinical condition characterised by high fever, dry cough and general malaise occurring during early Schistosoma spp. infection."], "exact_answer": [["Schistosoma spp"]], "concepts": [], "type": "factoid", "id": "56bb621fac7ad10019000009", "snippets": [{"offsetInBeginSection": 113, "offsetInEndSection": 274, "text": "The laboratory diagnosis of schistosomiasis and Katayama syndrome in returning travellers is difficult because the number of excreted eggs is often very limited.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916752", "endSection": "abstract"}, {"offsetInBeginSection": 1083, "offsetInEndSection": 1272, "text": "Eosinophilia (sometimes exceeding 50%) is often present in patients with acute schistosomiasis (Katayama fever), but may be limited or absent in late fibrotic manifestations of the disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Laboratory diagnosis of schistosomiasis and Katayama syndrome in returning travellers", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916752", "endSection": "title"}, {"offsetInBeginSection": 800, "offsetInEndSection": 942, "text": "The specific diagnosis of early schistosomiasis and Katayama fever relies essentially on serologic tests or preferably on PCR (if available). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "BACKGROUND: Katayama fever is an acute clinical condition characterised by high fever, dry cough and general malaise occurring during early Schistosoma spp. infection.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24985919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Schistosomiasis is a helminthic infection that is endemic in tropical and subtropical regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22470757", "endSection": "abstract"}, {"offsetInBeginSection": 169, "offsetInEndSection": 285, "text": "In Africa, it predominantly manifests as urogenital disease, and the main infective agent is Schistosoma hematobium.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24469437", "endSection": "abstract"}, {"offsetInBeginSection": 83, "offsetInEndSection": 172, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "OBJECTIVES: To investigate the characteristics of imported Katayama fever (acute schistosomiasis) as well as evolution and outcome under treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 572, "text": "RESULTS: Twenty-three patients were diagnosed with Katayama fever by Schistosoma egg detection and/or by seroconversion. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "The best therapeutic approach to acute schistosomiasis (Katayama fever) is still unsettled.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2515622", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Katayama fever is an acute clinical condition characterised by high fever, dry cough and general malaise occurring during early Schistosoma spp.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24985919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Acute schistosomiasis, called safari's fever in Africa and Katayama fever in Japan, is an immunoallergic reaction due to transcutaneous penetration of infective cercaria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15582175", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Acute schistosomiasis (Katayama fever): corticosteroid as adjunct therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Katayama fever or acute schistosomiasis probably occurs more commonly than is recorded.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1901428", "endSection": "abstract"}, {"offsetInBeginSection": 171, "offsetInEndSection": 260, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer's itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "endSection": "abstract"}, {"offsetInBeginSection": 480, "offsetInEndSection": 655, "text": "Three well-defined syndromes caused by schistosomiasis mansoni have been described: the stage of invasion, acute schistosomiasis (Katayama fever), and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "Katayama fever is an acute clinical condition characterised by high fever, dry cough and general malaise occurring during early Schistosoma spp.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24985919", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 83, "offsetInEndSection": 172, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Early detection of circulating anodic antigen (CAA) in a case of acute schistosomiasis mansoni with Katayama fever.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1411323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Acute schistosomiasis (Katayama fever): corticosteroid as adjunct therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "endSection": "title"}, {"offsetInBeginSection": 83, "offsetInEndSection": 172, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Early detection of circulating anodic antigen (CAA) in a case of acute schistosomiasis mansoni with Katayama fever.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1411323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Acute schistosomiasis (Katayama fever): corticosteroid as adjunct therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "endSection": "title"}, {"offsetInBeginSection": 83, "offsetInEndSection": 172, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Early detection of circulating anodic antigen (CAA) in a case of acute schistosomiasis mansoni with Katayama fever.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1411323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Acute schistosomiasis (Katayama fever): corticosteroid as adjunct therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "endSection": "title"}, {"offsetInBeginSection": 83, "offsetInEndSection": 172, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Early detection of circulating anodic antigen (CAA) in a case of acute schistosomiasis mansoni with Katayama fever.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1411323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Acute schistosomiasis (Katayama fever): corticosteroid as adjunct therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "endSection": "title"}, {"offsetInBeginSection": 83, "offsetInEndSection": 172, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Early detection of circulating anodic antigen (CAA) in a case of acute schistosomiasis mansoni with Katayama fever.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1411323", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "[Acute schistosomiasis (Katayama fever)].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7676521", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Acute schistosomiasis (Katayama fever): corticosteroid as adjunct therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511623", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": " A 35-year-old man presented with fever and severe urticaria after visiting Uganda. His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 176, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.  .", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 483, "text": "Three well-defined syndromes caused by schistosomiasis mansoni have been described: the stage of invasion, acute schistosomiasis (Katayama fever), and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer&apos;s itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": " To investigate the characteristics of imported Katayama fever (acute schistosomiasis) as well as evolution and outcome under treatment.  Between April 2000 and September 2004, we included prospectively all patients with confirmed diagnosis of Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "A 35-year-old man presented with fever and severe urticaria after visiting Uganda. His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 483, "text": "Three well-defined syndromes caused by schistosomiasis mansoni have been described: the stage of invasion, acute schistosomiasis (Katayama fever), and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer&apos;s itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "To investigate the characteristics of imported Katayama fever (acute schistosomiasis) as well as evolution and outcome under treatment.  Between April 2000 and September 2004, we included prospectively all patients with confirmed diagnosis of Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": " A 35-year-old man presented with fever and severe urticaria after visiting Uganda. His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 176, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.  .", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 483, "text": "Three well-defined syndromes caused by schistosomiasis mansoni have been described: the stage of invasion, acute schistosomiasis (Katayama fever), and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer&apos;s itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": " To investigate the characteristics of imported Katayama fever (acute schistosomiasis) as well as evolution and outcome under treatment.  Between April 2000 and September 2004, we included prospectively all patients with confirmed diagnosis of Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": " A 35-year-old man presented with fever and severe urticaria after visiting Uganda. His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 176, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.  .", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 483, "text": "Three well-defined syndromes caused by schistosomiasis mansoni have been described: the stage of invasion, acute schistosomiasis (Katayama fever), and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer&apos;s itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": " To investigate the characteristics of imported Katayama fever (acute schistosomiasis) as well as evolution and outcome under treatment.  Between April 2000 and September 2004, we included prospectively all patients with confirmed diagnosis of Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": " A 35-year-old man presented with fever and severe urticaria after visiting Uganda. His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 176, "text": "His symptoms were caused by acute invasive schistosomiasis, also known as Katayama fever.  .", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19009810", "endSection": "abstract"}, {"offsetInBeginSection": 308, "offsetInEndSection": 483, "text": "Three well-defined syndromes caused by schistosomiasis mansoni have been described: the stage of invasion, acute schistosomiasis (Katayama fever), and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10996126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Three distinct syndromes caused by schistosomiasis have been described: cercarial dermatitis or swimmer&apos;s itch, acute schistosomiasis or Katayama fever, and chronic schistosomiasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8115806", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": " To investigate the characteristics of imported Katayama fever (acute schistosomiasis) as well as evolution and outcome under treatment.  Between April 2000 and September 2004, we included prospectively all patients with confirmed diagnosis of Katayama fever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16169593", "endSection": "abstract"}]}, {"body": "What is the mode of inheritance of Wilson's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16932613", "http://www.ncbi.nlm.nih.gov/pubmed/20662462", "http://www.ncbi.nlm.nih.gov/pubmed/22610954", "http://www.ncbi.nlm.nih.gov/pubmed/8615372", "http://www.ncbi.nlm.nih.gov/pubmed/12152840", "http://www.ncbi.nlm.nih.gov/pubmed/8186659", "http://www.ncbi.nlm.nih.gov/pubmed/1940586", "http://www.ncbi.nlm.nih.gov/pubmed/2724779", "http://www.ncbi.nlm.nih.gov/pubmed/6620327", "http://www.ncbi.nlm.nih.gov/pubmed/6109943", "http://www.ncbi.nlm.nih.gov/pubmed/759736", "http://www.ncbi.nlm.nih.gov/pubmed/838566", "http://www.ncbi.nlm.nih.gov/pubmed/1248830"], "triples": [{"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4181", "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1198"}, {"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1198", "o": "Wilson_disease"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1198", "o": "http://www.dbpedia.org/resource/Wilson%27s_disease"}, {"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4181", "o": "Wilson disease, 277900"}], "ideal_answer": "Wilson's disease (WD) is an autosomal recessive disorder.", "exact_answer": ["autosomal recessive"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006527", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014918", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020739", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040582", "http://www.disease-ontology.org/api/metadata/DOID:893", "http://www.disease-ontology.org/api/metadata/DOID:2214", "http://www.disease-ontology.org/api/metadata/DOID:4"], "type": "factoid", "id": "52bf1b0a03868f1b06000009", "snippets": [{"offsetInBeginSection": 122, "offsetInEndSection": 272, "text": "The disease has an autosomal recessive mode of inheritance, and is characterized by excessive copper deposition, predominantly in the liver and brain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16932613", "endSection": "abstract"}, {"offsetInBeginSection": 178, "offsetInEndSection": 219, "text": " The inheritance is autosomal recessive. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20662462", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Wilson's disease (WD), or hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism caused by ATP7B gene mutation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22610954", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 193, "text": "Inheritance seems most likely to be autosomal recessive", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14580665", "endSection": "abstract"}, {"offsetInBeginSection": 1268, "offsetInEndSection": 1349, "text": "When familial, it is inherited recessively and has been linked to chromosome 20. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14580665", "endSection": "abstract"}, {"offsetInBeginSection": 183, "offsetInEndSection": 409, "text": "Inheritance of a pair of alleles of an autosomal recessive gene on chromosome 13 is necessary and sufficient to cause such copper accumulation in WD; reducing the dietary intake of copper cannot prevent the development of WD. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8615372", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 177, "text": "Wilson's disease is a treatable movement disorder with autosomal recessive inheritance which is associated with severe morbidity and mortality if not treated early. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12152840", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 388, "text": "The patient was considered heterozygote for hemochromatosis on the basis of the autosomal recessive inheritance for hemochromatosis, the frequency of the hemochromatosis gene, and the laboratory parameters defining her iron overload. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8186659", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Wilson's disease (WD) is an autosomal recessive disorder of copper accumulation leading to liver and/or brain damage. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1940586", "endSection": "abstract"}, {"offsetInBeginSection": 189, "offsetInEndSection": 305, "text": "Autosomal recessive inheritance indicates that siblings of affected patients are at 25% risk of having the disease. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1940586", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Wilson's disease is a rare genetic disorder of copper metabolism with autosomal recessive inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2724779", "endSection": "abstract"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1040, "text": "Recessive inheritance is, however, supported. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6620327", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 338, "text": "The autosomal recessive mode of inheritance strongly suggests that mutation of a single gene causes the impairment of both caeruloplasmin synthesis and biliary copper excretion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6109943", "endSection": "abstract"}, {"offsetInBeginSection": 1190, "offsetInEndSection": 1260, "text": "This is consistent with the autosomal-recessive pattern of inheritance", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/759736", "endSection": "abstract"}, {"offsetInBeginSection": 268, "offsetInEndSection": 408, "text": "The overall sex ratio of patients was nearly 1:1, and genetic analysis of 20 families confirmed an autosomal recessive mode of inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/838566", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 285, "text": "Dermatoglyphics of 11 patients with Wilson's disease and 16 of their clinically asymptomatic relatives of first degree were investigated; 11 of the latter ones were heterozygous in agreement with the turn over rates of Cu-67, 12 under the assumption of autosomal recessive inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1248830", "endSection": "abstract"}]}, {"body": "Which is the main regulatory molecule of SERCA2A function in the cardiac muscle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25451386", "http://www.ncbi.nlm.nih.gov/pubmed/23710633", "http://www.ncbi.nlm.nih.gov/pubmed/21266500", "http://www.ncbi.nlm.nih.gov/pubmed/18971376", "http://www.ncbi.nlm.nih.gov/pubmed/15598648", "http://www.ncbi.nlm.nih.gov/pubmed/11371203", "http://www.ncbi.nlm.nih.gov/pubmed/10555147", "http://www.ncbi.nlm.nih.gov/pubmed/19948724", "http://www.ncbi.nlm.nih.gov/pubmed/19112098", "http://www.ncbi.nlm.nih.gov/pubmed/18508637", "http://www.ncbi.nlm.nih.gov/pubmed/18415121"], "triples": [], "ideal_answer": ["SERCA2a activity is regulated by phosphorylation of another SR protein, Phospholamban (PLN). Phospholamban (PLB) inhibits the activity of SERCA2a, the Ca(2+)-ATPase in cardiac sarcoplasmic reticulum, by decreasing the apparent affinity of the enzyme for Ca(2+)."], "exact_answer": [["Phospholamban", "PLN", "plb"]], "concepts": [], "type": "factoid", "id": "54cb9c94f693c3b16b000005", "snippets": [{"offsetInBeginSection": 406, "offsetInEndSection": 705, "text": "SR Ca-transport is mediated by the SR Ca-ATPase (SERCA2a) and its regulatory phosphoprotein, phospholamban (PLN). Dephosphorylated PLN is an inhibitor of SERCA2a and phosphorylation by protein kinase A (PKA) or calcium-calmodulin-dependent protein kinases (CAMKII) relieves these inhibitory effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451386", "endSection": "abstract"}, {"offsetInBeginSection": 874, "offsetInEndSection": 976, "text": "SERCA2a activity can be regulated at multiple levels of a signaling cascade comprised of phospholamban", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Phospholamban (PLN), the reversible inhibitor of the sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2a), is a key regulator of myocyte Ca(2+) cycling with a significant role in heart failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21266500", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 271, "text": "The sarco(endo)plasmic reticulum (SR) Ca(2+) transport ATPase (SERCA2a) and its inhibitor phospholamban (PLN) control the uptake of Ca(2+) by SR membranes during relaxation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971376", "endSection": "abstract"}, {"offsetInBeginSection": 687, "offsetInEndSection": 762, "text": "phospholamban (PLN), a muscle-specific SR Ca(2+)-ATPase (SERCA2a) inhibitor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15598648", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Phospholamban (PLB) is a major target of the beta-adrenergic cascade in the heart, and functions as an endogenous inhibitor of Ca-ATPase transport activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11371203", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "Phospholamban (PLB) inhibits the activity of SERCA2a, the Ca(2+)-ATPase in cardiac sarcoplasmic reticulum, by decreasing the apparent affinity of the enzyme for Ca(2+).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19948724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Phospholamban has been suggested to be a key regulator of cardiac sarcoplasmic reticulum (SR) Ca cycling and contractility and a potential therapeutic target in restoring the depressed Ca cycling in failing hearts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19112098", "endSection": "abstract"}, {"offsetInBeginSection": 1269, "offsetInEndSection": 1304, "text": "phospholamban regulation of SERCA2a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19112098", "endSection": "abstract"}, {"offsetInBeginSection": 181, "offsetInEndSection": 530, "text": "SERCA2a activity is regulated by phosphorylation of another SR protein: Phospholamban (PLN). Dephosphorylated PLN inhibits SERCA2a. Phosphorylation of PLN by either cAMP or cGMP-dependent protein kinase at Ser16 or the Ca2+-calmodulin-dependent protein kinase (CaMKII), at Thr17, relieves this inhibition, increasing SR Ca2+ uptake and SR Ca2+ load.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18508637", "endSection": "abstract"}, {"offsetInBeginSection": 358, "offsetInEndSection": 532, "text": "The ablation of a muscle-specific sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) inhibitor, phospholamban, rescued the spectrum of phenotypes that resemble human heart failure.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10555147", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 495, "text": "The sarco(endo)plasmic reticulum Ca(2+) transport adenosine triphosphatase (SERCA2a) and its regulator phospholamban (PLN) have a central role in modulating Ca(2+) homeostasis and, therefore, cardiac function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18415121", "endSection": "abstract"}, {"offsetInBeginSection": 406, "offsetInEndSection": 705, "text": "SR Ca-transport is mediated by the SR Ca-ATPase (SERCA2a) and its regulatory phosphoprotein, phospholamban (PLN). Dephosphorylated PLN is an inhibitor of SERCA2a and phosphorylation by protein kinase A (PKA) or calcium-calmodulin-dependent protein kinases (CAMKII) relieves these inhibitory effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25451386", "endSection": "abstract"}, {"offsetInBeginSection": 874, "offsetInEndSection": 976, "text": "SERCA2a activity can be regulated at multiple levels of a signaling cascade comprised of phospholamban", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23710633", "endSection": "abstract"}]}, {"body": "What is the association between h-index and academic rank in academic neurosurgery?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24239737", "http://www.ncbi.nlm.nih.gov/pubmed/24055571", "http://www.ncbi.nlm.nih.gov/pubmed/23886815", "http://www.ncbi.nlm.nih.gov/pubmed/23872122", "http://www.ncbi.nlm.nih.gov/pubmed/23870040", "http://www.ncbi.nlm.nih.gov/pubmed/23820322", "http://www.ncbi.nlm.nih.gov/pubmed/22381859", "http://www.ncbi.nlm.nih.gov/pubmed/21495810", "http://www.ncbi.nlm.nih.gov/pubmed/20469986", "http://www.ncbi.nlm.nih.gov/pubmed/20380531", "http://www.ncbi.nlm.nih.gov/pubmed/19392590", "http://www.ncbi.nlm.nih.gov/pubmed/22544537", "http://www.ncbi.nlm.nih.gov/pubmed/23079075"], "triples": [], "ideal_answer": "Greater h-index is associated with greater academic rank in academic neurosurgery. The h indices increased significantly with increasing academic rank, with the median for instructors, assistant professors, associate professors, and professors was shown to be 2, 5, 10, and 19, respectively. In addition, h-index was shown to be predictive of NIH funding, fellowship training, academic productivity and salary.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000043", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009493"], "type": "summary", "id": "530cefaaad0bf1360c00000b", "snippets": [{"offsetInBeginSection": 944, "offsetInEndSection": 1037, "text": " The contemporary h-index was found to be significantly predictive of NIH funding (p<0.001). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239737", "endSection": "abstract"}, {"offsetInBeginSection": 1330, "offsetInEndSection": 1493, "text": "Bibliometric indices are higher for those with NIH funding compared to those without, but only the contemporary h-index was shown to be predictive of NIH funding. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24239737", "endSection": "abstract"}, {"offsetInBeginSection": 1513, "offsetInEndSection": 1650, "text": "However, when stratified by academic rank, a trend was observed showing greater mean h-index scores for those who completed fellowships. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24055571", "endSection": "abstract"}, {"offsetInBeginSection": 1704, "offsetInEndSection": 1834, "text": "Overall, being a senior faculty member corresponds with a greater h-index score, regardless of whether a fellowship was completed.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24055571", "endSection": "abstract"}, {"offsetInBeginSection": 866, "offsetInEndSection": 958, "text": "There was a positive association between the h-index, academic rank, and years posttraining.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23872122", "endSection": "abstract"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1651, "text": "Application of the h-index as a bibliometric in neurosurgery can distinguish academic productivity on the basis of academic rank, years posttraining, and neurosurgical subspecialties. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23872122", "endSection": "abstract"}, {"offsetInBeginSection": 973, "offsetInEndSection": 1217, "text": "Overall, the authors conclude that the h index metric is a reasonable measure of academic productivity in the pediatric neurosurgery arena that provides a robust measure of an individual's contribution to the pediatric neurosurgery literature. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23870040", "endSection": "abstract"}, {"offsetInBeginSection": 1342, "offsetInEndSection": 1490, "text": "The h index calculation also reveals the productivity of the pediatric neurosurgeons to be on par with the productivity of neurosurgeons in general.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23870040", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 803, "text": "The h-index frequency distribution conformed to both the log-linear variation of a power law (r                         (2)\u2009=\u2009.99) and the beta distribution with the same fitting exponents as previously described in a power law analysis of the productivity of neurosurgeons. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544537", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 1275, "text": "The h indices increased significantly with increasing academic rank, with the median for instructors, assistant professors, associate professors, and professors being 2, 5, 10, and 19, respectively (p < 0.0001, Kruskal-Wallis; all groups significantly different from each other except the difference between instructor and assistant professor [Conover]). Departmental chairs had a median h index of 22 (range 3-55) and program directors a median of 17 (range 0-62). Plot of the log of the rank versus h index demonstrated a remarkable linear pattern (R(2) = 0.995, p < 0.0001), suggesting that this is a power-law relationship.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469986", "endSection": "abstract"}, {"offsetInBeginSection": 1404, "offsetInEndSection": 1559, "text": "The distribution of the h index within an academic population is described for the first time and appears related to the ubiquitous power-law distribution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20469986", "endSection": "abstract"}, {"offsetInBeginSection": 1175, "offsetInEndSection": 1301, "text": "As expected, the h index increased with academic rank and there was a statistically significant difference between each rank. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19392590", "endSection": "abstract"}, {"offsetInBeginSection": 1795, "offsetInEndSection": 2034, "text": "Within the field of academic neurosurgery, clear differences of h indices between academic ranks exist. On average, an increase of the h index by 5 appears to correspond to the next highest academic rank, with the exception of chairperson.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19392590", "endSection": "abstract"}, {"offsetInBeginSection": 1447, "offsetInEndSection": 1536, "text": "Scopus h-index was of borderline significance in predicting physician salary (P = 0.12). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23820322", "endSection": "abstract"}]}, {"body": "Which is the gene most commonly mutated in Tay-Sachs disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/14648242", "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "http://www.ncbi.nlm.nih.gov/pubmed/7858168", "http://www.ncbi.nlm.nih.gov/pubmed/8411703", "http://www.ncbi.nlm.nih.gov/pubmed/8490625", "http://www.ncbi.nlm.nih.gov/pubmed/3375249", "http://www.ncbi.nlm.nih.gov/pubmed/3362213", "http://www.ncbi.nlm.nih.gov/pubmed/2967444"], "triples": [{"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4016", "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HEXA"}, {"p": "http://www.w3.org/2000/01/rdf-schema#label", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HEXA", "o": "HEXA"}, {"p": "http://www.w3.org/2004/02/skos/core#exactMatch", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HEXA", "o": "http://www.dbpedia.org/resource/HEXA"}, {"p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name", "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4016", "o": "Tay-Sachs disease, 272800"}], "ideal_answer": ["HEXA gene, encoding the alpha-subunit of the lysosomal enzyme, beta-N-acetylhexosaminidase A"], "exact_answer": [["HEXA"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013661", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005678", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D049290", "http://www.disease-ontology.org/api/metadata/DOID:3320"], "type": "factoid", "id": "536e46f27d100faa09000012", "snippets": [{"offsetInBeginSection": 9, "offsetInEndSection": 81, "text": "mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14648242", "endSection": "title"}, {"offsetInBeginSection": 4, "offsetInEndSection": 81, "text": "mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "endSection": "title"}, {"offsetInBeginSection": 4, "offsetInEndSection": 101, "text": "affected HEXA alleles were found in an Israeli Druze Tay-Sachs child born to first-cousin parents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 141, "text": "abnormalities in the gene coding for the beta-hexosaminidase alpha subunit were analysed from fibroblast's RNAs of 42 Tay-Sachs patients ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7858168", "endSection": "abstract"}, {"offsetInBeginSection": 667, "offsetInEndSection": 804, "text": "In the severest phenotype of Tay-Sachs disease (infantile form), mRNA of beta-hexosaminidase alpha subunit is not produced or is unstable", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8411703", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 69, "text": "novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8490625", "endSection": "title"}, {"offsetInBeginSection": 1, "offsetInEndSection": 140, "text": "ay-Sachs disease is an inherited disorder in which the alpha chain of the lysosomal enzyme beta-N-acetylhexosaminidase A bears the mutation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3375249", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 183, "text": "ay-Sachs disease is an autosomal recessive genetic disorder resulting from mutation of the HEXA gene encoding the alpha-subunit of the lysosomal enzyme, beta-N-acetylhexosaminidase A", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3362213", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 370, "text": "Tay-Sachs disease lack detectable alpha-chain message when analyzed by Northern blotting with complementary DNA encoding the alpha-chain of human beta-hexosaminidase A", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2967444", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22723944", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Molecular analysis of HEXA gene in Argentinean patients affected with Tay-Sachs disease: possible common origin of the prevalent c.459+5A>G mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441121", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Tay-Sachs disease (TSD) is a recessively inherited disorder caused by the deficient activity of hexosaminidase A due to mutations in the HEXA gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14648242", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Two mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "We have identified three mutations in the beta-hexoseaminidase A (HEXA) gene in a juvenile Tay-Sachs disease (TSD) patient, which exhibited a reduced level of HEXA mRNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20363167", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 81, "text": "mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14648242", "endSection": "title"}, {"offsetInBeginSection": 4, "offsetInEndSection": 81, "text": "mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs disease", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Two mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Two mutated HEXA alleles in a Druze patient with late-infantile Tay-Sachs disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9401008", "endSection": "title"}]}, {"body": "Describe a diet that reduces the chance of kidney stones.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24127678", "http://www.ncbi.nlm.nih.gov/pubmed/24026180", "http://www.ncbi.nlm.nih.gov/pubmed/23880796", "http://www.ncbi.nlm.nih.gov/pubmed/23827660", "http://www.ncbi.nlm.nih.gov/pubmed/23732207", "http://www.ncbi.nlm.nih.gov/pubmed/23674806", "http://www.ncbi.nlm.nih.gov/pubmed/23593205", "http://www.ncbi.nlm.nih.gov/pubmed/23568066", "http://www.ncbi.nlm.nih.gov/pubmed/23546565", "http://www.ncbi.nlm.nih.gov/pubmed/23535174", "http://www.ncbi.nlm.nih.gov/pubmed/23438422", "http://www.ncbi.nlm.nih.gov/pubmed/23221031", "http://www.ncbi.nlm.nih.gov/pubmed/22857835", "http://www.ncbi.nlm.nih.gov/pubmed/23634702", "http://www.ncbi.nlm.nih.gov/pubmed/16174292", "http://www.ncbi.nlm.nih.gov/pubmed/21369385", "http://www.ncbi.nlm.nih.gov/pubmed/23302672", "http://www.ncbi.nlm.nih.gov/pubmed/14552081", "http://www.ncbi.nlm.nih.gov/pubmed/11269613"], "triples": [{"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13727389", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}, {"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13688679", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}, {"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13725651", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}, {"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13688680", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}, {"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13903830", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}, {"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13816280", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}, {"p": "http://linkedlifedata.com/resource/pubmed/keyword", "s": "http://linkedlifedata.com/resource/pubmed/id/13688678", "o": "http://linkedlifedata.com/resource/pubmed/keyword/KIDNEY+DISEASES%2Fnutrition+and+diet"}], "ideal_answer": "People can help prevent kidney stones by making changes in fluid intake and, depending on the type of kidney stone, changes in consumption of sodium, animal protein, calcium, and oxalate.\nDrinking enough fluids each day is the best way to help prevent most types of kidney stones. Health care providers recommend that a person drink 2 to 3 liters of fluid a day. People with cystine stones may need to drink even more. Though water is best, other fluids may also help prevent kidney stones, such as citrus drinks.", "exact_answer": ["reducing sodium"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007669", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004032", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007668", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014545", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007674", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004035", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018753", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014676", "http://www.disease-ontology.org/api/metadata/DOID:585"], "type": "factoid", "id": "5311bcc2e3eabad021000005", "snippets": [{"offsetInBeginSection": 641, "offsetInEndSection": 727, "text": "calcium oxalate remains the dominant type accounting for 64% of stones in our dataset,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127678", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 849, "text": "Uric acid stones contributed 16% of contemporary stone compositions,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127678", "endSection": "abstract"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1015, "text": "Struvite stones showed a decreasing trend from 14% in the 1970s, to 12% in the 1980s and 7% in the current data.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24127678", "endSection": "abstract"}, {"offsetInBeginSection": 154, "offsetInEndSection": 263, "text": ". Given recent concerns that calcium supplements may raise risk for cardiovascular disease and kidney stones,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23880796", "endSection": "abstract"}]}, {"body": "What is the ubiquitin proteome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23764619", "http://www.ncbi.nlm.nih.gov/pubmed/23743150", "http://www.ncbi.nlm.nih.gov/pubmed/22178446"], "triples": [], "ideal_answer": "The ubiquitin proteome is the entire set ubiquitinated proteins and of their respective ubiquitination sites.", "exact_answer": ["The ubiquitin proteome is the entire set ubiquitinated proteins and of their respective ubiquitination sites."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014452", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054875", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D025801", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057149", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0031386", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016567", "http://www.uniprot.org/uniprot/UBIQ_CERCA"], "type": "factoid", "id": "532f1452d6d3ac6a34000030", "snippets": [{"offsetInBeginSection": 266, "offsetInEndSection": 422, "text": "Mass spectrometry now allows high throughput approaches for the identification of the thousands of ubiquitinated proteins and of their ubiquitination sites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23764619", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 543, "text": "we used Tandem repeated Ubiquitin Binding Entities (TUBEs) under non-denaturing conditions followed by mass spectrometry analysis to study global ubiquitylation events that may lead to the identification of potential drug targets.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22178446", "endSection": "abstract"}, {"offsetInBeginSection": 174, "offsetInEndSection": 339, "text": "To study the ubiquitin proteome we have established an immunoaffinity purification method for the proteomic analysis of endogenously ubiquitinated protein complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23743150", "endSection": "abstract"}]}, {"body": "What is the function of TALENs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22624882", "http://www.ncbi.nlm.nih.gov/pubmed/23000899", "http://www.ncbi.nlm.nih.gov/pubmed/23027955", "http://www.ncbi.nlm.nih.gov/pubmed/23555929"], "ideal_answer": ["Transcription Activator-Like Effector Nucleases (TALENs) consist of a nuclease domain fused to a DNA binding domain which is engineered to bind to any genomic sequence. These chimeric enzymes can be used to introduce a double strand break at a specific genomic site which then can become the substrate for error-prone non-homologous end joining (NHEJ), generating mutations at the site of cleavage. TALENs provide a powerful new approach for targeted genome editing and functional genomic applications.", " These chimeric enzymes can be used to introduce a double strand break at a specific genomic site which then can become the substrate for error-prone non-homologous end joining (NHEJ), generating mutations at the site of cleavage. Artificial transcription activator-like effector nucleases (TALENs) provide a powerful new approach for targeted zebrafish genome editing and functional genomic applications. Transcription Activator-Like Effector Nucleases (TALENs) consist of a nuclease domain fused to a DNA binding domain which is engineered to bind to any genomic sequence. Transcription activator-like effector nucleases (TALENs) are programmable nucleases that join FokI endonuclease with the modular DNA-binding domain of TALEs."], "type": "summary", "id": "515dc691298dcd4e5100001b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Transcription activator-like effector nucleases (TALENs) are programmable nucleases that join FokI endonuclease with the modular DNA-binding domain of TALEs", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23027955", "endSection": "sections.0"}]}, {"body": "Which gene has been found to be mutant in Lesch-Nyhan Disease patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24075303", "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "http://www.ncbi.nlm.nih.gov/pubmed/23691025", "http://www.ncbi.nlm.nih.gov/pubmed/22157001", "http://www.ncbi.nlm.nih.gov/pubmed/20159777", "http://www.ncbi.nlm.nih.gov/pubmed/2875930", "http://www.ncbi.nlm.nih.gov/pubmed/754871", "http://www.ncbi.nlm.nih.gov/pubmed/20544510", "http://www.ncbi.nlm.nih.gov/pubmed/23046577", "http://www.ncbi.nlm.nih.gov/pubmed/8851475", "http://www.ncbi.nlm.nih.gov/pubmed/15277709", "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "http://www.ncbi.nlm.nih.gov/pubmed/4624352", "http://www.ncbi.nlm.nih.gov/pubmed/204459", "http://www.ncbi.nlm.nih.gov/pubmed/7228031", "http://www.ncbi.nlm.nih.gov/pubmed/15140374", "http://www.ncbi.nlm.nih.gov/pubmed/15571229", "http://www.ncbi.nlm.nih.gov/pubmed/22132985", "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "http://www.ncbi.nlm.nih.gov/pubmed/3384338", "http://www.ncbi.nlm.nih.gov/pubmed/9799086", "http://www.ncbi.nlm.nih.gov/pubmed/7586656", "http://www.ncbi.nlm.nih.gov/pubmed/22042773", "http://www.ncbi.nlm.nih.gov/pubmed/6853716", "http://www.ncbi.nlm.nih.gov/pubmed/8485579", "http://www.ncbi.nlm.nih.gov/pubmed/2671903"], "triples": [], "ideal_answer": ["Lesch-Nyhan Disease (LND) is the result of mutations in the X-linked gene encoding the purine metabolic enzyme, hypoxanthine guanine phosphoribosyl transferase (HPRT)."], "exact_answer": [["Hypoxanthine guanine phosphoribosyl transferase (HPRT) gene"]], "concepts": [], "type": "factoid", "id": "5727ab040fd6f91b68000019", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "We describe a family of seven boys affected by Lesch-Nyhan disease with various phenotypes. Further investigations revealed a mutation c.203T>C in the gene encoding HGprt of all members, with substitution of leucine to proline at residue 68 (p.Leu68Pro)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24075303", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Lesch-Nyhan disease (LND) is caused by deficiency of hypoxanthine guanine phosphoribosyltransferase (HPRT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Lesch-Nyhan Disease (LND) is the result of mutations in the X-linked gene encoding the purine metabolic enzyme, hypoxanthine guanine phosphoribosyl transferase (HPRT)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23691025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Lesch-Nyhan disease and its attenuated variants are caused by mutations in the HPRT1 gene, which encodes the purine recycling enzyme hypoxanthine-guanine phosphoribosyltransferase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22157001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 421, "text": "The study of Lesch-Nyhan-diseased (LND) human brain is crucial for understanding how mutant hypoxanthine-phosphoribosyltransferase (HPRT) might lead to neuronal dysfunction. Since LND is a rare, inherited disorder caused by a deficiency of the enzyme HPRT, human neural stem cells (hNSCs) that carry this mutation are a precious source for delineating the consequences of HPRT deficiency and for developing new treatments", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20159777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Molecular characterization and structure analysis of HPRT in a Chinese patient with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "endSection": "title"}, {"offsetInBeginSection": 1118, "offsetInEndSection": 1341, "text": "An example is the isolation, by 6-thioguanine resistance, of cells deficient in hypoxanthine-guanine phosphoribosyl transferase -- the same deficiency that characterizes human patients with the X-linked Lesch-Nyhan disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/754871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Lesch-Nyhan disease (LND) is caused by deficiency of hypoxanthine guanine phosphoribosyltransferase (HPRT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "endSection": "abstract"}, {"offsetInBeginSection": 915, "offsetInEndSection": 1055, "text": "In this research we demonstrate a model for Lesch-Nyhan disease by mutating the HPRT1 gene in human ES cells using homologous recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15277709", "endSection": "abstract"}, {"offsetInBeginSection": 646, "offsetInEndSection": 839, "text": "Lesch-Nyhan disease is caused by a mutation in the HPRT1 gene that triggers an overproduction of uric acid, causing gout-like symptoms and urinary stones, in addition to neurological disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15277709", "endSection": "abstract"}, {"offsetInBeginSection": 1118, "offsetInEndSection": 1341, "text": "An example is the isolation, by 6-thioguanine resistance, of cells deficient in hypoxanthine-guanine phosphoribosyl transferase -- the same deficiency that characterizes human patients with the X-linked Lesch-Nyhan disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/754871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Lesch-Nyhan disease (LND) is caused by deficiency of hypoxanthine guanine phosphoribosyltransferase (HPRT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Molecular characterization and structure analysis of HPRT in a Chinese patient with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24001192", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Five independent mutations in the hypoxanthine guanine phosphoribosyltransferase (HPRT) gene were identified in a partially HPRT deficient patient with gout and in four Lesch-Nyhan patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}, {"offsetInBeginSection": 168, "offsetInEndSection": 386, "text": "Many different mutations throughout the HPRT coding region of Lesch-Nyhan patients have been described, including single base substitutions, partial or entire gene deletions, gene insertions or endoduplication of exons", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8851475", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 370, "text": "De novo purine biosynthesis has been studied in lymphocyte cell lines established from Lesch-Nyhan patients deficient in hypoxanthine-guanine phosphoribosyltransferase (HGPRT), in in vitro differentiating erythroleukaemic cell lines cloned from cells charactistic of virus-induced murine leukaemia, and in mutant hamster cells deficient in amidophosphoribosyltransferase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/204459", "endSection": "abstract"}, {"offsetInBeginSection": 900, "offsetInEndSection": 1122, "text": "An example is the isolation, by 6-thioguanine resistance, of cells deficient in hypoxanthine-guanine phosphoribosyl transferase -- the same deficiency that characterizes human patients with the X-linked Lesch-Nyhan disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/754871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "HGPRT structural gene mutation in Lesch-Nyhan-syndrome as indicated by antigenic activity and reversion of the enzyme deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7228031", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4624352", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Mutation carrier testing in Lesch-Nyhan syndrome families: HPRT mutant frequency and mutation analysis with peripheral blood T lymphocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15140374", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Adenosine transport in HPRT deficient lymphocytes from Lesch-Nyhan disease patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15571229", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Molecular characterization of a deletion in the HPRT1 gene in a patient with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132985", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Molecular description of three macro-deletions and an Alu-Alu recombination-mediated duplication in the HPRT gene in four patients with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "HGPRT structural gene mutation in Lesch-Nyhan-syndrome as indicated by antigenic activity and reversion of the enzyme deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7228031", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4624352", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Mutation carrier testing in Lesch-Nyhan syndrome families: HPRT mutant frequency and mutation analysis with peripheral blood T lymphocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15140374", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Adenosine transport in HPRT deficient lymphocytes from Lesch-Nyhan disease patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15571229", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Molecular characterization of a deletion in the HPRT1 gene in a patient with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132985", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Molecular description of three macro-deletions and an Alu-Alu recombination-mediated duplication in the HPRT gene in four patients with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "HGPRT structural gene mutation in Lesch-Nyhan-syndrome as indicated by antigenic activity and reversion of the enzyme deficiency.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7228031", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4624352", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Mutation carrier testing in Lesch-Nyhan syndrome families: HPRT mutant frequency and mutation analysis with peripheral blood T lymphocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15140374", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Adenosine transport in HPRT deficient lymphocytes from Lesch-Nyhan disease patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15571229", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Molecular characterization of a deletion in the HPRT1 gene in a patient with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132985", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Molecular description of three macro-deletions and an Alu-Alu recombination-mediated duplication in the HPRT gene in four patients with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Mutation carrier testing in Lesch-Nyhan syndrome families: HPRT mutant frequency and mutation analysis with peripheral blood T lymphocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15140374", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Molecular characterization of a deletion in the HPRT1 gene in a patient with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132985", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Molecular description of three macro-deletions and an Alu-Alu recombination-mediated duplication in the HPRT gene in four patients with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Genetic basis of hypoxanthine guanine phosphoribosyltransferase deficiency in a patient with the Lesch-Nyhan syndrome (HPRTFlint).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3384338", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "Molecular characterization of two deletion events involving Alu-sequences, one novel base substitution and two tentative hotspot mutations in the hypoxanthine phosphoribosyltransferase (HPRT) gene in five patients with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9799086", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Southern analysis reveals a large deletion at the hypoxanthine phosphoribosyltransferase locus in a patient with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7586656", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "MicroRNA-mediated dysregulation of neural developmental genes in HPRT deficiency: clues for Lesch-Nyhan disease?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22042773", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in a patient with the Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6853716", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8485579", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4624352", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Mutation carrier testing in Lesch-Nyhan syndrome families: HPRT mutant frequency and mutation analysis with peripheral blood T lymphocytes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15140374", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Adenosine transport in HPRT deficient lymphocytes from Lesch-Nyhan disease patients.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15571229", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Molecular characterization of a deletion in the HPRT1 gene in a patient with Lesch-Nyhan syndrome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132985", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Molecular description of three macro-deletions and an Alu-Alu recombination-mediated duplication in the HPRT gene in four patients with Lesch-Nyhan disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11336982", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Lesch-Nyhan syndrome is a rare X-linked recessive disorder of purine metabolism associated with a virtually complete deficiency of the enzyme hypoxanthine-guanine phosphoribosyl-transferase (HPRT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2671903", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Lesch-Nyhan syndrome is a rare X-linked recessive disorder of purine metabolism associated with a virtually complete deficiency of the enzyme hypoxanthine-guanine phosphoribosyl-transferase (HPRT).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2671903", "endSection": "abstract"}, {"offsetInBeginSection": 1298, "offsetInEndSection": 1627, "text": "Normally spliced HPRT mRNA was quantified by real-time PCR in this patient, in control subjects, and in two Lesch Nyhan patient with splice mutations excluding exon 4 (patient B) and exon 8 (patient C) who had clinically a Lesch Nyhan disease phenotype. A minor amount of normally spliced HPRT mRNA was found in all the patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20544510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 291, "text": " Lesch-Nyhan disease (LND) is caused by lack of hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity. Mutations in HPRT1 gene show variability in type and location within the gene, and in certain patients the HPRT coding sequence is normal and the molecular defect cannot be found.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046577", "endSection": "abstract"}, {"offsetInBeginSection": 1332, "offsetInEndSection": 1532, "text": "HPRT gene point mutations in three gouty arthritis and one Lesch-Nyhan patient have been identified by peptide sequencing. Six gross gene rearrangements have been identified in Lesch-Nyhan HPRT genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2875930", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 996, "text": "In two other mutants causing Lesch-Nyhan syndrome, a portion of the HPRT gene was deleted, and RNA splicing was missing in both mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Five independent mutations in the hypoxanthine guanine phosphoribosyltransferase (HPRT) gene were identified in a partially HPRT deficient patient with gout and in four Lesch-Nyhan patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 996, "text": "In two other mutants causing Lesch-Nyhan syndrome, a portion of the HPRT gene was deleted, and RNA splicing was missing in both mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Five independent mutations in the hypoxanthine guanine phosphoribosyltransferase (HPRT) gene were identified in a partially HPRT deficient patient with gout and in four Lesch-Nyhan patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 996, "text": "In two other mutants causing Lesch-Nyhan syndrome, a portion of the HPRT gene was deleted, and RNA splicing was missing in both mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}, {"offsetInBeginSection": 1298, "offsetInEndSection": 1551, "text": "Normally spliced HPRT mRNA was quantified by real-time PCR in this patient, in control subjects, and in two Lesch Nyhan patient with splice mutations excluding exon 4 (patient B) and exon 8 (patient C) who had clinically a Lesch Nyhan disease phenotype.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20544510", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 996, "text": "In two other mutants causing Lesch-Nyhan syndrome, a portion of the HPRT gene was deleted, and RNA splicing was missing in both mutants.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1483694", "endSection": "abstract"}]}, {"body": "DX-88 is investigational name of which drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21760740", "http://www.ncbi.nlm.nih.gov/pubmed/21481442", "http://www.ncbi.nlm.nih.gov/pubmed/19093699", "http://www.ncbi.nlm.nih.gov/pubmed/18613770", "http://www.ncbi.nlm.nih.gov/pubmed/18467921", "http://www.ncbi.nlm.nih.gov/pubmed/18220151", "http://www.ncbi.nlm.nih.gov/pubmed/16916274", "http://www.ncbi.nlm.nih.gov/pubmed/14572819"], "triples": [], "ideal_answer": ["DX-88 is investigational name of a drug Ecallantide, a 60-amino acid recombinant protein discovered through phage display technology, that is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute hereditary angioedema attacks."], "exact_answer": [["Ecallantide"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015507"], "type": "factoid", "id": "54f1e031c409818c32000001", "snippets": [{"offsetInBeginSection": 505, "offsetInEndSection": 635, "text": "Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760740", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21481442", "endSection": "title"}, {"offsetInBeginSection": 661, "offsetInEndSection": 992, "text": "Several novel therapies have completed phase III trials in the US, including: (i) plasma-derived C1-INH replacement therapies (Berinert P and Cinryze); (ii) a recombinant C1-INH replacement therapy (conestat alfa; Rhucin); (iii) a kallikrein inhibitor (ecallantide [DX-88]); and (iv) a bradykinin-2-receptor antagonist (icatibant).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19093699", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18613770", "endSection": "title"}, {"offsetInBeginSection": 315, "offsetInEndSection": 403, "text": "OBJECTIVE: Ecallantide (DX-88) is a potent and specific inhibitor of plasma kallikrein. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18613770", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 537, "text": "DX-88 (ecallantide), a 60-amino acid recombinant protein discovered through phage display technology, is a highly specific, potent inhibitor of human plasma kallikrein that has been used successfully in the treatment of patients experiencing acute HAE attacks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18467921", "endSection": "abstract"}, {"offsetInBeginSection": 983, "offsetInEndSection": 1204, "text": "DX-88 or ecallantide, a potent and specific inhibitor of plasma kallikrein, achieved all primary and secondary efficacy end points in a placebo-controlled, double-blind, phase 3 study, with a second phase 3 study ongoing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18220151", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 552, "text": "DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16916274", "endSection": "abstract"}, {"offsetInBeginSection": 505, "offsetInEndSection": 635, "text": "Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760740", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21481442", "endSection": "title"}, {"offsetInBeginSection": 387, "offsetInEndSection": 551, "text": "DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16916274", "endSection": "abstract"}]}, {"body": "What is the mode of inheritance of Romano Ward long QT syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/15950200", "http://www.ncbi.nlm.nih.gov/pubmed/9272155", "http://www.ncbi.nlm.nih.gov/pubmed/19862833", "http://www.ncbi.nlm.nih.gov/pubmed/10593671", "http://www.ncbi.nlm.nih.gov/pubmed/9302275", "http://www.ncbi.nlm.nih.gov/pubmed/8223759", "http://www.ncbi.nlm.nih.gov/pubmed/8048706", "http://www.ncbi.nlm.nih.gov/pubmed/8098062", "http://www.ncbi.nlm.nih.gov/pubmed/2771275", "http://www.ncbi.nlm.nih.gov/pubmed/8180509", "http://www.ncbi.nlm.nih.gov/pubmed/7695867", "http://www.ncbi.nlm.nih.gov/pubmed/10560244", "http://www.ncbi.nlm.nih.gov/pubmed/7994803"], "triples": [], "ideal_answer": "The Romano Ward long QT syndrome (LQTS) has an autosomal dominant mode of inheritance.", "exact_answer": ["autosomal dominant"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008133", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D029597", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040582"], "type": "factoid", "id": "52ee9f55c8da898910000009", "snippets": [{"offsetInBeginSection": 301, "offsetInEndSection": 550, "text": "KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15950200", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "The Romano Ward long QT syndrome (LQTS) has an autosomal dominant mode of inheritance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9272155", "endSection": "abstract"}, {"offsetInBeginSection": 662, "offsetInEndSection": 875, "text": "The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19862833", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 449, "text": "The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10593671", "endSection": "abstract"}, {"offsetInBeginSection": 402, "offsetInEndSection": 612, "text": "Different mutations in KVLQT1 cause the dominant Romano-Ward (RW) syndrome and the recessive Jervell and Lange-Nielsen (JLN) syndrome, which, in addition to cardiac abnormalities, includes congenital deafness. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9302275", "endSection": "abstract"}, {"offsetInBeginSection": 354, "offsetInEndSection": 450, "text": "The Romano-Ward syndrome shows an autosomal dominant pattern of inheritance and normal hearing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8223759", "endSection": "abstract"}, {"offsetInBeginSection": 126, "offsetInEndSection": 295, "text": "The Romano-Ward syndrome is of autosomal dominant inheritance, and the Jervell and Lange-Nielson syndrome, with associated deafness, of autosomal recessive inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8048706", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8098062", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2771275", "endSection": "abstract"}]}, {"body": "What is the synonym of the lubag disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25004170", "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "http://www.ncbi.nlm.nih.gov/pubmed/21047175", "http://www.ncbi.nlm.nih.gov/pubmed/20694531", "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "http://www.ncbi.nlm.nih.gov/pubmed/17579361", "http://www.ncbi.nlm.nih.gov/pubmed/16242937", "http://www.ncbi.nlm.nih.gov/pubmed/15596620", "http://www.ncbi.nlm.nih.gov/pubmed/15465396", "http://www.ncbi.nlm.nih.gov/pubmed/15390042", "http://www.ncbi.nlm.nih.gov/pubmed/12471465", "http://www.ncbi.nlm.nih.gov/pubmed/12465067", "http://www.ncbi.nlm.nih.gov/pubmed/8041372", "http://www.ncbi.nlm.nih.gov/pubmed/8351010", "http://www.ncbi.nlm.nih.gov/pubmed/8338342", "http://www.ncbi.nlm.nih.gov/pubmed/8341310", "http://www.ncbi.nlm.nih.gov/pubmed/1672807"], "triples": [], "ideal_answer": ["Lubag disease is also known as X-linked dystonia-parkinsonism (XDP). This disease is characterized by dystonia and parkinsonism, and afflicts Filipino men, and rarely, women originating principally from the Panay Island."], "exact_answer": [["X-linked dystonia-parkinsonism"]], "concepts": [], "type": "factoid", "id": "54df695b1388e8454a000004", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "IMPORTANCE: Despite recessive inheritance, X-linked dystonia-parkinsonism (Lubag disease) has also been described in women presenting with a late-onset isolated parkinsonian syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25004170", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Lubag disease is a genetic X-linked dystonia-parkinsonism syndrome afflicting Filipino men. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "X-chromosomal dystonia parkinsonism syndrome (XDP, 'lubag') is associated with sequence changes within the TAF1/DYT3 multiple transcript system. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, \"Lubag\").", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047175", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Sex-linked dystonia parkinsonism (XDP, DYT3, \"Lubag\") is an adult-onset, progressive, debilitating movement disorder first described in Filipino males from Panay Islands in 1975. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21047175", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 992, "text": "We cover dopa-responsive dystonia, Wilson's disease, Parkin-, PINK1-, and DJ-1-associated parkinsonism (PARK2, 6, and 7), x-linked dystonia-parkinsonism/Lubag (DYT3), rapid-onset dystonia-parkinsonism (DYT12) and DYT16 dystonia, the syndromes of Neurodegeneration with Brain Iron Accumulation (NBIA) including pantothenate kinase (PANK2)- and PLA2G6 (PARK14)-associated neurodegeneration, neuroferritinopathy, Kufor-Rakeb disease (PARK9) and the recently described SENDA syndrome; FBXO7-associated neurodegeneration (PARK15), autosomal-recessive spastic paraplegia with a thin corpus callosum (SPG11), and dystonia parkinsonism due to mutations in the SLC6A3 gene encoding the dopamine transporter.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20694531", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "X-Linked Dystonia-Parkinsonism (XDP or \"Lubag\") is a progressive neurodegenerative disorder unique to the Island of Panay in the Philippines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "First case of X-linked dystonia-parkinsonism (\"Lubag\") to demonstrate a response to bilateral pallidal stimulation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579361", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "\"Lubag\" or X-linked dystonia-parkinsonism (XDP) is a genetic syndrome afflicting Filipino men.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17579361", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "First case report of X linked dystonia parkinsonism (XDP) or 'lubag' in Australia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16242937", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "PURPOSE: To present the first genetically supported case of X linked dystonia parkinsonism (XDP) or 'lubag' reported in an Australian hospital. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16242937", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Phenotypic and molecular analyses of X-linked dystonia-parkinsonism (\"lubag\") in women.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15596620", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "BACKGROUND: X-linked dystonia-parkinsonism (XDP) or \"lubag\" is an X-linked recessive disorder that afflicts Filipino men, and rarely, women. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15596620", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Smell testing is abnormal in 'lubag' or X-linked dystonia-parkinsonism: a pilot study.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15465396", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 303, "text": "We administered a culturally corrected University of Pennsylvania Smell Identification Test (ccUPSIT) consisting of 25 odor items to 20 patients with 'Lubag' or X-linked dystonia-parkinsonism and 20 control subjects matched by sex, age, educational background, smoking history, and geographical origin. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15465396", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 458, "text": "Three affected siblings were found to share an identical haplotype at the X-linked dystonia-parkinsonism locus (XDP; Lubag; OMIM*314250).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15390042", "endSection": "abstract"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1216, "text": "These neuropathological findings differed from those of Parkinson's disease or juvenile parkinsonism, but mimic to those of X-linked dystonia parkinsonism (Lubag).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12471465", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Phenomenology of \"Lubag\" or X-linked dystonia-parkinsonism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12465067", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "X-linked dystonia-parkinsonism (XDP), or Lubag syndrome, is known to cause progressive dystonia, with or without parkinsonism, among Filipino male adults with maternal roots from the Philippine island of Panay. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12465067", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041372", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "We report a patient with Lubag (X-linked dystonia-parkinsonism) who presented with severe respiratory stridor from adductor laryngeal breathing dystonia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8041372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8351010", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Lubag (X-linked dystonia-parkinsonism) has been considered a sex-linked recessive trait and has been mapped to the pericentromeric region of the X chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8351010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "Regional and global metabolic rates for glucose (rCMRGlc and GMR) were estimated using [18F]fluorodeoxyglucose and positron emission tomography in 3 patients with Filipino X-linked dystonia-parkinsonism (lubag). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8338342", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Neuropathology of lubag (x-linked dystonia parkinsonism).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8341310", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Lubag is an x-linked recessive dystonia parkinsonism that affects Filipino men originating principally from the Panay Island.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8341310", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Genetic mapping of \"Lubag\" (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672807", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "\"Lubag\" is an X-linked disorder causing dystonia and parkinsonism that has only been described in families from the Philippines, principally from the island of Panay. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1672807", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "IMPORTANCE: Despite recessive inheritance, X-linked dystonia-parkinsonism (Lubag disease) has also been described in women presenting with a late-onset isolated parkinsonian syndrome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25004170", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "X-Linked Dystonia-Parkinsonism (XDP or \"Lubag\") is a progressive neurodegenerative disorder unique to the Island of Panay in the Philippines", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Lubag disease is a genetic X-linked dystonia-parkinsonism syndrome afflicting Filipino men", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Lubag disease is a genetic X-linked dystonia-parkinsonism syndrome afflicting Filipino men", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "title"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1215, "text": "These neuropathological findings differed from those of Parkinson's disease or juvenile parkinsonism, but mimic to those of X-linked dystonia parkinsonism (Lubag)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12471465", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Anesthesia for deep brain stimulation in a patient with X-linked dystonia-parkinsonism/Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Lubag disease is a genetic X-linked dystonia-parkinsonism syndrome afflicting Filipino men", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18609312", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "title"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1215, "text": "These neuropathological findings differed from those of Parkinson's disease or juvenile parkinsonism, but mimic to those of X-linked dystonia parkinsonism (Lubag)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12471465", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 90, "text": "Lubag disease is a genetic X-linked dystonia-parkinsonism syndrome afflicting Filipino men", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23614923", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23184149", "endSection": "title"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1215, "text": "These neuropathological findings differed from those of Parkinson's disease or juvenile parkinsonism, but mimic to those of X-linked dystonia parkinsonism (Lubag)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12471465", "endSection": "abstract"}]}, {"body": "Mutation of which gene is implicated in the familial isolated pituitary adenoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24078436", "http://www.ncbi.nlm.nih.gov/pubmed/23652674", "http://www.ncbi.nlm.nih.gov/pubmed/23633209", "http://www.ncbi.nlm.nih.gov/pubmed/23310926", "http://www.ncbi.nlm.nih.gov/pubmed/23286415", "http://www.ncbi.nlm.nih.gov/pubmed/22915287", "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "http://www.ncbi.nlm.nih.gov/pubmed/22291433", "http://www.ncbi.nlm.nih.gov/pubmed/21498161", "http://www.ncbi.nlm.nih.gov/pubmed/21454441", "http://www.ncbi.nlm.nih.gov/pubmed/20669561", "http://www.ncbi.nlm.nih.gov/pubmed/20616502", "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "http://www.ncbi.nlm.nih.gov/pubmed/20570174", "http://www.ncbi.nlm.nih.gov/pubmed/23371967", "http://www.ncbi.nlm.nih.gov/pubmed/23743763", "http://www.ncbi.nlm.nih.gov/pubmed/24789813", "http://www.ncbi.nlm.nih.gov/pubmed/17993773", "http://www.ncbi.nlm.nih.gov/pubmed/21450940", "http://www.ncbi.nlm.nih.gov/pubmed/20457215", "http://www.ncbi.nlm.nih.gov/pubmed/24423289", "http://www.ncbi.nlm.nih.gov/pubmed/20833337", "http://www.ncbi.nlm.nih.gov/pubmed/20506337", "http://www.ncbi.nlm.nih.gov/pubmed/17244780", "http://www.ncbi.nlm.nih.gov/pubmed/17893250", "http://www.ncbi.nlm.nih.gov/pubmed/21778740", "http://www.ncbi.nlm.nih.gov/pubmed/19883897", "http://www.ncbi.nlm.nih.gov/pubmed/24050928", "http://www.ncbi.nlm.nih.gov/pubmed/17961654", "http://www.ncbi.nlm.nih.gov/pubmed/24366639", "http://www.ncbi.nlm.nih.gov/pubmed/23038625", "http://www.ncbi.nlm.nih.gov/pubmed/24996936"], "triples": [], "ideal_answer": ["Mutation of aryl hydrocarbon receptor interacting protein (AIP) gene was implicated in the familial isolated pituitary adenoma (FIPA) syndrome. About 20% of the families with FIPA harbor inactivating mutation in AIP gene."], "exact_answer": [["aryl hydrocarbon receptor interacting protein"]], "concepts": [], "type": "factoid", "id": "551c23bc6b348bb82c00000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "The cause of familial isolated pituitary adenomas (FIPA) remains unknown in a high percentage of cases, but the AIP gene plays an important role in the etiology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "title"}, {"offsetInBeginSection": 883, "offsetInEndSection": 1014, "text": "We report a Spanish family with FIPA in whom a mutation in the AIP gene previously unreported in a familiar context was identified.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "abstract"}, {"offsetInBeginSection": 785, "offsetInEndSection": 1068, "text": "FIPA, an autosomal-dominant disease with variable penetrance, is explained in 20% of patients by germline mutations in the tumor suppressor aryl hydrocarbon receptor interacting protein(AIP), while no gene abnormality has been identified to date in the majority of the FIPA families.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652674", "endSection": "abstract"}, {"offsetInBeginSection": 1308, "offsetInEndSection": 1486, "text": "Understanding the tumorigenic process in AIP-positive and AIP-negative FIPA patients could result in better diagnostic and treatment options for both familial and sporadic cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652674", "endSection": "abstract"}, {"offsetInBeginSection": 93, "offsetInEndSection": 230, "text": "The aryl hydrocarbon receptor interacting protein (AIP) gene has a major role in the pathogenesis of familial isolated pituitary adenoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633209", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 581, "text": " The discovery of heterozygous, loss-of-function germline mutations in the gene encoding the aryl hydrocarbon receptor interacting protein (AIP) in 2006 has subsequently enabled the identification of a mutation in this gene in 20% of FIPA families and 20% of childhood-onset simplex soma- totroph adenomas.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23310926", "endSection": "abstract"}, {"offsetInBeginSection": 860, "offsetInEndSection": 977, "text": " This review aims to summarize currently available clinical data on AIP mutation-positive and negative FIPA patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23310926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "[Aryl hydrocarbon receptor interacting protein gene and familial isolated pituitary adenomas].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286415", "endSection": "title"}, {"offsetInBeginSection": 337, "offsetInEndSection": 424, "text": "Many heterozygous mutations have been discovered in AIP in about 20% of FIPA families. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286415", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 306, "text": "Germline mutations of aryl-hydrocarbon-receptor interacting protein (AIP) are associated with pituitary adenoma predisposition. They occur in 20\u00a0% of familial isolated pituitary adenoma (FIPA) and in about 3-5\u00a0% of sporadic pituitary adenomas, especially in early onset somatotropinomas and prolactinomas. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22915287", "endSection": "abstract"}, {"offsetInBeginSection": 1046, "offsetInEndSection": 1188, "text": "We report a FIPA family harbouring an AIP R16H change, supporting the hypothesis that the latter represents a variant of unknown significance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22915287", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 805, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 305, "offsetInEndSection": 633, "text": "About 20 % of the families with FIPA harbor inactivating mutation in aryl hydrocarbon receptor-interacting protein gene (AIP) associated with loss of heterozygosity of the same genetic locus (11q13) in the tumor. Rarely different types of extra-pituitary tumors have been described in the setting of AIP mutation-positive FIPA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 197, "text": "Mutations in AIP account only for 15-25% of FIPA families. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291433", "endSection": "abstract"}, {"offsetInBeginSection": 340, "offsetInEndSection": 559, "text": "In 20-40% of families with this syndrome, mutations have been identified in the aryl hydrocarbon receptor interacting protein gene while in the rest of the families the causative gene or genes have not been identified. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "Germline mutations in the aryl hydrocarbon receptor-interacting protein gene (AIP) predispose to young-onset pituitary tumours, most often to GH- or prolactin-secreting adenomas, and most of these patients belong to familial isolated pituitary adenoma families.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21454441", "endSection": "abstract"}, {"offsetInBeginSection": 1299, "offsetInEndSection": 1628, "text": "We also briefly describe the genetic basis of three other inherited states predisposing individuals to endocrine tumors, namely Carney's syndrome, hyperparathyroidism type 2 (HRPT2) and familial isolated pituitary adenoma (FIPA), which are related to inactivating mutations in the PRKAR1-alpha, HRPT2 and AIP genes, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20669561", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 425, "offsetInEndSection": 655, "text": "Several studies and reviews have assessed the genetic and clinical features of AIP-mutated FIPA patients, which range from a complete lack of symptoms in adult/elderly individuals to large, aggressive early-onset pituitary tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 353, "offsetInEndSection": 538, "text": "In 20% of FIPA families, heterozygous mutations have been described in the aryl hydrocarbon receptor interacting (AIP) gene, whereas in other families the causative gene(s) are unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20570174", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "A novel C-terminal nonsense mutation, Q315X, of the aryl hydrocarbon receptor-interacting protein gene in a Japanese familial isolated pituitary adenoma family.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789813", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371967", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371967", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371967", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371967", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 804, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Mutations of the aryl hydrocarbon receptor interacting protein (AIP) gene are associated with pituitary adenomas that usually occur as familial isolated pituitary adenomas (FIPA).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21450940", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24423289", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "The cause of familial isolated pituitary adenomas (FIPA) remains unknown in a high percentage of cases, but the AIP gene plays an important role in the etiology. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22291433", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 237, "text": "Although the cause of familial isolated pituitary adenoma (FIPA) remains unknown in many cases, germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene were identified in approximately 20 % of families with FIPA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789813", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The cause of familial isolated pituitary adenomas (FIPA) remains unknown in a high percentage of cases, but the AIP gene plays an important role in the etiology", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "abstract"}, {"offsetInBeginSection": 784, "offsetInEndSection": 1066, "text": "FIPA, an autosomal-dominant disease with variable penetrance, is explained in 20% of patients by germline mutations in the tumor suppressor aryl hydrocarbon receptor interacting protein(AIP), while no gene abnormality has been identified to date in the majority of the FIPA families", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652674", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 803, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 659, "offsetInEndSection": 803, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 622, "offsetInEndSection": 1111, "text": "To date, the number of molecular genetic factors unequivocally linked to pituitary tumours can be counted on the fingers of one hand: (1) GNAS1 activation in acromegaly; (2) the MENIN and p27Kip1 (CDKN1B) mutations associated with multiple endocrine neoplasia type 1; (3) mutations of PRKA1RA with loss of 17q22-24 in Carney complex, and (4) aryl hydrocarbon receptor interacting protein gene mutations in 15% of familial isolated pituitary adenomas and 50% of familial isolated acromegaly", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778740", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "title"}, {"offsetInBeginSection": 622, "offsetInEndSection": 1111, "text": "To date, the number of molecular genetic factors unequivocally linked to pituitary tumours can be counted on the fingers of one hand: (1) GNAS1 activation in acromegaly; (2) the MENIN and p27Kip1 (CDKN1B) mutations associated with multiple endocrine neoplasia type 1; (3) mutations of PRKA1RA with loss of 17q22-24 in Carney complex, and (4) aryl hydrocarbon receptor interacting protein gene mutations in 15% of familial isolated pituitary adenomas and 50% of familial isolated acromegaly", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778740", "endSection": "abstract"}, {"offsetInBeginSection": 659, "offsetInEndSection": 803, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "Familial isolated pituitary adenoma caused by a Aip gene mutation not described before in a family context.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24078436", "endSection": "title"}, {"offsetInBeginSection": 659, "offsetInEndSection": 803, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 622, "offsetInEndSection": 1111, "text": "To date, the number of molecular genetic factors unequivocally linked to pituitary tumours can be counted on the fingers of one hand: (1) GNAS1 activation in acromegaly; (2) the MENIN and p27Kip1 (CDKN1B) mutations associated with multiple endocrine neoplasia type 1; (3) mutations of PRKA1RA with loss of 17q22-24 in Carney complex, and (4) aryl hydrocarbon receptor interacting protein gene mutations in 15% of familial isolated pituitary adenomas and 50% of familial isolated acromegaly", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778740", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}, {"offsetInBeginSection": 659, "offsetInEndSection": 803, "text": "Germline mutations in the aryl-hydrocarbon interacting protein gene are identified in around 25% of familial isolated pituitary adenoma kindreds", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20616498", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22527616", "endSection": "title"}]}, {"body": "What are cancer driver genes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24233780", "http://www.ncbi.nlm.nih.gov/pubmed/24214964", "http://www.ncbi.nlm.nih.gov/pubmed/24084849", "http://www.ncbi.nlm.nih.gov/pubmed/24009526", "http://www.ncbi.nlm.nih.gov/pubmed/23694700", "http://www.ncbi.nlm.nih.gov/pubmed/23416983", "http://www.ncbi.nlm.nih.gov/pubmed/22851646", "http://www.ncbi.nlm.nih.gov/pubmed/21169372", "http://www.ncbi.nlm.nih.gov/pubmed/20707908", "http://www.ncbi.nlm.nih.gov/pubmed/19574499", "http://www.ncbi.nlm.nih.gov/pubmed/19081671", "http://www.ncbi.nlm.nih.gov/pubmed/18339846"], "triples": [], "ideal_answer": ["Recent sequencing and resequencing (i.e., polymorphism identification) efforts have catalyzed the quest for 'driver' mutations (i.e., those genetic alterations which contribute to the transformation of a normal cell to a proliferating cancerous cell) in distinction to 'passenger' mutations which reflect mutations that merely build up in course of normal and unchecked (i.e., cancerous) somatic cell replication and proliferation. Analysis of the frequency of specific mutations across different tumors has been able to identify some, but not all of the mutated genes that contribute to tumor initiation and progression. A subset of these mutations contribute to tumor progression (known as \"driver\" mutations) whereas the majority of these mutations are effectively neutral (known as \"passenger\" mutations)."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052138", "http://www.disease-ontology.org/api/metadata/DOID:162"], "type": "summary", "id": "534428feaeec6fbd0700000a", "snippets": [{"offsetInBeginSection": 225, "offsetInEndSection": 493, "text": "We constructed DriverDB (http://ngs.ym.edu.tw/driverdb/), a database which incorporates 6079 cases of exome-seq data, annotation databases (such as dbSNP, 1000 Genome and Cosmic) and published bioinformatics algorithms dedicated to driver gene/mutation identification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214964", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "DriverDB: an exome sequencing database for cancer driver gene identification.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214964", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes can now be undertaken in an unbiased manner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084849", "endSection": "abstract"}, {"offsetInBeginSection": 316, "offsetInEndSection": 452, "text": "Here we show that the combination of complementary methods allows identifying a comprehensive and reliable list of cancer driver genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084849", "endSection": "abstract"}, {"offsetInBeginSection": 819, "offsetInEndSection": 964, "text": "In summary, the catalog of driver genes and the methodology presented here open new avenues to better understand the mechanisms of tumorigenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24084849", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 270, "text": "A subset of these mutations contribute to tumor progression (known as \"driver\" mutations) whereas the majority of these mutations are effectively neutral (known as \"passenger\" mutations)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18339846", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 421, "text": "The ability to differentiate between drivers and passengers will be critical to the success of upcoming large-scale cancer DNA resequencing projects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18339846", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 1263, "text": " In fact, recent sequencing and resequencing (i.e., polymorphism identification) efforts have catalyzed the quest for protein kinase 'driver' mutations (i.e., those genetic alterations which contribute to the transformation of a normal cell to a proliferating cancerous cell) in distinction to kinase 'passenger' mutations which reflect mutations that merely build up in course of normal and unchecked (i.e., cancerous) somatic cell replication and proliferation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19081671", "endSection": "abstract"}, {"offsetInBeginSection": 913, "offsetInEndSection": 1213, "text": "This method was applied to available breast cancer, colorectal cancer, and glioblastoma sequence data, and identified Wnt/TGF-beta cross-talk, Wnt/VEGF signaling, and MAPK/focal adhesion kinase pathways as targets of rare driver mutations in breast, colorectal cancer, and glioblastoma, respectively.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574499", "endSection": "abstract"}, {"offsetInBeginSection": 125, "offsetInEndSection": 314, "text": "Analysis of the frequency of specific mutations across different tumors has been able to identify some, but not all of the mutated genes that contribute to tumor initiation and progression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574499", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 251, "text": "We are developing a cross-species comparison strategy to distinguish between cancer driver- and passenger gene alteration candidates, by utilizing the difference in genomic location of orthologous genes between the human and other mammals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707908", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 161, "text": "Major tumor sequencing projects have been conducted in the past few years to identify genes that contain 'driver' somatic mutations in tumor samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169372", "endSection": "abstract"}, {"offsetInBeginSection": 898, "offsetInEndSection": 1115, "text": "At the same time, we determined that some genes previously reported as drivers were not significant by the new analysis because mutations in these genes occurred mainly in tumors with large background mutation rates. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21169372", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22851646", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "Herein we report a proof-of-principle study illustrating a novel dog-human comparison strategy that addresses a central aim of cancer research, namely cancer driver-passenger distinction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416983", "endSection": "abstract"}, {"offsetInBeginSection": 1559, "offsetInEndSection": 1818, "text": "Expansion of this study would make more driver-passenger distinctions for cancers with large genomic amplifications or deletions, and address key questions regarding the relationship between cancer pathogenesis and epithelial cell polarity control in mammals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23416983", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Adjusting for background mutation frequency biases improves the identification of cancer driver genes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23694700", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "The identification of cancer drivers is a major goal of current cancer research", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009526", "endSection": "abstract"}, {"offsetInBeginSection": 1105, "offsetInEndSection": 1265, "text": "We conclude that zebrafish-human comparative analysis represents a powerful, and broadly applicable, tool to enrich for evolutionarily conserved cancer drivers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24009526", "endSection": "abstract"}]}, {"body": "What is DNAshape?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23703209"], "triples": [], "ideal_answer": ["DNAshape is  a method and web server for predicting DNA structural features in a high-throughput (HT) manner for massive sequence data. This approach provides the framework for the integration of DNA sequence and shape analyses in genome-wide studies. The HT methodology uses a sliding-window approach to mine DNA structural information obtained from Monte Carlo simulations. It requires only nucleotide sequence as input and instantly predicts multiple structural features of DNA (minor groove width, roll, propeller twist and helix twist). The results of rigorous validations of the HT predictions based on DNA structures solved by X-ray crystallography and NMR spectroscopy, hydroxyl radical cleavage data, statistical analysis and cross-validation, and molecular dynamics simulations provide strong confidence in this approach. The DNAshape web server is freely available at http://rohslab.cmb.usc.edu/DNAshape/."], "concepts": [], "type": "summary", "id": "56c8f7445795f9a73e00001b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 914, "text": "We present a method and web server for predicting DNA structural features in a high-throughput (HT) manner for massive sequence data. This approach provides the framework for the integration of DNA sequence and shape analyses in genome-wide studies. The HT methodology uses a sliding-window approach to mine DNA structural information obtained from Monte Carlo simulations. It requires only nucleotide sequence as input and instantly predicts multiple structural features of DNA (minor groove width, roll, propeller twist and helix twist). The results of rigorous validations of the HT predictions based on DNA structures solved by X-ray crystallography and NMR spectroscopy, hydroxyl radical cleavage data, statistical analysis and cross-validation, and molecular dynamics simulations provide strong confidence in this approach. The DNAshape web server is freely available at http://rohslab.cmb.usc.edu/DNAshape/.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703209", "endSection": "title"}]}, {"body": "Which inherited disorder is known to be caused by mutations in the NEMO gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22036144", "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "http://www.ncbi.nlm.nih.gov/pubmed/17569396", "http://www.ncbi.nlm.nih.gov/pubmed/16104114", "http://www.ncbi.nlm.nih.gov/pubmed/15833158", "http://www.ncbi.nlm.nih.gov/pubmed/22121116", "http://www.ncbi.nlm.nih.gov/pubmed/24339369", "http://www.ncbi.nlm.nih.gov/pubmed/23405946", "http://www.ncbi.nlm.nih.gov/pubmed/23378396", "http://www.ncbi.nlm.nih.gov/pubmed/16532398", "http://www.ncbi.nlm.nih.gov/pubmed/20434027", "http://www.ncbi.nlm.nih.gov/pubmed/10911992", "http://www.ncbi.nlm.nih.gov/pubmed/18350553", "http://www.ncbi.nlm.nih.gov/pubmed/22236433"], "triples": [], "ideal_answer": ["Incontinentia pigmenti (IP) or Bloch-Sulzberger syndrome (BSS) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait.", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait"], "exact_answer": [["Incontinentia pigmenti or Bloch-Sulzberger syndrome"]], "concepts": [], "type": "factoid", "id": "5721f4b30fd6f91b68000011", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Incontinentia pigmenti (IP) is a rare neurocutaneous disorder with a frequency of 1 in 50,000 newborn, and is associated with mutations in IKBKG gene (NEMO) in Xq28, inherited as an X-linked dominant trait", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22036144", "endSection": "abstract"}, {"offsetInBeginSection": 615, "offsetInEndSection": 754, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "De novo NEMO gene deletion (delta4-10)--a cause of incontinentia pigmenti in a female infant", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Incontinentia pigmenti (IP) is a rare, inherited, multisystem genodermatosis. It is transmitted as an X-linked dominant trait. The disorder is a consequence of mutations in the NEMO gene (Xq28) that completely abolish expression of the NF-kappaB essential modulator", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 536, "text": "Incontinentia pigmenti (IP) is a rare inherited multisystem disorder characterized by a distinctive swirling pattern of the skin; defects of teeth, hair, and nails; and ophthalmic, central nervous system, and musculoskeletal abnormalities. It progresses through several well-defined stages. IP is transmitted as a dominant X-linked trait with variable expressivity, but many--if not most--cases are sporadic. IP has been shown to result from mutations in the NEMO gene that completely abolish expression of NF-kappaB essential modulator", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17569396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Incontinentia pigmenti (IP; MIM308310) is a rare neurocutaneous X-dominant inherited disorder. Besides skin and neurological abnormalities, there is also ophthalmologic and dental involvement", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16104114", "endSection": "abstract"}, {"offsetInBeginSection": 552, "offsetInEndSection": 866, "text": "The disorder is observed almost exclusively in girls, but diseased boys are more seriously affected. The IP gene is localised on chromosome Xq28. Mutations in the NEMO-gene are responsible for IP. This gene codes for the nuclear factor-KB essential modulator protein (NEMO; synonym: inhibitor kappaB kinase (IKK)y)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16104114", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Incontinentia pigmenti (IP) is an X-linked-dominant Mendelian disorder caused by mutation in the IKBKG/NEMO gene, encoding for NEMO/IKKgamma, a regulatory protein of nuclear factor kappaB (NF-kB) signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339369", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 890, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 1141, "offsetInEndSection": 1218, "text": "In patients with incontinenia pigmenti, mutations in the NEMO gene are found.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378396", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1332, "text": "Mutations in the NEMO gene have been reported in association with hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID), OL-HED-ID, and incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405946", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 890, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "IKBKG/NEMO gene mutations cause an X-linked, dominant neuroectodermal disorder named Incontinentia Pigmenti (IP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22121116", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Incontinentia pigmenti (IP) is an X-linked-dominant Mendelian disorder caused by mutation in the IKBKG/NEMO gene, encoding for NEMO/IKKgamma, a regulatory protein of nuclear factor kappaB (NF-kB) signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24339369", "endSection": "abstract"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1332, "text": "Mutations in the NEMO gene have been reported in association with hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID), OL-HED-ID, and incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23405946", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "[NEMO Delta 4-10 deletion of NEMO gene in Chinese incontinentia pigmenti cases].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15833158", "endSection": "title"}, {"offsetInBeginSection": 1072, "offsetInEndSection": 1148, "text": "In patients with incontinenia pigmenti, mutations in the NEMO gene are found", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23378396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 324, "text": "Amorphic mutations in the NF- kappa B essential modulator (NEMO) cause X-dominant incontinentia pigmenti, which is lethal in males in utero, whereas hypomorphic mutations cause X-recessive anhidrotic ectodermal dysplasia with immunodeficiency, a complex developmental disorder and life-threatening primary immunodeficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 324, "text": "Amorphic mutations in the NF- kappa B essential modulator (NEMO) cause X-dominant incontinentia pigmenti, which is lethal in males in utero, whereas hypomorphic mutations cause X-recessive anhidrotic ectodermal dysplasia with immunodeficiency, a complex developmental disorder and life-threatening primary immunodeficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 324, "text": "Amorphic mutations in the NF- kappa B essential modulator (NEMO) cause X-dominant incontinentia pigmenti, which is lethal in males in utero, whereas hypomorphic mutations cause X-recessive anhidrotic ectodermal dysplasia with immunodeficiency, a complex developmental disorder and life-threatening primary immunodeficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "NEMO gene mutations in Chinese patients with incontinentia pigmenti.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20434027", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "De novo NEMO gene deletion (delta4-10)--a cause of incontinentia pigmenti in a female infant: a case report.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19149237", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 324, "text": "Amorphic mutations in the NF- kappa B essential modulator (NEMO) cause X-dominant incontinentia pigmenti, which is lethal in males in utero, whereas hypomorphic mutations cause X-recessive anhidrotic ectodermal dysplasia with immunodeficiency, a complex developmental disorder and life-threatening primary immunodeficiency. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16532398", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 328, "text": "Mutations in the inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma (IKBKG), also called nuclear factor-kappaB (NF-kB) essential modulator (NEMO), gene are the most common single cause of incontinentia pigmenti (IP) in females and anhydrotic ectodermal dysplasia with immunodeficiency (EDA-ID) in males.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18350553", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "NEMO/IKK gamma-deficient mice model incontinentia pigmenti.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10911992", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 328, "text": "Mutations in the inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma (IKBKG), also called nuclear factor-kappaB (NF-kB) essential modulator (NEMO), gene are the most common single cause of incontinentia pigmenti (IP) in females and anhydrotic ectodermal dysplasia with immunodeficiency (EDA-ID) in males.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18350553", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 884, "text": "Germline mutations in two genes, NEMO and CYBB, have long been known to cause other human diseases-incontinentia pigmenti (IP) and anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (NEMO/IKKG), and X-linked chronic granulomatous disease (CGD) (CYBB)-but specific mutations in either of these two genes have recently been shown to cause XR-MSMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236433", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 884, "text": "Germline mutations in two genes, NEMO and CYBB, have long been known to cause other human diseases-incontinentia pigmenti (IP) and anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (NEMO/IKKG), and X-linked chronic granulomatous disease (CGD) (CYBB)-but specific mutations in either of these two genes have recently been shown to cause XR-MSMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236433", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 756, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 884, "text": "Germline mutations in two genes, NEMO and CYBB, have long been known to cause other human diseases-incontinentia pigmenti (IP) and anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (NEMO/IKKG), and X-linked chronic granulomatous disease (CGD) (CYBB)-but specific mutations in either of these two genes have recently been shown to cause XR-MSMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236433", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 756, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 884, "text": "Germline mutations in two genes, NEMO and CYBB, have long been known to cause other human diseases-incontinentia pigmenti (IP) and anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (NEMO/IKKG), and X-linked chronic granulomatous disease (CGD) (CYBB)-but specific mutations in either of these two genes have recently been shown to cause XR-MSMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236433", "endSection": "abstract"}, {"offsetInBeginSection": 616, "offsetInEndSection": 756, "text": "Mutations in the NEMO gene give rise to a heterogeneous group of disorders, including the X-linked dominant disorder incontinentia pigmenti.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499091", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 884, "text": "Germline mutations in two genes, NEMO and CYBB, have long been known to cause other human diseases-incontinentia pigmenti (IP) and anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (NEMO/IKKG), and X-linked chronic granulomatous disease (CGD) (CYBB)-but specific mutations in either of these two genes have recently been shown to cause XR-MSMD.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236433", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "IKBKG/NEMO gene mutations cause an X-linked, dominant neuroectodermal disorder named Incontinentia Pigmenti (IP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22121116", "endSection": "abstract"}]}, {"body": "What is the role of Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) in development?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22185090", "http://www.ncbi.nlm.nih.gov/pubmed/21437264", "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "http://www.ncbi.nlm.nih.gov/pubmed/16905130", "http://www.ncbi.nlm.nih.gov/pubmed/11850401"], "triples": [], "ideal_answer": ["Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism. HPL-2 regulates the expression of germline genes, extracellular matrix components and genes involved in lipid metabolism. In addition, HPL-2 regulates the dauer developmental decision, a striking example of phenotypic plasticity in which environmental conditions determine developmental fate. Furthermore, it is required for the formation of a functional germline and for the development of the vulva by acting in an Rb-related pathway."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017173", "http://www.biosemantics.org/jochem#4262550", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D029742", "http://www.uniprot.org/uniprot/HP1_DROVI", "http://www.uniprot.org/uniprot/HP1_DROME", "http://amigo.geneontology.org/amigo/term/GO:0032502"], "type": "summary", "id": "56b9cabbac7ad10019000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 378, "offsetInEndSection": 834, "text": " We show that HPL-2 regulates the expression of germline genes, extracellular matrix components and genes involved in lipid metabolism. Comparison of our expression data with HPL-2 ChIP-on-chip profiles reveals that a significant number of genes up- and down-regulated in the absence of HPL-2 are bound by HPL-2. Germline genes are specifically up-regulated in hpl-2 mutants, consistent with the function of HPL-2 as a repressor of ectopic germ cell fate. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "abstract"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1060, "text": "HPL-2 regulates the dauer developmental decision, a striking example of phenotypic plasticity in which environmental conditions determine developmental fate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "abstract"}, {"offsetInBeginSection": 1340, "offsetInEndSection": 1546, "text": "Our results suggest that the worm HP1 homologue HPL-2 may coordinately regulate dauer diapause, longevity and lipid metabolism, three processes dependent on developmental input and environmental conditions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "abstract"}, {"offsetInBeginSection": 1431, "offsetInEndSection": 1679, "text": "Interestingly, lin-61 genetically interacts with two other synMuvB genes, hpl-2, an HP1 homologous H3K9me2/3 binding factor, and met-2, a SETDB1 homologous H3K9 methyl transferase (H3K9MT), in determining C. elegans vulva development and fertility.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21437264", "endSection": "abstract"}, {"offsetInBeginSection": 451, "offsetInEndSection": 652, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 421, "offsetInEndSection": 1277, "text": "While HPL-2 functions in vulval and germline development, no function has so far been attributed to HPL-1. Here we report the characterization of an hpl-1 null allele. We show that while the absence of hpl-1 alone results in no obvious phenotype, hpl-1;hpl-2 double mutants show synthetic, temperature sensitive phenotypes including larval lethality and severe defects in the development of the somatic gonad. Furthermore, we find that hpl-1 has an unexpected role in vulval development by acting redundantly with hpl-2, but not other genes previously implicated in vulval development. Localization studies show that like HPL-2, HPL-1 is a ubiquitously expressed nuclear protein. However, HPL-1 and HPL-2 localization does not completely overlap. Our results show that HPL-1 and HPL-2 play both unique and redundant functions in post-embryonic development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16905130", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 815, "text": "We show that one of the homologues, HPL-2, is required for the formation of a functional germline and for the development of the vulva by acting in an Rb-related pathway. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 649, "offsetInEndSection": 849, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 649, "offsetInEndSection": 849, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 451, "offsetInEndSection": 652, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 451, "offsetInEndSection": 652, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 451, "offsetInEndSection": 652, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 451, "offsetInEndSection": 652, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 451, "offsetInEndSection": 652, "text": "We have specifically characterized the intranuclear positioning of in vivo fluorescence of the Caenorhabditis elegans HP1 homologue HPL-2 as a marker for heterochromatin domains in developing embryos. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116703", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 671, "offsetInEndSection": 813, "text": "Germline genes are specifically up-regulated in hpl-2 mutants, consistent with the function of HPL-2 as a repressor of ectopic germ cell fate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Caenorhabditis elegans Heterochromatin protein 1 (HPL-2) links developmental plasticity, longevity and lipid metabolism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185090", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "A heterochromatin protein 1 homologue in Caenorhabditis elegans acts in germline and vulval development.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11850401", "endSection": "title"}]}, {"body": "Which signaling pathway is activating the dishevelled proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19561403", "http://www.ncbi.nlm.nih.gov/pubmed/15936275", "http://www.ncbi.nlm.nih.gov/pubmed/25358879"], "triples": [], "ideal_answer": ["Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling"], "exact_answer": [["Wnt signaling"]], "concepts": [], "type": "factoid", "id": "5708a845cf1c32585100000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 291, "text": "Wnt signaling is known to be important for diverse embryonic and post-natal cellular events and be regulated by the proteins Dishevelled and Axin. Although Dishevelled is activated by Wnt and involved in signal transduction, it is not clear how Dishevelled-mediated signaling is turned off. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19561403", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "The Dishevelled protein mediates several diverse biological processes. Intriguingly, within the same tissues where Xenopus Dishevelled (Xdsh) controls cell fate via canonical Wnt signaling,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15936275", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "Dishevelled (DVL) proteins, three of which have been identified in humans, are highly conserved components of canonical and noncanonical Wnt signaling pathways.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25358879", "endSection": "abstract"}]}, {"body": "What is the Her2 status in Li-Fraumeni syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23580068", "http://www.ncbi.nlm.nih.gov/pubmed/22878818", "http://www.ncbi.nlm.nih.gov/pubmed/22392042", "http://www.ncbi.nlm.nih.gov/pubmed/21761402", "http://www.ncbi.nlm.nih.gov/pubmed/20805372"], "triples": [], "ideal_answer": "In the background of a germline TP53 mutation of the Li-Fraumeni syndrome, the Her2 status was found to be positive in 63-83% of the cases.", "exact_answer": ["Her2 status is positive"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016864", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018734", "http://www.uniprot.org/uniprot/ERBB2_HUMAN", "http://www.disease-ontology.org/api/metadata/DOID:3012", "http://www.disease-ontology.org/api/metadata/DOID:0060079", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0038128"], "type": "factoid", "id": "5318929fb166e2b80600001b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Prevalence of germline TP53 mutations in HER2+ breast cancer patients", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580068", "endSection": "title"}, {"offsetInBeginSection": 158, "offsetInEndSection": 257, "text": "Recent data show that breast cancer in germline TP53 mutation carriers is commonly HER2+ (63-83 %).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23580068", "endSection": "abstract"}, {"offsetInBeginSection": 644, "offsetInEndSection": 818, "text": "As seen in this case, most breast cancers in patients with LFS exhibit a triple-positive phenotype (estrogen receptor-positive/progesterone receptor-positive/HER2-positive). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878818", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 403, "text": "Breast cancers in TP53 mutation carriers recently have more often been reported to be hormone receptor and HER-2 positive by immunohistochemistry and FISH in small series.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392042", "endSection": "abstract"}, {"offsetInBeginSection": 997, "offsetInEndSection": 1104, "text": "The 43 tumors from 39 women comprise 32 invasive ductal carcinomas and 11 ductal carcinomas in situ (DCIS).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392042", "endSection": "abstract"}, {"offsetInBeginSection": 1283, "offsetInEndSection": 1399, "text": "Sixty three percent of invasive and 73% of in situ carcinomas were positive for Her2/neu (IHC 3+ or FISH amplified).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392042", "endSection": "abstract"}, {"offsetInBeginSection": 1682, "offsetInEndSection": 1782, "text": "Most DCIS and invasive ductal carcinomas in LFS are hormone receptor positive and/or HER-2 positive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392042", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Early onset HER2-positive breast cancer is associated with germline TP53 mutations", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761402", "endSection": "title"}, {"offsetInBeginSection": 614, "offsetInEndSection": 895, "text": "Patients who tested positive for germlineTP53 mutations (n = 30) were compared with controls (n = 79). Human epidermal growth factor receptor 2 (HER2) amplification and/or overexpression was found in 67% of the tumors from the cases, compared with 25% for the controls (P = .0001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761402", "endSection": "abstract"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1556, "text": "This study suggests an association between germline TP53 mutations and early onset HER2-positive breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21761402", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805372", "endSection": "title"}, {"offsetInBeginSection": 14, "offsetInEndSection": 143, "text": "The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805372", "endSection": "abstract"}, {"offsetInBeginSection": 792, "offsetInEndSection": 1037, "text": "Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%);", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805372", "endSection": "abstract"}, {"offsetInBeginSection": 1099, "offsetInEndSection": 1253, "text": "These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805372", "endSection": "abstract"}]}, {"body": "What disease in Loxapine prominently used for?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22014696", "http://www.ncbi.nlm.nih.gov/pubmed/7914051"], "triples": [], "ideal_answer": "The best indication of loxapine is paranoid schizophrenia.", "exact_answer": ["schizophrenia"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008152", "http://www.biosemantics.org/jochem#4090321", "http://www.biosemantics.org/jochem#4274767", "http://www.biosemantics.org/jochem#4122154"], "type": "factoid", "id": "52b2e409f828ad283c00000e", "snippets": [{"offsetInBeginSection": 11, "offsetInEndSection": 135, "text": "To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014696", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 972, "text": "Antipsychotic recommendations were estimated using CDTI data in which schizophrenia was listed as the indication. RESULTS: First-generation antipsychotic (FGA) recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. There were notable increases in recommendations for chlorpromazine, loxapine, zuclopenthixol, and flupentixol.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22014696", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1212, "text": "Loxapine has been prescribed in France since 1980. Its pharmacological profile is close to that of clozapine: it has dopamine (D2), histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Its best indication seems to be paranoid schizophrenia, although some data suggest bipolar action.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7914051", "endSection": "abstract"}]}, {"body": "Are most driver gene mutations synonymous or non-synonymous?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24147068", "http://www.ncbi.nlm.nih.gov/pubmed/23935863", "http://www.ncbi.nlm.nih.gov/pubmed/23819581", "http://www.ncbi.nlm.nih.gov/pubmed/23799614", "http://www.ncbi.nlm.nih.gov/pubmed/23704925", "http://www.ncbi.nlm.nih.gov/pubmed/23694700", "http://www.ncbi.nlm.nih.gov/pubmed/23450047", "http://www.ncbi.nlm.nih.gov/pubmed/23015295", "http://www.ncbi.nlm.nih.gov/pubmed/22893128", "http://www.ncbi.nlm.nih.gov/pubmed/22649506", "http://www.ncbi.nlm.nih.gov/pubmed/22072984", "http://www.ncbi.nlm.nih.gov/pubmed/19633228", "http://www.ncbi.nlm.nih.gov/pubmed/15946860"], "triples": [], "ideal_answer": ["A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.", "A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.  ", "A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.  ", "A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.  ", "A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.  "], "exact_answer": [["non-synonymous"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369", "http://www.disease-ontology.org/api/metadata/DOID:162"], "type": "factoid", "id": "534427f8aeec6fbd07000009", "snippets": [{"offsetInBeginSection": 1649, "offsetInEndSection": 1869, "text": "Therefore, this study highlights the need for multiple biopsies and sequencing during progression of a cancer and combinatorial DNA and RNA sequencing approach for systematic identification of expressed driver mutations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147068", "endSection": "abstract"}, {"offsetInBeginSection": 703, "offsetInEndSection": 934, "text": "Whole genome sequencing of the index liver metastasis identified 44 non-synonymous somatic mutations in 42 genes (0.85 mutation/MB) and a large hemizygous deletion in the ATRX gene which has been recently reported in neuroblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24147068", "endSection": "abstract"}, {"offsetInBeginSection": 543, "offsetInEndSection": 650, "text": "In addition, we show that NetDiseaseSNP discriminates cancer driver and passenger mutations satisfactorily.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23935863", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 913, "text": "Our method outperforms other state-of-the-art methods on several disease/neutral datasets as well as on cancer driver/passenger mutation datasets and can thus be used to pinpoint and prioritize plausible disease candidates among nsSNPs for further investigation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23935863", "endSection": "abstract"}, {"offsetInBeginSection": 1411, "offsetInEndSection": 1704, "text": "Moreover, we find that a large fraction of the driver mutations are neither located in conserved functional sites, nor responsible for structural stability, but rather regulate protein activity through allosteric transitions, protein-protein interactions, or protein-nucleic acid interactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23819581", "endSection": "abstract"}, {"offsetInBeginSection": 128, "offsetInEndSection": 239, "text": "We used whole-exome sequencing to identify novel non-synonymous somatic mutations in squamous cell lung cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23799614", "endSection": "abstract"}, {"offsetInBeginSection": 240, "offsetInEndSection": 399, "text": "We identified 101 single-nucleotide variants (SNVs) including 77 non-synonymous SNVs (67 missense and 10 nonsense mutations) and 11 INDELs causing frameshifts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23799614", "endSection": "abstract"}, {"offsetInBeginSection": 781, "offsetInEndSection": 1066, "text": "Besides confirming the presence of known melanoma driver mutations (BRAF(V600E), NRAS(Q61R) ), we identified novel mutated genes involved in signalling pathways crucial for melanoma pathogenesis and already addressed by current targeted therapies (such as MAPK and glutamate pathways).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704925", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 260, "text": "A common goal of tumor sequencing projects is finding genes whose mutations are selected for during tumor development. This is accomplished by choosing genes that have more non-synonymous mutations than expected from an estimated background mutation frequency.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23694700", "endSection": "abstract"}]}, {"body": "What is known about maternal smoking and brain tumor risk?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24260161", "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "http://www.ncbi.nlm.nih.gov/pubmed/15191928", "http://www.ncbi.nlm.nih.gov/pubmed/12115571", "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "http://www.ncbi.nlm.nih.gov/pubmed/11452935", "http://www.ncbi.nlm.nih.gov/pubmed/10620527", "http://www.ncbi.nlm.nih.gov/pubmed/8850274", "http://www.ncbi.nlm.nih.gov/pubmed/8470663", "http://www.ncbi.nlm.nih.gov/pubmed/7139628"], "triples": [], "ideal_answer": ["Findings regarding association of maternal smoking and brain tumor risk are mixed. It was shown that children of women who smoked during pregnancy had an increased incidence of brain tumors (hazard ratio = 1.24; 95% confidence interval: 1.01-1.53). The increase in risk was similar for benign and malignant tumors, and was most apparent for astrocytoma. However, other authors did not find association between maternal smoking and brain tumor risk."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012907", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001932", "http://www.disease-ontology.org/api/metadata/DOID:1319", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009035", "http://www.disease-ontology.org/api/metadata/DOID:368"], "type": "summary", "id": "56c1d85fef6e394741000036", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 275, "text": "BACKGROUND: A recent meta-analysis suggested an association between exposure to paternal smoking during pregnancy and childhood brain tumor risk, but no studies have evaluated whether this association differs by polymorphisms in genes that metabolize tobacco-smoke chemicals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260161", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 225, "text": "OBJECTIVE: Studies of the effect of maternal smoking during pregnancy on development of brain tumors in the offspring generally have found no increase in risk but most have mainly relied on retrospective exposure assessment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "endSection": "abstract"}, {"offsetInBeginSection": 839, "offsetInEndSection": 1092, "text": "Children of women who smoked during pregnancy had an increased incidence of brain tumors (hazard ratio = 1.24; 95% confidence interval: 1.01-1.53). The increase in risk was similar for benign and malignant tumors, and was most apparent for astrocytoma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "endSection": "abstract"}, {"offsetInBeginSection": 1199, "offsetInEndSection": 1321, "text": "CONCLUSIONS: These results support a role for maternal smoking during pregnancy in the etiology of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "endSection": "abstract"}, {"offsetInBeginSection": 1197, "offsetInEndSection": 1360, "text": "Maternal occupational exposure to PAH before conception or during pregnancy was rare, and this exposure was not associated with any type of childhood brain tumor. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15191928", "endSection": "abstract"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1185, "text": "There was no association between the risk of brain tumors in the child and parental smoking prior to pregnancy, maternal smoking or regular exposure to others' cigarette smoke during pregnancy at home or at work, or passive smoking by the child during the first year of life.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12115571", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Maternal smoking during pregnancy and the risk of childhood brain tumors: a meta-analysis of 6566 subjects from twelve epidemiological studies.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "OBJECTIVE: Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 1485, "offsetInEndSection": 1707, "text": "Pooling all twelve reports yielded an RRs of 1.05 (0.90-1.21), a non-statistically significant result suggesting no clear association between maternal smoking during pregnancy and risk of childhood brain tumor development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 1911, "offsetInEndSection": 2075, "text": ".CONCLUSION: The available epidemiological data do not support a clear association between maternal smoking during pregnancy and pediatric brain tumor development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 654, "offsetInEndSection": 1024, "text": "We observed only few positive associations, namely, between CNS tumors and low birth weight [<2,500 g; odds ratio (OR), 1.73; 95% confidence interval (CI), 1.06-2.84], between ependymoma and maternal smoking during pregnancy (>10 cigarettes per day: OR, 4.71; 95% CI, 1.69-13.1), and between astrocytoma and exposure to wood preservatives (OR, 1.91; 95% CI, 1.22-3.01). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11452935", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1068, "text": "The results on exposure to paternal tobacco smoke suggest an association with brain tumors (RR 1.22; CI, 1.05-1. 40; based on 10 studies) and lymphomas (RR 2.08; CI, 1.08-3.98; 4 studies). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620527", "endSection": "abstract"}, {"offsetInBeginSection": 850, "offsetInEndSection": 1588, "text": "No association was found between the risk of CBTs and maternal or paternal smoking before pregnancy and there was no association between CBTs and maternal smoking during pregnancy [odds ratio (OR) = 0.98; 95% confidence interval (CI) = 0.72-1.3]. A slightly increased OR for CBTs was found for paternal smoking during pregnancy in the absence of maternal smoking (OR = 1.2; 95% CI = 0.90-1.5) and for maternal exposure to passive smoke from any source (OR = 1.2; 95% CI = 0.95-1.6). The results of this analysis are consistent with results from several prior epidemiological studies that showed no significant association between CBTs and maternal smoking before or during pregnancy or maternal exposure to passive smoke during pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8850274", "endSection": "abstract"}, {"offsetInBeginSection": 359, "offsetInEndSection": 1295, "text": "No significant differences in risks were found to be associated with maternal or paternal smoking at any time (odds ratio (OR) = 0.92 for mothers and 1.06 for fathers), during the year of birth of the child (which included both the prenatal and postnatal periods) (ORs = 0.84 for<1 pack/day and 1.0 for>or = 1 pack/day for mothers, and 0.68 for<1 pack/day and 1.07 for>or = 1 pack/day for fathers), or 2 years before the child was born, i.e., the pre-conception period (ORs = 0.75 for<1 pack/day and 1.01 for>or = 1 pack/day for mothers, and 0.90 for<1 pack/day and 1.15 for>or = 1 pack/day for fathers). Mothers were also specifically asked if they smoked during the pregnancy, and no association was found compared with never smokers (OR = 1.08, 95% confidence interval (CI) 0.80-1.45) or for ever-smokers who continued to smoke during pregnancy compared with those who stopped smoking during pregnancy (OR = 1.15, 95% CI 0.75-1.78). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470663", "endSection": "abstract"}, {"offsetInBeginSection": 1489, "offsetInEndSection": 1775, "text": "The lack of an effect of parental smoking was observed for both the major histologic types and locations of brain tumors. These findings and those from earlier studies provide no support for the hypothesis that parental cigarette smoking influences the risk of brain tumors in children.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470663", "endSection": "abstract"}, {"offsetInBeginSection": 334, "offsetInEndSection": 758, "text": "Increased risk was associated with maternal contact with nitrosamine-containing substances such as burning incense (odds ratio, 3.3; p = 0.005), sidestream cigarette smoke (odds ratio, 1.5; p = 0.03), and face makeup (odds ratio, 1.6; p = 0.02); with maternal use of diuretics (odds ratio, 2.0; p = 0.03) and antihistamines (odds ratio, 3.4; p = 0.002); and with the level of maternal consumption of cured meats (p = 0.008).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7139628", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Studies of the effect of maternal smoking during pregnancy on development of brain tumors in the offspring generally have found no increase in risk but most have mainly relied on retrospective exposure assessment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "endSection": "abstract"}, {"offsetInBeginSection": 1092, "offsetInEndSection": 1338, "text": "No association was found between the risk of CBTs and maternal or paternal smoking before pregnancy and there was no association between CBTs and maternal smoking during pregnancy [odds ratio (OR) = 0.98; 95% confidence interval (CI) = 0.72-1.3].", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8850274", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 213, "text": "Studies of the effect of maternal smoking during pregnancy on development of brain tumors in the offspring generally have found no increase in risk but most have mainly relied on retrospective exposure assessment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "endSection": "abstract"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1451, "text": "There was no association between the risk of brain tumors in the child and parental smoking prior to pregnancy, maternal smoking or regular exposure to others' cigarette smoke during pregnancy at home or at work, or passive smoking by the child during the first year of life.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12115571", "endSection": "abstract"}, {"offsetInBeginSection": 1092, "offsetInEndSection": 1338, "text": "No association was found between the risk of CBTs and maternal or paternal smoking before pregnancy and there was no association between CBTs and maternal smoking during pregnancy [odds ratio (OR) = 0.98; 95% confidence interval (CI) = 0.72-1.3].", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8850274", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1270, "text": "RESULTS: We found positive interaction odds ratios (ORs) for both maternal and paternal smoking during pregnancy, EPHX1 H139R, and childhood brain tumors (P(interaction)\u200a=\u200a0.02; 0.10), such that children with the high-risk (greater PAH activation) genotype were at a higher risk of brain tumors relative to children with the low-risk genotype when exposed to tobacco smoke during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260161", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1270, "text": "RESULTS: We found positive interaction odds ratios (ORs) for both maternal and paternal smoking during pregnancy, EPHX1 H139R, and childhood brain tumors (P(interaction)\u200a=\u200a0.02; 0.10), such that children with the high-risk (greater PAH activation) genotype were at a higher risk of brain tumors relative to children with the low-risk genotype when exposed to tobacco smoke during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260161", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1270, "text": "RESULTS: We found positive interaction odds ratios (ORs) for both maternal and paternal smoking during pregnancy, EPHX1 H139R, and childhood brain tumors (P(interaction)\u200a=\u200a0.02; 0.10), such that children with the high-risk (greater PAH activation) genotype were at a higher risk of brain tumors relative to children with the low-risk genotype when exposed to tobacco smoke during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260161", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1270, "text": "RESULTS: We found positive interaction odds ratios (ORs) for both maternal and paternal smoking during pregnancy, EPHX1 H139R, and childhood brain tumors (P(interaction)\u200a=\u200a0.02; 0.10), such that children with the high-risk (greater PAH activation) genotype were at a higher risk of brain tumors relative to children with the low-risk genotype when exposed to tobacco smoke during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260161", "endSection": "abstract"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1270, "text": "RESULTS: We found positive interaction odds ratios (ORs) for both maternal and paternal smoking during pregnancy, EPHX1 H139R, and childhood brain tumors (P(interaction)\u200a=\u200a0.02; 0.10), such that children with the high-risk (greater PAH activation) genotype were at a higher risk of brain tumors relative to children with the low-risk genotype when exposed to tobacco smoke during pregnancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24260161", "endSection": "abstract"}, {"offsetInBeginSection": 1311, "offsetInEndSection": 1504, "text": "Finally, no significant increase in risk of brain tumors was found for the child's passive exposure to parental smoking during the period from birth to diagnosis of the brain tumor in the case.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8470663", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 1532, "offsetInEndSection": 1691, "text": "a non-statistically significant result suggesting no clear association between maternal smoking during pregnancy and risk of childhood brain tumor development.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1286, "text": "These results support a role for maternal smoking during pregnancy in the etiology of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15801484", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Prior epidemiological studies suggest a possible association between maternal smoking during pregnancy and risk of childhood brain tumors.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12125967", "endSection": "abstract"}]}, {"body": "What is known about the effect of acupuncture in smoking cessation ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24030452", "http://www.ncbi.nlm.nih.gov/pubmed/22373002", "http://www.ncbi.nlm.nih.gov/pubmed/18405159", "http://www.ncbi.nlm.nih.gov/pubmed/17698433", "http://www.ncbi.nlm.nih.gov/pubmed/17264832", "http://www.ncbi.nlm.nih.gov/pubmed/16566674", "http://www.ncbi.nlm.nih.gov/pubmed/15861492", "http://www.ncbi.nlm.nih.gov/pubmed/15004442", "http://www.ncbi.nlm.nih.gov/pubmed/12416359", "http://www.ncbi.nlm.nih.gov/pubmed/12356614", "http://www.ncbi.nlm.nih.gov/pubmed/11154059", "http://www.ncbi.nlm.nih.gov/pubmed/10024707"], "triples": [], "ideal_answer": "Ear acupressure (EAP) and ear acupuncture have been used for smoking cessation, and some positive results have been reported.\nAuricular (ear) acupressure has been purported to be beneficial in achieving smoking cessation in some studies, while in others has been deemed insignificant.\nThe combined acupuncture-education group showing the greatest effect from treatment.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016540", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020831", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026881", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012907", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015669"], "type": "summary", "id": "535d78137d100faa09000005", "snippets": [{"offsetInBeginSection": 256, "offsetInEndSection": 380, "text": "Ear acupressure (EAP) and ear acupuncture have been used for smoking cessation, and some positive results have been reported", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030452", "endSection": "abstract"}, {"offsetInBeginSection": 138, "offsetInEndSection": 295, "text": "Auricular (ear) acupressure has been purported to be beneficial in achieving smoking cessation in some studies, while in others has been deemed insignificant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22373002", "endSection": "abstract"}, {"offsetInBeginSection": 725, "offsetInEndSection": 842, "text": "Acupuncture combined with auricular point sticking and pressing has reliable therapeutic effect for smoking cessation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18405159", "endSection": "abstract"}, {"offsetInBeginSection": 181, "offsetInEndSection": 307, "text": "Acupuncture has been promoted as a treatment modality for smoking cessation. However, its efficacy still remains controversial", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17698433", "endSection": "abstract"}, {"offsetInBeginSection": 1857, "offsetInEndSection": 2168, "text": "Our results showed that auricular acupuncture did not have a better efficacy in smoking cessation compared to sham acupuncture. Combined acupuncture with behavior counseling or with nicotine replacement therapy should be used in further smoking cessation trials to enhance the success rate of smoking cessation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17698433", "endSection": "abstract"}, {"offsetInBeginSection": 802, "offsetInEndSection": 958, "text": "Combining ten studies showed auricular acupuncture at 'correct' points to be more effective than control interventions, odds ratio 2.24 (95% CI 1.61, 3.10),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17264832", "endSection": "abstract"}, {"offsetInBeginSection": 1415, "offsetInEndSection": 1532, "text": "Auricular acupuncture appears to be effective for smoking cessation, but the effect may not depend on point location.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17264832", "endSection": "abstract"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1263, "text": "The combination of auricular acupressure and Internet-assisted smoking cessation program was more efficacious than auricular acupressure alone in terms of quit rate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16566674", "endSection": "abstract"}, {"offsetInBeginSection": 1520, "offsetInEndSection": 1579, "text": "auricular acupuncture in smoking cessation has some effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861492", "endSection": "abstract"}, {"offsetInBeginSection": 1509, "offsetInEndSection": 1750, "text": "With a one-year success rate of 41.1% ear acupuncture is a competitive alternative to orthodox medicine withdrawal methods. Acupuncture treatment can be applied and adapted individually, furthermore it is economical and without side effects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15004442", "endSection": "abstract"}, {"offsetInBeginSection": 388, "offsetInEndSection": 513, "text": "Auriculotherapy is an useful aid for giving up smoking. It is easy and painless, has no secondary effects and it is economic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12416359", "endSection": "abstract"}, {"offsetInBeginSection": 378, "offsetInEndSection": 462, "text": "the combined acupuncture-education group showing the greatest effect from treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12356614", "endSection": "abstract"}, {"offsetInBeginSection": 846, "offsetInEndSection": 1042, "text": "Acupuncture and education, alone and in combination, significantly reduce smoking; however, combined they show a significantly greater effect, as seen in subjects with a greater pack-year history.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12356614", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "A double blind, randomized, placebo-controlled clinical study was conducted to evaluate the efficacy of laser acupuncture treatment in adolescent smokers. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11154059", "endSection": "abstract"}, {"offsetInBeginSection": 668, "offsetInEndSection": 780, "text": "Thus, there was no significant difference in the rates of smoking cessation in the treatment and control groups.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11154059", "endSection": "abstract"}, {"offsetInBeginSection": 962, "offsetInEndSection": 1101, "text": "This simple ear electroacupuncture treatment was significantly more effective in helping volunteers to quit smoking than placebo treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10024707", "endSection": "abstract"}]}, {"body": "Which domain of TIA-1 is necessary for stress granule assembly?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24981173", "http://www.ncbi.nlm.nih.gov/pubmed/18775331", "http://www.ncbi.nlm.nih.gov/pubmed/15371533"], "triples": [], "ideal_answer": ["TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells."], "exact_answer": [["The glutamine-rich prion-related domain (PRD)"]], "concepts": [], "type": "factoid", "id": "56cdf4875795f9a73e000040", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Tia1/Pub1 is a stress granule component carrying a Q/N-rich prion domain", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981173", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18775331", "endSection": "title"}, {"offsetInBeginSection": 121, "offsetInEndSection": 490, "text": "We report an unanticipated link between stress granules and the serine/threonine kinase RSK2. In stressed breast cells, endogenous RSK2 colocalizes in granules with TIA-1 and poly(A)-binding protein 1, and the sequestration of RSK2 and TIA-1 exhibits codependency. The RSK2 N-terminal kinase domain controls the direct interaction with the prion-related domain of TIA-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18775331", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 596, "text": "TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "abstract"}, {"offsetInBeginSection": 598, "offsetInEndSection": 1078, "text": "The PRD of TIA-1 exhibits many characteristics of prions: concentration-dependent aggregation that is inhibited by the molecular chaperone heat shock protein (HSP)70; resistance to protease digestion; sequestration of HSP27, HSP40, and HSP70; and induction of HSP70, a feedback regulator of PRD disaggregation. Substitution of the PRD with the aggregation domain of a yeast prion, SUP35-NM, reconstitutes SG assembly, confirming that a prion domain can mediate the assembly of SGs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "abstract"}, {"offsetInBeginSection": 1281, "offsetInEndSection": 1421, "text": "Our results reveal that prion-like aggregation of TIA-1 regulates SG formation downstream of eIF2alpha phosphorylation in response to stress", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 334, "text": " TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Stress granule assembly is mediated by prion-like aggregation of TIA-1.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15371533", "endSection": "title"}]}, {"body": "What is the indication for prophylactic use of antibiotics in COPD?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22108462", "http://www.ncbi.nlm.nih.gov/pubmed/20477251", "http://www.ncbi.nlm.nih.gov/pubmed/11498704"], "ideal_answer": ["In a subset of patients with severe disease and prone to developing infections prophylactic use of antibiotics may reduce number of exacerbations and improve social and health care costs."], "exact_answer": ["Reduction of number of exacerbations"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D029424", "http://www.disease-ontology.org/api/metadata/DOID:3083", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000900", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019072"], "type": "factoid", "id": "515df063298dcd4e51000029", "snippets": [{"offsetInBeginSection": 193, "offsetInEndSection": 657, "text": "Yet recent well-designed studies have demonstrated that prophylactic antibiotic use is of significant benefit to patients prone to developing infections. Study patients suffered from recurrent urinary tract infections, COPD or were mechanically ventilated in intensive care units. In the first 2 populations, use of antibiotics was associated with an increase in carriage of antibiotic-resistant bacteria, but in intensive care patients the opposite was documented", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22108462", "endSection": "sections.0"}, {"offsetInBeginSection": 1293, "offsetInEndSection": 1459, "text": "Guidelines do not recommend the use of prophylactic antibiotics in COPD but there is preliminary evidence to suggest that they may reduce the number of exacerbations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20477251", "endSection": "sections.0"}, {"offsetInBeginSection": 585, "offsetInEndSection": 784, "text": "A short prophylactic treatment course with azithromycin is a good alternative in the management of patients with severe, advanced COPD, and could lead to an improvement in social and healthcare costs", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11498704", "endSection": "sections.0"}]}, {"body": "Which hormone receptor function is altered in patients with Donohue syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23990696", "http://www.ncbi.nlm.nih.gov/pubmed/23824322", "http://www.ncbi.nlm.nih.gov/pubmed/23229189", "http://www.ncbi.nlm.nih.gov/pubmed/22972224", "http://www.ncbi.nlm.nih.gov/pubmed/22768670", "http://www.ncbi.nlm.nih.gov/pubmed/21092701", "http://www.ncbi.nlm.nih.gov/pubmed/19882513", "http://www.ncbi.nlm.nih.gov/pubmed/19774849", "http://www.ncbi.nlm.nih.gov/pubmed/18411068", "http://www.ncbi.nlm.nih.gov/pubmed/17201797", "http://www.ncbi.nlm.nih.gov/pubmed/24498630"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#definition", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "MSH: Rare autosomal recessive syndrome of extreme insulin resistance due to mutations in the binding domain of INSULIN RECEPTOR. Clinical features include severe intrauterine and postnatal growth restriction, characteristic dysmorphic FACIES; HIRSUTISM; VIRILIZATION; multiple endocrine abnormalities, and early death.,NCI: A rare autosomal recessive genetic disorder caused by mutations in the insulin receptor gene. Signs and symptoms include a characteristic facial appearance (protuberant and low-set ears, thick lips, and flaring nostrils), intrauterine growth retardation, insulin resistance, and enlarged genitalia."}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17001090", "o": "Leprechaunisms"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A17001090"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17003896", "o": "Syndrome, Donohue"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A18430717"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A17012086"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A13286376", "o": "LEPRECHAUNISM"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A13288574"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A16995573"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18433068", "o": "Leprechaunism"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A18433068"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A18430717", "o": "Donohue Syndrome [Disease/Finding]"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A13288574", "o": "DONOHUE SYNDROME"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A17003896"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A17689250"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A18444972"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0265344", "o": "http://linkedlifedata.com/resource/umls/label/A13286376"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17012086", "o": "Donohue Syndrome"}], "ideal_answer": "Donohue syndrome (leprechaunism) is a rare, recessively inherited disorder of extreme insulin resistance due to mutations in the insulin receptor gene causing either defects in insulin binding or receptor autophosphorylation and tyrosine kinase activity. This syndrome is characterized by excessive hyperglycemia with hyperinsulinism, pre- and postnatal growth retardation, distinct dysmorphism and early death. Progressive obstructive cardiomyopathy and renal tubular dysfunction have been described in patients with Donohue syndrome. Milder form of insulin resistance due to insulin receptor gene mutation is coined as Rabson-Mendenhall syndrome.", "exact_answer": ["insulin"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056731", "http://www.disease-ontology.org/api/metadata/DOID:0050470", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051427", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018000", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006728", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051428"], "type": "factoid", "id": "5314bd7ddae131f847000006", "snippets": [{"offsetInBeginSection": 104, "offsetInEndSection": 247, "text": "This disease is caused by a defective insulin receptor and features abnormal glucose metabolism and retarded intrauterine and postnatal growth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990696", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Biallelic insulin receptor (INSR) gene mutations cause congenital syndromes of severe insulin resistance (SIR) known as Donohue syndrome (DS) and Rabson-Mendenhall syndrome (RMS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23824322", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229189", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 275, "text": "Donohue syndrome (leprechaunism; OMIM *246200) is a rare, recessively inherited disorder of extreme insulin resistance due to mutations in the insulin receptor gene (INSR) causing either defects in insulin binding or receptor autophosphorylation and tyrosine kinase activity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23229189", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Leprechaunism (Donohue syndrome): a case bearing novel compound heterozygous mutations in the insulin receptor gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22972224", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Leprechaunism (Donohue syndrome) is the most severe type of insulin receptor (INSR) gene anomaly with the majority of patients surviving for only 2 years.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22972224", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "A novel mutation of the insulin receptor gene in a preterm infant with Donohue syndrome and heart failure.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768670", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 124, "text": "Donohue syndrome (DS) is a rare autosomal recessive condition caused by mutations in the gene encoding the insulin receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768670", "endSection": "abstract"}, {"offsetInBeginSection": 318, "offsetInEndSection": 578, "text": "Any dysfunction of insulin signalling pathway as a result of insulin receptor gene mutations is linked with various forms of insulin resistance, including insulin resistance type A, Donohue or Rabson-Mendenhall syndrome, which differ in the level of severity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21092701", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Donohue syndrome in a neonate with homozygous deletion of exon 3 of the insulin receptor gene.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19774849", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Donohue syndrome describes the clinical consequences of the most severe genetic loss of insulin receptor function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19774849", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 378, "text": "Homozygous or compound heterozygous mutations within the insulin binding domain of the human insulin receptor (INSR) are usually associated with severe impairment of insulin binding leading to Donohue syndrome (\"Leprechaunism\"), which is characterized by excessive hyperglycemia with hyperinsulinism, pre- and postnatal growth retardation, distinct dysmorphism and early death. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18411068", "endSection": "abstract"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1159, "text": "The former mutation has been described in homozygous form in Donohue syndrome, while the latter is novel. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17201797", "endSection": "abstract"}]}, {"body": "What is the indication of Daonil (Glibenclamide)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22639778", "http://www.ncbi.nlm.nih.gov/pubmed/21608438", "http://www.ncbi.nlm.nih.gov/pubmed/16922811", "http://www.ncbi.nlm.nih.gov/pubmed/12460666", "http://www.ncbi.nlm.nih.gov/pubmed/10199151", "http://www.ncbi.nlm.nih.gov/pubmed/6805141"], "triples": [], "ideal_answer": "Glibenclamide is an antidiabetic and antiglycemic, used in severe NIDDM, and increasingly viewed as a rational alternative to insulin therapy.", "exact_answer": ["Diabetes mellitus"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005905", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006305", "http://www.biosemantics.org/jochem#4275786"], "type": "factoid", "id": "52b2e1d8f828ad283c00000c", "snippets": [{"offsetInBeginSection": 1096, "offsetInEndSection": 1299, "text": "Metformin and glibenclamide are now increasingly viewed as a rational alternative to insulin therapy--a treatment both preferred by the women and a less expensive one, during pregnancy and breastfeeding.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22639778", "endSection": "abstract"}, {"offsetInBeginSection": 574, "offsetInEndSection": 848, "text": "The effect of TFG on blood glucose were studied and the levels of lipid peroxidation [MDA (Malondialdehyde)] and antioxidant enzymes [SOD (Superoxide dismutase), GPx (Reduced Glutathione peroxidase)] were estimated and compared with standard drugs glibenclamide and insulin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608438", "endSection": "abstract"}, {"offsetInBeginSection": 858, "offsetInEndSection": 1016, "text": "Treatment with TFG, insulin and glibenclamide resulted in significantly reduced blood glucose in LM (8.71%) and HM (3.87%) in comparison with normal controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608438", "endSection": "abstract"}, {"offsetInBeginSection": 1418, "offsetInEndSection": 1612, "text": "Potency of TFG in restoring several parameters to normal values is comparable to glibenclamide, though not as efficient as insulin, an indication of its antihyperglycemic and antioxidant effect.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608438", "endSection": "abstract"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1456, "text": "However, dietary supplementation with PB (6 g/kg extract for 4 weeks administered orally using an intragastric tube) ameliorated the alloxan-induced diabetes in a manner comparable with that of the reference antidiabetic drug glibenclamide", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16922811", "endSection": "abstract"}, {"offsetInBeginSection": 650, "offsetInEndSection": 947, "text": "Moreover, the potassium-specific effects of both diazoxide and nicorandil on oxidative phosphorylation in skeletal muscle mitochondria were completely abolished by the antidiabetic sulfonylurea derivative glibenclamide, a well-known inhibitor of ATP-regulated potassium channels (K(ATP) channels).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12460666", "endSection": "abstract"}, {"offsetInBeginSection": 610, "offsetInEndSection": 722, "text": "In mild NIDDM, gliclazide, tolbutamide or acetohexamide is used, and in more severe NIDDM glibenclamide is used.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10199151", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 850, "text": "An improvement of the glucose tolerance could be observed up to 3 years, whereas after a 5-year glibenclamide therapy no certain influence on the glucose tolerance and insulin secretion could be proved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6805141", "endSection": "abstract"}, {"offsetInBeginSection": 851, "offsetInEndSection": 1087, "text": "In general the improvement of the glucose tolerance was not associated with an increased secretion of insulin, so that an extrapancreatic effect of glibenclamide (improvement of the peripheral insulin sensitivity?) seems to be possible.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6805141", "endSection": "abstract"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1541, "text": "From clinical and practical point of view the findings would support the opinion that normal weight persons with IGT, particularly in already decreased insulin secretion, have an indication for a glibenclamide therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6805141", "endSection": "abstract"}]}, {"body": "How does exercise affect thyroid hormone receptors expression in the heart?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21625820", "http://www.ncbi.nlm.nih.gov/pubmed/14704232", "http://www.ncbi.nlm.nih.gov/pubmed/11577024"], "ideal_answer": ["Exercise has been shown to increase  TR\u03b21 receptor expression in young rats.  Exercise has been shown to increase both TR\u03b11 and  TR\u03b21 receptor expression in aged rats."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", "http://www.uniprot.org/uniprot/THB_CAIMO", "http://www.uniprot.org/uniprot/THB_HUMAN", "http://www.uniprot.org/uniprot/THB_PAROL", "http://www.uniprot.org/uniprot/THB_MOUSE", "http://www.uniprot.org/uniprot/THB_DANRE", "http://www.uniprot.org/uniprot/THB_RAT", "http://www.uniprot.org/uniprot/THA_PIG", "http://www.uniprot.org/uniprot/THA_CAIMO", "http://www.uniprot.org/uniprot/THB_CHICK", "http://www.uniprot.org/uniprot/THBA_XENLA", "http://www.uniprot.org/uniprot/THB_LITCT", "http://www.uniprot.org/uniprot/THB_SHEEP", "http://www.uniprot.org/uniprot/THA_MOUSE", "http://www.uniprot.org/uniprot/THA_SALSA", "http://www.uniprot.org/uniprot/THA_HIPHI", "http://www.uniprot.org/uniprot/THAA_DANRE", "http://www.uniprot.org/uniprot/THAA_PAROL", "http://www.uniprot.org/uniprot/THA_APTPA", "http://www.uniprot.org/uniprot/THAA_XENLA", "http://www.uniprot.org/uniprot/THA_LITCT", "http://www.uniprot.org/uniprot/THA_SPAAU", "http://www.uniprot.org/uniprot/THA_HUMAN", "http://www.uniprot.org/uniprot/THA_SHEEP", "http://www.uniprot.org/uniprot/THA_CHICK", "http://www.uniprot.org/uniprot/THA_PYGAD", "http://www.uniprot.org/uniprot/THA_ELECQ", "http://www.uniprot.org/uniprot/THA_ONCMY", "http://www.uniprot.org/uniprot/THA_NECMA", "http://www.uniprot.org/uniprot/THA_RAT", "http://www.uniprot.org/uniprot/THBB_XENLA", "http://www.uniprot.org/uniprot/THAB_XENLA", "http://www.uniprot.org/uniprot/THAB_PAROL", "http://www.uniprot.org/uniprot/TR150_RAT", "http://www.uniprot.org/uniprot/TR150_MOUSE", "http://www.uniprot.org/uniprot/TR150_HUMAN", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0030375", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015444", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321"], "type": "summary", "id": "5159cc88d24251bc050000a4", "snippets": [{"offsetInBeginSection": 1107, "offsetInEndSection": 1162, "text": "Exercise increased the TR\u03b21 receptor, L-channel and NCX", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21625820", "endSection": "sections.0"}, {"offsetInBeginSection": 878, "offsetInEndSection": 1093, "text": "Expression of TR-alpha1 and TR-beta1 proteins in the heart were significantly lower in sedentary aged rats than in sedentary young rats and were significantly higher in trained aged rats than in sedentary aged rats.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704232", "endSection": "sections.0"}, {"offsetInBeginSection": 903, "offsetInEndSection": 1040, "text": "Myocyte TRbeta1 was upregulated in models with a hyperthyroid-like phenotype, TH (triiodothyronine, T3), in culture and exercise in vivo.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11577024", "endSection": "sections.0"}]}, {"body": "What was the aim of the COSS (Carotid Occlusion Surgery Study) clinical trial?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23909253", "http://www.ncbi.nlm.nih.gov/pubmed/23101451", "http://www.ncbi.nlm.nih.gov/pubmed/22244016", "http://www.ncbi.nlm.nih.gov/pubmed/22068990", "http://www.ncbi.nlm.nih.gov/pubmed/21960571", "http://www.ncbi.nlm.nih.gov/pubmed/22220280", "http://www.ncbi.nlm.nih.gov/pubmed/21772967", "http://www.ncbi.nlm.nih.gov/pubmed/24339571", "http://www.ncbi.nlm.nih.gov/pubmed/22645702", "http://www.ncbi.nlm.nih.gov/pubmed/22682265"], "triples": [{"p": "http://data.linkedct.org/resource/linkedct/description", "s": "http://data.linkedct.org/resource/trials/NCT00029146", "o": "\n      The overall purpose of this research is to determine if a surgical operation called\n      \"Extracranial-Intracranial Bypass\" can reduce the chance of a subsequent stroke in someone\n      who has complete blockage in one main artery in the neck (the carotid artery) that supplies\n      blood to the brain and has already suffered a small stroke. This surgery involves taking an\n      artery from the scalp outside the skull, making a small hole in the skull and then connecting\n      the scalp artery to a brain artery inside the skull. In this way the blockage of the carotid\n      artery in the neck is bypassed and more blood can flow to the brain. In some people natural\n      bypass arteries develop and the brain is already getting plenty of blood. These people have a\n      low risk of stroke if they take medicine. In other people, no natural bypass arteries develop\n      so less blood flows to their brains. This second group has a much higher risk of stroke while\n      taking medicine, as high as 25-50% within the next two years. It is this second group of\n      people who may benefit from having the bypass operation and who are the candidates for this\n      study.\n\n      This bypass surgery is considered experimental because it is not generally performed for this\n      condition and it is unknown whether it leads to a decrease, an increase or no change in the\n      risk of stroke. In order to determine if people fit into this second group of people who may\n      benefit from the bypass operation they need to have a test called a PET scan. The PET scan\n      measures the amount of blood that is getting to the brain and the amount of oxygen that the\n      brain is using. The PET scan uses radioactive oxygen and water and is experimental (not\n      approved by the United States Food and Drug Administration). If the PET scan shows that less\n      blood is getting to the brain, there will be a 50-50 chance (like a coin toss) of receiving\n      the bypass surgery or not. There will then be follow-up visits to the clinic one month later\n      and then every three months for two years to check on the appropriate medical treatment that\n      everyone will receive and to determine who has had a stroke.\n\n      The study hypothesis is that extracranial-intracranial bypass surgery when added to best\n      medical therapy can reduce by 40 percent  subsequent stroke within  two years in participants\n      with recent TIA ('ministroke\") or stroke (</= 120 days) due to blockage of the carotid artery\n      and reduced blood flow to the brain measured by PET.\n    "}, {"p": "http://data.linkedct.org/resource/linkedct/summary", "s": "http://data.linkedct.org/resource/trials/NCT00029146", "o": "\n      The purpose of this study is to determine if extracranial-intracranial bypass surgery when\n      added to best medical therapy can reduce the subsequent risk of ipsilateral stroke in\n      high-risk patients with recently symptomatic carotid occlusion and increased cerebral oxygen\n      extraction fraction measured by PET.\n    "}], "ideal_answer": "The Carotid Occlusion Surgery Study (COSS) was conducted to determine if superficial temporal artery-middle cerebral artery (STA-MCA) bypass, when added to the best medical therapy, would reduce subsequent ipsilateral stroke in patients with complete internal carotid artery (ICA) occlusion and an elevated oxygen extraction fraction (OEF) in the cerebral hemisphere distal to the occlusion.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002986"], "type": "summary", "id": "5314c045dae131f847000007", "snippets": [{"offsetInBeginSection": 8, "offsetInEndSection": 399, "text": "The Carotid Occlusion Surgery Study (COSS) was conducted to determine if superficial temporal artery-middle cerebral artery (STA-MCA) bypass, when added to the best medical therapy, would reduce subsequent ipsilateral stroke in patients with complete internal carotid artery (ICA) occlusion and an elevated oxygen extraction fraction (OEF) in the cerebral hemisphere distal to the occlusion.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23101451", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068990", "endSection": "title"}, {"offsetInBeginSection": 201, "offsetInEndSection": 436, "text": "To test the hypothesis that extracranial-intracranial (EC-IC) bypass surgery, added to best medical therapy, reduces subsequent ipsilateral ischemic stroke in patients with recently symptomatic AICAO and hemodynamic cerebral ischemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068990", "endSection": "abstract"}, {"offsetInBeginSection": 8, "offsetInEndSection": 343, "text": "The Carotid Occlusion Surgery Study (COSS) was a large, prospective clinical trial that examined whether superficial temporal artery-middle cerebral artery (STA-MCA) bypass, in addition to best medical therapy, reduced the risk of ipsilateral ischemic stroke in patients with carotid artery occlusion and hemodynamic cerebral ischemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23909253", "endSection": "abstract"}]}, {"body": "Describe Malgaigne fracture.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26046617", "http://www.ncbi.nlm.nih.gov/pubmed/15195043", "http://www.ncbi.nlm.nih.gov/pubmed/11775195", "http://www.ncbi.nlm.nih.gov/pubmed/10894080", "http://www.ncbi.nlm.nih.gov/pubmed/8769442", "http://www.ncbi.nlm.nih.gov/pubmed/7876010", "http://www.ncbi.nlm.nih.gov/pubmed/7555349", "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "http://www.ncbi.nlm.nih.gov/pubmed/1465304", "http://www.ncbi.nlm.nih.gov/pubmed/2766606", "http://www.ncbi.nlm.nih.gov/pubmed/1942182", "http://www.ncbi.nlm.nih.gov/pubmed/1498111", "http://www.ncbi.nlm.nih.gov/pubmed/1475128", "http://www.ncbi.nlm.nih.gov/pubmed/3230497", "http://www.ncbi.nlm.nih.gov/pubmed/3111770", "http://www.ncbi.nlm.nih.gov/pubmed/7204439", "http://www.ncbi.nlm.nih.gov/pubmed/7431445", "http://www.ncbi.nlm.nih.gov/pubmed/3967429", "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "http://www.ncbi.nlm.nih.gov/pubmed/24502106", "http://www.ncbi.nlm.nih.gov/pubmed/25135027"], "triples": [], "ideal_answer": ["Bilateral pubic rami fractures are characteristic to Malgaigne fractures. Patients with Malgaigne fractures are particularly prone to additional injuries."], "concepts": [], "type": "summary", "id": "56bce63cd36b5da37800000b", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "Fractures of the transverse processes in the lumbar vertebrae occur as the result of major forces such as direct blunt trauma, violent lateral flexion-extension forces, avulsion of the psoas muscle, or Malgaigne fractures of the pelvis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26046617", "endSection": "abstract"}, {"offsetInBeginSection": 607, "offsetInEndSection": 758, "text": "The anteroposterior radiographic view revealed ununited fractures at the left superior and inferior pubic ramus, noted as a type I Malgaigne fracture. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15195043", "endSection": "abstract"}, {"offsetInBeginSection": 511, "offsetInEndSection": 640, "text": "Posterior urethral injuries occur more commonly with vertically applied forces, which typically create Malgaigne-type fractures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11775195", "endSection": "abstract"}, {"offsetInBeginSection": 1520, "offsetInEndSection": 1707, "text": "Patients with bilateral pubic rami fractures or Malgaigne fractures were particularly prone to additional injuries; therefore, abdominal CT examinations are recommended in these patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10894080", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Pelvic fractures, especially those of a Malgaigne type, frequently occur in patients who are polytraumatized. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8769442", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 343, "text": "The authours report the case of a 27-year-old man who had suffered a severe polytrauma with blunt thoracic injury, fracture of the lumbar spine, Malgaigne-type fracture of the pelvis and fracture of the femoral shaft on the right side, 10 years before.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7876010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "The paper deals with the displacement of the uterus observed during management of Malgaigne type pelvic fracture in a 33 years old female. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7555349", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 668, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Eleven cases of sacroiliac dislocation and/or fracture (Malgaigne pattern) were successfully reduced and stabilized using two threaded compression rods.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2766606", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "We compared the mechanical performance of the Orthofix pelvic external fixator with that of the Pittsburgh triangular frame (PTF) on eight fresh-frozen cadaver pelves with experimentally created Malgaigne (double-vertical) fracture/dislocations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3230497", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "A 48-year-old woman developed symptomatic superior and inferior pubic rami fractures with a concomitant subluxation of the ipsilateral sacroiliac joint three years after pelvic irradiation for a gynecologic malignancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3111770", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 411, "text": "Twenty-six of the thirty-two cadavera that were examined radiographically and dissected had a double break in the pelvic ring (Malgaigne pattern).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7204439", "endSection": "abstract"}, {"offsetInBeginSection": 186, "offsetInEndSection": 333, "text": " Initial hypotension, Malgaigne and bilateral pubic rami fractures, and blood requirements exceeding 2,000 cc were suggestive of abdominal trauma. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7431445", "endSection": "abstract"}, {"offsetInBeginSection": 248, "offsetInEndSection": 341, "text": " Malgaigne-type fractures with sacroiliac disruptions were created in four cadaver pelvises. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3967429", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 267, "text": "Malgaigne fracture is referred to pelvic ring disruption at two sites, and is often treated surgically for its instability. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24502106", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Sacral fractures are generally accompanied by pelvic ring fractures. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25135027", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 374, "text": "Malgaigne fracture is referred to pelvic ring disruption at two sites, and is often treated surgically for its instability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24502106", "endSection": "abstract"}, {"offsetInBeginSection": 442, "offsetInEndSection": 667, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}, {"offsetInBeginSection": 306, "offsetInEndSection": 669, "text": "Another less frequently reported complication of pelvic fractures is the potential association with pregnancy and subsequent childbirth. This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 880, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth. A review of the literature reveals numerous articles addressing potential problems with parturition subsequent to a pelvic fracture and several articles dealing with pelvic fractures occurring during pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}, {"offsetInBeginSection": 306, "offsetInEndSection": 669, "text": "Another less frequently reported complication of pelvic fractures is the potential association with pregnancy and subsequent childbirth. This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 880, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth. A review of the literature reveals numerous articles addressing potential problems with parturition subsequent to a pelvic fracture and several articles dealing with pelvic fractures occurring during pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 669, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}, {"offsetInBeginSection": 306, "offsetInEndSection": 669, "text": "Another less frequently reported complication of pelvic fractures is the potential association with pregnancy and subsequent childbirth. This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 880, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth. A review of the literature reveals numerous articles addressing potential problems with parturition subsequent to a pelvic fracture and several articles dealing with pelvic fractures occurring during pregnancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}, {"offsetInBeginSection": 443, "offsetInEndSection": 669, "text": "This problem was first described by Malgaigne in 1857 in his classic article on double vertical fractures of the pelvis, in which he described a 34-year-old woman with a pelvic fracture who subsequently died during childbirth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1403261", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "The authors report 7 cases involving the surgical treatment of unstable pelvic ring fractures (Malgaigne type) using two compression bars, as described by Tile.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9269112", "endSection": "abstract"}]}, {"body": "Which thyroid hormone transporter is implicated in thyroid hormone resistance syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23392090", "http://www.ncbi.nlm.nih.gov/pubmed/22986150", "http://www.ncbi.nlm.nih.gov/pubmed/21459689", "http://www.ncbi.nlm.nih.gov/pubmed/18940949", "http://www.ncbi.nlm.nih.gov/pubmed/17574009", "http://www.ncbi.nlm.nih.gov/pubmed/17161330", "http://www.ncbi.nlm.nih.gov/pubmed/1422238", "http://www.ncbi.nlm.nih.gov/pubmed/8475937", "http://www.ncbi.nlm.nih.gov/pubmed/9092799", "http://www.ncbi.nlm.nih.gov/pubmed/21874823", "http://www.ncbi.nlm.nih.gov/pubmed/19541799", "http://www.ncbi.nlm.nih.gov/pubmed/12946875", "http://www.ncbi.nlm.nih.gov/pubmed/8115332", "http://www.ncbi.nlm.nih.gov/pubmed/17132274", "http://www.ncbi.nlm.nih.gov/pubmed/8594618", "http://www.ncbi.nlm.nih.gov/pubmed/17684393", "http://www.ncbi.nlm.nih.gov/pubmed/9350446", "http://www.ncbi.nlm.nih.gov/pubmed/8421095", "http://www.ncbi.nlm.nih.gov/pubmed/1580595", "http://www.ncbi.nlm.nih.gov/pubmed/7833674", "http://www.ncbi.nlm.nih.gov/pubmed/17040361", "http://www.ncbi.nlm.nih.gov/pubmed/2885829", "http://www.ncbi.nlm.nih.gov/pubmed/10687857"], "triples": [], "ideal_answer": "Hemizygous MCT8 mutations cuases TH resistance syndrome in males characterized by severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS).", "exact_answer": ["TH monocarboxylate transporter 8 (MCT8) mutation is implicated in the TH resistance syndrome"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018382", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014284", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011815", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D060467", "http://www.disease-ontology.org/api/metadata/DOID:11633", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009914"], "type": "factoid", "id": "52f8b2902059c6d71c000053", "snippets": [{"offsetInBeginSection": 489, "offsetInEndSection": 732, "text": "Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23392090", "endSection": "abstract"}, {"offsetInBeginSection": 720, "offsetInEndSection": 832, "text": " One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22986150", "endSection": "abstract"}, {"offsetInBeginSection": 137, "offsetInEndSection": 371, "text": " Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TR\u03b2, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21459689", "endSection": "abstract"}, {"offsetInBeginSection": 585, "offsetInEndSection": 728, "text": "One, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574009", "endSection": "abstract"}]}, {"body": "Which autophagy pathway is trigered by the KFERQ motif of cytosolic proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23452232", "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "http://www.ncbi.nlm.nih.gov/pubmed/16782460", "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "http://www.ncbi.nlm.nih.gov/pubmed/23880665", "http://www.ncbi.nlm.nih.gov/pubmed/19433452", "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "http://www.ncbi.nlm.nih.gov/pubmed/24323530", "http://www.ncbi.nlm.nih.gov/pubmed/12105396", "http://www.ncbi.nlm.nih.gov/pubmed/24477641"], "triples": [], "ideal_answer": ["Cytosolic proteins carrying the KFERQ motif (a specific lysosomal import consensus sequence) are directed to a selective form of lysosomal degradation, called chaperone-mediated autophagy (CMA), as chaperone protein Hsc73 and other chaperones are involved in this process."], "exact_answer": [["chaperone-mediated autophagy (CMA)"]], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006914", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001343", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054730"], "type": "factoid", "id": "5540fbce234c5a7c75000001", "snippets": [{"offsetInBeginSection": 304, "offsetInEndSection": 428, "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452232", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 354, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 448, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 445, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 420, "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1085, "offsetInEndSection": 1234, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1175, "text": "Furthermore, four annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes with high chaperone-mediated autophagy activity as expected for substrate proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 861, "text": "Using isolated lysosomes, only the annexins containing KFERQ-like sequences are degraded by chaperone mediated-autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 445, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 420, "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1085, "offsetInEndSection": 1234, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1175, "text": "Furthermore, four annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes with high chaperone-mediated autophagy activity as expected for substrate proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 861, "text": "Using isolated lysosomes, only the annexins containing KFERQ-like sequences are degraded by chaperone mediated-autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 445, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 420, "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1085, "offsetInEndSection": 1234, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1175, "text": "Furthermore, four annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes with high chaperone-mediated autophagy activity as expected for substrate proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 1157, "offsetInEndSection": 1425, "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "endSection": "abstract"}, {"offsetInBeginSection": 739, "offsetInEndSection": 861, "text": "Using isolated lysosomes, only the annexins containing KFERQ-like sequences are degraded by chaperone mediated-autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 445, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 295, "offsetInEndSection": 420, "text": "Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23452232", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1085, "offsetInEndSection": 1234, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 977, "offsetInEndSection": 1175, "text": "Furthermore, four annexins containing KFERQ-like sequences, annexins I, II, IV, and VI, are enriched in lysosomes with high chaperone-mediated autophagy activity as expected for substrate proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 1157, "offsetInEndSection": 1425, "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "endSection": "abstract"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1432, "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "AIMS: Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 354, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 447, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 946, "text": "In cell culture, growth factors suppress the lysosomal pathway of chaperone-mediated autophagy leading to the accumulation of specific cytoplasmic proteins containing KFERQ motifs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12105396", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 446, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1346, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.g., M2 pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pax2] were more abundant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1303, "text": "These results provide striking evidence for the importance of KFERQ motifs in substrates of chaperone-mediated autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 946, "text": "In cell culture, growth factors suppress the lysosomal pathway of chaperone-mediated autophagy leading to the accumulation of specific cytoplasmic proteins containing KFERQ motifs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12105396", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 446, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1346, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.g., M2 pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pax2] were more abundant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1303, "text": "These results provide striking evidence for the importance of KFERQ motifs in substrates of chaperone-mediated autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 946, "text": "In cell culture, growth factors suppress the lysosomal pathway of chaperone-mediated autophagy leading to the accumulation of specific cytoplasmic proteins containing KFERQ motifs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12105396", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 446, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1346, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.g., M2 pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pax2] were more abundant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1303, "text": "These results provide striking evidence for the importance of KFERQ motifs in substrates of chaperone-mediated autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1431, "text": "Macroautophagy is followed by chaperone-mediated autophagy (CMA), in which Hsc70 (Heat shock cognate 70) selectively binds proteins with exposed KFERQ motifs and pushes them inside lysosomes through the LAMP-2A (Lysosome-associated membrane protein type 2A) receptor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23070014", "endSection": "abstract"}, {"offsetInBeginSection": 111, "offsetInEndSection": 353, "text": "The significance of the receptor glycoprotein lamp2a in the chaperone-mediated autophagy of cytosolic proteins with KFERQ motif has been described in details as well as the chaperone protein Hsc73 and other chaperones involved in this process", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16209346", "endSection": "abstract"}, {"offsetInBeginSection": 767, "offsetInEndSection": 946, "text": "In cell culture, growth factors suppress the lysosomal pathway of chaperone-mediated autophagy leading to the accumulation of specific cytoplasmic proteins containing KFERQ motifs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12105396", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 446, "text": "We investigated chaperone-mediated autophagy, a lysosomal import pathway that depends on the 73-kDa heat shock cognate protein and allows the degradation of proteins containing a specific lysosomal import consensus sequence (KFERQ motif)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11262416", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Chaperone-mediated autophagy (CMA) is a selective mechanism for the degradation of soluble cytosolic proteins bearing the sequence KFERQ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23404999", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1346, "text": "The abundance of proteins containing that chaperone-mediated autophagy KFERQ signal motif increased 38% and individual KFERQ containing proteins [e.g., M2 pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pax2] were more abundant", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15149326", "endSection": "abstract"}, {"offsetInBeginSection": 1182, "offsetInEndSection": 1303, "text": "These results provide striking evidence for the importance of KFERQ motifs in substrates of chaperone-mediated autophagy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10938088", "endSection": "abstract"}]}, {"body": "Which translocation is harbored in the Askin tumor cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23674776", "http://www.ncbi.nlm.nih.gov/pubmed/17009618", "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "http://www.ncbi.nlm.nih.gov/pubmed/7571088", "http://www.ncbi.nlm.nih.gov/pubmed/1333942", "http://www.ncbi.nlm.nih.gov/pubmed/2162733", "http://www.ncbi.nlm.nih.gov/pubmed/7591257"], "triples": [], "ideal_answer": ["The Askin tumor is a primitive malignant small-cell tumor of the chest wall mostly seen among children and adolescents. It is closely related to Ewing's sarcoma of the same location, with both tumors harboring reciprocal translocation t(11;22) (q24;q12)."], "exact_answer": [["reciprocal translocation t(11;22) (q24;q12)"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:0050608"], "type": "factoid", "id": "553656c4bc4f83e828000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 231, "text": "The Ewing sarcoma family of tumors includes osseous Ewing sarcoma, extraskeletal Ewing sarcoma, primitive neuroectodermal tumor, and Askin tumor. They share a karyotype abnormality with translocation involving chromosomes 11 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23674776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Ewing tumor family consists of Ewing tumor of bone, extraosseous Ewing tumor, primitive neurectodermal tumor and Askin tumor. All of them share genetic abnormality, reciprocal translocation (11; 22) (q24; q12), and originate from the same primordial stem cell", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17009618", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 551, "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Malignant small cell tumor of the thoracopulmonary region (MSCT) was first described in 1979 and has been referred to as the Askin tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7571088", "endSection": "abstract"}, {"offsetInBeginSection": 1331, "offsetInEndSection": 1454, "text": "MSCT and PPNET have a common reciprocal cytogenetic translocation [t(11;22)q(24;q12)], which is shared with Ewing's sarcoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7571088", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "The Askin tumor, a primitive malignant small-cell tumor of the chest wall, is mostly seen among children and adolescents. It is closely related to Ewing's sarcoma of the same location, both tumors showing a chromosomal translocation t(11;22)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1333942", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 548, "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 548, "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 548, "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "endSection": "abstract"}, {"offsetInBeginSection": 405, "offsetInEndSection": 548, "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Ewing tumor family consists of Ewing tumor of bone, extraosseous Ewing tumor, primitive neurectodermal tumor and Askin tumor. All of them share genetic abnormality, reciprocal translocation (11; 22) (q24; q12), and originate from the same primordial stem cell", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17009618", "endSection": "abstract"}, {"offsetInBeginSection": 410, "offsetInEndSection": 552, "text": "Chromosomal analysis of the neoplastic cells revealed translocation (11;22)(q24;q12), which is often found in Ewing's sarcoma and Askin tumor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9213191", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 778, "text": "In Ewing's sarcoma (a tumor of unknown histogenesis), and in peripheral neuroepithelioma and Askin's tumor (tumors with evidence of neural origin), we have observed an indistinguishable t(11;22) translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3004699", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 366, "text": "Reciprocal translocations of chromosomes 11 and 22 are the most common cytogenetic abnormalities in Ewing's sarcoma and the related Askin's tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2162733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The t(11;22)(q24;q12) and t(21;22)(q22;q12) are specific chromosomal translocations found in the Ewing family of tumors including ES, PNET and Askin tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591257", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 778, "text": "In Ewing's sarcoma (a tumor of unknown histogenesis), and in peripheral neuroepithelioma and Askin's tumor (tumors with evidence of neural origin), we have observed an indistinguishable t(11;22) translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3004699", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 366, "text": "Reciprocal translocations of chromosomes 11 and 22 are the most common cytogenetic abnormalities in Ewing's sarcoma and the related Askin's tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2162733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The t(11;22)(q24;q12) and t(21;22)(q22;q12) are specific chromosomal translocations found in the Ewing family of tumors including ES, PNET and Askin tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591257", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 778, "text": "In Ewing's sarcoma (a tumor of unknown histogenesis), and in peripheral neuroepithelioma and Askin's tumor (tumors with evidence of neural origin), we have observed an indistinguishable t(11;22) translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3004699", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 366, "text": "Reciprocal translocations of chromosomes 11 and 22 are the most common cytogenetic abnormalities in Ewing's sarcoma and the related Askin's tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2162733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The t(11;22)(q24;q12) and t(21;22)(q22;q12) are specific chromosomal translocations found in the Ewing family of tumors including ES, PNET and Askin tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591257", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 778, "text": "In Ewing's sarcoma (a tumor of unknown histogenesis), and in peripheral neuroepithelioma and Askin's tumor (tumors with evidence of neural origin), we have observed an indistinguishable t(11;22) translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3004699", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 366, "text": "Reciprocal translocations of chromosomes 11 and 22 are the most common cytogenetic abnormalities in Ewing's sarcoma and the related Askin's tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2162733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The t(11;22)(q24;q12) and t(21;22)(q22;q12) are specific chromosomal translocations found in the Ewing family of tumors including ES, PNET and Askin tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591257", "endSection": "abstract"}, {"offsetInBeginSection": 569, "offsetInEndSection": 778, "text": "In Ewing's sarcoma (a tumor of unknown histogenesis), and in peripheral neuroepithelioma and Askin's tumor (tumors with evidence of neural origin), we have observed an indistinguishable t(11;22) translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3004699", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 366, "text": "Reciprocal translocations of chromosomes 11 and 22 are the most common cytogenetic abnormalities in Ewing's sarcoma and the related Askin's tumor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2162733", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "The t(11;22)(q24;q12) and t(21;22)(q22;q12) are specific chromosomal translocations found in the Ewing family of tumors including ES, PNET and Askin tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7591257", "endSection": "abstract"}]}, {"body": "Intact macromolecular assemblies are analysed by advanced mass spectrometry. How large complexes (in molecular weight) have been studied?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23064518", "http://www.ncbi.nlm.nih.gov/pubmed/19140748", "http://www.ncbi.nlm.nih.gov/pubmed/16939266", "http://www.ncbi.nlm.nih.gov/pubmed/8006040"], "ideal_answer": ["2.3 megadalton"], "exact_answer": ["2.3 megadalton"], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0065003", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0032991", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043933", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0034622", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046911", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046912", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0034621", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013058", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D021241", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018629", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013057", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053719", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008970"], "type": "factoid", "id": "514c3fd7d24251bc05000062", "snippets": [{"offsetInBeginSection": 165, "offsetInEndSection": 354, "text": "Here we show that the Orbitrap mass analyzer can be used to measure protein assemblies of molecular weights approaching one megadalton with sensitivity down to the detection of single ions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23064518", "endSection": "sections.0"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1015, "text": "Using this relationship we show that we can determine masses of both 30S subunits and intact 2.3 MDa 70S ribosomes from Thermus thermophilus.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16939266", "endSection": "sections.0"}, {"offsetInBeginSection": 1415, "offsetInEndSection": 1801, "text": "We confirm the existence of these subpopulations using tandem mass spectrometry of intact 30S subunits. Overall, the results show that, rather than uniform particles, gas-phase ribosomes consist of a number of discrete populations. More generally, the results establish a rigorous procedure for accurate mass measurement and spectral analysis of heterogeneous macromolecular assemblies.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16939266", "endSection": "sections.0"}]}, {"body": "What are the functions of the ESCRT machinery?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26040713", "http://www.ncbi.nlm.nih.gov/pubmed/26339479", "http://www.ncbi.nlm.nih.gov/pubmed/25690770", "http://www.ncbi.nlm.nih.gov/pubmed/25637630", "http://www.ncbi.nlm.nih.gov/pubmed/25624505", "http://www.ncbi.nlm.nih.gov/pubmed/25099357", "http://www.ncbi.nlm.nih.gov/pubmed/24482116", "http://www.ncbi.nlm.nih.gov/pubmed/24148098", "http://www.ncbi.nlm.nih.gov/pubmed/24641493", "http://www.ncbi.nlm.nih.gov/pubmed/24109596"], "triples": [], "ideal_answer": ["The endosomal sorting complexes required for transport (ESCRT) are needed for three distinct cellular functions in higher eukaryotes: (i) Multivesicular body formation for the degradation of transmembrane proteins in lysosomes, (ii) midbody abscission during cytokinesis and (iii) retroviral budding."], "concepts": [], "type": "summary", "id": "570a8dcfcf1c325851000027", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 412, "text": "The endosomal sorting complexes required for transport (ESCRTs) collectively comprise a machinery that was first known for its function in the degradation of transmembrane proteins in the endocytic pathway of eukaryotic cells. Since their discovery, however, ESCRTs have been recognized as playing important roles at the plasma membrane, which appears to be the original site of function for the ESCRT machinery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26339479", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Endosomal sorting complexes required for transport (ESCRTs) are involved in the formation of multivesicular bodies and sorting of targeted proteins to the yeast vacuole.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25690770", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Disassembly of the endosomal sorting complex required for transport (ESCRT) machinery from biological membranes is a critical final step in cellular processes that require the ESCRT function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637630", "endSection": "abstract"}, {"offsetInBeginSection": 99, "offsetInEndSection": 259, "text": "Evidence has accumulated revealing that efficient autophagic degradation requires functional endosomal sorting complex required for transport (ESCRT) machinery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 176, "text": "HIV-1 virions assemble at the plasma membrane of mammalian cells and recruit the endosomal sorting complex required for transport (ESCRT) machinery to enable particle release. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25099357", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 386, "text": "We found that endosomal sorting complex required for transport (ESCRT), involved previously in membrane budding and fission, plays a critical role in plasma membrane repair.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482116", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "The ESCRT (endosomal sorting complex required for transport) machinery is known to sort ubiquitinated transmembrane proteins into vesicles that bud into the lumen of multivesicular bodies (MVBs).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24148098", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "The endosomal sorting complexes required for transport (ESCRT) are needed for three distinct cellular functions in higher eukaryotes: (i) Multivesicular body formation for the degradation of transmembrane proteins in lysosomes, (ii) midbody abscission during cytokinesis and (iii) retroviral budding. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24641493", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 274, "text": "Recently it was shown that both recycling endosome and endosomal sorting complex required for transport (ESCRT) components are required for cytokinesis, in which they are believed to act in a sequential manner to bring about secondary ingression and abscission, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24109596", "endSection": "abstract"}]}, {"body": "Which is the E3 ubiquitin ligase of Hsp90?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23429937", "http://www.ncbi.nlm.nih.gov/pubmed/23344957", "http://www.ncbi.nlm.nih.gov/pubmed/20618441", "http://www.ncbi.nlm.nih.gov/pubmed/17209571"], "triples": [], "ideal_answer": "Carboxyl terminus of hsc70-interacting protein (CHIP) can mediate ubiquitination of the 90 kDa heat-shock protein (hsp90) in vitro, with subsequent proteasomal degradation of the chaperone.", "exact_answer": ["Carboxyl terminus of hsc70-interacting protein (CHIP)"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044767", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043743", "http://www.uniprot.org/uniprot/UB2E3_HUMAN", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004842", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0044389", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000151", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051879", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018841"], "type": "factoid", "id": "5319a7d2b166e2b806000029", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 232, "text": "C-terminal Hsp-interacting protein (CHIP) is an HSP70 and HSP90 interacting co-chaperone and an E3 ubiquitin ligase. Previous studies have reported the role of CHIP in cancer progression by targeting protein degradation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23429937", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The U-box E3 ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein) binds Hsp90 and/or Hsp70 via its tetratricopeptide repeat (TPR), facilitating ubiquitination of the chaperone-bound client proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344957", "endSection": "abstract"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1055, "text": "In vitro ubiquitination assays indicated that Ca(2+)/S100A2 and S100P are efficient and specific inhibitors of CHIP-mediated ubiquitination of Hsp70, Hsp90, HSF1, and Smad1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23344957", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The E3 ubiquitin ligase CHIP (C-terminus of Hsc70-interacting protein) is believed to be a central player in the cellular triage decision, as it links the molecular chaperones Hsp70/Hsc70 and Hsp90 to the ubiquitin proteasomal degradation pathway.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20618441", "endSection": "abstract"}, {"offsetInBeginSection": 596, "offsetInEndSection": 675, "text": "We found that CHIP has a sixfold higher affinity for Hsp90 compared with Hsc70.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20618441", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 208, "text": "Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90) in vitro", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209571", "endSection": "title"}, {"offsetInBeginSection": 619, "offsetInEndSection": 864, "text": "The analysis of the sucrose-gradient-fractionated in vitro translated AhR complexes revealed that CHIP can mediate hsp90 ubiquitination while cooperating with unidentified factors to promote the ubiquitination of mature unliganded AhR complexes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209571", "endSection": "abstract"}]}, {"body": "What is the role of brain natriuretic peptide in traumatic brain injury patients ?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23963125", "http://www.ncbi.nlm.nih.gov/pubmed/21808206", "http://www.ncbi.nlm.nih.gov/pubmed/19803787", "http://www.ncbi.nlm.nih.gov/pubmed/18325424", "http://www.ncbi.nlm.nih.gov/pubmed/17690842", "http://www.ncbi.nlm.nih.gov/pubmed/16774478", "http://www.ncbi.nlm.nih.gov/pubmed/16322908"], "triples": [], "ideal_answer": ["Brain natriuretic peptide concentrations are elevated in patients with traumatic brain during the acute phase and correlate with poor outcomes. In traumatic brain injury patients higher brain natriuretic peptide concentrations are associated with more extensive SAH,  elevated ICP and hyponatremia. Brain natriuretic peptide may play an adaptive role in recovery through augmentation of cerebral blood flow."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020097", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001930", "http://www.uniprot.org/uniprot/ANFB_MOUSE", "http://www.uniprot.org/uniprot/ANFB_OREMO", "http://www.uniprot.org/uniprot/ANFB_TAKRU", "http://www.uniprot.org/uniprot/ANFB_ACITR", "http://www.biosemantics.org/jochem#4250398", "http://www.biosemantics.org/jochem#4264708"], "type": "summary", "id": "5314d05adae131f84700000d", "snippets": [{"offsetInBeginSection": 1301, "offsetInEndSection": 1613, "text": "This study provides evidence that BNP plasma concentrations increase rapidly after TBI. Plasma BNP concentrations are correlated with hyponatremia in severe TBI patients but not in mild and moderate TBI patients. Furthermore, patients with elevated ICP have a higher serum BNP level in first 4 days after injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808206", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 1288, "text": "In average, the peak of BNP level was measured at 703.9 pg/mL\u00b1179.1 pg/mL on day 3 after injury, which was correlated to the severity of TBI. Among patients with severe TBI, plasma NT-proBNP concentrations in patients with hyponatremia were statistically higher than those without hyponatremia (p<0.05). In the hyponatremic group, the plasma NT-proBNP increased to a peak of 1001.16 pg/mL\u00b1131.52 pg/mL within 48 hours after injury and maintained at a high level for 3 days. In the normonatremic group, the plasma NT-proBNP reached a peak of 826.43 pg/mL\u00b1337.43 pg/mL on day 5 and quickly decreased thereafter. In addition, we found plasma NT-proBNP concentrations in patients with ICP>15 mm Hg were significantly higher than those in patients with ICP\u226415 mm Hg (p<0.01). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808206", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "There is emerging evidence to suggest that brain natriuretic peptide (BNP) is elevated after acute brain injury, and that it may play an adaptive role in recovery through augmentation of cerebral blood flow (CBF). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19803787", "endSection": "abstract"}, {"offsetInBeginSection": 1522, "offsetInEndSection": 1750, "text": "hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19803787", "endSection": "abstract"}, {"offsetInBeginSection": 434, "offsetInEndSection": 508, "text": "Here, we describe 2 cases of CSW in TBI patients with elevated BNP levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18325424", "endSection": "abstract"}, {"offsetInBeginSection": 934, "offsetInEndSection": 1058, "text": "These patients with TBI had findings consistent with CSW with elevated BNP levels in the setting of normal cardiac function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18325424", "endSection": "abstract"}, {"offsetInBeginSection": 559, "offsetInEndSection": 842, "text": "We measured NT-proBNP levels in cerebrospinal fluid (CSF) and serum of 14 patients suffering from severe TBI (GCS15 mm Hg (n=6), the serum (800+/-150 pg/mL) and CSF levels (55+/-9 pg/mL) of NT-proBNP were significantly increased after 24 h, as compared to patients with ICP15 mm Hg. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16774478", "endSection": "abstract"}, {"offsetInBeginSection": 1425, "offsetInEndSection": 1645, "text": "BNP plasma concentrations are elevated shortly after head injury and are continuously elevated during the acute phase in patients with more extensive SAH and in those with elevated ICP, and correlate with poor outcomes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16322908", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 232, "text": "BACKGROUND: According to the literature, serum beta-natriuretic peptide (BNP) levels have been shown to increase in adult trauma patients, specifically for those with traumatic brain injury and in those with intracranial hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20068481", "endSection": "abstract"}, {"offsetInBeginSection": 1301, "offsetInEndSection": 1613, "text": "This study provides evidence that BNP plasma concentrations increase rapidly after TBI. Plasma BNP concentrations are correlated with hyponatremia in severe TBI patients but not in mild and moderate TBI patients. Furthermore, patients with elevated ICP have a higher serum BNP level in first 4 days after injury.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808206", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 1288, "text": "In average, the peak of BNP level was measured at 703.9 pg/mL\u00b1179.1 pg/mL on day 3 after injury, which was correlated to the severity of TBI. Among patients with severe TBI, plasma NT-proBNP concentrations in patients with hyponatremia were statistically higher than those without hyponatremia (p<0.05). In the hyponatremic group, the plasma NT-proBNP increased to a peak of 1001.16 pg/mL\u00b1131.52 pg/mL within 48 hours after injury and maintained at a high level for 3 days. In the normonatremic group, the plasma NT-proBNP reached a peak of 826.43 pg/mL\u00b1337.43 pg/mL on day 5 and quickly decreased thereafter. In addition, we found plasma NT-proBNP concentrations in patients with ICP>15 mm Hg were significantly higher than those in patients with ICP\u226415 mm Hg (p<0.01). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21808206", "endSection": "abstract"}]}, {"body": "Which kinase is regulating stress granule biogenesis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25840010"], "triples": [], "ideal_answer": ["Multiple lines of evidence define the master metabolic regulator 5'-AMP-activated protein kinase alpha (AMPK-alpha) as a novel component of stress granules (SGs) that also controls their biogenesis.", "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis", "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis", "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis"], "concepts": [], "type": "summary", "id": "56cdf4675795f9a73e00003f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 645, "offsetInEndSection": 1162, "text": "Multiple lines of evidence link AMPK activity to SG biogenesis. First, pharmacological kinase inhibition interfered with SG formation. Second, AMPK-\u03b1 knockdown combined with in-depth quantitative SG analysis revealed isoform-specific changes of SG characteristics. Third, overexpression of mutant \u03b1-subunits further substantiated that AMPK regulates SG parameters. Finally, we identified the SG-nucleating protein G3BP1 as an AMPK-\u03b12 binding partner. This interaction is stimulated by stress and notably occurs in SGs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 1178, "offsetInEndSection": 1291, "text": "our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1292, "text": "Collectively, our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1292, "text": "Collectively, our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1292, "text": "Collectively, our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1292, "text": "Collectively, our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 1164, "offsetInEndSection": 1292, "text": "Collectively, our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "5'-AMP-activated protein kinase alpha regulates stress granule biogenesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1292, "text": "This interaction is stimulated by stress and notably occurs in SGs. Collectively, our data define the master metabolic regulator AMPK as a novel SG constituent that also controls their biogenesis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "5&apos;-AMP-activated protein kinase alpha regulates stress granule biogenesis..", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "5&apos;-AMP-activated protein kinase alpha regulates stress granule biogenesis..", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "5&apos;-AMP-activated protein kinase alpha regulates stress granule biogenesis..", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "5&apos;-AMP-activated protein kinase alpha regulates stress granule biogenesis..", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "5&apos;-AMP-activated protein kinase alpha regulates stress granule biogenesis..", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25840010", "endSection": "title"}]}, {"body": "Which is the most common editing modification in eukaryotic mRNA?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23543219", "http://www.ncbi.nlm.nih.gov/pubmed/21469143", "http://www.ncbi.nlm.nih.gov/pubmed/20198873", "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "http://www.ncbi.nlm.nih.gov/pubmed/23346095", "http://www.ncbi.nlm.nih.gov/pubmed/25577380", "http://www.ncbi.nlm.nih.gov/pubmed/25373143"], "triples": [], "ideal_answer": ["One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation."], "exact_answer": [["A-to-I"]], "concepts": ["http://amigo.geneontology.org/amigo/term/GO:0016556", "http://amigo.geneontology.org/amigo/term/GO:0009451", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012333", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017393"], "type": "factoid", "id": "56ffdc1ccf1c32585100000b", "snippets": [{"offsetInBeginSection": 205, "offsetInEndSection": 364, "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 404, "text": "Deamination of adenine by adenosine deaminases that act on RNA (ADARs) leads to the conversion of adenine into inosine (A-I editing) recognized by the splicing and translation systems as guanine.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20198873", "endSection": "abstract"}, {"offsetInBeginSection": 882, "offsetInEndSection": 1065, "text": "denosine deaminases editing adenines in transport RNAs (ADATs) convert adenine into inosine in tRNAs of all eukaryotes; as a result, the diversity of tRNA forms in the cell increases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20198873", "endSection": "abstract"}, {"offsetInBeginSection": 66, "offsetInEndSection": 131, "text": "A-to-I editing events in normal and cancerous human keratinocytes", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23543219", "endSection": "title"}, {"offsetInBeginSection": 430, "offsetInEndSection": 543, "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23543219", "endSection": "abstract"}, {"offsetInBeginSection": 277, "offsetInEndSection": 428, "text": "-to-I RNA editing is a post-transcriptional mechanism frequently used to expand and diversify transcriptome and proteome repertoire in eukaryotic cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23543219", "endSection": "abstract"}, {"offsetInBeginSection": 1340, "offsetInEndSection": 1603, "text": "This study describes for the first time A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP7 editing serves as a fine-tuning mechanism to maintain the equilibrium between proliferation and senescence in normal skin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23543219", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 255, "text": "Adenosine deaminases that act on RNA (ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in higher eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373143", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 255, "text": "Adenosine deaminases that act on RNA (ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in higher eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373143", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 255, "text": "Adenosine deaminases that act on RNA (ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in higher eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373143", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 255, "text": "Adenosine deaminases that act on RNA (ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in higher eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373143", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 255, "text": "Adenosine deaminases that act on RNA (ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in higher eukaryotes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25373143", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 371, "text": "RNA editing is observed in eukaryotic mRNA, transfer RNA, ribosomal RNA, and non-coding RNAs (ncRNA). The most common RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine (A to I).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23346095", "endSection": "abstract"}, {"offsetInBeginSection": 133, "offsetInEndSection": 365, "text": "It occurs in a wide variety of eukaryotic organisms and in some viruses. One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "endSection": "abstract"}, {"offsetInBeginSection": 214, "offsetInEndSection": 371, "text": "The most common RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine (A to I).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23346095", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 365, "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 485, "text": "RNA editing by adenosine deamination (A-to-I) is widespread in humans and can lead to a variety of biological effects depending on the RNA type or the RNA region involved in the editing modification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25577380", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 365, "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 485, "text": "RNA editing by adenosine deamination (A-to-I) is widespread in humans and can lead to a variety of biological effects depending on the RNA type or the RNA region involved in the editing modification.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25577380", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 365, "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "endSection": "abstract"}, {"offsetInBeginSection": 206, "offsetInEndSection": 365, "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20185571", "endSection": "abstract"}]}, {"body": "What is known as the cause of subacute thyroiditis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22819125", "http://www.ncbi.nlm.nih.gov/pubmed/19497087", "http://www.ncbi.nlm.nih.gov/pubmed/16284433"], "ideal_answer": ["Most cases of subacute thyroiditis are caused by a variety of viruses, for example, Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus"], "type": "summary", "id": "51406d6923fec90375000007", "snippets": [{"offsetInBeginSection": 95, "offsetInEndSection": 241, "text": "Most cases of subacute thyroiditis are caused by a variety of viruses, for example, Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22819125", "endSection": "sections.0"}]}, {"body": "What is known about the Digit Ratio (2D:4D) cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23623693", "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "http://www.ncbi.nlm.nih.gov/pubmed/23154605", "http://www.ncbi.nlm.nih.gov/pubmed/23146972", "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "http://www.ncbi.nlm.nih.gov/pubmed/21730975", "http://www.ncbi.nlm.nih.gov/pubmed/21445935", "http://www.ncbi.nlm.nih.gov/pubmed/21119657", "http://www.ncbi.nlm.nih.gov/pubmed/18203126", "http://www.ncbi.nlm.nih.gov/pubmed/12208164", "http://www.ncbi.nlm.nih.gov/pubmed/23131519", "http://www.ncbi.nlm.nih.gov/pubmed/20633006", "http://www.ncbi.nlm.nih.gov/pubmed/24677324", "http://www.ncbi.nlm.nih.gov/pubmed/12441204"], "triples": [], "ideal_answer": ["Digit ratio (2D:4D) is associated with gastric cancer, prostate cancer, breast cancer, cervical intraepithelial neoplasia and oral squamous cell carcinoma. 2D:4D was found to be higher in patients diagnosed with gastric cancer and prostate cancer  patients relative to controls. Among prostate cancer patients, 2D:4D shows strong differences between African-Americans and Caucasians; however, it does not correlate with disease severity in men already diagnosed with prostate cancer. However, other authors did not find an association between 2D:4D  and prostate cancer risk.\n 2D:4D is not associated with testicular germ cell tumors."], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:162"], "type": "summary", "id": "54f08fa494afd61504000017", "snippets": [{"offsetInBeginSection": 883, "offsetInEndSection": 1295, "text": "RESULTS: Right 2D:4D was not associated with TGCT [odds ratio (OR) for a one-standard deviation (SD) increase in right-hand 2D:4D: 1.12, 95% confidence interval (CI): 0.93-1.34]. The results were consistent when evaluating the association based on the left hand. The difference between right and left-hand 2D:4D was also not associated with TGCT risk [OR for a one-SD increase in \u0394R-L: 1.03, 95% CI: 0.87-1.23]. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23623693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Digit ratio (2D:4D) is associated with gastric cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "title"}, {"offsetInBeginSection": 1005, "offsetInEndSection": 1222, "text": "RESULTS: GCA group presented significantly higher left 2D:4D, but significantly lower R-L in comparison to healthy controls, particularly so for males. Digit ratio did not correlate to clinical staging or TNM staging.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "abstract"}, {"offsetInBeginSection": 1435, "offsetInEndSection": 1529, "text": "The 2D:4D pattern found for gastric cancer parallels that earlier described for breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Higher second fourth digit ratio predicts higher incidence of prostate cancer in prostate biopsy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23154605", "endSection": "title"}, {"offsetInBeginSection": 1015, "offsetInEndSection": 1091, "text": "2D/4D ratio >0,95 (OR (CI 95%) 4,4 (1,491-13,107) was related to neoplasia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23154605", "endSection": "abstract"}, {"offsetInBeginSection": 1206, "offsetInEndSection": 1363, "text": "CONCLUSION: High digit ratio predicts PCa in men undergoing prostate biopsy. Digit ratio >0,95 has 4-fold risk of PCa compared to men with digit ratio \u22640.95.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23154605", "endSection": "abstract"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1638, "text": "RESULTS: African-American men with prostate cancer are 3.70 times more likely to have a low 2D:4D digit ratio than Caucasian men with prostate cancer (95% confidence interval: 1.98, 6.92; P < 0.0001). There were no statistically significant differences in the presence of metastasis, Gleason score, family history or age at diagnosis by digit ratio. CONCLUSION: 2D:4D ratio shows strong differences between African-Americans and Caucasians; however, it does not correlate with disease severity in men already diagnosed with prostate cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23146972", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 1093, "text": "RESULTS: We found a direct association between left 2D:4D and breast cancer risk, an inverse association between \u0394(r-l) and risk of breast cancer, but no association between right 2D:4D and breast cancer risk. Among breast cancer cases, both right 2D:4D and \u0394(r-l) were inversely associated with age at diagnosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 1261, "offsetInEndSection": 1372, "text": "CONCLUSION: Digit ratio measures might be associated with breast cancer risk and age at onset of breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 280, "text": "Recent studies have reported a strong association between 2D:4D and risk of prostate cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21730975", "endSection": "abstract"}, {"offsetInBeginSection": 561, "offsetInEndSection": 707, "text": "RESULTS: No association was observed between 2D:4D and prostate cancer risk overall (HRs 1.00; 95% CIs, 0.92-1.08 for right, 0.93-1.08 for left). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21730975", "endSection": "abstract"}, {"offsetInBeginSection": 855, "offsetInEndSection": 1066, "text": "CONCLUSION: Our results are not consistent with an association between 2D:4D and overall prostate cancer risk, but we cannot exclude a weak inverse association between 2D:4D and early onset prostate cancer risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21730975", "endSection": "abstract"}, {"offsetInBeginSection": 993, "offsetInEndSection": 1295, "text": "Males in the OSCC group presented significantly higher digit ratio (P = 0.03) in comparison with males with OPLs and individuals without oral lesions. CONCLUSIONS: According to the results, males with the higher digit ratio seem to be more prone to undergo malignization of lesions in the oral cavity. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21445935", "endSection": "abstract"}, {"offsetInBeginSection": 265, "offsetInEndSection": 774, "text": "Compared with index finger shorter than ring finger (low 2D\u2009:\u20094D), men with index finger longer than ring finger (high 2D\u2009:\u20094D) showed a negative association, suggesting a protective effect with a 33% risk reduction (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.57-0.80). Risk reduction was even greater (87%) in age group <60 (OR 0.13, 95% CI 0.09-0.21). CONCLUSION: Pattern of finger lengths may be a simple marker of prostate cancer risk, with length of 2D greater than 4D suggestive of lower risk.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21119657", "endSection": "abstract"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1284, "text": "In the case-control analysis (n = 263), after controlling for ethnicity, women who developed CIN were significantly more likely to have a higher 2D:4D compared with HPV-negative women. A similar, nonsignificant trend was observed among women with a persistent HPV infection. CONCLUSION: Lower fetal androgen exposure may predispose to persistent HPV and increased risk of CIN.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18203126", "endSection": "abstract"}, {"offsetInBeginSection": 325, "offsetInEndSection": 448, "text": "Low numbers of CAG repeats and low 2D:4D are both associated with high sperm numbers and protection against breast cancer. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208164", "endSection": "abstract"}, {"offsetInBeginSection": 1221, "offsetInEndSection": 1320, "text": "Digit ratio measures might be associated with breast cancer risk and age at onset of breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 1331, "offsetInEndSection": 1478, "text": "A lower digit ratio is related to an increased detection rate of prostate cancer, a high percentage of core cancer volume and a high Gleason score.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23131519", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Digit ratio (2D:4D) is associated with gastric cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "title"}, {"offsetInBeginSection": 241, "offsetInEndSection": 311, "text": " Digit ratio could act as a possible marker for cancer predisposition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Right hand digit ratio (2D:4D) is associated with oral cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21445935", "endSection": "title"}, {"offsetInBeginSection": 1260, "offsetInEndSection": 1371, "text": "CONCLUSION: Digit ratio measures might be associated with breast cancer risk and age at onset of breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Second to fourth digit ratio: a predictor of prostate-specific antigen level and the presence of prostate cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20633006", "endSection": "title"}, {"offsetInBeginSection": 1271, "offsetInEndSection": 1375, "text": "CONCLUSIONS: Patients with a lower digit ratio have higher risks of prostate biopsy and prostate cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20633006", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Digit ratio (2D:4D) is associated with gastric cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "title"}, {"offsetInBeginSection": 697, "offsetInEndSection": 890, "text": "Second and fourth digit ratio has also found to be correlated with sexual orientation, left hand preference autism and some adult onset diseases such as breast cancer and myocardial infarction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12441204", "endSection": "abstract"}, {"offsetInBeginSection": 325, "offsetInEndSection": 447, "text": "Low numbers of CAG repeats and low 2D:4D are both associated with high sperm numbers and protection against breast cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208164", "endSection": "abstract"}, {"offsetInBeginSection": 592, "offsetInEndSection": 876, "text": "Findings from AR studies predict that low 2D:4D will be associated with prostate and hepatocellular cancer, urolithiasis, ADHD, ankylosing spondylitis, spontaneous abortion, and polycystic ovaries, while high 2D:4D will be associated with motor neuron diseases and endometrial cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12208164", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 960, "text": "We found a direct association between left 2D:4D and breast cancer risk, an inverse association between \u0394(r-l) and risk of breast cancer, but no association between right 2D:4D and breast cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 960, "text": "We found a direct association between left 2D:4D and breast cancer risk, an inverse association between \u0394(r-l) and risk of breast cancer, but no association between right 2D:4D and breast cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 1234, "offsetInEndSection": 1332, "text": "Digit ratio measures might be associated with breast cancer risk and age at onset of breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 960, "text": "We found a direct association between left 2D:4D and breast cancer risk, an inverse association between \u0394(r-l) and risk of breast cancer, but no association between right 2D:4D and breast cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 54, "text": "Digit ratio (2D:4D) is associated with gastric cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "title"}, {"offsetInBeginSection": 1390, "offsetInEndSection": 1483, "text": "The 2D:4D pattern found for gastric cancer parallels that earlier described for breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23218867", "endSection": "abstract"}, {"offsetInBeginSection": 1234, "offsetInEndSection": 1332, "text": "Digit ratio measures might be associated with breast cancer risk and age at onset of breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 960, "text": "We found a direct association between left 2D:4D and breast cancer risk, an inverse association between \u0394(r-l) and risk of breast cancer, but no association between right 2D:4D and breast cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 1234, "offsetInEndSection": 1332, "text": "Digit ratio measures might be associated with breast cancer risk and age at onset of breast cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}, {"offsetInBeginSection": 761, "offsetInEndSection": 960, "text": "We found a direct association between left 2D:4D and breast cancer risk, an inverse association between \u0394(r-l) and risk of breast cancer, but no association between right 2D:4D and breast cancer risk", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22990654", "endSection": "abstract"}]}, {"body": "What is the suggested therapy for Mycobacterium avium infection?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16584300", "http://www.ncbi.nlm.nih.gov/pubmed/9875582", "http://www.ncbi.nlm.nih.gov/pubmed/1387133", "http://www.ncbi.nlm.nih.gov/pubmed/1832527", "http://www.ncbi.nlm.nih.gov/pubmed/10714126", "http://www.ncbi.nlm.nih.gov/pubmed/11073759", "http://www.ncbi.nlm.nih.gov/pubmed/19929882", "http://www.ncbi.nlm.nih.gov/pubmed/8733409"], "triples": [], "ideal_answer": ["The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection. TLC G-65 in combination with rifapentine appears to be an attractive regimen for the treatment of infections caused by bacteria in the M. avium complex. Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks. In vivo phage treatment may also be used in some cases.", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection"], "exact_answer": [["Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks"]], "concepts": [], "type": "factoid", "id": "5710ade4cf1c32585100002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "The activity of TLC G-65 (a liposomal gentamicin preparation), alone and in combination with rifapentine, clarithromycin, clofazimine and ethambutol, was evaluated in the beige mouse (C57BL/6J--bgj/bgj) model of disseminated Mycobacterium avium infection", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1387133", "endSection": "abstract"}, {"offsetInBeginSection": 728, "offsetInEndSection": 880, "text": "TLC G-65 in combination with rifapentine appears to be an attractive regimen for the treatment of infections caused by bacteria in the M. avium complex.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1387133", "endSection": "abstract"}, {"offsetInBeginSection": 379, "offsetInEndSection": 621, "text": "Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9875582", "endSection": "abstract"}, {"offsetInBeginSection": 266, "offsetInEndSection": 493, "text": "TM4 is a lytic mycobacteriophage that kills both extracellular M. avium and M. tuberculosis. When delivered by M. smegmatis transiently infected with TM4, it kills both M. avium and M. tuberculosis within RAW 264.7 macrophages.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16584300", "endSection": "abstract"}, {"offsetInBeginSection": 753, "offsetInEndSection": 898, "text": "The patient was commenced on a 3-drug regimen with rifabutin, ethambutol and clarithromycin and has remained asymptomatic now for over 9 months. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714126", "endSection": "abstract"}, {"offsetInBeginSection": 753, "offsetInEndSection": 898, "text": "The patient was commenced on a 3-drug regimen with rifabutin, ethambutol and clarithromycin and has remained asymptomatic now for over 9 months. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714126", "endSection": "abstract"}, {"offsetInBeginSection": 753, "offsetInEndSection": 898, "text": "The patient was commenced on a 3-drug regimen with rifabutin, ethambutol and clarithromycin and has remained asymptomatic now for over 9 months. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 184, "text": "A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11073759", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1832527", "endSection": "title"}, {"offsetInBeginSection": 753, "offsetInEndSection": 898, "text": "The patient was commenced on a 3-drug regimen with rifabutin, ethambutol and clarithromycin and has remained asymptomatic now for over 9 months. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10714126", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Evolution was favorable with multiple-drug therapy including rifampicin, ethambutol, and clarithromycin, along with a slight reduction in immunosuppression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19929882", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The turning point in antimicrobial therapy of Mycobacterium avium infections came with the development of two new macrolides, clarithromycin and azithromycin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Clarithromycin against Mycobacterium avium complex infections.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The turning point in antimicrobial therapy of Mycobacterium avium infections came with the development of two new macrolides, clarithromycin and azithromycin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Clarithromycin against Mycobacterium avium complex infections.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The turning point in antimicrobial therapy of Mycobacterium avium infections came with the development of two new macrolides, clarithromycin and azithromycin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Clarithromycin against Mycobacterium avium complex infections.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "The turning point in antimicrobial therapy of Mycobacterium avium infections came with the development of two new macrolides, clarithromycin and azithromycin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8733409", "endSection": "abstract"}]}, {"body": "What is 2d 4d ratio in athletes.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25520769", "http://www.ncbi.nlm.nih.gov/pubmed/24949031", "http://www.ncbi.nlm.nih.gov/pubmed/23444944", "http://www.ncbi.nlm.nih.gov/pubmed/22185395", "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "http://www.ncbi.nlm.nih.gov/pubmed/20733526", "http://www.ncbi.nlm.nih.gov/pubmed/21993037", "http://www.ncbi.nlm.nih.gov/pubmed/20981610", "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "http://www.ncbi.nlm.nih.gov/pubmed/19843265", "http://www.ncbi.nlm.nih.gov/pubmed/16254897"], "triples": [], "ideal_answer": ["Lower 2D:4D ratio was reported to be lower in handball players,  kabaddi players, varsity athletes, football players, soccer players and rugby players. Low 2D:4D ratio correlates with better performance and with enhanced sporting prowess, particularly with regard to activities requiring endurance and dependent upon slow-twitch muscles."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056352"], "type": "summary", "id": "56bf4035ef6e394741000010", "snippets": [{"offsetInBeginSection": 756, "offsetInEndSection": 1015, "text": "RESULTS: A highly significant difference was found in 2D:4D ratios of both the hands with Kabaddi players having a lower ratio compared to their controls. There was no statistically significant difference in 2D:4D (\u0394 r-l) between Kabaddi players and controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25520769", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "BACKGROUND: Ratio of second and fourth digit (2D:4D) is known to be germane in analyzing utero concentrations of testosterone and estrogen in human and other vertebrates. 2D:4D had been linked to several traits like athletes' abilities, reproductive success, risk of cancer and cardiovascular disease (CVD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949031", "endSection": "abstract"}, {"offsetInBeginSection": 796, "offsetInEndSection": 857, "text": "There was also a lower digit ratio in both females and males.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23444944", "endSection": "abstract"}, {"offsetInBeginSection": 261, "offsetInEndSection": 489, "text": "Research from other fields is presented to suggest that healthy individuals with low 2D:4D ratio have enhanced sporting prowess, particularly with regard to activities requiring endurance and dependent upon slow-twitch muscles. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22185395", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 283, "offsetInEndSection": 405, "text": "The 2D:4D ratio has been negatively correlated with many factors, including aggression, physical fitness, and athleticism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 592, "offsetInEndSection": 1100, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes. Overall, males had significantly lower 2D:4D ratios than females (0.98 \u00b1 0.003 vs. 0.99 \u00b1 0.004). A smaller 2D:4D ratio appears to be consistent with participation in varsity sports among both males and females.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 462, "text": "Research suggests that prenatal levels of testosterone are related to finger length development and traits beneficial to athletic skill, such as power, endurance, visual-spatial skills, or sensation seeking and dominance behavior. In men, the second digit to fourth digit ratio (2D:4D) has been shown to correlate with success in competitive levels of football (soccer), which suggests that the 2D:4D ratio is a possible marker for level of attainment in sport. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20733526", "endSection": "abstract"}, {"offsetInBeginSection": 1023, "offsetInEndSection": 1456, "text": "Significant differences were found among the different groups (p = 0.000), with significantly lower ratios between football and crew (p = 0.000), football and nonathletes (p = 0.030), and gymnastics and crew (p = 0.001). This research provides a stronger level of evidence that the 2D:4D ratio may help indicate potential athleticism or competition-level achievement, but the external validity may be limited to only specific sports.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20733526", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 271, "text": "Low 2D:4D has been linked to various measures of performance in a range of sports (e.g., soccer, rugby). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21993037", "endSection": "abstract"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1295, "text": "We found that right 2D:4D (but not left 2D:4D or right-left 2D:4D) was significantly negatively correlated with coaches' ratings (r(s) = 0.58) and the competition result (r(s) = 0.30). It appears that in line with other sports that low right 2D:4D (high prenatal testosterone and low prenatal estrogen) correlates to high surfing ability in men.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21993037", "endSection": "abstract"}, {"offsetInBeginSection": 639, "offsetInEndSection": 1085, "text": "Compared with controls, players were larger and had lower 2D:4D for the right and left hand. With regard to number of caps, players with low 2D:4D in their right hand and low right 2D:4D compared with their left (right\u00a0-\u00a0left 2D:4D difference) had high numbers of caps. First-choice players did not differ significantly from second-choice players in their 2D:4D but they did have a lower right\u00a0-\u00a0left 2D:4D difference than second-choice players. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981610", "endSection": "abstract"}, {"offsetInBeginSection": 1194, "offsetInEndSection": 1306, "text": "We conclude that low right 2D:4D and low right\u00a0-\u00a0left 2D:4D difference are predictors of high rugby performance.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20981610", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Second-to-fourth digit ratio (2D:4D), a widely studied putative marker for masculinization through prenatal androgen exposure, is lower (more masculinized) in athletes than in general population controls, and athletes with lower 2D:4D have higher sporting success.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Digit ratio (2D:4D) predicts sporting success among female fencers independent from physical, experience, and personality factors.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843265", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 251, "text": "Research particularly focusing on male athletes and popular sports (running and soccer) suggests associations of lower (masculinized) second-to-fourth digit ratio (2D:4D), a putative marker of prenatal androgen action, with better sports performance. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843265", "endSection": "abstract"}, {"offsetInBeginSection": 710, "offsetInEndSection": 807, "text": "Among female, but not male, fencers, lower 2D:4D was related to better national fencing rankings.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843265", "endSection": "abstract"}, {"offsetInBeginSection": 1136, "offsetInEndSection": 1269, "text": "Athletes active in the most aggressive form (the sabre) had lower 2D:4D than those active in the other forms (\u00e9p\u00e9e and foil fencing).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843265", "endSection": "abstract"}, {"offsetInBeginSection": 1031, "offsetInEndSection": 1273, "text": "Our results showed that elite female athletes have significantly lower left hand 2D:4D ratios compared to the control group (P<0.05). Therefore, we can speculate that low 2D:4D ratio may be a positive correlate of sports potential in females.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16254897", "endSection": "abstract"}, {"offsetInBeginSection": 884, "offsetInEndSection": 1180, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 592, "offsetInEndSection": 888, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "Second-to-fourth digit ratio (2D:4D), a widely studied putative marker for masculinization through prenatal androgen exposure, is lower (more masculinized) in athletes than in general population controls, and athletes with lower 2D:4D have higher sporting success.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "endSection": "abstract"}, {"offsetInBeginSection": 407, "offsetInEndSection": 889, "text": "We compared 2D:4D finger ratios of (1) male and female varsity athletes (n = 99) versus male and female student non-athletes (n = 122), and (2) males (n = 104) versus females (n = 117). Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 972, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes. Overall, males had significantly lower 2D:4D ratios than females (0.98 \u00b1 0.003 vs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 885, "offsetInEndSection": 1170, "text": "We measured the 2D:4D ratios in elite and non-elite female athletes and compared them with female individuals not engaged in any sport activities. Our results showed that elite female athletes have significantly lower left hand 2D:4D ratios compared to the control group (P &lt; 0.05).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16254897", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 593, "offsetInEndSection": 889, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Second-to-fourth digit ratio (2D:4D), a widely studied putative marker for masculinization through prenatal androgen exposure, is lower (more masculinized) in athletes than in general population controls, and athletes with lower 2D:4D have higher sporting success.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 889, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Second-to-fourth digit ratio (2D:4D), a widely studied putative marker for masculinization through prenatal androgen exposure, is lower (more masculinized) in athletes than in general population controls, and athletes with lower 2D:4D have higher sporting success.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 889, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Second-to-fourth digit ratio (2D:4D), a widely studied putative marker for masculinization through prenatal androgen exposure, is lower (more masculinized) in athletes than in general population controls, and athletes with lower 2D:4D have higher sporting success.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "endSection": "abstract"}, {"offsetInBeginSection": 593, "offsetInEndSection": 889, "text": "Our results confirmed that both male (mean \u00b1 s(x) : 0.97 \u00b1 0.004) and female (0.98 \u00b1 0.005) varsity athletes had significantly lower ratios than their non-varsity peers (males: 0.99 \u00b1 0.004; females: 1.00 \u00b1 0.006), and that male athletes had significantly lower 2D:4D ratios than female athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Second-to-fourth digit ratio (2D:4D), a widely studied putative marker for masculinization through prenatal androgen exposure, is lower (more masculinized) in athletes than in general population controls, and athletes with lower 2D:4D have higher sporting success.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954495", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Varsity athletes have lower 2D:4D ratios than other university students.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22132823", "endSection": "title"}]}, {"body": "What is the use of emulsion PCR in Next Generation Sequencing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23900195", "http://www.ncbi.nlm.nih.gov/pubmed/23744319", "http://www.ncbi.nlm.nih.gov/pubmed/23665194", "http://www.ncbi.nlm.nih.gov/pubmed/23546785", "http://www.ncbi.nlm.nih.gov/pubmed/23398507", "http://www.ncbi.nlm.nih.gov/pubmed/23148498", "http://www.ncbi.nlm.nih.gov/pubmed/22668416", "http://www.ncbi.nlm.nih.gov/pubmed/22355625", "http://www.ncbi.nlm.nih.gov/pubmed/21543404", "http://www.ncbi.nlm.nih.gov/pubmed/21513157"], "triples": [], "ideal_answer": "Prior to Next Generation Sequencing reactions, DNA libraries are constructed, amplified with emulsion PCR, and enriched with the use of enrichment beads. The library samples are then loaded to a sequencing chip and analyzed on an NGS platform.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004655", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016133", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017422", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017421"], "type": "summary", "id": "5319a83bb166e2b80600002c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Emulsion PCR-coupled target enrichment: an effective fishing method for high-throughput sequencing of poorly preserved ancient DNA", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23900195", "endSection": "title"}, {"offsetInBeginSection": 325, "offsetInEndSection": 680, "text": "We present a unified strategy in which emulsion PCR is coupled with target enrichment followed by next-generation sequencing. The method made it possible to obtain efficiently non-duplicated reads mapped to target sequences of interest, and this can achieve deep and reliable sequencing of ancient DNA from typical materials, even though poorly preserved.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23900195", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 900, "text": "Three multiplex PCR reactions were carried out to amplify the coding exons of 328 genes including FBN1, TGFBR1 and TGFBR2. DNA fragments from different samples were ligated with barcoded sequencing adaptors. Template preparation and emulsion PCR, and Ion Sphere Particles enrichment were carried out using an Ion One Touch system. The ion sphere particles were sequenced on a 318 chip using the PGM platform.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23744319", "endSection": "abstract"}, {"offsetInBeginSection": 802, "offsetInEndSection": 1156, "text": "In our NGS approach, the 16,569-bp mtDNA is enriched by long-range PCR and the 108 nuclear genes (which represent 1301 amplicons and 680 kb) are enriched by RainDance emulsion PCR. Sequencing is performed on Illumina HiSeq 2000 or MiSeq platforms, and bioinformatics analysis is performed using commercial and in-house developed bioinformatics pipelines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23665194", "endSection": "abstract"}, {"offsetInBeginSection": 461, "offsetInEndSection": 684, "text": "However, pyrosequencing of emulsion PCR reactions, amplifying from only one molecule at a time, can generate megabases of clonally amplified loci at high coverage, thereby greatly simplifying allelic sequence determination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23546785", "endSection": "abstract"}, {"offsetInBeginSection": 861, "offsetInEndSection": 1319, "text": "During genomic PCR, in this 4-primer system, the outer set of primers containing the MID and the 454 adaptor sequences are incorporated into an amplicon generated by the inner HLA target-specific primers each containing a common sequence tag at the 5' end of the forward and reverse primers. Pools of the resulting amplicons are used for emulsion PCR and clonal sequencing on the 454 Life Sciences GS FLX System, followed by genotyping with Conexio software.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23398507", "endSection": "abstract"}, {"offsetInBeginSection": 428, "offsetInEndSection": 724, "text": "The purpose of our study was to compare NGS enrichment methods for a clinical assay targeting the nine genes known to be associated with aortopathy. RainDance emulsion PCR and SureSelect RNA-bait hybridization capture enrichment methods were directly compared by enriching DNA from eight samples.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23148498", "endSection": "abstract"}, {"offsetInBeginSection": 872, "offsetInEndSection": 1073, "text": "We show the efficacy by comparing the method to a commercial kit and further demonstrate that emulsion PCR can be used for bias free amplification and virtual immortalization of DNA template libraries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22668416", "endSection": "abstract"}, {"offsetInBeginSection": 281, "offsetInEndSection": 403, "text": "Here, we describe a novel approach for normalization of multiplex next generation sequencing libraries after emulsion PCR.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22355625", "endSection": "abstract"}, {"offsetInBeginSection": 404, "offsetInEndSection": 607, "text": "Briefly, amplified libraries carrying unique barcodes are prepared by fluorescent tagging of complementary sequences and then resolved by high-speed flow cytometric sorting of labeled emulsion PCR beads.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22355625", "endSection": "abstract"}, {"offsetInBeginSection": 608, "offsetInEndSection": 959, "text": "The protocol is simple and provides an even sequence distribution of multiplex libraries when sequencing the flow-sorted beads. Moreover, since many empty and mixed emulsion PCR beads are removed, the approach gives rise to a substantial increase in sequence quality and mean read length, as compared to that obtained by standard enrichment protocols.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22355625", "endSection": "abstract"}, {"offsetInBeginSection": 156, "offsetInEndSection": 307, "text": "Based on the mechanism of emulsion PCR, a unique DNA template would only generate a unique sequence read after being amplified and sequenced on GS FLX.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21543404", "endSection": "abstract"}, {"offsetInBeginSection": 763, "offsetInEndSection": 1015, "text": "Prior to SOLiD sequencing reaction, the libraries were amplified with emulsion PCR and enriched with the P2 enrichment beads. The library samples were loaded to sequencing Chip for Work Flow Analysis (WFA) or sequencing running with default parameters.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21513157", "endSection": "abstract"}]}, {"body": "Is the H3K4me3 histone mark related to transcriptional initiation or elongation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23355544", "http://www.ncbi.nlm.nih.gov/pubmed/23284292", "http://www.ncbi.nlm.nih.gov/pubmed/22904080", "http://www.ncbi.nlm.nih.gov/pubmed/22855832", "http://www.ncbi.nlm.nih.gov/pubmed/22768981", "http://www.ncbi.nlm.nih.gov/pubmed/22132139", "http://www.ncbi.nlm.nih.gov/pubmed/21435340", "http://www.ncbi.nlm.nih.gov/pubmed/18682226"], "ideal_answer": ["H3K4me3 is associated with transcriptionally active genes, but its function in the transcription process is still unclear. It is well known to occur in the promoter region of genes for transcription activation but its levels correlate positively with the antisense expression levels of the associated sense genes implying that it may be also involved in the activation of antisense transcription. Although it is mostly associated with transcription initiation H3K4me3 levels determine the efficiency of transcription elongation."], "exact_answer": ["transcriptional initiation"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015533", "http://www.biosemantics.org/jochem#4250488", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D048348", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035165", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035581", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051697", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035582", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035181", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050436", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061805", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051758", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020871", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042925"], "type": "factoid", "id": "512d2fff5274a5fb07000006", "snippets": [{"offsetInBeginSection": 659, "offsetInEndSection": 782, "text": "The histone marks appeared mainly in generic regions and were enriched around the transcription start sites (TSSs) of genes", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23355544", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Trimethylation of histone H3 Lys 4 (H3K4me3) is a mark of active and poised promoters.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22855832", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Histone H3 lysine 4 trimethylation (H3K4me3) is well known to occur in the promoter region of genes for transcription activation", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768981", "endSection": "sections.0"}, {"offsetInBeginSection": 348, "offsetInEndSection": 422, "text": "3'-H3K4me3 is associated with ~15% of protein-coding genes in both tissues", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768981", "endSection": "sections.0"}, {"offsetInBeginSection": 697, "offsetInEndSection": 912, "text": "Furthermore, 3'-H3K4me3 modification levels correlate positively with the antisense expression levels of the associated sense genes, implying that 3'-H3K4me3 is involved in the activation of antisense transcription.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768981", "endSection": "sections.0"}, {"offsetInBeginSection": 654, "offsetInEndSection": 853, "text": "Among these are forms of histone 3 that are mono- or tri-methylated at lysine 4 (H3K4me1 or H3K4me3, respectively), which bind preferentially to promoter and enhancer elements in the mammalian genome", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435340", "endSection": "sections.0"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1156, "text": "we find that H3K4me1 and H3K4me3 are enriched at transcriptional start sites in the genome", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435340", "endSection": "sections.0"}, {"offsetInBeginSection": 1676, "offsetInEndSection": 1734, "text": "H3K4me1 and H3K4me3 generally mark cis regulatory elements", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21435340", "endSection": "sections.0"}]}, {"body": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17241641", "http://www.ncbi.nlm.nih.gov/pubmed/18415121", "http://www.ncbi.nlm.nih.gov/pubmed/18971376", "http://www.ncbi.nlm.nih.gov/pubmed/19920172", "http://www.ncbi.nlm.nih.gov/pubmed/24550830"], "triples": [], "ideal_answer": ["The HS-1 associated protein X-1 (HAX-1) is a mitochondrial protein with anti-apoptotic function and presents with numerous similarities to Bcl-2. and was identified as a phospholamban-binding partner. Using the yeast-two-hybrid system, HS-1 associated protein X-1 (HAX-1) was identified as a PLN-binding partner.", "The sarco(endo)plasmic reticulum (SR) Ca(2+) transport ATPase (SERCA2a) and its inhibitor phospholamban (PLN) control the uptake of Ca(2+) by SR membranes during relaxation. Recently, the antiapoptotic HS-1-associated protein X-1 (HAX-1) was identified as a binding partner of PLN, and this interaction was postulated to regulate cell apoptosis.Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.The discovery of the PLN/HAX-1 interaction therefore unveils an important new link between Ca(2+) homeostasis and cell survival, with significant therapeutic potential.", "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.The discovery of the PLN/HAX-1 interaction therefore unveils an important new link between Ca(2+) homeostasis and cell survival, with significant therapeutic potential."], "exact_answer": [["The HS-1 associated protein X-1", "(HAX-1)"]], "concepts": ["http://www.uniprot.org/uniprot/PPLA_BOVIN", "http://www.uniprot.org/uniprot/PPLA_CHICK", "http://www.uniprot.org/uniprot/PPLA_MOUSE", "http://www.uniprot.org/uniprot/PPLA_RAT", "http://www.uniprot.org/uniprot/PPLA_CANFA", "http://www.uniprot.org/uniprot/PPLA_PIG", "http://www.uniprot.org/uniprot/PPLA_RABIT", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051017"], "type": "factoid", "id": "54f9cb34dd3fc62544000002", "snippets": [{"offsetInBeginSection": 260, "offsetInEndSection": 479, "text": "To identify additional proteins that may interact with PLN, we used the yeast-two-hybrid system to screen an adult human cardiac cDNA library. HS-1 associated protein X-1 (HAX-1) was identified as a PLN-binding partner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "abstract"}, {"offsetInBeginSection": 1348, "offsetInEndSection": 1669, "text": "Analysis of the anti-apoptotic function of HAX-1 revealed that the presence of PLN enhanced the HAX-1 protective effects from hypoxia/reoxygenation-induced cell death. These findings suggest a possible link between the Ca(2+) handling by the sarcoplasmic reticulum and cell survival mediated by the PLN/HAX-1 interaction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "abstract"}, {"offsetInBeginSection": 286, "offsetInEndSection": 800, "text": "The sarco(endo)plasmic reticulum Ca(2+) transport adenosine triphosphatase (SERCA2a) and its regulator phospholamban (PLN) have a central role in modulating Ca(2+) homeostasis and, therefore, cardiac function. Herein, we discuss the mechanisms through which SERCA2a and PLN control cardiomyocyte function in health and disease. Emphasis is placed on our newly identified PLN-binding partner HS-1-associated protein X-1 (HAX-1), which has an anti-apoptotic function and presents with numerous similarities to Bcl-2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18415121", "endSection": "abstract"}, {"offsetInBeginSection": 955, "offsetInEndSection": 1123, "text": "The discovery of the PLN/HAX-1 interaction therefore unveils an important new link between Ca(2+) homeostasis and cell survival, with significant therapeutic potential.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18415121", "endSection": "abstract"}, {"offsetInBeginSection": 97, "offsetInEndSection": 442, "text": "The sarco(endo)plasmic reticulum (SR) Ca(2+) transport ATPase (SERCA2a) and its inhibitor phospholamban (PLN) control the uptake of Ca(2+) by SR membranes during relaxation. Recently, the antiapoptotic HS-1-associated protein X-1 (HAX-1) was identified as a binding partner of PLN, and this interaction was postulated to regulate cell apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971376", "endSection": "abstract"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1038, "text": "On triple transfections with PLN, however, HAX-1 massively translocated to the ER membranes, where it codistributed with PLN and SERCA2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971376", "endSection": "abstract"}, {"offsetInBeginSection": 1343, "offsetInEndSection": 1473, "text": "These findings suggest that HAX-1 may promote cell survival through modulation of SERCA2 protein levels and thus ER Ca(2+) stores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18971376", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 407, "text": "The HS-1 associated protein X-1 (HAX-1) is a ubiquitously expressed protein that protects cardiomyocytes from programmed cell death. Here we identify HAX-1 as a regulator of contractility and calcium cycling in the heart. HAX-1 overexpression reduced sarcoplasmic reticulum Ca-ATPase (SERCA2) pump activity in isolated cardiomyocytes and in vivo, leading to depressed myocyte calcium kinetics and mechanics.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920172", "endSection": "abstract"}, {"offsetInBeginSection": 488, "offsetInEndSection": 723, "text": "The inhibitory effects of HAX-1 were abolished upon phosphorylation of phospholamban, which plays a fundamental role in controlling basal contractility and constitutes a key downstream effector of the beta-adrenergic signaling cascade.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920172", "endSection": "abstract"}, {"offsetInBeginSection": 748, "offsetInEndSection": 978, "text": " Furthermore, the effects of PLN and its phosphorylation on cardiac function are subject to additional regulation by its interacting partners, the anti-apoptotic HAX-1 protein and Gm or the anchoring unit of protein phosphatase 1.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24550830", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 609, "offsetInEndSection": 796, "text": " Emphasis is placed on our newly identified PLN-binding partner HS-1-associated protein X-1 (HAX-1), which has an anti-apoptotic function and presents with numerous similarities to Bcl-2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18415121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 260, "offsetInEndSection": 479, "text": "To identify additional proteins that may interact with PLN, we used the yeast-two-hybrid system to screen an adult human cardiac cDNA library. HS-1 associated protein X-1 (HAX-1) was identified as a PLN-binding partner.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 754, "offsetInEndSection": 982, "text": "Furthermore, the effects of PLN and its phosphorylation on cardiac function are subject to additional regulation by its interacting partners, the anti-apoptotic HAX-1 protein and Gm or the anchoring unit of protein phosphatase 1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24550830", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641", "endSection": "title"}, {"offsetInBeginSection": 754, "offsetInEndSection": 982, "text": "Furthermore, the effects of PLN and its phosphorylation on cardiac function are subject to additional regulation by its interacting partners, the anti-apoptotic HAX-1 protein and Gm or the anchoring unit of protein phosphatase 1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24550830", "endSection": "abstract"}]}, {"body": "Which is the most prevalent form of arrhythmia worldwide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25534665", "http://www.ncbi.nlm.nih.gov/pubmed/24828991", "http://www.ncbi.nlm.nih.gov/pubmed/23259476", "http://www.ncbi.nlm.nih.gov/pubmed/25432121", "http://www.ncbi.nlm.nih.gov/pubmed/24474959", "http://www.ncbi.nlm.nih.gov/pubmed/23541013", "http://www.ncbi.nlm.nih.gov/pubmed/25546992", "http://www.ncbi.nlm.nih.gov/pubmed/15922277", "http://www.ncbi.nlm.nih.gov/pubmed/21394037", "http://www.ncbi.nlm.nih.gov/pubmed/23795692"], "triples": [], "ideal_answer": ["Atrial fibrillation (AF) is the most common arrhythmia worldwide, and it has a significant effect on morbidity and mortality. It is a significant risk factor for stroke and peripheral embolization, and it has an effect on cardiac function. Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting up to 1-1.5% of the population."], "exact_answer": [["atrial fibrilation", "AF"]], "concepts": [], "type": "factoid", "id": "54d8ea2c4b1fd0d33c000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24828991", "endSection": "abstract"}, {"offsetInBeginSection": 29, "offsetInEndSection": 93, "text": "Atrial fibrillation is the most prevalent sustained arrhythmia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534665", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and has a significant impact on morbidity and mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23259476", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Atrial fibrillation is the most common heart rhythm disorder in the world, with major public health impact especially due to increased risk of stroke and hospitalizations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25432121", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Atrial fibrillation is the most common arrhythmia affecting patients today.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24474959", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 239, "text": "Atrial fibrillation (AF) is the most common arrhythmia worldwide, and it has a significant effect on morbidity and mortality. It is a significant risk factor for stroke and peripheral embolization, and it has an effect on cardiac function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541013", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting up to 1-1.5% of the population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25546992", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "Atrial fibrillation is the most prevalent form of cardiac arrhythmia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888755", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 257, "text": "Atrial fibrillation, the most prevalent arrhythmia, affects more than two million Americans annually and is associated with a twofold increase in mortality.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15922277", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Atrial fibrillation (AF) is associated with increased morbidity and is in addition the most prevalent cardiac arrhythmia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21394037", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24828991", "endSection": "abstract"}, {"offsetInBeginSection": 29, "offsetInEndSection": 93, "text": "Atrial fibrillation is the most prevalent sustained arrhythmia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534665", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in clinical practice associated with significant morbidity and mortality", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23795692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Atrial fibrillation is the most prevalent form of cardiac arrhythmia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19888755", "endSection": "abstract"}]}, {"body": "RTS S AS01 vaccine was developed to prevent which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25077418", "http://www.ncbi.nlm.nih.gov/pubmed/24468190", "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "http://www.ncbi.nlm.nih.gov/pubmed/19806009", "http://www.ncbi.nlm.nih.gov/pubmed/22739688", "http://www.ncbi.nlm.nih.gov/pubmed/21073995", "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "http://www.ncbi.nlm.nih.gov/pubmed/24292709", "http://www.ncbi.nlm.nih.gov/pubmed/23454164", "http://www.ncbi.nlm.nih.gov/pubmed/21782519", "http://www.ncbi.nlm.nih.gov/pubmed/20735271", "http://www.ncbi.nlm.nih.gov/pubmed/21604980", "http://www.ncbi.nlm.nih.gov/pubmed/25024381", "http://www.ncbi.nlm.nih.gov/pubmed/19859560", "http://www.ncbi.nlm.nih.gov/pubmed/25007730", "http://www.ncbi.nlm.nih.gov/pubmed/21816032", "http://www.ncbi.nlm.nih.gov/pubmed/21816030", "http://www.ncbi.nlm.nih.gov/pubmed/25072396", "http://www.ncbi.nlm.nih.gov/pubmed/23787092"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0049608", "o": "D004194"}], "ideal_answer": ["RTS,S/AS01 vaccine was developed for prevention of malaria."], "exact_answer": [["malaria"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014612"], "type": "factoid", "id": "56bc77a3ac7ad10019000015", "snippets": [{"offsetInBeginSection": 188, "offsetInEndSection": 401, "text": "This randomized, double-blind study (NCT01323972) assessed consistency of three RTS,S/AS01 malaria vaccine batches formulated from commercial-scale purified antigen bulk lots in terms of anti-CS-responses induced.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25077418", "endSection": "abstract"}, {"offsetInBeginSection": 84, "offsetInEndSection": 206, "text": "Until now, only one candidate malaria vaccine RTS,S/AS01 has shown modest protection in phase 3 trial in African infants. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24468190", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "endSection": "abstract"}, {"offsetInBeginSection": 3356, "offsetInEndSection": 3546, "text": "INTERPRETATION: RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "endSection": "abstract"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1376, "text": "WHO anticipates that the RTS,S/AS01 vaccine will be recommended for the 6-14 week age group for co-administration together with other vaccines as part of routine immunization programs in malaria endemic countries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22739688", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 474, "text": "Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292709", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 906, "text": "The RTS,S/AS01(E) malaria vaccine candidate has recently entered phase III testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073995", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454164", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1501, "text": "If the phase III results confirm the observations made during phase II testing, the RTS,S/AS01(E) vaccine, when broadly implemented and judiciously integrated with other malaria-prevention measures, would have a major public-health impact in sub-Saharan Africa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073995", "endSection": "abstract"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1376, "text": "WHO anticipates that the RTS,S/AS01 vaccine will be recommended for the 6-14 week age group for co-administration together with other vaccines as part of routine immunization programs in malaria endemic countries.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22739688", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 474, "text": "Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292709", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 906, "text": "The RTS,S/AS01(E) malaria vaccine candidate has recently entered phase III testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073995", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "The RTS,S/AS01(E) malaria vaccine candidate has recently entered Phase 3 testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19806009", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23454164", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 1240, "offsetInEndSection": 1501, "text": "If the phase III results confirm the observations made during phase II testing, the RTS,S/AS01(E) vaccine, when broadly implemented and judiciously integrated with other malaria-prevention measures, would have a major public-health impact in sub-Saharan Africa.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073995", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21782519", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735271", "endSection": "abstract"}, {"offsetInBeginSection": 161, "offsetInEndSection": 327, "text": "Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21604980", "endSection": "abstract"}, {"offsetInBeginSection": 135, "offsetInEndSection": 338, "text": "AS01 has been selected for the clinical development of several candidate vaccines including the RTS,S malaria vaccine and the subunit glycoprotein E varicella zoster vaccine (both currently in phase III)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25024381", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21782519", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859560", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007730", "endSection": "title"}, {"offsetInBeginSection": 3196, "offsetInEndSection": 3546, "text": "The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\ufffd2 per 1000 doses in young infants and 2\ufffd5 per 1000 doses in children.INTERPRETATION: RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816032", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859560", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007730", "endSection": "title"}, {"offsetInBeginSection": 3196, "offsetInEndSection": 3546, "text": "The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\ufffd2 per 1000 doses in young infants and 2\ufffd5 per 1000 doses in children.INTERPRETATION: RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816032", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859560", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007730", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816032", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816030", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859560", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007730", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816032", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 1579, "offsetInEndSection": 1932, "text": "Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively.CONCLUSIONS: RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25072396", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19859560", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007730", "endSection": "title"}, {"offsetInBeginSection": 3196, "offsetInEndSection": 3546, "text": "The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\ufffd2 per 1000 doses in young infants and 2\ufffd5 per 1000 doses in children.INTERPRETATION: RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25913272", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816032", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21816031", "endSection": "title"}, {"offsetInBeginSection": 125, "offsetInEndSection": 1517, "text": "This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23787092", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 329, "text": "the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21604980", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 329, "text": "the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21604980", "endSection": "abstract"}]}, {"body": "What is the rate of survival after commotio cordis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23107651", "http://www.ncbi.nlm.nih.gov/pubmed/21763255", "http://www.ncbi.nlm.nih.gov/pubmed/23015869", "http://www.ncbi.nlm.nih.gov/pubmed/11879111", "http://www.ncbi.nlm.nih.gov/pubmed/11555799", "http://www.ncbi.nlm.nih.gov/pubmed/20086611"], "triples": [], "ideal_answer": "Survival rates for commotio cordis are low, even when resuscitation is performed. Survival rates vary between 10% and 28%.", "exact_answer": ["10-28%"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056104", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013534"], "type": "factoid", "id": "530cf4e0c8a0b4a00c000007", "snippets": [{"offsetInBeginSection": 592, "offsetInEndSection": 779, "text": "At their commotio cordis event, 216 study patients were 0.2-51 years old (mean age 15\u00b19 years); 95% were males. Death occurred in 156 individuals (72%), while the other 60 (28%) survived.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23107651", "endSection": "abstract"}, {"offsetInBeginSection": 740, "offsetInEndSection": 864, "text": "In the 2 groups, events were largely similar demographically, including frequency of survival (26% in U.S. vs 25%; P = .84),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21763255", "endSection": "abstract"}, {"offsetInBeginSection": 1443, "offsetInEndSection": 1508, "text": "Survival of commotio cordis has risen from 10% to 15% since 2001.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23015869", "endSection": "abstract"}, {"offsetInBeginSection": 1388, "offsetInEndSection": 1622, "text": "Only 21 (16%) individuals survived their event, with particularly prompt cardiopulmonary resuscitation/defibrillation (most commonly reversing ventricular fibrillation) the only identifiable factor associated with a favorable outcome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11879111", "endSection": "abstract"}, {"offsetInBeginSection": 351, "offsetInEndSection": 435, "text": "Survival rates for commotio cordis are low, even with prompt CPR and defibrillation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11555799", "endSection": "abstract"}, {"offsetInBeginSection": 481, "offsetInEndSection": 536, "text": "Survival is low, even when resuscitation is performed. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20086611", "endSection": "abstract"}]}, {"body": "Which type of cell death is known as anoikis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23357260", "http://www.ncbi.nlm.nih.gov/pubmed/23830918", "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "http://www.ncbi.nlm.nih.gov/pubmed/21953325", "http://www.ncbi.nlm.nih.gov/pubmed/21352421", "http://www.ncbi.nlm.nih.gov/pubmed/21114588", "http://www.ncbi.nlm.nih.gov/pubmed/20577896", "http://www.ncbi.nlm.nih.gov/pubmed/20153362", "http://www.ncbi.nlm.nih.gov/pubmed/20031162", "http://www.ncbi.nlm.nih.gov/pubmed/19828453", "http://www.ncbi.nlm.nih.gov/pubmed/18719379", "http://www.ncbi.nlm.nih.gov/pubmed/18579285", "http://www.ncbi.nlm.nih.gov/pubmed/18045538", "http://www.ncbi.nlm.nih.gov/pubmed/15302871", "http://www.ncbi.nlm.nih.gov/pubmed/14702756", "http://www.ncbi.nlm.nih.gov/pubmed/14551156", "http://www.ncbi.nlm.nih.gov/pubmed/19062038", "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "http://www.ncbi.nlm.nih.gov/pubmed/25549223"], "triples": [], "ideal_answer": ["Anoikis (Greek for Homelessness) is a programmed cell death induced upon cell detachment from extracellular matrix, behaving as a critical mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus avoiding colonizing of distant organs. Anoikis is important in the normal physiologic development of the human body, as well as in disease states. Adhesion to structural glycoproteins of the extracellular matrix is necessary for survival of the differentiated adherent cells. Cancer cells harbor anoikis resistance allowing spread to occur.", "Ano?kis is defined as programmed cell death induced by the loss of cell/matrix interactions. Adhesion to structural glycoproteins of the extracellular matrix is necessary for survival of the differentiated adherent cells in the cardiovascular system, including endothelial cells, smooth muscle cells, fibroblasts, and cardiac myocytes.Developed organs display strict spatial organization of differentiated cells which is required for proper organ function. One important device that prevents tissue disorganization is the death of cells that lose anchorage to their native matrix, a signal that indicates potential loss of proper tissue context. Termed anoikis (Greek for Homelessness), this form of cell death is a specialized form of apoptosis.", "Ano?kis is defined as programmed cell death induced by the loss of cell/matrix interactions. Adhesion to structural glycoproteins of the extracellular matrix is necessary for survival of the differentiated adherent cells in the cardiovascular system, including endothelial cells, smooth muscle cells, fibroblasts, and cardiac myocytes.Developed organs display strict spatial organization of differentiated cells which is required for proper organ function. One important device that prevents tissue disorganization is the death of cells that lose anchorage to their native matrix, a signal that indicates potential loss of proper tissue context. Termed anoikis (Greek for Homelessness), this form of cell death is a specialized form of apoptosis."], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008219", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0043276", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016265", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:2000209", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010941"], "type": "summary", "id": "5525317687ecba3764000007", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "As a barrier to metastasis of cancer, cells that lost contact with the neighbouring cells or extracellular matrix(Extracellular matrix, ECM) will be subjected to apoptosis. This cell death process has been termed \"anoikis\".", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", "endSection": "abstract"}, {"offsetInBeginSection": 224, "offsetInEndSection": 417, "text": "When normal epithelial cells or solid tumor cells without metastatic potential detach from the primary site, and then enter into the circulatory system, the anoikis mechanism will be activated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", "endSection": "abstract"}, {"offsetInBeginSection": 418, "offsetInEndSection": 539, "text": "The significance of anoikis is to prevent the shedding cells from growing and implanting into other inappropriate sites. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Anoikis is a programmed cell death induced upon cell detachment from extracellular matrix, behaving as a critical mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus avoiding colonizing of distant organs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830918", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 357, "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": "Anoikis is a programmed cell death occurring upon cell detachment from the correct extracellular matrix, thus disrupting integrin ligation. It is a critical mechanism in preventing dysplastic cell growth or attachment to an inappropriate matrix. Anoikis prevents detached epithelial cells from colonizing elsewhere and is thus essential for tissue homeostasis and development. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21953325", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Detachment from the extracellular matrix induces a form of programmed cell death termed anoikis. Resistance to anoikis permits cancer cells to survive in systemic circulation and facilitates their metastasis to distant organs.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21352421", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Anoikis - apoptotic cell death triggered by loss of extracellular matrix (ECM) contacts - is dysregulated in many chronic debilitating and fatal diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21114588", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "The extracellular matrix (ECM) plays a key role in cell-cell communication and signaling, and the signals it propagates are important for tissue remodeling and survival. However, signals from disease-altered ECM may lead to anoikis-apoptotic cell death triggered by loss of ECM contacts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20577896", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Anoikis is a mode of apoptotic cell death, consequential to insufficient cell-matrix interactions and a critical player in tumor angiogenesis and metastasis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20153362", "endSection": "abstract"}, {"offsetInBeginSection": 953, "offsetInEndSection": 1258, "text": "Anoikis is also a physiologic process in normal cells used to maintain homeostasis, in which cell death is induced in response to loss of extracellular membrane (ECM) attachment. Cancer cells are notoriously resistant to anoikis, enabling metastasis and new tumor growth beyond their original environment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20031162", "endSection": "abstract"}, {"offsetInBeginSection": 141, "offsetInEndSection": 245, "text": "Anoikis is a subtype of apoptosis induced by detachment of adherent cells from the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828453", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 411, "text": "Developed organs display strict spatial organization of differentiated cells which is required for proper organ function. One important device that prevents tissue disorganization is the death of cells that lose anchorage to their native matrix, a signal that indicates potential loss of proper tissue context. Termed anoikis (Greek for Homelessness), this form of cell death is a specialized form of apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18719379", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 416, "text": "As a barrier to metastases, cells normally undergo apoptosis after they lose contact with their extra cellular matrix or their neighbouring cells. This cell death process has been termed \"anoikis\". Tumour cells that acquire malignant potential have developed mechanisms to resist anoikis and thereby survive after detachment from their primary site and while travelling through the lymphatic and circulatory systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18579285", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "Epithelial cells require attachment to extracellular matrix (ECM) to suppress an apoptotic cell death program termed anoikis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18045538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 207, "text": "Detachment of adherent epithelial cells from the extracellular matrix induces apoptosis, known as anoikis. Integrin stimulation protects cells from anoikis, but the responsible mechanisms are not well known.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15302871", "endSection": "abstract"}, {"offsetInBeginSection": 203, "offsetInEndSection": 536, "text": "Apoptosis triggered by cell detachment from the extracellular matrix, which occurs during hepatocyte isolation, is a phenomenon termed \"anoikis\". It's importance in the normal physiologic development of the human body, as well as in disease states, has been described. Cancer cells harbor anoikis resistance allowing spread to occur.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14702756", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 335, "text": "Ano\u00efkis is defined as programmed cell death induced by the loss of cell/matrix interactions. Adhesion to structural glycoproteins of the extracellular matrix is necessary for survival of the differentiated adherent cells in the cardiovascular system, including endothelial cells, smooth muscle cells, fibroblasts, and cardiac myocytes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14551156", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 739, "text": "Adhesion is also a key factor for the differentiation of mesenchymal stem cells. In particular, fibronectin is considered a factor of survival and differentiation for many adherent cells. Adhesion generates cell tensional integrity (tensegrity) and repression of apoptotic signals, whereas detachment has the opposite effect. Ano\u00efkis plays a physiological role by regulating cell homeostasis in tissues.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14551156", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Anoikis is a special type of programmed cell death after loss of cell-cell and cell-extracellular matrix interactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19062038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Detachment-induced cell death, or anoikis, is a type of apoptosis that occurs when epithelial cells lose their attachment to the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Anoikis is a special type of programmed cell death after loss of cell-cell and cell-extracellular matrix interactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19062038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Detachment-induced cell death, or anoikis, is a type of apoptosis that occurs when epithelial cells lose their attachment to the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Anoikis is a special type of programmed cell death after loss of cell-cell and cell-extracellular matrix interactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19062038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Detachment-induced cell death, or anoikis, is a type of apoptosis that occurs when epithelial cells lose their attachment to the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Anoikis is a special type of programmed cell death after loss of cell-cell and cell-extracellular matrix interactions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19062038", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Detachment-induced cell death, or anoikis, is a type of apoptosis that occurs when epithelial cells lose their attachment to the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Detachment-induced cell death, or anoikis, is a type of apoptosis that occurs when epithelial cells lose their attachment to the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "As a barrier to metastasis of cancer, cells that lost contact with the neighbouring cells or extracellular matrix(Extracellular matrix, ECM) will be subjected to apoptosis. This cell death process has been termed \"anoikis\".", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23357260", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 150, "text": "Detachment-induced cell death, or anoikis, is a type of apoptosis that occurs when epithelial cells lose their attachment to the extracellular matrix.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20670956", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Anoikis is a type of apoptosis due to the detachment from the extracellular matrix and neighboring cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18672025", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 106, "text": "Detachment of adherent epithelial cells from the extracellular matrix induces apoptosis, known as anoikis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15302871", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Anoikis is a programmed cell death induced upon cell detachment from extracellular matrix, behaving as a critical mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus avoiding colonization of distant organs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25549223", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 356, "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 356, "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Detachment of adherent epithelial cells from the extracellular matrix induces apoptosis, known as anoikis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15302871", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 356, "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 356, "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "endSection": "abstract"}, {"offsetInBeginSection": 170, "offsetInEndSection": 356, "text": "As a barrier to metastasis, cells normally undergo an apoptotic process known as \"anoikis,\" a form of cell death due to loss of contact with the extracellular matrix or neighboring cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505926", "endSection": "abstract"}]}, {"body": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23942795", "http://www.ncbi.nlm.nih.gov/pubmed/23666688", "http://www.ncbi.nlm.nih.gov/pubmed/23285088", "http://www.ncbi.nlm.nih.gov/pubmed/23233201", "http://www.ncbi.nlm.nih.gov/pubmed/23174189", "http://www.ncbi.nlm.nih.gov/pubmed/23090888", "http://www.ncbi.nlm.nih.gov/pubmed/23032801", "http://www.ncbi.nlm.nih.gov/pubmed/22985168", "http://www.ncbi.nlm.nih.gov/pubmed/22895079", "http://www.ncbi.nlm.nih.gov/pubmed/22893108", "http://www.ncbi.nlm.nih.gov/pubmed/22761178", "http://www.ncbi.nlm.nih.gov/pubmed/22519766", "http://www.ncbi.nlm.nih.gov/pubmed/22506320", "http://www.ncbi.nlm.nih.gov/pubmed/22461032", "http://www.ncbi.nlm.nih.gov/pubmed/22460758", "http://www.ncbi.nlm.nih.gov/pubmed/22349810", "http://www.ncbi.nlm.nih.gov/pubmed/22191306", "http://www.ncbi.nlm.nih.gov/pubmed/22160058", "http://www.ncbi.nlm.nih.gov/pubmed/22151181", "http://www.ncbi.nlm.nih.gov/pubmed/22087818", "http://www.ncbi.nlm.nih.gov/pubmed/22052279", "http://www.ncbi.nlm.nih.gov/pubmed/22037271", "http://www.ncbi.nlm.nih.gov/pubmed/21903771", "http://www.ncbi.nlm.nih.gov/pubmed/21892537", "http://www.ncbi.nlm.nih.gov/pubmed/21672900", "http://www.ncbi.nlm.nih.gov/pubmed/21672337", "http://www.ncbi.nlm.nih.gov/pubmed/21279819", "http://www.ncbi.nlm.nih.gov/pubmed/21203982", "http://www.ncbi.nlm.nih.gov/pubmed/17382013", "http://www.ncbi.nlm.nih.gov/pubmed/17379100", "http://www.ncbi.nlm.nih.gov/pubmed/17364993", "http://www.ncbi.nlm.nih.gov/pubmed/17292736", "http://www.ncbi.nlm.nih.gov/pubmed/16988930", "http://www.ncbi.nlm.nih.gov/pubmed/16850123", "http://www.ncbi.nlm.nih.gov/pubmed/16843101", "http://www.ncbi.nlm.nih.gov/pubmed/16757427", "http://www.ncbi.nlm.nih.gov/pubmed/16689455", "http://www.ncbi.nlm.nih.gov/pubmed/16475128", "http://www.ncbi.nlm.nih.gov/pubmed/16146726", "http://www.ncbi.nlm.nih.gov/pubmed/21061842", "http://www.ncbi.nlm.nih.gov/pubmed/20945321", "http://www.ncbi.nlm.nih.gov/pubmed/20875546", "http://www.ncbi.nlm.nih.gov/pubmed/20607973", "http://www.ncbi.nlm.nih.gov/pubmed/20529808", "http://www.ncbi.nlm.nih.gov/pubmed/20425400", "http://www.ncbi.nlm.nih.gov/pubmed/19860186", "http://www.ncbi.nlm.nih.gov/pubmed/19641300", "http://www.ncbi.nlm.nih.gov/pubmed/19254884", "http://www.ncbi.nlm.nih.gov/pubmed/19075651", "http://www.ncbi.nlm.nih.gov/pubmed/19064740", "http://www.ncbi.nlm.nih.gov/pubmed/18974832", "http://www.ncbi.nlm.nih.gov/pubmed/18533795", "http://www.ncbi.nlm.nih.gov/pubmed/18205699", "http://www.ncbi.nlm.nih.gov/pubmed/17970609", "http://www.ncbi.nlm.nih.gov/pubmed/17956348", "http://www.ncbi.nlm.nih.gov/pubmed/17929114", "http://www.ncbi.nlm.nih.gov/pubmed/17671641", "http://www.ncbi.nlm.nih.gov/pubmed/20425355", "http://www.ncbi.nlm.nih.gov/pubmed/17382020", "http://www.ncbi.nlm.nih.gov/pubmed/15899391", "http://www.ncbi.nlm.nih.gov/pubmed/15791812", "http://www.ncbi.nlm.nih.gov/pubmed/15739279", "http://www.ncbi.nlm.nih.gov/pubmed/15027317", "http://www.ncbi.nlm.nih.gov/pubmed/14744784", "http://www.ncbi.nlm.nih.gov/pubmed/14639002", "http://www.ncbi.nlm.nih.gov/pubmed/12869662", "http://www.ncbi.nlm.nih.gov/pubmed/12796373", "http://www.ncbi.nlm.nih.gov/pubmed/12783369", "http://www.ncbi.nlm.nih.gov/pubmed/12755554", "http://www.ncbi.nlm.nih.gov/pubmed/12750692", "http://www.ncbi.nlm.nih.gov/pubmed/12454739", "http://www.ncbi.nlm.nih.gov/pubmed/12411298", "http://www.ncbi.nlm.nih.gov/pubmed/12200353", "http://www.ncbi.nlm.nih.gov/pubmed/12176881", "http://www.ncbi.nlm.nih.gov/pubmed/12173333", "http://www.ncbi.nlm.nih.gov/pubmed/12082821", "http://www.ncbi.nlm.nih.gov/pubmed/11986206", "http://www.ncbi.nlm.nih.gov/pubmed/11870241", "http://www.ncbi.nlm.nih.gov/pubmed/11808344"], "triples": [], "ideal_answer": "The fusion protein BCR-ABL", "exact_answer": ["BCR-ABL"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015464", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010677", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011505", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016044", "http://www.disease-ontology.org/api/metadata/DOID:8552", "http://www.biosemantics.org/jochem#4275840"], "type": "factoid", "id": "5324a8ac9b2d7acc7e000018", "snippets": [{"offsetInBeginSection": 108, "offsetInEndSection": 193, "text": "CR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23942795", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 135, "text": "reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11), Philadelphia chromosome] creates a BCR-ABL1 fusion protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688", "endSection": "abstract"}, {"offsetInBeginSection": 655, "offsetInEndSection": 780, "text": "A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted treatment in most CML patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666688", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 184, "text": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib i", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23285088", "endSection": "abstract"}, {"offsetInBeginSection": 270, "offsetInEndSection": 492, "text": "The BCR/ABL fusion tyrosine kinase is expressed in chronic myeloid leukemia and Philadelphia-positive (Ph+) acute lymphoblastic leukemia cells, and its inhibition by the clinically used tyrosine kinase inhibitors imatinib ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23233201", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 183, "text": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189", "endSection": "abstract"}, {"offsetInBeginSection": 437, "offsetInEndSection": 556, "text": "Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174189", "endSection": "abstract"}, {"offsetInBeginSection": 217, "offsetInEndSection": 494, "text": "CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888", "endSection": "abstract"}, {"offsetInBeginSection": 668, "offsetInEndSection": 711, "text": "tyrosine kinase inhibitors (TKIs), imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090888", "endSection": "abstract"}, {"offsetInBeginSection": 143, "offsetInEndSection": 346, "text": "Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032801", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 176, "text": "Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168", "endSection": "abstract"}, {"offsetInBeginSection": 361, "offsetInEndSection": 398, "text": "ABL-kinase inhibitors (AKIs) Imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22985168", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 120, "text": "hiladelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079", "endSection": "abstract"}, {"offsetInBeginSection": 280, "offsetInEndSection": 324, "text": " BCR-ABL tyrosine kinase inhibitor imatinib ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22895079", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 56, "text": "matinib was the first BCR-ABL tyrosine kinase inhibitor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22893108", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 185, "text": "CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178", "endSection": "abstract"}, {"offsetInBeginSection": 322, "offsetInEndSection": 385, "text": "Imatinib mesylate, an orally available BCR-ABL kinase inhibitor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22761178", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 193, "text": "Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22519766", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 202, "text": "CML) originates from a hematopoietic stem cell carrying the Philadelphia (Ph) chromosome and oncogenic BCR-ABL1 fusion gene. The first tyrosine-kinase inhibitor (TKI) imatinib ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22506320", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 171, "text": "chronic myeloid leukemia (CML) patients ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032", "endSection": "abstract"}, {"offsetInBeginSection": 363, "offsetInEndSection": 455, "text": "Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22461032", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 152, "text": "matinib mesylate is the sole BCR-ABL tyrosine kinase inhibitor approved as first-line treatment of accelerated-phase (AP) chronic myeloid leukemia (CML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22460758", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 64, "text": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22349810", "endSection": "abstract"}, {"offsetInBeginSection": 16, "offsetInEndSection": 160, "text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22191306", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 575, "text": "The development of first-generation (imatinib) and second-generation (dasatinib and nilotinib) tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 fusion protein produced by the Ph chromosome revolutionized the treatment of chronic myelogenous leukemia (CML).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22160058", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 219, "text": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22151181", "endSection": "abstract"}, {"offsetInBeginSection": 3, "offsetInEndSection": 137, "text": "chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be successfully targeted with the BCRABL- inhibitors imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22087818", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 195, "text": "matinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279", "endSection": "abstract"}, {"offsetInBeginSection": 380, "offsetInEndSection": 448, "text": "Philadelphia chromosome positive chronic myelogenous leukemia (CML) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052279", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 263, "text": "CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22037271", "endSection": "abstract"}, {"offsetInBeginSection": 343, "offsetInEndSection": 357, "text": "BCR-ABL levels", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 125, "text": "Imatinib induces a durable response in most patients with Philadelphia chromosome-positive chronic myeloid leukemia,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21903771", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 295, "text": "CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537", "endSection": "abstract"}, {"offsetInBeginSection": 357, "offsetInEndSection": 373, "text": "imatinib therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892537", "endSection": "abstract"}, {"offsetInBeginSection": 971, "offsetInEndSection": 1186, "text": "The discovery of targeted tyrosine kinase inhibition of BCR-ABL kinase dramatically changed the treatment of CML. Imatinib, the first TKI approved for treatment of patients with Philadelphia chromosome--positive CML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672900", "endSection": "abstract"}, {"offsetInBeginSection": 27, "offsetInEndSection": 299, "text": "CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21672337", "endSection": "abstract"}, {"offsetInBeginSection": 492, "offsetInEndSection": 603, "text": "imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279819", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 848, "text": "CML is induced by the BCR-ABL oncogene, whose gene product is a BCR-ABL tyrosine kinase. Currently, inhibition of BCR-ABL kinase activity by its kinase inhibitor such as imatinib mesylate (Gleevec)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21203982", "endSection": "abstract"}, {"offsetInBeginSection": 414, "offsetInEndSection": 518, "text": "The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382013", "endSection": "abstract"}, {"offsetInBeginSection": 231, "offsetInEndSection": 352, "text": "Imatinib (Glivec, Gleevec), a specific small molecule inhibitor of Bcr-Abl, has become the standard drug therapy for CML,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17379100", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 416, "text": "Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17364993", "endSection": "abstract"}, {"offsetInBeginSection": 191, "offsetInEndSection": 429, "text": "CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736", "endSection": "abstract"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1005, "text": "emergence of imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17292736", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 210, "text": "matinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16988930", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 312, "text": "Ph) chromosome is the cytogenetic hallmark of chronic myeloid leukemia (CML). The translocation forms a chimeric gene, bcr-abl, which generates BCR-ABL. This fusion protein constitutively activate ABL tyrosine kinase and causes CML. Imatinib mesylate is a selective tyrosine kinase inhibitor on ABL", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16850123", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 244, "text": "CML) is characterized by the presence of a BCR-ABL fusion gene, which is the result of a reciprocal translocation between chromosomes 9 and 22, and is cytogenetically visible as a shortened chromosome 22 (Philadelphia)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101", "endSection": "abstract"}, {"offsetInBeginSection": 528, "offsetInEndSection": 595, "text": "imatinib mesylate was introduced into the treatment regimen for CML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843101", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 179, "text": "matinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757427", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 218, "text": "hronic myelogenous leukemia is characterized by the Philadelphia-chromosome, a shortened chromosome 22 which is the result of a reciprocal translocation between chromosome 9 and 22. The fusion gene is called BCR-ABL. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455", "endSection": "abstract"}, {"offsetInBeginSection": 594, "offsetInEndSection": 621, "text": "Imatinib mesylate (Glivec) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689455", "endSection": "abstract"}, {"offsetInBeginSection": 487, "offsetInEndSection": 611, "text": " BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16475128", "endSection": "abstract"}, {"offsetInBeginSection": 367, "offsetInEndSection": 450, "text": "Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 60, "text": "hronic myeloid leukemia cells contain a BCR-ABL oncoprotein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16146726", "endSection": "abstract"}, {"offsetInBeginSection": 16, "offsetInEndSection": 246, "text": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21061842", "endSection": "abstract"}, {"offsetInBeginSection": 93, "offsetInEndSection": 489, "text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20945321", "endSection": "abstract"}, {"offsetInBeginSection": 1135, "offsetInEndSection": 1157, "text": "original TKI, imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546", "endSection": "abstract"}, {"offsetInBeginSection": 518, "offsetInEndSection": 759, "text": "CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CM", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20875546", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 186, "text": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20607973", "endSection": "abstract"}, {"offsetInBeginSection": 93, "offsetInEndSection": 415, "text": "The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph) that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase (TK). The introduction of imatinib, a TK inhibitor (TKI) specific for BCR-ABL, was a major breakthrough in CML therapy", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529808", "endSection": "abstract"}, {"offsetInBeginSection": 338, "offsetInEndSection": 439, "text": "CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 150, "text": "CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425400", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 133, "text": "CML) is a paradigm for neoplasias that are defined by a unique genetic aberration, the BCR-ABL1 fusion gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186", "endSection": "abstract"}, {"offsetInBeginSection": 213, "offsetInEndSection": 257, "text": "protein tyrosine kinase inhibitor, imatinib,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19860186", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 150, "text": "BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300", "endSection": "abstract"}, {"offsetInBeginSection": 370, "offsetInEndSection": 406, "text": "CML patients with imatinib treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19641300", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 244, "text": "CML) is characterized by the presence of the Philadelphia chromosome (Ph), a genetic aberration that codes for bcrabl, which plays a key role in disease pathophysiology. The first oral inhibitor of Brc-Abl was imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19254884", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 328, "text": "CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two new genes, BCR-ABL on the 22q- (Ph chromosome) and the reciprocal ABL-BCR on 9q-. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651", "endSection": "abstract"}, {"offsetInBeginSection": 704, "offsetInEndSection": 801, "text": "tyrosine kinase inhibitor (TKI), introduced into clinical practice in 1998, was imatinib mesylate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19075651", "endSection": "abstract"}, {"offsetInBeginSection": 465, "offsetInEndSection": 613, "text": "BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19064740", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 290, "text": "CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974832", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 279, "text": "CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795", "endSection": "abstract"}, {"offsetInBeginSection": 545, "offsetInEndSection": 631, "text": "Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18533795", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 173, "text": "CR-ABL tyrosine kinase inhibitors, such as imatinib (Gleevec) are highly effective in treating human Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18205699", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 174, "text": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell cancer driven by the BCR-ABL fusion protein that arises from the translocation of chromosomes 9 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609", "endSection": "abstract"}, {"offsetInBeginSection": 969, "offsetInEndSection": 1005, "text": "BCR-ABL inhibitors, such as imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17970609", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 577, "text": "TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348", "endSection": "abstract"}, {"offsetInBeginSection": 5, "offsetInEndSection": 228, "text": "chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17956348", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 310, "text": "CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop molecular-targeted therapies. Imatinib mesylate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17929114", "endSection": "abstract"}, {"offsetInBeginSection": 3, "offsetInEndSection": 297, "text": " identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671641", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 441, "text": "CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425355", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 358, "text": "CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17382020", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 163, "text": "matinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15899391", "endSection": "abstract"}, {"offsetInBeginSection": 30, "offsetInEndSection": 431, "text": "CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15791812", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 458, "text": "CML was the first human cancer demonstrated to be strongly associated to the presence of a recurrent chromosomal translocation (the t(9;22)(q34;q11) that creates the Philadelphia (Ph)-chromosome) and to a specific molecular defect, the formation of a hybrid BCR-ABL gene ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 747, "text": "imatinib, (Glivec, Gleevec, Novartis), a potent tyrosine kinase inhibitor of the Bcr-Abl protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15739279", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 391, "text": "matinib mesylate is a new drug that can inhibit the tyrosine kinase activity of Bcr-Abl, the receptors for platelet-derived growth factor receptor(PDGF) and stem cell factor, or c-kit. Chronic myeloid leukemia (CML) is distinguished by the presence of a reciprocal translocation between chromosomes 9 and 22 that results in a shortened chromosome 22, termed the Philadelphia(Ph) chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15027317", "endSection": "abstract"}, {"offsetInBeginSection": 19, "offsetInEndSection": 51, "text": "IM) binds to the BCR-ABL protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14744784", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 224, "text": "Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002", "endSection": "abstract"}, {"offsetInBeginSection": 351, "offsetInEndSection": 416, "text": "Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14639002", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 167, "text": "CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662", "endSection": "abstract"}, {"offsetInBeginSection": 321, "offsetInEndSection": 380, "text": "Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869662", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 183, "text": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12796373", "endSection": "abstract"}, {"offsetInBeginSection": 319, "offsetInEndSection": 414, "text": "BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369", "endSection": "abstract"}, {"offsetInBeginSection": 545, "offsetInEndSection": 593, "text": "The kinase inhibitor imatinib mesylate (Gleevec)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783369", "endSection": "abstract"}, {"offsetInBeginSection": 5, "offsetInEndSection": 240, "text": "hiladelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 661, "text": "imatinib mesylate (Gleevec,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12755554", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 180, "text": "matinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12750692", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 174, "text": "matinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12454739", "endSection": "abstract"}, {"offsetInBeginSection": 30, "offsetInEndSection": 238, "text": "CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor of Bcr-Abl", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12411298", "endSection": "abstract"}, {"offsetInBeginSection": 314, "offsetInEndSection": 398, "text": "Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200353", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 328, "text": "Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12176881", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 320, "text": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12173333", "endSection": "abstract"}, {"offsetInBeginSection": 27, "offsetInEndSection": 497, "text": "CML) is characterised by the occurrence of the Philadelphia (Ph) chromosome (9/22 translocation) and the formation of a fusion protein--the BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase and consequent changes in the intracellular signal transduction, which is responsible for the deregulated myeloid cell proliferation. STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12082821", "endSection": "abstract"}, {"offsetInBeginSection": 199, "offsetInEndSection": 356, "text": "Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11986206", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 209, "text": "Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11870241", "endSection": "abstract"}, {"offsetInBeginSection": 26, "offsetInEndSection": 265, "text": "CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11808344", "endSection": "abstract"}]}, {"body": "What is evaluated with the Hydrocephalus Outcome Questionnaire?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21778677", "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "http://www.ncbi.nlm.nih.gov/pubmed/19714338", "http://www.ncbi.nlm.nih.gov/pubmed/20593981", "http://www.ncbi.nlm.nih.gov/pubmed/18754895", "http://www.ncbi.nlm.nih.gov/pubmed/17644917", "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "http://www.ncbi.nlm.nih.gov/pubmed/15835100"], "triples": [], "ideal_answer": ["The Hydrocephalus Outcome Questionnaire (HOQ) is a simple, reliable, and valid measure of health status in children with hydrocephalus."], "concepts": [], "type": "summary", "id": "56c1d84aef6e394741000030", "snippets": [{"offsetInBeginSection": 166, "offsetInEndSection": 395, "text": "We sought to describe the natural history of this disorder, specifically its clinical presentation, disease course and long-term health status impact using the validated, disease-specific Hydrocephalus Outcome Questionnaire (HOQ)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778677", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "OBJECT: The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 591, "text": "Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 507, "offsetInEndSection": 607, "text": "Measures of QOL were the Hydrocephalus Outcome Questionnaire and the Health Utilities Index Mark 3. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19714338", "endSection": "abstract"}, {"offsetInBeginSection": 339, "offsetInEndSection": 604, "text": "METHODS: The families of children between 5 and 18 years of age with previously treated hydrocephalus at 3 Canadian pediatric neurosurgery centers completed measures of QOL: the Hydrocephalus Outcome Questionnaire (HOQ) and the Health Utilities Index Mark 3 (HUI3).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20593981", "endSection": "abstract"}, {"offsetInBeginSection": 1160, "offsetInEndSection": 1285, "text": "In older children with hydrocephalus, the cHOQ appears to be a scientifically reliable means of assessing long-term outcome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18754895", "endSection": "abstract"}, {"offsetInBeginSection": 1325, "offsetInEndSection": 1424, "text": "The HOQ is a simple and very useful measurement for determining outcome in pediatric hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644917", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 322, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "OBJECTIVE: To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 1287, "text": "These include general outcome measures such as the Pediatric Evaluation of Disability Inventory and the Functional Independence Measure for Children, which measure physical function and independence in chronically ill and disabled children as well as disease-specific measures for hydrocephalus (Hydrocephalus Outcome Questionnaire), cerebral palsy (gross motor function and performance measures), head injury (Pediatric Cerebral Performance Category and Children's Coma Scale), and oncology (Pediatric Cancer Quality-of-Life Inventory).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 198, "offsetInEndSection": 410, "text": " The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 1745, "offsetInEndSection": 1959, "text": "CONCLUSIONS: The HOQ for children with hydrocephalus demonstrated excellent reliability and validity properties. This tool will be valuable for a wide range of clinical research projects in pediatric hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "OBJECT: In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 526, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 612, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 313, "offsetInEndSection": 526, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 401, "offsetInEndSection": 612, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 411, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "OBJECTIVE: To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 323, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "OBJECT: The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "OBJECT: In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 411, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "OBJECTIVE: To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 323, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "OBJECT: The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "OBJECT: In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 411, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "OBJECTIVE: To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 323, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "OBJECT: The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "OBJECT: In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 411, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "OBJECTIVE: To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 323, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "OBJECT: The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "OBJECT: In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 199, "offsetInEndSection": 411, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "OBJECTIVE: To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 109, "offsetInEndSection": 323, "text": "The authors' aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "OBJECT: The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 190, "text": "OBJECT: In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 191, "offsetInEndSection": 402, "text": "The authors developed a quantitative health status measure, the Hydrocephalus Outcome Questionnaire (HOQ), designed specifically for children with hydrocephalus, which can be completed by the children's parents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "To compare three separate methods for establishing interpretability for a health status measure, the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16426953", "endSection": "abstract"}, {"offsetInBeginSection": 1297, "offsetInEndSection": 1396, "text": "The HOQ is a simple and very useful measurement for determining outcome in pediatric hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644917", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1298, "text": "These include general outcome measures such as the Pediatric Evaluation of Disability Inventory and the Functional Independence Measure for Children, which measure physical function and independence in chronically ill and disabled children as well as disease-specific measures for hydrocephalus (Hydrocephalus Outcome Questionnaire), cerebral palsy (gross motor function and performance measures), head injury (Pediatric Cerebral Performance Category and Children&apos;s Coma Scale), and oncology (Pediatric Cancer Quality-of-Life Inventory).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 741, "text": "Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing. Clinical variables including number of shunt revisions, shunt infection and surgical decompression of foramen magnum, which may influence outcome, were investigated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 575, "text": " Adult patients under routine follow-up were assessed in a joint neurosurgery/neuropsychology clinic. Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 320, "text": "The authors&apos; aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1298, "text": "These include general outcome measures such as the Pediatric Evaluation of Disability Inventory and the Functional Independence Measure for Children, which measure physical function and independence in chronically ill and disabled children as well as disease-specific measures for hydrocephalus (Hydrocephalus Outcome Questionnaire), cerebral palsy (gross motor function and performance measures), head injury (Pediatric Cerebral Performance Category and Children&apos;s Coma Scale), and oncology (Pediatric Cancer Quality-of-Life Inventory).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Outcome in pediatric hydrocephalus: a comparison between previously used outcome measures and the hydrocephalus outcome questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644917", "endSection": "title"}, {"offsetInBeginSection": 452, "offsetInEndSection": 575, "text": "Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 320, "text": "The authors&apos; aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 491, "offsetInEndSection": 590, "text": "Measures of QOL were the Hydrocephalus Outcome Questionnaire and the Health Utilities Index Mark 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19714338", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1298, "text": "These include general outcome measures such as the Pediatric Evaluation of Disability Inventory and the Functional Independence Measure for Children, which measure physical function and independence in chronically ill and disabled children as well as disease-specific measures for hydrocephalus (Hydrocephalus Outcome Questionnaire), cerebral palsy (gross motor function and performance measures), head injury (Pediatric Cerebral Performance Category and Children&apos;s Coma Scale), and oncology (Pediatric Cancer Quality-of-Life Inventory).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Outcome in pediatric hydrocephalus: a comparison between previously used outcome measures and the hydrocephalus outcome questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644917", "endSection": "title"}, {"offsetInBeginSection": 452, "offsetInEndSection": 575, "text": "Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 320, "text": "The authors&apos; aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 491, "offsetInEndSection": 590, "text": "Measures of QOL were the Hydrocephalus Outcome Questionnaire and the Health Utilities Index Mark 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19714338", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1298, "text": "These include general outcome measures such as the Pediatric Evaluation of Disability Inventory and the Functional Independence Measure for Children, which measure physical function and independence in chronically ill and disabled children as well as disease-specific measures for hydrocephalus (Hydrocephalus Outcome Questionnaire), cerebral palsy (gross motor function and performance measures), head injury (Pediatric Cerebral Performance Category and Children&apos;s Coma Scale), and oncology (Pediatric Cancer Quality-of-Life Inventory).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 575, "text": "Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 102, "offsetInEndSection": 320, "text": "The authors&apos; aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "An instrument to measure the health status in children with hydrocephalus: the Hydrocephalus Outcome Questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835099", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 182, "text": "In the preceding article, the authors described the Hydrocephalus Outcome Questionnaire (HOQ), a simple, reliable, and valid measure of health status in children with hydrocephalus.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15835100", "endSection": "abstract"}, {"offsetInBeginSection": 756, "offsetInEndSection": 1298, "text": "These include general outcome measures such as the Pediatric Evaluation of Disability Inventory and the Functional Independence Measure for Children, which measure physical function and independence in chronically ill and disabled children as well as disease-specific measures for hydrocephalus (Hydrocephalus Outcome Questionnaire), cerebral palsy (gross motor function and performance measures), head injury (Pediatric Cerebral Performance Category and Children&apos;s Coma Scale), and oncology (Pediatric Cancer Quality-of-Life Inventory).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16238072", "endSection": "abstract"}, {"offsetInBeginSection": 452, "offsetInEndSection": 575, "text": "Patients completed lifestyle questionnaires, the hydrocephalus outcome questionnaire (HOQ) and underwent cognitive testing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21193992", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 134, "text": "Outcome in pediatric hydrocephalus: a comparison between previously used outcome measures and the hydrocephalus outcome questionnaire.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17644917", "endSection": "title"}, {"offsetInBeginSection": 102, "offsetInEndSection": 320, "text": "The authors&apos; aim was to quantify the QOL for children with hydrocephalus and identify predictors of long-term outcome, using a reliable and validated outcome measure: the Hydrocephalus Outcome Questionnaire (HOQ).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18459898", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "The Hydrocephalus Outcome Questionnaire (HOQ) is an established means of measuring quality of life, but the cognitive component of this questionnaire has never been formally compared with gold-standard neuropsychological test scores.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21961548", "endSection": "abstract"}]}, {"body": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23567651", "http://www.ncbi.nlm.nih.gov/pubmed/23314528", "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "http://www.ncbi.nlm.nih.gov/pubmed/11813001", "http://www.ncbi.nlm.nih.gov/pubmed/22232559", "http://www.ncbi.nlm.nih.gov/pubmed/18562315"], "triples": [], "ideal_answer": ["Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies, which are characteristic pathologic lesions of Parkinson disease.", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodiesApproximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated \u03b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodiesApproximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated \u03b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinsons disease patients where it mainly accumulates in the Lewy bodies", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson s disease patients where it mainly accumulates in the Lewy bodies  ", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson s disease patients where it mainly accumulates in the Lewy bodies  ", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson s disease patients where it mainly accumulates in the Lewy bodies  ", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson s disease patients where it mainly accumulates in the Lewy bodies  ", "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson s disease patients where it mainly accumulates in the Lewy bodies  "], "exact_answer": [["Serine 129"]], "concepts": ["http://www.uniprot.org/uniprot/SYUA_GORGO", "http://www.uniprot.org/uniprot/SYUA_ATEGE", "http://www.uniprot.org/uniprot/SYUA_SERCA", "http://www.uniprot.org/uniprot/SYUA_RAT", "http://www.uniprot.org/uniprot/SYUA_PANPA", "http://www.uniprot.org/uniprot/SYUA_PONAB", "http://www.uniprot.org/uniprot/SYUA_MOUSE", "http://www.uniprot.org/uniprot/SYUA_ERYPA", "http://www.uniprot.org/uniprot/SYUA_MACMU", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051844", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016631", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016310", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020961", "http://www.disease-ontology.org/api/metadata/DOID:12217"], "type": "factoid", "id": "550c4011a103b78016000009", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567651", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 649, "text": "Approximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated \u03b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314528", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 268, "text": "\ufffd-Synuclein is causative for autosomal dominant familial Parkinson disease and dementia with Lewy bodies, and the phosphorylation of \ufffd-synuclein at residue Ser-129 is a key posttranslational modification detected in Parkinson disease/dementia with Lewy bodies lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232559", "endSection": "abstract"}, {"offsetInBeginSection": 710, "offsetInEndSection": 939, "text": "Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11813001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Alpha-synuclein phosphorylated at serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23567651", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 649, "text": "Approximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain. This suggests that the accumulation of Ser129-phosphorylated \u03b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314528", "endSection": "abstract"}, {"offsetInBeginSection": 711, "offsetInEndSection": 940, "text": "Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11813001", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "alpha-Synuclein is a major protein component deposited in Lewy bodies and Lewy neurites that is extensively phosphorylated at Ser(129), although its role in neuronal degeneration is still elusive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18562315", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1802, "text": "These observations are most consistent with a model in which preferential accumulation of normally produced Ser-129 phosphorylated alpha-synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847063", "endSection": "abstract"}, {"offsetInBeginSection": 304, "offsetInEndSection": 406, "text": "The predominant modification of alpha-synuclein in Lewy bodies is a single phosphorylation at Ser-129.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847063", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 390, "text": "Approximately 90% of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129 (Ser129).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314528", "endSection": "abstract"}, {"offsetInBeginSection": 491, "offsetInEndSection": 655, "text": "This suggests that the accumulation of Ser129-phosphorylated \u00ce\u00b1-syn leads to the formation of Lewy bodies and dopaminergic neurodegeneration in Parkinson's disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314528", "endSection": "abstract"}, {"offsetInBeginSection": 711, "offsetInEndSection": 939, "text": "Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11813001", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1802, "text": "These observations are most consistent with a model in which preferential accumulation of normally produced Ser-129 phosphorylated alpha-synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847063", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15834418", "endSection": "abstract"}, {"offsetInBeginSection": 711, "offsetInEndSection": 939, "text": "Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11813001", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1802, "text": "These observations are most consistent with a model in which preferential accumulation of normally produced Ser-129 phosphorylated alpha-synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847063", "endSection": "abstract"}, {"offsetInBeginSection": 711, "offsetInEndSection": 939, "text": "Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11813001", "endSection": "abstract"}, {"offsetInBeginSection": 1563, "offsetInEndSection": 1802, "text": "These observations are most consistent with a model in which preferential accumulation of normally produced Ser-129 phosphorylated alpha-synuclein is the key event responsible for the formation of Lewy bodies in various Lewy body diseases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16847063", "endSection": "abstract"}]}, {"body": "What is the treatment of interferon-induced thyroiditis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22148004", "http://www.ncbi.nlm.nih.gov/pubmed/21214950", "http://www.ncbi.nlm.nih.gov/pubmed/19054259"], "ideal_answer": ["An altered thyroid function is frequently observed during interferon treatment with a pattern similar to Hashimoto Thyroiditis or Graves disease.\nVery frequently the alterations of thyroid hormones related to interferon-induced thyroiditis spontaneosly diseapper in  a few months\nTreatment when necessary is propanolol and  antithyroid drugs for the Graves like form and thyroxine for chronic hypothyroidism indiced by interferon"], "type": "summary", "id": "517545168ed59a060a00002b", "snippets": []}, {"body": "Can DMSO as an additive improve proteomic analysis results?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18926777", "http://www.ncbi.nlm.nih.gov/pubmed/23975139", "http://www.ncbi.nlm.nih.gov/pubmed/18393531"], "triples": [], "ideal_answer": "Quantitative precisions improved significantly when DMSO (dimethylsulfoxide) was added to the matrix solution.\nIntroducing to the 80% formic acid injection solution an organic solvent such as acetonitrile or acetonitrile-DMSO induced further retention selectivity, and increasing levels of organic solvents reduced on-column retention.\nLow percentages of dimethylsulfoxide (DMSO) in liquid chromatography solvents lead to a strong enhancement of electrospray ionization of peptides, improving the sensitivity of protein identification in bottom-up proteomics by up to tenfold.", "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004121", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901", "http://www.biosemantics.org/jochem#4275915"], "type": "summary", "id": "52f89fba2059c6d71c00004f", "snippets": [{"offsetInBeginSection": 597, "offsetInEndSection": 821, "text": "Introducing to the 80% formic acid injection solution an organic solvent such as acetonitrile or acetonitrile-DMSO induced further retention selectivity, and increasing levels of organic solvents reduced on-column retention.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18926777", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 256, "text": "We report that low percentages of dimethylsulfoxide (DMSO) in liquid chromatography solvents lead to a strong enhancement of electrospray ionization of peptides, improving the sensitivity of protein identification in bottom-up proteomics by up to tenfold. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23975139", "endSection": "abstract"}, {"offsetInBeginSection": 336, "offsetInEndSection": 464, "text": "We found that the quantitative precisions improved significantly when DMSO (dimethylsulfoxide) was added to the matrix solution.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18393531", "endSection": "abstract"}]}, {"body": "What is the risk in G-CSF treatment for severe congenital neutropenia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22371884", "http://www.ncbi.nlm.nih.gov/pubmed/21052952", "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "http://www.ncbi.nlm.nih.gov/pubmed/12555210", "http://www.ncbi.nlm.nih.gov/pubmed/20237318"], "triples": [], "ideal_answer": ["Severe congenital neutropenia is a rare hematological condition causing severe chronic neutropenia. Treatment with the myeloid growth factor, granulocyte-colony stimulating factor (G-CSF) is usually effective, but the dose of G-CSF required to normalize blood neutrophils varies greatly. Ten to thirty percent of the patients evolve to develop acute myeloid leukemia or myelodysplastic syndromes, necessitating careful clinical monitoring."], "concepts": ["http://www.uniprot.org/uniprot/CSF3_CANFA", "http://www.biosemantics.org/jochem#4250245", "http://www.disease-ontology.org/api/metadata/DOID:0050590"], "type": "summary", "id": "55031406e9bde69634000021", "snippets": [{"offsetInBeginSection": 211, "offsetInEndSection": 1301, "text": "We obtained serial hematopoietic samples from an SCN patient who developed AML 17 years after the initiation of G-CSF treatment. Next- generation sequencing was performed to identify mutations during disease progression. In the AML phase, we found 12 acquired nonsynonymous mutations. Three of these, in CSF3R, LLGL2, and ZC3H18, co-occurred in a subpopulation of progenitor cells already in the early SCN phase. This population expanded over time, whereas clones harboring only CSF3R mutations disappeared from the BM. The other 9 mutations were only apparent in the AML cells and affected known AML-associated genes (RUNX1 and ASXL1) and chromatin remodelers (SUZ12 and EP300). In addition, a novel CSF3R mutation that conferred autonomous proliferation to myeloid progenitors was found. We conclude that progression from SCN to AML is a multistep process, with distinct mutations arising early during the SCN phase and others later in AML development. The sequential gain of 2 CSF3R mutations implicates abnormal G-CSF signaling as a driver of leukemic transformation in this case of SCN", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371884", "endSection": "abstract"}, {"offsetInBeginSection": 173, "offsetInEndSection": 441, "text": "This chapter focuses on cyclic and congenital neutropenia, two very interesting and rare hematological conditions causing severe chronic neutropenia. Both disorders respond well to treatment with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", "endSection": "abstract"}, {"offsetInBeginSection": 1688, "offsetInEndSection": 1957, "text": "Treatment with G-CSF is usually effective, but the dose of G-CSF required to normalize blood neutrophils varies greatly. Ten to thirty percent of severe congenital neutropenia patients evolve to develop acute myeloid leukemia, necessitating careful clinical monitoring.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21052952", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 248, "text": "In severe congenital neutropenia (SCN), long-term therapy with granulocyte colony-stimulating factor (G-CSF) has reduced mortality from sepsis, revealing an underlying predisposition to myelodysplastic syndrome and acute myeloid leukaemia (MDS/AML)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "abstract"}, {"offsetInBeginSection": 145, "offsetInEndSection": 332, "text": "Granulocyte colony-stimulating factor (G-CSF) therapy has significantly reduced the frequency and severity of infections, but its possible influence on the risk of malignancy is not known", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 1054, "offsetInEndSection": 1238, "text": "No septic deaths occurred during G-CSF therapy. Thirteen cases of MDS/AL were recorded. The cumulative incidence of MDS/AL was 2.7% (SD 1.3%) at 10 years and 8.1% (SD 2.7%) at 20 years", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 1488, "offsetInEndSection": 1706, "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "title"}, {"offsetInBeginSection": 899, "offsetInEndSection": 1139, "text": "This specifically applies to children with severe congenital neutropenia who receive lifelong treatment with G-CSF and in which the high susceptibility to develop MDS and acute myeloid leukemia (AML) has now become a major clinical concern.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20237318", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 1301, "text": "We obtained serial hematopoietic samples from an SCN patient who developed AML 17 years after the initiation of G-CSF treatment. Next- generation sequencing was performed to identify mutations during disease progression. In the AML phase, we found 12 acquired nonsynonymous mutations. Three of these, in CSF3R, LLGL2, and ZC3H18, co-occurred in a subpopulation of progenitor cells already in the early SCN phase. This population expanded over time, whereas clones harboring only CSF3R mutations disappeared from the BM. The other 9 mutations were only apparent in the AML cells and affected known AML-associated genes (RUNX1 and ASXL1) and chromatin remodelers (SUZ12 and EP300). In addition, a novel CSF3R mutation that conferred autonomous proliferation to myeloid progenitors was found. We conclude that progression from SCN to AML is a multistep process, with distinct mutations arising early during the SCN phase and others later in AML development. The sequential gain of 2 CSF3R mutations implicates abnormal G-CSF signaling as a driver of leukemic transformation in this case of SCN", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371884", "endSection": "abstract"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1622, "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1205, "text": "As of January 1, 2000, myelodysplasia (MDS) or acute myelogenous leukemia (AML) has occurred in 35 of 387 patients with congenital neutropenia with a cumulative risk of 13% after 8 years of G-CSF treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12555210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "title"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1622, "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1205, "text": "As of January 1, 2000, myelodysplasia (MDS) or acute myelogenous leukemia (AML) has occurred in 35 of 387 patients with congenital neutropenia with a cumulative risk of 13% after 8 years of G-CSF treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12555210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "title"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1622, "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1205, "text": "As of January 1, 2000, myelodysplasia (MDS) or acute myelogenous leukemia (AML) has occurred in 35 of 387 patients with congenital neutropenia with a cumulative risk of 13% after 8 years of G-CSF treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12555210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "title"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1622, "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20456363", "endSection": "title"}, {"offsetInBeginSection": 1403, "offsetInEndSection": 1622, "text": "Owing to their particular susceptibility to infections, patients with severe congenital neutropenia had the strongest exposure to G-CSF; the risk of leukemia increased with the degree of G-CSF exposure in this subgroup.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15642668", "endSection": "abstract"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1205, "text": "As of January 1, 2000, myelodysplasia (MDS) or acute myelogenous leukemia (AML) has occurred in 35 of 387 patients with congenital neutropenia with a cumulative risk of 13% after 8 years of G-CSF treatment", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12555210", "endSection": "abstract"}]}, {"body": "What is considered a reliable technique for the definitive cytogenetic diagnosis of Fanconi anemia homozygosity?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3133104", "http://www.ncbi.nlm.nih.gov/pubmed/19278965", "http://www.ncbi.nlm.nih.gov/pubmed/22052692"], "triples": [], "ideal_answer": ["In vitro enhancement of chromosome breakage by diepoxybutane (DEB) and mitomycin C (MMC) are reliable techniques for the definitive cytogenetic diagnosis of Fanconi anemia homozygosity.", "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020732", "http://www.disease-ontology.org/api/metadata/DOID:13636", "http://www.disease-ontology.org/api/metadata/DOID:1062"], "type": "summary", "id": "54eded8c94afd6150400000c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The in vitro enhancement of chromosome breakage by diepoxybutane (DEB) and mitomycin C (MMC) was studied in 24 Fanconi's anemia (FA) homozygotes and 28 heterozygotes. Both drugs were shown to enhance chromosome breakage significantly in the homozygotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 251, "offsetInEndSection": 390, "text": " In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 512, "text": "The diagnosis of Fanconi anemia was confirmed by increased chromosomal breakage abnormalities observed in cultured cells that were treated with cross-linking agents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22052692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "The in vitro enhancement of chromosome breakage by diepoxybutane (DEB) and mitomycin C (MMC) was studied in 24 Fanconi's anemia (FA) homozygotes and 28 heterozygotes. Both drugs were shown to enhance chromosome breakage significantly in the homozygotes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 392, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 396, "text": "The cytogenetic test was shown to be reliable in ascertaining the diagnosis of FA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8374893", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 396, "text": "The cytogenetic test was shown to be reliable in ascertaining the diagnosis of FA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8374893", "endSection": "abstract"}, {"offsetInBeginSection": 1867, "offsetInEndSection": 2038, "text": "For that purpose, the flow-based mitomycin C sensitivity test here described proved to be a reliable alternative method to evaluate Fanconi anemia phenotype in fibroblasts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19278965", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 396, "text": "The cytogenetic test was shown to be reliable in ascertaining the diagnosis of FA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8374893", "endSection": "abstract"}, {"offsetInBeginSection": 1867, "offsetInEndSection": 2038, "text": "For that purpose, the flow-based mitomycin C sensitivity test here described proved to be a reliable alternative method to evaluate Fanconi anemia phenotype in fibroblasts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19278965", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 396, "text": "The cytogenetic test was shown to be reliable in ascertaining the diagnosis of FA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8374893", "endSection": "abstract"}, {"offsetInBeginSection": 1867, "offsetInEndSection": 2038, "text": "For that purpose, the flow-based mitomycin C sensitivity test here described proved to be a reliable alternative method to evaluate Fanconi anemia phenotype in fibroblasts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19278965", "endSection": "abstract"}, {"offsetInBeginSection": 254, "offsetInEndSection": 391, "text": "In the great majority of cases, DEB and MMC stressing are reliable techniques for the definitive cytogenetic diagnosis of FA homozygosity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3133104", "endSection": "abstract"}, {"offsetInBeginSection": 315, "offsetInEndSection": 396, "text": "The cytogenetic test was shown to be reliable in ascertaining the diagnosis of FA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8374893", "endSection": "abstract"}]}, {"body": "Which gene is involved in CADASIL?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22664156", "http://www.ncbi.nlm.nih.gov/pubmed/22878905", "http://www.ncbi.nlm.nih.gov/pubmed/23308019", "http://www.ncbi.nlm.nih.gov/pubmed/21702048", "http://www.ncbi.nlm.nih.gov/pubmed/21038489", "http://www.ncbi.nlm.nih.gov/pubmed/19788051", "http://www.ncbi.nlm.nih.gov/pubmed/19539236", "http://www.ncbi.nlm.nih.gov/pubmed/19018300", "http://www.ncbi.nlm.nih.gov/pubmed/17622327", "http://www.ncbi.nlm.nih.gov/pubmed/19255248", "http://www.ncbi.nlm.nih.gov/pubmed/17996090", "http://www.ncbi.nlm.nih.gov/pubmed/17726918", "http://www.ncbi.nlm.nih.gov/pubmed/20224942", "http://www.ncbi.nlm.nih.gov/pubmed/18313300", "http://www.ncbi.nlm.nih.gov/pubmed/17854869"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945", "o": "UMLS_CUI:C0751587"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945", "o": "cadasil"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945", "o": "MSH2010_2010_02_22:D046589"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945", "o": "cadasil"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "C499374"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "Notch homolog 3 (Drosophila) protein, human"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "NOTCH3 protein, human"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400718"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400738"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "CADASIL protein, human"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "C499374"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "Notch homolog 3 (Drosophila) protein, human"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "NOTCH3 protein, human"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400718"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400738"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "CADASIL protein, human"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "C499374"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "Notch homolog 3 (Drosophila) protein, human"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "NOTCH3 protein, human"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400718"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400738"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "CADASIL protein, human"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "Notch homolog 3 (Drosophila) protein, human"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "NOTCH3 protein, human"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400718"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400738"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "CADASIL protein, human"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "Notch homolog 3 (Drosophila) protein, human"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "NOTCH3 protein, human"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400718"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400738"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "CADASIL protein, human"}, {"p": "http://www.w3.org/2004/02/skos/core#note", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "MeSH"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400738", "o": "Notch homolog 3 (Drosophila) protein, human"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8400718", "o": "NOTCH3 protein, human"}, {"p": "http://linkedlifedata.com/resource/umls/prefMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400718"}, {"p": "http://linkedlifedata.com/resource/umls/altMetaMap", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8407072"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1452875", "o": "http://linkedlifedata.com/resource/umls/label/A8400738"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A8407072", "o": "CADASIL protein, human"}], "ideal_answer": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common form of familial vascular dementia, is caused by mutations of the NOTCH3 gene.", "exact_answer": ["Notch3 gene"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046589", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011506", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015870", "http://www.disease-ontology.org/api/metadata/DOID:13945"], "type": "factoid", "id": "5323640b9b2d7acc7e000014", "snippets": [{"offsetInBeginSection": 71, "offsetInEndSection": 195, "text": "leukoencephalopathy (CADASIL), the most common form of familial vascular dementia, is caused by mutations of the NOTCH3 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664156", "endSection": "abstract"}, {"offsetInBeginSection": 301, "offsetInEndSection": 594, "text": "Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary disease caused by mutations of the Notch3 gene encoding the Notch3 protein. Notch3 is involved in the regulation of apoptosis, modulating Fas-Ligand (Fas-L)- induced apoptosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878905", "endSection": "abstract"}, {"offsetInBeginSection": 9, "offsetInEndSection": 189, "text": ": Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23308019", "endSection": "abstract"}, {"offsetInBeginSection": 263, "offsetInEndSection": 467, "text": "Mutations in Notch3 gene are linked to cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a disorder characterized by stroke and dementia in young adults", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21702048", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 252, "text": "(CADASIL) is caused by mutations in the NOTCH3 gene and is clinically characterized by recurrent stroke, cognitive decline, psychiatric disturbances and migraine", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21038489", "endSection": "abstract"}, {"offsetInBeginSection": 11, "offsetInEndSection": 298, "text": "To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19788051", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 616, "text": "NOTCH3 (Notch homolog 3), the gene involved in CADASIL, encodes a transmembrane receptor primarily expressed in systemic arterial smooth-muscle cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19539236", "endSection": "abstract"}, {"offsetInBeginSection": 91, "offsetInEndSection": 352, "text": "(CADASIL) is a vascular dementing disease caused by mutations in the NOTCH3 gene, most which are missense mutations leading to an uneven number of cysteine residues in epidermal growth factor-like repeats in the extracellular domain of Notch3 receptor (N3ECD). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17622327", "endSection": "abstract"}]}, {"body": "Describe the mechanism of action of drisapersen", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24321374", "http://www.ncbi.nlm.nih.gov/pubmed/24292388", "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "http://www.ncbi.nlm.nih.gov/pubmed/25209738", "http://www.ncbi.nlm.nih.gov/pubmed/24229740", "http://www.ncbi.nlm.nih.gov/pubmed/24620745"], "triples": [], "ideal_answer": ["Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. It has potential for treatment of Duchenne muscular dystrophy."], "concepts": [], "type": "summary", "id": "54fc98f16ad7dcbc12000003", "snippets": [{"offsetInBeginSection": 167, "offsetInEndSection": 319, "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "UNLABELLED: Chronic administration of drisapersen, a 2'-OMe phosphorothioate antisense oligonucleotide (AON) to mice and monkeys resulted in renal tubular accumulation, with secondary tubular degeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292388", "endSection": "abstract"}, {"offsetInBeginSection": 544, "offsetInEndSection": 646, "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 319, "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "UNLABELLED: Chronic administration of drisapersen, a 2'-OMe phosphorothioate antisense oligonucleotide (AON) to mice and monkeys resulted in renal tubular accumulation, with secondary tubular degeneration.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24292388", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 610, "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 317, "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374", "endSection": "abstract"}, {"offsetInBeginSection": 404, "offsetInEndSection": 664, "text": "Fast forward 25 years, and two phase 2b/3 trials have been carried out with agents designed to induce de novo dystrophin production in DMD patient's muscle; ataluren (stop codon read through) with 174 patients, and drisapersen (exon skipping) with 186 patients", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24229740", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 610, "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 610, "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "endSection": "abstract"}, {"offsetInBeginSection": 509, "offsetInEndSection": 610, "text": "Currently, the most promising potential drugs are the exon-skipping agents eteplirsen and drisapersen", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23995279", "endSection": "abstract"}, {"offsetInBeginSection": 167, "offsetInEndSection": 317, "text": "Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the reading frame of the mRNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321374", "endSection": "abstract"}]}, {"body": "How does thyroid hormone regulate mitochondrial biogenesis in the myocardium?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20100314", "http://www.ncbi.nlm.nih.gov/pubmed/17962579", "http://www.ncbi.nlm.nih.gov/pubmed/15543939", "http://www.ncbi.nlm.nih.gov/pubmed/15893763", "http://www.ncbi.nlm.nih.gov/pubmed/12734114", "http://www.ncbi.nlm.nih.gov/pubmed/12388124", "http://www.ncbi.nlm.nih.gov/pubmed/22109994", "http://www.ncbi.nlm.nih.gov/pubmed/21914860", "http://www.ncbi.nlm.nih.gov/pubmed/21568860", "http://www.ncbi.nlm.nih.gov/pubmed/20515651", "http://www.ncbi.nlm.nih.gov/pubmed/19462004", "http://www.ncbi.nlm.nih.gov/pubmed/19036942", "http://www.ncbi.nlm.nih.gov/pubmed/18575627", "http://www.ncbi.nlm.nih.gov/pubmed/7556180", "http://www.ncbi.nlm.nih.gov/pubmed/6157679", "http://www.ncbi.nlm.nih.gov/pubmed/2773621", "http://www.ncbi.nlm.nih.gov/pubmed/1321044", "http://www.ncbi.nlm.nih.gov/pubmed/215035"], "ideal_answer": ["T4 increases myocardial mitochondrial bioenergetic capacity, oxygen consumption and markers of mitochondrial biogenesis. The marked, parallel increases in PPARalpha levels suggest its potential involvement in mediating myocardial-specific remodeling of mitochondria in response to T4.  T3 induces mitochondrial biogenesis. In fact, T3 treatment for 72h  increases activity of respiratory complexes II, IV, V and citrate synthase (CS), levels of mitochondrial enzyme subunits (e.g. COXI, COXIV) and nuclear-encoded transcription factors, involved in mitochondrial biogenesis (e.g. PGC-1, mtTFA and PPAR-alpha).  Furthermore, L-T3 increases  the expression of factors involved in mitochondrial DNA transcription and biogenesis, such as hypoxic inducible factor-1\u03b1, mitochondrial transcription factor A and peroxisome proliferator activated receptor \u03b3 coactivator-1\u03b1, in the LV peri-infarct zone.\nThe activation of TFAM and TFB2M expression is shown to be required for the induction of mtDNA biogenesis by T3. Truncated forms of the nuclear receptor TR\u03b11, with molecular weights of 43 kDa (p43) and 28 Kda have been previously identified in mitochondria. P43 is a mitochondrial T3 receptor which stimulates mitochondrial transcription and protein synthesis in the presence of T3. p43 depletion in mice decreases mitochondrial DNA replication and respiratory chain activity."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008929", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070327", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0070324", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006590", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010861", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0046966", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008928", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0002154", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013974", "http://www.uniprot.org/uniprot/THB_SHEEP", "http://www.uniprot.org/uniprot/THB_CAIMO", "http://www.uniprot.org/uniprot/THB_CHICK", "http://www.uniprot.org/uniprot/THB_PAROL", "http://www.uniprot.org/uniprot/THBA_XENLA", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021", "http://www.uniprot.org/uniprot/THA_APTPA", "http://www.uniprot.org/uniprot/THAA_DANRE", "http://www.uniprot.org/uniprot/THA_SALSA", "http://www.uniprot.org/uniprot/THA_CAIMO", "http://www.biosemantics.org/jochem#4250045", "http://www.uniprot.org/uniprot/THB_RAT", "http://www.uniprot.org/uniprot/THB_DANRE", "http://www.uniprot.org/uniprot/THB_MOUSE", "http://www.uniprot.org/uniprot/THB_HUMAN", "http://www.uniprot.org/uniprot/THB_LITCT", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206"], "type": "summary", "id": "515ac941d24251bc050000ab", "snippets": [{"offsetInBeginSection": 1083, "offsetInEndSection": 1364, "text": "L-T3 significantly increased the expression of factors involved in mitochondrial DNA transcription and biogenesis, such as hypoxic inducible factor-1\u03b1, mitochondrial transcription factor A and peroxisome proliferator activated receptor \u03b3 coactivator-1\u03b1, in the LV peri-infarct zone", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100314", "endSection": "sections.0"}, {"offsetInBeginSection": 1692, "offsetInEndSection": 1918, "text": "the T(3)-induced phosphorylation of p38 and AMPK in both slow- and fast-twitch skeletal muscles suggests that these events may be important in mediating hormone-induced increases in mitochondrial biogenesis in skeletal muscle.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17962579", "endSection": "sections.0"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1498, "text": "Our findings indicate parallel increases in myocardial mitochondrial bioenergetic capacity, oxygen consumption and markers of mitochondrial biogenesis with 15-day T4", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15543939", "endSection": "sections.0"}, {"offsetInBeginSection": 1589, "offsetInEndSection": 1751, "text": "The marked, parallel increases in PPARalpha levels suggest its potential involvement in mediating myocardial-specific remodeling of mitochondria in response to T4", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15543939", "endSection": "sections.0"}, {"offsetInBeginSection": 1099, "offsetInEndSection": 1287, "text": "T3 mediates an early stimulation of enzymes containing mtDNA encoded subunits (e.g. complex IV and V) in contrast to a different regulatory pattern for the entirely nuclear-encoded enzymes", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15893763", "endSection": "sections.0"}, {"offsetInBeginSection": 386, "offsetInEndSection": 682, "text": "Activity of respiratory complexes II, IV, V and citrate synthase (CS), levels of mitochondrial enzyme subunits (e.g. COXI, COXIV) and nuclear-encoded transcription factors, involved in mitochondrial biogenesis (e.g. PGC-1, mtTFA and PPAR-alpha), were significantly elevated with 72 h T3 treatment", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15893763", "endSection": "sections.0"}, {"offsetInBeginSection": 1085, "offsetInEndSection": 1209, "text": "T(3) increased PGC-1alpha content similarly in both fast- and slow-twitch muscle, as well as in the liver, but not in heart.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734114", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 228, "text": "Thyroid hormone [3,5,3'-triiodo-l-thyronine (T(3))] induces phenotypic alterations in cardiac mitochondria, in part by influencing protein import and the expression of the import motor mitochondrial heat shock protein (mtHsp70).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388124", "endSection": "sections.0"}, {"offsetInBeginSection": 1259, "offsetInEndSection": 1436, "text": "These findings indicate that import machinery components are differentially regulated in response to stimuli that induce mitochondrial biogenesis, like T(3) and differentiation.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12388124", "endSection": "sections.0"}, {"offsetInBeginSection": 159, "offsetInEndSection": 422, "text": "We have previously identified a mitochondrial triiodothyronine receptor (p43) regulating mitochondrial transcription and mitochondrial biogenesis. When overexpressed in skeletal muscle, it increases mitochondrial DNA content, stimulates mitochondrial respiration,", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109994", "endSection": "sections.0"}, {"offsetInBeginSection": 548, "offsetInEndSection": 679, "text": "Here we show that a p43 depletion in mice decreases mitochondrial DNA replication and respiratory chain activity in skeletal muscle", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109994", "endSection": "sections.0"}, {"offsetInBeginSection": 692, "offsetInEndSection": 1147, "text": "The contribution of TFAM, TFB2M, and helicase Twinkle in thyroid-induced mtDNA biogenesis was assessed. The activation of TFAM and TFB2M expression is shown to be required for the induction of mtDNA biogenesis. The role of helicase Twinkle, the expression induction of which is also observed after triiodothyronine addition, remains unclear. The analysis of factors that activate TFAM and TFB2M expression showed that NRF-1 is the determinative regulator:", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21568860", "endSection": "sections.0"}, {"offsetInBeginSection": 558, "offsetInEndSection": 730, "text": "in rat cerebellum show that hypothyroidism causes reduction in expression of nuclear encoded genes controlling mitochondrial biogenesis like PGC-1alpha, NRF-1alpha and Tfam", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20515651", "endSection": "sections.0"}, {"offsetInBeginSection": 957, "offsetInEndSection": 1108, "text": "These results thus indicate an integrated nuclear-mitochondrial cross talk in regulation of mitochondrial transcription by TH during brain development.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20515651", "endSection": "sections.0"}, {"offsetInBeginSection": 1759, "offsetInEndSection": 1942, "text": "T(3) acts to reduce cellular oxidative stress, which may help attenuate ROS-mediated damage, along with improving mitochondrial function and energy status in cells with mtDNA defects.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19036942", "endSection": "sections.0"}, {"offsetInBeginSection": 1254, "offsetInEndSection": 1583, "text": "These findings suggest the existence of compensatory mechanisms operating at the translational and/or post-translational levels which promote proliferation of mitochondria in the hypothyroid liver. However, when the liver mass was considered, hypothyroidism significantly reduced overall mitochondrial proliferation in rat liver.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7556180", "endSection": "sections.0"}, {"offsetInBeginSection": 1333, "offsetInEndSection": 1595, "text": "Total liver mitochondrial DNA levels in thyroid-treated animals were greater than age-paired controls by 79% at 7 days but only 67% at 14 days since a small gain occurred in control animals and no further increase occurred in treated rats during the second week.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6157679", "endSection": "sections.0"}, {"offsetInBeginSection": 1809, "offsetInEndSection": 1917, "text": "thyroid hormone treatment produces hyperplasia and an increase in mitochondrial number and mass in rat liver", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6157679", "endSection": "sections.0"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1340, "text": "It is concluded that T3 exerts a direct, rather than permissive, effect on mitochondrial biogenesis, and that high affinity binding sites for GH are not present in rat liver mitochondria.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2773621", "endSection": "sections.0"}, {"offsetInBeginSection": 1024, "offsetInEndSection": 1248, "text": "These data strengthen the view that thyroid hormone regulates synthesis of specific components within each respiratory-chain complex and that these products apparently play key roles in inner-membrane biogenesis and assembly", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1321044", "endSection": "sections.0"}, {"offsetInBeginSection": 1053, "offsetInEndSection": 1312, "text": "It is concluded that thyroid hormone causes an increase in the mitochondrial mass, mitochondrial cytochrome content, and respiratory rate, and consequently expands the capacity of oxidative metabolism without an uncoupling effect on oxidative phosphorylation.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/215035", "endSection": "sections.0"}]}, {"body": "What is the catalytic mechanism of DNA (cytosine-5) methyltransferases? ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/3558369", "http://www.ncbi.nlm.nih.gov/pubmed/18567810", "http://www.ncbi.nlm.nih.gov/pubmed/12787669", "http://www.ncbi.nlm.nih.gov/pubmed/11087417", "http://www.ncbi.nlm.nih.gov/pubmed/7473738", "http://www.ncbi.nlm.nih.gov/pubmed/23528166", "http://www.ncbi.nlm.nih.gov/pubmed/16606828", "http://www.ncbi.nlm.nih.gov/pubmed/16472822", "http://www.ncbi.nlm.nih.gov/pubmed/8441637", "http://www.ncbi.nlm.nih.gov/pubmed/21163962", "http://www.ncbi.nlm.nih.gov/pubmed/16926025", "http://www.ncbi.nlm.nih.gov/pubmed/16681387", "http://www.ncbi.nlm.nih.gov/pubmed/9925782", "http://www.ncbi.nlm.nih.gov/pubmed/9576871", "http://www.ncbi.nlm.nih.gov/pubmed/9207015", "http://www.ncbi.nlm.nih.gov/pubmed/8772199", "http://www.ncbi.nlm.nih.gov/pubmed/8441638", "http://www.ncbi.nlm.nih.gov/pubmed/1598200", "http://www.ncbi.nlm.nih.gov/pubmed/6884360"], "triples": [{"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_413849585033007", "o": "Cytosine-C5 specific DNA methyltransferase"}], "ideal_answer": ["The catalytic mechanism of the DNA (Cytosine-5-)-methyltransferase involves nucleophilic attack of the C6 of the substrate cytosine by the single conserved cysteine of the enzyme, followed by C5 nucleophilic replacement of the methyl group of the cofactor S-adenosyl-L-methionine (AdoMet) to produce 5-methyl-6-Cys-81-S-5,6-dihydrocytosine. It has been also demonstrated that Phe and Glu, which are found in the catalytic motifs I and II of the enzyme are important for AdoMet binding and catalysis."], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0009008", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0003886", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004248", "http://www.uniprot.org/uniprot/DCM_ECOLI", "http://www.uniprot.org/uniprot/CMT1_DICDI", "http://www.uniprot.org/uniprot/DCM_ECO57", "http://www.uniprot.org/uniprot/DNMT_FRG3G", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0051719", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0051720"], "type": "summary", "id": "515da5b5298dcd4e5100000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine. It has been proposed that this cysteine initiates catalysis by attacking the C6 of cytosine and thereby activating the normally inert C5 position.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8441637", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Kinetic and catalytic mechanism of HhaI methyltransferase.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3558369", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 383, "text": "Kinetic and catalytic properties of the DNA (cytosine-5)-methyltransferase HhaI are described. With poly(dG-dC) as substrate, the reaction proceeds by an equilibrium (or processive) ordered Bi-Bi mechanism in which DNA binds to the enzyme first, followed by S-adenosylmethionine (AdoMet). After methyl transfer, S-adenosylhomocysteine (AdoHcy) dissociates followed by methylated DNA.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3558369", "endSection": "sections.0"}, {"offsetInBeginSection": 1062, "offsetInEndSection": 1268, "text": "Our studies reveal that the catalytic mechanism of DNA (cytosine-5)-methyltransferases involves attack of the C6 of substrate cytosines by an enzyme nucleophile and formation of a transient covalent adduct.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3558369", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", "endSection": "title"}, {"offsetInBeginSection": 1116, "offsetInEndSection": 1348, "text": "We propose that correct positioning of the flipped base and the cofactor and binding to the transition state of methyl group transfer are the most important roles of the Dnmt3a enzyme in the catalytic cycle of methyl group transfer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 367, "text": "Co-transfections of reporter plasmids and plasmids encoding the catalytic domain of the murine Dnmt3a DNA methyltransferase lead to inhibition of reporter gene expression. As Dnmt3a mutants with C-->A and E-->A exchanges in the conserved PCQ and ENV motifs in the catalytic center of the enzyme also cause repression, we checked for their catalytic activity in vitro.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", "endSection": "sections.0"}, {"offsetInBeginSection": 536, "offsetInEndSection": 730, "text": "In contrast, enzyme variants carrying E-->A, E-->D or E-->Q exchanges of the ENV glutamate are catalytically almost inactive, demonstrating that this residue has a central function in catalysis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", "endSection": "sections.0"}, {"offsetInBeginSection": 1024, "offsetInEndSection": 1348, "text": "Therefore, covalent complex formation is not essential in the reaction mechanism of Dnmt3a. We propose that correct positioning of the flipped base and the cofactor and binding to the transition state of methyl group transfer are the most important roles of the Dnmt3a enzyme in the catalytic cycle of methyl group transfer.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12787669", "endSection": "sections.0"}, {"offsetInBeginSection": 1331, "offsetInEndSection": 1482, "text": "Our results point to a possible connection between the catalytic mechanism of C5 Mtases and of enzymes that transfer methyl groups to N(4) of cytosine.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11087417", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 230, "text": "Previous X-ray crystallographic studies have revealed that the catalytic domain of a DNA methyltransferase (Mtase) generating C5-methylcytosine bears a striking structural similarity to that of a Mtase generating N6-methyladenine.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7473738", "endSection": "sections.0"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1228, "text": "Spontaneous and reversible proton transfer between a conserved Glu in the active site and cytosine N3 at the transition state was observed in our simulations, revealing the chemical participation of this Glu residue in the catalytic mechanism.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528166", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 301, "text": "The mechanism of DNA cytosine-5-methylation catalyzed by the bacterial M.HhaI enzyme has been considered as a stepwise nucleophilic addition of Cys-81-S- to cytosine C6 followed by C5 nucleophilic replacement of the methyl of S-adenosyl-L-methionine to produce 5-methyl-6-Cys-81-S-5,6-dihydrocytosine.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606828", "endSection": "sections.0"}, {"offsetInBeginSection": 797, "offsetInEndSection": 893, "text": "Hydroxide at 10(-7) mole fraction (pH = 7) is shown to be sufficient for the required catalysis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606828", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "On the basis of amino acid sequence alignments and structural data of related enzymes, we have performed a mutational analysis of 14 amino acid residues in the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", "endSection": "sections.0"}, {"offsetInBeginSection": 616, "offsetInEndSection": 938, "text": "We demonstrate that Phe50 (motif I) and Glu74 (motif II) are important for AdoMet binding and catalysis. D96A (motif III) showed reduced AdoMet binding but increased activity under conditions of saturation with S-adenosyl-L-methionine (AdoMet), indicating that the contact of Asp96 to AdoMet is not required for catalysis.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", "endSection": "sections.0"}, {"offsetInBeginSection": 1077, "offsetInEndSection": 1268, "text": "R130A displayed a strong reduction in catalytic activity and a complete change in flanking sequence preferences, indicating that Arg130 has an important role in the DNA interaction of Dnmt3a.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", "endSection": "sections.0"}, {"offsetInBeginSection": 1546, "offsetInEndSection": 1840, "text": "While Asn167 might contribute to the positioning of residues from motif VI, according to structural data Arg202 has a role in catalysis of cytosine-C5 methyltransferases. The R295A variant was catalytically inactive most likely because of destabilization of the hinge sub-domain of the protein.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16472822", "endSection": "sections.0"}, {"offsetInBeginSection": 467, "offsetInEndSection": 603, "text": "These two methyltransferases recognize CpG and GCGC sequences, respectively, and transfer a methyl group to the C5 atom of cytosine (C).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16681387", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Most prokaryotic (cytosine-5)-DNA methyltransferases increase the frequency of deamination at the cytosine targeted for methylation in vitro in the absence of the cofactor S-adenosylmethionine (AdoMet) or the reaction product S-adenosylhomocysteine (AdoHcy).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9576871", "endSection": "sections.0"}, {"offsetInBeginSection": 642, "offsetInEndSection": 844, "text": "The target (methylatable) cytosine, if flipped out of the double helical DNA as seen for DNA methyltransferases that generate 5-methylcytosine, would fit into the concave active site next to the AdoMet.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9207015", "endSection": "sections.0"}, {"offsetInBeginSection": 244, "offsetInEndSection": 462, "text": "These methylation patterns are established and maintained by DNA cytosine-5 methyltransferase (MTase), a approximately 1500 amino acid enzyme containing a regulatory N-terminal domain and a catalytic C-terminal domain.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8772199", "endSection": "sections.0"}, {"offsetInBeginSection": 485, "offsetInEndSection": 749, "text": "These results lend strong support to a catalytic mechanism in which an enzyme sulfhydryl group undergoes Michael addition to the C5-C6 double bond, thus activating position C-5 of the substrate DNA cytosine residue for electrophilic attack by the methyl donor SAM.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8441638", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 308, "text": "2'-Deoxyoligonucleotides with 5-fluorocytosine residues incorporated at specific positions of the nucleotide sequence are tools of great potential in the study of the catalytic mechanism by which DNA cytosine methyltransferases methylate the 5-position of DNA cytosine residues in specific sequence contexts.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1598200", "endSection": "sections.0"}, {"offsetInBeginSection": 79, "offsetInEndSection": 201, "text": "The enzyme has Mr 130 000, and introduces methyl groups from S-adenosylmethionine into the 5 position of cytosines in DNA.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6884360", "endSection": "sections.0"}]}, {"body": "What is the role of music therapy in coma patients.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25287735", "http://www.ncbi.nlm.nih.gov/pubmed/25071434", "http://www.ncbi.nlm.nih.gov/pubmed/23816631", "http://www.ncbi.nlm.nih.gov/pubmed/12046234", "http://www.ncbi.nlm.nih.gov/pubmed/7513085", "http://www.ncbi.nlm.nih.gov/pubmed/20663643"], "triples": [], "ideal_answer": ["Several studies have shown that music can boost cognitive functions in patients with a disorder of consciousness but it is difficult to conclude since they did not use quantified measures and a control condition/group. Active improvised music therapy may offer an adjuvant form of treatment in the early rehabilitation of severe brain-injured patients."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009147", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003128"], "type": "summary", "id": "56bf5b0cef6e394741000014", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "[Beneficial effect of preferred music on cognitive functions in minimally conscious state patients].", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287735", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 315, "text": "Several studies have shown that music can boost cognitive functions in normal and brain-damaged subjects. A few studies have suggested a beneficial effect of music in patients with a disorder of consciousness but it is difficult to conclude since they did not use quantified measures and a control condition/group. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287735", "endSection": "abstract"}, {"offsetInBeginSection": 964, "offsetInEndSection": 1082, "text": ". This new protocol suggests that preferred music has a beneficial effect on the cognitive abilities of MCS patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287735", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "This review presents an overview of the use of music therapy in neurological early rehabilitation of patients with coma and other disorders of consciousness (DOC) such as unresponsive wakefulness syndrome (UWS) or minimally conscious state (MCS). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071434", "endSection": "abstract"}, {"offsetInBeginSection": 578, "offsetInEndSection": 789, "text": "The programs' content consisted of recreation and communication options, which involved activating music, videos, and basic requests, sending and receiving (listening to) text messages, and placing phone calls. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23816631", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Active music therapy in the rehabilitation of severe brain injured patients during coma recovery.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12046234", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Active improvised music therapy may offer an adjuvant from of treatment in the early rehabilitation of severe brain-injured patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12046234", "endSection": "abstract"}, {"offsetInBeginSection": 564, "offsetInEndSection": 791, "text": "Our preliminary results show a significant improvement of the collaboration of the severe brain-injured patients and a reduction of undesired behaviours such as inertia (reduced psychomotor initiative) or psychomotor agitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12046234", "endSection": "abstract"}, {"offsetInBeginSection": 416, "offsetInEndSection": 654, "text": "Hence, it is possible for music therapy to both establish contact with the seemingly non-responsive patient and re-stimulate the person's fundamental communication competencies and experience at the emotional, social and cognitive levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7513085", "endSection": "abstract"}, {"offsetInBeginSection": 467, "offsetInEndSection": 549, "text": "Six studies focused on the provision of multisensory stimulation or music therapy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20663643", "endSection": "abstract"}]}, {"body": "What is the sedimentation coefficient of the mammalian mitoribosome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11943462", "http://www.ncbi.nlm.nih.gov/pubmed/11402041", "http://www.ncbi.nlm.nih.gov/pubmed/6284743", "http://www.ncbi.nlm.nih.gov/pubmed/19567276", "http://www.ncbi.nlm.nih.gov/pubmed/15966747", "http://www.ncbi.nlm.nih.gov/pubmed/14757048"], "triples": [], "ideal_answer": ["The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S, consisting of 39 S large and 28 S small subunits."], "exact_answer": [["55 S"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012270", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005840", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005761", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005762", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0003735"], "type": "factoid", "id": "55201a316b348bb82c000019", "snippets": [{"offsetInBeginSection": 75, "offsetInEndSection": 119, "text": " The mammalian mitochondrial ribosomes (55S)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11943462", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 187, "text": "The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S, consisting of 39 S large and 28 S small subunits.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11402041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "The 55 S mammalian mitochondrial ribosome (referred to hereafter as \"mitoribosome\") is protein-rich, containing nearly twice as much protein as the Escherichia coli ribosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6284743", "endSection": "abstract"}, {"offsetInBeginSection": 751, "offsetInEndSection": 860, "text": "59 of 78 proteins of the 55S mitoribosome, several TIM and TOM proteins and cell death proteins were present.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19567276", "endSection": "abstract"}, {"offsetInBeginSection": 275, "offsetInEndSection": 344, "text": "The sedimentation coefficient of the intact monosome was about 55 S. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15966747", "endSection": "abstract"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1024, "text": "Though the nematode mitoribosome has a larger size than the bacterial ribosome, it does not differ significantly in size from mammalian mitoribosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15966747", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "The mammalian mitochondrial (mt) ribosome (mitoribosome) is a bacterial-type ribosome but has a highly protein-rich composition.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14757048", "endSection": "abstract"}]}, {"body": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25870109"], "triples": [], "ideal_answer": ["TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis."], "exact_answer": [["Control of Mouse Erythropoiesis"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050982", "http://www.uniprot.org/uniprot/TAF10_HUMAN", "http://www.uniprot.org/uniprot/TAF10_ARATH", "http://www.uniprot.org/uniprot/TAF10_YEAST", "http://www.uniprot.org/uniprot/GATA1_ARATH", "http://www.uniprot.org/uniprot/GATA1_HUMAN", "http://www.uniprot.org/uniprot/GATA1_CHICK", "http://www.uniprot.org/uniprot/GAT1A_XENLA"], "type": "factoid", "id": "56a8b8b5a17756b72f000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 1110, "offsetInEndSection": 1235, "text": "we show that TAF10 interacts directly with GATA1 and that TAF10 is enriched on the GATA1 locus in human fetal erythroid cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25870109", "endSection": "title"}]}, {"body": "Which domain allowing self-association do exist in TDP-43 and FUS proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24842888", "http://www.ncbi.nlm.nih.gov/pubmed/25002999", "http://www.ncbi.nlm.nih.gov/pubmed/22445064", "http://www.ncbi.nlm.nih.gov/pubmed/22065782", "http://www.ncbi.nlm.nih.gov/pubmed/20356930", "http://www.ncbi.nlm.nih.gov/pubmed/22454397", "http://www.ncbi.nlm.nih.gov/pubmed/23629963", "http://www.ncbi.nlm.nih.gov/pubmed/21844169", "http://www.ncbi.nlm.nih.gov/pubmed/10521526", "http://www.ncbi.nlm.nih.gov/pubmed/24920338", "http://www.ncbi.nlm.nih.gov/pubmed/24262168", "http://www.ncbi.nlm.nih.gov/pubmed/22563080", "http://www.ncbi.nlm.nih.gov/pubmed/21327870", "http://www.ncbi.nlm.nih.gov/pubmed/20720006"], "triples": [], "ideal_answer": ["Two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion proteins.", "Mutations in related RNA-binding proteins TDP-43, FUS/TLS and TAF15 have been connected to ALS. These three proteins share several features, including the presence of a bioinformatics-predicted prion domain, aggregation-prone nature in vitro and in vivo and toxic effects when expressed in multiple model systems. TDP-43, FUS and TAF15 share similar properties, including aggregation-prone behavior in vitro and ability to confer neurodegeneration in Drosophila. For TDP-43, both the RRM1 and the C-terminal glycine-rich domain are required for SG localization. Moreover, two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion protein", "Two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion proteins.", "Scouring the human genome with this algorithm enriches a select group of RNA-binding proteins harboring a canonical RNA recognition motif (RRM) and a putative prion domain. Moreover, two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion proteins. PrLDs are over-represented in human RNA-binding proteins and mediate phase transitions underpinning RNP granule assembly. For example, TDP-43 and FUS form cytoplasmic inclusions in amyotrophic lateral sclerosis (ALS) and mutations in TDP-43 and FUS can cause ALS.", "PRION PROTEINS"], "exact_answer": [["Prion-like domain"]], "concepts": ["http://www.uniprot.org/uniprot/TADBP_MOUSE", "http://www.uniprot.org/uniprot/TADBP_XENTR", "http://www.uniprot.org/uniprot/TADBP_HUMAN", "http://www.uniprot.org/uniprot/TADBP_PONAB", "http://www.uniprot.org/uniprot/TADBP_CHICK", "http://www.uniprot.org/uniprot/FUS_HUMAN", "http://www.uniprot.org/uniprot/FUS_BOVIN", "http://www.uniprot.org/uniprot/FUS_MOUSE", "http://amigo.geneontology.org/amigo/term/GO:0043621", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054730"], "type": "factoid", "id": "56c83f365795f9a73e000011", "snippets": [{"offsetInBeginSection": 288, "offsetInEndSection": 873, "text": "Using transient expression of a panel of deletion and chimeric FUS variants in various cultured cells, we demonstrated that FUS accumulating in the cytoplasm nucleates a novel type of RNA granules, FUS granules (FGs), that are structurally similar but not identical to physiological RNA transport granules. Formation of FGs requires FUS N-terminal prion-like domain and the ability to bind specific RNAs. Clustering of FGs coupled with further recruitment of RNA and proteins produce larger structures, FUS aggregates (FAs), that resemble but are clearly distinct from stress granules.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24842888", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 620, "text": "Approximately 1% of human proteins harbor a prion-like domain (PrLD) of similar low complexity sequence and amino acid composition to domains that drive prionogenesis of yeast proteins like Sup35. PrLDs are over-represented in human RNA-binding proteins and mediate phase transitions underpinning RNP granule assembly. This modality renders PrLDs prone to misfold into conformers that accrue in pathological inclusions that characterize various fatal neurodegenerative diseases. For example, TDP-43 and FUS form cytoplasmic inclusions in amyotrophic lateral sclerosis (ALS) and mutations in TDP-43 and FUS can cause ALS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25002999", "endSection": "abstract"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1534, "text": "FUS and TDP-43, which rank 1st and 10th among RRM-bearing prion candidates, form cytoplasmic inclusions in the degenerating motor neurons of ALS patients and mutations in TDP-43 and FUS cause familial ALS. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22445064", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "Amyotrophic lateral sclerosis (ALS) is a devastating and universally fatal neurodegenerative disease. Mutations in two related RNA-binding proteins, TDP-43 and FUS, that harbor prion-like domains, cause some forms of ALS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22065782", "endSection": "abstract"}, {"offsetInBeginSection": 601, "offsetInEndSection": 790, "text": "two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion proteins.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930", "endSection": "abstract"}, {"offsetInBeginSection": 98, "offsetInEndSection": 411, "text": "Mutations in related RNA-binding proteins TDP-43, FUS/TLS and TAF15 have been connected to ALS. These three proteins share several features, including the presence of a bioinformatics-predicted prion domain, aggregation-prone nature in vitro and in vivo and toxic effects when expressed in multiple model systems.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454397", "endSection": "abstract"}, {"offsetInBeginSection": 591, "offsetInEndSection": 789, "text": "Moreover, two RNA-binding proteins, FUS and TDP-43, which form cytoplasmic aggregates in amyotrophic lateral sclerosis, harbor a 'prion domain' similar to those found in several yeast prion proteins", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20356930", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 440, "text": "TDP-43 and FUS and several related RNA-binding proteins harbor aggregation-promoting prion-like domains that allow them to rapidly self-associate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 440, "text": "TDP-43 and FUS and several related RNA-binding proteins harbor aggregation-promoting prion-like domains that allow them to rapidly self-associate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 440, "text": "TDP-43 and FUS and several related RNA-binding proteins harbor aggregation-promoting prion-like domains that allow them to rapidly self-associate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 440, "text": "TDP-43 and FUS and several related RNA-binding proteins harbor aggregation-promoting prion-like domains that allow them to rapidly self-associate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963", "endSection": "abstract"}, {"offsetInBeginSection": 294, "offsetInEndSection": 440, "text": "TDP-43 and FUS and several related RNA-binding proteins harbor aggregation-promoting prion-like domains that allow them to rapidly self-associate.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629963", "endSection": "abstract"}, {"offsetInBeginSection": 486, "offsetInEndSection": 705, "text": "Molecular cloning of subunit 4 of the complex revealed that it is a proteasome-COP9 complex-eIF3 domain protein encoded by a gene that maps to chromosome 5, near the chromosomal location of the cop8 and fus4 mutations. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10521526", "endSection": "abstract"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1328, "text": "Deletions in the C-terminal domain of TDP-43 that preclude interactions with hnRNP A2/B1 abolish TDP-43-dependent rescue of CGG repeat toxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24920338", "endSection": "abstract"}, {"offsetInBeginSection": 745, "offsetInEndSection": 897, "text": "The rescue appears specific to TDP-43, as co-expression of another ALS-associated RNA-binding protein, FUS, exacerbates the toxic effects of CGG repeats", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24920338", "endSection": "abstract"}, {"offsetInBeginSection": 209, "offsetInEndSection": 455, "text": "Recently, through Next-Generation Exome sequencing approaches a mutation resulting in a substitution (p.Q290X) in the nuclear export domain of the FUS protein was nominated as a cause of autosomal dominant essential tremor (ET) in a large kindred", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24262168", "endSection": "abstract"}, {"offsetInBeginSection": 547, "offsetInEndSection": 602, "text": "TDP-43 is another RNA-binding protein implicated in ALS", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24262168", "endSection": "abstract"}, {"offsetInBeginSection": 947, "offsetInEndSection": 1183, "text": "We also provide multiple independent lines of in vitro and in vivo evidence that EWSR1 has similar properties as TDP-43, FUS and TAF15, including aggregation-prone behavior in vitro and ability to confer neurodegeneration in Drosophila.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22454397", "endSection": "abstract"}, {"offsetInBeginSection": 876, "offsetInEndSection": 974, "text": "For TDP-43, both the RRM1 and the C-terminal glycine-rich domain are required for SG localization.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22563080", "endSection": "abstract"}, {"offsetInBeginSection": 1628, "offsetInEndSection": 1733, "text": "Furthermore, TDP-43 and FUS display distinct domain requirements in aggregate formation and cytotoxicity.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21327870", "endSection": "abstract"}, {"offsetInBeginSection": 672, "offsetInEndSection": 878, "text": "Binding was mediated by an unstructured TDP-43 C-terminal domain and occurred within the context of a 300-400-kDa complex that also contained C-terminal cleavage products of TDP-43 linked to neuropathology.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720006", "endSection": "abstract"}, {"offsetInBeginSection": 121, "offsetInEndSection": 330, "text": "It was recently found that dominant mutations in two related RNA-binding proteins, TDP-43 (43-kDa TAR DNA-binding domain protein) and FUS/TLS (fused in sarcoma/translated in liposarcoma) cause a subset of ALS.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20720006", "endSection": "abstract"}]}, {"body": "What is the role of the RUNX1-MYEF2 complex?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22801375"], "triples": [], "ideal_answer": ["A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells."], "exact_answer": [["The repression of hematopoietic genes in erythroid cells."]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D041905", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006412", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015672"], "type": "factoid", "id": "56ae70050a360a5e4500000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1086, "text": "Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1087, "text": "Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 997, "text": "Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and microarray expression analysis were used to show that RUNX1 binds approximately 9,000 target sites in erythroid cells and is primarily active in the undifferentiated state. Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1087, "text": "Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 997, "text": "Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and microarray expression analysis were used to show that RUNX1 binds approximately 9,000 target sites in erythroid cells and is primarily active in the undifferentiated state. Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1087, "text": "Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 997, "text": "Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and microarray expression analysis were used to show that RUNX1 binds approximately 9,000 target sites in erythroid cells and is primarily active in the undifferentiated state. Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1087, "text": "Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 997, "text": "Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and microarray expression analysis were used to show that RUNX1 binds approximately 9,000 target sites in erythroid cells and is primarily active in the undifferentiated state. Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "title"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1087, "text": "Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knockdown of Myef2 expression in developing zebrafish results in a reduced number of HSC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}, {"offsetInBeginSection": 634, "offsetInEndSection": 997, "text": "Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and microarray expression analysis were used to show that RUNX1 binds approximately 9,000 target sites in erythroid cells and is primarily active in the undifferentiated state. Functional analysis shows that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22801375", "endSection": "abstract"}]}, {"body": "What is the average diameter of intermediate filaments?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2264817", "http://www.ncbi.nlm.nih.gov/pubmed/22848616", "http://www.ncbi.nlm.nih.gov/pubmed/22126386", "http://www.ncbi.nlm.nih.gov/pubmed/19656809", "http://www.ncbi.nlm.nih.gov/pubmed/21669844", "http://www.ncbi.nlm.nih.gov/pubmed/19559031", "http://www.ncbi.nlm.nih.gov/pubmed/18726512", "http://www.ncbi.nlm.nih.gov/pubmed/18523546", "http://www.ncbi.nlm.nih.gov/pubmed/17289402", "http://www.ncbi.nlm.nih.gov/pubmed/16458019", "http://www.ncbi.nlm.nih.gov/pubmed/15373777"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A0059267", "o": "Filaments, Intermediate"}], "ideal_answer": ["Intermediate filaments have an average diameter of 10 nanometers (nm)."], "exact_answer": ["10 nanometers", "10 nm"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007382"], "type": "factoid", "id": "515db3d8298dcd4e51000015", "snippets": [{"offsetInBeginSection": 553, "offsetInEndSection": 801, "text": "Negative staining showed that supernatants from the centrifugation assays contained protofilaments, protofibrils and short particles (less than 300 nm), but pellets contained long filaments (greater than 1 micron) with an average diameter of 10 nm.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2264817", "endSection": "sections.0"}, {"offsetInBeginSection": 1072, "offsetInEndSection": 1197, "text": "Ultrastructurally, rhabdoid cells showed paranuclear aggregates and whorls of intermediate filaments with a 9-10 nm diameter.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22126386", "endSection": "sections.0"}, {"offsetInBeginSection": 437, "offsetInEndSection": 650, "text": "After removing IFs by calcination, electron microscopy revealed hollow silica nanotubes several micrometers long, with outer diameters of 35-55 nm and an average inner diameter of 10 nm (comparable to that of IFs)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19656809", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "Intermediate filaments are filaments 10\u2009nm in diameter that make up an important component of the cytoskeleton in most metazoan taxa.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21669844", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 259, "text": "Neurofilaments (NFs) are essential cytoskeletal filaments that impart mechanical integrity to nerve cells. They are assembled from three distinct molecular mass proteins that bind to each other to form a 10-nm-diameter filamentous rod with sidearm extensions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19559031", "endSection": "sections.0"}, {"offsetInBeginSection": 108, "offsetInEndSection": 312, "text": "Scanning tunneling microscope (STM) and transmission electron microscope (TEM) micrographs showed that acidic keratins and basic keratins can assemble into dimers and further into 10 nm filamentsin vitro.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18726512", "endSection": "sections.0"}, {"offsetInBeginSection": 151, "offsetInEndSection": 289, "text": "Intermediate in diameter between microtubules and microfilaments, IFs constitute the third cytoskeletal filament system of metazoan cells.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17289402", "endSection": "sections.0"}, {"offsetInBeginSection": 613, "offsetInEndSection": 720, "text": "Just above the bulb, the filaments are characterized by a diameter of 100 Angstroms and a low-density core.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16458019", "endSection": "sections.0"}, {"offsetInBeginSection": 1656, "offsetInEndSection": 2023, "text": "Further, using cryo-transmission electron microscopy on native, fully hydrated, vitreous epidermis we show that the subfilametous keratin electron density pattern consists, both in corneocytes and in viable keratinocytes, of one axial subfilament surrounded by an undetermined number of peripheral subfilaments forming filaments with a diameter of approximately 8 nm.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15373777", "endSection": "sections.0"}]}, {"body": "Which pituitary adenoma is common cause of infertility is women?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23090264", "http://www.ncbi.nlm.nih.gov/pubmed/12477530", "http://www.ncbi.nlm.nih.gov/pubmed/10649815", "http://www.ncbi.nlm.nih.gov/pubmed/10649814", "http://www.ncbi.nlm.nih.gov/pubmed/9152623", "http://www.ncbi.nlm.nih.gov/pubmed/2738821", "http://www.ncbi.nlm.nih.gov/pubmed/2803131", "http://www.ncbi.nlm.nih.gov/pubmed/2520800", "http://www.ncbi.nlm.nih.gov/pubmed/6868876", "http://www.ncbi.nlm.nih.gov/pubmed/6788711"], "ideal_answer": ["Prolactinoma is a pituitary adenoma that is strongly associated with infertility in women mainly due to increased prolactin secretion causing hyperprolactinemia. Other pituitary lesions can also be associated with infertility."], "exact_answer": ["prolactinoma"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010911", "http://www.disease-ontology.org/api/metadata/DOID:3829", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007246", "http://www.disease-ontology.org/api/metadata/DOID:5223", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014930", "http://www.disease-ontology.org/api/metadata/DOID:5395", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007247", "http://www.disease-ontology.org/api/metadata/DOID:5394", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015175"], "type": "factoid", "id": "514a51c2d24251bc0500005c", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "Prolactinoma is the most common secreting pituitary adenoma. It is typically diagnosed in women of reproductive age and is common cause of infertility.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090264", "endSection": "sections.0"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1308, "text": "Examination of the tissue excised by transsphenoidal excision of the mass showed a pituitary adenoma that stained strongly for FSH. RESULTS: Regular menses resumed soon after excision of the gonadotroph adenoma, followed by a spontaneous pregnancy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12477530", "endSection": "sections.0"}, {"offsetInBeginSection": 1309, "offsetInEndSection": 1529, "text": "CONCLUSIONS: Gonadotroph adenoma should be suspected in a reproductive age woman with oligomenorrhea or amenorrhea, infertility, multiple preovulatory follicles, and a persistently elevated serum estradiol concentration.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12477530", "endSection": "sections.0"}, {"offsetInBeginSection": 199, "offsetInEndSection": 614, "text": "Hyperprolactinemia is the most common endocrine disorder of the hypothalamic-pituitary axis, occurring mostly in women and presenting most commonly with amenorrhea and galactorrhea. Causes of hyperprolactinemia include physiologic, pharmacologic and pathologic factors; pituitary adenoma is a common pathologic cause. Women may present with decreased libido, infertility, oligomenorrhea/amenorrhea and galactorrhea.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10649815", "endSection": "sections.0"}, {"offsetInBeginSection": 443, "offsetInEndSection": 788, "text": "When specific treatable underlying causes have been eliminated and in cases of severe hyperprolactinemia, the most likely cause is a prolactin (PRL)-secreting pituitary adenoma. Microadenomas should be treated medically, with a dopamine agonist, if there is an indication for therapy (such as amenorrhea, infertility or bothersome galactorrhea).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10649814", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Pregnancy in a woman with active acromegaly is very rare, because amenorrhea, due to hyperprolactinemia and disturbed pituitary gonadotropin secretion may cause infertility.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9152623", "endSection": "sections.0"}, {"offsetInBeginSection": 943, "offsetInEndSection": 1318, "text": "Of the remaining six patients who had been investigated for infertility, no demonstrable cause of infertility was found in three. Of the other three patients, one showed evidence of bilateral tubal occlusion secondary to pelvic inflammatory disease, one has had a right ectopic pregnancy followed by two abortions, and the third patient was found to have a pituitary adenoma.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2738821", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Results in 136 hyperprolactinaemic women who presented with infertility, amenorrhoea, menstrual irregularities and/or galactorrhoea are reported. There was radiographic evidence of pituitary microadenoma in 21 (15.4%) patients and 5 (3.7%) had macroadenoma.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2803131", "endSection": "sections.0"}, {"offsetInBeginSection": 474, "offsetInEndSection": 778, "text": "Patients with pituitary adenoma had a significantly higher (p less than 0.001) baseline serum prolactin level (182 +/- 4.6 ng/ml) than those with no adenoma (59.2 +/- 4.2 ng/ml). All patients in the study were treated with bromocriptine (2.5-10 mg) to normalize serum prolactin or to achieve a pregnancy.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2803131", "endSection": "sections.0"}, {"offsetInBeginSection": 1349, "offsetInEndSection": 1462, "text": "There was no significant difference in the pregnancy rate between the patients with or without pituitary adenoma.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2803131", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "Two hyperprolactinemic infertile women, one with and one without a pituitary adenoma, who were resistant to bromocriptine treatment, were treated orally with Hachimijiogan, a Chinese herbal medicine.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2520800", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Infertility caused by hyperprolactinemic amenorrhea may be complicated by pituitary adenoma.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6868876", "endSection": "sections.0"}]}, {"body": "What is a mitochondrial nucleoid?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23721879", "http://www.ncbi.nlm.nih.gov/pubmed/23637282", "http://www.ncbi.nlm.nih.gov/pubmed/23220174", "http://www.ncbi.nlm.nih.gov/pubmed/20577028", "http://www.ncbi.nlm.nih.gov/pubmed/19704786", "http://www.ncbi.nlm.nih.gov/pubmed/19703654", "http://www.ncbi.nlm.nih.gov/pubmed/15126284"], "triples": [], "ideal_answer": ["A naked mtDNA molecule is longer than a typical mitochondrion and is therefore compacted in vivo to form a nucleoprotein complex, denoted the mitochondrial nucleoid."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024101", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042645", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090144", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0009295", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090143"], "type": "summary", "id": "552016a36b348bb82c000018", "snippets": [{"offsetInBeginSection": 208, "offsetInEndSection": 373, "text": "A naked mtDNA molecule is longer than a typical mitochondrion and is therefore compacted in vivo to form a nucleoprotein complex, denoted the mitochondrial nucleoid.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23721879", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "The packaging of mitochondrial DNA (mtDNA) into DNA-protein assemblies called nucleoids provides an efficient segregating unit of mtDNA,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637282", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Mitochondrial DNA (mtDNA) is organized in nucleoids in complex with accessory proteins, proteins of mtDNA replication and gene expression machinery.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23220174", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "The independent mitochondrial genetic information is organized in so-called mitochondrial nucleoids", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20577028", "endSection": "abstract"}, {"offsetInBeginSection": 32, "offsetInEndSection": 179, "text": " packaging of mitochondrial DNA (mtDNA) into protein-DNA assemblies called nucleoids confers higher-order organization to the mitochondrial genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19704786", "endSection": "abstract"}, {"offsetInBeginSection": 264, "offsetInEndSection": 420, "text": "mitochondrial DNA is packaged into macromolecular assemblies called nucleoids, composed of one or more copies of mitochondrial DNA and associated proteins. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19703654", "endSection": "abstract"}, {"offsetInBeginSection": 71, "offsetInEndSection": 178, "text": "human mitochondrial DNA (mtDNA) had long been believed to be rather naked because mitochondria lack histone", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15126284", "endSection": "abstract"}]}, {"body": "Name monoclonal antibody against SLAMF7.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26035255", "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "http://www.ncbi.nlm.nih.gov/pubmed/25312647", "http://www.ncbi.nlm.nih.gov/pubmed/24941981"], "triples": [], "ideal_answer": ["Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer cell-mediated antibody-dependent cellular cytotoxicity of SLAMF7-expressing myeloma cells."], "exact_answer": [["signaling lymphocytic activation molecule-F7"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000911", "http://www.uniprot.org/uniprot/SLAF7_HUMAN"], "type": "factoid", "id": "56c077e9ef6e394741000021", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 276, "text": "BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035255", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 280, "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "endSection": "abstract"}, {"offsetInBeginSection": 183, "offsetInEndSection": 275, "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", "endSection": "abstract"}, {"offsetInBeginSection": 165, "offsetInEndSection": 347, "text": "One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941981", "endSection": "abstract"}, {"offsetInBeginSection": 273, "offsetInEndSection": 365, "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", "endSection": "abstract"}, {"offsetInBeginSection": 273, "offsetInEndSection": 365, "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 347, "text": " New agents are awaited for the treatment of multiple myeloma and research is ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is highly expressed in plasma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24941981", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "endSection": "abstract"}, {"offsetInBeginSection": 184, "offsetInEndSection": 276, "text": "This led to development of an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25312647", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as CS1, CD319, or CRACC) that enhances natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) of SLAMF7-expressing myeloma cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25287778", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 265, "text": "Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035255", "endSection": "abstract"}]}, {"body": "Which is the most abundant membrane protein on Earth?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24018323", "http://www.ncbi.nlm.nih.gov/pubmed/23933017", "http://www.ncbi.nlm.nih.gov/pubmed/23298812", "http://www.ncbi.nlm.nih.gov/pubmed/21718685", "http://www.ncbi.nlm.nih.gov/pubmed/19403948", "http://www.ncbi.nlm.nih.gov/pubmed/16307124"], "triples": [], "ideal_answer": ["LHCII, the largest plant photosynthetic pigment-protein complex of photosystem II, is a most abundant membrane protein in living organisms and comprises approximately half of the pool of chlorophyll molecules in the biosphere."], "exact_answer": [["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008565", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051380", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008566", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D026901", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016020", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051205"], "type": "factoid", "id": "5519a7d5622b194345000015", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "LHCII, the largest plant photosynthetic pigment-protein complex of photosystem II, is a most abundant membrane protein in living organisms and comprises approximately half of the pool of chlorophyll molecules in the biosphere. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24018323", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "LHCII is the most abundant membrane protein on earth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23933017", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. I", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298812", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Light-harvesting pigment-protein complex of Photosystem II (LHCII) is the largest photosynthetic antenna complex of plants and the most abundant membrane protein in the biosphere.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21718685", "endSection": "abstract"}, {"offsetInBeginSection": 204, "offsetInEndSection": 462, "text": "still very little is known about protein degradation and its regulation. The degradation of the most abundant membrane protein on Earth, the light-harvesting complex of Photosystem II (LHC II), is highly regulated under different environmental conditions, e.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16307124", "endSection": "abstract"}]}, {"body": "What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25151172", "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "http://www.ncbi.nlm.nih.gov/pubmed/19771334", "http://www.ncbi.nlm.nih.gov/pubmed/17534848", "http://www.ncbi.nlm.nih.gov/pubmed/21091444", "http://www.ncbi.nlm.nih.gov/pubmed/23317900", "http://www.ncbi.nlm.nih.gov/pubmed/18155474", "http://www.ncbi.nlm.nih.gov/pubmed/18573091", "http://www.ncbi.nlm.nih.gov/pubmed/17406412"], "triples": [], "ideal_answer": ["Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context."], "exact_answer": [["The study of protein-protein interactions in a physiologically relevant developing context."]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004330", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004331", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013050", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005453"], "type": "factoid", "id": "56c868a95795f9a73e000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 598, "text": "Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms. This method was recently developed in the fruit fly Drosophila melanogaster, allowing analyzing protein interaction properties in a physiologically relevant developing context. Here we present a detailed protocol for performing BiFC with the Venus fluorescent protein in live Drosophila embryos, taking the Hox-PBC partnership as an illustrative test case. This protocol applies to any transcription factor and split fluorescent protein in general.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25151172", "endSection": "abstract"}, {"offsetInBeginSection": 101, "offsetInEndSection": 416, "text": "The understanding of developmental complexity will, therefore, require the characterization of protein interactions within their proper environment. The bimolecular fluorescence complementation (BiFC) technology offers this possibility as it enables the direct visualization of protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 575, "offsetInEndSection": 1119, "text": "Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo. Importantly, all BiFC parameters were established with constructs that were stably expressed under the control of endogenous promoters. Under these physiological conditions, we showed that BiFC is specific and sensitive enough to analyse dynamic protein interactions. We next used BiFC in a candidate interaction screen, which led to the identification of several Hox protein partners.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 463, "offsetInEndSection": 657, "text": "Using fluorescent proteins, we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "endSection": "abstract"}, {"offsetInBeginSection": 417, "offsetInEndSection": 562, "text": "The bimolecular fluorescence complementation (BiFC) assay represents one of these imaging tools for direct visualization of PPIs in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091444", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 455, "text": "The bimolecular fluorescence complementation (BiFC) assay provides an approach for the visualization of protein interactions and modifications in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19771334", "endSection": "abstract"}, {"offsetInBeginSection": 417, "offsetInEndSection": 580, "text": "The bimolecular fluorescence complementation (BiFC) assay provides a direct approach for the visualization of molecular interactions in living cells and organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18155474", "endSection": "abstract"}, {"offsetInBeginSection": 718, "offsetInEndSection": 949, "text": "The purpose of this protocol is to calculate signal-to-noise (S/N) ratio in the bimolecular fluorescence complementation (BiFC) assay and to provide a semi-quantitative analysis of protein-protein interaction (PPI) in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23317900", "endSection": "abstract"}, {"offsetInBeginSection": 479, "offsetInEndSection": 605, "text": "Bimolecular fluorescence complementation (BiFC) analysis enables direct visualization of protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18573091", "endSection": "abstract"}, {"offsetInBeginSection": 417, "offsetInEndSection": 562, "text": "The bimolecular fluorescence complementation (BiFC) assay represents one of these imaging tools for direct visualization of PPIs in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091444", "endSection": "abstract"}, {"offsetInBeginSection": 296, "offsetInEndSection": 455, "text": "The bimolecular fluorescence complementation (BiFC) assay provides an approach for the visualization of protein interactions and modifications in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19771334", "endSection": "abstract"}, {"offsetInBeginSection": 417, "offsetInEndSection": 580, "text": "The bimolecular fluorescence complementation (BiFC) assay provides a direct approach for the visualization of molecular interactions in living cells and organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18155474", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "The bimolecular fluorescence complementation (BiFC) assay has been widely accepted for studying in vivo detection of protein-protein interactions in several organisms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17534848", "endSection": "abstract"}, {"offsetInBeginSection": 718, "offsetInEndSection": 949, "text": "The purpose of this protocol is to calculate signal-to-noise (S/N) ratio in the bimolecular fluorescence complementation (BiFC) assay and to provide a semi-quantitative analysis of protein-protein interaction (PPI) in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23317900", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 567, "offsetInEndSection": 735, "text": "RESULTS: Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17406412", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 567, "offsetInEndSection": 735, "text": "RESULTS: Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17406412", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 567, "offsetInEndSection": 735, "text": "RESULTS: Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17406412", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 417, "offsetInEndSection": 735, "text": "However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels. RESULTS: Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17406412", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 567, "offsetInEndSection": 735, "text": "RESULTS: Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 146, "text": "Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17406412", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 406, "offsetInEndSection": 715, "text": "However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels.  Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 239, "offsetInEndSection": 555, "text": "The bimolecular fluorescence complementation (BiFC) technology offers this possibility as it enables the direct visualization of protein interactions in living cells. However, its potential has rarely been applied in embryos of animal model organisms and was only performed under transient protein expression levels.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 300, "offsetInEndSection": 466, "text": "we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 556, "offsetInEndSection": 715, "text": "Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 466, "text": "Using fluorescent proteins, we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 272, "offsetInEndSection": 466, "text": "Using fluorescent proteins, we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 556, "offsetInEndSection": 715, "text": "Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 466, "text": "Using fluorescent proteins, we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "title"}, {"offsetInBeginSection": 556, "offsetInEndSection": 715, "text": "Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241", "endSection": "abstract"}, {"offsetInBeginSection": 272, "offsetInEndSection": 466, "text": "Using fluorescent proteins, we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041", "endSection": "abstract"}]}, {"body": "Which syndrome is associated with OATP1B1 and OATP1B3 deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22232210", "http://www.ncbi.nlm.nih.gov/pubmed/22982575"], "triples": [], "ideal_answer": ["Complete and simultaneous deficiency of the organic anion transporting polypeptides OATP1B1 and OATP1B3 due to mutations in their corresponding genes, has been linked to Rotor syndrome."], "exact_answer": [["Rotor syndrome"]], "concepts": [], "type": "factoid", "id": "571e40a8bb137a4b0c000009", "snippets": [{"offsetInBeginSection": 518, "offsetInEndSection": 741, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 738, "offsetInEndSection": 961, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 738, "offsetInEndSection": 961, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1864, "offsetInEndSection": 2104, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1775, "offsetInEndSection": 1927, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 518, "offsetInEndSection": 740, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 1632, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 742, "text": "The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 211, "offsetInEndSection": 742, "text": "The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 519, "offsetInEndSection": 902, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal hepatocyte membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 902, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal hepatocyte membrane.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1634, "offsetInEndSection": 1874, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1874, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1634, "offsetInEndSection": 1874, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1634, "offsetInEndSection": 1874, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1634, "offsetInEndSection": 1874, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "title"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 519, "offsetInEndSection": 742, "text": "Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}, {"offsetInBeginSection": 1634, "offsetInEndSection": 1874, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982575", "endSection": "abstract"}, {"offsetInBeginSection": 1633, "offsetInEndSection": 1785, "text": "Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22232210", "endSection": "abstract"}]}, {"body": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21880664", "http://www.ncbi.nlm.nih.gov/pubmed/22315228", "http://www.ncbi.nlm.nih.gov/pubmed/21789513", "http://www.ncbi.nlm.nih.gov/pubmed/18937352", "http://www.ncbi.nlm.nih.gov/pubmed/17924338", "http://www.ncbi.nlm.nih.gov/pubmed/16096717", "http://www.ncbi.nlm.nih.gov/pubmed/15851108", "http://www.ncbi.nlm.nih.gov/pubmed/12574890", "http://www.ncbi.nlm.nih.gov/pubmed/11691526", "http://www.ncbi.nlm.nih.gov/pubmed/10902626"], "triples": [], "ideal_answer": ["A homozygous loss-of-function mutation of the Plakoglobin (Jup) gene, had been identified in Naxos Disease patients, a subset of ARVC, which is characterized by cutaneous disorder.", "Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.", "A homozygous loss-of-function mutation of the Plakoglobin (Jup) gene, which encodes a major component of the desmosome and the adherens junction, had been identified in Naxos patients, although the underlying mechanism remained elusive.", "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.  ", "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.  ", "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.  ", "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.  ", "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.  "], "exact_answer": [["The Plakoglobin gene", "plakoglobin[jup]"]], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:4", "http://www.disease-ontology.org/api/metadata/DOID:0050431", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009202"], "type": "factoid", "id": "54f9ae2506d9727f76000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 517, "text": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable myocardial disorder associated with fibrofatty replacement of myocardium and ventricular arrhythmia. A subset of ARVC is categorized as Naxos disease, which is characterized by ARVC and a cutaneous disorder. A homozygous loss-of-function mutation of the Plakoglobin (Jup) gene, which encodes a major component of the desmosome and the adherens junction, had been identified in Naxos patients, although the underlying mechanism remained elusive.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880664", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Loss-of-function mutation of Jup has been associated with Naxos disease, which is characterized by arrhythmogenic cardiomyopathy and the cutaneous disorder palmoplantar keratoderma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22315228", "endSection": "abstract"}, {"offsetInBeginSection": 182, "offsetInEndSection": 337, "text": "Previously, we have shown that genetic ablation of Jup in cardiomyocytes in mice leads to arrhythmogenic cardiomyopathy similar to Naxos disease in humans.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22315228", "endSection": "abstract"}, {"offsetInBeginSection": 309, "offsetInEndSection": 520, "text": "As similar phenotypes have been described in Naxos disease and Carvajal syndrome, respectively, the genes for plakoglobin (JUP) and desmoplakin (DSP) were screened for mutations using direct genomic sequencing. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21789513", "endSection": "abstract"}, {"offsetInBeginSection": 396, "offsetInEndSection": 554, "text": "One is a C-terminal mutation causing Naxos disease, a recessive syndrome of arrhythmogenic right ventricular cardiomyopathy (ARVC) and abnormal skin and hair.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18937352", "endSection": "abstract"}, {"offsetInBeginSection": 271, "offsetInEndSection": 394, "text": "In this study, we examined the effects of two different mutations in plakoglobin on cell migration, stiffness, and adhesion", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18937352", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 303, "text": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardiocutaneous syndrome characterized by ARVC and abnormalities of hair and skin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17924338", "endSection": "abstract"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1517, "text": "Three other genes implicated for ARVC, plakoglobin (Naxos disease), desmoplakin (ARVC8) and plakophilin (ARVC9) have prompted the speculation that ARVC is primarily a disease of desmosomes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16096717", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 271, "text": "We tested the hypothesis that defective interactions between adhesion junctions and the cytoskeleton caused by the plakoglobin mutation in Naxos disease lead to remodeling of gap junctions and altered expression of the major gap junction protein, connexin43. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15851108", "endSection": "abstract"}, {"offsetInBeginSection": 283, "offsetInEndSection": 568, "text": "Naxos disease, a recessive form of arrhythmogenic right ventricular cardiomyopathy, is associated with a high incidence of arrhythmias and sudden cardiac death. Naxos disease is caused by a mutation in plakoglobin, a protein that links cell-cell adhesion molecules to the cytoskeleton.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15851108", "endSection": "abstract"}, {"offsetInBeginSection": 1463, "offsetInEndSection": 1736, "text": "However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12574890", "endSection": "abstract"}, {"offsetInBeginSection": 274, "offsetInEndSection": 490, "text": "Naxos disease is a recessively inherited ARVC caused by a mutation in the gene encoding plakoglobin (cell adhesion protein) in which the cardiac phenotype is associated with palmoplantar keratoderma and woolly hair. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11691526", "endSection": "abstract"}, {"offsetInBeginSection": 1545, "offsetInEndSection": 1734, "text": "Autosomal recessive ARVC caused by a mutation in plakoglobin was 100% penetrant by adolescence. Affected subjects who were homozygous experienced progressive disease with adverse prognosis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11691526", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 546, "text": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, and sudden death. Previously we mapped the genetic locus for the triad of autosomal recessive ARVC, palmoplantar keratoderma, and woolly hair (Naxos disease) to chromosome 17q21, in which the gene for plakoglobin is encoded. This protein is a key component of desmosomes and adherens junctions, and is important for the tight adhesion of many cell types, including those in the heart and skin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10902626", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 157, "text": "Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10902626", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease).", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15851108", "endSection": "title"}]}, {"body": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21332651", "http://www.ncbi.nlm.nih.gov/pubmed/18722880", "http://www.ncbi.nlm.nih.gov/pubmed/16616117", "http://www.ncbi.nlm.nih.gov/pubmed/11984797", "http://www.ncbi.nlm.nih.gov/pubmed/11919388", "http://www.ncbi.nlm.nih.gov/pubmed/9916508", "http://www.ncbi.nlm.nih.gov/pubmed/8697423", "http://www.ncbi.nlm.nih.gov/pubmed/8656667", "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "http://www.ncbi.nlm.nih.gov/pubmed/17001000", "http://www.ncbi.nlm.nih.gov/pubmed/1434792", "http://www.ncbi.nlm.nih.gov/pubmed/17987804", "http://www.ncbi.nlm.nih.gov/pubmed/22783385", "http://www.ncbi.nlm.nih.gov/pubmed/1423227", "http://www.ncbi.nlm.nih.gov/pubmed/3670297", "http://www.ncbi.nlm.nih.gov/pubmed/2157692", "http://www.ncbi.nlm.nih.gov/pubmed/21279819", "http://www.ncbi.nlm.nih.gov/pubmed/8490164", "http://www.ncbi.nlm.nih.gov/pubmed/11535505"], "triples": [], "ideal_answer": ["The Philadelphia chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22.", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. The Philadelphia chromosome and its corresponding fusion gene, BCR-ABL, is one of the best-known genetic abnormalities in hematological malignancies. Major BCR-ABL translocation is much more common in chronic myelogenous leukemia (CML) and minor BCR-ABL in acute lymphoblastic leukemia. ", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. The Philadelphia chromosome and its corresponding fusion gene, BCR-ABL, is one of the best-known genetic abnormalities in hematological malignancies. Major BCR-ABL translocation is much more common in chronic myelogenous leukemia (CML) and minor BCR-ABL in acute lymphoblastic leukemia. ", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome.   ", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome.   ", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome.   ", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome.   ", "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome.   "], "exact_answer": [["The BCR/ABL gene fusion", "ABL/BCR fusion"]], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010677", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014178", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005694"], "type": "factoid", "id": "55149f156a8cde6b72000013", "snippets": [{"offsetInBeginSection": 5, "offsetInEndSection": 307, "text": "Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) is a common cytogenetic abnormality associated with poor outcome in adults. This preliminary study, in the absence of substantial evidence, reported the prevalence of the BCR-ABL gene fusion in ALL patients by RT-PCR in Pakistan.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21332651", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "The Philadelphia chromosome and its corresponding fusion gene, BCR-ABL, is one of the best-known genetic abnormalities in hematological malignancies. Major BCR-ABL translocation is much more common in chronic myelogenous leukemia (CML) and minor BCR-ABL in acute lymphoblastic leukemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18722880", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16616117", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 198, "text": "The t(9;22)(q34;q11) translocation leading to the Philadelphia (Ph) chromosome resulting in BCR-ABL gene fusion is associated with a poor prognosis in acute lymphoblastic leukemia (ALL).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11984797", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 234, "text": "Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11919388", "endSection": "abstract"}, {"offsetInBeginSection": 187, "offsetInEndSection": 761, "text": "Ph chromosome was identified in CML in 1960 and was found to clearly result from reciprocal translocation between chromosome 9 and chromosome 22 (t(q;22)) (q34;q11). CML arises from a single pluripotent hematopoietic stem cell with the Ph chromosome and demonstration of the Ph chromosome in blood or marrow cells establishes and unequivocal diagnosis of CML. The Ph chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9916508", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8697423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 263, "text": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8656667", "endSection": "abstract"}, {"offsetInBeginSection": 1012, "offsetInEndSection": 1351, "text": "There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8656667", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Chronic myeloid leukemia (CML) is associated with the Philadelphia chromosome, which arises by a reciprocal translocation between chromosomes 9 and 22 and harbors the BCR-ABL fusion oncogene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17001000", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 336, "text": "The translocation event creates on the Philadelphia chromosome a fusion between two genes: bcr and abl.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1434792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 336, "text": "The translocation event creates on the Philadelphia chromosome a fusion between two genes: bcr and abl.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1434792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "endSection": "abstract"}, {"offsetInBeginSection": 232, "offsetInEndSection": 336, "text": "The translocation event creates on the Philadelphia chromosome a fusion between two genes: bcr and abl.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1434792", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Chronic myelogenous leukemia (CML) is genetically characterized by the reciprocal translocation of chromosome 9 and 22, t(9;22)(q34;q11) which results in the fusion of BCR/ABL gene observed on the derivative chromosome 22 called Philadelphia (Ph) chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17987804", "endSection": "abstract"}, {"offsetInBeginSection": 669, "offsetInEndSection": 939, "text": "Using specific probes for the BCR and ABL genes, results of FISH showed a three-way variant Philadelphia translocation (9;22;21)(q34;q11;p12) with a BCR/ABL fusion residing on the der(22) and the 3BCR region translocated on the short arm of the derivative chromosome 21.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22783385", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 533, "text": "We report a cytogenetic study of a patient with chronic myelogenous leukemia (CML) who, while displaying a Philadelphia (Ph) chromosome, resulting from a standard t(9;22) at diagnosis, during the chronic phase (CP) showed disappearance of the Ph and occurrence of new chromosome changes, including a marker probably arising from a translocation involving chromosome 17 and the Ph. In situ hybridization confirmed the cytogenetic appearance and demonstrated that the breakpoint on the Ph marker occurred below the BCR-ABL fusion gene.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1423227", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 278, "text": "The translocation of the c-abl oncogene from chromosome 9 to the bcr gene on chromosome 22 in cases of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) generates an aberrant bcr-abl fusion transcript which may be intimately related to the pathogenesis of CML.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/3670297", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "BACKGROUND: The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 446, "text": "In the great majority of patients with chronic myelogenous leukemia (CML) the reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), resulting in the Philadelphia (Ph) chromosome produces fusion DNA sequences consisting of the 5 part of the major breakpoint cluster region-1 (M-BCR-1) and the ABL protooncogene which encodes for the P210BCR-ABL phosphoprotein with tyrosine kinase activity implicated in the pathogenesis of CML.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2157692", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 287, "text": "The Philadelphia chromosome and its corresponding fusion gene, BCR-ABL, is one of the best-known genetic abnormalities in hematological malignancies. Major BCR-ABL translocation is much more common in chronic myelogenous leukemia (CML) and minor BCR-ABL in acute lymphoblastic leukemia. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18722880", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2820585", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 92, "text": "Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8490164", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 180, "text": "Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11535505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8697423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730117", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Chronic myelogenous leukemia (CML) is genetically characterized by the reciprocal translocation of chromosome 9 and 22, t(9;22)(q34;q11) which results in the fusion of BCR/ABL gene observed on the derivative chromosome 22 called Philadelphia (Ph') chromosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17987804", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22058195", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279819", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Chronic myelogenous leukemia (CML) is genetically characterized by the reciprocal translocation of chromosome 9 and 22, t(9;22)(q34;q11) which results in the fusion of BCR/ABL gene observed on the derivative chromosome 22 called Philadelphia (Ph') chromosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17987804", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8697423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730117", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Chronic myelogenous leukemia (CML) is genetically characterized by the reciprocal translocation of chromosome 9 and 22, t(9;22)(q34;q11) which results in the fusion of BCR/ABL gene observed on the derivative chromosome 22 called Philadelphia (Ph') chromosome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17987804", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8697423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730117", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8697423", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12730117", "endSection": "abstract"}]}, {"body": "What is the life expectancy of professional athletes in respect to the general population?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22811911", "http://www.ncbi.nlm.nih.gov/pubmed/23450998", "http://www.ncbi.nlm.nih.gov/pubmed/21435018", "http://www.ncbi.nlm.nih.gov/pubmed/20061269", "http://www.ncbi.nlm.nih.gov/pubmed/19574095", "http://www.ncbi.nlm.nih.gov/pubmed/18369530", "http://www.ncbi.nlm.nih.gov/pubmed/17436206", "http://www.ncbi.nlm.nih.gov/pubmed/11761838", "http://www.ncbi.nlm.nih.gov/pubmed/9177584", "http://www.ncbi.nlm.nih.gov/pubmed/8164540", "http://www.ncbi.nlm.nih.gov/pubmed/8450727", "http://www.ncbi.nlm.nih.gov/pubmed/2253729", "http://www.ncbi.nlm.nih.gov/pubmed/23241269", "http://www.ncbi.nlm.nih.gov/pubmed/20424397", "http://www.ncbi.nlm.nih.gov/pubmed/16389882", "http://www.ncbi.nlm.nih.gov/pubmed/17214401", "http://www.ncbi.nlm.nih.gov/pubmed/21618162", "http://www.ncbi.nlm.nih.gov/pubmed/18634917", "http://www.ncbi.nlm.nih.gov/pubmed/22625998", "http://www.ncbi.nlm.nih.gov/pubmed/17849604"], "triples": [], "ideal_answer": "It remains unclear if high-intensity sports activities further increase life expectancy.\nCompetitive exercise does not induce cardiac damage in individuals with healthy hearts, but does induce physiological functional and structural cardiac adaptations which have positive effects on life expectancy\nIt appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity.", "exact_answer": ["No clear results indicating improved life expectancy in professional athletes"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008017", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056352", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013177", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008136"], "type": "factoid", "id": "52e62bae98d0239505000015", "snippets": [{"offsetInBeginSection": 1197, "offsetInEndSection": 1359, "text": "In conclusion, while regular physical activity increases life expectancy, it remains unclear if high-intensity sports activities further increase life expectancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811911", "endSection": "abstract"}, {"offsetInBeginSection": 1247, "offsetInEndSection": 1458, "text": "Competitive exercise does not induce cardiac damage in individuals with healthy hearts, but does induce physiological functional and structural cardiac adaptations which have positive effects on life expectancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23450998", "endSection": "abstract"}, {"offsetInBeginSection": 645, "offsetInEndSection": 1039, "text": "It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19574095", "endSection": "abstract"}]}, {"body": "What is the function of the MTH1 enzyme in cancer cells?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24277933", "http://www.ncbi.nlm.nih.gov/pubmed/23295485", "http://www.ncbi.nlm.nih.gov/pubmed/22790201", "http://www.ncbi.nlm.nih.gov/pubmed/22757673", "http://www.ncbi.nlm.nih.gov/pubmed/22556419", "http://www.ncbi.nlm.nih.gov/pubmed/21787772", "http://www.ncbi.nlm.nih.gov/pubmed/21389046", "http://www.ncbi.nlm.nih.gov/pubmed/21195604", "http://www.ncbi.nlm.nih.gov/pubmed/20542142", "http://www.ncbi.nlm.nih.gov/pubmed/20144704", "http://www.ncbi.nlm.nih.gov/pubmed/17917452", "http://www.ncbi.nlm.nih.gov/pubmed/17425590", "http://www.ncbi.nlm.nih.gov/pubmed/17207658", "http://www.ncbi.nlm.nih.gov/pubmed/17071637", "http://www.ncbi.nlm.nih.gov/pubmed/16716086", "http://www.ncbi.nlm.nih.gov/pubmed/16607562", "http://www.ncbi.nlm.nih.gov/pubmed/16621731"], "triples": [], "ideal_answer": ["The MTH1 protein catalyzes hydrolysis of oxidatively damaged purine nucleotides including 8-hydroxy-dGTP to the monophosphates. The MTH1 protein seems to act as an important defense system against mutagenesis, carcinogenesis, and cell death induced by oxidized purine nucleotides."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004798", "http://www.uniprot.org/uniprot/MTH1_YEAST", "http://www.uniprot.org/uniprot/8ODP_MOUSE", "http://www.uniprot.org/uniprot/8ODP_HUMAN", "http://www.uniprot.org/uniprot/8ODP_RAT"], "type": "summary", "id": "551af9106b348bb82c000002", "snippets": [{"offsetInBeginSection": 220, "offsetInEndSection": 268, "text": "the glucose-responsive transcription factor Mth1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23468525", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Human MTH1 (hMTH1) is an enzyme that hydrolyses several oxidized purine nucleoside triphosphates to their corresponding nucleoside monophosphates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295485", "endSection": "abstract"}, {"offsetInBeginSection": 193, "offsetInEndSection": 428, "text": " We have recently shown that oncogenic RAS-induced DNA damage and attendant premature senescence can be prevented by overexpressing human MutT Homolog 1 (MTH1), the major mammalian detoxifier of the oxidized DNA precursor, 8-oxo-dGTP. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22790201", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Human Mut T Homolog 1 (MTH1): a roadblock for the tumor-suppressive effects of oncogenic RAS-induced ROS.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22790201", "endSection": "title"}, {"offsetInBeginSection": 602, "offsetInEndSection": 667, "text": "MutT homolog 1 (oxidized purine nucleoside triphosphatase, MTH1),", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22757673", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 803, "text": "MTH1 cleaves 8-oxo-dGTP", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22556419", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "MTH1 hydrolyzes oxidized nucleotide triphosphates, thereby preventing them from being incorporated into DNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21787772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 250, "text": "MutT-related proteins, including Escherichia coli MutT and the human MTH1 (NUDT1), degrade 8-oxo-7, 8-dihydrodeoxyguanosine triphosphate (8-oxo-dGTP) to 8-oxo-dGMP and thereby prevent mutations caused by the misincorporation of 8-oxoguanine into DNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21389046", "endSection": "abstract"}, {"offsetInBeginSection": 221, "offsetInEndSection": 325, "text": "MTH1 (or NUDT1) are also involved in the repair of 7,8-dihydro-8-oxoguanine (8-oxo-G), previous studies,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21195604", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 645, "text": "To counteract such deleterious effects of nucleotide pool damage, mammalian cells possess MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphatase and related enzymes, thus minimizing the accumulation of oxidized bases in cellular DNA", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20542142", "endSection": "abstract"}, {"offsetInBeginSection": 780, "offsetInEndSection": 928, "text": "These results indicate that all three of the human MTH1, MTH2, and NUDT5 proteins act as a defense against the mutagenesis induced by oxidized dGTP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20144704", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Human MTH1, an oxidized purine nucleoside triphosphatase, hydrolyzes 8-oxo-dGTP thereby preventing its misincorporation into DNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17917452", "endSection": "abstract"}, {"offsetInBeginSection": 722, "offsetInEndSection": 922, "text": "MTH1 is a mammalian ortholog of Escherichia coli MutT, which hydrolyzes 8-oxo-dGTP to its monophosphate form in nucleotide pools, thereby preventing incorporation of the mutagenic substrate into DNA. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17425590", "endSection": "abstract"}, {"offsetInBeginSection": 193, "offsetInEndSection": 419, "text": "Several pathways are involved in the repair of DNA lesions caused by oxidative stress, such as the base excision repair system (BER), which repairs mutation involving 8-oxoguanine and comprises the MUTYH, OGG1 and MTH1 genes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17207658", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 281, "text": "The MTH1 protein catalyzes hydrolysis of oxidatively damaged purine nucleotides including 8-hydroxy-dGTP to the monophosphates. The MTH1 protein seems to act as an important defense system against mutagenesis, carcinogenesis, and cell death induced by oxidized purine nucleotides. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17071637", "endSection": "abstract"}, {"offsetInBeginSection": 466, "offsetInEndSection": 756, "text": "In mammalian cells, MTH1 and NUDT5 proteins degrade 8-oxoGTP and 8-oxoGDP to 8-oxoGMP, which is an unusable form for RNA synthesis. In a search for proteins functioning at the RNA level, polynucleotide phosphorylase (PNP) protein has been suggested to be a good candidate for such a role. T", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16716086", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 257, "text": "Human MTH1 protein hydrolyzes oxidized purine nucleotides 8-oxo-2'-deoxyguanosine triphosphate (8-oxo-dGTP), 2-OH-dATP or their ribo-forms to their monophosphates, thus minimizing replicational and transcriptional errors both in the nuclei and mitochondria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16607562", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 321, "text": "In human and rodent cells, MTH1, an oxidized purine nucleoside triphosphatase, efficiently hydrolyzes oxidized dGTP, GTP, dATP and ATP such as 2'-deoxy-8-oxoguanosine triphosphate (8-oxo-dGTP) and 2'-deoxy-2-hydroxyadenosine triphosphate (2-OH-dATP) in nucleotide pools, thus avoiding their incorporation into DNA or RNA.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16621731", "endSection": "abstract"}]}, {"body": "What is the effect that EZH2 has on chromatin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25680271", "http://www.ncbi.nlm.nih.gov/pubmed/23688634", "http://www.ncbi.nlm.nih.gov/pubmed/21892963", "http://www.ncbi.nlm.nih.gov/pubmed/19954516", "http://www.ncbi.nlm.nih.gov/pubmed/19026781", "http://www.ncbi.nlm.nih.gov/pubmed/18980972", "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "http://www.ncbi.nlm.nih.gov/pubmed/9214638", "http://www.ncbi.nlm.nih.gov/pubmed/22821416", "http://www.ncbi.nlm.nih.gov/pubmed/24040281", "http://www.ncbi.nlm.nih.gov/pubmed/24077602", "http://www.ncbi.nlm.nih.gov/pubmed/25617436", "http://www.ncbi.nlm.nih.gov/pubmed/22966008", "http://www.ncbi.nlm.nih.gov/pubmed/15520282"], "triples": [], "ideal_answer": ["Ez that catalyzes di- and trimethylation of histone H3 lysine 27 (H3K37me2/3), marks repressive to transcription. The mammalian homologs Ezh1 and Ezh2 form similar PRC2 complexes but exhibit contrasting repressive roles. PRC2-Ezh2 catalyzes H3K27me2/3 and its knockdown affects global H3K27me2/3 levels. EZH2 thus maintains chromatin in a repressive state.", "Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms", "Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms", "Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms"], "concepts": ["http://www.uniprot.org/uniprot/EZH2B_XENLA", "http://www.uniprot.org/uniprot/EZH2A_XENLA", "http://www.uniprot.org/uniprot/EZH2_XENTR", "http://www.uniprot.org/uniprot/EZH2_MOUSE", "http://www.uniprot.org/uniprot/EZH2_HUMAN", "http://www.uniprot.org/uniprot/EZH2_DANRE", "http://www.uniprot.org/uniprot/EZH2_MACFA", "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002843", "http://amigo.geneontology.org/amigo/term/GO:0000785"], "type": "summary", "id": "570906fecf1c325851000010", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026781", "endSection": "title"}, {"offsetInBeginSection": 164, "offsetInEndSection": 399, "text": "Ez that catalyzes di- and trimethylation of histone H3 lysine 27 (H3K37me2/3), marks repressive to transcription. We report that the mammalian homologs Ezh1 and Ezh2 form similar PRC2 complexes but exhibit contrasting repressive roles.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026781", "endSection": "abstract"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1185, "text": "During progenitor cell differentiation and ageing, PcG silencer EZH2 attenuates, causing loss of PRC binding and transcriptional activation of INK4b and INK4a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19954516", "endSection": "abstract"}, {"offsetInBeginSection": 547, "offsetInEndSection": 780, "text": "the PRC2-Ezh2 complex, which is bound to the myogenin (MyoG) promoter and muscle creatine kinase (mCK) enhancer in proliferating myoblasts, and the PRC2-Ezh1 complex, which replaces PRC2-Ezh2 on MyoG promoter in post-mitotic myotubes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21892963", "endSection": "abstract"}, {"offsetInBeginSection": 394, "offsetInEndSection": 564, "text": "In this study, we found the inverse correlation between FOXP3 and Ezh2, an enzyme for histone H3K27 trimethylation (H3K27me3) and a central epigenetic regulator in cancer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688634", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680271", "endSection": "title"}, {"offsetInBeginSection": 291, "offsetInEndSection": 427, "text": "CD28 co-stimulation, an extracellular cue intrinsically required for Treg cell maintenance, induced the chromatin-modifying enzyme, Ezh2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680271", "endSection": "abstract"}, {"offsetInBeginSection": 429, "offsetInEndSection": 617, "text": "Treg-specific ablation of Ezh2 resulted in spontaneous autoimmunity with reduced Foxp3(+) cells in non-lymphoid tissues and impaired resolution of experimental autoimmune encephalomyelitis", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680271", "endSection": "abstract"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1120, "text": "These studies reveal a critical role for Ezh2 in the maintenance of Treg cell identity during cellular activation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680271", "endSection": "abstract"}, {"offsetInBeginSection": 842, "offsetInEndSection": 1037, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 1701, "offsetInEndSection": 1960, "text": "We found that siRNAs Ezh2 and post-transcriptional silencing of Ezh2 by let-7 g rescued this effect suggesting that Ezh2 up-regulation is in part responsible for increased H3K27me3 and decreased rates of up-regulation of differentiation genes in Dicer(-/-)ES.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040281", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in transcriptional repression through chromatin remodeling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980972", "endSection": "abstract"}, {"offsetInBeginSection": 1183, "offsetInEndSection": 1339, "text": "Chromatin immunoprecipitation analysis revealed binding of EZH2 at the p57kip2 promoter and reduction of histone H3K27 trimethylation upon gene suppression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22821416", "endSection": "abstract"}, {"offsetInBeginSection": 842, "offsetInEndSection": 1037, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1490, "text": "The E(z) gene family reveals a striking functional conservation in mediating gene repression in eukaryotic chromatin: extra gene copies of human EZH2 or Drosophila E(z) in transgenic flies enhance position effect variegation of the heterochromatin-associated white gene, and expression of either human EZH2 or murine Ezh1 restores gene repression in Saccharomyces cerevisiae mutants that are impaired in telomeric silencing.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9214638", "endSection": "abstract"}, {"offsetInBeginSection": 1701, "offsetInEndSection": 1960, "text": "We found that siRNAs Ezh2 and post-transcriptional silencing of Ezh2 by let-7 g rescued this effect suggesting that Ezh2 up-regulation is in part responsible for increased H3K27me3 and decreased rates of up-regulation of differentiation genes in Dicer(-/-)ES.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24040281", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in transcriptional repression through chromatin remodeling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980972", "endSection": "abstract"}, {"offsetInBeginSection": 1102, "offsetInEndSection": 1228, "text": "The authors further showed that forced expression of SAFB1 increases H3K27me3 at AR target loci and this effect requires EZH2.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24077602", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 651, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 290, "text": "Enhancer of zeste homologue 2 (EZH2), a histone methyltransferase, plays a key role in transcriptional repression through chromatin remodeling. Our objectives were to determine the expression pattern of EZH2 and to assess the anticancer effect of EZH2 depletion in pancreatic cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18980972", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 875, "offsetInEndSection": 1165, "text": "EZH2 interacts directly with Snail2, and Snail2 fails to expand the neural crest domains in the absence of Ezh2. Chromatin immunoprecipitation analysis shows that Snail2 regulates EZH2 occupancy and histone H3K27 trimethylation levels at the promoter region of the Snail2 target E-cadherin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617436", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1123, "text": "To identify direct target genes of Ezh2, we performed chromatin immunoprecipitation experiments followed by whole-genome promoter arrays (chromatin immunoprecipitation-on-chip) and identified 5585 genes associated with trimethylation of lysine 27 in histone 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966008", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1123, "text": "To identify direct target genes of Ezh2, we performed chromatin immunoprecipitation experiments followed by whole-genome promoter arrays (chromatin immunoprecipitation-on-chip) and identified 5585 genes associated with trimethylation of lysine 27 in histone 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966008", "endSection": "abstract"}, {"offsetInBeginSection": 1035, "offsetInEndSection": 1191, "text": "Chromatin immunoprecipitation analysis revealed binding of EZH2 at the p57kip2 promoter and reduction of histone H3K27 trimethylation upon gene suppression.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22821416", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1123, "text": "To identify direct target genes of Ezh2, we performed chromatin immunoprecipitation experiments followed by whole-genome promoter arrays (chromatin immunoprecipitation-on-chip) and identified 5585 genes associated with trimethylation of lysine 27 in histone 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966008", "endSection": "abstract"}, {"offsetInBeginSection": 834, "offsetInEndSection": 973, "text": "YY1 was required for Ezh2 binding because RNA interference of YY1 abrogated chromatin recruitment of Ezh2 and prevented H3-K27 methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520282", "endSection": "abstract"}, {"offsetInBeginSection": 988, "offsetInEndSection": 1165, "text": "Chromatin immunoprecipitation analysis shows that Snail2 regulates EZH2 occupancy and histone H3K27 trimethylation levels at the promoter region of the Snail2 target E-cadherin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617436", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1123, "text": "To identify direct target genes of Ezh2, we performed chromatin immunoprecipitation experiments followed by whole-genome promoter arrays (chromatin immunoprecipitation-on-chip) and identified 5585 genes associated with trimethylation of lysine 27 in histone 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966008", "endSection": "abstract"}, {"offsetInBeginSection": 988, "offsetInEndSection": 1165, "text": "Chromatin immunoprecipitation analysis shows that Snail2 regulates EZH2 occupancy and histone H3K27 trimethylation levels at the promoter region of the Snail2 target E-cadherin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25617436", "endSection": "abstract"}, {"offsetInBeginSection": 652, "offsetInEndSection": 847, "text": "We assessed the effect of efficient RNA interference-mediated knockdown of EZH2 on RUNX3 levels, cell viability and H3K27 trimethylation of the RUNX3 promoter using chromatin immunoprecipitation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20631058", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026781", "endSection": "title"}, {"offsetInBeginSection": 863, "offsetInEndSection": 1123, "text": "To identify direct target genes of Ezh2, we performed chromatin immunoprecipitation experiments followed by whole-genome promoter arrays (chromatin immunoprecipitation-on-chip) and identified 5585 genes associated with trimethylation of lysine 27 in histone 3.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966008", "endSection": "abstract"}, {"offsetInBeginSection": 834, "offsetInEndSection": 973, "text": "YY1 was required for Ezh2 binding because RNA interference of YY1 abrogated chromatin recruitment of Ezh2 and prevented H3-K27 methylation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520282", "endSection": "abstract"}]}, {"body": "What constitutes an increased risk for individuals with Fanconi anemia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17909071", "http://www.ncbi.nlm.nih.gov/pubmed/24259538", "http://www.ncbi.nlm.nih.gov/pubmed/23146055", "http://www.ncbi.nlm.nih.gov/pubmed/22937327", "http://www.ncbi.nlm.nih.gov/pubmed/21355096", "http://www.ncbi.nlm.nih.gov/pubmed/21131752", "http://www.ncbi.nlm.nih.gov/pubmed/10994546", "http://www.ncbi.nlm.nih.gov/pubmed/18786261", "http://www.ncbi.nlm.nih.gov/pubmed/12750283", "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "http://www.ncbi.nlm.nih.gov/pubmed/21109493", "http://www.ncbi.nlm.nih.gov/pubmed/22965917", "http://www.ncbi.nlm.nih.gov/pubmed/22504776", "http://www.ncbi.nlm.nih.gov/pubmed/12354784", "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "http://www.ncbi.nlm.nih.gov/pubmed/19728769", "http://www.ncbi.nlm.nih.gov/pubmed/12685843", "http://www.ncbi.nlm.nih.gov/pubmed/1084238"], "triples": [], "ideal_answer": ["Fanconi anemia is a rare genetic disorder associated with an increased risk of leukemias and solid tumors."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199", "http://www.disease-ontology.org/api/metadata/DOID:13636", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856", "http://www.disease-ontology.org/api/metadata/DOID:1062"], "type": "summary", "id": "54ede5a494afd61504000005", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Fanconi anemia (FA) is a rare autosomal recessive disease characterized by a greatly increased risk of cancer among those diagnosed with the syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17909071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Fanconi anaemia (FA) is an inherited condition characterised by congenital and developmental abnormalities and a strong cancer predisposition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259538", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 313, "text": "Fanconi anemia (FA) is a heterogeneous disease characterized by spontaneous chromosomal breaks and abnormal DNA repair. Major clinical problems in FA include congenital abnormalities, endocrinopathies, early onset bone marrow failure and increased risk of myelodysplastic syndrome, acute leukemia and solid tumors", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23146055", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Fanconi anemia is associated with an increased risk of malignancy. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937327", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Fanconi anemia (FA) is a rare genetic disorder characterized by bone marrow failure, congenital abnormalities, and an increased risk for cancer and leukemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21355096", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 261, "text": "Fanconi anemia (FA) is an autosomal recessive, cancer susceptibility disorder characterized by diverse clinical features, such as short stature, skeletal or skin abnormalities, progressive bone marrow (BM) failure, and increased risk of malignancies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21131752", "endSection": "abstract"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1457, "text": "The FA patients have a high risk of developing malignancies", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21131752", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 175, "text": "Fanconi anemia (FA) is an autosomal recessive DNA repair disorder with affected individuals having a high risk of developing acute myeloid leukaemia and certain solid tumours.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18786261", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1193, "text": "In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 227, "text": "Fanconi anemia (FA) is an inherited disease characterized by bone marrow failure, increased cancer risk and hypersensitivity to DNA cross-linking agents, implying a role for this pathway in the maintenance of genomic stability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109493", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "BACKGROUND: Fanconi anemia (FA) is a rare autosomal recessive genetic disorder characterized by bone marrow failure and increased risk of cancers including acute myelogenous leukemia and various solid tumors, especially head and neck cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22965917", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "Fanconi anemia (FA) is a rare recessive DNA repair disorder that is clinically characterized by congenital malformations, progressive bone marrow failure, and increased incidence of malignancies, especially acute myeloid leukemia and squamous cell carcinomas of the head and neck (HNSCCs) and the anogenital regions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22504776", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Fanconi anemia (FA) is a rare autosomal recessive disease characterized by a greatly increased risk of cancer among those diagnosed with the syndrome", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17909071", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "Fanconi anaemia (FA) is an inherited condition characterised by congenital and developmental abnormalities and a strong cancer predisposition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24259538", "endSection": "abstract"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1205, "text": "In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 437, "text": "FA is one of a group of recessive syndromes characterized by excessive spontaneous chromosomal breakage in which heterozygote carriers appear to display an increased risk of cancer and there is some indirect evidence that FA carriers may also be at increased risk of AML.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12685843", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Mutations in Fanconi anemia genes and the risk of esophageal cancer.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "title"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1271, "text": "The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Fanconi anemia is a genetically heterogeneous disorder associated with chromosome instability and a highly elevated risk for developing cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19728769", "endSection": "abstract"}, {"offsetInBeginSection": 190, "offsetInEndSection": 407, "text": "BRCA2 is an FA gene and additionally conveys an inherited risk for breast, ovarian, and pancreatic cancer for individuals carrying a single mutated allele [N. G. Howlett et al., Science (Wash. DC), 297: 606-609, 2002]", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12750283", "endSection": "abstract"}, {"offsetInBeginSection": 76, "offsetInEndSection": 165, "text": "Around 10-15% of individuals with recessively inherited Fanconi anaemia (FA) develop AML.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12685843", "endSection": "abstract"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1270, "text": "The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 347, "offsetInEndSection": 565, "text": "It is postulated that both T and B cells could be involved in the development of leukemia in Fanconi's anemia patients, assuming that chromosome breaks constitute a factor predisposing to the development of malignancy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1084238", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1193, "text": "In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Patients with Fanconi Anemia (FANC) have a well documented increased risk to develop malignancies, especially Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10994546", "endSection": "abstract"}, {"offsetInBeginSection": 1890, "offsetInEndSection": 2032, "text": "The findings within this family support the hypothesis of an increased risk to develop malignancies in heterozygous carriers of FANC-mutations", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10994546", "endSection": "abstract"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1270, "text": "The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1270, "text": "The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 436, "text": "FA is one of a group of recessive syndromes characterized by excessive spontaneous chromosomal breakage in which heterozygote carriers appear to display an increased risk of cancer and there is some indirect evidence that FA carriers may also be at increased risk of AML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12685843", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Fanconi anemia (FA) is a rare autosomal recessive disease characterized by skeletal defects, anemia, chromosomal instability and increased risk of leukemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12354784", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1193, "text": "In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Patients with Fanconi Anemia (FANC) have a well documented increased risk to develop malignancies, especially Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10994546", "endSection": "abstract"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1270, "text": "The co-occurrence of brain tumors, Fanconi anemia, and breast cancer observed in one of these kindreds constitutes a new syndromic association", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14559878", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Fanconi anemia (FA) is a rare autosomal recessive disease characterized by skeletal defects, anemia, chromosomal instability and increased risk of leukemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12354784", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 436, "text": "FA is one of a group of recessive syndromes characterized by excessive spontaneous chromosomal breakage in which heterozygote carriers appear to display an increased risk of cancer and there is some indirect evidence that FA carriers may also be at increased risk of AML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12685843", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1193, "text": "In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Patients with Fanconi Anemia (FANC) have a well documented increased risk to develop malignancies, especially Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10994546", "endSection": "abstract"}, {"offsetInBeginSection": 166, "offsetInEndSection": 436, "text": "FA is one of a group of recessive syndromes characterized by excessive spontaneous chromosomal breakage in which heterozygote carriers appear to display an increased risk of cancer and there is some indirect evidence that FA carriers may also be at increased risk of AML", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12685843", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Fanconi anemia (FA) is a rare autosomal recessive disease characterized by skeletal defects, anemia, chromosomal instability and increased risk of leukemia", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12354784", "endSection": "abstract"}, {"offsetInBeginSection": 1039, "offsetInEndSection": 1193, "text": "In summary, both heterozygous and homozygous mutations in several Fanconi anemia-predisposing genes are associated with an increased risk of ESCC in Iran.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279724", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Patients with Fanconi Anemia (FANC) have a well documented increased risk to develop malignancies, especially Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10994546", "endSection": "abstract"}]}, {"body": "Is APOBEC3B protein predominantly cytoplasmic or nuclear?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22446380", "http://www.ncbi.nlm.nih.gov/pubmed/21715505", "http://www.ncbi.nlm.nih.gov/pubmed/23388464", "http://www.ncbi.nlm.nih.gov/pubmed/23389445", "http://www.ncbi.nlm.nih.gov/pubmed/18667511", "http://www.ncbi.nlm.nih.gov/pubmed/16648136"], "triples": [], "ideal_answer": ["Contrary to other APOBEC family members, APOBEC3B was found to predominantly concentrate to the cell nucleus."], "exact_answer": [[" nuclear"]], "concepts": ["http://www.uniprot.org/uniprot/ABC3B_HUMAN"], "type": "factoid", "id": "54e0ace81388e8454a000010", "snippets": [{"offsetInBeginSection": 350, "offsetInEndSection": 418, "text": "A3B is the only family member with steady-state nuclear localization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", "endSection": "abstract"}, {"offsetInBeginSection": 420, "offsetInEndSection": 685, "text": "Here, we show that A3B nuclear import is an active process requiring at least one amino acid (Val54) within an N-terminal motif analogous to the nuclear localization determinant of the antibody gene diversification enzyme AID (activation-induced cytosine deaminase)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", "endSection": "abstract"}, {"offsetInBeginSection": 1067, "offsetInEndSection": 1238, "text": "Our studies suggest that the present-day A3B enzyme retained the nuclear import mechanism of an ancestral AID protein during the expansion of the APOBEC3 locus in primates", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", "endSection": "abstract"}, {"offsetInBeginSection": 110, "offsetInEndSection": 322, "text": "However, we found that the predominantly nuclear A3B only weakly restricted infection by HIV-1, HIV-1\u0394vif, and human T-cell leukemia virus type 1 (HTLV-1), while significantly inhibiting LINE-1 retrotransposition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", "endSection": "abstract"}, {"offsetInBeginSection": 517, "offsetInEndSection": 887, "text": "In contrast to the exclusively cytoplasmic A3G, which is inactive against LINE-1 retrotransposition, the A3G/B protein, while localized mainly to the cytoplasm, was also present in the nucleus. Further mutational analysis revealed that residues 18, 19, 22, and 24 in A3B were the major determinants for nuclear versus cytoplasmic localization and antiretroviral activity", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", "endSection": "abstract"}, {"offsetInBeginSection": 1465, "offsetInEndSection": 1705, "text": "these observations suggest that changing 4 residues in the amino terminus of A3B not only retargets the protein from the nucleus to the cytoplasm but also enhances its ability to restrict HIV while retaining inhibition of retrotransposition", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21715505", "endSection": "abstract"}, {"offsetInBeginSection": 904, "offsetInEndSection": 999, "text": "After mitosis, APOBEC3B becomes nuclear, and APOBEC3D, APOBEC3F and APOBEC3G become cytoplasmic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388464", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 508, "text": "To define the domains of APOBEC3G that determine cytoplasmic localization, comparisons were made with APOBEC3B, which is predominantly nuclear.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18667511", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 674, "text": "The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648136", "endSection": "abstract"}, {"offsetInBeginSection": 350, "offsetInEndSection": 418, "text": "A3B is the only family member with steady-state nuclear localization", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", "endSection": "abstract"}, {"offsetInBeginSection": 420, "offsetInEndSection": 685, "text": "Here, we show that A3B nuclear import is an active process requiring at least one amino acid (Val54) within an N-terminal motif analogous to the nuclear localization determinant of the antibody gene diversification enzyme AID (activation-induced cytosine deaminase)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22446380", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 832, "text": "Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389445", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 673, "text": "The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648136", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 507, "text": "To define the domains of APOBEC3G that determine cytoplasmic localization, comparisons were made with APOBEC3B, which is predominantly nuclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18667511", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 673, "text": "The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648136", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 832, "text": "Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389445", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 507, "text": "To define the domains of APOBEC3G that determine cytoplasmic localization, comparisons were made with APOBEC3B, which is predominantly nuclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18667511", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 673, "text": "The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648136", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 832, "text": "Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389445", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 507, "text": "To define the domains of APOBEC3G that determine cytoplasmic localization, comparisons were made with APOBEC3B, which is predominantly nuclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18667511", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 673, "text": "The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648136", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 832, "text": "Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389445", "endSection": "abstract"}, {"offsetInBeginSection": 904, "offsetInEndSection": 999, "text": "After mitosis, APOBEC3B becomes nuclear, and APOBEC3D, APOBEC3F and APOBEC3G become cytoplasmic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388464", "endSection": "abstract"}, {"offsetInBeginSection": 365, "offsetInEndSection": 507, "text": "To define the domains of APOBEC3G that determine cytoplasmic localization, comparisons were made with APOBEC3B, which is predominantly nuclear", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18667511", "endSection": "abstract"}, {"offsetInBeginSection": 499, "offsetInEndSection": 673, "text": "The mechanism of L1 inhibition did not correlate with an obvious subcellular protein distribution as APOBEC3B appeared predominantly nuclear and APOBEC3F was mostly cytosolic", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648136", "endSection": "abstract"}, {"offsetInBeginSection": 682, "offsetInEndSection": 832, "text": "Endogenous APOBEC3B protein is predominantly nuclear and the only detectable source of DNA C-to-U editing activity in breast cancer cell-line extracts", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389445", "endSection": "abstract"}]}, {"body": "What is the genomic structure of the FAA (FANCA) gene?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9169126"], "triples": [], "ideal_answer": ["The FAA (FANCA) gene contains 43 exons spanning approximately 80 kb. Exons range from 34 to 188 bp, whereas sequence analysis of the 5' region upstream of the putative transcription start site showed no obvious TATA and CAAT boxes, but did show a GC-rich region, typical of housekeeping genes."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D052217"], "type": "summary", "id": "54edf27e94afd61504000010", "snippets": [{"offsetInBeginSection": 249, "offsetInEndSection": 553, "text": "In the present study we describe the genomic structure of the FAA gene. The gene contains 43 exons spanning approximately 80 kb as determined by the alignment of four cosmids and the fine localization of the first and the last exons in restriction fragments of these clones. Exons range from 34 to 188 bp", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169126", "endSection": "abstract"}, {"offsetInBeginSection": 827, "offsetInEndSection": 1011, "text": "Sequence analysis of the 5' region upstream of the putative transcription start site showed no obvious TATA and CAAT boxes, but did show a GC-rich region, typical of housekeeping genes", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169126", "endSection": "abstract"}, {"offsetInBeginSection": 249, "offsetInEndSection": 553, "text": "In the present study we describe the genomic structure of the FAA gene. The gene contains 43 exons spanning approximately 80 kb as determined by the alignment of four cosmids and the fine localization of the first and the last exons in restriction fragments of these clones. Exons range from 34 to 188 bp", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9169126", "endSection": "abstract"}]}, {"body": "Which is the primary distinction between the Reverse Warburg effect and the conventional Warburg effect?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23844381", "http://www.ncbi.nlm.nih.gov/pubmed/23388463", "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "http://www.ncbi.nlm.nih.gov/pubmed/22313602", "http://www.ncbi.nlm.nih.gov/pubmed/22236875", "http://www.ncbi.nlm.nih.gov/pubmed/21778829", "http://www.ncbi.nlm.nih.gov/pubmed/21558814", "http://www.ncbi.nlm.nih.gov/pubmed/21300172", "http://www.ncbi.nlm.nih.gov/pubmed/21521946", "http://www.ncbi.nlm.nih.gov/pubmed/20818174", "http://www.ncbi.nlm.nih.gov/pubmed/20562527", "http://www.ncbi.nlm.nih.gov/pubmed/20495363", "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "http://www.ncbi.nlm.nih.gov/pubmed/25197670", "http://www.ncbi.nlm.nih.gov/pubmed/23443971"], "triples": [], "ideal_answer": ["The conventional \"Warburg effect\" reffers to  the metabolic shift of cancer cells towards aerobic glycolysis, due to mitochondrial dysfunction. The \"reverse Warburg effect\" or \"parasitic\" energy-transfer, is a model of \"two-compartment tumor metabolism\". In this model, cancer cells secrete hydrogen peroxide (H2O2), initiating oxidative stress and aerobic glycolysis in the tumor stroma. The cancer-associated fibroblasts of the stroma are glycolytic and lack detectable mitochondria. These glycolytic stromal cells produce mitochondrial fuels (L-lactate, ketone bodies and chemical building blocks, such as amino acids -glutamine-, and nucleotides) that are then transferred to oxidative epithelial cancer cells. Lactate and ketones drive cancer cell  oxidative mitochondrial metabolism (OXPHOS), and building blocks sustain the anabolic needs of rapidly proliferating cancer cells. Therefore, according to the \"reverse Warburg effect\", stromal catabolism fuels anabolic tumor growth via energy transfer. Thus, in \"reverse Warburg effect\" the cancer-associated fibroblasts of the stroma undergo aerobic glycolysis, rather than epithelial cancer cells themselves, as proposed by the conventional \"Warburg effect\"."], "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004129"], "type": "summary", "id": "554403395beec11c10000001", "snippets": [{"offsetInBeginSection": 717, "offsetInEndSection": 1017, "text": "The metabolic energy transduction pathways are strongly affected in cancers. Mitochondrial dysfunction in cancer cells (Warburg effect) or in fibroblasts associated with cancer cells (reverse Warburg effect) results in decreased or increased power of the generated electromagnetic field, respectively", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844381", "endSection": "abstract"}, {"offsetInBeginSection": 1001, "offsetInEndSection": 1209, "text": "cigarette smoke induces catabolism in the local microenvironment, directly fueling oxidative mitochondrial metabolism (OXPHOS) in neighboring epithelial cancer cells, actively promoting anabolic tumor growth.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388463", "endSection": "abstract"}, {"offsetInBeginSection": 1736, "offsetInEndSection": 1962, "text": "our current findings are consistent with the idea that cigarette smoke induces the \"reverse Warburg effect,\" thereby fueling \"two-compartment tumor metabolism\" and oxidative mitochondrial metabolism in epithelial cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388463", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 537, "text": "We have recently proposed a new two-compartment model for understanding the Warburg effect in tumor metabolism. In this model, glycolytic stromal cells produce mitochondrial fuels (L-lactate and ketone bodies) that are then transferred to oxidative epithelial cancer cells, driving OXPHOS and mitochondrial metabolism. Thus, stromal catabolism fuels anabolic tumor growth via energy transfer. We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 916, "offsetInEndSection": 1151, "text": "Consistent with the \"reverse Warburg effect,\" our results indicate that metastatic breast cancer cells amplify oxidative mitochondrial metabolism (OXPHOS) and that adjacent stromal cells are glycolytic and lack detectable mitochondria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 1738, "offsetInEndSection": 1903, "text": "\"glycolytic\" cancer cells were rarely observed, indicating that the conventional \"Warburg effect\" does not frequently occur in cancer-positive lymph node metastases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 718, "text": "We have recently proposed a new model of cancer metabolism to explain the role of aerobic glycolysis and L-lactate production in fueling tumor growth and metastasis. In this model, cancer cells secrete hydrogen peroxide (H2O2), initiating oxidative stress and aerobic glycolysis in the tumor stroma. This, in turn, drives L-lactate secretion from cancer-associated fibroblasts. Secreted L-lactate then fuels oxidative mitochondrial metabolism (OXPHOS) in epithelial cancer cells, by acting as a paracrine onco-metabolite. We have previously termed this type of two-compartment tumor metabolism the \"Reverse Warburg Effect,\" as aerobic glycolysis takes place in stromal fibroblasts, rather than epithelial cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602", "endSection": "abstract"}, {"offsetInBeginSection": 1850, "offsetInEndSection": 1909, "text": "the \"Reverse Warburg Effect\" or \"parasitic\" energy-transfer", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22313602", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 627, "text": "We have previously demonstrated that enhanced aerobic glycolysis and/or autophagy in the tumor stroma supports epithelial cancer cell growth and aggressive behavior, via the secretion of high-energy metabolites. These nutrients include lactate and ketones, as well as chemical building blocks, such as amino acids (glutamine) and nucleotides. Lactate and ketones serve as fuel for cancer cell oxidative metabolism, and building blocks sustain the anabolic needs of rapidly proliferating cancer cells. We have termed these novel concepts the \"Reverse Warburg Effect,\" and the \"Autophagic Tumor Stroma Model of Cancer Metabolism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22236875", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 667, "text": "Previously, we proposed that cancer cells behave as metabolic parasites, as they use targeted oxidative stress as a \"weapon\" to extract recycled nutrients from adjacent stromal cells. Oxidative stress in cancer-associated fibroblasts triggers autophagy and\u00a0 mitophagy, resulting in compartmentalized cellular catabolism, loss of mitochondrial function, and the onset of aerobic glycolysis, in the tumor stroma. As such, cancer-associated fibroblasts produce high-energy nutrients (such as lactate and ketones) that fuel mitochondrial biogenesis, and oxidative metabolism in cancer cells. We have termed this new energy-transfer mechanism the \"reverse Warburg effect.\"", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21778829", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 450, "text": "Recently, we proposed a new mechanism for understanding the Warburg effect in cancer metabolism. In this new paradigm, cancer-associated fibroblasts undergo aerobic glycolysis, and extrude lactate to \"feed\" adjacent cancer cells, which then drives mitochondrial biogenesis and oxidative mitochondrial metabolism in cancer cells. Thus, there is vectorial transport of energy-rich substrates from the fibroblastic tumor stroma to anabolic cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21558814", "endSection": "abstract"}, {"offsetInBeginSection": 2073, "offsetInEndSection": 2487, "text": " the \"reverse Warburg effect,\" which states that cancer-associated fibroblasts undergo aerobic glycolysis, thereby producing lactate, which is utilized as a metabolic substrate by adjacent cancer cells. In this model, \"energy transfer\" or \"metabolic-coupling\" between the tumor stroma and epithelial cancer cells \"fuels\" tumor growth and metastasis, via oxidative mitochondrial metabolism in anabolic cancer cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21558814", "endSection": "abstract"}, {"offsetInBeginSection": 395, "offsetInEndSection": 701, "text": "the Warburg effect in cancer cells may be due to culturing cancer cells by themselves, out of their normal stromal context or tumor microenvironment. In fact, when cancer cells are co-cultured with fibroblasts, then cancer cells increase their mitochondrial mass, while fibroblasts lose their mitochondria.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300172", "endSection": "abstract"}, {"offsetInBeginSection": 1367, "offsetInEndSection": 1637, "text": " stromal catabolism, via autophagy and mitophagy, fuels the anabolic growth of tumor cells, promoting tumor progression and metastasis. We have previously termed this new paradigm \"The Autophagic Tumor Stroma Model of Cancer Metabolism\", or the \"Reverse Warburg Effect\".", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300172", "endSection": "abstract"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1606, "text": "Our findings are consistent with the recently proposed \"Reverse Warburg Effect\" and the \"Autophagic Tumor Stroma Model of Cancer Metabolism.\" In these two complementary models, cancer cells induce oxidative stress in adjacent stromal cells, which then forces these stromal fibroblasts to undergo autophagy/mitophagy and aerobic glycolysis. This, in turn, produces recycled nutrients (lactate, ketones and glutamine) to feed anabolic cancer cells, which are undergoing oxidative mitochondrial metabolism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21521946", "endSection": "abstract"}, {"offsetInBeginSection": 112, "offsetInEndSection": 418, "text": "cancer-associated fibroblasts undergo aerobic glycolysis and the resulting energy-rich metabolites are then transferred to epithelial cancer cells, where they enter the TCA cycle, resulting in high ATP production via oxidative phosphorylation. We have termed this new paradigm \"The Reverse Warburg Effect.\"", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20818174", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 408, "text": "Previously, we proposed a new model for understanding the Warburg effect in tumorigenesis and metastasis. In this model, the stromal fibroblasts would undergo aerobic glycolysis (a.k.a., the Warburg effect)--producing and secreting increased pyruvate/lactate that could then be used by adjacent epithelial cancer cells as \"fuel\" for the mitochondrial TCA cycle, oxidative phosphorylation, and ATP production.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20562527", "endSection": "abstract"}, {"offsetInBeginSection": 648, "offsetInEndSection": 1228, "text": "In this alternative model of tumorigenesis, the epithelial cancer cells instruct the normal stroma to transform into a wound-healing stroma, providing the necessary energy-rich micro-environment for facilitating tumor growth and angiogenesis. In essence, the fibroblastic tumor stroma would directly feed the epithelial cancer cells, in a type of host-parasite relationship. We have termed this new idea the \"Reverse Warburg Effect.\" In this scenario, the epithelial tumor cells \"corrupt\" the normal stroma, turning it into a factory for the production of energy-rich metabolites.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "abstract"}, {"offsetInBeginSection": 1277, "offsetInEndSection": 1370, "text": "Warburg's original observation that tumors show a metabolic shift towards aerobic glycolysis.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 389, "offsetInEndSection": 534, "text": "We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 389, "offsetInEndSection": 534, "text": "We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 389, "offsetInEndSection": 534, "text": "We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1208, "text": "Thus, we conclude that ketones and lactate fuel tumor growth and metastasis, providing functional evidence to support the \"Reverse Warburg Effect\".", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20818174", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 389, "offsetInEndSection": 534, "text": "We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 393, "offsetInEndSection": 536, "text": "We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}, {"offsetInBeginSection": 393, "offsetInEndSection": 536, "text": "We have termed this new cancer paradigm the \"reverse Warburg effect,\" because stromal cells undergo aerobic glycolysis, rather than tumor cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22395432", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19923890", "endSection": "title"}]}, {"body": "What is the involvement of PDGFRB in metastatic medulloblastoma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19417143"], "triples": [], "ideal_answer": ["Platelet-derived growth factor (PDGF) receptor B (PDGFRB) expression was shown to correlate with metastatic medulloblastoma, while PDGFRB tyrosine kinase activity was demonstrated to be critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR."], "concepts": ["http://www.uniprot.org/uniprot/PGFRB_TAKRU", "http://www.disease-ontology.org/api/metadata/DOID:3858", "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020797"], "type": "summary", "id": "55391b2cbc4f83e828000017", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Platelet-derived growth factor (PDGF) receptor (PDGFR) expression correlates with metastatic medulloblastoma. PDGF stimulation of medulloblastoma cells phosphorylates extracellular signal-regulated kinase (ERK) and promotes migration", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1004, "offsetInEndSection": 1900, "text": "Imatinib (1 \u03bcmol/L) treatment of DAOY and D556 cells inhibited PDGF-BB- and serum-mediated migration and invasion at 24 and 48 h, respectively, and concomitantly inhibited PDGF-BB activation of PDGFRB, Akt, and ERK but increased PTEN expression and activity. Imatinib treatment also induced DAOY cell apoptosis at 72 h and inhibited DAOY and D556 cell proliferation at 48 h. siRNA silencing of PDGFRB similarly inhibited signaling, migration, and survival and both siRNA and imatinib treatment inhibited PDGF-BB-mediated EGFR transactivation, indicating that the effects of imatinib treatment are specific to PDGFRB target inhibition. These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1629, "offsetInEndSection": 1891, "text": "These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1629, "offsetInEndSection": 1891, "text": "These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1629, "offsetInEndSection": 1891, "text": "These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1629, "offsetInEndSection": 1891, "text": "These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1639, "offsetInEndSection": 1900, "text": "These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 200, "text": "Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 233, "text": "Platelet-derived growth factor (PDGF) receptor (PDGFR) expression correlates with metastatic medulloblastoma. PDGF stimulation of medulloblastoma cells phosphorylates extracellular signal-regulated kinase (ERK) and promotes migration", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}, {"offsetInBeginSection": 1639, "offsetInEndSection": 1899, "text": "These results indicate that PDGFRB tyrosine kinase activity is critical for migration and invasion of medulloblastoma cells possibly by transactivating EGFR; thus, imatinib may represent an important novel therapeutic agent for the treatment of medulloblastoma", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417143", "endSection": "abstract"}]}, {"body": "Approximately how many recombination hotspots have been found in the yeast genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19557188", "http://www.ncbi.nlm.nih.gov/pubmed/18682829", "http://www.ncbi.nlm.nih.gov/pubmed/18449558", "http://www.ncbi.nlm.nih.gov/pubmed/17478517", "http://www.ncbi.nlm.nih.gov/pubmed/16640774", "http://www.ncbi.nlm.nih.gov/pubmed/8290959"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#broader", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0010844", "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0003677"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0003677", "o": "DNA binding"}, {"p": "http://www.w3.org/2004/02/skos/core#altLabel", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0010844", "o": "DNA binding, recombination hotspot"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0010844", "o": "recombination hotspot binding"}, {"p": "http://www.w3.org/2004/02/skos/core#relatedSynonym", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0003677", "o": "microtubule/chromatin interaction"}, {"p": "http://www.w3.org/2004/02/skos/core#narrowSynonym", "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0003677", "o": "plasmid binding"}], "ideal_answer": "In the fission yeast genome DSBs are located within 194 prominent peaks separated on average by 65-kbp intervals of DNA that are largely free of DSBs.", "exact_answer": ["Approximately 200", "200", "~200"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011995", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010844", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006312", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051598", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015003", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012441"], "type": "factoid", "id": "534e364e288f4dae47000001", "snippets": [{"offsetInBeginSection": 387, "offsetInEndSection": 536, "text": "In the fission yeast genome DSBs are located within 194 prominent peaks separated on average by 65-kbp intervals of DNA that are largely free of DSBs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18682829", "endSection": "abstract"}, {"offsetInBeginSection": 288, "offsetInEndSection": 385, "text": "Most meiotic recombination is positioned at hotspots, but knowledge of the mechanisms is nebulous", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18682829", "endSection": "abstract"}, {"offsetInBeginSection": 14, "offsetInEndSection": 214, "text": "meiotic recombination is initiated by double-strand DNA breaks (DSBs) which occur at relatively high frequencies in some genomic regions (hotspots) and relatively low frequencies in others (coldspots)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17478517", "endSection": "abstract"}]}, {"body": "What is known about MER41 repeat sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20625510", "http://www.ncbi.nlm.nih.gov/pubmed/9204548"], "triples": [], "ideal_answer": ["The sequences of five families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses. Age estimations place the origin of most MER repeats at the time of decline in MIR (Mammalian-wide Interspersed Repeats) retroposition and before the origin of the Alu family. MER41 repeat sequences contain inducible STAT1 binding sites. The observation of the binding of activated STAT1 protein to a specific repetitive element bolsters similar reports concerning p53 and other TFs, and strengthens the notion of an involvement of repeats in gene regulation.", "We report eleven new families of MEdium Reiteration frequency (MER) interspersed repeats in the genomes of Primates, Rodentia, and Lagomorpha. Two families of the human repeats, MER 46 and MER 47, represent non-autonomous DNA transposons. These sequences are flanked by TA target site duplications and have terminal inverted repeats (TIRs) similar to TIRs of DNA transposons. The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses. A potential involvement of some of the reported MER repeats in the regulation of transcription and genetic rearrangements is suggested. Age estimations place the origin of most MER repeats at the time of decline in MIR (Mammalian-wide Interspersed Repeats) retroposition and before the origin of the Alu familyMER41 repeat sequences contain inducible STAT1 binding sites", "We report eleven new families of MEdium Reiteration frequency (MER) interspersed repeats in the genomes of Primates, Rodentia, and Lagomorpha. Two families of the human repeats, MER 46 and MER 47, represent non-autonomous DNA transposons. These sequences are flanked by TA target site duplications and have terminal inverted repeats (TIRs) similar to TIRs of DNA transposons. The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses. A potential involvement of some of the reported MER repeats in the regulation of transcription and genetic rearrangements is suggested. Age estimations place the origin of most MER repeats at the time of decline in MIR (Mammalian-wide Interspersed Repeats) retroposition and before the origin of the Alu familyMER41 repeat sequences contain inducible STAT1 binding sites", "We report eleven new families of MEdium Reiteration frequency (MER) interspersed repeats in the genomes of Primates, Rodentia, and Lagomorpha. Two families of the human repeats, MER 46 and MER 47, represent non-autonomous DNA transposons. These sequences are flanked by TA target site duplications and have terminal inverted repeats (TIRs) similar to TIRs of DNA transposons. The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses. A potential involvement of some of the reported MER repeats in the regulation of transcription and genetic rearrangements is suggested. Age estimations place the origin of most MER repeats at the time of decline in MIR (Mammalian-wide Interspersed Repeats) retroposition and before the origin of the Alu family  MER41 repeat sequences contain inducible STAT1 binding sites  ", "We report eleven new families of MEdium Reiteration frequency (MER) interspersed repeats in the genomes of Primates, Rodentia, and Lagomorpha. Two families of the human repeats, MER 46 and MER 47, represent non-autonomous DNA transposons. These sequences are flanked by TA target site duplications and have terminal inverted repeats (TIRs) similar to TIRs of DNA transposons. The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses. A potential involvement of some of the reported MER repeats in the regulation of transcription and genetic rearrangements is suggested. Age estimations place the origin of most MER repeats at the time of decline in MIR (Mammalian-wide Interspersed Repeats) retroposition and before the origin of the Alu family  MER41 repeat sequences contain inducible STAT1 binding sites  "], "concepts": [], "type": "summary", "id": "55414e4f472cfd8617000002", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 822, "text": "We report eleven new families of MEdium Reiteration frequency (MER) interspersed repeats in the genomes of Primates, Rodentia, and Lagomorpha. Two families of the human repeats, MER 46 and MER 47, represent non-autonomous DNA transposons. These sequences are flanked by TA target site duplications and have terminal inverted repeats (TIRs) similar to TIRs of DNA transposons. The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses. A potential involvement of some of the reported MER repeats in the regulation of transcription and genetic rearrangements is suggested. Age estimations place the origin of most MER repeats at the time of decline in MIR (Mammalian-wide Interspersed Repeats) retroposition and before the origin of the Alu family", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "MER41 repeat sequences contain inducible STAT1 binding sites", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 701, "offsetInEndSection": 1973, "text": "Contrary to previous claims, we find no evidence that STAT1 binds to multiple distinct motifs upon interferon-gamma stimulation in vivo. While a large majority of genomic sites with high ChIP-seq signal is associated with a nucleotide sequence resembling a STAT1 binding site, only a very small subset of the over 5 million potential STAT1 binding sites in the human genome is covered by ChIP-seq data. Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41). The observation of the binding of activated STAT1 protein to a specific repetitive element bolsters similar reports concerning p53 and other TFs, and strengthens the notion of an involvement of repeats in gene regulation. Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents. On a methodological aspect, the presence of large numbers of nearly identical binding sites in repetitive sequences may lead to wrong conclusions about intrinsic binding preferences of TF as illustrated by the spacing analysis STAT1 tandem motifs. Therefore, ChIP-seq data should be analyzed independently within repetitive and non-repetitive sequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 508, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1229, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1449, "offsetInEndSection": 1611, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 508, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1229, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1449, "offsetInEndSection": 1611, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 508, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1229, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1449, "offsetInEndSection": 1611, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 372, "offsetInEndSection": 508, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1229, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1449, "offsetInEndSection": 1611, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 511, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1236, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 376, "offsetInEndSection": 511, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1620, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 376, "offsetInEndSection": 510, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1235, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1619, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 376, "offsetInEndSection": 510, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1235, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1619, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 376, "offsetInEndSection": 510, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1235, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1619, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "MER41 repeat sequences contain inducible STAT1 binding sites.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "title"}, {"offsetInBeginSection": 376, "offsetInEndSection": 510, "text": "The sequences of five other families of repeats, MER41, MER48, MER50, MER51, and RMER3, resemble long terminal repeats of retroviruses", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9204548", "endSection": "abstract"}, {"offsetInBeginSection": 1104, "offsetInEndSection": 1235, "text": "Furthermore a surprisingly large fraction of the ChIP-seq signal (5%) is absorbed by a small family of repetitive sequences (MER41)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}, {"offsetInBeginSection": 1459, "offsetInEndSection": 1619, "text": "Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625510", "endSection": "abstract"}]}, {"body": "What is the evolutionary process described by the \"Muller's ratchet\" model?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24244123", "http://www.ncbi.nlm.nih.gov/pubmed/23100362", "http://www.ncbi.nlm.nih.gov/pubmed/23046686", "http://www.ncbi.nlm.nih.gov/pubmed/23028310", "http://www.ncbi.nlm.nih.gov/pubmed/22649084", "http://www.ncbi.nlm.nih.gov/pubmed/22661327", "http://www.ncbi.nlm.nih.gov/pubmed/19305500", "http://www.ncbi.nlm.nih.gov/pubmed/4448362", "http://www.ncbi.nlm.nih.gov/pubmed/18302772", "http://www.ncbi.nlm.nih.gov/pubmed/12967275", "http://www.ncbi.nlm.nih.gov/pubmed/8570657", "http://www.ncbi.nlm.nih.gov/pubmed/11164046", "http://www.ncbi.nlm.nih.gov/pubmed/8380072", "http://www.ncbi.nlm.nih.gov/pubmed/16957730", "http://www.ncbi.nlm.nih.gov/pubmed/20657178", "http://www.ncbi.nlm.nih.gov/pubmed/16709275", "http://www.ncbi.nlm.nih.gov/pubmed/9369098", "http://www.ncbi.nlm.nih.gov/pubmed/8365659", "http://www.ncbi.nlm.nih.gov/pubmed/16924405", "http://www.ncbi.nlm.nih.gov/pubmed/14741203", "http://www.ncbi.nlm.nih.gov/pubmed/17720933", "http://www.ncbi.nlm.nih.gov/pubmed/18366680"], "triples": [], "ideal_answer": ["The vast majority of mutations are deleterious and are eliminated by purifying selection. Yet in finite populations, purifying selection cannot completely prevent the accumulation of deleterious mutations. Muller's ratchet is a paradigmatic model for the accumulation of deleterious mutations in a population of finite size, due to genetic drift. Muller's ratchet suggests that population bottlenecks, which may constrain the genetic diversity of a population, could lead to extinction of all individuals with the least number of deleterious mutations, due to a stochastic fluctuation. When the most-fit class of genotypes is lost, it is lost irreversibly."], "concepts": [], "type": "summary", "id": "554a0cadf35db7552600000f", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Muller's ratchet is a paradigmatic model for the accumulation of deleterious mutations in a population of finite size. A click of the ratchet occurs when all individuals with the least number of deleterious mutations are lost irreversibly due to a stochastic fluctuation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24244123", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Population bottlenecks can have major effects in the evolution of RNA viruses, but their possible influence in the evolution of DNA viruses is largely unknown.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100362", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 222, "text": "The accumulation of deleterious mutations of a population directly contributes to the fate as to how long the population would exist, a process often described as Muller's ratchet with the absorbing phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046686", "endSection": "abstract"}, {"offsetInBeginSection": 108, "offsetInEndSection": 515, "text": "Genetic diversity is thought to be important in allowing RNA viruses to explore sequence space, facilitating adaptation to changing environments and hosts. Some arboviruses that infect both a mosquito vector and a mammalian host are known to experience population bottlenecks in their vectors, which may constrain their genetic diversity and could potentially lead to extinction events via Muller's ratchet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23028310", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "The accumulation of deleterious mutations is driven by rare fluctuations that lead to the loss of all mutation free individuals, a process known as Muller's ratchet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 317, "text": "The vast majority of mutations are deleterious and are eliminated by purifying selection. Yet in finite asexual populations, purifying selection cannot completely prevent the accumulation of deleterious mutations due to Muller's ratchet: once lost by stochastic drift, the most-fit class of genotypes is lost forever.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22661327", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 261, "text": "Primary bacterial endosymbionts of insects (p-endosymbionts) are thought to be undergoing the process of Muller's ratchet where they accrue slightly deleterious mutations due to genetic drift in small populations with negligible recombination rates.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19305500", "endSection": "abstract"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1108, "text": "Computer simulations of substitution of favorable mutants and of the long-term increase of deleterious mutants verified the essential correctness of the original Fisher-Muller argument and the reality of the Muller ratchet mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4448362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The theory of Muller' Ratchet predicts that small asexual populations are doomed to accumulate ever-increasing deleterious mutation loads as a consequence of the magnified power of genetic drift and mutation that accompanies small population size.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18302772", "endSection": "abstract"}, {"offsetInBeginSection": 704, "offsetInEndSection": 875, "text": "It also predicts the \"ratchet mechanism\" discovered by Muller, who pointed out that deleterious mutants would more readily increase in a population without recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4448362", "endSection": "abstract"}, {"offsetInBeginSection": 428, "offsetInEndSection": 617, "text": "We also demonstrate that during repeated genetic bottleneck passages, accumulation of deleterious mutations does occur in a stepwise (ratchet-like) manner as originally proposed by Muller.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8380072", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Muller proposed that an asexual organism will inevitably accumulate deleterious mutations, resulting in an increase of the mutational load and an inexorable, ratchet-like, loss of the least mutated class [Muller, H.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8570657", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 540, "text": "In asexual populations, as Muller noted, the loss is irreversible and the load of deleterious mutations increases in a ratchet-like manner with the successive loss of the least-mutated individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2247152", "endSection": "abstract"}, {"offsetInBeginSection": 874, "offsetInEndSection": 1108, "text": "Computer simulations of substitution of favorable mutants and of the long-term increase of deleterious mutants verified the essential correctness of the original Fisher-Muller argument and the reality of the Muller ratchet mechanism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4448362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The theory of Muller' Ratchet predicts that small asexual populations are doomed to accumulate ever-increasing deleterious mutation loads as a consequence of the magnified power of genetic drift and mutation that accompanies small population size.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18302772", "endSection": "abstract"}, {"offsetInBeginSection": 704, "offsetInEndSection": 875, "text": "It also predicts the \"ratchet mechanism\" discovered by Muller, who pointed out that deleterious mutants would more readily increase in a population without recombination.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/4448362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "Muller proposed that an asexual organism will inevitably accumulate deleterious mutations, resulting in an increase of the mutational load and an inexorable, ratchet-like, loss of the least mutated class [Muller, H.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8570657", "endSection": "abstract"}, {"offsetInBeginSection": 342, "offsetInEndSection": 540, "text": "In asexual populations, as Muller noted, the loss is irreversible and the load of deleterious mutations increases in a ratchet-like manner with the successive loss of the least-mutated individuals.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2247152", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The theory of Muller' Ratchet predicts that small asexual populations are doomed to accumulate ever-increasing deleterious mutation loads as a consequence of the magnified power of genetic drift and mutation that accompanies small population size.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18302772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 247, "text": "The theory of Muller' Ratchet predicts that small asexual populations are doomed to accumulate ever-increasing deleterious mutation loads as a consequence of the magnified power of genetic drift and mutation that accompanies small population size.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18302772", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 221, "text": "BACKGROUND: The accumulation of deleterious mutations of a population directly contributes to the fate as to how long the population would exist, a process often described as Mullers ratchet with the absorbing phenomenon.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046686", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "The accumulation of deleterious mutations is driven by rare fluctuations that lead to the loss of all mutation free individuals, a process known as Mullers ratchet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "The accumulation of deleterious mutations is driven by rare fluctuations that lead to the loss of all mutation free individuals, a process known as Muller's ratchet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22649084", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Deleterious mutations can accumulate in asexual haploid genomes through the process known as Muller's ratchet.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17720933", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Deleterious mutations can accumulate in asexual haploid genomes through the process known as Muller's ratchet", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17720933", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The accumulation of deleterious mutations of a population directly contributes to the fate as to how long the population would exist, a process often described as Muller's ratchet with the absorbing phenomenon", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046686", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The accumulation of deleterious mutations of a population directly contributes to the fate as to how long the population would exist, a process often described as Muller's ratchet with the absorbing phenomenon", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046686", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "The accumulation of deleterious mutations of a population directly contributes to the fate as to how long the population would exist, a process often described as Muller's ratchet with the absorbing phenomenon", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046686", "endSection": "abstract"}]}, {"body": "What is Cerebral Cavernous Malformation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26109568", "http://www.ncbi.nlm.nih.gov/pubmed/26523262", "http://www.ncbi.nlm.nih.gov/pubmed/24401931", "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "http://www.ncbi.nlm.nih.gov/pubmed/21543988", "http://www.ncbi.nlm.nih.gov/pubmed/8596595", "http://www.ncbi.nlm.nih.gov/pubmed/12140362", "http://www.ncbi.nlm.nih.gov/pubmed/22711159"], "triples": [], "ideal_answer": ["Cerebral cavernous malformations (CMs) are vascular malformations of the central nervous system, causing hemorrhagic strokes, seizures, and neurological deficits.", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences "], "concepts": [], "type": "summary", "id": "571f2e8e0fd6f91b68000001", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26109568", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 316, "text": "Cerebral cavernous malformations (CMs) are vascular malformations of the central nervous system, which can be detected in the absence of any clinical symptoms. Nodules and cysts with mixed signal intensity and a peripheral hemosiderin rim are considered brain magnetic resonance imaging (MRI) findings typical of CMs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26523262", "endSection": "abstract"}, {"offsetInBeginSection": 12, "offsetInEndSection": 196, "text": "Cerebral cavernous malformations (CCM) are enlarged vascular lesions affecting 0.1-0.5% of the population worldwide and causing hemorrhagic strokes, seizures, and neurological deficits", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24401931", "endSection": "abstract"}, {"offsetInBeginSection": 1887, "offsetInEndSection": 2229, "text": "Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "Mutations in Krev1 interaction trapped gene 1 (KRIT1) cause cerebral cavernous malformation, an autosomal dominant disease featuring malformation of cerebral capillaries resulting in cerebral hemorrhage, strokes, and seizures.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12140362", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8596595", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Cerebral cavernous malformation (CCM) is a common vascular disease in central nervous system that frequently predisposes to stroke, seizure, and cerebral hemorrhage", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22711159", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26109568", "endSection": "abstract"}, {"offsetInBeginSection": 1553, "offsetInEndSection": 2078, "text": "Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations. Cerebral cavernous malformations represented as hemosiderin deposition without central core (type IV) have a lower tendency to rebleed than other types and do not need any treatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 1451, "offsetInEndSection": 1895, "text": "Adverse reaction of irradiation was observed in five of 22 patients treated with gamma knife surgery. Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 118, "offsetInEndSection": 356, "text": "Cerebral cavernous malformations often remain clinically silent until a mutation carrier suffers a stroke or seizure. Presymptomatic genetic testing has been valuable to follow and manage cerebral cavernous malformation mutation carriers.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21543988", "endSection": "abstract"}, {"offsetInBeginSection": 1553, "offsetInEndSection": 1895, "text": "Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8596595", "endSection": "abstract"}, {"offsetInBeginSection": 1553, "offsetInEndSection": 1895, "text": "Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8596595", "endSection": "abstract"}, {"offsetInBeginSection": 1553, "offsetInEndSection": 1895, "text": "Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8596595", "endSection": "abstract"}, {"offsetInBeginSection": 1553, "offsetInEndSection": 1895, "text": "Although most cerebral cavernous malformations showed evolution of hemorrhage or no change in size or shape on follow-up MR images, cerebral cavernous malformations represented as mixture of subacute and chronic hemorrhage with hemosiderin rim (type II) have a higher frequency to rebleed than other types of cerebral cavernous malformations.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10235015", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Cerebral cavernous malformation is a vascular disease of the brain causing headaches, seizures, and cerebral hemorrhage.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8596595", "endSection": "abstract"}]}, {"body": "How is myotonic dystrophy inherited?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22332444", "http://www.ncbi.nlm.nih.gov/pubmed/18228241", "http://www.ncbi.nlm.nih.gov/pubmed/12970845", "http://www.ncbi.nlm.nih.gov/pubmed/12577208", "http://www.ncbi.nlm.nih.gov/pubmed/8154209"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A1189440", "o": "myotonic dystrophy"}, {"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A12058083", "o": "Myotonic Dystrophy"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C0027126", "o": "http://linkedlifedata.com/resource/umls/label/A12058083"}], "ideal_answer": ["Myotonic dystrophy (DM) is a heterogeneous neuromuscular disease with an autosomal dominant pattern of inheritance."], "exact_answer": ["autosomal dominant"], "concepts": ["http://www.disease-ontology.org/api/metadata/DOID:11722", "http://www.disease-ontology.org/api/metadata/DOID:450", "http://www.disease-ontology.org/api/metadata/DOID:655", "http://www.disease-ontology.org/api/metadata/DOID:9884"], "type": "factoid", "id": "51635202298dcd4e5100004f", "snippets": [{"offsetInBeginSection": 12, "offsetInEndSection": 229, "text": "Myotonic dystrophy type 2 (DM2) is an autosomal dominant, multisystem disorder caused by a CCTG tetranucleotide repeat expansion located in intron 1 of the zinc finger protein 9 gene (ZNF9 gene) on chromosome 3q 21.3.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22332444", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228241", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 362, "text": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12970845", "endSection": "sections.0"}, {"offsetInBeginSection": 470, "offsetInEndSection": 677, "text": "proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12970845", "endSection": "sections.0"}, {"offsetInBeginSection": 859, "offsetInEndSection": 905, "text": "All patients have the DM2 (CCTG)(n) expansion.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12970845", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 195, "text": "Myotonic dystrophy type 1 is a neuromuscular, degenerative and progressive disease, with an autosomal dominant pattern of inheritance, variable expressivity and incomplete penetrance.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12577208", "endSection": "sections.0"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1259, "text": "The worldwide intergenerational behavior of the DM1 mutation is similar in Costa Rica", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12577208", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Dystrophic myotonia is a sufficiently rare disease inherited mainly by the autosomal dominant type.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8154209", "endSection": "sections.0"}]}, {"body": "Which disease can be treated with Delamanid?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26288734", "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "http://www.ncbi.nlm.nih.gov/pubmed/25327169", "http://www.ncbi.nlm.nih.gov/pubmed/24729727", "http://www.ncbi.nlm.nih.gov/pubmed/22670901"], "triples": [{"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A20909765", "o": "C516022"}, {"p": "http://www.w3.org/2004/02/skos/core#notation", "s": "http://linkedlifedata.com/resource/umls/label/A0049608", "o": "D004194"}], "ideal_answer": ["Delamanid is used in patients with multidrug-resistant tuberculosis."], "exact_answer": [["tuberculosis"]], "concepts": [], "type": "factoid", "id": "56bc7d71ac7ad10019000018", "snippets": [{"offsetInBeginSection": 189, "offsetInEndSection": 362, "text": "Recently approved anti-Tb drugs (bedaquiline and delamanid) have the potential to induce arrhythmia and are recommended in patients with MDR-Tb when other alternatives fail.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26288734", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 242, "text": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 527, "offsetInEndSection": 758, "text": "In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 1653, "offsetInEndSection": 1769, "text": "In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25327169", "endSection": "title"}, {"offsetInBeginSection": 272, "offsetInEndSection": 533, "text": "This review covers the efficacy and safety of delamanid for MDR-TB.AREA COVERED: This paper reviews the pharmacological profile of delamanid and the results of clinical trials evaluating its efficacy for treating MDR-TB in combination with other anti-TB drugs. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25327169", "endSection": "abstract"}, {"offsetInBeginSection": 597, "offsetInEndSection": 750, "text": "EXPERT OPINION: Delamanid showed potent activity against drug-susceptible and -resistant Mycobacterium tuberculosis in both in vitro and in vivo studies.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25327169", "endSection": "abstract"}, {"offsetInBeginSection": 986, "offsetInEndSection": 1097, "text": "In addition, decreased mortality was observed in MDR-TB patients who received>6 months of delamanid treatment. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25327169", "endSection": "abstract"}, {"offsetInBeginSection": 1228, "offsetInEndSection": 1455, "text": "Therefore, delamanid could be used as part of an appropriate combination regimen for pulmonary MDR-TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25327169", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "Delamanid for multidrug-resistant pulmonary tuberculosis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22670901", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 741, "text": "BACKGROUND: Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.METHODS: In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22670901", "endSection": "abstract"}, {"offsetInBeginSection": 2099, "offsetInEndSection": 2206, "text": "This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22670901", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1484, "text": "Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1484, "text": "Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1484, "text": "Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 1233, "offsetInEndSection": 1444, "text": "Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729727", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1484, "text": "Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}, {"offsetInBeginSection": 1233, "offsetInEndSection": 1444, "text": "Linezolid may represent a valuable drug to treat cases of XDR-TB. Delamanid, bedaquiline, and PA-824 are new anti-TB agents in the development pipeline that have the potential to enhance the cure rate of XDR-TB.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729727", "endSection": "abstract"}, {"offsetInBeginSection": 1193, "offsetInEndSection": 1484, "text": "Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404020", "endSection": "abstract"}]}, {"body": "Which is the clinical meaning of the presence of delayed enhancement in patients with hypertrophic cardiomyopathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23097128", "http://www.ncbi.nlm.nih.gov/pubmed/22641976", "http://www.ncbi.nlm.nih.gov/pubmed/21498307", "http://www.ncbi.nlm.nih.gov/pubmed/20102955", "http://www.ncbi.nlm.nih.gov/pubmed/19808288", "http://www.ncbi.nlm.nih.gov/pubmed/19477402", "http://www.ncbi.nlm.nih.gov/pubmed/18552138", "http://www.ncbi.nlm.nih.gov/pubmed/18387438"], "triples": [], "ideal_answer": "Occurrence of myocardial fibrosis in hypertrophic cardiomyopathy is associated with left atrial and ventricular dysfunction as well as with the severity of heart failure symptoms and arrhythmic risk factors.", "exact_answer": ["In patients with hypertrophic cardiomyopathy delayed enhancement is associated with heart failure symptoms and left ventricular systolic dysfunction and arrhythmic risk"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002312", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009682", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008279", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010361", "http://www.disease-ontology.org/api/metadata/DOID:11984", "http://www.disease-ontology.org/api/metadata/DOID:11986", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D024741", "http://www.disease-ontology.org/api/metadata/DOID:0050700", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009202"], "type": "factoid", "id": "5339edd6d6d3ac6a34000061", "snippets": [{"offsetInBeginSection": 1464, "offsetInEndSection": 1664, "text": "The extent of regional myocardial fibrosis is associated with regional myocardial function independently of morphological changes of the myocardium, and the correlation extended to global LV function.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097128", "endSection": "abstract"}, {"offsetInBeginSection": 1606, "offsetInEndSection": 1785, "text": "Occurrence of myocardial fibrosis in hypertrophic cardiomyopathy is associated with left atrial and ventricular dysfunction as well as with the severity of heart failure symptoms.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22641976", "endSection": "abstract"}, {"offsetInBeginSection": 1376, "offsetInEndSection": 1595, "text": "Patients with symptomatic apical HCMshowed myocardial hyperenhancement involving the subendocardial layer, which might be related to regional systolic dysfunction, serious clinical symptoms, and ventricular arrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498307", "endSection": "abstract"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1269, "text": "In conclusion, late gadolinium enhancement was associated with nonsustained ventricular tachycardia, arrhythmic risk factors, and worse New York Heart Association class.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20102955", "endSection": "abstract"}, {"offsetInBeginSection": 666, "offsetInEndSection": 798, "text": "The presence of DE was related to occurrence of heart failure symptoms (P=0.05) and left ventricular systolic dysfunction (P=0.001).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808288", "endSection": "abstract"}, {"offsetInBeginSection": 1066, "offsetInEndSection": 1183, "text": "DE (7%+/-7% of left ventricle) was present in 54 patients who were asymptomatic (and with normal ejection fraction). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19808288", "endSection": "abstract"}, {"offsetInBeginSection": 1122, "offsetInEndSection": 1330, "text": "In HCM, the DE was associated with higher NYHA classes and prevalence of VT, impaired global LV function and asymmetrical hypertrophy, and conduction disturbance, abnormal Q waves, and giant negative T waves.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19477402", "endSection": "abstract"}, {"offsetInBeginSection": 1482, "offsetInEndSection": 1951, "text": " In myocardial segments exhibiting DCE, hMBF is reduced. DCE extent is inversely correlated and hMBF directly correlated with systolic thickening. In segments without DCE but contiguous to DCE areas, hMBF is significantly lower than in those remote from DCE and is similar to the value obtained in nontransmural DCE segments. These results suggest that increasing degrees of coronary microvascular dysfunction might play a causative role for myocardial fibrosis in HCM.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18552138", "endSection": "abstract"}, {"offsetInBeginSection": 1334, "offsetInEndSection": 1683, "text": "In this large HCM cohort with no or only mild symptoms, myocardial fibrosis detected by CMR was associated with greater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulatory Holter ECG. Therefore, contrast-enhanced CMR identifies HCM patients with increased susceptibility to ventricular tachyarrhythmias.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18387438", "endSection": "abstract"}]}, {"body": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18816693", "http://www.ncbi.nlm.nih.gov/pubmed/18941145", "http://www.ncbi.nlm.nih.gov/pubmed/17702273", "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "http://www.ncbi.nlm.nih.gov/pubmed/11912113", "http://www.ncbi.nlm.nih.gov/pubmed/12217621", "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "http://www.ncbi.nlm.nih.gov/pubmed/16092100"], "triples": [], "ideal_answer": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "concepts": [], "type": "summary", "id": "56c1f033ef6e39474100004f", "snippets": [{"offsetInBeginSection": 296, "offsetInEndSection": 583, "text": "The clinical entity was a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients were distinguished.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18816693", "endSection": "abstract"}, {"offsetInBeginSection": 95, "offsetInEndSection": 494, "text": "One-half of the patients with this tauopathy have dopa-resistant parkinsonism, tremor, subcortical dementia and abnormal eye movements suggestive of progressive supranuclear palsy (PSP). They also have hallucinations, dysautonomia, which are not characteristic of PSP. Furthermore, the oculomotor abnormalities and the tremor, which is jerky, differ from what is observed in classical PSP patients. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941145", "endSection": "abstract"}, {"offsetInBeginSection": 1502, "offsetInEndSection": 1730, "text": "In conclusion, Gd-PSP patients have cortical myoclonus and cortical oculomotor impairments, but only minor signs of brainstem oculomotor dysfunction, suggesting that cortical dysfunction predominates over brainstem impairments. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702273", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 253, "text": "STUDY OBJECTIVE: To describe sleep characteristics and rapid eye movement (REM) sleep behavior disorder in patients with Guadeloupean atypical parkinsonism (Gd-PSP), a tauopathy resembling progressive supranuclear palsy that mainly affects the midbrain.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702273", "endSection": "abstract"}, {"offsetInBeginSection": 742, "offsetInEndSection": 1033, "text": "RESULTS: REM sleep behavior disorder was found in 78% patients with Gd-PSP (43% of patients reported having this disorder several years before the onset of parkinsonism), 44% of patients with idiopathic Parkinson disease, 33% of patients with progressive supranuclear palsy, and no controls.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702273", "endSection": "abstract"}, {"offsetInBeginSection": 1502, "offsetInEndSection": 1599, "text": "CONCLUSION: Although Gd-PSP is a tauopathy, most patients experience REM sleep behavior disorder.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702273", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 299, "text": "Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 1183, "offsetInEndSection": 1679, "text": "Patients with a PSP-like syndrome developed levodopa-resistant parkinsonism, associated with early postural instability and supranuclear oculomotor dysfunction. They differed, however, from classical PSP patients by the frequency of tremor (>50%), dysautonomia (50%) and the occurrence of hallucinations (59%). PDC patients had levodopa-resistant parkinsonism associated with frontosubcortical dementia, 52% of these patients had hallucinations, but, importantly, none had oculomotor dysfunction.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 1754, "offsetInEndSection": 2450, "text": "Cerebral atrophy was seen in the majority of the PSP-like and PDC patients, with enlargement of the third ventricle and marked T2-hypointensity in the basal ganglia, particularly the substantia nigra. Consumption of soursop was significantly greater in both PSP-like and PDC patients than in controls and Parkinson's disease patients. In conclusion, atypical Guadeloupean parkinsonism comprises two forms of parkinsonism and dementia that differ clinically by the presence of oculomotor signs, but have similar cognitive profiles and neuroimaging features, suggesting that they may constitute a single disease entity, and both were similarly exposed to annonaceous neurotoxins, notably annonacin.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11912113", "endSection": "title"}, {"offsetInBeginSection": 128, "offsetInEndSection": 380, "text": "Postural instability with early falls, prominent frontal lobe dysfunction and pseudo-bulbar palsy were common and three-quarters of the patients were L-dopa unresponsive. One-third of all patients seen had probable progressive supranuclear palsy (PSP).", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11912113", "endSection": "abstract"}, {"offsetInBeginSection": 1947, "offsetInEndSection": 2037, "text": "Guadeloupean parkinsonism may prove to be a tauopathy identical or closely related to PSP.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11912113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12217621", "endSection": "title"}, {"offsetInBeginSection": 147, "offsetInEndSection": 299, "text": " Now on Guadeloupe in the Carribbean French West Indies, Caparros-Lefebvre is identifying many patients with similar clinical and histological features.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12217621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": ": On Guadeloupe, atypical parkinsonism is abnormally frequent, and represents 75% of progressive parkinsonism while Parkinson's disease (PD) accounts for only 25%, which is an inversed percentage in comparison with Europe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "On the French West Indian island of Guadeloupe, atypical parkinsonian patients represent two-thirds of all cases of parkinsonism, which is exceptionally frequent compared to epidemiological data from European countries where atypical parkinsonism accounts for only approximately 5% of all cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18816693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Atypical unclassifiable parkinsonism on Guadeloupe: an environmental toxic hypothesis.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "In Guadeloupe, there is an abnormally high frequency of atypical parkinsonism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Atypical parkinsonism is extremely frequent in Guadeloupe and may have an environmental cause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18816693", "endSection": "title"}, {"offsetInBeginSection": 2496, "offsetInEndSection": 2716, "text": "The development of atypical parkinsonism in Guadeloupe and probably elsewhere, could result from synergistic toxicity, but acetogenins are probably the most potent neurotoxin, acting as mitochondrial complex I inhibitor.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": ": On Guadeloupe, atypical parkinsonism is abnormally frequent, and represents 75% of progressive parkinsonism while Parkinson's disease (PD) accounts for only 25%, which is an inversed percentage in comparison with Europe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "abstract"}, {"offsetInBeginSection": 757, "offsetInEndSection": 920, "text": "Two hundred and twenty consecutive patients with Parkinson's syndrome seen by the neurology service at Pointe \u00e0 Pitre, Guadeloupe University Hospital were studied.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11912113", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "In Guadeloupe, there is an abnormally high frequency of atypical parkinsonism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Atypical parkinsonism is extremely frequent in Guadeloupe and may have an environmental cause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 222, "text": ": On Guadeloupe, atypical parkinsonism is abnormally frequent, and represents 75% of progressive parkinsonism while Parkinson's disease (PD) accounts for only 25%, which is an inversed percentage in comparison with Europe.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 295, "text": "On the French West Indian island of Guadeloupe, atypical parkinsonian patients represent two-thirds of all cases of parkinsonism, which is exceptionally frequent compared to epidemiological data from European countries where atypical parkinsonism accounts for only approximately 5% of all cases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18816693", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "In Guadeloupe, there is an abnormally high frequency of atypical parkinsonism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Atypical parkinsonism is extremely frequent in Guadeloupe and may have an environmental cause.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18941145", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18816693", "endSection": "title"}, {"offsetInBeginSection": 79, "offsetInEndSection": 299, "text": "Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 299, "text": "Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 299, "text": "Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 299, "text": "Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 79, "offsetInEndSection": 299, "text": "Only one-third of the patients that develop parkinsonian symptoms were reported to present the classical features of idiopathic Parkinson disease and one-third a syndrome resembling progressive supranuclear palsy (PSP). ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303592", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "We characterize the clinical features of Parkinson&apos;s syndrome on Guadeloupe and describe possible environmental causes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 508, "offsetInEndSection": 591, "text": "The subjects were 265 patients with Parkinson&apos;s syndrome living on Guadeloupe,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "We characterize the clinical features of Parkinson&apos;s syndrome on Guadeloupe and describe possible environmental causes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 508, "offsetInEndSection": 591, "text": "The subjects were 265 patients with Parkinson&apos;s syndrome living on Guadeloupe,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "We characterize the clinical features of Parkinson&apos;s syndrome on Guadeloupe and describe possible environmental causes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 508, "offsetInEndSection": 591, "text": "The subjects were 265 patients with Parkinson&apos;s syndrome living on Guadeloupe,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "We characterize the clinical features of Parkinson&apos;s syndrome on Guadeloupe and describe possible environmental causes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 131, "text": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21783505", "endSection": "title"}, {"offsetInBeginSection": 508, "offsetInEndSection": 591, "text": "The subjects were 265 patients with Parkinson&apos;s syndrome living on Guadeloupe,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16092100", "endSection": "abstract"}]}, {"body": "Which is the enzymatic activity of the myotubularin family of proteins?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23857703", "http://www.ncbi.nlm.nih.gov/pubmed/23818870", "http://www.ncbi.nlm.nih.gov/pubmed/23114011", "http://www.ncbi.nlm.nih.gov/pubmed/21372139", "http://www.ncbi.nlm.nih.gov/pubmed/21510942", "http://www.ncbi.nlm.nih.gov/pubmed/22578719", "http://www.ncbi.nlm.nih.gov/pubmed/22647598", "http://www.ncbi.nlm.nih.gov/pubmed/23086420", "http://www.ncbi.nlm.nih.gov/pubmed/21175430", "http://www.ncbi.nlm.nih.gov/pubmed/20736309", "http://www.ncbi.nlm.nih.gov/pubmed/20188094", "http://www.ncbi.nlm.nih.gov/pubmed/19325702", "http://www.ncbi.nlm.nih.gov/pubmed/17346927", "http://www.ncbi.nlm.nih.gov/pubmed/16914545", "http://www.ncbi.nlm.nih.gov/pubmed/16828287", "http://www.ncbi.nlm.nih.gov/pubmed/16787938", "http://www.ncbi.nlm.nih.gov/pubmed/16410353", "http://www.ncbi.nlm.nih.gov/pubmed/16289848", "http://www.ncbi.nlm.nih.gov/pubmed/16262718", "http://www.ncbi.nlm.nih.gov/pubmed/15998640", "http://www.ncbi.nlm.nih.gov/pubmed/14690594", "http://www.ncbi.nlm.nih.gov/pubmed/12925573", "http://www.ncbi.nlm.nih.gov/pubmed/12829232", "http://www.ncbi.nlm.nih.gov/pubmed/12788949", "http://www.ncbi.nlm.nih.gov/pubmed/12646134", "http://www.ncbi.nlm.nih.gov/pubmed/12554688", "http://www.ncbi.nlm.nih.gov/pubmed/12118066", "http://www.ncbi.nlm.nih.gov/pubmed/12045210", "http://www.ncbi.nlm.nih.gov/pubmed/12018406", "http://www.ncbi.nlm.nih.gov/pubmed/11846405", "http://www.ncbi.nlm.nih.gov/pubmed/11733541", "http://www.ncbi.nlm.nih.gov/pubmed/11275328"], "triples": [], "ideal_answer": ["The myotubularin family of proteins are lipid inositol phosphatases"], "exact_answer": [["lipid inositol phosphatase activity"]], "concepts": [], "type": "factoid", "id": "54d6562c3706e8952800000b", "snippets": [{"offsetInBeginSection": 518, "offsetInEndSection": 554, "text": "myotubularin family of phosphatases.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23857703", "endSection": "abstract"}, {"offsetInBeginSection": 114, "offsetInEndSection": 282, "text": "Myotubularin belongs to a large family of conserved lipid phosphatases that include both catalytically active and inactive myotubularin-related proteins (i.e., \"MTMRs\")", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23818870", "endSection": "abstract"}, {"offsetInBeginSection": 432, "offsetInEndSection": 463, "text": "myotubalarin family phosphatase", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23114011", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "MTMR2 is a member of the myotubularin family of inositol lipid phosphatases, ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21372139", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "Myotubularin related protein 2 (MTMR2) is a member of the myotubularin family of phosphoinositide lipid phosphatases. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21510942", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22578719", "endSection": "title"}, {"offsetInBeginSection": 481, "offsetInEndSection": 795, "text": "Although myotubularin was thought to be a dual-specificity protein phosphatase, recent results indicate that it is primarily a lipid phosphatase, acting on phosphatidylinositol 3-monophosphate, and might be involved in the regulation of phosphatidylinositol 3-kinase (PI 3-kinase) pathway and membrane trafficking.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11275328", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Myotubularin is the archetype of a family of highly conserved protein-tyrosine phosphatase-like enzymes. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11733541", "endSection": "abstract"}, {"offsetInBeginSection": 245, "offsetInEndSection": 364, "text": "we and others have characterized myotubularin as a potent and specific phosphatidylinositol 3-phosphate 3-phosphatase. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11846405", "endSection": "abstract"}, {"offsetInBeginSection": 292, "offsetInEndSection": 544, "text": "MTMR2 encodes a member of the myotubularin family of phosphoinositide-3-phosphatases, which dephosphorylate phosphatidylinositol 3-phosphate (PI(3)P) and bisphosphate PI(3,5)P2. MTMR13 encodes a large, uncharacterized member of the myotubularin family.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998640", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Myotubularin-related proteins are a large subfamily of protein tyrosine phosphatases (PTPs) that dephosphorylate D3-phosphorylated inositol lipids.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690594", "endSection": "abstract"}, {"offsetInBeginSection": 289, "offsetInEndSection": 409, "text": "Myotubularin, the gene mutated in myotubular myopathy, functions as a lipid phosphatase with specificity for PtdIns(3)P.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12018406", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "The myotubularin family: novel phosphoinositide regulators.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12018406", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "The myotubularins are a large family of inositol polyphosphate 3-phosphatases that", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647598", "endSection": "abstract"}, {"offsetInBeginSection": 172, "offsetInEndSection": 422, "text": "The myotubularin family consists of 16 different proteins, 9 members of which possess catalytic activity, dephosphorylating phosphatidylinositol 3-phosphate [PtdIns(3)P] and phosphatidylinositol 3,5-bisphosphate [PtdIns(3,5)P(2)] at the D-3 position.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647598", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "Myotubularin phosphoinositide phosphatases in human diseases.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086420", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "The MTM (myotubularin)/MTMR (myotubularin-related) protein family is comprised of 15 lipid phosphatases, of which nine members are catalytically active. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175430", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "The myotubularin family of lipid phosphatases ", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21175430", "endSection": "title"}]}, {"body": "Where is the protein CLIC1 localized?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21055175", "http://www.ncbi.nlm.nih.gov/pubmed/15827065", "http://www.ncbi.nlm.nih.gov/pubmed/9880541"], "triples": [{"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/Q5E9B7", "o": "http://linkedlifedata.com/resource/#_51354539423700E"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_51354539423700E", "o": "CLIC1"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_51354539423700C", "o": "Chloride intracellular channel protein 1"}, {"p": "http://purl.uniprot.org/core/encodedBy", "s": "http://purl.uniprot.org/uniprot/Q95MF9", "o": "http://linkedlifedata.com/resource/#_5139354D463900A"}, {"p": "http://www.w3.org/2004/02/skos/core#prefLabel", "s": "http://linkedlifedata.com/resource/#_5139354D463900A", "o": "CLIC1"}, {"p": "http://purl.uniprot.org/core/fullName", "s": "http://linkedlifedata.com/resource/#_5139354D4639009", "o": "Chloride intracellular channel protein 1"}], "ideal_answer": "CLIC1 is an intracellular chloride ion channel that is localized both to the nucleus and to the cytolasm.", "concepts": ["http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051179", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0008104", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0051234", "http://www.uniprot.org/uniprot/CLIC1_RAT", "http://www.uniprot.org/uniprot/CLIC1_MOUSE", "http://www.uniprot.org/uniprot/CLIC1_BOVIN", "http://www.uniprot.org/uniprot/CLIC1_RABIT", "http://www.uniprot.org/uniprot/CLIC1_PIG", "http://www.uniprot.org/uniprot/CLIC1_HUMAN"], "type": "summary", "id": "53319916d6d3ac6a3400003f", "snippets": [{"offsetInBeginSection": 611, "offsetInEndSection": 706, "text": "CLIC1 expression was obtained in the cytoplasm and plasma membrane of cells in both cell lines.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21055175", "endSection": "abstract"}, {"offsetInBeginSection": 641, "offsetInEndSection": 686, "text": "CLIC1, an intracellular chloride ion channel,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827065", "endSection": "abstract"}, {"offsetInBeginSection": 612, "offsetInEndSection": 678, "text": "Like NCC27/CLIC1, CLIC3 is predominantly localized in the nucleus ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9880541", "endSection": "abstract"}, {"offsetInBeginSection": 1270, "offsetInEndSection": 1357, "text": "the nuclear localization pattern of CLIC1 was remarkably changed by insulin stimulation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15827065", "endSection": "abstract"}]}, {"body": "What is the use of MammaPrint and Oncotype DX?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23573359", "http://www.ncbi.nlm.nih.gov/pubmed/23462680", "http://www.ncbi.nlm.nih.gov/pubmed/23411384", "http://www.ncbi.nlm.nih.gov/pubmed/23337633", "http://www.ncbi.nlm.nih.gov/pubmed/22359236", "http://www.ncbi.nlm.nih.gov/pubmed/21998967", "http://www.ncbi.nlm.nih.gov/pubmed/21501481", "http://www.ncbi.nlm.nih.gov/pubmed/21479927", "http://www.ncbi.nlm.nih.gov/pubmed/20587405", "http://www.ncbi.nlm.nih.gov/pubmed/23495982", "http://www.ncbi.nlm.nih.gov/pubmed/19585214", "http://www.ncbi.nlm.nih.gov/pubmed/19101988"], "triples": [{"p": "http://www.w3.org/2008/05/skos-xl#literalForm", "s": "http://linkedlifedata.com/resource/umls/label/A17680439", "o": "MammaPrint"}, {"p": "http://www.w3.org/2008/05/skos-xl#prefLabel", "s": "http://linkedlifedata.com/resource/umls/id/C2827401", "o": "http://linkedlifedata.com/resource/umls/label/A17680439"}, {"p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", "s": "http://linkedlifedata.com/resource/umls/label/A10812803", "o": "http://www.w3.org/2008/05/skos-xl#Label"}, {"p": "http://www.w3.org/2008/05/skos-xl#altLabel", "s": "http://linkedlifedata.com/resource/umls/id/C1709318", "o": "http://linkedlifedata.com/resource/umls/label/A10812803"}], "ideal_answer": ["The MammaPrint and Oncotype DX assays are used to predict breast cancer recurrence risk and guide adjuvant chemotherapy decisions."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045506"], "type": "summary", "id": "5167d47e298dcd4e5100005e", "snippets": [{"offsetInBeginSection": 122, "offsetInEndSection": 599, "text": "Molecular tests such as the 21 gene expression test (Oncotype DX(TM)) and 70 gene microarray test (MammaPrint(\u00ae)) have revolutionized the predictive and prognostic tools in the clinic. By stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the treatment outcomes of using chemotherapy, HER2 targeted therapy or endocrine therapy or the combination of the therapies for patients with particular genetic expressions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23573359", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 697, "text": "Gene expression profiling tests are used in an attempt to determine the right treatment for the right person with early-stage breast cancer that may have spread to nearby lymph nodes but not to distant parts of the body. These new diagnostic approaches are designed to spare people who do not need additional treatment (adjuvant therapy) the side effects of unnecessary treatment, and allow people who may benefit from adjuvant therapy to receive it. In the present review we discuss in detail the major diagnostic tests available such as MammaPrint dx, Oncotype dx, PAM50, Mammostrat, IHC4, MapQuant DX, Theros-Breast Cancer Gene Expression Ratio Assay, and their potential clinical applications.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462680", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Oncotype DX, PAM50, and MammaPrint are multigene tests that are being used clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23411384", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 504, "text": "We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit. METHODS: Independent evaluation of six genomic tests [Oncotype Dx\u2122, MammaPrint(\u00ae), Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP criteria. PANEL", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23337633", "endSection": "sections.0"}, {"offsetInBeginSection": 12, "offsetInEndSection": 526, "text": "Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph node-negative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the cost effectiveness of recurrence score-guided treatment using 2 commercially available GEP tests, Oncotype DX (Genomic Health, Redwood City, Calif) and MammaPrint (Agendia Inc., Irvine, Calif), from a third-party payer's perspective.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22359236", "endSection": "sections.0"}, {"offsetInBeginSection": 128, "offsetInEndSection": 686, "text": "genomic tumor signatures that predict a patient's risk of breast cancer recurrence and response to chemotherapy. The paper builds on empirical evidence from the two trials to explore the emergence of diverse regulatory-scientific hybrids; that is, the paper discusses configurations of genomic practice and bioclinical work that depend on linkages between technical, commercial, patient, clinical, and legal interests and institutions. The development of the genomic signatures for each trial--Oncotype DX and MammaPrint--has followed quite different routes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21998967", "endSection": "sections.0"}, {"offsetInBeginSection": 1350, "offsetInEndSection": 1694, "text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927", "endSection": "sections.0"}, {"offsetInBeginSection": 476, "offsetInEndSection": 903, "text": "We will review the primary tools in clinical use: Adjuvant!, Oncotype DX, and MammaPrint as well as intrinsic subtypes and the plans for their further assessment in the clinical trial setting. The expected benefit from these models are that treatment recommendations for women with early-stage breast cancer will become more individualized and thereby appropriate by combining standard clinicopathologic and molecular features.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587405", "endSection": "sections.0"}, {"offsetInBeginSection": 559, "offsetInEndSection": 914, "text": "newer prognostic markers with a focus on the 21-gene recurrence score (Oncotype DX(\u2122)), 70-gene prognosis profile (Mammaprint(\u00ae)), and Adjuvant! Online. Conclusion: These techniques differ in their execution and application and have been demonstrated to provide further data on risk stratification as compared with conventional breast-cancer-risk factors.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23495982", "endSection": "sections.0"}, {"offsetInBeginSection": 18, "offsetInEndSection": 496, "text": "diagnostic tools such as MammaPrint and oncotype-DX are beginning to have impact on clinical practice of breast cancer. They are based on gene expression profiling, i.e., gene expression analysis of a large number of genes. Their unique characteristic is the use of a score calculated from expression values of a number of genes, for which the Food and Drug Administration (FDA) created a new diagnostic category entitled \"in vitro diagnostic multivariate index assay (IVDMIA).\"", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19585214", "endSection": "sections.0"}, {"offsetInBeginSection": 699, "offsetInEndSection": 970, "text": "the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101988", "endSection": "sections.0"}]}, {"body": "Which cyclin- dependent kinase inhibitor is regulated by Bmi-1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20661663", "http://www.ncbi.nlm.nih.gov/pubmed/20591222", "http://www.ncbi.nlm.nih.gov/pubmed/20551323", "http://www.ncbi.nlm.nih.gov/pubmed/19321450", "http://www.ncbi.nlm.nih.gov/pubmed/18371338", "http://www.ncbi.nlm.nih.gov/pubmed/18371328", "http://www.ncbi.nlm.nih.gov/pubmed/18275833", "http://www.ncbi.nlm.nih.gov/pubmed/17989730", "http://www.ncbi.nlm.nih.gov/pubmed/17651940", "http://www.ncbi.nlm.nih.gov/pubmed/17145810", "http://www.ncbi.nlm.nih.gov/pubmed/17102614", "http://www.ncbi.nlm.nih.gov/pubmed/16537449", "http://www.ncbi.nlm.nih.gov/pubmed/16157028", "http://www.ncbi.nlm.nih.gov/pubmed/16155021", "http://www.ncbi.nlm.nih.gov/pubmed/14982841", "http://www.ncbi.nlm.nih.gov/pubmed/14574365", "http://www.ncbi.nlm.nih.gov/pubmed/12714971", "http://www.ncbi.nlm.nih.gov/pubmed/12482990", "http://www.ncbi.nlm.nih.gov/pubmed/9923679", "http://www.ncbi.nlm.nih.gov/pubmed/21928107", "http://www.ncbi.nlm.nih.gov/pubmed/18346113", "http://www.ncbi.nlm.nih.gov/pubmed/21496667", "http://www.ncbi.nlm.nih.gov/pubmed/21164364", "http://www.ncbi.nlm.nih.gov/pubmed/19907431", "http://www.ncbi.nlm.nih.gov/pubmed/19390085", "http://www.ncbi.nlm.nih.gov/pubmed/19389366", "http://www.ncbi.nlm.nih.gov/pubmed/17597110", "http://www.ncbi.nlm.nih.gov/pubmed/17233832", "http://www.ncbi.nlm.nih.gov/pubmed/16869752", "http://www.ncbi.nlm.nih.gov/pubmed/16778197", "http://www.ncbi.nlm.nih.gov/pubmed/15964994", "http://www.ncbi.nlm.nih.gov/pubmed/15892997", "http://www.ncbi.nlm.nih.gov/pubmed/14732230", "http://www.ncbi.nlm.nih.gov/pubmed/14536079", "http://www.ncbi.nlm.nih.gov/pubmed/11355949"], "triples": [], "ideal_answer": "p16INK4 (also known as CDKN2A)", "exact_answer": ["p16INK4"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050756", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019941", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004861", "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045736", "http://www.uniprot.org/uniprot/CD2A1_MONDO"], "type": "factoid", "id": "533abc76d6d3ac6a34000064", "snippets": [{"offsetInBeginSection": 663, "offsetInEndSection": 748, "text": "the knockdown of BMI-1 expression could lead to significant up-regulation of p16INK4a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20661663", "endSection": "abstract"}, {"offsetInBeginSection": 1621, "offsetInEndSection": 1694, "text": "In EC9706 cells transfected by Bmi-1 siRNA, the expression levels of p16 ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20591222", "endSection": "abstract"}, {"offsetInBeginSection": 270, "offsetInEndSection": 392, "text": "One important pathway regulated by Bmi-1 is that involving two cyclin-dependent kinase inhibitors, p16(Ink4a) and p19(Arf)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20551323", "endSection": "abstract"}, {"offsetInBeginSection": 643, "offsetInEndSection": 814, "text": "We also observe that ROS-induced up-regulation of p16(Ink4a) occurs correlatively with ERK1/2-dependent down-regulation and subsequent dissociation from chromatin of Bmi-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321450", "endSection": "abstract"}, {"offsetInBeginSection": 51, "offsetInEndSection": 214, "text": "Bmi-1 is important for postnatal, but not embryonic, neural stem cell (NSC) self-renewal and have identified the cell-cycle inhibitors p16/p19 as molecular targets", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371338", "endSection": "abstract"}, {"offsetInBeginSection": 180, "offsetInEndSection": 307, "text": "Bmi-1 function in stem cells during development that, surprisingly, seems to involve regulation of the cell-cycle inhibitor p21", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371328", "endSection": "abstract"}, {"offsetInBeginSection": 823, "offsetInEndSection": 892, "text": "Our data therefore implicate p21 as an important Bmi-1 target in NSCs", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371338", "endSection": "abstract"}, {"offsetInBeginSection": 628, "offsetInEndSection": 663, "text": "Bmi-1-mediated repression of Cdkn2A", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18275833", "endSection": "abstract"}, {"offsetInBeginSection": 798, "offsetInEndSection": 894, "text": "decreased expression of proliferating cell nuclear antigen and Bmi-1; upregulation of p16(INK4a)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17989730", "endSection": "abstract"}, {"offsetInBeginSection": 573, "offsetInEndSection": 701, "text": "BMI-1 promotes self-renewal of stem cells largely by interfering with two central cellular tumor suppressor pathways, p16(Ink4a)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17651940", "endSection": "abstract"}, {"offsetInBeginSection": 104, "offsetInEndSection": 327, "text": "p16INK4a and p14ARF tumor suppressors, human telomerase reverse transcriptase (h-TERT), and oncoprotein c-Myc have been implicated in the regulation of the cell cycle and proliferation mediated by PcG proteins, mainly Bmi-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145810", "endSection": "abstract"}, {"offsetInBeginSection": 395, "offsetInEndSection": 492, "text": "involving the polycomb group repressor Bmi-1 and the cyclin-dependent kinase inhibitor p16(INK4a)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17102614", "endSection": "abstract"}, {"offsetInBeginSection": 399, "offsetInEndSection": 596, "text": "increased frequency to a telomere-independent senescent state mediated by the cyclin-dependent kinase inhibitor p16(INK4a). p16(INK4a) expression was regulated by the Polycomb group repressor Bmi-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16537449", "endSection": "abstract"}, {"offsetInBeginSection": 1445, "offsetInEndSection": 1549, "text": "The antisense Bmi-1 gene can inhibit the growth of K562 cell and upgrade expression of p16 in K562 cells", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16157028", "endSection": "abstract"}, {"offsetInBeginSection": 912, "offsetInEndSection": 989, "text": "overexpression of BMI-1, a transcriptional repressor of the p16(INK4a) locus,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16155021", "endSection": "abstract"}, {"offsetInBeginSection": 800, "offsetInEndSection": 874, "text": "experimental model systems indicate that p16 is a downstream target of Bmi", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14982841", "endSection": "abstract"}, {"offsetInBeginSection": 629, "offsetInEndSection": 777, "text": "In the absence of Bmi-1, the cyclin-dependent kinase inhibitor gene p16Ink4a is upregulated in neural stem cells, reducing the rate of proliferation", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574365", "endSection": "abstract"}, {"offsetInBeginSection": 686, "offsetInEndSection": 935, "text": "A gene expression analysis revealed that the expression of stem cell associated genes, cell survival genes, transcription factors, and genes modulating proliferation including p16Ink4a and p19Arf was altered in bone marrow cells of the Bmi-1-/- mice", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12714971", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 106, "text": "polycomb protein Bmi-1 represses the INK4a locus, which encodes the tumor suppressors p16 and p14(ARF)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12482990", "endSection": "abstract"}, {"offsetInBeginSection": 17, "offsetInEndSection": 110, "text": "Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9923679", "endSection": "title"}, {"offsetInBeginSection": 777, "offsetInEndSection": 912, "text": "in bmi-1-deficient lymphocytes, the expression of the tumour suppressors p16 and p19Arf, which are encoded by ink4a, is raised markedly", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9923679", "endSection": "abstract"}, {"offsetInBeginSection": 1493, "offsetInEndSection": 1526, "text": "BMI-1-mediated INK4a/ARF pathway ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21928107", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 320, "text": " expression of the polycomb protein BMI-1 and its downstream targets p16(Ink4a)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18346113", "endSection": "abstract"}, {"offsetInBeginSection": 905, "offsetInEndSection": 1029, "text": "reduced expression of Bmi-1, OC, DSP, and BSP compared with rapidly proliferating cells, whereas p16(INK4A) level increased.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496667", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 52, "text": "16Ink4a suppression of lung adenocarcinoma by Bmi-1", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164364", "endSection": "title"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1460, "text": "The suppression of p16Ink4a occurred in parallel with an increase in Bmi-1", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21164364", "endSection": "abstract"}, {"offsetInBeginSection": 1224, "offsetInEndSection": 1282, "text": "Bmi-1 overexpression reduced p16(INK4a) promoter activity ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19907431", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 35, "text": "mi-1 regulates the Ink4a/Arf locus", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19390085", "endSection": "title"}, {"offsetInBeginSection": 212, "offsetInEndSection": 291, "text": "derepression of the Ink4a/Arf locus is associated with decreased Bmi-1 binding,", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19390085", "endSection": "abstract"}, {"offsetInBeginSection": 1029, "offsetInEndSection": 1152, "text": "pronounced effects of Bmi-1 over-expression in culture were largely attributable to the attenuated induction of p16(Ink4a) ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19389366", "endSection": "abstract"}, {"offsetInBeginSection": 364, "offsetInEndSection": 443, "text": "BMI-1 is a transcriptional repressor of the Ink4a/Arf locus encoding p16(ink4a)", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17597110", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 442, "text": "introduction of Bmi-1 can inhibit p16(INK4a) expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17233832", "endSection": "abstract"}, {"offsetInBeginSection": 635, "offsetInEndSection": 718, "text": "Bmi-1 promotes stem cell self-renewal partly by repressing the expression of Ink4a ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16869752", "endSection": "abstract"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1060, "text": "Overexpression of Bmi-1 in NPECs led to the induction of human telomerase reverse transcriptase activity and reduction of p16(INK4a) expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778197", "endSection": "abstract"}, {"offsetInBeginSection": 657, "offsetInEndSection": 742, "text": "Bmi-1 thus prevents the premature senescence of neural stem cells by repressing Ink4a", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15964994", "endSection": "abstract"}, {"offsetInBeginSection": 355, "offsetInEndSection": 442, "text": "overexpression of the polycomb-group gene BMI-1 might also down-regulate p16 expression", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15892997", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 113, "text": "Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14732230", "endSection": "title"}, {"offsetInBeginSection": 809, "offsetInEndSection": 925, "text": "modulation of Bmi-1 protein might be involved in human colorectal carcinogenesis by repressing the INK4a/ARF protein", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14732230", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 29, "text": "mi-1 regulation of INK4A-ARF", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14536079", "endSection": "title"}, {"offsetInBeginSection": 294, "offsetInEndSection": 428, "text": "expression of BMI-1, a lymphoid oncogene whose product functions as a transcriptional repressor of the INK4A-ARF tumor suppressor locu", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/14536079", "endSection": "abstract"}, {"offsetInBeginSection": 4, "offsetInEndSection": 126, "text": "bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11355949", "endSection": "title"}, {"offsetInBeginSection": 419, "offsetInEndSection": 495, "text": "bmi-1 overexpression induces immortalization due to repression of p16/p19ARF", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11355949", "endSection": "abstract"}]}, {"body": "How are lincRNA affecting the regulation of gene expression?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24268656", "http://www.ncbi.nlm.nih.gov/pubmed/24022994", "http://www.ncbi.nlm.nih.gov/pubmed/23597480", "http://www.ncbi.nlm.nih.gov/pubmed/22403033", "http://www.ncbi.nlm.nih.gov/pubmed/24316222", "http://www.ncbi.nlm.nih.gov/pubmed/24080187", "http://www.ncbi.nlm.nih.gov/pubmed/23965803", "http://www.ncbi.nlm.nih.gov/pubmed/23541921", "http://www.ncbi.nlm.nih.gov/pubmed/22841487"], "triples": [], "ideal_answer": ["lincRNA may function either as modulators of epigenetic mark deposition or as endogenous antagonists for microRNA binding. A lincRNA, linc-RoR, may function as a key competing endogenous RNA to link the network of miRNAs and core TFs, e.g., Oct4, Sox2, and Nanog. Mdig is involved in the regulation of H3K9me3 to influence the heterochromatin structure of the genome and the expression of genes important for cell growth or transformation. Observed biases in lincRNA genomic locations and expression profiles are consistent with some of these lincRNAs being involved in the regulation of neighboring protein-coding genes with developmental functions."], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D062085"], "type": "summary", "id": "533c3571c45e133714000005", "snippets": [{"offsetInBeginSection": 259, "offsetInEndSection": 483, "text": "We detected a considerable number of cis expression quantitative trait loci (cis-eQTLs) and demonstrated that the genetic regulation of lincRNA expression is independent of the regulation of neighboring protein-coding genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24268656", "endSection": "abstract"}, {"offsetInBeginSection": 713, "offsetInEndSection": 930, "text": "We observe biases in lincRNA genomic locations and expression profiles that are consistent with some of these lincRNAs being involved in the regulation of neighboring protein-coding genes with developmental functions.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22403033", "endSection": "abstract"}, {"offsetInBeginSection": 106, "offsetInEndSection": 337, "text": "In\u00a0this issue of Developmental Cell, Wang et\u00a0al. (2013) find that linc-RoR maintains human embryonic stem cell self-renewal by functioning as a sponge to trap miR-145, thus regulating core pluripotency factors Oct4, Nanog, and Sox2", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23597480", "endSection": "abstract"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1175, "text": "Enrichment of expressed lincRNA promoters in enhancer marks provides an additional argument for the involvement of lincRNAs in the regulation of transcription in cis. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24268656", "endSection": "abstract"}, {"offsetInBeginSection": 750, "offsetInEndSection": 938, "text": "Together, these findings suggest that lincRNA-p21 is an important player in the regulation of the Warburg effect and also implicate lincRNA-p21 as a valuable therapeutic target for cancer.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24316222", "endSection": "abstract"}, {"offsetInBeginSection": 1387, "offsetInEndSection": 1675, "text": "Our findings implicate a novel RNA gene, lincRNA AC068718.1, as risk factor for PTSD in women and add to emerging evidence that non-coding RNA genes may play a crucial role in shaping the landscape of gene regulation with putative pathological effects that lead to phenotypic differences.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24080187", "endSection": "abstract"}, {"offsetInBeginSection": 1252, "offsetInEndSection": 1466, "text": "Taken together, our results imply that mdig is involved in the regulation of H3K9me3 to influence the heterochromatin structure of the genome and the expression of genes important for cell growth or transformation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23965803", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 110, "text": "ndogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541921", "endSection": "title"}, {"offsetInBeginSection": 386, "offsetInEndSection": 552, "text": "Here, we demonstrate that a lincRNA, linc-RoR, may function as a key competing endogenous RNA to link the network of miRNAs and core TFs, e.g., Oct4, Sox2, and Nanog.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541921", "endSection": "abstract"}, {"offsetInBeginSection": 728, "offsetInEndSection": 848, "text": "We suggest that linc-RoR forms a feedback loop with core TFs and miRNAs to regulate ESC maintenance and differentiation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23541921", "endSection": "abstract"}, {"offsetInBeginSection": 1, "offsetInEndSection": 96, "text": "ammalian long intergenic noncoding RNAs (lincRNAs) are best known for modulating transcription.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841487", "endSection": "abstract"}, {"offsetInBeginSection": 785, "offsetInEndSection": 875, "text": "Our findings uncover a role for lincRNA as a posttranscriptional inhibitor of translation.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841487", "endSection": "abstract"}]}, {"body": "At which kind of individuals is pharmacological treatment of subclinical hypothyroidism effective in reducing cardiovascular events?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23559085", "http://www.ncbi.nlm.nih.gov/pubmed/22529180", "http://www.ncbi.nlm.nih.gov/pubmed/19463607", "http://www.ncbi.nlm.nih.gov/pubmed/19114542", "http://www.ncbi.nlm.nih.gov/pubmed/17544610", "http://www.ncbi.nlm.nih.gov/pubmed/16542047", "http://www.ncbi.nlm.nih.gov/pubmed/16026106", "http://www.ncbi.nlm.nih.gov/pubmed/17636722"], "triples": [], "ideal_answer": "Treatment of subclinical hypothyroidism is associated with fewer cardiovascular events in younger individuals, but this issue has not been resolved yet in elderly people.", "exact_answer": ["effective in younger individuals"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007037", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002318"], "type": "factoid", "id": "52efbfccc8da898910000018", "snippets": [{"offsetInBeginSection": 1447, "offsetInEndSection": 2119, "text": "sHT in older people should be not regarded as a unique condition, and moderately old patients (aged <70-75 y) could be considered clinically similar to the adult population, albeit with a higher optimal TSH target value. Conversely, the oldest old subjects should be carefully followed with a wait-and-see strategy, generally avoiding hormonal treatment. The decision to treat elderly people is still an unresolved clinical challenge--first, due to a lack of appropriately powered randomized controlled trials of L-T4 in sHT patients, examining cardiovascular hard endpoints in various classes of age; and second, because of the negative effects of possible overtreatment.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559085", "endSection": "abstract"}, {"offsetInBeginSection": 1535, "offsetInEndSection": 1796, "text": "Treatment of SCH with levothyroxine was associated with fewer IHD events in younger individuals, but this was not evident in older people. An appropriately powered randomized controlled trial of levothyroxine in SCH examining vascular outcomes is now warranted.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529180", "endSection": "abstract"}, {"offsetInBeginSection": 1415, "offsetInEndSection": 1709, "text": "SCH appears to influence the postoperative outcome for patients by increasing the development of postoperative atrial fibrillation. However, it is still unproven whether preoperative thyroxine replacement therapy for patients with SCH might prevent postoperative atrial fibrillation after CABG.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19463607", "endSection": "abstract"}, {"offsetInBeginSection": 1497, "offsetInEndSection": 1800, "text": "Sustained normalization of thyroid function during l-T(4) replacement therapy significantly decreases baPWV in female subclinical hypothyroid patients with autoimmune chronic thyroiditis, suggesting the improvement of arterial stiffening and, consequently, possible prevention of cardiovascular disease.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19114542", "endSection": "abstract"}, {"offsetInBeginSection": 1467, "offsetInEndSection": 1806, "text": "Our results suggest that L-T(4) replacement therapy may be especially beneficial in female subclinical hypothyroid patients with high baseline baPWV and pulse pressure. The beneficial effects of L-T(4) replacement therapy in decreasing arterial stiffening and thus preventing cardiovascular disease might be limited to this sub-population.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17544610", "endSection": "abstract"}, {"offsetInBeginSection": 1695, "offsetInEndSection": 2027, "text": "Although a consensus is still lacking, the strongest evidence for a beneficial effect of levothyroxine replacement on markers of cardiovascular risk is the substantial demonstration that restoration of euthyroidism can lower both total and low-density lipoprotein-cholesterol levels in most patients with subclinical hypothyroidism.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16542047", "endSection": "abstract"}, {"offsetInBeginSection": 2028, "offsetInEndSection": 2165, "text": "However, the actual effectiveness of thyroid hormone substitution in reducing the risk of cardiovascular events remains to be elucidated.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16542047", "endSection": "abstract"}, {"offsetInBeginSection": 970, "offsetInEndSection": 1633, "text": "Restoration of euthyroidism by levothyroxine (LT4) treatment may correct the lipid profile and cardiac abnormalities, especially in patients with an initially higher deviation from normality and higher serum TSH levels. Importantly, a strong association between SH and atherosclerotic cardiovascular disease, independent of the traditional risk factors, has been recently reported in a large cross-sectional survey (the Rotterdam Study). However, whether SH confers a high risk for cardiovascular disease, and whether LT4 therapy has a long-term benefit that clearly outweighs the risks of overzealous treatment in these individuals, remain topics of controversy.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16026106", "endSection": "abstract"}]}, {"body": "How many genes does the human hoxD cluster contain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22879880", "http://www.ncbi.nlm.nih.gov/pubmed/10364522"], "ideal_answer": ["The human HOXD complex contains nine genes: HOXD1, HOXD3, HOXD4, HOXD8, HOXD9, HOXD10, HOXD11, HOXD12 and HOXD13, which are clustered from 3\u2032 to 5\u2032 in an approximately 100-kb stretch on chromosome 2q31.1 with HOXD1 at the 3' end and HOXD13 the 5\u2032 end."], "exact_answer": ["9"], "type": "factoid", "id": "515db083298dcd4e51000012", "snippets": [{"offsetInBeginSection": 699, "offsetInEndSection": 828, "text": "Both children are heterozygous for a deletion that eliminates at least eight (HOXD3-HOXD13) of the nine genes in the HOXD cluster", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10364522", "endSection": "sections.0"}]}, {"body": "What is the number of protein coding genes in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20175080", "http://www.ncbi.nlm.nih.gov/pubmed/22955987", "http://www.ncbi.nlm.nih.gov/pubmed/18040051", "http://www.ncbi.nlm.nih.gov/pubmed/15034132"], "triples": [], "ideal_answer": "The number of protein coding genes in the human genome is currently estimated between 20,000 and 25,000", "exact_answer": ["Between 20,000 and 25,000"], "concepts": ["http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011506", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016366", "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005796"], "type": "factoid", "id": "535d3c069a4572de6f000006", "snippets": [{"offsetInBeginSection": 277, "offsetInEndSection": 556, "text": "Here, seven membrane protein topology prediction methods based on different underlying algorithms, such as hidden Markov models, neural networks and support vector machines, have been used for analysis of the protein sequences from the 21,416 annotated genes in the human genome.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20175080", "endSection": "abstract"}, {"offsetInBeginSection": 364, "offsetInEndSection": 523, "text": "he GENCODE 7 release contains 20,687 protein-coding and 9640 long noncoding RNA loci and has 33,977 coding transcripts not represented in UCSC genes and RefSeq", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955987", "endSection": "abstract"}, {"offsetInBeginSection": 136, "offsetInEndSection": 220, "text": "Current catalogs list a total of approximately 24,500 putative protein-coding genes.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18040051", "endSection": "abstract"}, {"offsetInBeginSection": 252, "offsetInEndSection": 442, "text": "Clustering of these sequences using cross-species relationships suggests that millions of expressed sequences may correspond to only approximately 20,000 distinct protein-coding transcripts.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15034132", "endSection": "abstract"}]}, {"body": "Where does TORC1 sequester during heat stress?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22727621"], "triples": [], "ideal_answer": ["Upon heat stress, TORC1 is recruited to stress granules."], "concepts": [], "type": "summary", "id": "56cdf4fe5795f9a73e000044", "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 240, "offsetInEndSection": 537, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses. Ectopic formation of SGs achieved by Pbp1 overexpression in unstressed cells sequesters TORC1 in this compartment, thereby blunting TORC1 signaling", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 539, "offsetInEndSection": 705, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 717, "offsetInEndSection": 872, "text": "TORC1 reactivation is directed through SG disassembly, suggesting that SGs act as a key determinant for TORC1 reactivation during recovery from heat stress", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 702, "offsetInEndSection": 869, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 387, "offsetInEndSection": 536, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 702, "offsetInEndSection": 869, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 387, "offsetInEndSection": 536, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 240, "offsetInEndSection": 707, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses. Ectopic formation of SGs achieved by Pbp1 overexpression in unstressed cells sequesters TORC1 in this compartment, thereby blunting TORC1 signaling. Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress. ", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 391, "offsetInEndSection": 707, "text": "Ectopic formation of SGs achieved by Pbp1 overexpression in unstressed cells sequesters TORC1 in this compartment, thereby blunting TORC1 signaling. Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 539, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses. Ectopic formation of SGs achieved by Pbp1 overexpression in unstressed cells sequesters TORC1 in this compartment, thereby blunting TORC1 signaling.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 540, "offsetInEndSection": 874, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress. Moreover, TORC1 reactivation is directed through SG disassembly, suggesting that SGs act as a key determinant for TORC1 reactivation during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 131, "offsetInEndSection": 390, "text": "Although TORC1 signaling is repressed by various stresses in yeast, the underlying mechanisms remain elusive. Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 241, "offsetInEndSection": 390, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 540, "offsetInEndSection": 707, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 390, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 540, "offsetInEndSection": 707, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 241, "offsetInEndSection": 390, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 540, "offsetInEndSection": 707, "text": "Upon heat stress, a physiological SG-inducing condition, TORC1 is also recruited to SGs, which delays reactivation of TORC1 signaling during recovery from heat stress.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "Transient sequestration of TORC1 into stress granules during heat stress.", "beginSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "title"}, {"offsetInBeginSection": 241, "offsetInEndSection": 390, "text": "Here we report that TORC1 signaling upon heat stress is regulated by stress granules (SGs), which are cytoplasmic foci formed under certain stresses.", "beginSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22727621", "endSection": "abstract"}]}, {"body": "Which is the neurodevelopmental disorder associated to mutations in the X- linked gene mecp2?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23449173", "http://www.ncbi.nlm.nih.gov/pubmed/22670134", "http://www.ncbi.nlm.nih.gov/pubmed/11269512", "http://www.ncbi.nlm.nih.gov/pubmed/22982301", "http://www.ncbi.nlm.nih.gov/pubmed/21982064", "http://www.ncbi.nlm.nih.gov/pubmed/19495527", "http://www.ncbi.nlm.nih.gov/pubmed/18337588", "http://www.ncbi.nlm.nih.gov/pubmed/18332345", "http://www.ncbi.nlm.nih.gov/pubmed/17387578", "http://www.ncbi.nlm.nih.gov/pubmed/17089071", "http://www.ncbi.nlm.nih.gov/pubmed/12111643", "http://www.ncbi.nlm.nih.gov/pubmed/11960578", "http://www.ncbi.nlm.nih.gov/pubmed/11738860", "http://www.ncbi.nlm.nih.gov/pubmed/10577905", "http://www.ncbi.nlm.nih.gov/pubmed/10767337", "http://www.ncbi.nlm.nih.gov/pubmed/11055898", "http://www.ncbi.nlm.nih.gov/pubmed/11524741", "http://www.ncbi.nlm.nih.gov/pubmed/11462237", "http://www.ncbi.nlm.nih.gov/pubmed/11402105", "http://www.ncbi.nlm.nih.gov/pubmed/11313756"], "ideal_answer": ["The neurodevelopmental disorder named Rett syndrome, originally termed as cerebroatrophic hyperammonemia. Although most exclusively affects females, has also been found in male patients."], "exact_answer": ["Rett syndrome"], "concepts": ["http://www.uniprot.org/uniprot/MECP2_MACFA", "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051783"], "type": "factoid", "id": "517818508ed59a060a000035", "snippets": [{"offsetInBeginSection": 553, "offsetInEndSection": 650, "text": "Rett syndrome is caused by mutations in the gene coding for methyl CpG-binding protein 2 (MeCP2).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23449173", "endSection": "sections.0"}, {"offsetInBeginSection": 0, "offsetInEndSection": 397, "text": "Rett syndrome is one of the most common causes of complex disability in girls. It is characterized by early neurological regression that severely affects motor, cognitive and communication skills, by autonomic dysfunction and often a seizure disorder. It is a monogenic X-linked dominant neurodevelopmental disorder related to mutation in MECP2, which encodes the methyl-CpG-binding protein MeCP2.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22670134", "endSection": "sections.0"}, {"offsetInBeginSection": 189, "offsetInEndSection": 541, "text": "Recently, this syndrome has been associated with mutations of the MECP2 gene, a transcriptional repressor of still unknown target genes. Here we report a detailed mutational analysis of 62 patients from UK and Italian archives, representing the first comparative study among different populations and one of the largest number of cases so far analyzed.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11269512", "endSection": "sections.0"}, {"offsetInBeginSection": 1097, "offsetInEndSection": 1219, "text": "Out of the 365 cases, 315 had MECP2 gene mutations and 3 had de novo CDKL5 gene mutations. No patients had FOXG1 mutation.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22982301", "endSection": "sections.0"}, {"offsetInBeginSection": 1153, "offsetInEndSection": 1284, "text": "Mutations were detected in \u2248 70% of classic and \u2248 21% of variant RTT, respectively. Amongst MR cases, 2.1% carried MECP2 mutations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21982064", "endSection": "sections.0"}, {"offsetInBeginSection": 692, "offsetInEndSection": 775, "text": "Mutations in the MECP2 gene were detected in 13 of the 20 (65 percent) RS patients.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19495527", "endSection": "sections.0"}, {"offsetInBeginSection": 1093, "offsetInEndSection": 1351, "text": "This multicenter investigation into the phenotypic correlates of MECP2 mutations in Rett syndrome has provided a greater depth of understanding than hitherto available about the specific phenotypic characteristics associated with commonly occurring mutations", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18332345", "endSection": "sections.0"}, {"offsetInBeginSection": 821, "offsetInEndSection": 923, "text": "Mutation screening revealed 31 different mutations in 68 patients and 12 non-pathogenic polymorphisms.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17387578", "endSection": "sections.0"}, {"offsetInBeginSection": 151, "offsetInEndSection": 374, "text": "In this study, the MECP2 sequences in 121 unrelated Chinese patients with classical or atypical RTT were screened for deletions and mutations. In all, we identified 45 different MECP2 mutations in 102 of these RTT patients.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17089071", "endSection": "sections.0"}, {"offsetInBeginSection": 387, "offsetInEndSection": 429, "text": "Mutations in MECP2 were found in about 55%", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12111643", "endSection": "sections.0"}, {"offsetInBeginSection": 206, "offsetInEndSection": 368, "text": "We identified mutations in the MECP2 gene and documented the clinical manifestations in 65 Rett syndrome patients to characterize the genotype-phenotype spectrum.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11960578", "endSection": "sections.0"}, {"offsetInBeginSection": 177, "offsetInEndSection": 506, "text": "We searched for mutations by sequencing the MECP2 coding region in 45 sporadic cases (35 with classic RTT, eight with variant forms and two males) and in seven families with two or more affected females. Following our previous report of mutations in two families and eight sporadic cases, we here present 18 additional mutations.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11738860", "endSection": "sections.0"}, {"offsetInBeginSection": 148, "offsetInEndSection": 433, "text": "The responsible gene, encoding methyl-CpG binding protein 2 (MeCP2), was recently discovered. Here we explore the spectrum of phenotypes resulting from MECP2 mutations. Both nonsense (R168X and R255X) and missense (R106W and R306C) mutations have been found, with multiple recurrences.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10577905", "endSection": "sections.0"}, {"offsetInBeginSection": 566, "offsetInEndSection": 747, "text": "Mutations were identified in 44/55 (80%) unrelated classical sporadic and familial RTT patients, but only 1/5 (20%) sporadic cases with suggestive but non-diagnostic features of RTT", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10767337", "endSection": "sections.0"}, {"offsetInBeginSection": 872, "offsetInEndSection": 1244, "text": "Collectively, we tested 228 unrelated female patients with a diagnosis of possible (209) or classic (19) RTT and found MECP2 mutations in 83 (40%) of 209 and 16 (84%) of 19 of the patients, respectively. Thirty-two different mutations were identified (8 missense, 9 nonsense, 1 splice site, and 14 frameshifts), of which 12 are novel and 9 recurrent in unrelated patients.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11055898", "endSection": "sections.0"}, {"offsetInBeginSection": 405, "offsetInEndSection": 513, "text": "Mutations in MECP2 were identified from most of the patients with classical and variant RTT (25 of 27 cases)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11524741", "endSection": "sections.0"}, {"offsetInBeginSection": 855, "offsetInEndSection": 994, "text": "In our series, 19 different de novo MECP2 mutations, eight of which were previously unreported, were found in 35 out of 50 Rett girls (70%)", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11462237", "endSection": "sections.0"}, {"offsetInBeginSection": 306, "offsetInEndSection": 542, "text": "Causative mutations in the MeCP2 gene were identified in 63% of patients, representing a total of 30 different mutations. Mutations were identified in 72% of patients with classical RTT and one third of atypical cases studied (8 of 25).", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11402105", "endSection": "sections.0"}, {"offsetInBeginSection": 426, "offsetInEndSection": 506, "text": "We have identified 15 different MECP2 mutations in 26 of 30 Danish RTT patients.", "beginSection": "sections.0", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11313756", "endSection": "sections.0"}]}]}